<DOC>
<DOCNO>WT14-B39-1</DOCNO>
<DOCOLDNO>IA057-000937-B017-460</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/index.html 193.128.22.20 19970109093618 text/html 2454
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:26:31 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:39 GMT
Content-length: 2263
Content-type: text/html
</DOCHDR>
<html><head>
<title>Contact Glaxo Wellcome</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<img src="icon.gif" border=0 align=left>

<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Contact Glaxo Wellcome</font></h1>
<hr size=4>
<br>

<font size=5>This section of our web site contains information and mechanisms designed to help you contact Glaxo Wellcome.</font><p>

At present, we are able to provide you with the following resources:<p>

<dl>
<dt><a href="addresses/">Worldwide contacts</a>
<dd>This web site is maintained by Glaxo Wellcome plc in London U.K. If
you have an enquiry please contact your local Glaxo Wellcome company for
the quickest response. Certain GW companies have their own Web sites.<p>

<dt>On this web site it is our practice not to put up e-mail addresses of
individual members of staff without their express permission.  If you wish
to contact a Glaxo Wellcome employee by e-mail please, in the first
instance, get in touch with the appropriate Glaxo Wellcome company; address
details and telephone numbers can be found in this section of the Glaxo
Wellcome web site.<p>

<a href="mailto:feedback@glaxowellcome.co.uk">What do you think of this site?</a>
<dd>We welcome your comments and suggestions on the Glaxo Wellcome web site.<p>
</dl>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-2</DOCNO>
<DOCOLDNO>IA057-000937-B010-457</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/hsenv/index.html 193.128.22.20 19970109082457 text/html 2012
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:15:09 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:21 GMT
Content-length: 1821
Content-type: text/html
</DOCHDR>

<html><head>
<title>Health, safety and the environment</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Health, safety and the environment</font></h1>
<hr size=4>



<h2><font size=6>A statement of the policy of the Glaxo Wellcome group of companies</font></h2>


<img align="left" src="gwmed.gif" alt="Glaxo Wellcome Medicines Research Centre, Stevenage" hspace=5 vspace=5><font size=3>Glaxo Wellcome Medicines Research Centre, Stevenage</font>
<br clear=left><br><p>

<font size=5>

<p>
<a href="hse1.html">A message from Sir Richard Sykes</a>
<p>
<a href="hse2.html">Health, safety and environment policy</a>
<p>
<a href="hse3.html">Implementation</a>
<p>
</font>
<a href="../">Return to: Glaxo Wellcome world contents page</a>
<p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-3</DOCNO>
<DOCOLDNO>IA057-000937-B008-72</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/public/index.html 193.128.22.20 19970109080436 text/html 3905
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:54:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:43 GMT
Content-length: 3714
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome news</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome news</font></h1>
<hr size=4>

<h2><font size=6>Publications with Glaxo Wellcome authors</font></h2>

The following is a selection of recent key publications by Glaxo
Wellcome employees (identified in <b>bold</b> in the abstracts). They
are provided courtesy of the <a
href="http://www.isinet.com/">Institute for Scientific
Information</a>, a database publishing company that supplies
researchers with access to high quality current research
information.<p>

This section will be updated regularly.<p>

<dl>
<dt><a href="ddcr.html">A death-domain-containing receptor that mediates apoptosis</a>
<dd>Nature<p>
<dt><a href="mice.html">Elevated blood pressures in mice lacking endothelial nitric oxide synthase</a>
<dd>Proceedings of the National Academy of Sciences of the USA<p>

<dt><a href="raf.html">The solution structure of the RAF-1 cysteine-rich domain - a novel RAS and Phospholipid binding site</a>
<dd>Proceedings of the National Academy of Sciences of the USA<p>
<dt><a href="kat1.html">Changes in voltage activation, CS+ sensitivity, and ion permeability in H5  mutants of the plant K+ channel KAT1</a>
<dd>Proceedings of the National Academy of Sciences of the USA<p>
<dt><a href="atpgate.html">Differential distribution of two atp-gated ion channels (p-2x receptors)  determined by immunocytochemistry</a>
<dd>Proceedings of the National Academy of Sciences of the USA
<p>
<dt><a href="beige.html">Identification of the homologous beige and Chediak-Higashi syndrome gene</a>
<dd>Nature<p>
<dt><a href="equiv.html">Trials to assess equivalence - the importance of rigorous methods</a>
<dd>British Medical Journal
<p>
<dt><a href="aer.html">Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome</a>
<dd>New England Journal Of Medicine
<p>

<dt><a href="hep.html">Viral dynamics in hepatitis B virus infection</a>
<dd>Proceedings of the National Academy of Sciences of the USA<p>
<dt><a href="chelates.html">Iron chelates bind nitric oxide and decrease mortality in an experimental model of septic shock</a>
<dd>Proceedings of the National Academy of Sciences of the USA<p>
<dt><a href="cloning.html">Cloning, expression, and distribution of a Ca2+-activated K+ channel beta-subunit from human brain</a>
<dd>Proceedings of the National Academy of Sciences of the USA<p>
<dt><a href="bcell.html">B-Cell-Specific coactivator OBF-1 OCA-B/BOB1 required for immune response and germinal centre formation</a>
<dd>Nature<p>
</dl>
<p>
<a href="../">Return to: Glaxo Wellcome news</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-4</DOCNO>
<DOCOLDNO>IA057-000937-B010-475</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/count/index.html 193.128.22.20 19970109082524 text/html 1793
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:15:36 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:18 GMT
Content-length: 1602
Content-type: text/html
</DOCHDR>

<html><head>
<title>Pharmaceutical Counterfeiting</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Pharmaceutical Counterfeiting</font></h1>
<hr size=4>

<h2><font size=6>A statement of the policy of the Glaxo Wellcome group of companies</font></h2>

<font size=5>

<p>
<a href="count1.html">Introduction: a message from Sir Richard Sykes</a>
<p>
<a href="count2.html">The policy of Glaxo Wellcome on Pharmaceutical Counterfeiting</a>
<p>

</font>
<a href="../">Return to: Glaxo Wellcome world contents page</a>
<p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-5</DOCNO>
<DOCOLDNO>IA057-000937-B009-416</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/index.html 193.128.22.20 19970109081658 text/html 2704
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:07:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 2513
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome financial results</font></h1>
<hr size=4><br>

<h2><font size=6>Preliminary announcement of results for the 18 months to 31st December 1995</font></h1>

<font size=5><strong>Issued:</strong> March 6 1996, London<p>

Following the acquisition of Wellcome plc, the Company changed its financial year end from 30th June to 31st December and extended the current financial period by six months to 31st December 1995.  This review covers the 18 month period to 31st December 1995.</font></p>

<dl>
  <dt><a href="summary.html">Financial summary</a>
  <dt><a href="highl.html">Financial highlights</a>
  <dt><a href="placc1.html">Consolidated profit and loss account 1</a>
  <dt><a href="placc2.html">Consolidated profit and loss account 2</a>
  <dt><a href="cbs.html">Consolidated balance sheet</a>
  <dt><a href="ccfs.html">Consolidated cash flow statement</a>
  <dt><a href="trgl.html">Statement of total recognised gains and losses</a>
  <dt><a href="recon.html">Reconciliation of movements in equity shareholders' funds</a>
  <dt><a href="review/">Trading and financial review</a>
  <dt><a href="notes/">Notes on the preliminary results</a>
  <dt><a href="suppl/">Supplementary financial information</a>
</dl><p>
<hr><p>
<a href="../finance.html">Return to: Financial results contents page</a><p>

<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-6</DOCNO>
<DOCOLDNO>IA057-000937-B009-435</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/summary.html 193.128.22.20 19970109081712 text/html 4779
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:07:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 4588
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Financial Summary</font></h2>
<p>


<table border="1" cellpadding=2 cellspacing=2>
<tr><td colspan=3></td><th colspan=3>Calendar basis</th></tr>

<tr><td></td>
<th colspan=2>18 months to 31.12.95</th>
<td><em>Unaudited 12 months to 31.12.95</em></td>
<td><em>Unaudited 12 months to 31.12.94</em></td>
<td>Audited 12 months to 30.6.94</td>
</tr>

<tr><td></td>
<th>Glaxo Wellcome before integration<br> &#163;m</th>
<th>Total<br> &#163;m</th>
<td align=center><em>Glaxo Wellcome<br> &#163;m</em></th>
<td align=center><em>Glaxo<br> &#163;m</em></th>
<td align=center>Glaxo<br> &#163;m</td>
</tr>


<tr>
<td>Sales</td>
<th>10,490</th>	<th>10,490</th>	<td align=center><em>7,638</em></td> <td align=center><em>5,705</em></td>	<td align=center>5,656</td></tr>

<tr><td>Trading profit before integration costs</td>
<th>3,597</th>	<th>3,597</th>	<td align=center><em>2,581</em></td>	<td align=center><em>1,907</em></td>	<td align=center>1,817</td></tr>

<tr><td>Integration costs</td>
<th>-</th>       <th>(1,215)</th><td align=center><em>-</em></td>     <td align=center><em> -</em></td>       <td align=center>-</td></tr>

<tr><td>Trading profit after integration costs</td>
<th>3,597</th>	<th>2,382</th>	<td align=center><em>2,581</em></td>	<td align=center><em>1,907</em></td>	<td align=center>1,817</td></tr>

<tr><td>Net (interest payable)/investment income</td>
<th>(87)</th>	<th>(87)</th>	<td align=center><em>(136)</em></td>	<td align=center><em>(3)</em></td>       <td align=center>21</td></tr>

<tr><td>Profit before taxation</td>
<th>3,602</th>	<th>2,387</th>	<td align=center><em>2,505</em></td>	<td align=center><em>1,934</em></td>	<td align=center>1,835</td></tr>

<tr><td>Tax rate</td>
<th>30.5%</th>	<th>36.3%</th>	<td align=center><em>30.7%</em></td>	<td align=center><em>29.4%</em></td>  <td align=center>28.5%</td></tr>

<tr><td>Profit for the period/Net income</td>
<th>2,443</th>       <th>1,458</th>  <td align=center><em>1,702</em></td>	<td align=center><em>1,331</em></td>	<td align=center>1,299</td></tr>

<tr><td>Earnings per Ordinary Share</td>
<th>74.6p</th>	<th>44.5p</th>	<td align=center><em>50.3p</em></td>	<td align=center><em>43.6p</em></td>	<td align=center>42.7p</td></tr>

<tr><td>Dividends per Ordinary Share</td>
<th>45.0p</th>	<th>45.0p</th>	<td align=center><em>30.0p</em></td>	<td align=center><em>28.0p</em></td>	<td align=center>27.0p</td></tr>

</table><p>

The results for the 12 months to 30th June 1994 have been restated for the change of accounting policy described in <a href="notes/2.html">Note 2</a> on the Preliminary Results.<p>

In view of the change in financial year end from 30th June to 31st December, the results before integration for the 18 months to 31st December 1995 and the 12 months to 30th June 1994 have been presented on a calendar basis for both 1995 and 1994 to provide a more useful comparison of business performance.  The dividend shown for 1995 is two thirds of the total dividend for the 18 month period to 31st December 1995. The dividend shown for 1994 is the combination of the final dividend for the year to 30th June 1994 and the first interim dividend in respect of the six months to 31st December 1994.  <p>

<a href="highl.html">Forward to: Financial highlights</a><p>
<a href="index.html">Return to: Preliminary results contents page</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-7</DOCNO>
<DOCOLDNO>IA057-000937-B009-449</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/highl.html 193.128.22.20 19970109081722 text/html 3550
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:07:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 3359
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Financial highlights</font></h2>
<p>

<font size=5>The results are for the 18 months to 31st December 1995.  Wellcome is consolidated from 16th March 1995.</font><p>



<strong>Earnings</strong><br>
<ul type=blank>
<li>Earnings per share for the 18 months before integration costs were 74.6p, which compares with 42.7p for the 12 months to 30th June 1994.

<li>On a calendar year basis earnings per share for the 12 months to 31st December 1995 before integration costs were 50.3p.  This compares with earnings per share of 43.6p in calendar 1994 and represents an increase of 15%.
 </ul><p>

<strong>Integration</strong><br>
<ul type=blank>
<li> Integration plans have been finalised and integration remains on target.  Total estimated integration costs of &#163;1,215 million have been charged in the results to 31st December 1995.
 </ul><p>

 <strong>Sales</strong><br>
<ul type=blank>
<li> Sales on a pro forma basis in calendar 1995 (Glaxo and Wellcome combined from 1st January 1995) were &#163;7,973 million.  At constant exchange rates (CER), growth was 3%.
 
<li> Zantac sales were &#163;2,255 million, a decline of 4% at CER.  The decline was principally in the USA and Europe; in the Rest of the World volume growth was 10%.
 
<li> Excluding Zantac, sales growth was 7% at CER.  Sales of new products launched by Glaxo and Wellcome since 1990 grew by 43%, contributing &#163;407 million of growth - more than 3 times the decline in Zantac sales. 
 </ul><p>

<strong> Profit</strong><br>
<ul type=blank>
<li> Trading profit improved from 33.4% in calendar 1994 to 33.8% in calendar 1995.  Had certain non recurring expenses in 1995 been excluded, the trading margin in 1995 would have been 1% higher.
 </ul><p>

<strong> Dividend</strong><br>
 <ul type=blank>
<li>The Board is proposing a final dividend of 15p, producing a total of 45p for the 18 month period.
 </ul>
 <p>

<a href="placc1.html">Forward to: Consolidated profit and loss account 1</a><p>
<a href="summary.html">Back to: Financial summary</a><p>
<a href="index.html">Return to: Preliminary results contents page</a>
  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-8</DOCNO>
<DOCOLDNO>IA057-000937-B009-464</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/placc1.html 193.128.22.20 19970109081734 text/html 5480
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:07:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 5289
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Consolidated profit and loss account 1</font></h2>
<p>



<table border=2 cellpadding=2 cellspacing=2>

<tr><td></td><th colspan=3>18 months to 31.12.95</th><td rowspan=2 align=center>12 months to 30.6.94 (restated) <br>&#163;m</td></tr>
<tr><td></td><th>Combined business<br>&#163;m</th>
                  <th>Integration<br>&#163;m</th>
		      <th>Total<br>&#163;m</th></tr>


<tr><td>TURNOVER <a href="notes/14.html#turn">(14)</a></td><th>10,490</th>	<th>-</th>	<th>10,490</th>	        <td align=center>5,656</td></tr>
<tr><td>Operating costs <a href="notes/4.html">(4)</a></td>                <th>(6,893)</th> <th>-</th>	<th>(6,893)</th>	<td align=center>(3,839)</td></tr>
<tr><td>Integration costs <a href="notes/4.html#integ">(4)</a></td>               <th>-</th>	<th>(1,215)</th>	<th>(1,215)</th>	<td align=center>-</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>TRADING PROFIT <a href="notes/14.html">(14)</a></td>	                <th>3,597</th>	<th>(1,215)</th><th>2,382</th>	<td align=center>1,817</td></tr>
<tr><td>Profit on disposal of business <a href="notes/5.html">(5)</a></td>  <th>35</th>	<th>-</th>	<th>35</th>	<td align=center>-</td></tr>
<tr><td>Share of profits/(losses) of associated undertakings <a href="notes/6.html">(6)</a></td>		<th>57</th>	<th>-</th>	<th>57</th>	<td align=center>(3)</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>PROFIT BEFORE INTEREST</td>		                           <th>3,689</th>	<th>(1,215)</th><th>2,474</th>	<td align=center>1,814</td></tr>
<tr><td>Net (interest payable)/investment income <a href="notes/7.html">(7)</a></td>		<th>(87)</th>	<th>-</th>	<th>(87)</th>	<td align=center>21</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION <a href="notes/14.html">(14)</a></td>	 	<th>3,602</th>	<th>(1,215)</th><th>2,387</th>	<td align=center>1,835</td></tr>
<tr><td>Taxation <a href="notes/8.html">(8)</a></td>	                                              <th>1,097</th>	<th>(230)</th>	<th>867</th>	<td align=center>524</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES AFTER TAXATION</td>		     <th>2,505</th>	<th>(985)</th>	<th>1,520</th>	<td align=center>1,311</td></tr>
<tr><td>Minority interests</td>                                               <th>62</th>	<th>-</th>	<th>62</th>	<td align=center>12</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>		               <th>2,443</th>	<th>(985)</th>	<th>1,458</th>	<td align=center>1,299</td></tr>
<tr><td>Dividends <a href="notes/10.html">(10)</a></td>                                <th>1,530</th>	<th>-</th>	<th>1,530</th>	<td align=center>823</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>RETAINED PROFIT</td>		                                         <th>913</th>	<th>(985)</th>	<th>(72)</th>	<td align=center>476</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>EARNINGS PER ORDINARY SHARE <a href="notes/9.html">(9)</a></td>	  	<th>74.6p</th>	<td><br></td>	<th>44.5p</th>	<td align=center>42.7p</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>WEIGHTED AVERAGE NUMBER OF SHARES IN ISSUE (MILLIONS)</td>              <th>3,274</th>	<td><br></td>	<th>3,274</th>	<td align=center>3,040</td></tr>
<tr><td colspan=6></td></tr>
<tr><td>DIVIDENDS PER ORDINARY SHARE <a href="notes/10.html">(10)</a></td>	        <th>45.0p</th>	<td><br></td>	<th>45.0p</th>	<td align=center>27.0p</td></tr>

</table><p>


<strong>Note:</strong><br>

"Combined business" is analysed in the <a href="placc2.html">Consolidated profit and loss account 2</a><br>
"Integration" is the costs of integrating the Glaxo and Wellcome businesses.<br>
"Total" is combined business plus integration.<p>

For <a href="notes/">further notes</a> and financial information, follow the numbered links from the highlighted headings.<p>
<hr>

<a href="placc2.html">Forward to: Consolidated profit and loss account 2</a><p>
<a href="highl.html">Back to: Financial highlights</a><p>
<a href="index.html">Return to: Preliminary results contents page</a>
  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-9</DOCNO>
<DOCOLDNO>IA057-000937-B010-9</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/placc2.html 193.128.22.20 19970109081746 text/html 5488
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:07:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 5297
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Consolidated profit and loss account 2</font></h2>
<p>
<table border=1 cellpadding=2 cellspacing=2>
<tr><td></td>
  <td align=center colspan=2>12 months to 30.06.95</td>
  <td align=center>6 months to 31.12.95</td>
  <th>18 months to 31.12.95</th></tr>
  
<tr><td></td>
<td align=center>Glaxo continuing business<br>&#163;m</th>
    <td align=center>Acquisitions<br>&#163;m</td>
       <td align=center>Merged business<br>&#163;m</td>
<th>Combined business<br>&#163;m</th></tr>




<tr><td>TURNOVER <a href="notes/14.html#turn">(14)</a></td>	<td align=center>5,834</td>	<td align=center>638</td>	<td align=center>4,018</td>	<th>10,490</th></tr>
<tr><td>Operating costs <a href="notes/4.html">(4)</a></td>		<td align=center>(3,863)</td>	<td align=center>(438)</td>	<td align=center>(2,592)</td>	<th>(6,893)</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>TRADING PROFIT <a href="notes/14.html">(14)</a></td>		<td align=center>1,971</td>	<td align=center>200</td>	<td align=center>1,426</td>	<th>3,597</th></tr>
<tr><td>Profit on disposal of business <a href="notes/5.html">(5)</a></td>	<td align=center>35</td>	<td align=center>-</td>	<td align=center>-</td>	<th>35</th></tr>
<tr><td>Share of profits/(losses) of associated undertakings <a href="notes/6.html">(6)</a></td>		<td align=center>(8)</td>	<td align=center>26</td>	<td align=center>39</td>	<th>57</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>PROFIT BEFORE INTEREST</td>	<td align=center>1,998</td>	<td align=center>226</td> <td align=center>1,465</td>	<th>3,689</th></tr>
<tr><td>Net (interest payable)/investment income <a href="notes/7.html">(6)</a></td>		<td align=center>130</td>	<td align=center>(96)</td>	<td align=center>(121)</td>	<th>(87)</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</td>	<td align=center>2,128</td>	<td align=center>130</td>	<td align=center>1,344</td>	<th>3,602</th></tr>
<tr><td>Taxation</td>	<td align=center>627</td>	<td align=center>53</td>	<td align=center>417</td>	<th>1,097</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>PROFIT ON ORDINARY ACTIVITIES AFTER TAXATION</td>		<td align=center>1,501</td>	<td align=center>77</td>	<td align=center>927</td>	<th>2,505</th></tr>
<tr><td>Minority interests</td>	<td align=center>39</td>	<td align=center>5</td>	<td align=center>18</td>	<th>62</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>	<td align=center>1,462</td>	<td align=center>72</td>	<td align=center>909</td>	<th>2,443</th></tr>
<tr><td>Dividends <a href="notes/10.html">(10)</a></td><td align=center>1,004</td>	<td align=center>-</td>	<td align=center>526</td>	<th>1,530</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>RETAINED PROFIT</td>	<td align=center>458</td>	<td align=center>72</td>	<td align=center>383</td>	<th>913</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>EARNINGS PER ORDINARY SHARE <a href="notes/9.html">(9)</a></td>	<td align=center>47.8p</td><td align=center colspan=2><br></td><th>74.6p</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>WEIGHTED AVERAGE NUMBER OF SHARES IN ISSUE (MILLIONS)</td><td align=center>3,056</td><td align=center colspan=2><br></td>	<th>3,274</th></tr>
<tr><td colspan=6></td></tr>

<tr><td>DIVIDENDS PER ORDINARY SHARE <a href="notes/10.html">(10)</a></td><td align=center colspan=3><br></td>	<th>45.0p</th></tr>

    </table><p>


<strong>Note:</strong><br>

"Glaxo continuing business" is Glaxo alone for the 12 months to 30th June 1995.<br>

"Acquisitions" is Wellcome from 16th March 1995, and other acquisitions, to 30th June 1995.<br>

"Merged business" is the merged Glaxo and Wellcome business for the 6 months to 31st December 1995.<p>

For <a href="notes/">further notes</a> and financial information, follow the numbered links from the highlighted headings.<p>
<hr>

<a href="cbs.html">Forward to: Consolidated balance sheet</a><p>
<a href="placc1.html">Back to: Consolidated profit and loss account 1</a><p>
<a href="index.html">Return to: Preliminary results contents page</a>

  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-10</DOCNO>
<DOCOLDNO>IA057-000937-B010-31</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/cbs.html 193.128.22.20 19970109081759 text/html 4870
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:08:08 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:43 GMT
Content-length: 4679
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Consolidated balance sheet</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>

  <tr><td></td><th>At 31.12.95<br>&#163;m</th><th>At 30.6.94<br>(restated)<br>&#163;m</th></tr>

<tr><td colspan=4>FIXED ASSETS</td></tr>
<tr><td>Tangible assets <a href="notes/11.html">(11)</a></td>  <th>4,165</th>	<td align=center>3,184</td></tr>
<tr><td>Investments</td>		<th>96</th>	<td align=center>55</td></tr>
<tr><td colspan=3></td></tr>

<tr><td></td>			<th>4,261</th>	<td align=center>3,239</td></tr>

<tr><td colspan=4>CURRENT ASSETS</td></tr>
<tr><td>Stocks</td>		<th>811</th>	<td align=center>575</td></tr>
<tr><td>Debtors</td>	<th>2,045</th>	<td align=center>1,310</td></tr>
<tr><td>Asset for disposal</td>			<th>150</th>	<td align=center>-</td></tr>
<tr><td>Investments <a href="notes/12.html">(12)</a></td>		<th>1,041</th>	<td align=center>2,708</td></tr>
<tr><td>Cash at bank <a href="notes/12.html">(12)</a></td>		<th>233</th>	<td align=center>55</td></tr>
<tr><td colspan=3></td></tr>
<tr>		<td></td>	<th>4,280</th>	<td align=center>4,648</td></tr>

<tr><td colspan=4>CREDITORS:  Amounts due within one year</td></tr>
<tr><td>Loans and overdrafts <a href="notes/12.html">(12)</a></td>	<th>3,004</th><td align=center>400</td></tr>
<tr><td>Other creditors</td>			<th>2,462</th>	<td align=center>1,730</td></tr>
<tr><td colspan=3></td></tr>
<tr>		<td></td>	<th>5,466</th>	<td align=center>2,130</td></tr>
<tr><td>NET CURRENT (LIABILITIES)/ASSETS</td>		<th>(1,186)</th>	<td align=center>2,518</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>TOTAL ASSETS LESS CURRENT LIABILITIES</td>			<th>3,075</th>	<td align=center>5,757</td></tr>
<tr><td colspan=4>CREDITORS: Amounts due after one year</td></tr>
<tr><td>Loans <a href="notes/12.html">(12)</a></td>	<th>1,343</th>	<td align=center>143</td></tr>
<tr><td>Convertible bonds <a href="notes/12.html">(12)</a></td>	<th>123</th>	<td align=center>129</td></tr>
<tr><td>Other creditors</td>			<th>71</th>	<td align=center>26</td></tr>
<tr><td colspan=3></td></tr>
<tr>		<td></td><th>1,537</th>	<td align=center>298</td></tr>

<tr><td>PROVISIONS FOR LIABILITIES AND CHARGES <a href="notes/13.html">(13)</a></td>	<th>1,317</th>	<td align=center>310</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>NET ASSETS <a href="notes/14.html#assets">(14)</a></td>	<th>221</th>	<td align=center>5,149</td></tr>
<tr><td colspan=3></td></tr>
<tr><td colspan=4>CAPITAL AND RESERVES</td></tr>
<tr><td>Called up share capital	</td>		<th>876</th>	<td align=center>762</td></tr>
<tr><td>Share premium account</td>			<th>373</th>	<td align=center>229</td></tr>
<tr><td>Goodwill reserve</td>		<th>(5,197)</th>	<td align=center>-</td></tr>
<tr><td>Other reserves	</td>		<th>4,039</th>	<td align=center>4,035</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>EQUITY SHAREHOLDERS' FUNDS</td>		<th>91</th>	<td align=center>5,026</td></tr>
<tr><td>EQUITY MINORITY INTERESTS</td>		<th>130</th>	<td align=center>123</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>CAPITAL EMPLOYED</td>			<th>221</th>	<td align=center>5,149</td></tr>

</table><p>

For <a href="notes/">further notes</a> and financial information, follow the numbered links from the highlighted headings.<p>
<hr>

<a href="ccfs.html">Forward to: Consolidated cash flow statement</a><p>
<a href="placc2.html">Back to: Consolidated profit and loss account 2</a><p>
<a href="index.html">Return to: Preliminary results contents page</a>
  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-11</DOCNO>
<DOCOLDNO>IA057-000937-B010-46</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/ccfs.html 193.128.22.20 19970109081817 text/html 5630
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:08:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 5439
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Consolidated cash flow statement</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>
 <tr><td></td><th>18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 31.06.94<br>&#163;m</td></tr>
<tr><td>NET CASH INFLOW FROM OPERATING ACTIVITIES <a href="notes/15.html#inflow">(15)</a></td>	<th>3,835</th>	<td align=center>2,145</td></tr>
<tr><td colspan=3>RETURNS ON INVESTMENTS AND SERVICING OF FINANCE</td></tr>
<tr><td>Interest received</td>	<th>291</th>	<td align=center>168</td></tr>
<tr><td>Interest paid</td>		<th>(288)</th>	<td align=center>(42)</td></tr>
<tr><td>Costs of financing</td>		<th>(9)</th>	<td align=center>-</td></tr>
<tr><td>Losses on investment activities</td>		<th>(1)</th>	<td align=center>-</td></tr>
<tr><td>Dividends received from associated undertakings</td>		<th>39</th>	<td align=center>-</td></tr>
<tr><td>Dividends paid to ordinary shareholders</td>		<th>(1,508)</th>	<td align=center>(698)</td></tr>
<tr><td>Dividends paid to minority shareholders</td>		<th>(17)</th>	<td align=center>(7)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>NET CASH OUTFLOW FROM RETURNS ON INVESTMENTS AND SERVICING OF FINANCE</td>		<th>(1,493)</th>	<td align=center>(579)</td></tr>
<tr><td>TAXATION PAID</td>		<th>(1,070)</th>	<td align=center>(513)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td colspan=3>INVESTING ACTIVITIES</td></tr>
<tr><td>Purchase of tangible fixed assets</td>	<th>(684)</th>	<td align=center>(575)</td></tr>
<tr><td>Sale of tangible fixed assets</td>		<th>61</th>	<td align=center>22</td></tr>
<tr><td>Purchase of fixed asset investments</td>		<th>(35)</th>	<td align=center>(4)</td></tr>
<tr><td>Sale of fixed asset investments</td>		<th>37</th>	<td align=center>-</td></tr>
<tr><td>Purchase of subsidiary undertakings <a href="notes/15b.html#subs">(15)</a></td><th>(6,187)</th>	<td align=center>(2)</td></tr>
<tr><td>Disposal of businesses <a href="notes/15b.html#disp">(15)</a></td>	<th>132</th>	<td align=center>-</td></tr>
<tr><td>Other movements	</td>	<th>-</th>	<td align=center>4</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Net cash outflow on fixed assets</td>	<th>(6,676)</th>	<td align=center>(555)</td></tr>
<tr><td>Purchase of non cash equivalent current asset investments</td>		<th>(5,974)</th>	<td align=center>(12,849)</td></tr>
<tr><td>Sale of non cash equivalent current asset investments	</td>	<th>8,044</th>	<td align=center>12,041</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>NET CASH OUTFLOW FROM INVESTING ACTIVITIES</td>	<th>(4,606)</th>	<td align=center>(1,363)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>NET CASH OUTFLOW BEFORE FINANCING</td>		<th>(3,334)</th>	<td align=center>(310)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td colspan=3>FINANCING</td></tr>
<tr><td>Issue of Ordinary Share capital</td>		<th>106</th>	<td align=center>51</td></tr>
<tr><td>New long term loans</td>		<th>8,424</th>	<td align=center>-</td></tr>
<tr><td>Repayment of long term loans</td>		<th>(7,290)</th>	<td align=center>-</td></tr>
<tr><td>New short term loans</td>		<th>11,298</th>	<td align=center>1,638</td></tr>
<tr><td>Repayment of short term loans</td>		<th>(8,697)</th>	<td align=center>(1,650)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>NET CASH INFLOW FROM FINANCING</td>		<th>3,841</th>	<td align=center>39</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS <a href="notes/15.html#cequiv">(15)</a></td>  <th>507</th>	<td align=center>(271)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>INCREASE IN NET (DEBT)/FUNDS <a href="notes/15.html#funds">(15)</a></td> <th>(5,287)</th>	<td align=center>403</td></tr>
</table><p>

The reconciliation between the increase/(decrease) in cash & cash equivalents and the increase in net (debt)/funds is set out in <a href="notes/15.html">Note 15</a>.<p>

For <a href="notes/">further notes</a> and financial information, follow the numbered links from the highlighted headings.<p>
<hr>

<a href="trgl.html">Forward to: Statement of total recognised gains and losses</a><p>
<a href="cbs.html">Back to: Consolidated balance sheet</a><p>
<a href="index.html">Return to: Preliminary results contents page</a>
  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-12</DOCNO>
<DOCOLDNO>IA057-000937-B010-69</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/trgl.html 193.128.22.20 19970109081843 text/html 2424
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:08:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:50 GMT
Content-length: 2233
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Statement of total recognised gains and losses</font></h2>


<table border=2 cellpadding=2 cellspacing=2>


<tr><td></td><th>18 months to 31.12.95<br>&#163;m</th>
    <td align=center>12 months to 30.6.94 (restated)<br>&#163;m</td></tr>
   
<tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>	<th>1,458</th>	<td align=center>1,299</td></tr>
<tr><td>Exchange adjustments</td>		<th>76</th>	<td align=center>(61)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>TOTAL RECOGNISED GAINS AND LOSSES FOR THE PERIOD</td>		<th>1,534</th>	<td align=center>1,238</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Prior period adjustment</td>		<th>(17)</th> <td rowspan=3><br>
</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>TOTAL GAINS AND LOSSES RECOGNISED SINCE 30TH JUNE 1994</td>	<th>1,517</th></tr>

</table>
<p>


<a href="recon.html">Forward to: Reconciliation of movements in equity shareholders' funds</a><p>
<a href="ccfs.html">Back to: Consolidated cash flow statement</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-13</DOCNO>
<DOCOLDNO>IA057-000937-B010-86</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/recon.html 193.128.22.20 19970109081855 text/html 3421
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:09:08 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 3230
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Reconciliation of movements in equity shareholders' funds</font></h2>

<table border=2 cellpadding=2 cellspacing=2>
<tr><td></td><th>18 months to 31.12.95<br>&#163;m</th>
    <td align=center>12 months to 30.6.94 (restated)<br>&#163;m</td></tr>
  
<tr><td>At beginning of period as previously stated</td><th>5,043</th>	<td align=center>4,546</td></tr>
<tr><td>Prior period adjustment</td>	<th>(17)</th>	<td align=center>	(14)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>At beginning of period restated</td>	<th>5,026</th>	<td align=center>	4,532</td></tr>
<tr><td>Total recognised gains and losses for the period</td>	<th>1,534	</th>	<td align=center>1,238</td></tr>
<tr><td>Dividends</td>	<th>(1,530)</th>	<td align=center>	(823)</td></tr>
<tr><td colspan=3>Ordinary Shares issued:</td></tr>
<tr><td>	Ordinary Shares issued on acquisition of Wellcome plc</td>	<th>107</th>	<td align=center> -</td></tr>
<tr><td>	Merger reserve arising on acquisition of Wellcome plc</td>	<th>2,834	</th>	<td align=center>-</td></tr>
<tr><td>Ordinary Shares issued under share option schemes</td>	<th>106</th>	<td align=center>	51</td></tr>
<tr><td>	Ordinary Shares issued in lieu of cash dividends</td>	<th>45</th>	<td align=center>	31</td></tr>
<tr><td>Goodwill arising during the period</td>	<th>(8,031)</th>	<td align=center>	(3)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>At end of period</td>	<th>91</th>	<td align=center>5,026</td></tr>

</table> <p>
   
&#163;2,834 million of the goodwill arising on the acquisition of Wellcome plc has been applied against the merger reserve created on the acquisition of Wellcome plc.  The balance of goodwill arising during the period of &#163;5,197 million has been established as a goodwill reserve.<p>


<a href="review/">Forward to: Trading and financial review</a><p>
<a href="trgl.html">Back to: Statement of total recognised gains and losses</a><p>
<a href="index.html">Return to: Preliminary results contents page</a>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-14</DOCNO>
<DOCOLDNO>IA057-000937-B010-103</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/ 193.128.22.20 19970109081906 text/html 2609
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:09:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 2418
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Trading and financial review</font></h2>

<font size=5></font>
 

Following the acquisition of Wellcome plc, the Company changed its financial year end from 30th June to 31st December and extended the current financial period by six months to 31st December 1995.  This review covers the 18 month period to 31st December 1995.</font><p>

<dl>
  <dt><a href="1.html">Financial summary</a>
  <dt><a href="2.html">Trading profit</a>
  <dt><a href="3.html">Profit before interest</a>
  <dt><a href="4.html">Interest payable</a>
  <dt><a href="5.html">Taxation</a>
  <dt><a href="6.html">Earnings and dividends</a>
  <dt><a href="7.html">Balance sheet</a>
  <dt><a href="8.html">Net debt</a>
  <dt><a href="9.html">Cash flow and liquidity</a>
  <dt><a href="10.html">Pro forma sales</a>
  <dt><a href="11.html">Sales by theraputic area</a>
  <dt><a href="12.html">Sales by geographic area</a>
</dl><p>
<hr><p>
<a href="../notes/">Forward to: Notes on the preliminary results</a><p>
<a href="../recon.html">Back to: Reconciliation of movements in equity shareholders funds</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-15</DOCNO>
<DOCOLDNO>IA057-000937-B010-120</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/ 193.128.22.20 19970109081919 text/html 2521
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:09:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 2330
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Notes on the preliminary results</font></h2>

<ol>
  <li><a href="1.html">General</a>
  <li><a href="2.html">Accounting policies</a>
  <li><a href="3.html">Exchange rates</a>
  <li><a href="4.html">Operating costs</a>
  <li><a href="5.html">Profit on disposal of business</a>
  <li><a href="6.html">Share of profits/(losses) of associated undertakings</a>
  <li><a href="7.html">Net (interest payable)/investment income</a>
  <li><a href="8.html">Taxation</a>
  <li><a href="9.html">Earnings per Ordinary Share</a>
  <li><a href="10.html">Dividends</a>
  <li><a href="11.html">Tangible fixed assets</a>
  <li><a href="12.html">Net (debt)/funds</a>
  <li><a href="13.html">Provisions for liabilities and charges</a>
  <li><a href="14.html">Segment information</a>
  <li><a href="15.html">Consolidated cash flow statement</a>  
</ol><p>
<hr><p>
<a href="../suppl/">Forward to: Supplementary financial information</a><p>
<a href="../review/">Back to: Trading and financial review</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-16</DOCNO>
<DOCOLDNO>IA057-000937-B010-188</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/suppl/ 193.128.22.20 19970109082032 text/html 3291
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:10:33 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 3100
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Supplementary financial information</font></h2>
<p>
<font size=5>In view of the change in financial year end from 30th June to 31st December and the effect of the acquisition of Wellcome plc, the financial information set out below has been prepared to indicate the results of Glaxo Wellcome on a calendar year basis, so as to provide comparative data for the 1996 financial year.  The information is presented on statutory and pro forma bases.</font><p>
  

<dl>
<dt><a href="stat.html">Statutory basis</a>
<dd>The results of Glaxo Wellcome for calendar years 1995 and 1994.  In 1995 Wellcome is consolidated from its date of acquisition on 16th March 1995.  The 1994 results represent Glaxo alone.<p>


<dt><a href="prof.html">Pro forma basis</a>
<dd>The combined pro forma results of Glaxo and Wellcome for calendar year 1995 on a consistent basis of presentation as if Glaxo Wellcome had existed as a combined entity from 1st January 1995.<p>


<dt><a href="sales.html">Pro forma sales</a>
<dd>The combined pro forma sales of Glaxo and Wellcome, with respect to the criteria mentioned above.
</dl><p>
<hr>
Notes:
<ol>
  <li>Adjustments have been made to the Wellcome results:<br>
      <ul type=blank><li>to reflect Glaxo accounting policies 
      <li>to incorporate at 1st January 1995 the fair value adjustments implemented as of 16th March 1995.</ul>
<li> The Wellcome exceptional item of &#163;27 million in respect of bid defence costs in the six months to 30th June 1995 has been excluded.
<li>The costs of financing the acquisition have been reflected from 1st January 1995.
<li>The costs of integrating the Glaxo and Wellcome businesses have been excluded.
</ol><p>
<hr>


<a href="../review/">Back to: Notes on the preliminary results</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-17</DOCNO>
<DOCOLDNO>IA057-000937-B021-6</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/2.html 193.128.22.20 19970109100005 text/html 3009
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:50:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:45 GMT
Content-length: 2818
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>2. Accounting policies</font></h2>
<p>

  
<font size=5>The Preliminary Results have been prepared in accordance with the Company's accounting policies, which, except for the change of accounting policy described below, are as set out in the Annual Report and Accounts for the year to 30th June 1994.</font><p>


In accordance with Urgent Issues Task Force Abstract 6, the accounting policy for post retirement benefits other than pensions provided for employees has been changed with effect from 1st July 1994.  The cost of such benefits, principally post retirement healthcare, is now recognised on an accruals basis over the working life of employees, whereas in prior years the cost was accounted for on a cash basis after employees had retired.  The cumulative adjustment in respect of the accrued cost at 1st July 1994, net of deferred taxation relief, amounts to &#163;17 million and has been charged directly against reserves as a prior year adjustment.  The comparative figures for the 12 months to 30th June 1994 have been restated: the effect on the results of that period is to reduce trading profit by &#163;5 million and taxation by &#163;1 million.  The effect on the results for the 18 months to 31st December 1995 is to reduce trading profit before integration costs by &#163;13 million, increase integration costs by &#163;30 million and reduce taxation by &#163;14 million.<p>


<a href="3.html">Forward to: Exchange rates</a><p>
<a href="1.html">Back to: General</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-18</DOCNO>
<DOCOLDNO>IA057-000937-B021-19</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/14.html 193.128.22.20 19970109100027 text/html 5765
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:50:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:45 GMT
Content-length: 5574
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>14. Segment information</font></h2>
<p>

 <font size=5>The Group continues to operate in a single business segment.  	An analysis of turnover, profit before taxation and net assets by geographical segment is set out below. </font><p>


 The Group's activities are organised on a worldwide basis.  The segmental figures are therefore influenced by the location of the Group's operating resources and by variations over time in intra group trading and funding arrangements.  Comparative figures for 1994 have been restated for the change in accounting policy described in <a href="2.html">Note 2</a> and to reflect the current presentation of net assets.<p>


<a name="turn">  
<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>(restated)<br>&#163;m</td></tr>

  <tr><th align=left colspan=3>Turnover by location of customer:</th> </tr>

  <tr><td>USA</td>    <th>4,408</th>    <td align=center>2,459</td>    </tr>
  <tr><td>Europe</td>    <th>3,618</th>    <td align=center>1,978</td>    </tr>
  <tr><td>Rest of the World</td>    <th>2,464</th>    <td align=center>1,219</td>    </tr>
  
<tr><td colspan=3></td></tr>
  <tr><td>External turnover</td>    <th>10,490</th>    <td align=center>5,656</td>    </tr>
<tr><td colspan=3></td></tr>

  <tr><th align=left colspan=3>Turnover by location of subsidiary undertaking:</th>  </tr>

  <tr><td>USA</td>    <th>4,329</th>    <td align=center>2,475</td>    </tr>
  <tr><td>Europe</td>    <th>5,33</th>    <td align=center>3,027</td>    </tr>
  <tr><td>Rest of the World</td>    <th>3,210</th>    <td align=center>1,630</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Gross turnover</td>    <th>12,872</th>    <td align=center>7,132</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><th align=left colspan=3>Inter segment turnover:</th>   </tr>

  <tr><td>USA</td>    <th>(29)</th>    <td align=center>(20)</td>    </tr>
  <tr><td>Europe</td>    <th>(1,562)</th>    <td align=center>(984)</td>    </tr>
  <tr><td>Rest of the World</td>    <th>(791)</th>    <td align=center>(472)</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>External turnover</td>    <th>10,490</th>    <td align=center>5,656</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><th align=left colspan=3>Profit before taxation by location of subsidiary undertaking:</th>    </tr>

  <tr><td>USA</td>    <th>1,447</th>    <td align=center>723</td>    </tr>
  <tr><td>Europe</td>    <th>1,217</th>    <td align=center>586</td>    </tr>
  <tr><td>Rest of the World</td>    <th>933</th>    <td align=center>508</td>

  <tr><td>Trading profit before integration costs</td>    <th>3,597</th>    <td align=center>1,817</td>    </tr>
  <tr><td>Integration costs</td>    <th>(1,215)</th>    <td align=center>-</td>    </tr>
  <tr><td>Profit on disposal of business</td>    <th>35</th>    <td align=center>-</td>    </tr>
  <tr><td>Share of profits/(losses) of associated undertakings</td>    <th>57</th>    <td align=center>(3)</td>    </tr>
  <tr><td>Net (interest payable)/investment income</td>    <th>(87)</th>    <td align=center>21</td>    </tr>
<tr><td colspan=3></td></tr>
<a name="profit">
  <tr><td>Profit before taxation</td>    <th>2,387</th>    <td align=center>1,835</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><th align=left colspan=3>Net assets:</th></tr>

  <tr><td>USA</td>    <th>516</th>    <td align=center>524</td>    </tr>
  <tr><td>Europe</td>    <th>2,463</th>    <td align=center>1,663</td>    </tr>
  <tr><td>Rest of the World</td>    <th>1,094</th>    <td align=center>871</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Net operating assets</td>    <th>4,073</th>    <td align=center>3,058</td>    </tr>
  <tr><td>Provisions for integration costs (net of taxation)</td>    <th>(656)</th>    <td align=center>-</td>    </tr>
  <tr><td>Net (debt)/funds</td>    <th>(3,196)</th>    <td align=center>2,091</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Net assets</td>    <th>221</th>    <td align=center>5,149</td>    </tr>
</table><a name="assets"><p>


  
<a href="15.html">Forward to: Consolidated cash flow statement</a><p>
<a href="13.html">Back to: Provisions for liabilities and charges</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-19</DOCNO>
<DOCOLDNO>IA057-000937-B021-36</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/4.html 193.128.22.20 19970109100048 text/html 3420
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:50:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:46 GMT
Content-length: 3229
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>4. Operating costs</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>

  <tr><td></td><th colspan=6>18 months to 31.12.95</th><td align=center>12 months to<br>30.6.94<br>
 (restated)</td></tr>
  <tr><td></td><th>Glaxo continuing business<br>&#163;m</th>
  <th>Acquisitions<br>&#163;m</th>
  <th>Merged business<br>&#163;m</th>
  <th>Combined business<br>&#163;m</th>
  <th>Integration<br>&#163;m</th>
  <th>Total<br>&#163;m</th>
  <td align=center>&#163;m</td></tr>

  
<tr><td>Cost of sales</td><th>	1,037</th><th>	115	</th><th>654	</th><th>1,806</th><th>	558	</th><th>2,364	</th><td align=center>1,004</td></tr>
<tr><td>S,G&amp;A</td><th>	1,986	</th><th>227	</th><th>1,368	</th><th>3,581	</th><th>400	</th><th>3,981</th><td align=center>	1,988</td></tr>
<tr><td>R&amp;D</td><th>852	</th><th>103</th><th>585</th><th>1,540</th><th>257</th><th>1,797</th><td align=center>858</td></tr>
<tr><td>Other operating income</td></th> <th>(12)</th><th>(7)</th><th>(15)</th><th>(34)</th><th>-</th><th>(34)</th><td align=center>(11)</td></tr>
<tr><td colspan=8></td></tr>
<tr><td>Operating costs</td><th>3,863</th><th>438</th><th>2,592</th><th>6,893</th><th>1,215</th><th>8,108</th><td align=center>3,839</td></tr>


<caption align=bottom>S,G&amp;A= Selling, general and administrative expenditure.<br>R&amp;D = Research and development expenditure.</caption></table><p>

<a name="integ">
Costs expected to be incurred in integrating the businesses of Glaxo and Wellcome are estimated at &#163;1,215 million, comprising severances and other cash costs of &#163;763 million and losses on disposal of fixed assets of &#163;452 million.  Costs of &#163;384 million had been incurred by 31st December 1995 and provision for further costs of &#163;831 million has been made at that date.<p>

<a href="5.html">Forward to: Profit on disposal of business</a><p>
<a href="3.html">Back to: Exchange rates</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-20</DOCNO>
<DOCOLDNO>IA057-000937-B021-59</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/5.html 193.128.22.20 19970109100108 text/html 2021
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:51:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:46 GMT
Content-length: 1830
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>5. Profit on disposal of business</font></h2>
<p>
<font size=5>Glaxo India Limited sold its foods division on 30th September 1994.  The profit on disposal was &#163;35 million; the taxation and minority interest attributable to the disposal were &#163;7 million and &#163;14 million  respectively; the Group share of the profit was &#163;14 million.</font><p>



<a href="6.html">Forward to: Share of profits/(losses) of associated undertakings</a><p>
<a href="4.html">Back to: Operating costs</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-21</DOCNO>
<DOCOLDNO>IA057-000937-B021-76</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/6.html 193.128.22.20 19970109100121 text/html 2155
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:51:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:46 GMT
Content-length: 1964
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>6. Share of profits/(losses) of associated undertakings</font></font></h2>

<table border=2 cellpadding=2 cellspacing=2>
<tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>

<tr><td>	Warner Wellcome</td><th>				74	</th><td align=center>-</td></tr>
<tr><td>	Glaxo Warner-Lambert	</td><th>			(17)	</th><td align=center>(3)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td><br></td><th>57</th><td align=center>(3)</td></tr>
</table><p>



<a href="7.html">Forward to: Net (interest payable)/investment income</a><p>
<a href="5.html">Back to: Profit on disposal of business</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-22</DOCNO>
<DOCOLDNO>IA057-000937-B021-89</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/7.html 193.128.22.20 19970109100129 text/html 2590
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:51:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:46 GMT
Content-length: 2399
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>7. Net (interest payable)/investment income</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
<tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>
<tr><td>Interest payable</td><th>		337</th><td align=center>	44</td></tr>
<tr><th align=left colspan=3>	Investment income:</th></tr>
<tr><td>	Interest income</td><th>		265</th><td align=center>	180</td></tr>
<tr><td>	Realised losses and market value adjustments	</td><th>	(15)	</th><td align=center>(115)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td><br></td><th>250</th><td align=center>65</td></tr>
<tr><td colspan=3></td></tr>
<tr><td><br></td><th>(87)</th><td align=center>21</td></tr>
</table><p>
	
The analysis of net interest payable for the 18 months to 31st December 1995 between continuing business, acquisitions and merged business is shown on the face of the consolidated profit and loss account.
<p>

  
<a href="8.html">Forward to: Taxation</a><p>
<a href="6.html">Back to: Share of profits/(losses) of associated undertakings</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-23</DOCNO>
<DOCOLDNO>IA057-000937-B021-104</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/8.html 193.128.22.20 19970109100141 text/html 2337
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:51:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:46 GMT
Content-length: 2146
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>8. Taxation</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>(restated)<br>&#163;m</td></tr>

  <tr><td>UK</td>    <th>421</th>    <td align=center>269</td>    </tr>
  <tr><td>Overseas taxation</td>    <th>660</th>    <td align=center>311</td>    </tr>
  <tr><td>Deferred taxation</td>    <th>(251)</th>    <td align=center>(56)</td>    </tr>
  <tr><td>Irrecoverable Advance Corporation Tax</td>    <th>37</th>    <td align=center>-</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td><br></td>    <th>867</th>    <td align=center>524</td>    </tr>
  </table><p>


  
<a href="9.html">Forward to: Earnings per Ordinary Share</a><p>
<a href="7.html">Back to: Net (interest payable)/investment income</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-24</DOCNO>
<DOCOLDNO>IA057-000937-B021-119</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/10.html 193.128.22.20 19970109100153 text/html 2514
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:52:05 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 2323
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>10. Dividends</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>

  <tr><td>First Interim<br>10.0p per Ordinary Share (1994 - 9.0p)	</td>    <th>306</th>    <td align=center>274</td>    </tr>
  <tr><td>Second Interim<br>20.0p per Ordinary Share (1994 - nil)</td>    <th>698</th>    <td align=center>-</td>    </tr>
  <tr><td>Final - proposed<br>15.0p per Ordinary Share (1994 - 18.0p)</td>    <th>526</th>    <td align=center>549</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td><br></td>    <th>1,530</th>    <td align=center>823</td>    </tr>
  
  
  </table><p>

The first interim dividend was paid on 10th April 1995 and the second interim dividend on 23rd October 1995.  The proposed final dividend is payable on 20th May 1996.<p>

  
<a href="11.html">Forward to: Tangible fixed assets</a><p>
<a href="9.html">Back to: Earnings per Ordinary Share</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-25</DOCNO>
<DOCOLDNO>IA057-000937-B021-135</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/9.html 193.128.22.20 19970109100214 text/html 3317
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:52:27 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:46 GMT
Content-length: 3126
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>9. Earnings per Ordinary Share</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>Pence</th><td align=center>12 months to 30.6.94<br>(restated)<br>Pence</td></tr>

  <tr><td>Earnings per Ordinary Share</td>    <th>44.5</th>    <td align=center>42.7</td>    </tr>
  <tr><td>Adjustment in respect of integration</td>    <th>30.1</th>    <td align=center>-</td>    </tr>
  <tr><td>Earnings per Ordinary Share before integration</td>    <th>74.6</th>    <td align=center>42.7</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Weighted average number of shares in issue (millions)</td>    <th>3,274</th>    <td align=center>3,040</td>    </tr>
  
  </table><p>

The earnings per Ordinary Share of 44.5p has been calculated by dividing the profit attributable to shareholders of &#163;1,458 million by the weighted average number of shares in issue during the 18 months to 31st December 1995.  Earnings per Ordinary Share is also shown calculated by reference to earnings before integration costs and related taxation in order to provide an indication of continuing business performance.<p>

The earnings per Ordinary Share is not materially different in either financial period when calculated on a fully diluted basis.  <p>

Earnings per Ordinary Share as shown on the face of the consolidated profit and loss account - 2 for the Glaxo continuing business for the 12 months to 30th June 1995 has been calculated by dividing the profit attributable to shareholders for that period of &#163;1,462 million by 3,056 million, the weighted average number of shares in issue during that period excluding shares issued on the acquisition of Wellcome plc.<p>

  
<a href="10.html">Forward to: Dividends</a><p>
<a href="8.html">Back to: Taxation</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-26</DOCNO>
<DOCOLDNO>IA057-000937-B021-153</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/11.html 193.128.22.20 19970109100241 text/html 2531
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:52:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 2340
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>11. Tangible fixed assets</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>

  <tr><td>Net book value at beginning of period</td>    <th>3,184</th>    <td align=center>2,959</td>    </tr>
  <tr><td>Exchange adjustments</td>    <th>44</th>    <td align=center>(21)</td>    </tr>
  <tr><td>Additions</td>    <th>634</th>    <td align=center>543</td>    </tr>
  <tr><td>Acquisition of subsidiary undertakings</td>    <th>936</th>    <td align=center>2</td>    </tr>
  <tr><td>Depreciation</td>    <th>(533)</th>    <td align=center>(282)</td>    </tr>
  <tr><td>Disposals</td>    <th>(100)</th>    <td align=center>(17)</td>    </tr>

  <tr><td colspan=3></td></tr>
  <tr><td>Net book value at end of period</td>    <th>4,165</th>    <td align=center>3,184</td>    </tr>

</table><p>


  
<a href="12.html">Forward to: Net (debt)/funds</a><p>
<a href="10.html">Back to: Dividends</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-27</DOCNO>
<DOCOLDNO>IA057-000937-B021-192</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/12.html 193.128.22.20 19970109100329 text/html 4099
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:53:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 3908
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>12. Net (debt)/funds</font></h2>
<p>
<font size=5>As the Group is now in a net debt position, net liquid funds at 30th June 1994 have been restated to include all debt.</font><p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th>At 31.12.95<br>&#163;m</th><td align=center>At 30.6.94<br>(restated)<br>&#163;m</td></tr>

  <tr><td>Current asset investments</td>    <th>1,041</th>    <td align=center>2,708</td>    </tr>
  <tr><td>Cash at bank</td>    <th>233</th>    <td align=center>55</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>1,274</th>    <td align=center>2,763</td>    </tr>
  <tr><td colspan=3></td></tr>

  
  <tr><td colspan=3>Loans and overdrafts due within one year:</td></tr>
  <tr><td>Bank loans and overdrafts</td>    <th>(437)</th>    <td align=center>(322)</td>    </tr>
  <tr><td>Commercial paper</td>    <th>(2,566)</th>    <td align=center>(75)</td>    </tr>
  <tr><td>Other loans</td>    <th>(1)</th>    <td align=center>(3)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>(3,004)</th>    <td align=center>(400)</td>    </tr>
  <tr><td colspan=3></td></tr>

  
  <tr><td colspan=3>Loans due after one year:</td>    </tr>
  <tr><td>Bank loans</td>    <th>(105)</th>    <td align=center>(122)</td>    </tr>
  <tr><td>8.75% Unsecured sterling Euro Bond</td>    <th>(496)</th>    <td align=center>-</td>    </tr>
  <tr><td>6.75% Unsecured US$ Euro Note 2000</td>    <th>(321)</th>    <td align=center>-</td>    </tr>
  <tr><td>Other loans</td>    <th>(421)</th>    <td align=center>(21)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>1,343</th>    <td align=center>(143)</td>    </tr>
  <tr><td colspan=3></td></tr>
  
  <tr><td>Convertible bonds</td>    <th>(123)</th>    <td align=center>(129)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td>Net (debt)/funds</td>    <th>(3,196)</th>    <td align=center>2,091</td>    </tr>
  <tr><td colspan=3></td></tr>
  
  <tr><td colspan=3>of which cash & cash equivalents were:</td></tr>
  <tr><td>Current asset investments</td>    <th>674</th>    <td align=center>438</td>    </tr>
  <tr><td>Cash at bank</td>    <th>233</th>    <td align=center>55</td>    </tr>

  <tr><td>Loans and overdrafts due within one year</td>    <th>(207)</th>    <td align=center>(305)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td><br></td>    <th>700</th>    <td align=center>188</td>    </tr>
  </table><p>


 
<a href="13.html">Forward to: Provisions for liabilities and charges</a><p>
<a href="11.html">Back to: Tangible fixed assets</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-28</DOCNO>
<DOCOLDNO>IA057-000937-B021-203</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/13.html 193.128.22.20 19970109100339 text/html 1871
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:53:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:45 GMT
Content-length: 1680
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>13. Provisions for liabilities and charges</font></h2>
<p>

  
<font size=5>Included in provisions for liabilities and charges is a provision of &#163;831 million for the costs of integrating the businesses of Glaxo and Wellcome.</font><p>



<a href="14.html">Forward to: Segment information</a><p>
<a href="12.html">Back to: Net (debt)/funds</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-29</DOCNO>
<DOCOLDNO>IA057-000937-B021-214</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/15.html 193.128.22.20 19970109100350 text/html 6573
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:53:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:45 GMT
Content-length: 6382
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>15. Consolidated cash flow statement</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>

<tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>(restated)<br>&#163;m</td></tr>

<tr><th align=left colspan=3>Reconciliation of trading profit to net<br>cash inflow from operating activities:</th></tr>
  
  <tr><td>Trading profit excluding integration costs</td>    <th>3,597</th>    <td align=center>1,817</td>    </tr>
  <tr><td>Depreciation</td>    <th>533</th>    <td align=center>282</td>    </tr>
  <tr><td>Loss/(profit) on sale of tangible fixed assets</td>    <th>8</th>    <td align=center>(4)</td>    </tr>
  <tr><td>Decrease in stocks</td>    <th>8</th>    <td align=center>5</td>    </tr>
  <tr><td>(Increase)/decrease in debtors</td>    <th>(291)</th>    <td align=center>8</td>    </tr>
  <tr><td>Increase in creditors</td>    <th>163</th>    <td align=center>39</td>    </tr>
  <tr><td>Increase/(decrease) in pension and other provisions</td>    <th>74</th>    <td align=center>(2)</td>    </tr>
  <tr><td>Other movements</td>    <th>12</th>    <td align=center>-</td>    </tr>
<tr><td colspan=3></td></tr>

<a name="inflow">
  <tr><td>Net cash inflow from operating activities
      excluding integration costs</td>    <th>4,104</th>    <td align=center>2,145</td>    </tr>
  <tr><td>Integration costs paid</td>    <th>(269)</th>    <td align=center>-</td>    </tr>
<tr><td colspan=3></td></tr>
  
  <tr><td>Net cash inflow from operating activities</td>    <th>3,835</th>    <td align=center>2,145</td>    </tr>
<tr><td colspan=3></td></tr>
  
   <tr><th align=left colspan=3>Financing</th></tr>
  <tr><td>Balance at beginning of the period</td>    <th>1,358</th>    <td align=center>1,279</td>    </tr>
  <tr><td>Net cash inflow from financing</td>    <th>3,841</th>    <td align=center>39</td>    </tr>
  <tr><td>Ordinary Shares issued in lieu of cash dividends</td>    <th>45</th>    <td align=center>31</td>    </tr>
   <tr><td>Ordinary Shares issued on acquisition of Wellcome plc</td>    <th>2,941</th>    <td align=center>-</td>    </tr>
  <tr><td>Goodwill applied against merger reserve</td>    <th>(2,834)</th>    <td align=center>-</td>    </tr>
  <tr><td>Net non cash equivalents of subsidiary undertakings acquired</td>    <th>129</th>    <td align=center>1</td>    </tr>
  <tr><td>Exchange adjustments</td>    <th>18</th>    <td align=center>8</td>    </tr>
   <tr><td>Other movements</td>    <th>14</th>    <td align=center>-</td>    </tr>
 <tr><td colspan=3></td></tr>
 
  <tr><td>Balance at end of the period</td>    <th>5,512</th>    <td align=center>1,358</td>    </tr>
 <tr><td colspan=3></td></tr>
 
 <tr><td colspan=3>Financing comprises called up share capital, share premium account, Eurobonds, loan stocks, convertible bonds, other loans, commercial paper and bank loans and overdrafts repayable in three months or more from the date of the advance of &#163;335 million (12 months to 30th June 1994 - &#163;139 million).</td></tr>

<a name="cequiv">

 <tr><th align=left colspan=3>Cash &amp; cash equivalents:</th></tr>
 
 <tr><td>Balance at beginning of period</td>    <th>188</th>    <td align=center>441</td>    </tr>
  <tr><td>Increase/(decrease) in cash &amp; cash equivalents</td>    <th>507</th>    <td align=center>(271)</td>    </tr>
  <tr><td>Exchange adjustments</td>    <th>5</th>    <td align=center>18</td>    </tr>
  <tr><td colspan=3></td></tr> 
  <tr><td>Balance at end of period</td>    <th>700</th>    <td align=center>188</td>    </tr>

  

  <tr> <th align=left colspan=3>Reconciliation between the increase/(decrease) in cash &amp; cash equivalents and the increase in net (debt)/funds:</th></tr>
  
  <tr><td>Increase/(decrease) in cash &amp; cash equivalents</td>    <th>507</th>    <td align=center>(271)</td>    </tr>
 <tr><td colspan=3></td></tr>  
  <tr><td colspan=3>Non cash equivalents movements in net (debt)/funds:</td></tr>
  <tr><td>Net (sale)/purchase of non cash equivalent
current asset investments</td>    <th>(2,070)</th>    <td align=center>808</td>    </tr>
  <tr><td>Net advance of long term loans</td>    <th>(1,134)</th>    <td align=center>-</td>    </tr>
  <tr><td>Net advance of short term loans (1994 - repayment)</td>    <th>(2,601)</th>    <td align=center>12</td>    </tr>
  <tr><td>Net non cash equivalents of subsidiary undertakings acquired</td>    <th>54</th>    <td align=center>(1)</td>    </tr>
 <tr><td colspan=3></td></tr>
  <tr><td>Exchange adjustments</td>    <th>4</th>    <td align=center>(124)</td>    </tr>
  <tr><td>Other non cash movements</td>    <th>(47)</th>    <td align=center>(21)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>(5,794)</th>    <td align=center>	674</td>    </tr>
<tr><td colspan=3></td></tr>

<tr><td>Increase in net (debt)/funds</td>    <th>(5,287)</th>    <td align=center>403</td>    </tr>

  </table><p>


  
<a href="15b.html">Forward to: Consolidated cash flow statement (continued)</a><p>
<a href="14.html">Back to: Segment information</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-30</DOCNO>
<DOCOLDNO>IA057-000937-B021-228</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/15b.html 193.128.22.20 19970109100400 text/html 4152
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:54:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:45 GMT
Content-length: 3961
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>15. Consolidated cash flow statement (continued)</font></h2>
<p>
<a name="subs">
<strong>Purchase of subsidiary undertakings:</strong><p>

<table border=2 cellpadding=2 cellspacing=2>


<tr><td></td><th colspan=5>18 months to 31.12.95</th></tr>
<tr><td></td><th>Wellcome plc<br>&#163;m</th>
<th>Affymax N.V.<br>&#163;m</th>
<th>Cascan<br>&#163;m</th>
<th>Glaxo Korea<br>&#163;m</th>
<th>Total<br>&#163;m</th></tr>

<tr><td>	Total purchase consideration	</td><th>	9,333</th><th>	347	</th><th>67	</th><th>18	</th><th>9,765</th></tr>
<tr><td colspan=6>	Non cash element of consideration:</td></tr>
<tr><td>	Tax relief on US share options	</td><th>	42</th><th>	-	</th><th>-	</th><th>-	</th><th>42</th></tr>
<tr><td>	Shares issued</td><th>		                (2,941)</th><th>	-	</th><th>-	</th><th>-	</th><th>(2,941)</th></tr>
	<tr><td colspan=6></td></tr>
<tr><td>	Cash consideration paid	</td><th>	        6,434	</th><th>347</th><th>	67	</th><th>18	</th><th>6,866</th></tr>
<tr><td>	Cash &amp; cash equivalents acquired	</td><th>(730)</th><th>	(66)	</th><th>-	</th><th>(2)	</th><th>(798)</th></tr>
	<tr><td colspan=6></td></tr>
<tr><td>	Net cash payment on acquisition</td><th>		5,704</th><th>	281	</th><th>67	</th><th>16	</th><th>6,068</th></tr>
<tr><td>	Dividend paid to Wellcome plc shareholders</td><th>119</th><th>	-	</th><th>-	</th><th>-	</th><th>119</th></tr>
	<tr><td colspan=6></td></tr>
<tr><td><br></td><th>			5,823</th><th>	281</th><th>	67	</th><th>16</th><th>	6,187</th></tr>


</table><p>

  
Wellcome plc, which was acquired on 16th March 1995, contributed &#163;187 million to the Group's net operating cash flows before integration costs, paid &#163;20 million of integration costs, received &#163;25 million in respect of net returns on investments and servicing of finance, paid &#163;151 million in respect of taxation and received &#163;38 million from investing activities in the period to 30th June 1995.  Since that date it is not feasible to report separately the cash flows of the acquired business.<p>

<a name="disp">  
<strong>Disposal of businesses:</strong><br>
The net cash proceeds received from the disposal of the foods division of Glaxo India Limited were &#163;39 million, consisting of consideration received of &#163;42 million less cash & cash equivalents disposed of &#163;3 million.  The net consideration received from the disposal of Hazeline, the Singapore based consumer products business, was &#163;93 million.  The total consideration received from the disposal of businesses in the period was &#163;132 million.<p>

  

<a href="15.html">Back to: Consolidated cash flow statement </a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-31</DOCNO>
<DOCOLDNO>IA057-000937-B021-243</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/index.html 193.128.22.20 19970109100414 text/html 2609
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:54:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 2418
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Trading and financial review</font></h2>

<font size=5></font>
 

Following the acquisition of Wellcome plc, the Company changed its financial year end from 30th June to 31st December and extended the current financial period by six months to 31st December 1995.  This review covers the 18 month period to 31st December 1995.</font><p>

<dl>
  <dt><a href="1.html">Financial summary</a>
  <dt><a href="2.html">Trading profit</a>
  <dt><a href="3.html">Profit before interest</a>
  <dt><a href="4.html">Interest payable</a>
  <dt><a href="5.html">Taxation</a>
  <dt><a href="6.html">Earnings and dividends</a>
  <dt><a href="7.html">Balance sheet</a>
  <dt><a href="8.html">Net debt</a>
  <dt><a href="9.html">Cash flow and liquidity</a>
  <dt><a href="10.html">Pro forma sales</a>
  <dt><a href="11.html">Sales by theraputic area</a>
  <dt><a href="12.html">Sales by geographic area</a>
</dl><p>
<hr><p>
<a href="../notes/">Forward to: Notes on the preliminary results</a><p>
<a href="../recon.html">Back to: Reconciliation of movements in equity shareholders funds</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-32</DOCNO>
<DOCOLDNO>IA057-000937-B021-266</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/1.html 193.128.22.20 19970109100439 text/html 2972
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:54:47 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 2781
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Financial summary</font></h2>
<p>
<font size=5></font><p>

The results have several unusual features.  The financial period is for 18 months.  There were a number of acquisitions during the period : the major acquisition of Wellcome plc, effective from 16th March 1995,  and the acquisition of Affymax N.V. and a controlling interest in Glaxo Korea Limited, also both effective from March 1995.</font><p>


The results have four principal components:<p>
<ul type=blank>
<li> the Glaxo continuing business for the 12 months to 30th June 1995;
<li> the acquired businesses of Wellcome, Affymax and Glaxo Korea from their date of acquisition to 30th June 1995, together with the cost of borrowings taken out to finance the acquisitions;
<li> the results of the merged business for the period from 1st July 1995 to 31st December 1995, following the integration of the Glaxo and Wellcome businesses; and
<li> the costs of integrating the Glaxo business and the acquired businesses into a combined Group.
</ul><p>


The results of each of these components are shown separately in the <a href="../placc1.html">consolidated profit and loss accounts</a>.  The results of Wellcome have been consolidated into the Group results from 16th March 1995.  The results to 30th June 1995 of the Glaxo continuing business and the acquired businesses were reported in the Second Interim Report.<p>

<a href="2.html">Forward to: Trading Profit</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-33</DOCNO>
<DOCOLDNO>IA057-000937-B021-285</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/2.html 193.128.22.20 19970109100513 text/html 4780
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:55:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 4589
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Trading profit</font></h2>
<p>
<font size=5></font><p>
  

<font size=5>Merged business<p>

Following the acquisition of Wellcome, a structured process of integrating the Glaxo and Wellcome businesses commenced.  Joint Glaxo Wellcome task forces, organised on a market and functional basis, developed plans and financial targets for achieving integration. </font><p>

In the majority of territories, where there was both a Glaxo and a Wellcome company, management integration was achieved by 30th June 1995, and the two businesses were effectively managed on a merged basis from 1st July 1995.  The results for the period from 1st July 1995 to 31st December 1995 are therefore presented on that basis.  In a few territories, notably where there is a minority interest in either the Glaxo or Wellcome company, the process of integration will take longer to achieve and both the Glaxo and Wellcome companies continue to be managed independently.<p>

Sales of the merged business for the six months totalled &#163;4,018 million.  Continued close management of expenses produced a trading profit of &#163;1,426 million, representing a trading margin of 35%.  This was achieved despite the inclusion of certain non recurring expenses in this period.<p>

<strong>Integration</strong><br>

Plans and financial targets for integration, as developed by the integration task forces in the period to June 1995, were referred to in the Second Interim Report.  The plans and targets were updated in November and December 1995.  Compared with the separate forward plans of Glaxo and Wellcome prior to Glaxo's bid for Wellcome, the new plan for the combined Group envisaged the achievement of cost savings year by year amounting to &#163;700 million per year by the end of 1998, and progress is being made towards this objective.<p>


The costs expected to be incurred in achieving these savings are forecast at &#163;1,215 million.  Some &#163;452 million of the costs relate to potential losses on asset disposals resulting from site closures.  Cumulative savings are expected to achieve payback of total costs by around the end of 1997.  In terms of the cash costs of &#163;763 million, payback will be achieved earlier.  The proceeds of asset disposals will reduce the net cash costs of integration.<p>


To recognise the impact of integration activities, the anticipated costs of &#163;1,215 million have been charged in the accounts at 31st December 1995.  The charge comprises costs incurred by December of &#163;384 million, and a provision for a further &#163;831 million of costs.  Taxation relief on integration amounts to &#163;230 million.  In calculating the attributable taxation, no taxation relief has been assumed on asset write downs.<p>


<strong>Combined business</strong><br>

Trading profit for the period before integration costs, representing the aggregate trading profit of the Glaxo continuing business, the acquired business and the merged business, amounted to &#163;3,597 million.  This gives a trading margin of 34%.  After integration costs of &#163;1,215 million, the trading profit was &#163;2,382 million.<p>

<a href="3.html">Forward to: Profit before interest</a><p>
<a href="1.html">Back to: Financial summary</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>
  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-34</DOCNO>
<DOCOLDNO>IA057-000937-B021-301</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/3.html 193.128.22.20 19970109100529 text/html 2608
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:55:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 2417
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Profit before interest</font></h2>
<p>

  

<font size=5>Profit before interest, comprising trading profit after integration costs and a number of other items described below, amounted to &#163;2,474 million for the 18 month period.</font><p>

In September 1994 Glaxo India Limited disposed of its foods division, producing an exceptional profit of &#163;35 million.  After taxation and minority interests, the Group share of the profit was &#163;14 million.<p>

The share of profits of associated undertakings reflects principally the results of the joint ventures with Warner-Lambert (WL) which had been previously established by both Glaxo and Wellcome.  The Glaxo-WL joint venture has launched OTC versions of Zantac and Beconase in the UK market and has undertaken development work to launch OTC Zantac in the US market.  The Wellcome-WL joint venture markets Zovirax in OTC form and is responsible for the marketing of the Wellcome range of OTC products.<p>

<a href="4.html">Forward to: Interest payable</a><p>
<a href="2.html">Back to: Trading profit</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-35</DOCNO>
<DOCOLDNO>IA057-000937-B021-316</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/4.html 193.128.22.20 19970109100545 text/html 2242
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:55:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 2051
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Interest payable</font></h2>
<p>

  
<font size=5>Aggregate net interest expense for the 18 month period was &#163;87 million.</font><p>


Net interest payable during the six months to 31st December 1995 was &#163;121 million.  During this period the majority of the Glaxo and Wellcome investment funds were used to reduce the borrowings taken out to finance the acquisitions, with a consequent reduction in the gross amounts of both interest receivable and interest payable.  The effective rate of interest payable on the Group's principal borrowings during the period was approximately 7%.<p>



<a href="5.html">Forward to: Taxation</a><p>
<a href="3.html">Back to: Profit before interest</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-36</DOCNO>
<DOCOLDNO>IA057-000937-B021-337</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/5.html 193.128.22.20 19970109100601 text/html 2026
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:56:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 1835
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Taxation</font></h2>
<p>
<font size=5>The taxation charge on the combined business for the period before integration was &#163;1,097 million.</font><p>

  As a percentage of profit before taxation of &#163;3,602 million, this represents a rate of taxation of 30.5%.  The rate of taxation on the merged business for the six month period to 31st December 1995 was 31.0%.<p>


<a href="6.html">Forward to: Earnings and dividends</a><p>
<a href="4.html">Back to: Interest payable</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-37</DOCNO>
<DOCOLDNO>IA057-000937-B021-349</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/6.html 193.128.22.20 19970109100608 text/html 3627
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:56:21 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 3436
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Earnings and dividends</font></h2>
<p>
<font size=5>The total Group consolidated result for the period, after aggregating the components of Glaxo continuing business, acquisitions, merged business and integration, is a profit attributable to shareholders of &#163;1,458 million, which produces earnings per Ordinary Share of 44.5p.</font><p>
  
Excluding integration costs and related taxation which are non recurring, the profit attributable to shareholders is &#163;2,443 million, producing earnings per Ordinary Share of 74.6p.<p>


Allowing for the 18 month period, this represents significant growth over earnings per Ordinary Share of 42.7p for Glaxo alone in the 12 months to 30th June 1994.  Adjusting to a calendar year basis, which will be the Group's financial period in future, earnings attributable to the 12 months to 31st December 1995 before integration costs were 50.3p per Ordinary Share.<p>


The Board is recommending the payment of a final dividend of 15p per Ordinary Share.  Together with the first interim dividend of 10p per Ordinary Share paid on 10th April 1995 and the second interim dividend of 20p per Ordinary Share paid on 23rd October 1995, this makes a total dividend of 45p for the 18 months to 31st December 1995.  On an annualised basis, this represents an annual dividend of 30p, which represents an increase of 11% over the dividend of 27p for the 12 months to 30th June 1994.  The final dividend will be paid on 20th May 1996 (30th May 1996 to ADR holders) to shareholders on the register on 26th March 1996.  A scrip dividend alternative will be offered to shareholders in respect of the final dividend.<p>


Dividend cover, being the relationship between earnings and dividends, is 1.7 for the 18 month financial period based on earnings before integration costs.  It is the Board's intention that dividends should increase broadly in line with earnings growth, taking into account the Group's funding situation and the prospects for the future.<p>

<a href="7.html">Forward to: Balance sheet</a><p>
<a href="5.html">Back to: Taxation</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-38</DOCNO>
<DOCOLDNO>IA057-000937-B021-363</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/7.html 193.128.22.20 19970109100624 text/html 3086
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:56:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 2895
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Balance sheet</font></h2>
<p>

  

<font size=5>The Group balance sheet at 31st December 1995 is summarised below:</font><p>


<table border=1 cellspacing=1 cellpadding=1>
  <tr><td></td><th>31.12.95<br>&#163;m</th><td align=center>30.6.94<br>&#163;m</td></tr>	

<tr><td>Net operating assets</td><th>3,417</th><td align=center>3,058</td></tr>
<tr><td>Net (debt)/funds</td><th>(3,196)</th><td align=center>2,091</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Net assets</td><th>221</th><td align=center>5,149</td></tr>
<tr><td colspan=3></td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Share capital and reserves</td><th>5,288</th><td align=center>5,026</td></tr>
<tr><td>Goodwill reserve</td><th>(5,197)</th><td align=center>	-</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Shareholders' funds</td><th>91</th><td align=center>5,026</td></tr>
<tr><td>Minority interests</td><th>130</th><td align=center>123</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Financing</td><th>221</th><td align=center>5,149</td></tr>
<tr><td colspan=3></td></tr>
</table><p>


The reduction in net assets reflects the debt taken on to finance the Wellcome acquisition.  The reduction in shareholders' funds reflects the goodwill arising on acquisition taken to reserves and the impact of integration.  It is expected that profit generated from the merged business, and the consequential cash flow, will progressively rebuild shareholders' funds and net assets.<p>

<a href="8.html">Forward to: Net debt</a><p>
<a href="6.html">Back to: Earnings and dividends</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>






<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-39</DOCNO>
<DOCOLDNO>IA057-000937-B021-380</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/8.html 193.128.22.20 19970109100643 text/html 3180
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:56:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 2989
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Net debt</font></h2>
<p>

  

<font size=5>To finance the acquisition of Wellcome, Glaxo entered into revolving credit facility agreements with nine banks, whereby each bank agreed to lend up to &#163;900 million, to provide an aggregate facility of &#163;8.1 billion.</font><p>


A total of &#163;6 billion was drawn down against the facilities to fund the cash consideration payable to Wellcome shareholders.  Drawings on the facilities were progressively reduced: by realising a substantial part of the Group's cash investments; by utilising existing commercial paper programmes; from the proceeds of issue of two Eurobonds, both issued in London and listed on the London Stock Exchange; and from cash generated from operations.  A new US$5 billion US commercial paper programme was arranged in New York, supported by committed bank facilities of US$3.8 billion.  Issues of commercial paper under this programme were used to repay in full the drawings under the revolving credit facilities, which were then cancelled.<p>


At 31st December 1995 the Group's net debt amounted to &#163;3,196 million.  Net debt included borrowings of &#163;1.7 billion denominated in foreign currencies which are treated as hedged against the Group's overseas assets.<p>


Net debt was established on an initial approximate 50:50 fixed:floating interest rate split.  A limited number of interest rate swaps have been established to help achieve this profile.  The ratio has been allowed to fluctuate in line with subsequent cash generation.<p>

<a href="9.html">Forward to: Cash flow and liquidity</a><p>
<a href="7.html">Back to: Balance sheet</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>




  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-40</DOCNO>
<DOCOLDNO>IA057-000937-B021-398</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/9.html 193.128.22.20 19970109100713 text/html 2730
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:57:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 2539
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Cash flow and liquidity</font></h2>
<p>
<font size=5>As indicated by the consolidated cash flow statement, during the period the Group generated net cash from operating activities of &#163;3,835 million after integration costs paid of &#163;269 million. </font><p>
  


 The funds generated were sufficient to meet all the Group's cash requirements during the period, including dividend payments of &#163;1,525 million, payments to tax authorities of &#163;1,070 million and capital expenditure of &#163;684 million.  The rate of capital expenditure has fallen from the previous year's level, reflecting completion of the Medicines Research Centre at Stevenage and a curtailment of capital spending pending review of all projects as part of the integration process.<p>


The Group expects that future operating cash flow will be sufficient to fund its operating and debt service costs, to satisfy future capital expenditure and other commitments and to permit progressive repayment of debt.  Capital expenditure is expected to be approximately &#163;450 million in the 1996 financial year.<p>


<a href="10.html">Forward to: Pro forma sales</a><p>
<a href="8.html">Back to: Net debt</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-41</DOCNO>
<DOCOLDNO>IA057-000937-B021-447</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/10.html 193.128.22.20 19970109100756 text/html 7473
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:58:05 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 7282
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Pro forma sales</font></h2>
<p>
<font size=5>To illustrate sales performance by product and market, analyses are given below of the combined sales of Glaxo and Wellcome for the year to 31st December 1995, as if Glaxo Wellcome had existed as a combined entity from 1st January 1995.</font><p>
 

<table border=1 cellpadding=1 cellspacing=1>

<tr><td colspan=2><th>&#163;m</th><th>% of total</th><th>% CER* growth</th></tr>

<tr><th>THERAPEUTIC AREA</th>	<th>MAJOR PRODUCTS</th></tr>

<tr><th>Gastro-intestinal</th>   <th align=left>Total</th>   <th>2,255</th>   <th>28</th>   <th>(4)</th></tr>
<tr><td></td>   <td>Zantac</td>   <td align=center>2,255</td>   <td></td>   <td align=center>(4)</td></tr>
<tr><th>Respiratory</th>   <th align=left>Total</th>   <th>1,603</th>   <th>20</th>   <th>20</th></tr>
<tr><td></td>   <td>Ventolin</td>   <td align=center>526</td>   <td></td>   <td align=center>3</td></tr>
<tr><td></td>   <td>Becotide</td>   <td align=center>397</td>   <td></td>   <td align=center>4</td></tr>
<tr><td></td>   <td>Serevent</td>   <td align=center>271</td>   <td></td>   <td align=center>58</td></tr>
<tr><td></td>   <td>Beconase</td>   <td align=center>156</td>   <td></td>   <td align=center>(2)</td></tr>
<tr><td></td>   <td> Flixonase</td>   <td align=center>119</td>   <td></td>   <td align=center>+100</td></tr>
<tr><td></td>   <td> Flixotide</td>   <td align=center>88</td>   <td></td>   <td align=center>+100</td></tr>
<tr><th>Viral infections</th>   <th align=left>Total</th>   <th>1,099</th>   <th>14</th>   <th>-</th></tr>
<tr><td></td>   <td>Zovirax</td>   <td align=center>856</td>   <td></td>   <td align=center>(1)</td></tr>
<tr><td></td>   <td>Retrovir</td>   <td align=center>201</td>   <td></td>   <td align=center>(3)</td></tr>
<tr><td></td>   <td>Valtrex</td>   <td align=center>9</td>   <td></td>   <td align=center>+100</td></tr>
<tr><th>Bacterial infections</th>   <th align=left>Total</th>   <th>963</th>   <th>12</th>   <th>-</th></tr>
<tr><td></td>   <td>Zinnat</td>   <td align=center>393</td>   <td></td>   <td align=center>	9</td></tr>
<tr><td></td>   <td>Fortum</td>   <td align=center>306</td>   <td></td>   <td align=center>(4)</td></tr>
<tr><td></td>   <td>Zinacef</td>   <td align=center>125</td>   <td></td>   <td align=center>-</td></tr>
<tr><th>CNS disorders</th>   <th align=left>Total</th>   <th>	501</th>   <th>6</th>   <th>31</th></tr>
<tr><td></td>   <td>Imigran</td>   <td align=center>366	</td>   <td></td>   <td align=center>	29</td></tr>
<tr><td></td>   <td>Lamictal</td>   <td align=center>	65	</td>   <td></td>   <td align=center>	+100</td></tr>
<tr><th>Oncology</th>   <th align=left>Total</th>   <th>	451	</th>   <th>6	</th>   <th>5</th></tr>
<tr><td></td>   <td>Zofran</td>   <td align=center>386	</td>   <td></td>   <td align=center>	(2)</td></tr>
<tr><th>Dermatologicals</th>   <th align=left>Total</th>   <th>	205	</th>   <th>3	</th>   <th>5</th></tr>
<tr><th>Cardiovascular</th>   <th align=left>Total</th>   <th>	187	</th>   <th>2	</th>   <th>-</th></tr>
<tr><th>Anaesthesia</th>   <th align=left>	Total</th>   <th>	117	</th>   <th>2	</th>   <th>(14)</th></tr>
<tr><th>Others</th>   <th align=left>  	Total</th>   <th>	592	</th>   <th>7	</th>   <th>(4)</th></tr>
<tr><td></td>   <td>		Zyloric</td>   <td align=center>	115	</td>   <td></td>   <td align=center>	-</td></tr>
<tr><td></td>   <td>		Imuran</td>   <td align=center>	105	</td>   <td></td>   <td align=center>	2</td></tr>
<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td></td><th>7,973</th>  <th>100</th>	<th>3</th></tr>
<tr><td colspan=5></td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5></td></tr>
  
<tr><th>REGION</th><th>MAJOR MARKETS</th><td colspan=3></td></tr>

<tr><th>USA</th>   <th align=left>Total</th>   <th>3,309</th>   <th>42</th>   <th>3</th></tr>
<tr><th>Europe</th>   <th align=left>Total</th>   <th>	2,739</th>   <th>34</th><th>-</th></tr>
<tr><td></td><td>UK</td>  <td align=center>628</td>  <td align=center>	8	</td>  <td align=center>2</td></tr>
<tr><td></td><td>France</td>  <td align=center>	450	</td>  <td align=center>6	</td>  <td align=center>5</td></tr>
<tr><td></td><td>Germany	</td>  <td align=center>346	</td>  <td align=center>4	</td>  <td align=center>(7)</td></tr>
<tr><td></td><td>Italy	</td>  <td align=center>333	</td>  <td align=center>4	</td>  <td align=center>(13)</td></tr>
<tr><td></td><td>Eastern Europe</td>  <td align=center>	79	</td>  <td align=center>1	</td>  <td align=center>8</td></tr>
<tr><th>Rest of the World</th>   <th align=left>Total</th>   <th>	1,925</th>	<th>24</th>	<th>8</th></tr>
<tr><td></td><td>Japan	</td>  <td align=center>701	</td>  <td align=center>9	</td>  <td align=center>15</td></tr>
<tr><td></td><td>Asia Pacific	</td>  <td align=center>409	</td>  <td align=center>5	</td>  <td align=center>4</td></tr>
<tr><td></td><td>Latin America</td>  <td align=center>	266	</td>  <td align=center>4	</td>  <td align=center>2</td></tr>
<tr><td></td><td>Africa/Middle East</td>  <td align=center>197</td>  <td align=center>	2</td>  <td align=center>	15</td></tr>

<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td><br></td><th>7,973</th>  <th>100</th>	<th>3</th></tr>
<p>


<caption align=bottom>*Constant exchange rate (CER) growth represents growth over the combined sales of Glaxo and Wellcome for the year to 31st December 1994 excluding currency movements, calculated as if the exchange rates used to translate the results of overseas companies into sterling had remained unchanged from those used in 1994.</caption>
</table>
<hr>

Pro forma sales by Glaxo Wellcome for the 12 months to 31st December 1995 were &#163;7,973 million, representing an increase of 4% in sterling terms or 3% at CER.  Volume growth was 4%, but pricing pressure had a net 1% adverse effect on sales revenue.<p>

<a href="11.html">Forward to: Sales by theraputic area</a><p>
<a href="9.html">Back to: Cash flow and liquidity</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-42</DOCNO>
<DOCOLDNO>IA057-000937-B021-459</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/11.html 193.128.22.20 19970109100804 text/html 6819
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:58:16 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 6628
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Sales by therapeutic area</font></h2>


<strong>Gastro-intestinal - ulcers and related conditions</strong><br>

Zantac is still the largest selling pharmaceutical product in the world and the only one to have exceeded sales of &#163;2 billion per annum.  It holds a 31% Moving Annual Total share of the anti-peptic ulcerant market.  Zantac has been facing competition for several years from other H2 antagonists and proton pump inhibitors such as omeprazole.  It also faces generic competition in a number of markets.  The realisation that Helicobacter pylori is a causative agent in ulcers has provided the opportunity to introduce Pylorid/Tritec, designed to be used with antibiotics for the eradication of Helicobacter pylori.<p>


<strong>Respiratory - asthma, bronchitis and allergic rhinitis</strong><br>

The treatment of respiratory diseases is the second most important therapy area for Glaxo Wellcome. It is based on a range of established and new products now available in a wide choice of delivery systems.  These include the design award winning Diskus (known as the Accuhaler in some markets), a novel multi dose powder inhaler.<p>

Sales of Ventolin continued to grow in its 26th year (an increase of 3% at CER) with notable contributions from the USA, France, Germany and Japan.  Ventolin was again the market leader in the &#163;5 billion respiratory market, followed by Becotide/Beclovent, which also achieved sales growth in its 23rd year since the first launch in the UK in 1972.  In the longer term, the main growth potential is centred on Serevent, Flixotide/Flovent and Flixonase/Flonase.<p>


<strong>Viral infections</strong><br>

Zovirax is the second largest product in the Group, with annual sales of &#163;856 million, but is facing generic competition in Canada and Europe.  The recent launch of Valtrex in the UK, Germany and the USA should help to offset a decline in sales of Zovirax and maintain the Group's franchise in the global viral infections market.<p>

Retrovir continues to be the mainstay of AIDS/HIV therapy and the results of recent trials in combination with Epivir demonstrated a significant advantage in combination therapy.  Epivir's regulatory approval in 1995 in the USA and its early launch there is a major boost for the Group's products in the treatment of AIDS/HIV.<p>


<strong>Bacterial infections</strong><br>

Competition in this market has always been intense with multiple entries from new competitors.  Despite this, Zinnat/Ceftin has retained a strong position in treating community acquired infections of the lower respiratory tract with a 4% share of the &#163;10 billion global oral market.  Fortum/Fortaz, a key product for the treatment of life threatening conditions, and Zinacef, used for routine infections and prophylaxis, together hold an 8% share of the largely hospital based &#163;6 billion injectable antibiotic market.<p>


<strong>CNS disorders</strong><br>

Imigran/Imitrex achieved sales of &#163;366 million in the year, providing migraineurs with relief from migraine symptoms through either injectable or, increasingly, oral therapy.  The launch of Imitrex tablets in the USA, based on the new, lower dose tablets (25mg and 50mg), boosted sales and the 50mg tablet, launched in Europe, was readily adopted in most markets.
Lamictal for epilepsy was launched by Glaxo Wellcome in 1990 and is the market leader in the UK with a 24% market share; it was launched recently in the USA.  In January 1996, Lamictal was awarded the UK Prix Galien award for the most innovative product.<p>

<strong>Oncology</strong><br>

Zofran, the first 5-HT3 antagonist to be launched worldwide, has achieved success in all major markets, based on its therapeutic innovation and ability to improve the quality of life of cancer patients by controlling emesis, nausea and vomiting associated with chemotherapy.  This success has attracted competition from other products.  Price competition in a relatively small market (&#163;1 billion) has restricted further growth opportunities for Zofran in cancer treatment.  The product is also used for the prevention and treatment of post operative nausea and vomiting.<p>

Panorex, a colorectal cancer treatment, is the first monoclonal antibody to be licensed for cancer therapy.  <p>

<strong>Dermatologicals</strong><br>

Glaxo Wellcome has developed a range of anti-inflammatory steroid products to treat skin diseases such as eczema and psoriasis.  Betnovate and Dermovate have been providing relief to patients for many years.<p>


<strong>Cardiovascular</strong><br>
In this intensely competitive area, Glaxo Wellcome products have achieved sales of &#163;187 million and have consistently maintained their market share.  Lanoxin, Trandate and Lacipil are all recognised as standard effective products in the treatment of cardiovascular disease, while Flolan is available in the USA for the treatment of primary pulmonary hypertension.  <p>

<strong>Anaesthesia</strong><br>

The Company has a significant presence in this market with a range of neuromuscular blocking agents including Tracrium and Mivacron with combined sales of &#163;117 million.<p>

<a href="12.html">Forward to: Sales by geographic area</a><p>
<a href="10.html">Back to: Pro forma sales</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>





<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-43</DOCNO>
<DOCOLDNO>IA057-000937-B021-475</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/review/12.html 193.128.22.20 19970109100817 text/html 5458
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:58:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:48 GMT
Content-length: 5267
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Sales by geographic area</font></h2>
<p>


<strong>USA</strong><br>


Sales in the USA accounted for 42% of Glaxo Wellcome's total in 1995 and grew by 3% at CER.  Increased competitive pressure on major products - Zantac and Zovirax - was offset by encouraging sales of new products.  The majority of Group products launched since 1990 have been approved and launched in the USA.  Epivir was launched in November 1995 to boost the status and sales of products in the treatment of HIV/AIDS.  Four major launches are expected in 1996 - Flovent/Flixotide, Pylorid/Tritec, Ultiva and Nimbex.<p>

The growth in managed care provided Glaxo Wellcome with an opportunity to consolidate sales of major products and generally provide a favourable environment to new product launches.<p>

The agreement in October 1995 settling the Genpharm Pharmaceuticals Inc. litigation removes a potential threat to Zantac prior to July 1997, the extended expiry date of the patent under the terms of the intellectual property provisions of the General Agreement on Tariffs and Trade.  This has provided the US subsidiary, Glaxo Wellcome Inc. with more time to establish its new product range and to reduce overall dependency on Zantac and Zovirax sales.<p>


<strong>Europe</strong><br>

In Europe, despite market growth of 8%, sales were unchanged at CER primarily because of the effect of competition to Zantac and Zovirax.  Sales in the UK were particularly affected by generic competition to Ventolin, Becotide and Zovirax; products introduced since 1990 contributed 25% of total UK sales.<p>

Zantac and Zovirax in Germany are both facing generic competition which caused a decline in overall sales and future growth there will be derived from the emerging respiratory range including Flixotide, Flixonase, and Serevent and neurological products such as Imigran and Lamictal.  Despite delays in product approvals and launches in France - there have been only three since 1990 - sales growth was good, aided by established products, including Ventolin, Zovirax, Retrovir, together with Serevent.  In common with most companies, Glaxo Wellcome experienced difficult market conditions in Italy: sales of Serevent, Becotide and Zinnat continued to grow but overall there were reduced sales and a declining market share.<p>

New product sales in Eastern Europe continued to grow strongly, particularly Zofran, Imigran and Serevent.  Zinnat remains the leading Group product in Eastern Europe.<p>


<strong>Rest of the World</strong><br>

This area includes Japan, the second biggest market in the world.  Based on combined sales, the two Glaxo Wellcome operating companies there form the biggest Glaxo Wellcome pharmaceutical company after the USA.  Glaxo Wellcome has experienced long delays in approval and launch times in Japan compared with Europe and the USA.  Only Zofran and Flunase have been launched since 1990.  Despite these limitations, Glaxo Wellcome achieved sales growth of 15% at CER because of the continued growth of Zantac and Zovirax.<p>

In Canada, sales growth for new products was limited because of government policies which continued to affect most major companies.<p>

The Asia Pacific region benefited from the continued strength of the bacterial infections and viral infections ranges and total sales increased by 4% at CER.  <p>

Competition to the major Glaxo Wellcome products in Australia reduced growth to 7% at CER and pricing pressures limited the uptake of new products including Imigran and Serevent.<p>

In Latin America, overall sales growth was adversely affected by economic conditions in Mexico.  Sales in the rest of the region grew by 20% at CER.<p>

The Africa and Middle East region recorded sustained growth for established products, including Zantac and Ventolin, with emerging contributions from Zofran, Imigran and Serevent.<p>


<a href="11.html">Back to: Sales by theraputic area</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-44</DOCNO>
<DOCOLDNO>IA057-000937-B022-9</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/index.html 193.128.22.20 19970109100828 text/html 2521
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:58:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:47 GMT
Content-length: 2330
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Notes on the preliminary results</font></h2>

<ol>
  <li><a href="1.html">General</a>
  <li><a href="2.html">Accounting policies</a>
  <li><a href="3.html">Exchange rates</a>
  <li><a href="4.html">Operating costs</a>
  <li><a href="5.html">Profit on disposal of business</a>
  <li><a href="6.html">Share of profits/(losses) of associated undertakings</a>
  <li><a href="7.html">Net (interest payable)/investment income</a>
  <li><a href="8.html">Taxation</a>
  <li><a href="9.html">Earnings per Ordinary Share</a>
  <li><a href="10.html">Dividends</a>
  <li><a href="11.html">Tangible fixed assets</a>
  <li><a href="12.html">Net (debt)/funds</a>
  <li><a href="13.html">Provisions for liabilities and charges</a>
  <li><a href="14.html">Segment information</a>
  <li><a href="15.html">Consolidated cash flow statement</a>  
</ol><p>
<hr><p>
<a href="../suppl/">Forward to: Supplementary financial information</a><p>
<a href="../review/">Back to: Trading and financial review</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-45</DOCNO>
<DOCOLDNO>IA057-000937-B022-19</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/1.html 193.128.22.20 19970109100836 text/html 2284
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:58:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:44 GMT
Content-length: 2093
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>1. General</font></h2>
<p>
<font size=5>The Profit and Loss Account and Cash Flow Statement for the 18 months ended, and the Balance Sheet at, 31st December 1995 are subject to completion of the audit.</font><p>

 The Profit and Loss Account and Cash Flow Statement for the year ended, and the Balance Sheet, at 30th June 1994 are an abridged statement of the full Group accounts for that year, restated for the change of accounting policy described in Note 2 below, which have been delivered to the Registrar of Companies.  The report of the auditors on the Accounts for that year was unqualified and did not contain a statement under either section 237(2) or section 237(3) of the Companies Act 1985.<p>

<a href="2.html">Forward to: Accounting policies</a><p>
<a href="index.html">Return to: Notes contents page</a><p>




  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-46</DOCNO>
<DOCOLDNO>IA057-000937-B022-31</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/notes/3.html 193.128.22.20 19970109100856 text/html 2365
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:59:08 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:45 GMT
Content-length: 2174
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>3. Exchange rates</font></h2>
<p>


The Group uses the average of exchange rates prevailing during the period to translate the results of overseas Group subsidiary and associated undertakings into sterling and period end rates to translate the net assets of those undertakings.  The currency which most influences these translations is the US dollar and the relevant exchange rates were:<p>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th>18 months to 31.12.95</th>
      <td align=center>12 months to 30.6.94</td></tr>

<tr><td>Average rates &#163;/US $</td><th>1.58</th>
      <td align=center>1.50</td></tr>
<tr><td>Period end rates &#163;/US $</td><th>1.55</th>
      <td align=center>1.54</td></tr>

      </table><p>

<a href="4.html">Forward to: Operating costs</a><p>
<a href="2.html">Back to: Accounting policies</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-47</DOCNO>
<DOCOLDNO>IA057-000937-B022-45</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/suppl/index.html 193.128.22.20 19970109100905 text/html 3291
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:59:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 3100
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Supplementary financial information</font></h2>
<p>
<font size=5>In view of the change in financial year end from 30th June to 31st December and the effect of the acquisition of Wellcome plc, the financial information set out below has been prepared to indicate the results of Glaxo Wellcome on a calendar year basis, so as to provide comparative data for the 1996 financial year.  The information is presented on statutory and pro forma bases.</font><p>
  

<dl>
<dt><a href="stat.html">Statutory basis</a>
<dd>The results of Glaxo Wellcome for calendar years 1995 and 1994.  In 1995 Wellcome is consolidated from its date of acquisition on 16th March 1995.  The 1994 results represent Glaxo alone.<p>


<dt><a href="prof.html">Pro forma basis</a>
<dd>The combined pro forma results of Glaxo and Wellcome for calendar year 1995 on a consistent basis of presentation as if Glaxo Wellcome had existed as a combined entity from 1st January 1995.<p>


<dt><a href="sales.html">Pro forma sales</a>
<dd>The combined pro forma sales of Glaxo and Wellcome, with respect to the criteria mentioned above.
</dl><p>
<hr>
Notes:
<ol>
  <li>Adjustments have been made to the Wellcome results:<br>
      <ul type=blank><li>to reflect Glaxo accounting policies 
      <li>to incorporate at 1st January 1995 the fair value adjustments implemented as of 16th March 1995.</ul>
<li> The Wellcome exceptional item of &#163;27 million in respect of bid defence costs in the six months to 30th June 1995 has been excluded.
<li>The costs of financing the acquisition have been reflected from 1st January 1995.
<li>The costs of integrating the Glaxo and Wellcome businesses have been excluded.
</ol><p>
<hr>


<a href="../review/">Back to: Notes on the preliminary results</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-48</DOCNO>
<DOCOLDNO>IA057-000937-B022-61</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/suppl/stat.html 193.128.22.20 19970109100925 text/html 3846
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:59:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:50 GMT
Content-length: 3655
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Statutory basis</font></h2>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 12 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 31.12.94<br>&#163;m</td></tr>

<tr><td>TURNOVER</td>    <th>7,638</th>    <td align=center>5,705</td>    </tr>
     <tr><td>Cost of sales</td>    <th>1,313</th>    <td align=center>1,003</td>    </tr>
  <tr><td>Selling, general and administrative expenditure</td>    <th>2,643</th>    <td align=center>1,954</td>    </tr>
  <tr><td>Research and development expenditure</td>    <th>1,130</th>    <td align=center>851</td>    </tr>
  <tr><td>Other operating income</td>    <th>(29)</th>    <td align=center>(10)</td>    </tr>
 <tr><td colspan=3></td></tr>
  <tr><td>Operating costs</td>    <th>5,057</th>    <td align=center>3,798</td>    </tr>
 <tr><td colspan=3></td></tr>  
<tr><td>TRADING PROFIT</td>    <th>2,581</th>    <td align=center>1,907</td>    </tr>
  <tr><td>Profit on disposal of business</td>    <th>-</th>    <td align=center>35</td>    </tr>
  <tr><td>Share of profits/(losses) of associated undertakings</td>    <th>60</th>    <td align=center>(5)</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>PROFIT BEFORE INTEREST</td>    <th>2,641</th>    <td align=center>1,937</td>    </tr>
  <tr><td>Net interest payable</td>    <th>(136)</th>    <td align=center>(3)</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</td>    <th>2,505</th>    <td align=center>1,934</td>    </tr>
  <tr><td>Taxation</td>    <th>768</th>    <td align=center>569</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES AFTER TAXATION</td>    <th>1,737</th>    <td align=center>1,365</td>    </tr>
  <tr><td>Minority interests</td>    <th>35</th>    <td align=center>34</td>    </tr>
 <tr><td colspan=3></td></tr>
  <tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>    <th>1,702</th>    <td align=center>1,331</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>EARNINGS PER ORDINARY SHARE</td>    <th>50.3p</th>    <td align=center>43.6p</td>    </tr>

<tr><td>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES IN ISSUE (MILLIONS)</td>    <th>3,386</th>    <td align=center>3,049</td>    </tr>



  
  </table><p>


  
<a href="prof.html">Forward to: Pro forma basis</a><p>
<a href="index.html">Return to: Supplementary financial information contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-49</DOCNO>
<DOCOLDNO>IA057-000937-B022-77</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/suppl/prof.html 193.128.22.20 19970109100942 text/html 4278
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:59:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:49 GMT
Content-length: 4087
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Pro forma basis</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><td align=center> 6 months to 30.06.95<br>&#163;m</td><td align=center>6 months to 31.12.95<br>&#163;m</td><th>12 months to 31.12.95<br>&#163;m</th></tr>

<tr><td>TURNOVER</td>        <td align=center>3,955</td>  <td align=center>4,018</td>    <th>7,973</th> </tr>
     <tr><td>Cost of sales</td><td align=center>725</td>  <td align=center>654</td>    <th>1,379</th> </tr>
     
  <tr><td>Selling, general and administrative expenditure</td> 	 <td align=center>1,417</td>  <td align=center>	1,368</td>    <th>	2,785</th></tr>
  <tr><td>Research and development expenditure</td>  <td align=center>615</td>  <td align=center>	585	</td>    <th>1,200</th></tr>
  <tr><td>Other operating income</td>   <td align=center>(17)</td>  <td align=center>	(15)	</td>    <th>(32)</th></tr>
 <tr><td colspan=4></td></tr>
  <tr><td>Operating costs</td>   <td align=center>2,740</td>  <td align=center>	2,592	</td>    <th>5,332</th></tr>
 <tr><td colspan=4></td></tr>
 
<tr><td>TRADING PROFIT</td>  <td align=center>1,215</td>  <td align=center>	1,426	</td>    <th>2,641</th></tr>
   <tr><td>Share of profits of associated undertakings</td> <td align=center> 33</td>  <td align=center>	39	</td>    <th>72</th></tr>
 <tr><td colspan=4></td></tr>
 
<tr><td>PROFIT BEFORE INTEREST</td>  <td align=center>1,248	</td>  <td align=center>1,465	</td>    <th>2,713</th></tr>
  <tr><td>Net interest payable</td>   <td align=center>(98)</td>  <td align=center>	(121)	</td>    <th>(219)</th></tr>
 <tr><td colspan=4></td></tr>
 
<tr><td>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</td> 	 <td align=center>1,150</td>  <td align=center>	1,344	</td>    <th>2,494  </th></tr>
  <tr><td>Taxation</td>    <td align=center>315</td>  <td align=center>	417	</td>    <th>732</th></tr>
 <tr><td colspan=4></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES AFTER TAXATION</td>   <td align=center>835	</td>  <td align=center>927	</td>    <th>1,762 </th></tr>
  <tr><td>Minority interests</td>   <td align=center>19	</td>  <td align=center>18	</td>    <th>37</th></tr>
 <tr><td colspan=4></td></tr>
  <tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>  <td align=center>816	</td>  <td align=center>909	</td>    <th>1,725  </th></tr>
 <tr><td colspan=4></td></tr>
<tr><td>EARNINGS PER ORDINARY SHARE</td>   <td align=center> 23.4p	</td>  <td align=center>26.0p	</td>    <th>49.4p</th></tr>

<tr><td>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES IN ISSUE (MILLIONS)</td>    <td align=center>3,490	</td>  <td align=center>3,497	</td>    <th>3,494</th></tr>




  </table><p>


  
<a href="sales.html">Forward to: Pro forma sales</a><p>
<a href="stat.html">Back to: Statutory basis</a><p>
<a href="index.html">Return to: Supplementary financial information contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-50</DOCNO>
<DOCOLDNO>IA057-000937-B022-89</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/report/suppl/sales.html 193.128.22.20 19970109100954 text/html 6953
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:00:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:50 GMT
Content-length: 6762
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Pro forma sales</font></h2>

<table border=2 cellpadding=2 cellspacing=2>
  <tr>
    <td colspan=2></td><td align=center>6 months to 30.06.95<br>&#163;m</td><td align=center>6 months to 31.12.95<br>&#163;m</td><th>12 months to 31.12.95<br>&#163;m</th></tr>

<tr><th>THERAPEUTIC AREA</th>	<th colspan>MAJOR PRODUCTS</th><td colspan=3><br></td></tr>

<tr><th>Gastro-intestinal</th>   <th align=left>Total</th>   <th>1,173</th>   <th>1,082</th>   <th>2,255</th></tr>
<tr><td></td>   <td>Zantac</td>   <td align=center>1,173</td>   <td align=center>1,082</td>   <td align=center>2,255</td></tr>

<tr><th>Respiratory</th>   <th align=left>Total</th> <th>791</th> <th>812</th>  <th>1,603</th></tr>
<tr><td></td>   <td>Ventolin</td> <td align=center>263</td>  <td align=center>263</td>  <td align=center>526</td>  </tr>
<tr><td></td>   <td>Becotide</td> <td align=center>196</td>  <td align=center>201</td>  <td align=center>397</td>   </tr>
<tr><td></td>   <td>Serevent</td> <td align=center>125</td>  <td align=center>146</td>  <td align=center>271</td>   </tr>
<tr><td></td>   <td>Beconase</td> <td align=center>92</td>  <td align=center>64</td>  <td align=center>156</td>   </tr>
<tr><td></td>   <td> Flixonase</td> <td align=center>58</td>  <td align=center>61</td>  <td align=center>119</td>   </tr>
<tr><td></td>   <td> Flixotide</td> <td align=center>36</td>  <td align=center>52</td>  <td align=center>88</td>   </tr>
<tr><th>Viral infections</th>   <th align=left>Total</th>  <th>522</th> <th>577</th> <th>1,099</th></tr>
<tr><td></td>   <td>Zovirax</td>  <td align=center>415</td>  <td align=center>441</td> <td align=center>856</td>  </tr>
<tr><td></td>   <td>Retrovir</td> <td align=center>96</td>  <td align=center>105</td>  <td align=center>201</td>  </tr>
<tr><td></td>   <td>Valtrex</td> <td align=center>1</td>  <td align=center>8</td>  <td align=center>9</td>  </tr>
<tr><th>Bacterial infections</th>   <th align=left>Total</th> <th>501</th> <th>462</th>  <th>963</th> </tr>
<tr><td></td>   <td>Zinnat</td>  <td align=center>211</td>  <td align=center>182</td> <td align=center>393</td>   </tr>
<tr><td></td>   <td>Fortum</td> <td align=center>157</td>  <td align=center>149</td>  <td align=center>306</td>   </tr>
<tr><td></td>   <td>Zinacef</td><td align=center>66</td>  <td align=center>59</td>   <td align=center>125</td>   </tr>
<tr><th>CNS disorders</th>   <th align=left>Total</th>  <th>207</th> <th>294</th> <th>	501</th>  </tr>
<tr><td></td>   <td>Imigran</td> <td align=center>142</td>  <td align=center>224</td>  <td align=center>366	</td>  </tr>
<tr><td></td>   <td>Lamictal</td> <td align=center>30</td>  <td align=center>35</td>  <td align=center>	65	</td> </tr>
<tr><th>Oncology</th>   <th align=left>Total</th> <th>220</th> <th>231</th>  <th>	451	</th>  </tr>
<tr><td></td>   <td>Zofran</td> <td align=center>191</td>  <td align=center>195</td>  <td align=center>386	</td>  </tr>
<tr><th>Dermatologicals</th>   <th align=left>Total</th> <th>105</th> <th>100</th>  <th>	205	</tr>
<tr><th>Cardiovascular</th>   <th align=left>Total</th> <th>88</th> <th>99</th>  <th>	187	</th>   </tr>
<tr><th>Anaesthesia</th>   <th align=left>	Total</th> <th>55</th> <th>62</th>  <th>	117	</th> </tr>
<tr><th>Others</th>   <th align=left>  	Total</th> <th>293</th> <th>299</th>  <th>	592	</th> </tr>
<tr><td></td>   <td>		Zyloric</td> <td align=center>56</td>  <td align=center>59</td>  <td align=center>115	</td> </tr>
<tr><td></td>   <td>		Imuran</td> <td align=center>48</td>  <td align=center>57</td>  <td align=center>	105	</td>  </tr>
<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td><br></td> <th>3,955</th> <th>4,018</th> <th>7,973</th></tr>
<tr><td colspan=5></td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5></td></tr>
  
<tr><th>REGION</th><th>MAJOR MARKETS</th><td colspan=3><br></td></tr>

<tr><th>USA</th>   <th align=left>Total</th> <th>1,618</th> <th>1,691</th>  <th>3,309</th>  </tr>
<tr><th>Europe</th>   <th align=left>Total</th>  <th>1,376</th> <th>1,363</th> <th>	2,739</th>  </tr>
<tr><td></td><td>UK</td> <td align=center>302</td>  <td align=center>326</td> <td align=center>628</td>  </tr>
<tr><td></td><td>France</td> <td align=center>231</td>  <td align=center>219</td> <td align=center>	450	</td> </tr>
<tr><td></td><td>Germany	</td> <td align=center>187</td>  <td align=center>159</td> <td align=center>346</td>	 </tr>
<tr><td></td><td>Italy	</td> <td align=center>165</td>  <td align=center>168</td> <td align=center>333	</td> </tr>
<tr><td></td><td>Eastern Europe</td> <td align=center>41</td>  <td align=center>38</td> <td align=center>	79	</td> </tr>
<tr><th>Rest of the World</th>   <th align=left>Total</th>  <th>961</th> <th>964</th> <th>	1,925</th>	</tr>
<tr><td></td><td>Japan	</td> <td align=center>357</td>  <td align=center>344</td> <td align=center>701	</td> </tr>
<tr><td></td><td>Asia Pacific	</td> <td align=center>204</td>  <td align=center>205</td> <td align=center>409	</td> </tr>
<tr><td></td><td>Latin America</td> <td align=center>128</td>  <td align=center>138</td> <td align=center>	266	</td> </tr>
<tr><td></td><td>Africa/Middle East</td> <td align=center>100</td>  <td align=center>97</td> <td align=center>197</td> </tr>

<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td><br></td><th>3,955</th><th>4,018</th><th>7,973</th> </tr>



  
  
  </table><p>


  

<a href="prof.html">Back to: Pro forma basis</a><p>
<a href="index.html">Return to: Supplementary financial information contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-51</DOCNO>
<DOCOLDNO>IA057-000937-B020-512</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/index.html 193.128.22.20 19970109095946 text/html 2702
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:49:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:18 GMT
Content-length: 2511
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>Contents</font></h2>
<p>

<font size=5>"A company is linked closely to the communities in which it
operates, locally, nationally or globally. It cannot exist in isolation."
</font> <p> <dl>

<dt><a href="comm1.html">A message from Sir Richard Sykes</a>
<p>
<dt><a href="comm2.html">Our policy for giving
</a><dd>Corporate citizenship applied to healthcare, education, the environment and the arts
<p>
<dt><a href="comm3.html">Healthcare
</a><dd>New medical facilities and other initiatives to improve healthcare in the UK
<p>
<dt><a href="comm4.html">Education
</a><dd>Working with the academic community to improve the teaching of science and medicine
<p>
<dt><a href="comm5.html">International healthcare
</a><dd>Meeting primary healthcare needs in the developing world
<p>
<dt><a href="comm6.html">The environment
</a><dd>Protecting and conserving the environment worldwide
<p>
<dt><a href="comm7.html">The arts
</a><dd>Encouraging the creation, performance and display of diverse works
<p>
<dt><a href="comm8.html">Community projects around the world
</a><dd>Supporting local needs through funds and employee involvement
</dl>
<p>
<a href="../proj.html">Return to: Community projects</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-52</DOCNO>
<DOCOLDNO>IA057-000937-B010-337</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm1.html 193.128.22.20 19970109082314 text/html 3219
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:13:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 3028
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>A message from Sir Richard Sykes</font></h2>
<p>

<font size=5>A company is linked closely to the communities in which it
operates, locally, nationally or globally. It cannot exist in
isolation.</font> <p> 

For Glaxo Wellcome, being a good corporate citizen is
one of our values. We are committed to the communities in which we work and
charitable and community support is one of the means by which we invest in
society. <p> 

Our programme of charitable and community participation is an
important aspect of the way we work. We participate actively in many forms,
including healthcare, education, the environment and the arts. <p> 

Glaxo Wellcome's programme of giving has evolved
over a long period. We are stringent and consistent in our selection of
charities to support and we challenge these charities to be innovative,
dynamic and cost effective with our donations. But it is not just a matter of
providing money. We try to see where we can add value in a creative way. <p>
My personal involvement with two major charities in the UK has shown me that
close links with our communities are vital. <p> I am determined that Glaxo
Wellcome's proud record of community and charitable involvement will
continue. <p> 

The following pages explain in more detail what we are doing to
maintain this commitment to the community and how we are meeting our
responsibility of good corporate citizenship. <p> 

<IMG  WIDTH=150 HEIGHT=148 SRC="gifs/richa.gif">
<p>
  <font size=5>Sir Richard Sykes</font><br>Deputy Chairman and Chief Executive
  <br>Glaxo Wellcome plc

<p>

<a href="comm2.html">Forward to: Policy for giving</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>

<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-53</DOCNO>
<DOCOLDNO>IA057-000937-B010-348</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm2.html 193.128.22.20 19970109082326 text/html 4092
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:13:39 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 3901
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>
<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>Our policy for giving</font></h2>
<p>

<font size=5>Through its products and business operations, Glaxo Wellcome
improves the health and quality of life of people throughout the world. Our
programme of charitable and community contributions is a further aspect of
this activity which we regard as a proper part of our role in society - to be
a good corporate citizen worldwide.</font> <p>

Internationally, individual Glaxo Wellcome companies adopt their own approach
to charitable giving which depend on the needs and circumstances of their
local communities. In some cases, Glaxo Wellcome employees are encouraged to
become involved. <p>

<IMG  WIDTH=150 HEIGHT=150 SRC="gifs/book.gif" alt="computer and book - educational tools"><p>

In 1993/94, Glaxo Wellcome spent more than &#163;1 million on various charitable
and community projects around the world. <p> 

Through the Group Appeals Committee, Glaxo Wellcome plc contributes to
charitable endeavours on behalf of the Group as a whole, as well as running a
national charitable programme in the UK. In selecting the projects to
support, priority is given to those which improve healthcare and promote
scientific and medical education. We also support initiatives which improve
the environment and sponsor a variety of projects in the visual and
performing arts. <p> 

Glaxo Wellcome's policy is to support those appeals which are innovative,
with clear-cut and tangible aims, made by organisations which are able to
convince us that they will make efficient use of our donation. Additionally,
we seek situations in which the Glaxo Wellcome contribution is a major
factor in accomplishing these aims. <p>

Glaxo Wellcome plc is a founder member of the UK Per Cent Club, which
encourages British industry to increase its corporate giving by contributing
an annual percentage of profits. We have consistently exceeded the
recommended percentage. In the year to the end of June 1994, Glaxo Wellcome
companies in the UK gave a total of &#163;7.4 million to charitable and community
projects, which was equivalent to 4.4 per cent of that share of Group pre-tax
profit proportional to the UK contribution to Group turnover. <p>

In pursuit
of this policy, Glaxo Wellcome has given over the years to a wide range of
national and international initiatives.  Some of these recent projects are
described on the following pages. 

<p>

<a href="comm3.html">Forward to: Healthcare</a><p>
<a href="comm1.html">Back to: A message from Sir Richard Sykes</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-54</DOCNO>
<DOCOLDNO>IA057-000937-B010-368</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm3.html 193.128.22.20 19970109082345 text/html 5731
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:13:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 5540
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>Healthcare</font></h2>
<p>

<font size=5>The largest share of the Group's donations goes to improving healthcare. In the UK, our aim is to strengthen the healthcare structure and help Britain's health
services extend the range and quality of treatment available. Through new facilities and medical research financed by Glaxo Wellcome, the quality of life for many thousands of
patients is being enhanced. </font> <p> 

<IMG  WIDTH=150 HEIGHT=149 SRC="gifs/childbed.gif" alt="child in hospital"> <p> 

<h2>New medical facilities</h2>
<p>

Between 1989 and 1992 a total of 8 million was spent on a special programme of charitable donations to help
Britain's health services extend the range and quality of treatment available. The projects supported cover a broad range of
healthcare needs and provide new facilities in different parts of the UK, often near our own operations.
<p>

  In seeking
projects to support, we were concerned to identify those initiatives which contributed to the improvement of healthcare and were
of major significance to the local community. They were also of a size such that they could not have taken place at the time
without Glaxo Wellcome's support. <p> All but one of the nine projects under the special programme have been completed. The Glaxo
Wellcome Neurological Centre in Liverpool, a centre for the elderly mentally ill at Lister Hospital in Stevenage and the Glaxo
Wellcome Renal Unit at the Birmingham Heartlands Hospital are among those which were finished and opened during 1994. <p> 

In addition, construction work has begun on a new pharmacy at King's College Hospital in London, made possible by a donation of
1.25 million from Glaxo Wellcome.  An innovative academic practice unit will be accommodated at the pharmacy to provide a
pharmaceutical education service for local doctors and other healthcare professionals in the area. <p> 

We have continued our support for major healthcare facilities beyond the special programme, and a gift of 1 million has enabled
the opening of a new Glaxo Wellcome Lung Investigation, Treatment and Research Unit at Wythenshawe Hospital in Manchester. Part of
the internationally renowned North West Lung Centre, the Glaxo Wellcome unit carries out research into lung cancer and the
environmental causes of asthma and allergies. <p> More recently, a 1.2 million gift to the National Society for Epilepsy is
helping the installation of the world's first magnetic resonance imaging (MRI) brain scanner unit dedicated to epilepsy treatment
and research. It was one of our biggest single donations and allowed the society to close the capital stage of its appeal to raise
money for the unit. <p> 

<IMG  WIDTH=130 HEIGHT=195 SRC="gifs/loom.gif" alt="community project - weaving"> <p>

<h2>Other healthcare initiatives</h2>
<p>

Complementing our support for new medical facilities, a number of other healthcare initiatives have been launched.

<p>
Each year, we select five projects with medical research charities at a level of up to 100,000 each. One example is 'Regulation of Raf Kinases and Ras Proteins', work by the Imperial Cancer Research Fund to identify a possible tumour - blocking drug, which was chosen because the Ras protein is involved in a large percentage of cancers, particularly lung cancer.<p>

Disadvantaged groups such as the homeless and the disabled also benefit from our programme of support. Glaxo Wellcome works with a number of charitable and welfare organisations to establish facilities that will reduce hardship among such groups. The Princess of Wales opened the Glaxo Wellcome Refuge for Children and Young People, operated by Centrepoint to help keep homeless young people off the streets of London. It was the first unit in the UK to be registered for runaways under the age of 16.
<p>
Our support for the homeless, which also includes a hostel for young people in west London and a community care unit in the capital operated by the Wytham Hall Trust, has been expressed in donations totalling 1 million.  
<p>

<a href="comm4.html">Forward to: Education</a><p>
<a href="comm2.html">Back to: Policy for giving</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-55</DOCNO>
<DOCOLDNO>IA057-000937-B010-388</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm4.html 193.128.22.20 19970109082400 text/html 3916
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:14:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 3725
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>Education</font></h2>
<p>

<font size=5> Continual improvement in the standards of scientific and medical education is crucial to the community and any
science-based company. For many years, Glaxo Wellcome has worked alongside the academic community in the knowledge that many
important scientific advances are made in that environment.
</font>
<p>

<IMG  WIDTH=170 HEIGHT=139 SRC="gifs/butter.gif" alt="insect"><p>

<h2>Support programmes</h2>
<p>

Our charitable support for scientific education includes a programme of academic endowments and assistance to help
upgrade the scientific infrastructure of universities and other teaching establishments.
<p>
In this last year we have
endowed a new Glaxo Wellcome Chair in Clinical Pharmacology at the University of Liverpool. This will concentrate on bringing
clinical pharmacology into the sphere of primary healthcare.  <p> 

In addition, we are to create a new chair in respiratory science at a UK university to mark the British Lung Foundation's tenth
anniversary in 1995. <p>

At Birkbeck College, part of the University of London, the Department of Crystallography has been given a donation to improve the
research and teaching facilities. Birkbeck's top-rated structural science research was previously housed in an old, unventilated
and poorly-lit X-ray laboratory; our donation is allowing the college to refurbish and upgrade the space into a new multimedia
seminar room and 'visualisation laboratory'. Also within this support programme, the North Hertfordshire College of Further
Education has been given the resource to establish a new science laboratory and upgrade existing facilities. <p>

<IMG  WIDTH=138 HEIGHT=135 SRC="gifs/protein.gif" alt="molecular imaging"><p>

Glaxo Wellcome grants have also helped to promote education in other ways. Many students who want to read medicine are deterred by
the cost of tuition and subsistence. Over the past three years, 36 such students have been granted Glaxo Wellcome Bursaries, 
administered by the British Medical Association Charitable Trust. <p>

We also support scientific and technical museums in their work to stimulate early interest and curiosity in the young scientists
of tomorrow. 

<p>

<a href="comm5.html">Forward to: International healthcare</a><p>
<a href="comm3.html">Back to: Healthcare</a><p>
<a href="index.html">Return to: Glaxo Welcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-56</DOCNO>
<DOCOLDNO>IA057-000937-B010-410</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm5.html 193.128.22.20 19970109082415 text/html 4442
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:14:28 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 4251
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>International healthcare</font></h2>
<p>

<font size=5> Our commitment to healthcare is not confined to the UK. Glaxo Wellcome plc responds on behalf of the Group as a
whole to provide a rapid response to international natural disasters and supports organisations which offer immediate emergency
relief to countries around the world. We also support innovative projects which address primary healthcare needs in the developing
world, particularly projects that can be replicated elsewhere. </font> <p> 

<IMG  WIDTH=110 HEIGHT=126 SRC="gifs/clinic.gif" alt="healthcare clinic"><p>

<h2>Relief projects</h2>
<p>

In 1994, the plight of the many thousands of refugees in Rwanda came to the world's attention. Glaxo Wellcome was able to help in 
the on-going battle to alleviate the crisis by its support of MERLIN - Medical Emergency Relief International - a specialist 
organisation skilled in assessing initial needs in emergencies or natural disasters. In the same year we sponsored another MERLIN 
expedition to the TB - stricken region of Siberia.
<p>

Such prompt response followed by money or medical supplies can save thousands of lives and help to reduce suffering. On many 
occasions, Glaxo Wellcome has been able to help the victims of devastating natural occurrences such as the earthquake in the 
Indian state of Maharashtra, estimated to have killed more than 20,000 people. <p>

In this case, Glaxo Wellcome plc assisted by supplementing donations made by our local operating company in India. And when a
large earthquake struck Egypt, shortly after the Indian tremor, Glaxo Wellcome in that country was able to provide large supplies
 of antibiotics as part of the relief programme. <p> 

Not all our efforts to improve healthcare are made in reaction to such emergencies. Glaxo Wellcome has boosted the work of 
Medecins Sans Frontieres, the international relief agency, in helping
displaced people around Rangoon, capital of Myanmar. The money was used by MSF in the first relief programme it operated 
exclusively with the use of corporate funds. <p>

<IMG  WIDTH=185 HEIGHT=125 SRC="gifs/baby.gif" alt="child in hospital"><p>

The Centre for International Child Health, part of the University of London, received funds from Glaxo Wellcome that will help its
research into the prevention of disease and illness among mothers and their children in developing countries. <p>

In addition, the work of Tropical Health and Education Trust, which establishes collaborations with UK hospitals and universities 
to improve healthcare training in poor tropical countries, has received our support. One project  is a three-year study of 
different population groups in Ghana to measure how closely asthma is linked with lifestyle.

<p>

<a href="comm6.html">Forward to: The environment</a><p>
<a href="comm4.html">Back to: Education</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT14-B39-57</DOCNO>
<DOCOLDNO>IA057-000937-B010-424</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm6.html 193.128.22.20 19970109082425 text/html 4594
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:14:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:18 GMT
Content-length: 4403
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>The environment</font></h2>
<p>

<font size=5>
Protection of the environment is an essential aspect of the good corporate citizenship to which our Group has long been 
committed. It is reflected both in the stringent standards that we apply to ensure that we operate in an environmentally safe and 
sustainable manner and in our close relations with those communities in which our companies are located. </font><p>

<IMG  WIDTH=125 HEIGHT=191 SRC="gifs/eleph.gif" alt="elephent in savannah"><p>

<h2>Environmental projects</h2>
<p>


Through our charitable  programme, our aim is to support a wide range of:
<ul type=disc>
<li> high quality research projects to assess the gravity of environmental problems and identify 
remedies; 
<li> educational activities both for the general public and managers of industry;
<li> initiatives which bring about direct environmental improvements of benefit to people or 
resources such as the protection and conservation of wildlife. </ul>

<p>
The Natural History Museum in London houses some 67 million specimens and is one of the best 
collections in the world. After years of planning, the museum is launching a new membership scheme 
to provide individuals and families with a wide range of benefits.  We are sponsoring the scheme, 
which will increase the public's access to the museum and bring to the fore its less well known 
role as a centre of excellence for scientific research. It will also help build a firm financial 
base to safeguard this important resource for future generations.
<p>
A new scheme for the labelling of timber, established under the Responsible Forestry Programme and 
organised by the Soil Association, has also received our support. The 'Woodmark' trademark enables 
consumers to choose wood products from genuine sustainably-managed forests and helps satisfy a 
growing demand from the public for ethical timber production. <p>

<IMG  WIDTH=180 HEIGHT=123 SRC="gifs/tree.gif" alt="woodland scene"><p>

We have made donations to Earthwatch to support environmental initiatives in Prague and Mallorca 
and to send teachers from the UK to participate in these projects. Our cash gift to the Wildfowl 
and Wetlands Trust will enable the construction of a discovery centre at Tyne and Wear in the UK 
which will provide an environmental educational facility for schools and families in the region.
<p>
There has been international concern over the escalating destruction of indigenous woodland in the 
arid and semi-arid areas of southern Africa. Glaxo Wellcome has been able to support efforts in 
Zimbabwe to provide a cheap supply of vigorous native tree saplings to replenish the ravaged areas 
and to study different  types of trees that will provide the best species for the conditions. In 
addition, this programme has been supported by a series of chamber music concerts at Kew Botanical 
Gardens in London.

<p>

<a href="comm7.html">Forward to: The arts</a><p>
<a href="comm5.html">Back to: International healthcare</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-58</DOCNO>
<DOCOLDNO>IA057-000937-B009-402</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm7.html 193.128.22.20 19970109081648 text/html 5639
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:07:02 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:18 GMT
Content-length: 5448
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>The arts</font></h2>
<p>

<font size=5>Glaxo Wellcome's arts sponsorship philosophy is to encourage the creation, performance and display of diverse and
enlightening works as well as to support innovative educational opportunities for young people. We aim to sponsor important
exhibitions, performances and productions that without our support might not be available to the public. </font><p>

<IMG  WIDTH=150 HEIGHT=163 SRC="gifs/tyre.gif" alt="acrobat"><p>
<p>

<h2>Support for the arts</h2>
<p>


Our commitment includes backing for the visual arts, sculpture, music, theatre, opera and dance, 
both in the UK and overseas. We also commission, acquire and display on company premises works by 
contemporary artists. We support a number of leading organisations with capital donations for the 
improvement of their facilities and with corporate membership schemes.<p>

Our main sponsorship in 1995 is an exhibition of Spanish still life paintings which is the largest 
arts initiative Glaxo Wellcome has supported. This major exhibition comprises 69 of the finest 
Spanish still life paintings from around the world. The display includes works by artists such as 
Velzaquez and Goya, as well as examples by less familiar names such as Sanchez Coton, a 
monk-painter from Toledo, Zurbarn and Melendez. Held at the National Gallery, it is the first 
exhibition in the UK devoted to the subject.<p>

<IMG  WIDTH=165 HEIGHT=138 SRC="gifs/velas.gif" alt="fine art">
<p>
In February 1994, we sponsored an exhibition at The Courtauld Institute of Art in London, entitled 
'Theatre in the Age of David Garrick (1740-85)'. Some 60 rare English mezzotints illustrating 
theatre in the time of the famous actor/manager were displayed. The engravings, from a private 
collection, had never previously been exhibited. <p>

A successful series of chamber music concerts at Kew Botanical Gardens, London, is also sponsored 
by Glaxo Wellcome to help raise awareness of a variety of environmental projects being undertaken 
at this foremost scientific institution. World class performers such as guitarist John Williams 
and percussionist Evelyn Glennie have appeared. The prestigious concerts raised funds for the 
first database of the world's Rattan palms and for a fuelwood project in Zimbabwe. <p>

Over a period of three years, we are sponsoring 'Music for Youth', a festival of music which 
involves regional competitions and culminates in a national Proms event at the Royal Albert Hall. 
Also with youth in mind, we are supporting a project by the Pavilion Opera Educational Trust to 
introduce opera to children in west London. Through school visits, the opera company encourages 
children to learn about opera and be fully involved in performances themselves. <p>
A project in London to recreate one of the world's most famous theatres, William Shakespeare's 
Globe, continues to receive our support and our most recent donation has enabled the completion 
of one of the 20 oak bays which make up the theatre on the banks of the River Thames.
<p>

The discovery of hundreds of drawings by Modigliani gave us the opportunity of supporting 'The 
Unknown Modigliani', an exhibition of what one commentator described as 'the greatest discovery in 
art of the 20th century'. The display of more than 240 previously unseen drawings was organised in 
association with a national newspaper and held at the Royal Academy of Arts in London, attracting 
over 130,000 visitors. <p>

The therapeutic value of music is acknowledged and we encourage its use through our continued 
support of 'Overtures'. This programme, run by the Royal Opera House and now in its fifth year, 
enables singers and musicians from the famous opera company to entertain patients in hospitals and 
hospices throughout the UK. <p>

Read about Glaxo Wellcome's support for the National Youth Theatre on the <a 
href="../../news/theatre.html">Glaxo Wellcome Noticeboard</a>. <p>
<a href="comm8.html">Forward to: Projects around the world</a><p>
<a href="comm6.html">Back to: The environment</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-59</DOCNO>
<DOCOLDNO>IA057-000937-B010-437</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/commun/comm8.html 193.128.22.20 19970109082433 text/html 6039
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:14:47 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:18 GMT
Content-length: 5848
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>Community projects around the world</font></h2>
<p>

<font size=5> In addition to the support given by Glaxo Wellcome plc through its charitable programme, there are numerous examples
of Glaxo Wellcome operating companies around the world supporting community initiatives and identifying projects which best meet
local needs. </font>
<p>

<IMG  WIDTH=185 HEIGHT=122 SRC="gifs/comp.gif" alt="IT training"><p>

<h2>Local initiatives</h2>
<p>

Glaxo Wellcome companies provide not only much-needed funds but also practical help, advice, ideas and expertise to
charities, job creation, youth training and enterprise schemes. In some cases Glaxo Wellcome employees are encouraged to become
involved and, in response, commit their time and energy.<p>

Initiatives are varied and include supporting an early intervention centre for young children in Australia, donating computers and
TVs to hospitals in Ecuador, arranging musical performances for hospital staff and patients in Taiwan, and sponsoring exhibitions
in Germany and the UK of cartoons showing the lighter side of how Germans and Britons sometimes see each other. <p>

In the USA, Glaxo Wellcome Inc supported the Healthy Start Foundation to research infant mortality and to establish broader access
to healthcare in remote communities. Counselling to increase the awareness of the importance of pre-natal care is also a feature
of the programme. Modular office buildings, used as health clinics for mothers and their babies, have also been donated by the
company. <p>

Glaxo Wellcome Inc has also launched a new healthcare journal called 'Healthy Lives', intended to give consumers accurate
information about common diseases and health matters. The first issue, on the subject of diabetes, was greeted with enthusiasm by
both lay and professional readers. <p>

In Canada, $1.5 million has been committed over five years for the creation of the Quebec Centre of Excellence in Respiratory
Health, the country's first partnership between the provincial government, which will supervise the centre, university researchers
and a pharmaceutical company. The centre will conduct research into respiratory illness, with a focus on asthma. <p>

'Kasper the Chemo Man' is an illustrated and easy-to-read book explaining to children what happens to their bodies when they
receive chemotherapy. The book, a result of Glaxo Wellcome Denmark's co-operation with the Danish Cancer Society, has been so
popular it has been translated into three languages. And in Spain, Glaxo Wellcome helps brighten the lives of children with cancer
with an annual national colouring competition. <p>

<IMG  WIDTH=160 HEIGHT=163 SRC="gifs/basket.gif" alt="basketball game"><p>

Our company in the Philippines has for some years been an active supporter of the government's 'Cure TB' campaign and provides
money and practical assistance for intensive screening, diagnosis and treatment as well as basic health education. Recently, Glaxo
Wellcome decided to extend its involvement by co-operating with interested government and private medical groups on applied
research on tuberculosis in children. In addition, the company has started a programme of helping doctors travel to remote areas
of the country, where there are thought to be nearly 300 communities or 'barrios' without a doctor. 

<p> Under a programme called 'One Plus One', employees in Chile give money each month - the total is matched by the company - to
an institute for helping orphan children. In addition, our company organises entertainment for children at the centre. <p>

Doctors and medical managers at St Petersburg in Russia have taken part in an exchange visit scheme with their UK counterparts
organised by Glaxo Wellcome. The scheme was part of our support for the healthcare section of the visit by the Prince of Wales to
St Petersburg in 1994, which included the visit of four specialists from UK hospitals. <p>

Science laboratories and libraries have been installed in numerous schools in South Africa as part of Glaxo Wellcome South
Africa's policy of supporting its local communities. Backing for teacher training and other educational activities make up a large
part of the assistance programme.
<p>

The restoration of two of the earliest tombs in the famous St Mark's Cathedral in Venice, dating from the 11th century, was
sponsored by Glaxo Wellcome in Italy and completed in 1994. 

<p>

<a href="comm7.html">Back to: The arts</a><p>
<a href="index.html">Return to: Glaxo Wellcome in the community contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-60</DOCNO>
<DOCOLDNO>IA057-000937-B020-162</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/index.html 193.128.22.20 19970109095430 text/html 1763
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:44:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:19 GMT
Content-length: 1572
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7>Geneva Biomedical Research Institute 
</font></H1>
<HR size=4><br>

<h2><font size=6>Contents</font></h2>
<p>

<a href="intro.html">Introduction</a>
<p>	

<a href="project.html">Research highlights: A selection of projects</a><p>
<a href="genmap.html">How to find GBRI</A><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-61</DOCNO>
<DOCOLDNO>IA057-000937-B007-416</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/intro.html 193.128.22.20 19970109080324 text/html 3436
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:53:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 3245
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>GBRI, Switzerland</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Geneva Biomedical Research Institute</font></h1>
<hr size=4>
<br>
<h2><font size=6>Introduction</font></h2>

<font size=5>Two important developments in the field of  biomedical sciences are revolutionising the way in which therapeutic treatments will be discovered in the future. </font><p>

Molecular biology is providing increasingly powerful tools for the direct manipulation of genes and pathways which are leading to a clear understanding of  the complex  mechanisms that 
control key biological processes. <p>
 
Rapid advances are being made in human molecular genetics. For a growing number of important diseases, specific genes have been identified that are strongly associated with the 
condition.<p>

These two developments provide outstanding opportunities for creating new therapies; molecular biology and genetics are now undoubtedly providing the basis for the drugs 
of the future. The pathology of diseases that have remained unclear despite their 
importance in human, social and economic terms are at last being understood at the 
molecular level thanks to the revolution taking place in the biomolecular sciences. <P> 

An understanding of the molecular basis of a disease facilitates a much more direct and rapid identification of good drug targets. The drug target is usually a macromolecule, often a 
protein, whose activity is modified by a drug to provide a therapy. In future, in some cases, the target molecule or another protein interacting with it may be replaced by gene 
therapy. The identification of good drug targets is a key step in the drug discovery process, and modern biology makes this increasingly amenable to experimentation. The quality of the 
target in terms of specificity and selectivity, as reflected in a clear understanding of its role in health and disease, is directly  related to the quality of the drug which is 
developed to act on the molecule. <P> 

<a href="role.html">Forward to: The role of GBRI</a>
<p>
<a href="index.html">Return to: GBRI contents page</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-62</DOCNO>
<DOCOLDNO>IA057-000937-B007-431</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/project.html 193.128.22.20 19970109080338 text/html 1874
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:53:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 1683
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7>Geneva Biomedical Research Institute 
</font></H1>
<HR size=4><br>

<h2><font size=6>Research highlights</font></h2><p>

A selection of research projects<p>
<ul type=disc>
<A HREF=neuro.html>Neurodegeneration</A><br>
<A HREF=immuno.html>Immunoregulation</A><br>
<A HREF=il5.html>Interleukin-5</A><br>
<A HREF=trans.html>Transcription</A><br>
<A HREF=yeast.html>Signal transduction in yeast</A>
</ul>

<p>

<a href="index.html">Return to: GBRI contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-63</DOCNO>
<DOCOLDNO>IA057-000937-B008-13</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/genmap.html 193.128.22.20 19970109080350 text/html 1636
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:54:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:19 GMT
Content-length: 1445
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7>Geneva Biomedical Research Institute 
</font></H1>
<HR size=4><br>

<h2><font size=6>How to find GBRI</font></h2>
<p>
<IMG  WIDTH=307 HEIGHT=278 SRC="genmap.gif">

<p>
<a href="index.html">Return to: GBRI contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-64</DOCNO>
<DOCOLDNO>IA057-000937-B020-152</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/role.html 193.128.22.20 19970109095423 text/html 5579
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:44:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 5388
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>GBRI, Switzerland</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Geneva Biomedical Research Institute</font></h1>
<hr size=4>
<br>
<h2><font size=6>The role of the Institute</font></h2>

<font size=5>The role of Geneva Biomedical Research Institute (GBRI) is to understand disease mechanisms at the molecular level  in order to identify selective and 
specific molecular targets for new drug development programmes. </font><p>

The identification  and validation of a new target provides an important interface between GBRI scientists and scientists at other Glaxo Wellcome R&amp;D sites who are using another set 
of rapidly developing technologies for designing, identifying and testing compounds that interact with targets to modify their activities. <P>

The Institute is concentrating on  diseases of the immune and nervous systems 
where the advances in molecular biology and genetics  are creating major opportunities for developing new therapies.  Research on the immune system is focused on asthma, allergies and 
autoimmune diseases. Our studies on the nervous system concentrate on neurodegenerative conditions such as Alzheimer's disease. 
 <P>

In addition to our research on specific diseases,  we have projects aimed at understanding key biological mechanisms, particularly the functioning of receptors and ion channels as well 
as their signal transduction mechanisms. Much of the research at GBRI is driven by the creative interactions between the two kinds of project team - those with a specific disease 
focus and those aimed at understanding a particular biological mechanism. For example, the progress we have made towards understanding the signalling mechanisms of mammalian receptors 
expressed in yeast cells is of great value for dissecting the pathways that lead to the death of neurones. 
 <P>

The projects summarised on the following pages represent about half of all our ongoing 
research programmes.  In addition, we have projects on the structure and function of seven transmembrane receptors, ion channels and chemokines. The summaries illustrate some important 
themes common to all our projects, such as the interdisciplinary approach and the value placed on collaborations with leading researchers throughout the world, including those at other 
Glaxo Wellcome research laboratories.   <P>

We place particular emphasis on developing and maintaining  strong links with other top research groups around the world and our good publication record is evidence of this. The 
Universities of Geneva and Lausanne are obviously very important to us; several new research collaborations have started this year and we organise joint symposia. Another important 
trend is the increasing number of scientists from Glaxo Wellcome research centres in Europe, the U.S.A. and Japan who spend some  time working at the Institute.  This strengthens our ties with 
other Glaxo Wellcome laboratories and helps to ensure that the discoveries made  by GBRI scientists are translated into drug development programmes at other R&D sites. Our 
interactions with Glaxo Wellcome's strategic alliance partners  form an important part of several projects. <P>

Since its founding in 1987, GBRI's staff has grown to 140, not including the visiting scientists and students who make a significant contribution to the Institute's activities.  Our 
post-doctoral programme has developed very well; we currently have ten scientists who  have just received their PhDs and spend three years working with us on questions of fundamental 
importance.  Geneva has proved an ideal location for creating a truly international team of leading researchers; scientists from more than 20 countries work at GBRI. Geneva's many 
advantages include its international atmosphere, a central location in a very attractive part of Europe with excellent communications and all the benefits of the quality of life in 
Switzerland. <P> 

 The Geneva Biomedical Research Institute, in Switzerland,  looks forward to participating in the exciting developments taking place in molecular biology to understand the molecular 
mechanisms of disease and provide the basis for new therapies. 
 <P>
<a href="index.html">Return to: GBRI contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-65</DOCNO>
<DOCOLDNO>IA057-000937-B020-177</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/neuro.html 193.128.22.20 19970109095439 text/html 4850
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:44:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 4659
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Neurodegeneration</font></h2>

<font size=5>Our goal is to understand the molecular basis of neuronal  cell death. Neuronal death has been recognized for many years as an essential feature of nervous system development; more than half of the neurones that are generated die during the, 

so-called,  naturally occurring cell death period. Massive neuronal death 
is also an obvious feature of pathologies in the adult nervous system, 
including Alzheimer's, Parkinson's and motorneurone diseases. </font>
<p>
The causes of these neurodegenerative diseases are largely unknown. Our 
hypothesis is that neuronal survival or death, both during development 
and in adults, is determined by the balance of expression of positive and 
negative regulatory genes. Several such regulatory genes have been 
identified; their mechanisms of action are providing important 
information about how neuronal survival and death is controlled.<p>

During development, the tips of growing axons are guided to their targets
where they establish connections. Typically, half of the neurones form
synapses and differentiate further, while the rest are eliminated during
the naturally occurring cell death pe riod. Although the mechanisms that
lead either to the death or to the differentiation of neurones are
unknown, appropriate cell-cell interactions, electrical activity and gene
expression play important roles in both pathways.  The same mechanisms may
also contribute to the remodelling of nerve terminals that occurs in the 
adult brain as a morphological corollary to memory and learning. Our 
strategy for identifying novel genes associated with synapse formation 
and neuronal selection is based on cloning genes that are specifically 
expressed during 
synaptogenesis and which are regulated by electrical activity.<P>

<b>Stathmin is involved in the transduction of signals induced by NGF</b><p>

We cloned the stathmin cDNA by screening for genes that were more highly
expressed at particular stages of development. Stathmin is a
phosphoprotein enriched in the nervous system. The regulation of its
expression and phosphorylation during development co ntrols cell
proliferation and differentiation. We found that treatment of PC12 cells
with stathmin antisense oligonucleotides prevented the nerve growth factor
(NGF)-induced differentiation of these cells <cite>in vitro</cite> and
also prevented the effec ts of NGF on cell survival in serum free 
conditions.  Thus stathmin appears to form part of the NGF signal 
transduction pathways that control both differentiation and survival. <P>

Both stathmin and a neurone-specific homologue, SCG-10, show a strong 
peak of expression during developmental cell death and synapse formation. 
At this stage, however, neurones express different levels of both 
proteins, suggesting that the level of expression may correlate with the 
fate (death or survival) of the cell.<P>

Our research on stathmin and SCG-10 indicate that the mechanisms 
regulating the
expression of such proteins, which transmit neurotrophic factor signals, 
may have important roles in neuronal survival and in successful sprouting 
during developmental cell death, ageing or disease. <P>

<a href="neuro2.html">Forward to: SNAP-25 and the bcl-2a protooncogene</a><p>
<a href="project.html">Return to: Research projects contents page</a>

<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-66</DOCNO>
<DOCOLDNO>IA057-000937-B020-190</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/immuno.html 193.128.22.20 19970109095454 text/html 9594
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:45:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:19 GMT
Content-length: 9403
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Immunoregulation</font></h2><p>

<font size=5>Our goal is to understand the molecular and cellular mechanisms that regulate human IgE production. IgE is the key 
immunoglobulin that is involved in more than 90% of cases of allergic diseases such as allergic asthma, allergic rhinitis, hay 
fever and food allergies. IgE binds to the high affinity receptor for IgE on basophils and mast cells. Crosslinking of the 
bound IgE by allergens leads to the release of various inflammatory mediators from these cells. </font><p>

IgE is produced by B cells in response to two sets of signals. The first signal is given by cytokines IL-4 and IL-13, which are 
produced by the Th2 class of T lymphocyte and by basophils. This signal induces the e germline sterile transcript (a precursor 
mRNA for IgE synthesis). The second signal is provided by the physical interaction of B cells with T 
cells which results in the synthesis of the mature e transcript and hence to IgE secretion. <p>
We have identified two pairs of leukocyte surface molecules that have critical roles in IgE synthesis. By interacting with CD21 
(Aubry et al., 1992), the CD23 molecule regulates the 
antigen-specific IgE response in an isotype-selective manner (Flores-Romo et al., 1993), i.e. the CD23/CD21 interaction 
stimulates synthesis of the IgE isotype but not the production 
of other immunoglobulin isotypes, such as IgG. Another cell surface molecule, CD40L, is also necessary for IgE synthesis and is 
involved in general isotype switching as well, through 
its interaction with CD40 (Di Santo et al., 1993). Moreover, functional CD40L was identified on the surfaces of basophils and 
mast cells, enabling these cells to directly regulate IgE production independently of T cells (Gauchat et al., 1993).<p>

Immunoglobulin E (IgE) is central to the induction of allergic diseases through its binding to the high affinity receptor 
(Fc*R1) on mast cells and basophils. Cross-linking of the bound IgE by allergens leads to the release of inflammatory 
mediators. IgE production by B cells requires a physical interaction with T cells, involving a number of surface adhesion 
molecules, as well as the soluble factors (IL-4) and IL-13 that are produced by T cells, basophils and mast cells. <P>

The first indication that the interaction between CD40 and CD40L is a key event in the Ig switching that is required for IgE 
synthesis came from studies using anti-CD40 monoclonal 
antibodies and CD40L transfectants. Several factors that are known to control IgE production have also been shown to regulate 
CD40L expression. Furthermore,  T cell-mediated 
stimulation of IgE synthesis can be inhibited by soluble forms of CD40. Finally, we provided direct evidence for the importance 
of CD40L in Ig switching through our collaborative 
research with the INSERM U132 research unit in Paris; patients with hyper-IgM syndrome, were shown to have  mutations in the 
gene for CD40L (Di Santo et al., 1993).<P>

<b>Mast cells and basophils.</b><p>

Our subsequent studies on CD40L brought to light a potentially very important role of mast cells and basophils in controlling 
IgE synthesis. To identify new cellular mechanisms that 
control IgE production, we tested whether, in the absence of T cells, other cell types could induce IgE synthesis by purified B 
cells that have been stimulated with IL-4. Freshly isolated 
mast cells, purified from human lung, and blood basophils were shown to express CD40L and to induce IgE production.  Basophils 
were able to induce IgE synthesis even in the absence of exogenous IL-4. This suggests that mast cells and basophils may play key 
roles in allergy not only by producing inflammatory mediators, but also by directly regulating IgE production independently of 
T cells. Thus, Ig switching which was previously thought to take place only in the germinal centres of lymph nodes, may also 
occur in peripheral organs such as the lung or the skin.<P>

The immunosupressive drug cyclosporin A has recently been shown to be of therapeutic benefit in the treatment of certain atopic 
diseases. We found that cyclosporin A inhibited the increase in CD40L mRNA synthesis that was induced by treating mast cells 
with calcium ionophore and phorbol ester. There was a corresponding decrease in the expression of the CD40L protein (Gauchat et 
al., 
1993). The inhibition of CD40L synthesis by mast cells might therefore contribute to the beneficial action of cyclosporin A. <P>

<b>CD23 and CD21</b><p>

The observation that IL-4 and IL-13, which induce IgE-switching, were able to increase CD23 expression, suggested that CD23 is 
also involved in the specific control of IgE production. 
This was confirmed by studies using anti-CD23 antibodies and recombinant soluble CD23, which were shown to regulate 
IL-4-induced IgE production. CD23 is a 45 kDa type II transmembrane 
glycoprotein that is expressed in many cell types. It was originally defined as a low affinity IgE receptor. Based on our 
observation that CD23 interacts with a ligand other than IgE, 
namely CD21, we have proposed a model whereby CD23/CD21 molecules facilitate the T cell/B cell interaction that is necessary 
for IgE production. CD23 is one of several molecules that 
are involved in the T cell/B cell interaction, along with LFA-1/ICAM-1, CD2/LFA-3, CD28/B7 and CD5/CD72. However, the 
particular characteristic of the CD21/CD23 pair, when compared to 
the others, is that this pairing specifically controls IgE synthesis; it does not affect the synthesis of other immunoglobulin 
isotypes.<P>

Studies on induction of the IgE response <cite>in vivo</cite>, in the rat, confirmed the crucial role played by CD23 (Flores-Romo et al., 
1993). A rabbit polyclonal antiserum, Rb55, raised against 
a truncated version of recombinant human CD23, was found to inhibit IL-4-induced IgE production by human mononuclear cells <cite>in 
vitro</cite> in an isotype-specific manner. Rb55  apparently also 
recognizes the rat homologue of CD23 since it binds to a cell surface molecule that is expressed on the surface of splenic B 
cells of rats that have been stimulated with IgE, a process 
known to induce a low affinity IgE receptor. Administration of Rb55 antibody to rats when  an allergen (ovalbumin)-specific IgE 
response was induced resulted in up to 90% inhibition of 
ovalbumin-specific IgE synthesis. The mechanism of inhibition is believed to be the prevention of T cell/B cell interaction, 
which is known to be essential for IgE production. Rb55 Fab 
fragments as well as intact Rb55 IgG both inhibited IgE production, <cite>in vitro</cite> and <cite>in vivo</cite>, and were also shown to prevent T 
cell/B cell conjugate formation. These results show for the 
first time that CD23 plays a central role in the regulation of IgE synthesis <cite>in vivo</cite> and may therefore be important in a number 
of allergic diseases. The identification of these new 
molecular and cellular pathways has greatly increased our understanding of human IgE regulation.<P>

<b>Some recent publications:</b><p>

Aubry, J.-P., Pochon, S., Graber, P., Jansen, K. and J.-Y. Bonnefoy. (1992).
CD21 is a ligand for CD23 and regulates IgE 
production. <i>Nature</i> 358: 505-7.<P>

Flores-Romo, L., Shields, J., Humbert, Y., Graber, P., Aubry, J.-P., Gauchat, J.-F., Ayala, G., Allet, B., Chavez, M., Bazin, H., 
Capron, M. and J.-Y. Bonnefoy. (1993).
Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. 
<i>Science</i> 261:1038-41.<P>

Di Santo, J.-P., Bonnefoy, J.-Y., Gauchat, J.-F., Fischer, A. and G. de Saint-Basile. (1993).
CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM.
<i>Nature</i> 361: 541-3.<P>

Gauchat, J.-F., Henchoz, S., Mazzei, G., Aubry, J.-P., Brunner, T., Blasey, H., Life, P., Talabot, D., Flores-Romo, L., Thompson, J., Kishi, K., Butterfield, J., Dahinden, C. and J.-Y. 
Bonnefoy. (1993).
Induction of human IgE synthesis in B cells by mast cells and basophils. <i>Nature</i> 365: 340-3. <P>

<a href="project.html">Return to: Research projects contents page</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-67</DOCNO>
<DOCOLDNO>IA057-000937-B020-204</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/il5.html 193.128.22.20 19970109095503 text/html 4296
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:45:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:19 GMT
Content-length: 4105
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Interleukin-5</font></h2>

<p>
<font size=5>One of the key events in chronic asthma is the migration into the lungs of a set of leukocytes known as 
eosinophils.  Upon activation of these cells, a variety of protein, lipid and other small molecule mediators are released into the
 surrounding tissues, resulting in inflammation and the destruction of cells.  The normal function of this reaction <cite>in vivo</cite> is to 
combat and eliminate invading parasites.  The aberrant recruitment and activation of eosinophils in asthma may therefore be a 
misfiring of the body's natural defences.</font><p>

A variety of factors can recruit eosinophils into inflammatory sites.  However, only one of these, interleukin-5 (IL-5), has been shown to have the three-fold ability to enhance the 
production of eosinophils, as well as their recruitment and activation. IL-5 is a dimeric protein with a molecular weight of 26 000 Da. Studies using animal models of allergic asthma 
have shown that antibodies against IL-5 block the recruitment of inflammatory cells into the lung.  Therapeutically, it would be useful to have a molecule that is not a protein, but 
which blocks the interaction of IL-5 with its receptor. As part of a programme to obtain such a molecule, we are defining  the active regions (the pharmacophores) in both the IL-5 
molecule and its receptor, which control their interaction.  It is not simply a question of identifying which amino acids are important, but also of defining their precise three dimensional location.<p>

The project has two underlying themes:<p>
<ul  type=disc>
<li>  First, to study the structure of IL-5 and its receptor by X-ray crystallography and by site-directed mutagenesis, so that we can define a pharmacophore, and from this identify 
new molecules which will help reduce the chronic inflammation in asthma. 

<li> Second, to draw conclusions from this study that will be generally applicable to the rational design of small molecules which 
can block protein-protein interactions.</ul><p>

<b>Dimeric protein</b><p>

<IMG  WIDTH=337 HEIGHT=201 SRC="bioinf4.gif"><p>

Interleukin-5 is a dimeric protein; the two subunits are identical and joined together by a pair of disulphide bridges.  We produced the protein in E. coli, in which it forms insoluble 
aggregates (inclusion bodies).  The IL-5 was subsequently extracted, refolded and purified.  After careful adjustment of the conditions (protein concentration, reductant, etc.) our 
'scale-up' protein purification laboratory produced 100 mg batches of pure, active IL-5. This was crystallised by our colleagues at the  Glaxo Research Institute  in North Carolina.<P> 

<a href="il52.html">Forward to: Protein structure</a><p>
<a href="project.html">Return to: Research projects contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-68</DOCNO>
<DOCOLDNO>IA057-000937-B020-218</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/trans.html 193.128.22.20 19970109095517 text/html 6457
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:45:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 6266
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30"> <basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Transcription</font></h2>

<p>
<font size=5>The goals of our research on gene regulation are to understand the mechanisms that lead to the specificity 
of gene regulation, how these different mechanisms interact and to determine the points of potential therapeutic intervention in gene transcription.</font><p>
One part of our work is focused on understanding the mechanisms of induction of the cellular adhesion molecule E-selectin.  By studying the molecular events that regulate expression of 
this gene we have identified several targets for modulating its production.  Modulating E-selectin expression would significantly affect the pathological inflammatory events seen in 
important diseases such as asthma, allergy and arthritis. <p>

In a second approach we are studying a particular class of transcription factors. Novel members of the family have been identified and we have obtained evidence about their potential 
roles.<p>

The biological basis for our research on E-selectin is the discovery that circulating leukocytes are selected by contact with blood vessel cells (endothelial cells) to perform their 
tasks.  The problem of selecting the appropriate circulating cells to participate in the inflammatory response is complex.   The endothelial cells must have mechanisms for signalling a 
site of inflammation and for recruiting  the appropriate circulating cells. <p>
A potent and selective mechanism that is used is the induction by inflammatory mediators (e.g., cytokines) of cellular adhesion molecules on endothelial cells.  These adhesion proteins 
interact with their counterparts on the circulating cells to select and adhere the correct cell types to the endothelial cells.  E-selectin is one of three similar adhesion proteins 
(selectins) which, by virtue of their lectin (or sugar affinity) structure, select leukocytes that express proteins carrying the counterpart carbohydrate molecules. <p>

Cells selected by E-selectin include neutrophils, monocytes, and some memory T-cells.  This is a critical group of cells in the inflammatory response; they provide both an immediate 
defence (neutrophils/monocytes) and a longer term response (memory T-cells).  Moreover E-selectin is the only adhesion molecule to be both exclusively expressed on endothelial cells 
and to be highly regulated.   E-selectin is found on the surface of endothelial cells, only following induction by an inflammatory signal.<P>

We found that treatment of endothelial cells with cytokines IL-1 or TNFa results in a dramatic increase (approximately 1000-fold) 
in the amount of E-selectin mRNA in the cells. This massive increase results from an equally impressive increase in the rate 
of transcription of the gene. We have identified four regions of the E-selectin promoter which bind proteins that control  its 
activity (Fig. 1).  Three of the four protein complexes that bind to the promoter have been extensively characterised.  Most important to the induction of transcription is the binding 
of the inducible transcription factor, NF-kB. <p>

In the absence of cytokine induction, NF-kB does not bind to its consensus binding sequence in the E-selectin promoter.  However, 
nuclear extracts from cells induced by cytokines have NF-kB that binds to this site.  Thus, IL-1 causes the NF-kB complex to migrate to the nucleus and bind the E-selectin promoter.  
In contrast to the inducible binding of NF-kB to the E-selectin promoter, we have identified a complex of ATF transcription factors which bind constitutively.  This complex is most 
probably a hete rodimer composed of two members of the ATF family (e.g. ATFa/ATF2) that bind to a sequence similar to the binding sequence of the 
CREB transcription factor.  <P>

Our demonstration that the NF-kB and ATF complexes physically interact with one another is particularly interesting because this protein/protein interaction may account for our 
observations on the interdependence of the two sites in promoting transcription; the amount of transcription when only one site is functional is much less than when both sites are 
active.  A third complex that we have recently identified is composed of the DNA binding protein HMG-I and most probably NF-kB.  HMG-I has been shown to bind DNA specifically and to 
interact with both ATFs and NF-kB.<P>

In summary, our data indicate that the dramatic induction of E-selectin expression by inflammatory signals such as IL-1 results from the following series of events. NF-kB is released 
from its complex with inhibitor and migrates to the nucleus where it binds to both its consensus sequence and to several other sites where it is stabilized by HMG-I.  The ATFs and the 
multiple NF-kBs then interact to form a potent transcription initiation complex which binds and activates the RNA polymerase complex.<P>

<a href="trans2.html">Forward to: Intracellular receptors</a><p>
<a href="project.html">Return to: Research projects contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-69</DOCNO>
<DOCOLDNO>IA057-000937-B020-241</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/yeast.html 193.128.22.20 19970109095539 text/html 8192
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:45:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:21 GMT
Content-length: 8001
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30"> <basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>
<h2><font size=6>Signal transduction in yeast</font></h2>
<p>

<font size=5>The power of yeast genetics provides unique opportunities 
for dissecting signal transduction pathways. We are taking full 
advantage of this to study signal transduction pathways that regulate cell wall synthesis. The components of such regulatory pathways are potential targets for developing new antifungal drugs.</font><p>

Yeast also provides the means for analysing mammalian signal transduction pathways. There are many yeast homologues of mammalian 
signal transduction components and, furthermore,  several mammalian receptors can function in yeast. This gives us exciting 
opportunities, working with members of the neurobiology group, to analyse the pathways that operate in neuronal outgrowth and 
survival.<p>

<b>Regulation of cell wall synthesis: protein kinase C1</b><p>

The regulation and timing of fungal cell wall synthesis must be intimately coupled to cell growth and progression through the cell 
cycle. The key enzymes involved in this process are likely to be important cell control proteins and may also be interesting 
regulatory targets for novel antifungal drugs.<P>

An opportunity for studying such an enzyme came when we identified a gene whose inactivation led to lysis of the Saccharomyces 
cerevisiae cell and which to our surprise was found to encode a yeast homologue of mammalian protein kinase C (PKC). In fact it 
proved to be the PKC1 gene that had been  previously identified by David Levin (Johns Hopkins University) on the basis of sequence 
similarity with mammalian homologues. Our subsequent research showed that the PKC1 gene product is a key player in a novel and 
complex pathway of signal transduction that regulates cell wall assembly in yeast. Homologues of mammalian kinases, MAP kinase 
(MPK) MAP kinase kinase (MEK) and MAP kinase kinase kinase (MEKKinase) were discovered to be part of this pathway. This has 
strengthened the view that such kinase cascades have been conserved in evolution, but have different functions in different 
cells, e.g. response to growth factor stimuli in human cells, but regulation of cell wall synthesis in yeast.<P>

In subsequent work, we have been analysing in detail the activity of the PKC1 gene product to discover the signals that tell a 
yeast cell when, and when not, to make cell wall.<P> 

<b>Mammalian receptors in yeast</b><p>

The conservation of signalling pathways between yeast and mammalian cells has been the springboard for another project, to use 
yeast as a host for  expressing components of mammalian signal transduction pathways. We are studying their interactions and 
regulation to derive insights about  how these pathways operate, particularly in neuronal development, and to determine their 
roles  in a variety of disease states.<P>

Mammalian signalling pathways respond to extracellular stimuli largely through ligands that bind to cell surface receptors which 
trigger intracellular signalling cascades. Broadly speaking, receptors fall into three families: those with seven transmembrane 
spanning domains (7TMs); growth factor receptors 
(tyrosine kinase or TK receptors) that, upon activation, often have the intrinsic ability to phosphorylate  tyrosine residues 
on key downstream effector molecules;  and ion channels which may or may not be activated by external ligands.<P>

We have expressed several types of receptor on the yeast cell surface. For example, a ligand gated ion channel, the 5HT3 receptor 
which responds to the ligand serotonin, can be expressed in a correct orientation at the cell surface of S. cerevisiae  and is 
pharmacologically indistinguishable from the same 
receptor found on  mammalian cells.  Both S. cerevisiae and the fission yeast Schizosaccharomyces pombe  can express several 
members of the 7TM class of receptor, in a functional 
form,  at the cell surface. We have developed a new range of S. pombe secretion vectors using the highly regulated promoter nmt 
to drive the synthesis of these recombinant proteins. <P>

<b>TK receptors.</b><p>

However, by far the most difficult class of receptor to express at the cell surface has been the TK receptors. Yeast cells do 
not appear to have endogeneous TK receptors;  this gives 
us the possibility of rebuilding mammalian signalling pathways in an otherwise naive host to allow detailed studies of 
regulatory mechanisms.  We have successfully produced an active 
form of the platelet-derived growth factor (PDGF) receptor in S. pombe. Although the receptor is probably not expressed at the 
cell surface, it is nevertheless able to phosphorylate <cite>in 
vivo</cite> known downstream effectors such as phospholipase-Cg and to activate them, a process which mimics that found in a mammalian 
growth factor-activated cascade. <P>

Through a number of important collaborations with groups outside Glaxo, we are studying the downstream events in neuronal growth 
factor signalling. Our plans are to couple activation of mammalian receptors to a visible change in yeast cells which would 
allow us to tell if the receptor is activated or regulated. 
One way of doing this is to activate yeast PKCs by receptor activation and to this end we have extended our studies on yeast PKCs to include the cloning of PKCs from yeasts other than 
S. cerevisiae, including C. albicans and S. pombe. The discovery of PKCs in yeast is surprising  since in mammalian cells they 
respond to 
extracellular signals. In yeast, these receptors might respond to intracellular signals, such as cell cycle checkpoints, or 
perhaps  
there are extracellular signals to which yeasts respond and for which they may have as yet undiscovered receptors. The study of  
yeast signalling pathways and their similarities to analogous pathways in mammals is a very exciting area of research which 
should give important insights into the regulation of mammalian signal transduction pathways in health and disease.<P>


<b>Some recent publications:</b><p>

Paravicini G., Cooper, M., Friedli, L., Smith, D.J., Carpentier, J.-L. , Klig, L.S. and M.A. Payton. (1992). 
The osmotic integrity of the yeast cell requires a functional PKC1 gene 
product. <i> Mol. Cell. Biol.</i>  12:4896-905.<P>

Mazzei, G.J., Schmid, E.M.,  Knowles, J.K.C., Payton, M.A. and K.G. Maundrell.
(1993). 
 A Ca2+ - independent protein kinase C from fission yeast. <i> J. Biol. Chem.</i> 268:7401-6.<P>

Antonsson, B., Montessuit, S., Friedli, L., Payton, M.A. and G. Paravicini.  (1994). 
Protein kinase C in yeast: characteristics of the S.cerevisiae PKC1 gene product. <i>  
J.Biol. Chem.</i> (in press).<P>

<a href="project.html">Return to: Research projects contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-70</DOCNO>
<DOCOLDNO>IA057-000937-B024-134</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/neuro2.html 193.128.22.20 19970109102829 text/html 5925
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:18:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 5734
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30">
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>
<h2><font size=6>SNAP-25</font></h2>

<font size=5>SNAP-25 is involved in axonal growth and transmitter release, processes that form the basis of cognition-related 
plasticity.</font><p>

The cDNA encoding SNAP-25 was also cloned by screening for genes that are differentially expressed during development. SNAP-25 is 
expressed in axonal growth cones during late stages of elongation. When we selectively inhibited SNAP-25 expression, by 
antisense oligonucleotides, we found that it prevented the 
elongation of neurites that were produced by rat cortical neurones and PC12 cells <cite>in vitro</cite> as well as those produced by 
amacrine cells of the developing chick retina <cite>in vivo</cite>. The results show that SNAP-25 plays a key role in axonal growth. They also suggest that the high levels of SNAP-25 expression that are found in 
specific areas of the adult brain may contribute to nerve terminal plasticity.<P>
SNAP-25 is also involved in regulating the release of neurotransmitters. In collaboration with scientists at the University of 
Padova, we showed that botulinum neurotoxins act as zinc-endoproteases that are specific for SNAP-25 (Schiavo et al. <cite>J. Biol. Chem.</cite> 268:23784-7. 1993). These toxins dramatically block 
transmitter release, indicating that SNAP-25 is involved in controlling 
transmitter release as well as axonal growth. Both mechanisms are known to be involved in the functional and morphological 
plasticity of nerve terminals that relate to cognitive events 
in the brain. Alterations of these mechanisms may therefore play important roles in cognitive decline during ageing and 
neurodegenerative diseases. <P>

<b>The proto-oncogene Bcl-2a blocks neuronal death in vivo.</b><p>
Bcl-2a blocks apoptosis in non-neuronal cells and we had previously found that it could also rescue neurones from apoptosis 
that was induced by depriving them of neurotrophic factor <cite>in 
vitro</cite>. (Garcia, I., Martinou, I., Tsujimoto, Y. and J.-C. Martinou.  Science 258:302-4, 1992). To find out whether bcl-2a could 
also rescue neurones <cite>in vivo</cite>, we generated, in 
collaboration with scientists at the University of Geneva, transgenic mice overexpressing bcl-2a under the control of the 
neurone-specific enolase promoter. The transgenic had 30-40% 
more neurones in the facial motor nucleus and in the ganglion cell layer of the retina, indicating that bcl-2a reduces the 
extent of naturally occurring neuronal death during 
development.<p> 

Bcl-2a overexpression also increases the survival of facial motorneurones whose axons have been cut. In wild type animals, the 
lesioned nerve and the corresponding 
motorneurone cell bodies underwent rapid degeneration, as expected. However, in transgenic mice, the facial motorneurones 
survived axotomy. bcl-2a also protects neurones from ischaemia 
induced by permanent middle cerebral artery occlusion; in transgenic mice the infarct area was reduced by approximately 50%.<p>

Regions of the bcl-2a protein that are required for subcellular localization, activity and interaction with other proteins are 
being determined by creating deletions, truncations and point mutations in regions that are most conserved between the different
 bcl-2 species. We found that membrane attachment is not required for the effects of bcl-2a on neurone survival.<P>
The mechanisms regulated by bcl-2a and other novel genes involved in neuronal survival are giving important insights that should 
lead to the development of novel strategies to treat neurodegenerative disease. Our goal therefore is to obtain a greater 
understanding of these mechanisms, for example by identifying 
proteins that interact with gene products that control neuronal survival and that transmit the signals for survival or death. <P>

<b>Some recent publications:</b><p>

Osen-Sand, A., Catsicas, S., Staple, J.K., Jones, K.A. and G. Ayala. (1993). 
Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. <i> Nature</i> 
364: 445-8.<P>
Dubois-Dauphin, M., Frankowski, H., Tsuijimoto, Y., Huarte, J. and J.-C. Martinou. (1994). 
Neonatal motoneurons overexpressing the bcl-2 protooncogene in transgenic mice are 
protected from axotomy-induced cell death. <i> Proc.Natl. Acad. Sci. U.S.A.</i> 91:3309-13.<p><p>

<a href="neuro.html">Back to: Neurodegeneration</a><p>
<a href="project.html">Return to: Research projects contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-71</DOCNO>
<DOCOLDNO>IA057-000937-B024-152</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/il52.html 193.128.22.20 19970109102849 text/html 5715
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:19:01 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:19 GMT
Content-length: 5524
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>
<h2><font size=6>Protein structure</font></h2>

<p>

<font size=5>One of the problems in using X-ray crystallography to solve the 
structures of proteins is that heavy atom derivatives 
are required to phase the diffraction spots.  Heavy metal salts are often used for this purpose, but this method is difficult 
to use with small proteins which sometimes do not contain distinct heavy atom binding sites.  We used a new approach (Graber et 
al., 1993) to obtain our derivatives.</font>
<p>

By growing an E. coli methionine auxotroph expressing IL-5 on seleno-methionine, we were able to produce a protein in which the 
sulphur atoms of the methionine were specifically replaced by the much heavier selenium.  This has the added advantage that we 
know exactly where the heavy atoms are located in  the protein sequence. <P> 

The structure of IL-5 has now been solved to a resolution of 2.4 angstroms (Milburn et al., 1993).  The protein is an intimate 
dimer, both sub-units being four helical bundles.  The 
individual subunits are coloured red and blue in the figure below.  It can be seen that there are two bundles or domains placed end to 
end, and that each domain contains secondary structure from 
both chains.  Starting with the N-terminus, the polypeptide chain of IL-5 forms three a-helices followed by a b-strand, all 
tightly packed together.  At this point (cysteine-86), the 
backbone crosses into the other half of the dimer to form a second b-strand and the final a-helix.  This sharing of one helix 
and a b-strand between the two domains is novel for 
cytokines.  It was not completely unexpected, since we had already demonstrated that the disulphide bonding pattern was "head 
to tail", in other words cysteine-86 from one subunit 
forms a disulphide bridge to cysteine-44 of the other subunit.  The reason why IL-5 is a dimer is also clear from the 
structure.  Many hydrophobic residues which are normally present 
in the core of the dimer would be exposed to solvent. By forming a dimer, some 7000 square angstroms of surface area is buried 
within the protein.<P>

<img src="bioinf4.gif"><p>

The topology of the four helical bundles of IL-5 is the same as that seen for many other cytokines such as IL-4, IL-2 and the 
colony stimulating factors.  This three dimensional 
similarity is all the more striking since there are no clear similarities between the primary sequences of the proteins. 
However IL-5 is unusual in that it is a dimer, and also that it 
is the only cytokine in which structural elements are shared between the two domains. <P> 
We are currently identifying the regions which are important in receptor binding.  Using site-directed mutagenesis we have 
already shown that, contrary to the published evidence, the 
fourth helix is not the essential one for interaction with the receptor.  This is important since it has been shown by other 
groups that antagonist variants of IL-4 can be made by 
mutating residues in the fourth helix.  This scenario does not appear to hold for IL-5; clearly cytokines are using a four 
helical bundle scaffold to hold together different 
pharmacophores. By using scanning mutagenesis techniques, we are refining our understanding of which amino acids are essential 
for binding and for the subsequent signalling events.  To 
address why the protein should exist as a dimer and whether residues from both halves of the molecule are really needed, we 
have developed a system for making heterodimers of mutant IL-5 molecules.<P> 

 
<b>Some recent publications:</b><p>

Graber, P., Bernard, A. R., Hassell, A. M., Milburn, M. V., Jordan, S. R., Proudfoot, A. E. I., Fattah, D. and T.N.C. Wells. 
(1993). Purification, characterisation and crystallisation of selenomethional recombinant human interleukin-5 from Escherichia coli. <i> Eur. J. Biochem.</i> 212:751-5.<P>

Milburn, M. V., Hassell, A. M., Lambert, M. H., Jordan, S. R., Proudfoot, A. E. I., Graber, P. and T.N.C. Wells. (1993). A novel dimer configuration revealed by the crystal structure at 2.4A resolution of human interleukin-5. <i> Nature </i>363: 172-6.<P>


 

<a href="il5.html">Back to: Interleukin-5</a><p>

<a href="project.html">Return to: Research projects contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-72</DOCNO>
<DOCOLDNO>IA057-000937-B024-171</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/geneva/trans2.html 193.128.22.20 19970109102924 text/html 4932
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:19:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:20 GMT
Content-length: 4741
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30"> <basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Intracellular receptors</font></h2>
<p>

This important class of receptors includes the steroid hormone receptors, which are ligand-activated transcription factors.  
Most intracellular receptors are transcriptional regulators 
that are themselves regulated by ligands. Small molecules that antagonize or agonize these receptors may be useful as 
therapeutics. Certain steroids analogues, for example,  are used to 
control inflammatory and immune reactions. Identification of new members of this family of receptors as well as a greater 
understanding of how they work, may well provide novel targets for regulating gene expression and for treating  diseases.<P>

The unifying and conserved feature of intracellular receptors is the presence of a DNA binding domain which is made up of two 
protein loops, each stablized by a zinc ion that gives them the name "zinc fingers".  Based on the conservation of amino acid 
residues in the DNA binding domain we have identified 
several novel intracellular receptors. The two most intriguing receptors are members of a new subfamily.  We have named these 
the Retinoid Z Receptors (RZRa and b) because of the high 
degree of homology of their DNA binding domains to those of the retinoid binding receptors, RAR and RXR.<P>

Both RZRs bind to DNA sequences that contain an extended retinoid response element.  The need for additional nucleotides allows 
a clear distinction to be made between the binding 
requirements of RZR and RAR/RXR.  Although RZRa and RZRb function similarly on the same response element, they differ markedly 
in their tissue distribution.  RZRa mRNA is found in many 
different tissues although the highest levels are found in skin and leukocytes.  In contrast, RZRb mRNA is highly localized.  
RZBb expression is primarily found in the brain. The particular location of RZRb-mRNA within the brain provides some clues as 
to its role in processing light input.<P>

Our research is now focused on understanding the functions of RZRs: which genes do they regulate; how are they regulated during 
development or differentiation; do they have roles in pathological states as well as in normal cell functioning?<P>

<b>Some recent publications:</b><p>

Hooft van Huijsduijnen, R., Whelan, J., Pescini, R., Becker-Andre, M., Schenk, A.-M. and J.F. DeLamarter (1992).  A T-cell enhancer cooperates with NF-kB to yield cytokine induction of E-selectin gene transcription in endothelial cells.
 <i> J. Biol. Chem.</i> 267:22385-91.<P>

Kaszubska, W., Hooft van Huijsduijnen, R., Ghersa, P., DeRaemy-Schenk, A.-M.,
Chen, B.P.C., Hai, T., DeLamarter, J.F. and J. Whelan (1993). Cyclic AMP-independent ATF family members interact with NFkB and function in the activation of the E-selectin promoter in response to cytokines. <i> Mol. Cell. Biol.</i> 13: 7180-90.<P>

Carlberg, C., Hooft van Huijsduijnen, R., Staple, J., DeLamarter, J.F. and M. Becker-Andre  (1993). RZRs, a new family of retinoid-related orphan receptors that function as both monomes and homodimers. <i> Mol. Endo.</i>  8:757-70. <P>

Lewis, H., Kaszubska, W., DeLamarter, J.F. and J. Whelan, J. (1994). Cooperativity between two NFkB complexes, mediated by HMG-I(Y), is essential for cytokine induced expression of the E-selectin promoter. <i> Mol. Cell. Biol. </i> (in press).<P>

<a href="trans.html">Back to: Transcription</a><p>
<a href="project.html">Return to: Research projects contents page</a>

<p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-73</DOCNO>
<DOCOLDNO>IA057-000937-B020-256</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/affymax/index.html 193.128.22.20 19970109095550 text/html 4176
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:46:03 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 3985
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>


<h2><font size=6>A unique approach to drugs discovery</font></h2>

<font size=5>"Rather than having a hand-crafted Swiss watch made by
talented craftsmen it's much more cost effective to produce low cost,
high tech versions like a Swatch that tell the time just as
well."</font><p>

This is the philosophy that drives Affymax, the Californian-based drugs
discovery company acquired by Glaxo Wellcome last year, according to Dr
Gordon Ringold, its chief executive officer.<p>

"In much the same way, rather than having highly skilled chemists worrying
about hand crafting one drug molecule at a time, you'd prefer them to be
thinking about developing automated processes that create a greater
diversity of molecules," explains Dr Ringold.<p>

While the $539 million acquisition of Affymax was to some extent
overshadowed by the merger between Glaxo and Wellcome, the biotech company
is already forging major research links that are being felt throughout the
new organisation. Technology transfer programmes are underway with Glaxo
Wellcome scientists around the world visiting California to learn the
unique Affymax approach to drugs research.<p>

The strategic alliance is intended to provide Glaxo Wellcome with a
technology and discovery centre for identifying novel drugs for the 21st
century and Affymax with the expertise of a major pharmaceutical company in
drugs development.<p>

Affymax was formed in 1989 by Alejandro Zaffaroni, a US scientist and
entrepreneur, with the goal of creating technology to develop cheap
automated processes for drugs discovery. His approach was to first identify
the problems and then bring together a diverse array of talented people to
devise radical solutions. The company, based at Palo Alto, is now an
acknowledged leader in the emerging field of combinatorial chemistry,
providing Glaxo Wellcome with state of the art technology for its efforts
in discovering drugs.<p>

Combinatorial chemistry functions by creating large numbers of diverse
compounds or libraries to test against different disease targets.
Scientists at Affymax have developed <a href="affytech.html">ingenious
automated technologies</a> for taking the smaller sub-units or
building blocks that comprise different compounds and assembling them
with others to create all possible combinations. These include the
technologies of:<p> <ul type=disc> <li><a
href="affytech.html#esl">Encoded Synthetic Libraries (ESL)</a>, <li><a
href="affytech.html#rpd">Recombinant Peptide Diversity (RPD)</a> and
<li><a href="affytech.html#vlsips">Very Large Scale Immobilised
Polymer Synthesis (VLSIPS)</a>.  </ul> <p>

<a href="affymax2.html">Forward to: Automated drug research</a><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>








<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-74</DOCNO>
<DOCOLDNO>IA057-000937-B008-33</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/affymax/affytech.html 193.128.22.20 19970109080403 text/html 3013
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:54:16 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:17 GMT
Content-length: 2822
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>




<h2><font size=6>Technologies for the next century</font></h2>

<a name="rpd">
<font size=5>Recombinant Peptide Diversity (RPD)</font><p>
RPD is a technology developed by Affymax in 1990 that involves the use of
living organisms such as bacteriophages to generate pools or libraries of
millions of peptides (short proteins). The compounds are then screened for
affinity against the disease targets.
<p>

<a name="vlsips">
<font size=5>Very Large Scale Immobilised Polymer Synthesis (VLSIPS)</font><p>
This involves the synthesis and screening of new drug candidates on silica
chips similar to those used in the semiconductor industry. The technology
uses light to control whether a sub-unit is added at each specific location
on the chip. Computer programs are able to plan what compounds are made at
a given location. Each 2cm by 2cm chip allows Affymax to generate up to
100,000 separate compounds. the technology is being developed further by
the spin-off company Affymetrix for genetic screening tests.
<p>
<a name="esl">
<font size=5>Encoded Synthetic Libraries (ESL)</font><p>
ESL is a technology developed at Affymax for generating and screening
hundreds of thousands of chemical compounds on the surface of microscopic
plastic beads. A tag giving the recipe for the compound is built on to the
individual bead. The approach has the advantage of allowing screening of
large libraries of diverse classes of compounds, including small organic
molecules.<p>

<a href="index.html">Back to: Affinity for Affymax</a><p>

<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-75</DOCNO>
<DOCOLDNO>IA057-000937-B008-52</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/affymax/affymax2.html 193.128.22.20 19970109080419 text/html 5973
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:54:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:16 GMT
Content-length: 5782
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>

<h2><font size=6>Automated drug research</font></h2>

<font size=5>The need for automated drug research has been brought to
the forefront by the human genome project - a worldwide research
effort aimed an uncovering all the genes controlling human
development.</font><p>

By knowing the gene responsible for different diseases, scientists
hope to develop new drugs to reverse the natural course of the
disease. Drugs might work, for example, by blocking the effect of
proteins produced by the aberrant gene.  The human genome project is
poised to make thousands of potential new drug targets available.<p>

By using manual techniques a typical chemist can synthesise and test only
50-100 compounds in a year. The estimated cost associated with producing
each individual compound is $5,000-$10,000.<p>

"Our quest is for efficiency, which is a combination of identifying new
drug targets and utilising rapid and cost-effective means of identifying
the compounds that interact with them," says Ron Barrett, senior vice
president at Affymax.<p>

Through a combination of innovative molecular biology techniques,
sophisticated software and semi-automated instrumentation technology,
Affymax now has the ability to rapidly synthesise and screen millions of
compounds simultaneously.<p>

Until recently, combinatorial chemistry could only generate peptides -
small proteins - and oligonucleotides - sequences of DNA - as potential
drugs. Now the advent of the new Affymax technology ESL allows them to also
generate organic molecules, making the approach of far greater interest to
the pharmaceutical industry.<p>

An important aspect of the Glaxo Wellcome acquisition is the transfer of
Affymax technology to the rest of the company. In a formal programme of
technology transfer, five scientists from Glaxo Wellcome in the UK have
spent several months at Affymax to learn the techniques of combinatorial
chemistry. The scientists' agenda included learning how to build and
dismantle the equipment, proving they could use it effectively.<p>

"By building their own equipment we're convinced that they'll be able to
trouble-shoot any problems that arise if it ever breaks down at their
base," says Russell Howard, president and scientific director of Affymax.
An additional advantage is that by fully understanding the equipment they
will also be able to adapt it to meet their own needs.<p>

<strong>Combinatorial libraries</strong><br>
In another type of interaction, scientists from different parts of Glaxo
Wellcome can use Affymax facilities to create combinatorial libraries to
discover drug "hits" against their own targets.<p>

Recent secondments to Affymax included a scientist from Glaxo Wellcome in
Verona, Italy, who visited California to make libraries for testing in
anti-bacterial screening, and another from the company in Madrid, Spain,
who made libraries for anti-fungal screening.<p>

"We hope they'll act as ambassadors, persuading other people to introduce
the technology back home," says Dr Howard. "Our dream is that one day every
chemist and biologist in Glaxo Wellcome will have access to our equipment."

Affymax is unconcerned that such widespread distribution of its technology
will make it obsolete. From past experience, the Affymax team knows that
all technology is capable of improvement and that identifying candidates is
only the first part of the drug discovery process.  The team hopes to
develop new assays for bioavailability that can gauge at an early stage how
well a compound behaves inside the body and whether it needs to be
administered as an injection or in pill form.<p>

Do not let Affymax's idyllic setting amidst palm trees and ornamental
fountains in the Californian sunshine fool you into thinking it is a
holiday camp. Alejandro Zaffaroni's original vision was to create a relaxed
environment with no organisational barriers between different disciplines,
providing people with plenty of opportunity to come together for the
exchange of ideas.<p>

Affymax believes it owes much of its success to an integrated approach,
combining teams of biologists, chemists and engineers. To this end it
created three operational teams of interdisciplinary groups working
together on different projects, rather than having, say, just one
department specialising in molecular biology or another dealing solely with
chemistry.<p>

<a href="affymax3.html">Forward to: Entrepreneurial culture</a><p>
<a href="index.html">Back to: Affinity for Affymax</a><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-76</DOCNO>
<DOCOLDNO>IA057-000937-B020-271</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/affymax/affymax3.html 193.128.22.20 19970109095611 text/html 3357
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:46:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:16 GMT
Content-length: 3166
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>

<h2><font size=6>Entrepreneurial culture</font></h2>

<font size=5>"The hallmark of technological invention comes from
having people with different backgrounds and perspectives looking at
the same problem from their own local vantage point and together
figuring out how to solve it," says Dr Ringold.</font><p>

Such approaches are already being developed by the rest of the Glaxo
Wellcome organisation. When the company recently reorganised its research
structure in the UK the advantages were recognised and adopted at the new
Medicines Research Centre at Stevenage.<p>

The entrepreneurial company culture encourages individual Affymax
scientists to have ideas and develop them through to working models.
Another mark of the company's flexibility has been the opportunity to
launch "spin off" companies, using outside finance, based on technology
whose applications are regarded as peripheral to Affymax's core interests.<p>

<strong>Interesting ideas</strong><br>
"If you put good ideas on the shelf there's a danger that you take away the
incentive of your most creative people, making it increasingly difficult to
attract and retain them," says Dr Ringold.<p>

To this end, 1993 saw the launch of Affymetrix, a company that is
developing the chip technology originally created for drug discovery to
produce diagnostic tests to screen for genetic diseases such as cystic
fibrosis.<p>

Owning Affymax has also allowed Glaxo Wellcome to establish a physical
presence in the high tech environment of the west coast of the USA.<p>

Dr Ringold: "We can serve as Glaxo Wellcome's eyes and ears to California's
academic and biotech community and provide the company with a technology
magnet that attracts people with interesting ideas to us."<p>

<a href="affyfile.html">Forward to: Affymax fact file</a><p>
<a href="affymax2.html">Back to: Automated drug research</a><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-77</DOCNO>
<DOCOLDNO>IA057-000937-B024-212</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/affymax/affyfile.html 193.128.22.20 19970109102959 text/html 2639
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:20:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:16 GMT
Content-length: 2448
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>



<h2><font size=6>Affymax fact file</font></h2>

<ul type=disc>

<li>The name Affymax is a distillation of the term affinity matrix,
which occurs when many disease targets are mixed with lots of molecules,
producing compounds with an affinity for each other in the combinatorial
process.<p>

<li>In December 1991 the first public offering of Affymax raised $92
million, the third largest in biotechnology. This allowed rapid growth in
1992 from 65 employees to 200.<p>

<li>In 1993, Affymetrix Inc, a subsidiary of Affymax, was created.
Glaxo Wellcome now owns about 48 per cent of the equity of Affymetrix.<p>

<li>In March 1995, Affymax was acquired by Glaxo, now Glaxo Wellcome.
Structurally, within Glaxo Wellcome, Affymax reports to Dr Barry Ross,
director of Research Strategy and Alliances. Functionally, it reports to
all Glaxo Wellcome research centres.<p>

<li>Affymax currently employs 215 people. Of these, 80 are biologists,
66 chemists and 13 engineers, with the remainder being support staff.
Affymax has two sites - Palo Alto and, not far away, Santa Clara.

</ul>
<p>
<a href="affymax3.html">Back to: Entrepreneurial culture</a><p>

<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-78</DOCNO>
<DOCOLDNO>IA057-000937-B008-136</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/workshop/index.html 193.128.22.20 19970109080547 text/html 2619
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:56:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:50 GMT
Content-length: 2428
Content-type: text/html
</DOCHDR>
 
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Conference announcement</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Conference announcement</font></h1>
<hr size=4>

<h2><font size=6>Transient gene expression in animal cells</b></font></h2>
<font size=5>11 - 14 May 1997. Hotel de France, Jersey<p>
Introduction<p>

Delivery of foreign DNA sequences into animal cells is a powerful tool to study the structure and function of proteins.  For these purposes, a wide variety of viral and non-viral approaches are being used.  Analytical and preparative applications of these systems will be addressed during this conference.</font> <p>

The conference invites presentations in the following areas:<p>

<ul type=disc>
<li>Baculovirus expression.
<li>Mammalian viral expression (SFV, Sindbis Vaccinia, Adeno, Retro).
<li>Non-viral expression (receptor-based, calcium phosphate, electroporation and liposome based transfection).
</ul>
</font>

<p>
<font size=4>You may currently choose to view the following:</font>
<p>
<dl>
<dd><a href="prog.html"><font size=4>Preliminary programme</font></a><br>
<a href="register.html"><font size=4>Registration and fees</font></a><br>
<a href="office.html"><font size=4>Organising committee</font></a><br>
</dl><p>
<a href="../notice.html">Return to: Glaxo Wellcome Noticeboard</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-79</DOCNO>
<DOCOLDNO>IA057-000937-B017-141</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/index.html 193.128.22.20 19970109093116 text/html 1746
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:21:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:23 GMT
Content-length: 1555
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7>Geneva Biomedical Research Institute 
</font></H1>
<HR size=4><br>

<h2><font size=6>Contents</font></h2>
<p>

<a href="intro.html">Introduction</a>
<p>	

<a href="project.html">Research highlights: A selection of projects</a><p>
<a href="genmap.html">How to find GBRI</A><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-80</DOCNO>
<DOCOLDNO>IA057-000937-B017-484</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/commun/index.html 193.128.22.20 19970109093639 text/html 2676
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:26:50 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:22 GMT
Content-length: 2485
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome in the community</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome in the community</font></h1>
<hr size=4>
<br>
<h2><font size=6>Contents</font></h2>
<p>

<font size=5>"A company is linked closely to the communities in which it
operates, locally, nationally or globally. It cannot exist in isolation."
</font> <p> <dl>

<dt><a href="comm1.html">A message from Sir Richard Sykes</a>
<p>
<dt><a href="comm2.html">Our policy for giving
</a><dd>Corporate citizenship applied to healthcare, education, the environment and the arts
<p>
<dt><a href="comm3.html">Healthcare
</a><dd>New medical facilities and other initiatives to improve healthcare in the UK
<p>
<dt><a href="comm4.html">Education
</a><dd>Working with the academic community to improve the teaching of science and medicine
<p>
<dt><a href="comm5.html">International healthcare
</a><dd>Meeting primary healthcare needs in the developing world
<p>
<dt><a href="comm6.html">The environment
</a><dd>Protecting and conserving the environment worldwide
<p>
<dt><a href="comm7.html">The arts
</a><dd>Encouraging the creation, performance and display of diverse works
<p>
<dt><a href="comm8.html">Community projects around the world
</a><dd>Supporting local needs through funds and employee involvement
</dl>
<p>
<a href="../proj.html">Return to: Community projects</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-81</DOCNO>
<DOCOLDNO>IA057-000937-B010-318</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/natprod/index.html 193.128.22.20 19970109082243 text/html 2005
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:12:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:22 GMT
Content-length: 1814
Content-type: text/html
</DOCHDR>
<html><head><title>Discovering modern medicines from natural products</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<H1><font size=7>Discovering modern medicines from natural products</font></H1>
<HR size=4><br>

<h2><font size=6>A statement of the policy of the Glaxo Wellcome group of companies</font></h2><p>

<IMG SRC="gifs/fluller.gif" align=center hspace=5 vspace=5><font size=2><cite>Catharansus roseus</cite>, the source of two important anti-cancer medicines.</font><br clear=left>
<p>
<dl>
<dt><a href="nprod1.html">Introduction</a><p></a><p>
<dt><a href="nprod2.html">Acquisitions policy</a><p>
<dt><a href="nprod3.html">Glaxo Wellcome and natural products discovery</a><p>
</dl>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-82</DOCNO>
<DOCOLDNO>IA057-000937-B008-154</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/nature/index.html 193.128.22.20 19970109080601 text/html 2253
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:56:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:01 GMT
Content-length: 2062
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Redesigning drug discovery</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Redesigning drug discovery</font></h1>
<hr size=4>
<h2><font size=6>An article from <a href="http://www.nature.com"><em>Nature</em></a><br><font size=4> Vol 384 . Supp . 7 November 1996</font></font></h2>


<font size=5>Glaxo Wellcome has introduced a radical new approach to
Research and Development, which, if successful, will make it a role
model in an industry which has previously treated R&amp;D as a series of
small one-off projects.</font><p>

<a href="nature1.html">Introduction</a><p>
<a href="nature2.html">Case study: <em>H. pylori</em></a><p>
<a href="nature3.html">Robotic screening</a><p>
<a href="nature4.html">Bioinformatics</a><p>
<a href="nature5.html">Combinatorial chemistry</a><p>
<a href="nature6.html">Systematization of research</a><p>

<a href="../">Return to: Glaxo Wellcome science contents page</a><p>





<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-83</DOCNO>
<DOCOLDNO>IA057-000937-B008-268</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/index.html 193.128.22.20 19970109080805 text/html 4020
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:58:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:38 GMT
Content-length: 3829
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - The Glaxo Wellcome Journal of Innovation in Healthcare</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=77 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>ODYSSEY</font></h1>
<hr size=4>
<br>
<h2><font size=6>The Glaxo Wellcome Journal of Innovation in Healthcare</font></h2><br>

<font size=5>Odyssey is a journal designed to contribute to the 
international exchange of information on innovative work related to the 
improvement of healthcare through research, clinical practice, health 
policies and administration.</font><p>

Every effort will be made by Glaxo Wellcome and the publishers to achieve the 
highest standards of objectivity and scientific balance throughout.  
Editorial matter will be subject to peer review or independent scrutiny 
as necessary to maintain integrity.<p>

Odyssey, as a service to science/medical education, welcomes suggestions 
for subject matter, and will give positive consideration to requests to 
use the journal's editorial and visual contents.<p>

Odyssey is published in printed form, three times yearly (usually in 
February, June and October).  Requests for inclusion on the mailing list 
  can be directed to the <a href="../../contact">national Glaxo Wellcome company</a> or to <a href="publish.html">the publishers.</a><p>

<font size=5>Odyssey articles currently available on this site:</font><p>
<dl>
<dt><font size=5><a href="menop/">Management of the menopause</a></font>
<dd>Is it all downhill from here?<br>
by Professor Henry G. Burger,<br>
Director of the Prince Henry's Institute of Medical Research,<br>
Melbourne, Australia,<br>
and President of the International Menopause Society<p>


<dt><font size=5><a href="cellbio/">Cell biology in clinical medicine</a></font>
<dd>Cinderella's reversal of fortune<br>
by Jan James,<br>
Professor Emeritus of Histology and Cell Biology,<br>
Academic Medical Centre in Amsterdam</font><p>  

<dt><font size=5><a href="worth/">Worthwhile persistence</font></a>
<dd>The process of new drug development<br>
by Kenneth I. Kaitin, PhD,<br>
Associate Director,<br>
Tufts Center For The Study of Drug Development,<br>
Tufts University, Boston, Massachusetts;<br>
and Huub Houben, MD,<br>
Publisher of Odyssey<p>
    
<dt><font size=5><a href="tuberc/">Tuberculosis</a></font>
<dd>The return of an old nemesis<br>

by Douglas B. Young,<br>
Department of Medical Microbiology<br>
St Mary's Hospital Medical School<br>
London, UK<p>

    
<dt><font size=5><a href="fungi/">Mushrooming problems</a></font>
<dd>Responding to the rise of fungal infection<br>
By J. Verhoef, I.M. Hoepelman and M. Lipovsky,<br>
Eijkman-Winkler Institute of Medical and Clinical Microbiology,<br>
University Hospital Utrecht, the Netherlands<p>
</dl>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-84</DOCNO>
<DOCOLDNO>IA057-000937-B017-247</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/affymax/index.html 193.128.22.20 19970109093252 text/html 4163
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:23:05 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:20 GMT
Content-length: 3972
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>


<h2><font size=6>A unique approach to drugs discovery</font></h2>

<font size=5>"Rather than having a hand-crafted Swiss watch made by
talented craftsmen it's much more cost effective to produce low cost,
high tech versions like a Swatch that tell the time just as
well."</font><p>

This is the philosophy that drives Affymax, the Californian-based drugs
discovery company acquired by Glaxo Wellcome last year, according to Dr
Gordon Ringold, its chief executive officer.<p>

"In much the same way, rather than having highly skilled chemists worrying
about hand crafting one drug molecule at a time, you'd prefer them to be
thinking about developing automated processes that create a greater
diversity of molecules," explains Dr Ringold.<p>

While the $539 million acquisition of Affymax was to some extent
overshadowed by the merger between Glaxo and Wellcome, the biotech company
is already forging major research links that are being felt throughout the
new organisation. Technology transfer programmes are underway with Glaxo
Wellcome scientists around the world visiting California to learn the
unique Affymax approach to drugs research.<p>

The strategic alliance is intended to provide Glaxo Wellcome with a
technology and discovery centre for identifying novel drugs for the 21st
century and Affymax with the expertise of a major pharmaceutical company in
drugs development.<p>

Affymax was formed in 1989 by Alejandro Zaffaroni, a US scientist and
entrepreneur, with the goal of creating technology to develop cheap
automated processes for drugs discovery. His approach was to first identify
the problems and then bring together a diverse array of talented people to
devise radical solutions. The company, based at Palo Alto, is now an
acknowledged leader in the emerging field of combinatorial chemistry,
providing Glaxo Wellcome with state of the art technology for its efforts
in discovering drugs.<p>

Combinatorial chemistry functions by creating large numbers of diverse
compounds or libraries to test against different disease targets.
Scientists at Affymax have developed <a href="affytech.html">ingenious
automated technologies</a> for taking the smaller sub-units or
building blocks that comprise different compounds and assembling them
with others to create all possible combinations. These include the
technologies of:<p> <ul type=disc> <li><a
href="affytech.html#esl">Encoded Synthetic Libraries (ESL)</a>, <li><a
href="affytech.html#rpd">Recombinant Peptide Diversity (RPD)</a> and
<li><a href="affytech.html#vlsips">Very Large Scale Immobilised
Polymer Synthesis (VLSIPS)</a>.  </ul> <p>

<a href="affymax2.html">Forward to: Automated drug research</a><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>










<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-85</DOCNO>
<DOCOLDNO>IA057-000937-B020-131</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/stevenage/index.html 193.128.22.20 19970109095406 text/html 2175
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:44:19 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:23 GMT
Content-length: 1984
Content-type: text/html
</DOCHDR>
<html><head><title>Glaxo Wellcome Medicines Research Centre, Stevenage</title></head><body background="back2.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=5>

<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>The Glaxo Wellcome Medicines Research Centre, Stevenage</font></h1>
<hr size=4>
<br>
<h2><font size=4>Opened by Her Majesty the Queen on 19 April 1995</font></h2><p>
<hr size=4>
<br>
<p align=center>
<IMG SRC="gifs/logo.gif"><br>
<IMG SRC="gifs/building.gif"></p>

<font size=6>Contents</font><p>

<dl>
<dt><a href="steve2.html">Research and development</a><p>
<dt><a href="steve4.html">Facilities and innovations</a><p>
<dt><a href="steve5.html">Design and layout</a><p>
<dt><a href="steve6.html">Working environment</a><p>
<dt><a href="steve7.html">Research programmes</a><p>
<dt><a href="steve8.html">The opening day motif</a><p>
</dl>
<p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-86</DOCNO>
<DOCOLDNO>IA057-000937-B007-372</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/stevenage/steve6.html 193.128.22.20 19970109080229 text/html 3109
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:52:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:24 GMT
Content-length: 2918
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>Glaxo Wellcome Medicines Research Centre, Stevenage</title></head>
<body background="back2.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">

<basefont size=4><a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a><br clear=left>
<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>The Glaxo Wellcome Medicines Research Centre, Stevenage</font></h1>
<hr size=4>
<br>

<h2><font size=6>Working environment</font></h2>

<font size=5>Both pilot plants at Stevenage are large, state-of-the-art facilities. Their size recognises the level of investment pharmaceutical companies have to make if they are to 
compete internationally.</font><p>


Two-thirds of the staff at Stevenage are scientists, the remaining 500 are support staff. The 150,000m<sup>(2)</sup> building area has to be operated and maintained, equipment has to be serviced 
and everyone has to be fed. Scientists need clean lab coats, specially-designed equipment and well-functioning software; they also need the latest research papers, so a sophisticated information service, including a library and many on-line services, has 
been established.<p>

Whatever their role, all the staff have been given a pleasant working environment. Externally, this is most evident in the land-scaping of the site. By the time the whole programme has 
been completed, some 150,000 shrubs and 28,000 trees will have been planted, there are even fish in the lake.<p>

Staff and those who live near to the site have also been given a safe environment. Safety has been paramount in this immense construction project; the record during the construction 
period was nine times better than the average for building work. The laboratory designs accommodate the highest building regulation standards.<p>


<a href="steve7.html">Forward to: Research programmes</a><p>
<a href="steve5.html">Back to: Design and layout</a><p>
<a href="index.html">Return to: Medicines Research Centre contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-87</DOCNO>
<DOCOLDNO>IA057-000937-B007-384</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/stevenage/steve7.html 193.128.22.20 19970109080249 text/html 3083
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:52:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:24 GMT
Content-length: 2892
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Medicines Research Centre, Stevenage</title>

</head><body background="back2.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">

<basefont size=4><a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif"  align=left border=0></a><br clear=left>
<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>The Glaxo Wellcome Medicines Research Centre, Stevenage</font></h1>
<hr size=4>
<br>

<h2><font size=6>Research programmes</font></h2>

<font size=5>Some of the specific diseases being addressed by Glaxo Wellcome research programmes are:</font><p>

<IMG  WIDTH=160 HEIGHT=330 SRC="gifs/musc.gif" align="right" vspace=5 hspace=5>
<ul type=disc>
<li>Migraine
<li>Chronic pain
<li>Alzheimer's
<li>Asthma
<li>Breast, lung, prostate cancers
<li>Eczema and psoriasis
<li>Hypertension and coronary heart disease
<li>Influenza
<li>Hepatitis B
<li>AIDS
<li>Bacterial infections
<li>Fungal infections
<li>Diabetes
<li>Rheumatoid arthritis
<li>Irritable bowel syndrome
<li>Sleeping disorders
<li>Osteoporosis
<li>Gastric ulcers
<li>Tuberculosis
<li>Epilepsy
<li>Depression
<li>Herpes
</ul>
<br clear=left><p><p>

While Glaxo Wellcome has the largest corporate R&amp;D resource in the pharmaceutical industry, it is insufficient to cover all the scientific possibilities.  Hence, the Group has 
collaborations with many universities around the world and also alliances with 
small biotechnology companies that have homed in on specific aspects of modern biology and developed them quickly. <p>

Glaxo Wellcome has committed &#163;40 million over 10 years towards the establishment of the Edward Jenner Institute for Vaccines Research. <p> 
In the UK, Glaxo Wellcome is currently supporting 335 PhD students and 160 post doctorates. <p>

<a href="steve8.html">Forward to: About the opening day motif</a><p>
<a href="steve6.html">Back to: Working environment</a><p>
<a href="index.html">Return to: Medicines Research Centre contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-88</DOCNO>
<DOCOLDNO>IA057-000937-B007-404</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/world/stevenage/steve8.html 193.128.22.20 19970109080315 text/html 2472
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:53:21 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:24 GMT
Content-length: 2281
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Medicines Research Centre, Stevenage</title></head>
<body background="back2.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">

<basefont size=4><a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a><br clear=left>
<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>The Glaxo Wellcome Medicines Research Centre, Stevenage</font></h1>
<hr size=4>
<br>

<h2><font size=6>About the opening day motif</font></h2>


<p align=center><IMG SRC="gifs/motif.gif"></p>
<font size=5>The  snakes in our Opening Day motif represent the healing arts practised by Aesculapius, the Greek physician and god of medicine. In ancient Greece, certain snakes were 
deemed sacred and it was believed that if they licked the wounds of the injured, healing would be promoted.<p>
</font>
The snakes emerge from a DNA molecule, which contains the fundamental genetic information for all human life.<p>
Overall, the symbol expresses our aspirations for the Glaxo Wellcome Medicines Research Centre: to provide a creative environment where our innovative scientists can work together to 
discover vital new medicines and therefore improve the health of future generations.<p><p>


<a href="steve7.html">Back to: Research programmes</a><p>
<a href="index.html">Return to: Medicines Research Centre contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-89</DOCNO>
<DOCOLDNO>IA057-000937-B017-92</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/stevenage/index.html 193.128.22.20 19970109093029 text/html 2149
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:20:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:26 GMT
Content-length: 1958
Content-type: text/html
</DOCHDR>
<html><head><title>Glaxo Wellcome Medicines Research Centre, Stevenage</title></head><body background="back2.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=5>

<a href="../index.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul>


<h1><font size=7>The Glaxo Wellcome Medicines Research Centre, Stevenage</font></h1>
<hr size=4>
<br>
<h2><font size=4>Opened by Her Majesty the Queen on 19 April 1995</font></h2><p>
<hr size=4>
<br>
<p align=center>
<IMG SRC="gifs/logo.gif"><br>
<IMG SRC="gifs/building.gif"></p>

<font size=6>Contents</font><p>

<dl>
<dt><a href="steve2.html">Research and development</a><p>
<dt><a href="steve4.html">Facilities and innovations</a><p>
<dt><a href="steve5.html">Design and layout</a><p>
<dt><a href="steve6.html">Working environment</a><p>
<dt><a href="steve7.html">Research programmes</a><p>
<dt><a href="steve8.html">The opening day motif</a><p>
</dl>
<p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-90</DOCNO>
<DOCOLDNO>IA057-000937-B018-464</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/index.html 193.128.22.20 19970109094525 text/html 2505
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:35:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:49 GMT
Content-length: 2314
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Notes on the preliminary results</font></h2>

<ol>
  <li><a href="1.html">General</a>
  <li><a href="2.html">Accounting policies</a>
  <li><a href="3.html">Exchange rates</a>
  <li><a href="4.html">Operating costs</a>
  <li><a href="5.html">Profit on disposal of business</a>
  <li><a href="6.html">Share of profits/(losses) of associated undertakings</a>
  <li><a href="7.html">Net (interest payable)/investment income</a>
  <li><a href="8.html">Taxation</a>
  <li><a href="9.html">Earnings per Ordinary Share</a>
  <li><a href="10.html">Dividends</a>
  <li><a href="11.html">Tangible fixed assets</a>
  <li><a href="12.html">Net (debt)/funds</a>
  <li><a href="13.html">Provisions for liabilities and charges</a>
  <li><a href="14.html">Segment information</a>
  <li><a href="15.html">Consolidated cash flow statement</a>  
</ol><p>
<hr><p>
<a href="../suppl/">Forward to: Supplementary financial information</a><p>
<a href="../review/">Back to: Trading and financial review</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-91</DOCNO>
<DOCOLDNO>IA057-000937-B018-477</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/1.html 193.128.22.20 19970109094533 text/html 2268
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:35:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:47 GMT
Content-length: 2077
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>1. General</font></h2>
<p>
<font size=5>The Profit and Loss Account and Cash Flow Statement for the 18 months ended, and the Balance Sheet at, 31st December 1995 are subject to completion of the audit.</font><p>

 The Profit and Loss Account and Cash Flow Statement for the year ended, and the Balance Sheet, at 30th June 1994 are an abridged statement of the full Group accounts for that year, restated for the change of accounting policy described in Note 2 below, which have been delivered to the Registrar of Companies.  The report of the auditors on the Accounts for that year was unqualified and did not contain a statement under either section 237(2) or section 237(3) of the Companies Act 1985.<p>

<a href="2.html">Forward to: Accounting policies</a><p>
<a href="index.html">Return to: Notes contents page</a><p>




  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-92</DOCNO>
<DOCOLDNO>IA057-000937-B017-506</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/2.html 193.128.22.20 19970109093657 text/html 2993
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:27:01 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 2802
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>2. Accounting policies</font></h2>
<p>

  
<font size=5>The Preliminary Results have been prepared in accordance with the Company's accounting policies, which, except for the change of accounting policy described below, are as set out in the Annual Report and Accounts for the year to 30th June 1994.</font><p>


In accordance with Urgent Issues Task Force Abstract 6, the accounting policy for post retirement benefits other than pensions provided for employees has been changed with effect from 1st July 1994.  The cost of such benefits, principally post retirement healthcare, is now recognised on an accruals basis over the working life of employees, whereas in prior years the cost was accounted for on a cash basis after employees had retired.  The cumulative adjustment in respect of the accrued cost at 1st July 1994, net of deferred taxation relief, amounts to &#163;17 million and has been charged directly against reserves as a prior year adjustment.  The comparative figures for the 12 months to 30th June 1994 have been restated: the effect on the results of that period is to reduce trading profit by &#163;5 million and taxation by &#163;1 million.  The effect on the results for the 18 months to 31st December 1995 is to reduce trading profit before integration costs by &#163;13 million, increase integration costs by &#163;30 million and reduce taxation by &#163;14 million.<p>


<a href="3.html">Forward to: Exchange rates</a><p>
<a href="1.html">Back to: General</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-93</DOCNO>
<DOCOLDNO>IA057-000937-B018-492</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/3.html 193.128.22.20 19970109094545 text/html 2349
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:35:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 2158
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>3. Exchange rates</font></h2>
<p>


The Group uses the average of exchange rates prevailing during the period to translate the results of overseas Group subsidiary and associated undertakings into sterling and period end rates to translate the net assets of those undertakings.  The currency which most influences these translations is the US dollar and the relevant exchange rates were:<p>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th>18 months to 31.12.95</th>
      <td align=center>12 months to 30.6.94</td></tr>

<tr><td>Average rates &#163;/US $</td><th>1.58</th>
      <td align=center>1.50</td></tr>
<tr><td>Period end rates &#163;/US $</td><th>1.55</th>
      <td align=center>1.54</td></tr>

      </table><p>

<a href="4.html">Forward to: Operating costs</a><p>
<a href="2.html">Back to: Accounting policies</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-94</DOCNO>
<DOCOLDNO>IA057-000937-B018-23</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/4.html 193.128.22.20 19970109093800 text/html 3404
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:28:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 3213
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>4. Operating costs</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>

  <tr><td></td><th colspan=6>18 months to 31.12.95</th><td align=center>12 months to<br>30.6.94<br>
 (restated)</td></tr>
  <tr><td></td><th>Glaxo continuing business<br>&#163;m</th>
  <th>Acquisitions<br>&#163;m</th>
  <th>Merged business<br>&#163;m</th>
  <th>Combined business<br>&#163;m</th>
  <th>Integration<br>&#163;m</th>
  <th>Total<br>&#163;m</th>
  <td align=center>&#163;m</td></tr>

  
<tr><td>Cost of sales</td><th>	1,037</th><th>	115	</th><th>654	</th><th>1,806</th><th>	558	</th><th>2,364	</th><td align=center>1,004</td></tr>
<tr><td>S,G&amp;A</td><th>	1,986	</th><th>227	</th><th>1,368	</th><th>3,581	</th><th>400	</th><th>3,981</th><td align=center>	1,988</td></tr>
<tr><td>R&amp;D</td><th>852	</th><th>103</th><th>585</th><th>1,540</th><th>257</th><th>1,797</th><td align=center>858</td></tr>
<tr><td>Other operating income</td></th> <th>(12)</th><th>(7)</th><th>(15)</th><th>(34)</th><th>-</th><th>(34)</th><td align=center>(11)</td></tr>
<tr><td colspan=8></td></tr>
<tr><td>Operating costs</td><th>3,863</th><th>438</th><th>2,592</th><th>6,893</th><th>1,215</th><th>8,108</th><td align=center>3,839</td></tr>


<caption align=bottom>S,G&amp;A= Selling, general and administrative expenditure.<br>R&amp;D = Research and development expenditure.</caption></table><p>

<a name="integ">
Costs expected to be incurred in integrating the businesses of Glaxo and Wellcome are estimated at &#163;1,215 million, comprising severances and other cash costs of &#163;763 million and losses on disposal of fixed assets of &#163;452 million.  Costs of &#163;384 million had been incurred by 31st December 1995 and provision for further costs of &#163;831 million has been made at that date.<p>

<a href="5.html">Forward to: Profit on disposal of business</a><p>
<a href="3.html">Back to: Exchange rates</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-95</DOCNO>
<DOCOLDNO>IA057-000937-B018-38</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/5.html 193.128.22.20 19970109093822 text/html 2005
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:28:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 1814
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>5. Profit on disposal of business</font></h2>
<p>
<font size=5>Glaxo India Limited sold its foods division on 30th September 1994.  The profit on disposal was &#163;35 million; the taxation and minority interest attributable to the disposal were &#163;7 million and &#163;14 million  respectively; the Group share of the profit was &#163;14 million.</font><p>



<a href="6.html">Forward to: Share of profits/(losses) of associated undertakings</a><p>
<a href="4.html">Back to: Operating costs</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-96</DOCNO>
<DOCOLDNO>IA057-000937-B018-85</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/6.html 193.128.22.20 19970109093909 text/html 2139
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:29:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:49 GMT
Content-length: 1948
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>6. Share of profits/(losses) of associated undertakings</font></font></h2>

<table border=2 cellpadding=2 cellspacing=2>
<tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>

<tr><td>	Warner Wellcome</td><th>				74	</th><td align=center>-</td></tr>
<tr><td>	Glaxo Warner-Lambert	</td><th>			(17)	</th><td align=center>(3)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td><br></td><th>57</th><td align=center>(3)</td></tr>
</table><p>



<a href="7.html">Forward to: Net (interest payable)/investment income</a><p>
<a href="5.html">Back to: Profit on disposal of business</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-97</DOCNO>
<DOCOLDNO>IA057-000937-B018-98</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/7.html 193.128.22.20 19970109093917 text/html 2574
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:29:30 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:49 GMT
Content-length: 2383
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>7. Net (interest payable)/investment income</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
<tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>
<tr><td>Interest payable</td><th>		337</th><td align=center>	44</td></tr>
<tr><th align=left colspan=3>	Investment income:</th></tr>
<tr><td>	Interest income</td><th>		265</th><td align=center>	180</td></tr>
<tr><td>	Realised losses and market value adjustments	</td><th>	(15)	</th><td align=center>(115)</td></tr>
<tr><td colspan=3></td></tr>
<tr><td><br></td><th>250</th><td align=center>65</td></tr>
<tr><td colspan=3></td></tr>
<tr><td><br></td><th>(87)</th><td align=center>21</td></tr>
</table><p>
	
The analysis of net interest payable for the 18 months to 31st December 1995 between continuing business, acquisitions and merged business is shown on the face of the consolidated profit and loss account.
<p>

  
<a href="8.html">Forward to: Taxation</a><p>
<a href="6.html">Back to: Share of profits/(losses) of associated undertakings</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-98</DOCNO>
<DOCOLDNO>IA057-000937-B018-111</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/8.html 193.128.22.20 19970109093929 text/html 2321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:29:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:49 GMT
Content-length: 2130
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>8. Taxation</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>(restated)<br>&#163;m</td></tr>

  <tr><td>UK</td>    <th>421</th>    <td align=center>269</td>    </tr>
  <tr><td>Overseas taxation</td>    <th>660</th>    <td align=center>311</td>    </tr>
  <tr><td>Deferred taxation</td>    <th>(251)</th>    <td align=center>(56)</td>    </tr>
  <tr><td>Irrecoverable Advance Corporation Tax</td>    <th>37</th>    <td align=center>-</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td><br></td>    <th>867</th>    <td align=center>524</td>    </tr>
  </table><p>


  
<a href="9.html">Forward to: Earnings per Ordinary Share</a><p>
<a href="7.html">Back to: Net (interest payable)/investment income</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-99</DOCNO>
<DOCOLDNO>IA057-000937-B018-142</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/9.html 193.128.22.20 19970109093953 text/html 3301
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:30:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:49 GMT
Content-length: 3110
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>9. Earnings per Ordinary Share</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>Pence</th><td align=center>12 months to 30.6.94<br>(restated)<br>Pence</td></tr>

  <tr><td>Earnings per Ordinary Share</td>    <th>44.5</th>    <td align=center>42.7</td>    </tr>
  <tr><td>Adjustment in respect of integration</td>    <th>30.1</th>    <td align=center>-</td>    </tr>
  <tr><td>Earnings per Ordinary Share before integration</td>    <th>74.6</th>    <td align=center>42.7</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Weighted average number of shares in issue (millions)</td>    <th>3,274</th>    <td align=center>3,040</td>    </tr>
  
  </table><p>

The earnings per Ordinary Share of 44.5p has been calculated by dividing the profit attributable to shareholders of &#163;1,458 million by the weighted average number of shares in issue during the 18 months to 31st December 1995.  Earnings per Ordinary Share is also shown calculated by reference to earnings before integration costs and related taxation in order to provide an indication of continuing business performance.<p>

The earnings per Ordinary Share is not materially different in either financial period when calculated on a fully diluted basis.  <p>

Earnings per Ordinary Share as shown on the face of the consolidated profit and loss account - 2 for the Glaxo continuing business for the 12 months to 30th June 1995 has been calculated by dividing the profit attributable to shareholders for that period of &#163;1,462 million by 3,056 million, the weighted average number of shares in issue during that period excluding shares issued on the acquisition of Wellcome plc.<p>

  
<a href="10.html">Forward to: Dividends</a><p>
<a href="8.html">Back to: Taxation</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-100</DOCNO>
<DOCOLDNO>IA057-000937-B018-126</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/10.html 193.128.22.20 19970109093943 text/html 2498
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:29:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:47 GMT
Content-length: 2307
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>10. Dividends</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>

  <tr><td>First Interim<br>10.0p per Ordinary Share (1994 - 9.0p)	</td>    <th>306</th>    <td align=center>274</td>    </tr>
  <tr><td>Second Interim<br>20.0p per Ordinary Share (1994 - nil)</td>    <th>698</th>    <td align=center>-</td>    </tr>
  <tr><td>Final - proposed<br>15.0p per Ordinary Share (1994 - 18.0p)</td>    <th>526</th>    <td align=center>549</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td><br></td>    <th>1,530</th>    <td align=center>823</td>    </tr>
  
  
  </table><p>

The first interim dividend was paid on 10th April 1995 and the second interim dividend on 23rd October 1995.  The proposed final dividend is payable on 20th May 1996.<p>

  
<a href="11.html">Forward to: Tangible fixed assets</a><p>
<a href="9.html">Back to: Earnings per Ordinary Share</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-101</DOCNO>
<DOCOLDNO>IA057-000937-B018-161</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/11.html 193.128.22.20 19970109094015 text/html 2515
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:30:27 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:47 GMT
Content-length: 2324
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>11. Tangible fixed assets</font></h2>
<p>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>&#163;m</td></tr>

  <tr><td>Net book value at beginning of period</td>    <th>3,184</th>    <td align=center>2,959</td>    </tr>
  <tr><td>Exchange adjustments</td>    <th>44</th>    <td align=center>(21)</td>    </tr>
  <tr><td>Additions</td>    <th>634</th>    <td align=center>543</td>    </tr>
  <tr><td>Acquisition of subsidiary undertakings</td>    <th>936</th>    <td align=center>2</td>    </tr>
  <tr><td>Depreciation</td>    <th>(533)</th>    <td align=center>(282)</td>    </tr>
  <tr><td>Disposals</td>    <th>(100)</th>    <td align=center>(17)</td>    </tr>

  <tr><td colspan=3></td></tr>
  <tr><td>Net book value at end of period</td>    <th>4,165</th>    <td align=center>3,184</td>    </tr>

</table><p>


  
<a href="12.html">Forward to: Net (debt)/funds</a><p>
<a href="10.html">Back to: Dividends</a><p>
<a href="index.html">Return to: Notes contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-102</DOCNO>
<DOCOLDNO>IA057-000937-B018-176</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/12.html 193.128.22.20 19970109094036 text/html 4083
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:30:36 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:47 GMT
Content-length: 3892
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>12. Net (debt)/funds</font></h2>
<p>
<font size=5>As the Group is now in a net debt position, net liquid funds at 30th June 1994 have been restated to include all debt.</font><p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th>At 31.12.95<br>&#163;m</th><td align=center>At 30.6.94<br>(restated)<br>&#163;m</td></tr>

  <tr><td>Current asset investments</td>    <th>1,041</th>    <td align=center>2,708</td>    </tr>
  <tr><td>Cash at bank</td>    <th>233</th>    <td align=center>55</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>1,274</th>    <td align=center>2,763</td>    </tr>
  <tr><td colspan=3></td></tr>

  
  <tr><td colspan=3>Loans and overdrafts due within one year:</td></tr>
  <tr><td>Bank loans and overdrafts</td>    <th>(437)</th>    <td align=center>(322)</td>    </tr>
  <tr><td>Commercial paper</td>    <th>(2,566)</th>    <td align=center>(75)</td>    </tr>
  <tr><td>Other loans</td>    <th>(1)</th>    <td align=center>(3)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>(3,004)</th>    <td align=center>(400)</td>    </tr>
  <tr><td colspan=3></td></tr>

  
  <tr><td colspan=3>Loans due after one year:</td>    </tr>
  <tr><td>Bank loans</td>    <th>(105)</th>    <td align=center>(122)</td>    </tr>
  <tr><td>8.75% Unsecured sterling Euro Bond</td>    <th>(496)</th>    <td align=center>-</td>    </tr>
  <tr><td>6.75% Unsecured US$ Euro Note 2000</td>    <th>(321)</th>    <td align=center>-</td>    </tr>
  <tr><td>Other loans</td>    <th>(421)</th>    <td align=center>(21)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>1,343</th>    <td align=center>(143)</td>    </tr>
  <tr><td colspan=3></td></tr>
  
  <tr><td>Convertible bonds</td>    <th>(123)</th>    <td align=center>(129)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td>Net (debt)/funds</td>    <th>(3,196)</th>    <td align=center>2,091</td>    </tr>
  <tr><td colspan=3></td></tr>
  
  <tr><td colspan=3>of which cash & cash equivalents were:</td></tr>
  <tr><td>Current asset investments</td>    <th>674</th>    <td align=center>438</td>    </tr>
  <tr><td>Cash at bank</td>    <th>233</th>    <td align=center>55</td>    </tr>

  <tr><td>Loans and overdrafts due within one year</td>    <th>(207)</th>    <td align=center>(305)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td><br></td>    <th>700</th>    <td align=center>188</td>    </tr>
  </table><p>


 
<a href="13.html">Forward to: Provisions for liabilities and charges</a><p>
<a href="11.html">Back to: Tangible fixed assets</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-103</DOCNO>
<DOCOLDNO>IA057-000937-B018-201</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/13.html 193.128.22.20 19970109094108 text/html 1855
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:31:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:47 GMT
Content-length: 1664
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>13. Provisions for liabilities and charges</font></h2>
<p>

  
<font size=5>Included in provisions for liabilities and charges is a provision of &#163;831 million for the costs of integrating the businesses of Glaxo and Wellcome.</font><p>



<a href="14.html">Forward to: Segment information</a><p>
<a href="12.html">Back to: Net (debt)/funds</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-104</DOCNO>
<DOCOLDNO>IA057-000937-B018-3</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/14.html 193.128.22.20 19970109093736 text/html 5749
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:27:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 5558
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>14. Segment information</font></h2>
<p>

 <font size=5>The Group continues to operate in a single business segment.  	An analysis of turnover, profit before taxation and net assets by geographical segment is set out below. </font><p>


 The Group's activities are organised on a worldwide basis.  The segmental figures are therefore influenced by the location of the Group's operating resources and by variations over time in intra group trading and funding arrangements.  Comparative figures for 1994 have been restated for the change in accounting policy described in <a href="2.html">Note 2</a> and to reflect the current presentation of net assets.<p>


<a name="turn">  
<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>(restated)<br>&#163;m</td></tr>

  <tr><th align=left colspan=3>Turnover by location of customer:</th> </tr>

  <tr><td>USA</td>    <th>4,408</th>    <td align=center>2,459</td>    </tr>
  <tr><td>Europe</td>    <th>3,618</th>    <td align=center>1,978</td>    </tr>
  <tr><td>Rest of the World</td>    <th>2,464</th>    <td align=center>1,219</td>    </tr>
  
<tr><td colspan=3></td></tr>
  <tr><td>External turnover</td>    <th>10,490</th>    <td align=center>5,656</td>    </tr>
<tr><td colspan=3></td></tr>

  <tr><th align=left colspan=3>Turnover by location of subsidiary undertaking:</th>  </tr>

  <tr><td>USA</td>    <th>4,329</th>    <td align=center>2,475</td>    </tr>
  <tr><td>Europe</td>    <th>5,33</th>    <td align=center>3,027</td>    </tr>
  <tr><td>Rest of the World</td>    <th>3,210</th>    <td align=center>1,630</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Gross turnover</td>    <th>12,872</th>    <td align=center>7,132</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><th align=left colspan=3>Inter segment turnover:</th>   </tr>

  <tr><td>USA</td>    <th>(29)</th>    <td align=center>(20)</td>    </tr>
  <tr><td>Europe</td>    <th>(1,562)</th>    <td align=center>(984)</td>    </tr>
  <tr><td>Rest of the World</td>    <th>(791)</th>    <td align=center>(472)</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>External turnover</td>    <th>10,490</th>    <td align=center>5,656</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><th align=left colspan=3>Profit before taxation by location of subsidiary undertaking:</th>    </tr>

  <tr><td>USA</td>    <th>1,447</th>    <td align=center>723</td>    </tr>
  <tr><td>Europe</td>    <th>1,217</th>    <td align=center>586</td>    </tr>
  <tr><td>Rest of the World</td>    <th>933</th>    <td align=center>508</td>

  <tr><td>Trading profit before integration costs</td>    <th>3,597</th>    <td align=center>1,817</td>    </tr>
  <tr><td>Integration costs</td>    <th>(1,215)</th>    <td align=center>-</td>    </tr>
  <tr><td>Profit on disposal of business</td>    <th>35</th>    <td align=center>-</td>    </tr>
  <tr><td>Share of profits/(losses) of associated undertakings</td>    <th>57</th>    <td align=center>(3)</td>    </tr>
  <tr><td>Net (interest payable)/investment income</td>    <th>(87)</th>    <td align=center>21</td>    </tr>
<tr><td colspan=3></td></tr>
<a name="profit">
  <tr><td>Profit before taxation</td>    <th>2,387</th>    <td align=center>1,835</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><th align=left colspan=3>Net assets:</th></tr>

  <tr><td>USA</td>    <th>516</th>    <td align=center>524</td>    </tr>
  <tr><td>Europe</td>    <th>2,463</th>    <td align=center>1,663</td>    </tr>
  <tr><td>Rest of the World</td>    <th>1,094</th>    <td align=center>871</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Net operating assets</td>    <th>4,073</th>    <td align=center>3,058</td>    </tr>
  <tr><td>Provisions for integration costs (net of taxation)</td>    <th>(656)</th>    <td align=center>-</td>    </tr>
  <tr><td>Net (debt)/funds</td>    <th>(3,196)</th>    <td align=center>2,091</td>    </tr>
<tr><td colspan=3></td></tr>
  <tr><td>Net assets</td>    <th>221</th>    <td align=center>5,149</td>    </tr>
</table><a name="assets"><p>


  
<a href="15.html">Forward to: Consolidated cash flow statement</a><p>
<a href="13.html">Back to: Provisions for liabilities and charges</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-105</DOCNO>
<DOCOLDNO>IA057-000937-B018-217</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/15.html 193.128.22.20 19970109094123 text/html 6557
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:31:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 6366
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>15. Consolidated cash flow statement</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>

<tr><td></td><th> 18 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 30.6.94<br>(restated)<br>&#163;m</td></tr>

<tr><th align=left colspan=3>Reconciliation of trading profit to net<br>cash inflow from operating activities:</th></tr>
  
  <tr><td>Trading profit excluding integration costs</td>    <th>3,597</th>    <td align=center>1,817</td>    </tr>
  <tr><td>Depreciation</td>    <th>533</th>    <td align=center>282</td>    </tr>
  <tr><td>Loss/(profit) on sale of tangible fixed assets</td>    <th>8</th>    <td align=center>(4)</td>    </tr>
  <tr><td>Decrease in stocks</td>    <th>8</th>    <td align=center>5</td>    </tr>
  <tr><td>(Increase)/decrease in debtors</td>    <th>(291)</th>    <td align=center>8</td>    </tr>
  <tr><td>Increase in creditors</td>    <th>163</th>    <td align=center>39</td>    </tr>
  <tr><td>Increase/(decrease) in pension and other provisions</td>    <th>74</th>    <td align=center>(2)</td>    </tr>
  <tr><td>Other movements</td>    <th>12</th>    <td align=center>-</td>    </tr>
<tr><td colspan=3></td></tr>

<a name="inflow">
  <tr><td>Net cash inflow from operating activities
      excluding integration costs</td>    <th>4,104</th>    <td align=center>2,145</td>    </tr>
  <tr><td>Integration costs paid</td>    <th>(269)</th>    <td align=center>-</td>    </tr>
<tr><td colspan=3></td></tr>
  
  <tr><td>Net cash inflow from operating activities</td>    <th>3,835</th>    <td align=center>2,145</td>    </tr>
<tr><td colspan=3></td></tr>
  
   <tr><th align=left colspan=3>Financing</th></tr>
  <tr><td>Balance at beginning of the period</td>    <th>1,358</th>    <td align=center>1,279</td>    </tr>
  <tr><td>Net cash inflow from financing</td>    <th>3,841</th>    <td align=center>39</td>    </tr>
  <tr><td>Ordinary Shares issued in lieu of cash dividends</td>    <th>45</th>    <td align=center>31</td>    </tr>
   <tr><td>Ordinary Shares issued on acquisition of Wellcome plc</td>    <th>2,941</th>    <td align=center>-</td>    </tr>
  <tr><td>Goodwill applied against merger reserve</td>    <th>(2,834)</th>    <td align=center>-</td>    </tr>
  <tr><td>Net non cash equivalents of subsidiary undertakings acquired</td>    <th>129</th>    <td align=center>1</td>    </tr>
  <tr><td>Exchange adjustments</td>    <th>18</th>    <td align=center>8</td>    </tr>
   <tr><td>Other movements</td>    <th>14</th>    <td align=center>-</td>    </tr>
 <tr><td colspan=3></td></tr>
 
  <tr><td>Balance at end of the period</td>    <th>5,512</th>    <td align=center>1,358</td>    </tr>
 <tr><td colspan=3></td></tr>
 
 <tr><td colspan=3>Financing comprises called up share capital, share premium account, Eurobonds, loan stocks, convertible bonds, other loans, commercial paper and bank loans and overdrafts repayable in three months or more from the date of the advance of &#163;335 million (12 months to 30th June 1994 - &#163;139 million).</td></tr>

<a name="cequiv">

 <tr><th align=left colspan=3>Cash &amp; cash equivalents:</th></tr>
 
 <tr><td>Balance at beginning of period</td>    <th>188</th>    <td align=center>441</td>    </tr>
  <tr><td>Increase/(decrease) in cash &amp; cash equivalents</td>    <th>507</th>    <td align=center>(271)</td>    </tr>
  <tr><td>Exchange adjustments</td>    <th>5</th>    <td align=center>18</td>    </tr>
  <tr><td colspan=3></td></tr> 
  <tr><td>Balance at end of period</td>    <th>700</th>    <td align=center>188</td>    </tr>

  

  <tr> <th align=left colspan=3>Reconciliation between the increase/(decrease) in cash &amp; cash equivalents and the increase in net (debt)/funds:</th></tr>
  
  <tr><td>Increase/(decrease) in cash &amp; cash equivalents</td>    <th>507</th>    <td align=center>(271)</td>    </tr>
 <tr><td colspan=3></td></tr>  
  <tr><td colspan=3>Non cash equivalents movements in net (debt)/funds:</td></tr>
  <tr><td>Net (sale)/purchase of non cash equivalent
current asset investments</td>    <th>(2,070)</th>    <td align=center>808</td>    </tr>
  <tr><td>Net advance of long term loans</td>    <th>(1,134)</th>    <td align=center>-</td>    </tr>
  <tr><td>Net advance of short term loans (1994 - repayment)</td>    <th>(2,601)</th>    <td align=center>12</td>    </tr>
  <tr><td>Net non cash equivalents of subsidiary undertakings acquired</td>    <th>54</th>    <td align=center>(1)</td>    </tr>
 <tr><td colspan=3></td></tr>
  <tr><td>Exchange adjustments</td>    <th>4</th>    <td align=center>(124)</td>    </tr>
  <tr><td>Other non cash movements</td>    <th>(47)</th>    <td align=center>(21)</td>    </tr>
  <tr><td colspan=3></td></tr>
  <tr><td></td>    <th>(5,794)</th>    <td align=center>	674</td>    </tr>
<tr><td colspan=3></td></tr>

<tr><td>Increase in net (debt)/funds</td>    <th>(5,287)</th>    <td align=center>403</td>    </tr>

  </table><p>


  
<a href="15b.html">Forward to: Consolidated cash flow statement (continued)</a><p>
<a href="14.html">Back to: Segment information</a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-106</DOCNO>
<DOCOLDNO>IA057-000937-B018-232</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/notes/15b.html 193.128.22.20 19970109094135 text/html 4136
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:31:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:48 GMT
Content-length: 3945
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>15. Consolidated cash flow statement (continued)</font></h2>
<p>
<a name="subs">
<strong>Purchase of subsidiary undertakings:</strong><p>

<table border=2 cellpadding=2 cellspacing=2>


<tr><td></td><th colspan=5>18 months to 31.12.95</th></tr>
<tr><td></td><th>Wellcome plc<br>&#163;m</th>
<th>Affymax N.V.<br>&#163;m</th>
<th>Cascan<br>&#163;m</th>
<th>Glaxo Korea<br>&#163;m</th>
<th>Total<br>&#163;m</th></tr>

<tr><td>	Total purchase consideration	</td><th>	9,333</th><th>	347	</th><th>67	</th><th>18	</th><th>9,765</th></tr>
<tr><td colspan=6>	Non cash element of consideration:</td></tr>
<tr><td>	Tax relief on US share options	</td><th>	42</th><th>	-	</th><th>-	</th><th>-	</th><th>42</th></tr>
<tr><td>	Shares issued</td><th>		                (2,941)</th><th>	-	</th><th>-	</th><th>-	</th><th>(2,941)</th></tr>
	<tr><td colspan=6></td></tr>
<tr><td>	Cash consideration paid	</td><th>	        6,434	</th><th>347</th><th>	67	</th><th>18	</th><th>6,866</th></tr>
<tr><td>	Cash &amp; cash equivalents acquired	</td><th>(730)</th><th>	(66)	</th><th>-	</th><th>(2)	</th><th>(798)</th></tr>
	<tr><td colspan=6></td></tr>
<tr><td>	Net cash payment on acquisition</td><th>		5,704</th><th>	281	</th><th>67	</th><th>16	</th><th>6,068</th></tr>
<tr><td>	Dividend paid to Wellcome plc shareholders</td><th>119</th><th>	-	</th><th>-	</th><th>-	</th><th>119</th></tr>
	<tr><td colspan=6></td></tr>
<tr><td><br></td><th>			5,823</th><th>	281</th><th>	67	</th><th>16</th><th>	6,187</th></tr>


</table><p>

  
Wellcome plc, which was acquired on 16th March 1995, contributed &#163;187 million to the Group's net operating cash flows before integration costs, paid &#163;20 million of integration costs, received &#163;25 million in respect of net returns on investments and servicing of finance, paid &#163;151 million in respect of taxation and received &#163;38 million from investing activities in the period to 30th June 1995.  Since that date it is not feasible to report separately the cash flows of the acquired business.<p>

<a name="disp">  
<strong>Disposal of businesses:</strong><br>
The net cash proceeds received from the disposal of the foods division of Glaxo India Limited were &#163;39 million, consisting of consideration received of &#163;42 million less cash & cash equivalents disposed of &#163;3 million.  The net consideration received from the disposal of Hazeline, the Singapore based consumer products business, was &#163;93 million.  The total consideration received from the disposal of businesses in the period was &#163;132 million.<p>

  

<a href="15.html">Back to: Consolidated cash flow statement </a><p>
<a href="index.html">Return to: Notes contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-107</DOCNO>
<DOCOLDNO>IA057-000937-B018-508</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/suppl/index.html 193.128.22.20 19970109094558 text/html 3275
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:36:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:52 GMT
Content-length: 3084
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Supplementary financial information</font></h2>
<p>
<font size=5>In view of the change in financial year end from 30th June to 31st December and the effect of the acquisition of Wellcome plc, the financial information set out below has been prepared to indicate the results of Glaxo Wellcome on a calendar year basis, so as to provide comparative data for the 1996 financial year.  The information is presented on statutory and pro forma bases.</font><p>
  

<dl>
<dt><a href="stat.html">Statutory basis</a>
<dd>The results of Glaxo Wellcome for calendar years 1995 and 1994.  In 1995 Wellcome is consolidated from its date of acquisition on 16th March 1995.  The 1994 results represent Glaxo alone.<p>


<dt><a href="prof.html">Pro forma basis</a>
<dd>The combined pro forma results of Glaxo and Wellcome for calendar year 1995 on a consistent basis of presentation as if Glaxo Wellcome had existed as a combined entity from 1st January 1995.<p>


<dt><a href="sales.html">Pro forma sales</a>
<dd>The combined pro forma sales of Glaxo and Wellcome, with respect to the criteria mentioned above.
</dl><p>
<hr>
Notes:
<ol>
  <li>Adjustments have been made to the Wellcome results:<br>
      <ul type=blank><li>to reflect Glaxo accounting policies 
      <li>to incorporate at 1st January 1995 the fair value adjustments implemented as of 16th March 1995.</ul>
<li> The Wellcome exceptional item of &#163;27 million in respect of bid defence costs in the six months to 30th June 1995 has been excluded.
<li>The costs of financing the acquisition have been reflected from 1st January 1995.
<li>The costs of integrating the Glaxo and Wellcome businesses have been excluded.
</ol><p>
<hr>


<a href="../review/">Back to: Notes on the preliminary results</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>


 

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-108</DOCNO>
<DOCOLDNO>IA057-000937-B018-521</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/suppl/stat.html 193.128.22.20 19970109094609 text/html 3830
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:36:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:53 GMT
Content-length: 3639
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Statutory basis</font></h2>

<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><th> 12 months to 31.12.95<br>&#163;m</th><td align=center>12 months to 31.12.94<br>&#163;m</td></tr>

<tr><td>TURNOVER</td>    <th>7,638</th>    <td align=center>5,705</td>    </tr>
     <tr><td>Cost of sales</td>    <th>1,313</th>    <td align=center>1,003</td>    </tr>
  <tr><td>Selling, general and administrative expenditure</td>    <th>2,643</th>    <td align=center>1,954</td>    </tr>
  <tr><td>Research and development expenditure</td>    <th>1,130</th>    <td align=center>851</td>    </tr>
  <tr><td>Other operating income</td>    <th>(29)</th>    <td align=center>(10)</td>    </tr>
 <tr><td colspan=3></td></tr>
  <tr><td>Operating costs</td>    <th>5,057</th>    <td align=center>3,798</td>    </tr>
 <tr><td colspan=3></td></tr>  
<tr><td>TRADING PROFIT</td>    <th>2,581</th>    <td align=center>1,907</td>    </tr>
  <tr><td>Profit on disposal of business</td>    <th>-</th>    <td align=center>35</td>    </tr>
  <tr><td>Share of profits/(losses) of associated undertakings</td>    <th>60</th>    <td align=center>(5)</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>PROFIT BEFORE INTEREST</td>    <th>2,641</th>    <td align=center>1,937</td>    </tr>
  <tr><td>Net interest payable</td>    <th>(136)</th>    <td align=center>(3)</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</td>    <th>2,505</th>    <td align=center>1,934</td>    </tr>
  <tr><td>Taxation</td>    <th>768</th>    <td align=center>569</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES AFTER TAXATION</td>    <th>1,737</th>    <td align=center>1,365</td>    </tr>
  <tr><td>Minority interests</td>    <th>35</th>    <td align=center>34</td>    </tr>
 <tr><td colspan=3></td></tr>
  <tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>    <th>1,702</th>    <td align=center>1,331</td>    </tr>
 <tr><td colspan=3></td></tr>
<tr><td>EARNINGS PER ORDINARY SHARE</td>    <th>50.3p</th>    <td align=center>43.6p</td>    </tr>

<tr><td>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES IN ISSUE (MILLIONS)</td>    <th>3,386</th>    <td align=center>3,049</td>    </tr>



  
  </table><p>


  
<a href="prof.html">Forward to: Pro forma basis</a><p>
<a href="index.html">Return to: Supplementary financial information contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-109</DOCNO>
<DOCOLDNO>IA057-000937-B019-9</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/suppl/prof.html 193.128.22.20 19970109094617 text/html 4262
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:36:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:52 GMT
Content-length: 4071
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Pro forma basis</font></h2>
<p>


<table border=2 cellpadding=2 cellspacing=2>
  <tr><td></td><td align=center> 6 months to 30.06.95<br>&#163;m</td><td align=center>6 months to 31.12.95<br>&#163;m</td><th>12 months to 31.12.95<br>&#163;m</th></tr>

<tr><td>TURNOVER</td>        <td align=center>3,955</td>  <td align=center>4,018</td>    <th>7,973</th> </tr>
     <tr><td>Cost of sales</td><td align=center>725</td>  <td align=center>654</td>    <th>1,379</th> </tr>
     
  <tr><td>Selling, general and administrative expenditure</td> 	 <td align=center>1,417</td>  <td align=center>	1,368</td>    <th>	2,785</th></tr>
  <tr><td>Research and development expenditure</td>  <td align=center>615</td>  <td align=center>	585	</td>    <th>1,200</th></tr>
  <tr><td>Other operating income</td>   <td align=center>(17)</td>  <td align=center>	(15)	</td>    <th>(32)</th></tr>
 <tr><td colspan=4></td></tr>
  <tr><td>Operating costs</td>   <td align=center>2,740</td>  <td align=center>	2,592	</td>    <th>5,332</th></tr>
 <tr><td colspan=4></td></tr>
 
<tr><td>TRADING PROFIT</td>  <td align=center>1,215</td>  <td align=center>	1,426	</td>    <th>2,641</th></tr>
   <tr><td>Share of profits of associated undertakings</td> <td align=center> 33</td>  <td align=center>	39	</td>    <th>72</th></tr>
 <tr><td colspan=4></td></tr>
 
<tr><td>PROFIT BEFORE INTEREST</td>  <td align=center>1,248	</td>  <td align=center>1,465	</td>    <th>2,713</th></tr>
  <tr><td>Net interest payable</td>   <td align=center>(98)</td>  <td align=center>	(121)	</td>    <th>(219)</th></tr>
 <tr><td colspan=4></td></tr>
 
<tr><td>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</td> 	 <td align=center>1,150</td>  <td align=center>	1,344	</td>    <th>2,494  </th></tr>
  <tr><td>Taxation</td>    <td align=center>315</td>  <td align=center>	417	</td>    <th>732</th></tr>
 <tr><td colspan=4></td></tr>
<tr><td>PROFIT ON ORDINARY ACTIVITIES AFTER TAXATION</td>   <td align=center>835	</td>  <td align=center>927	</td>    <th>1,762 </th></tr>
  <tr><td>Minority interests</td>   <td align=center>19	</td>  <td align=center>18	</td>    <th>37</th></tr>
 <tr><td colspan=4></td></tr>
  <tr><td>PROFIT ATTRIBUTABLE TO SHAREHOLDERS</td>  <td align=center>816	</td>  <td align=center>909	</td>    <th>1,725  </th></tr>
 <tr><td colspan=4></td></tr>
<tr><td>EARNINGS PER ORDINARY SHARE</td>   <td align=center> 23.4p	</td>  <td align=center>26.0p	</td>    <th>49.4p</th></tr>

<tr><td>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES IN ISSUE (MILLIONS)</td>    <td align=center>3,490	</td>  <td align=center>3,497	</td>    <th>3,494</th></tr>




  </table><p>


  
<a href="sales.html">Forward to: Pro forma sales</a><p>
<a href="stat.html">Back to: Statutory basis</a><p>
<a href="index.html">Return to: Supplementary financial information contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-110</DOCNO>
<DOCOLDNO>IA057-000937-B019-25</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/suppl/sales.html 193.128.22.20 19970109094627 text/html 6937
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:36:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:52 GMT
Content-length: 6746
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Pro forma sales</font></h2>

<table border=2 cellpadding=2 cellspacing=2>
  <tr>
    <td colspan=2></td><td align=center>6 months to 30.06.95<br>&#163;m</td><td align=center>6 months to 31.12.95<br>&#163;m</td><th>12 months to 31.12.95<br>&#163;m</th></tr>

<tr><th>THERAPEUTIC AREA</th>	<th colspan>MAJOR PRODUCTS</th><td colspan=3><br></td></tr>

<tr><th>Gastro-intestinal</th>   <th align=left>Total</th>   <th>1,173</th>   <th>1,082</th>   <th>2,255</th></tr>
<tr><td></td>   <td>Zantac</td>   <td align=center>1,173</td>   <td align=center>1,082</td>   <td align=center>2,255</td></tr>

<tr><th>Respiratory</th>   <th align=left>Total</th> <th>791</th> <th>812</th>  <th>1,603</th></tr>
<tr><td></td>   <td>Ventolin</td> <td align=center>263</td>  <td align=center>263</td>  <td align=center>526</td>  </tr>
<tr><td></td>   <td>Becotide</td> <td align=center>196</td>  <td align=center>201</td>  <td align=center>397</td>   </tr>
<tr><td></td>   <td>Serevent</td> <td align=center>125</td>  <td align=center>146</td>  <td align=center>271</td>   </tr>
<tr><td></td>   <td>Beconase</td> <td align=center>92</td>  <td align=center>64</td>  <td align=center>156</td>   </tr>
<tr><td></td>   <td> Flixonase</td> <td align=center>58</td>  <td align=center>61</td>  <td align=center>119</td>   </tr>
<tr><td></td>   <td> Flixotide</td> <td align=center>36</td>  <td align=center>52</td>  <td align=center>88</td>   </tr>
<tr><th>Viral infections</th>   <th align=left>Total</th>  <th>522</th> <th>577</th> <th>1,099</th></tr>
<tr><td></td>   <td>Zovirax</td>  <td align=center>415</td>  <td align=center>441</td> <td align=center>856</td>  </tr>
<tr><td></td>   <td>Retrovir</td> <td align=center>96</td>  <td align=center>105</td>  <td align=center>201</td>  </tr>
<tr><td></td>   <td>Valtrex</td> <td align=center>1</td>  <td align=center>8</td>  <td align=center>9</td>  </tr>
<tr><th>Bacterial infections</th>   <th align=left>Total</th> <th>501</th> <th>462</th>  <th>963</th> </tr>
<tr><td></td>   <td>Zinnat</td>  <td align=center>211</td>  <td align=center>182</td> <td align=center>393</td>   </tr>
<tr><td></td>   <td>Fortum</td> <td align=center>157</td>  <td align=center>149</td>  <td align=center>306</td>   </tr>
<tr><td></td>   <td>Zinacef</td><td align=center>66</td>  <td align=center>59</td>   <td align=center>125</td>   </tr>
<tr><th>CNS disorders</th>   <th align=left>Total</th>  <th>207</th> <th>294</th> <th>	501</th>  </tr>
<tr><td></td>   <td>Imigran</td> <td align=center>142</td>  <td align=center>224</td>  <td align=center>366	</td>  </tr>
<tr><td></td>   <td>Lamictal</td> <td align=center>30</td>  <td align=center>35</td>  <td align=center>	65	</td> </tr>
<tr><th>Oncology</th>   <th align=left>Total</th> <th>220</th> <th>231</th>  <th>	451	</th>  </tr>
<tr><td></td>   <td>Zofran</td> <td align=center>191</td>  <td align=center>195</td>  <td align=center>386	</td>  </tr>
<tr><th>Dermatologicals</th>   <th align=left>Total</th> <th>105</th> <th>100</th>  <th>	205	</tr>
<tr><th>Cardiovascular</th>   <th align=left>Total</th> <th>88</th> <th>99</th>  <th>	187	</th>   </tr>
<tr><th>Anaesthesia</th>   <th align=left>	Total</th> <th>55</th> <th>62</th>  <th>	117	</th> </tr>
<tr><th>Others</th>   <th align=left>  	Total</th> <th>293</th> <th>299</th>  <th>	592	</th> </tr>
<tr><td></td>   <td>		Zyloric</td> <td align=center>56</td>  <td align=center>59</td>  <td align=center>115	</td> </tr>
<tr><td></td>   <td>		Imuran</td> <td align=center>48</td>  <td align=center>57</td>  <td align=center>	105	</td>  </tr>
<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td><br></td> <th>3,955</th> <th>4,018</th> <th>7,973</th></tr>
<tr><td colspan=5></td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5></td></tr>
  
<tr><th>REGION</th><th>MAJOR MARKETS</th><td colspan=3><br></td></tr>

<tr><th>USA</th>   <th align=left>Total</th> <th>1,618</th> <th>1,691</th>  <th>3,309</th>  </tr>
<tr><th>Europe</th>   <th align=left>Total</th>  <th>1,376</th> <th>1,363</th> <th>	2,739</th>  </tr>
<tr><td></td><td>UK</td> <td align=center>302</td>  <td align=center>326</td> <td align=center>628</td>  </tr>
<tr><td></td><td>France</td> <td align=center>231</td>  <td align=center>219</td> <td align=center>	450	</td> </tr>
<tr><td></td><td>Germany	</td> <td align=center>187</td>  <td align=center>159</td> <td align=center>346</td>	 </tr>
<tr><td></td><td>Italy	</td> <td align=center>165</td>  <td align=center>168</td> <td align=center>333	</td> </tr>
<tr><td></td><td>Eastern Europe</td> <td align=center>41</td>  <td align=center>38</td> <td align=center>	79	</td> </tr>
<tr><th>Rest of the World</th>   <th align=left>Total</th>  <th>961</th> <th>964</th> <th>	1,925</th>	</tr>
<tr><td></td><td>Japan	</td> <td align=center>357</td>  <td align=center>344</td> <td align=center>701	</td> </tr>
<tr><td></td><td>Asia Pacific	</td> <td align=center>204</td>  <td align=center>205</td> <td align=center>409	</td> </tr>
<tr><td></td><td>Latin America</td> <td align=center>128</td>  <td align=center>138</td> <td align=center>	266	</td> </tr>
<tr><td></td><td>Africa/Middle East</td> <td align=center>100</td>  <td align=center>97</td> <td align=center>197</td> </tr>

<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td><br></td><th>3,955</th><th>4,018</th><th>7,973</th> </tr>



  
  
  </table><p>


  

<a href="prof.html">Back to: Pro forma basis</a><p>
<a href="index.html">Return to: Supplementary financial information contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-111</DOCNO>
<DOCOLDNO>IA057-000937-B018-253</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/index.html 193.128.22.20 19970109094156 text/html 2593
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:32:05 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:52 GMT
Content-length: 2402
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Trading and financial review</font></h2>

<font size=5></font>
 

Following the acquisition of Wellcome plc, the Company changed its financial year end from 30th June to 31st December and extended the current financial period by six months to 31st December 1995.  This review covers the 18 month period to 31st December 1995.</font><p>

<dl>
  <dt><a href="1.html">Financial summary</a>
  <dt><a href="2.html">Trading profit</a>
  <dt><a href="3.html">Profit before interest</a>
  <dt><a href="4.html">Interest payable</a>
  <dt><a href="5.html">Taxation</a>
  <dt><a href="6.html">Earnings and dividends</a>
  <dt><a href="7.html">Balance sheet</a>
  <dt><a href="8.html">Net debt</a>
  <dt><a href="9.html">Cash flow and liquidity</a>
  <dt><a href="10.html">Pro forma sales</a>
  <dt><a href="11.html">Sales by theraputic area</a>
  <dt><a href="12.html">Sales by geographic area</a>
</dl><p>
<hr><p>
<a href="../notes/">Forward to: Notes on the preliminary results</a><p>
<a href="../recon.html">Back to: Reconciliation of movements in equity shareholders funds</a><p>
<a href="../index.html">Return to: Preliminary results contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-112</DOCNO>
<DOCOLDNO>IA057-000937-B018-269</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/1.html 193.128.22.20 19970109094209 text/html 2956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:32:19 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:50 GMT
Content-length: 2765
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Financial summary</font></h2>
<p>
<font size=5></font><p>

The results have several unusual features.  The financial period is for 18 months.  There were a number of acquisitions during the period : the major acquisition of Wellcome plc, effective from 16th March 1995,  and the acquisition of Affymax N.V. and a controlling interest in Glaxo Korea Limited, also both effective from March 1995.</font><p>


The results have four principal components:<p>
<ul type=blank>
<li> the Glaxo continuing business for the 12 months to 30th June 1995;
<li> the acquired businesses of Wellcome, Affymax and Glaxo Korea from their date of acquisition to 30th June 1995, together with the cost of borrowings taken out to finance the acquisitions;
<li> the results of the merged business for the period from 1st July 1995 to 31st December 1995, following the integration of the Glaxo and Wellcome businesses; and
<li> the costs of integrating the Glaxo business and the acquired businesses into a combined Group.
</ul><p>


The results of each of these components are shown separately in the <a href="../placc1.html">consolidated profit and loss accounts</a>.  The results of Wellcome have been consolidated into the Group results from 16th March 1995.  The results to 30th June 1995 of the Glaxo continuing business and the acquired businesses were reported in the Second Interim Report.<p>

<a href="2.html">Forward to: Trading Profit</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-113</DOCNO>
<DOCOLDNO>IA057-000937-B018-280</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/2.html 193.128.22.20 19970109094227 text/html 4764
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:32:39 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 4573
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Trading profit</font></h2>
<p>
<font size=5></font><p>
  

<font size=5>Merged business<p>

Following the acquisition of Wellcome, a structured process of integrating the Glaxo and Wellcome businesses commenced.  Joint Glaxo Wellcome task forces, organised on a market and functional basis, developed plans and financial targets for achieving integration. </font><p>

In the majority of territories, where there was both a Glaxo and a Wellcome company, management integration was achieved by 30th June 1995, and the two businesses were effectively managed on a merged basis from 1st July 1995.  The results for the period from 1st July 1995 to 31st December 1995 are therefore presented on that basis.  In a few territories, notably where there is a minority interest in either the Glaxo or Wellcome company, the process of integration will take longer to achieve and both the Glaxo and Wellcome companies continue to be managed independently.<p>

Sales of the merged business for the six months totalled &#163;4,018 million.  Continued close management of expenses produced a trading profit of &#163;1,426 million, representing a trading margin of 35%.  This was achieved despite the inclusion of certain non recurring expenses in this period.<p>

<strong>Integration</strong><br>

Plans and financial targets for integration, as developed by the integration task forces in the period to June 1995, were referred to in the Second Interim Report.  The plans and targets were updated in November and December 1995.  Compared with the separate forward plans of Glaxo and Wellcome prior to Glaxo's bid for Wellcome, the new plan for the combined Group envisaged the achievement of cost savings year by year amounting to &#163;700 million per year by the end of 1998, and progress is being made towards this objective.<p>


The costs expected to be incurred in achieving these savings are forecast at &#163;1,215 million.  Some &#163;452 million of the costs relate to potential losses on asset disposals resulting from site closures.  Cumulative savings are expected to achieve payback of total costs by around the end of 1997.  In terms of the cash costs of &#163;763 million, payback will be achieved earlier.  The proceeds of asset disposals will reduce the net cash costs of integration.<p>


To recognise the impact of integration activities, the anticipated costs of &#163;1,215 million have been charged in the accounts at 31st December 1995.  The charge comprises costs incurred by December of &#163;384 million, and a provision for a further &#163;831 million of costs.  Taxation relief on integration amounts to &#163;230 million.  In calculating the attributable taxation, no taxation relief has been assumed on asset write downs.<p>


<strong>Combined business</strong><br>

Trading profit for the period before integration costs, representing the aggregate trading profit of the Glaxo continuing business, the acquired business and the merged business, amounted to &#163;3,597 million.  This gives a trading margin of 34%.  After integration costs of &#163;1,215 million, the trading profit was &#163;2,382 million.<p>

<a href="3.html">Forward to: Profit before interest</a><p>
<a href="1.html">Back to: Financial summary</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>
  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-114</DOCNO>
<DOCOLDNO>IA057-000937-B018-298</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/3.html 193.128.22.20 19970109094257 text/html 2592
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:32:50 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 2401
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Profit before interest</font></h2>
<p>

  

<font size=5>Profit before interest, comprising trading profit after integration costs and a number of other items described below, amounted to &#163;2,474 million for the 18 month period.</font><p>

In September 1994 Glaxo India Limited disposed of its foods division, producing an exceptional profit of &#163;35 million.  After taxation and minority interests, the Group share of the profit was &#163;14 million.<p>

The share of profits of associated undertakings reflects principally the results of the joint ventures with Warner-Lambert (WL) which had been previously established by both Glaxo and Wellcome.  The Glaxo-WL joint venture has launched OTC versions of Zantac and Beconase in the UK market and has undertaken development work to launch OTC Zantac in the US market.  The Wellcome-WL joint venture markets Zovirax in OTC form and is responsible for the marketing of the Wellcome range of OTC products.<p>

<a href="4.html">Forward to: Interest payable</a><p>
<a href="2.html">Back to: Trading profit</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-115</DOCNO>
<DOCOLDNO>IA057-000937-B018-321</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/4.html 193.128.22.20 19970109094328 text/html 2226
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:33:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 2035
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Interest payable</font></h2>
<p>

  
<font size=5>Aggregate net interest expense for the 18 month period was &#163;87 million.</font><p>


Net interest payable during the six months to 31st December 1995 was &#163;121 million.  During this period the majority of the Glaxo and Wellcome investment funds were used to reduce the borrowings taken out to finance the acquisitions, with a consequent reduction in the gross amounts of both interest receivable and interest payable.  The effective rate of interest payable on the Group's principal borrowings during the period was approximately 7%.<p>



<a href="5.html">Forward to: Taxation</a><p>
<a href="3.html">Back to: Profit before interest</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-116</DOCNO>
<DOCOLDNO>IA057-000937-B018-336</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/5.html 193.128.22.20 19970109094338 text/html 2010
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:33:48 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 1819
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Taxation</font></h2>
<p>
<font size=5>The taxation charge on the combined business for the period before integration was &#163;1,097 million.</font><p>

  As a percentage of profit before taxation of &#163;3,602 million, this represents a rate of taxation of 30.5%.  The rate of taxation on the merged business for the six month period to 31st December 1995 was 31.0%.<p>


<a href="6.html">Forward to: Earnings and dividends</a><p>
<a href="4.html">Back to: Interest payable</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-117</DOCNO>
<DOCOLDNO>IA057-000937-B018-357</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/6.html 193.128.22.20 19970109094348 text/html 3611
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:33:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 3420
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Earnings and dividends</font></h2>
<p>
<font size=5>The total Group consolidated result for the period, after aggregating the components of Glaxo continuing business, acquisitions, merged business and integration, is a profit attributable to shareholders of &#163;1,458 million, which produces earnings per Ordinary Share of 44.5p.</font><p>
  
Excluding integration costs and related taxation which are non recurring, the profit attributable to shareholders is &#163;2,443 million, producing earnings per Ordinary Share of 74.6p.<p>


Allowing for the 18 month period, this represents significant growth over earnings per Ordinary Share of 42.7p for Glaxo alone in the 12 months to 30th June 1994.  Adjusting to a calendar year basis, which will be the Group's financial period in future, earnings attributable to the 12 months to 31st December 1995 before integration costs were 50.3p per Ordinary Share.<p>


The Board is recommending the payment of a final dividend of 15p per Ordinary Share.  Together with the first interim dividend of 10p per Ordinary Share paid on 10th April 1995 and the second interim dividend of 20p per Ordinary Share paid on 23rd October 1995, this makes a total dividend of 45p for the 18 months to 31st December 1995.  On an annualised basis, this represents an annual dividend of 30p, which represents an increase of 11% over the dividend of 27p for the 12 months to 30th June 1994.  The final dividend will be paid on 20th May 1996 (30th May 1996 to ADR holders) to shareholders on the register on 26th March 1996.  A scrip dividend alternative will be offered to shareholders in respect of the final dividend.<p>


Dividend cover, being the relationship between earnings and dividends, is 1.7 for the 18 month financial period based on earnings before integration costs.  It is the Board's intention that dividends should increase broadly in line with earnings growth, taking into account the Group's funding situation and the prospects for the future.<p>

<a href="7.html">Forward to: Balance sheet</a><p>
<a href="5.html">Back to: Taxation</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>



  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-118</DOCNO>
<DOCOLDNO>IA057-000937-B018-376</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/7.html 193.128.22.20 19970109094402 text/html 3070
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:34:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 2879
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Balance sheet</font></h2>
<p>

  

<font size=5>The Group balance sheet at 31st December 1995 is summarised below:</font><p>


<table border=1 cellspacing=1 cellpadding=1>
  <tr><td></td><th>31.12.95<br>&#163;m</th><td align=center>30.6.94<br>&#163;m</td></tr>	

<tr><td>Net operating assets</td><th>3,417</th><td align=center>3,058</td></tr>
<tr><td>Net (debt)/funds</td><th>(3,196)</th><td align=center>2,091</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Net assets</td><th>221</th><td align=center>5,149</td></tr>
<tr><td colspan=3></td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Share capital and reserves</td><th>5,288</th><td align=center>5,026</td></tr>
<tr><td>Goodwill reserve</td><th>(5,197)</th><td align=center>	-</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Shareholders' funds</td><th>91</th><td align=center>5,026</td></tr>
<tr><td>Minority interests</td><th>130</th><td align=center>123</td></tr>
<tr><td colspan=3></td></tr>
<tr><td>Financing</td><th>221</th><td align=center>5,149</td></tr>
<tr><td colspan=3></td></tr>
</table><p>


The reduction in net assets reflects the debt taken on to finance the Wellcome acquisition.  The reduction in shareholders' funds reflects the goodwill arising on acquisition taken to reserves and the impact of integration.  It is expected that profit generated from the merged business, and the consequential cash flow, will progressively rebuild shareholders' funds and net assets.<p>

<a href="8.html">Forward to: Net debt</a><p>
<a href="6.html">Back to: Earnings and dividends</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>






<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-119</DOCNO>
<DOCOLDNO>IA057-000937-B018-392</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/8.html 193.128.22.20 19970109094410 text/html 3164
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:34:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:51 GMT
Content-length: 2973
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Net debt</font></h2>
<p>

  

<font size=5>To finance the acquisition of Wellcome, Glaxo entered into revolving credit facility agreements with nine banks, whereby each bank agreed to lend up to &#163;900 million, to provide an aggregate facility of &#163;8.1 billion.</font><p>


A total of &#163;6 billion was drawn down against the facilities to fund the cash consideration payable to Wellcome shareholders.  Drawings on the facilities were progressively reduced: by realising a substantial part of the Group's cash investments; by utilising existing commercial paper programmes; from the proceeds of issue of two Eurobonds, both issued in London and listed on the London Stock Exchange; and from cash generated from operations.  A new US$5 billion US commercial paper programme was arranged in New York, supported by committed bank facilities of US$3.8 billion.  Issues of commercial paper under this programme were used to repay in full the drawings under the revolving credit facilities, which were then cancelled.<p>


At 31st December 1995 the Group's net debt amounted to &#163;3,196 million.  Net debt included borrowings of &#163;1.7 billion denominated in foreign currencies which are treated as hedged against the Group's overseas assets.<p>


Net debt was established on an initial approximate 50:50 fixed:floating interest rate split.  A limited number of interest rate swaps have been established to help achieve this profile.  The ratio has been allowed to fluctuate in line with subsequent cash generation.<p>

<a href="9.html">Forward to: Cash flow and liquidity</a><p>
<a href="7.html">Back to: Balance sheet</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>




  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-120</DOCNO>
<DOCOLDNO>IA057-000937-B018-403</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/9.html 193.128.22.20 19970109094419 text/html 2714
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:34:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:52 GMT
Content-length: 2523
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Cash flow and liquidity</font></h2>
<p>
<font size=5>As indicated by the consolidated cash flow statement, during the period the Group generated net cash from operating activities of &#163;3,835 million after integration costs paid of &#163;269 million. </font><p>
  


 The funds generated were sufficient to meet all the Group's cash requirements during the period, including dividend payments of &#163;1,525 million, payments to tax authorities of &#163;1,070 million and capital expenditure of &#163;684 million.  The rate of capital expenditure has fallen from the previous year's level, reflecting completion of the Medicines Research Centre at Stevenage and a curtailment of capital spending pending review of all projects as part of the integration process.<p>


The Group expects that future operating cash flow will be sufficient to fund its operating and debt service costs, to satisfy future capital expenditure and other commitments and to permit progressive repayment of debt.  Capital expenditure is expected to be approximately &#163;450 million in the 1996 financial year.<p>


<a href="10.html">Forward to: Pro forma sales</a><p>
<a href="8.html">Back to: Net debt</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-121</DOCNO>
<DOCOLDNO>IA057-000937-B018-422</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/10.html 193.128.22.20 19970109094438 text/html 7457
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:34:48 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:50 GMT
Content-length: 7266
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Pro forma sales</font></h2>
<p>
<font size=5>To illustrate sales performance by product and market, analyses are given below of the combined sales of Glaxo and Wellcome for the year to 31st December 1995, as if Glaxo Wellcome had existed as a combined entity from 1st January 1995.</font><p>
 

<table border=1 cellpadding=1 cellspacing=1>

<tr><td colspan=2><th>&#163;m</th><th>% of total</th><th>% CER* growth</th></tr>

<tr><th>THERAPEUTIC AREA</th>	<th>MAJOR PRODUCTS</th></tr>

<tr><th>Gastro-intestinal</th>   <th align=left>Total</th>   <th>2,255</th>   <th>28</th>   <th>(4)</th></tr>
<tr><td></td>   <td>Zantac</td>   <td align=center>2,255</td>   <td></td>   <td align=center>(4)</td></tr>
<tr><th>Respiratory</th>   <th align=left>Total</th>   <th>1,603</th>   <th>20</th>   <th>20</th></tr>
<tr><td></td>   <td>Ventolin</td>   <td align=center>526</td>   <td></td>   <td align=center>3</td></tr>
<tr><td></td>   <td>Becotide</td>   <td align=center>397</td>   <td></td>   <td align=center>4</td></tr>
<tr><td></td>   <td>Serevent</td>   <td align=center>271</td>   <td></td>   <td align=center>58</td></tr>
<tr><td></td>   <td>Beconase</td>   <td align=center>156</td>   <td></td>   <td align=center>(2)</td></tr>
<tr><td></td>   <td> Flixonase</td>   <td align=center>119</td>   <td></td>   <td align=center>+100</td></tr>
<tr><td></td>   <td> Flixotide</td>   <td align=center>88</td>   <td></td>   <td align=center>+100</td></tr>
<tr><th>Viral infections</th>   <th align=left>Total</th>   <th>1,099</th>   <th>14</th>   <th>-</th></tr>
<tr><td></td>   <td>Zovirax</td>   <td align=center>856</td>   <td></td>   <td align=center>(1)</td></tr>
<tr><td></td>   <td>Retrovir</td>   <td align=center>201</td>   <td></td>   <td align=center>(3)</td></tr>
<tr><td></td>   <td>Valtrex</td>   <td align=center>9</td>   <td></td>   <td align=center>+100</td></tr>
<tr><th>Bacterial infections</th>   <th align=left>Total</th>   <th>963</th>   <th>12</th>   <th>-</th></tr>
<tr><td></td>   <td>Zinnat</td>   <td align=center>393</td>   <td></td>   <td align=center>	9</td></tr>
<tr><td></td>   <td>Fortum</td>   <td align=center>306</td>   <td></td>   <td align=center>(4)</td></tr>
<tr><td></td>   <td>Zinacef</td>   <td align=center>125</td>   <td></td>   <td align=center>-</td></tr>
<tr><th>CNS disorders</th>   <th align=left>Total</th>   <th>	501</th>   <th>6</th>   <th>31</th></tr>
<tr><td></td>   <td>Imigran</td>   <td align=center>366	</td>   <td></td>   <td align=center>	29</td></tr>
<tr><td></td>   <td>Lamictal</td>   <td align=center>	65	</td>   <td></td>   <td align=center>	+100</td></tr>
<tr><th>Oncology</th>   <th align=left>Total</th>   <th>	451	</th>   <th>6	</th>   <th>5</th></tr>
<tr><td></td>   <td>Zofran</td>   <td align=center>386	</td>   <td></td>   <td align=center>	(2)</td></tr>
<tr><th>Dermatologicals</th>   <th align=left>Total</th>   <th>	205	</th>   <th>3	</th>   <th>5</th></tr>
<tr><th>Cardiovascular</th>   <th align=left>Total</th>   <th>	187	</th>   <th>2	</th>   <th>-</th></tr>
<tr><th>Anaesthesia</th>   <th align=left>	Total</th>   <th>	117	</th>   <th>2	</th>   <th>(14)</th></tr>
<tr><th>Others</th>   <th align=left>  	Total</th>   <th>	592	</th>   <th>7	</th>   <th>(4)</th></tr>
<tr><td></td>   <td>		Zyloric</td>   <td align=center>	115	</td>   <td></td>   <td align=center>	-</td></tr>
<tr><td></td>   <td>		Imuran</td>   <td align=center>	105	</td>   <td></td>   <td align=center>	2</td></tr>
<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td></td><th>7,973</th>  <th>100</th>	<th>3</th></tr>
<tr><td colspan=5></td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5></td></tr>
  
<tr><th>REGION</th><th>MAJOR MARKETS</th><td colspan=3></td></tr>

<tr><th>USA</th>   <th align=left>Total</th>   <th>3,309</th>   <th>42</th>   <th>3</th></tr>
<tr><th>Europe</th>   <th align=left>Total</th>   <th>	2,739</th>   <th>34</th><th>-</th></tr>
<tr><td></td><td>UK</td>  <td align=center>628</td>  <td align=center>	8	</td>  <td align=center>2</td></tr>
<tr><td></td><td>France</td>  <td align=center>	450	</td>  <td align=center>6	</td>  <td align=center>5</td></tr>
<tr><td></td><td>Germany	</td>  <td align=center>346	</td>  <td align=center>4	</td>  <td align=center>(7)</td></tr>
<tr><td></td><td>Italy	</td>  <td align=center>333	</td>  <td align=center>4	</td>  <td align=center>(13)</td></tr>
<tr><td></td><td>Eastern Europe</td>  <td align=center>	79	</td>  <td align=center>1	</td>  <td align=center>8</td></tr>
<tr><th>Rest of the World</th>   <th align=left>Total</th>   <th>	1,925</th>	<th>24</th>	<th>8</th></tr>
<tr><td></td><td>Japan	</td>  <td align=center>701	</td>  <td align=center>9	</td>  <td align=center>15</td></tr>
<tr><td></td><td>Asia Pacific	</td>  <td align=center>409	</td>  <td align=center>5	</td>  <td align=center>4</td></tr>
<tr><td></td><td>Latin America</td>  <td align=center>	266	</td>  <td align=center>4	</td>  <td align=center>2</td></tr>
<tr><td></td><td>Africa/Middle East</td>  <td align=center>197</td>  <td align=center>	2</td>  <td align=center>	15</td></tr>

<tr><td colspan=5></td></tr>
<tr><th>Total sales</th><td><br></td><th>7,973</th>  <th>100</th>	<th>3</th></tr>
<p>


<caption align=bottom>*Constant exchange rate (CER) growth represents growth over the combined sales of Glaxo and Wellcome for the year to 31st December 1994 excluding currency movements, calculated as if the exchange rates used to translate the results of overseas companies into sterling had remained unchanged from those used in 1994.</caption>
</table>
<hr>

Pro forma sales by Glaxo Wellcome for the 12 months to 31st December 1995 were &#163;7,973 million, representing an increase of 4% in sterling terms or 3% at CER.  Volume growth was 4%, but pricing pressure had a net 1% adverse effect on sales revenue.<p>

<a href="11.html">Forward to: Sales by theraputic area</a><p>
<a href="9.html">Back to: Cash flow and liquidity</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-122</DOCNO>
<DOCOLDNO>IA057-000937-B018-436</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/11.html 193.128.22.20 19970109094447 text/html 6803
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:34:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:50 GMT
Content-length: 6612
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Sales by therapeutic area</font></h2>


<strong>Gastro-intestinal - ulcers and related conditions</strong><br>

Zantac is still the largest selling pharmaceutical product in the world and the only one to have exceeded sales of &#163;2 billion per annum.  It holds a 31% Moving Annual Total share of the anti-peptic ulcerant market.  Zantac has been facing competition for several years from other H2 antagonists and proton pump inhibitors such as omeprazole.  It also faces generic competition in a number of markets.  The realisation that Helicobacter pylori is a causative agent in ulcers has provided the opportunity to introduce Pylorid/Tritec, designed to be used with antibiotics for the eradication of Helicobacter pylori.<p>


<strong>Respiratory - asthma, bronchitis and allergic rhinitis</strong><br>

The treatment of respiratory diseases is the second most important therapy area for Glaxo Wellcome. It is based on a range of established and new products now available in a wide choice of delivery systems.  These include the design award winning Diskus (known as the Accuhaler in some markets), a novel multi dose powder inhaler.<p>

Sales of Ventolin continued to grow in its 26th year (an increase of 3% at CER) with notable contributions from the USA, France, Germany and Japan.  Ventolin was again the market leader in the &#163;5 billion respiratory market, followed by Becotide/Beclovent, which also achieved sales growth in its 23rd year since the first launch in the UK in 1972.  In the longer term, the main growth potential is centred on Serevent, Flixotide/Flovent and Flixonase/Flonase.<p>


<strong>Viral infections</strong><br>

Zovirax is the second largest product in the Group, with annual sales of &#163;856 million, but is facing generic competition in Canada and Europe.  The recent launch of Valtrex in the UK, Germany and the USA should help to offset a decline in sales of Zovirax and maintain the Group's franchise in the global viral infections market.<p>

Retrovir continues to be the mainstay of AIDS/HIV therapy and the results of recent trials in combination with Epivir demonstrated a significant advantage in combination therapy.  Epivir's regulatory approval in 1995 in the USA and its early launch there is a major boost for the Group's products in the treatment of AIDS/HIV.<p>


<strong>Bacterial infections</strong><br>

Competition in this market has always been intense with multiple entries from new competitors.  Despite this, Zinnat/Ceftin has retained a strong position in treating community acquired infections of the lower respiratory tract with a 4% share of the &#163;10 billion global oral market.  Fortum/Fortaz, a key product for the treatment of life threatening conditions, and Zinacef, used for routine infections and prophylaxis, together hold an 8% share of the largely hospital based &#163;6 billion injectable antibiotic market.<p>


<strong>CNS disorders</strong><br>

Imigran/Imitrex achieved sales of &#163;366 million in the year, providing migraineurs with relief from migraine symptoms through either injectable or, increasingly, oral therapy.  The launch of Imitrex tablets in the USA, based on the new, lower dose tablets (25mg and 50mg), boosted sales and the 50mg tablet, launched in Europe, was readily adopted in most markets.
Lamictal for epilepsy was launched by Glaxo Wellcome in 1990 and is the market leader in the UK with a 24% market share; it was launched recently in the USA.  In January 1996, Lamictal was awarded the UK Prix Galien award for the most innovative product.<p>

<strong>Oncology</strong><br>

Zofran, the first 5-HT3 antagonist to be launched worldwide, has achieved success in all major markets, based on its therapeutic innovation and ability to improve the quality of life of cancer patients by controlling emesis, nausea and vomiting associated with chemotherapy.  This success has attracted competition from other products.  Price competition in a relatively small market (&#163;1 billion) has restricted further growth opportunities for Zofran in cancer treatment.  The product is also used for the prevention and treatment of post operative nausea and vomiting.<p>

Panorex, a colorectal cancer treatment, is the first monoclonal antibody to be licensed for cancer therapy.  <p>

<strong>Dermatologicals</strong><br>

Glaxo Wellcome has developed a range of anti-inflammatory steroid products to treat skin diseases such as eczema and psoriasis.  Betnovate and Dermovate have been providing relief to patients for many years.<p>


<strong>Cardiovascular</strong><br>
In this intensely competitive area, Glaxo Wellcome products have achieved sales of &#163;187 million and have consistently maintained their market share.  Lanoxin, Trandate and Lacipil are all recognised as standard effective products in the treatment of cardiovascular disease, while Flolan is available in the USA for the treatment of primary pulmonary hypertension.  <p>

<strong>Anaesthesia</strong><br>

The Company has a significant presence in this market with a range of neuromuscular blocking agents including Tracrium and Mivacron with combined sales of &#163;117 million.<p>

<a href="12.html">Forward to: Sales by geographic area</a><p>
<a href="10.html">Back to: Pro forma sales</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>





<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-123</DOCNO>
<DOCOLDNO>IA057-000937-B018-452</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/news/report/review/12.html 193.128.22.20 19970109094513 text/html 5442
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:35:21 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:50 GMT
Content-length: 5251
Content-type: text/html
</DOCHDR>
<html><head>
<title>Preliminary results</title></head><body 
background="back1.gif" bgcolor="#ffffff" 
text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="index.html"><img src="icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Preliminary results</font></h1>
<hr size=4><br>

<h2><font size=6>Sales by geographic area</font></h2>
<p>


<strong>USA</strong><br>


Sales in the USA accounted for 42% of Glaxo Wellcome's total in 1995 and grew by 3% at CER.  Increased competitive pressure on major products - Zantac and Zovirax - was offset by encouraging sales of new products.  The majority of Group products launched since 1990 have been approved and launched in the USA.  Epivir was launched in November 1995 to boost the status and sales of products in the treatment of HIV/AIDS.  Four major launches are expected in 1996 - Flovent/Flixotide, Pylorid/Tritec, Ultiva and Nimbex.<p>

The growth in managed care provided Glaxo Wellcome with an opportunity to consolidate sales of major products and generally provide a favourable environment to new product launches.<p>

The agreement in October 1995 settling the Genpharm Pharmaceuticals Inc. litigation removes a potential threat to Zantac prior to July 1997, the extended expiry date of the patent under the terms of the intellectual property provisions of the General Agreement on Tariffs and Trade.  This has provided the US subsidiary, Glaxo Wellcome Inc. with more time to establish its new product range and to reduce overall dependency on Zantac and Zovirax sales.<p>


<strong>Europe</strong><br>

In Europe, despite market growth of 8%, sales were unchanged at CER primarily because of the effect of competition to Zantac and Zovirax.  Sales in the UK were particularly affected by generic competition to Ventolin, Becotide and Zovirax; products introduced since 1990 contributed 25% of total UK sales.<p>

Zantac and Zovirax in Germany are both facing generic competition which caused a decline in overall sales and future growth there will be derived from the emerging respiratory range including Flixotide, Flixonase, and Serevent and neurological products such as Imigran and Lamictal.  Despite delays in product approvals and launches in France - there have been only three since 1990 - sales growth was good, aided by established products, including Ventolin, Zovirax, Retrovir, together with Serevent.  In common with most companies, Glaxo Wellcome experienced difficult market conditions in Italy: sales of Serevent, Becotide and Zinnat continued to grow but overall there were reduced sales and a declining market share.<p>

New product sales in Eastern Europe continued to grow strongly, particularly Zofran, Imigran and Serevent.  Zinnat remains the leading Group product in Eastern Europe.<p>


<strong>Rest of the World</strong><br>

This area includes Japan, the second biggest market in the world.  Based on combined sales, the two Glaxo Wellcome operating companies there form the biggest Glaxo Wellcome pharmaceutical company after the USA.  Glaxo Wellcome has experienced long delays in approval and launch times in Japan compared with Europe and the USA.  Only Zofran and Flunase have been launched since 1990.  Despite these limitations, Glaxo Wellcome achieved sales growth of 15% at CER because of the continued growth of Zantac and Zovirax.<p>

In Canada, sales growth for new products was limited because of government policies which continued to affect most major companies.<p>

The Asia Pacific region benefited from the continued strength of the bacterial infections and viral infections ranges and total sales increased by 4% at CER.  <p>

Competition to the major Glaxo Wellcome products in Australia reduced growth to 7% at CER and pricing pressures limited the uptake of new products including Imigran and Serevent.<p>

In Latin America, overall sales growth was adversely affected by economic conditions in Mexico.  Sales in the rest of the region grew by 20% at CER.<p>

The Africa and Middle East region recorded sustained growth for established products, including Zantac and Ventolin, with emerging contributions from Zofran, Imigran and Serevent.<p>


<a href="11.html">Back to: Sales by theraputic area</a><p>
<a href="index.html">Return to: Trading and financial review contents page</a><p>


  

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-124</DOCNO>
<DOCOLDNO>IA057-000937-B010-260</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/menop/index.html 193.128.22.20 19970109082150 text/html 2722
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:11:54 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:38 GMT
Content-length: 2531
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Management of the menopause</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Management of the menopause</font></h1>
<hr size=4>
<br>
<h2><font size=6>Is it all downhill from here?</font></h2><br>



<font size=5>The ending of ovulation should not mean the end of an
active, healthy lifestyle, says Professor Henry Burger, president of
the International Menopause Society. The challenge for healthcare
professionals is to identify those women who need short-term
symptomatic relief and those who have a high risk of suffering
menopause-related health problems in the long term. Appropriate
choices must then be made from the wide range of therapeutic options
available, so that each woman's individual healthcare needs are
met.</font>


<p> by Professor Henry G. Burger,<br> 
<font size=3>Director of the Prince Henry's Institute of Medical Research,
<br>Melbourne, Australia,<br>
and President of the International Menopause Society</font><p>

<a href="meno1.html">Introduction</a><p>
<a href="meno2.html">Ovarian function</a><p>
<a href="meno3.html">Menopausal transition</a><p>
<a href="meno4.html">Management options</a><p>   
<a href="meno5.html">Menopause and cardiovascular disease</a><p>
<a href="meno6.html">Advances and challenges</a><p>
<a href="meno7.html">Menopause management guidelines</a>
<p>

<a href="../">Return to: Odyssey contents page</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-125</DOCNO>
<DOCOLDNO>IA057-000937-B020-394</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/index.html 193.128.22.20 19970109095751 text/html 2664
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:48:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:38 GMT
Content-length: 2473
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Responding to the rise of fungal infection</font></h2><br>


<font size=5>The incidence of bloodstream infection by <a
href="fungpix.html"><cite>Candida albicans</cite></a> increased by almost
50% in the last decade, and other fungal fellows are gaining ground as
well. Odyssey surveys the urgent challenges clinicians face as mycoses
proliferate and new resistant strains of fungi develop. </font><p>

by J. Verhoef, I.M. Hoepelman and M. Lipovsky,<br><font size=3>
Eijkman-Winkler Institute of Medical and Clinical Microbiology,<br>
University Hospital Utrecht, the Netherlands<br></font>

<IMG  WIDTH=120 HEIGHT=167 SRC="gifs/front.gif" align=absmiddle hspace=5 
vspace=5><font size=3><cite>Aspergillus flavus</cite></font> <a href="../copy.html#fung">&copy;</a><p>

<p>
<a href="fung1.html">Introduction</a><p>
<a href="fung2.html">Taking quick action</a><p>
<a href="fung3.html">Case scenarios</a><p>
<a href="fung4.html">Pathogenesis of a fungal disease</a><p>
<a href="fung5.html">Laboratory diagnosis</a><p>
<a href="fung6.html">Treatment</a><p>
<a href="fung7.html">Fungi and the future</a><p>
<a href="../">Return to: Odyssey contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-126</DOCNO>
<DOCOLDNO>IA057-000937-B009-239</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fungpix.html 193.128.22.20 19970109081410 text/html 1291
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:04:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 1100
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Some common fungal infections</font></h2><br>
<cite>
<IMG  WIDTH=120 HEIGHT=167 SRC="gifs/asp.gif" align=absmiddle vspace=5 hspace=5>Aspergillus niger <a href="../copy.html#fung">&copy;</a><p>
<IMG  WIDTH=120 HEIGHT=166 SRC="gifs/cand.gif" align=absmiddle vspace=5 hspace=5>Candida albicans <a href="../copy.html#fung">&copy;</a><p>
<IMG  WIDTH=120 HEIGHT=166 SRC="gifs/cry.gif" align=absmiddle vspace=5 hspace=5>Cryptococcus neoformans <a href="../copy.html#fung">&copy;</a><p>
</cite>
<p>
<a href="fung1.html">Forward to: Introduction</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>


</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-127</DOCNO>
<DOCOLDNO>IA057-000937-B008-289</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/copy.html 193.128.22.20 19970109080818 text/html 2853
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:58:27 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:38 GMT
Content-length: 2662
Content-type: text/html
</DOCHDR>
<html><head>
<title>Acknowledgements and copyrights</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Image acknowledgements and copyrights</font></h1>
<hr size=4>
<br>
<a name="cell"><h2><font size=6>Cell biology in clinical medicine</font></h2></a>

<dl>
<dt>Contents page
<dd>Courtesy Prof. J. James
<dt>Introduction: Prophase/Metaphase/Anaphase/Telophase
<dd>Science Photo Library (SPL)/CNRI
<dt>The growth of cytology
<dd>SPL/CNRI
<dt>Organelles with specific functions
<dd>Courtesy Amsterdam University Press/Prof. J. James
<dt>Cell-membrane receptors and coatings
<dd>MID/Rob C. B. Kreuger
<dt>Cell-cell and cell-matrix interactions
<dd>Courtesy Amsterdam University Press/Prof. J.James

</dl>

<a name="worth"><h2><font size=6>Worthwhile persistence</font></h2></a>

All icons : Silvan Steenbrink<p>

<a name="tuber"><h2><font size=6>Tuberculosis</font></h2></a>

<dl>
<dt>Contents page
<dd>Courtesy Dr R. Frei, Kantonsspital Basel, Switzerland
<dt>Reasons for resurgence
<dd>Jim Richardson/West Light/ABC-Press
<dt>Tuberculosis and immune response
<dd>Custom Medical Stock Photo
</dl>

<a name="fung"><h2><font size=6>Mushrooming problems</font></h2></a>

<dl>
<dt>Contents page
<dd>E. Gueho-CNRI/SPL
<dt>Introduction
<dd>E. Gueho/SPL
<dt>Taking quick action
<dd>John Durham/SPL
<dt>Case scenarios
<dd>Manfred Kage/SPL<br>
Biophoto Associates/SPL
<dt>Some common fungal infections
<dd>David Scharf/SPL
<br>
Alfred Pasieka/SPL
<br>
Alfred Pasieka/SPL
</dl>
<p>

<a href="index.html">Return to: Odyssey contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>

</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-128</DOCNO>
<DOCOLDNO>IA057-000937-B009-262</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung1.html 193.128.22.20 19970109081431 text/html 3647
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:04:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 3456
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Introduction</font></h2><br>

<font size=5>Fungi play a vital role in the healthy working of our
ecosystem, being responsible for the breakdown of waste products in the
environment. But once they enter the body in the form of an infection or
"mycosis" (from the Greek word <cite>mykhes</cite>, meaning mushroom) they
are capable of frustrating our most technically advanced efforts at
healthcare.</font><p>

Heart transplant patients, for example, often successfully ward off
bacterial infection only to be killed by invasive fungi, which are
structurally much more complicated microorganisms than the prokaryotic
bacteria.<p>

Fungal infection is on the rise in our hospitals, where it is increasingly
becoming a significant cause of morbidity and mortality. In the course of
the 1980s, the rate of bloodstream infection by <cite>Candida
albicans</cite>, for example, surged by 48%.  Patients at particular risk
of mycoses are those with diminished immune defences - not only organ
transplant patients or those receiving intensive treatment for cancer, but
also diabetics or people with indwelling catheters.<p>

Fungi occur in a wide variety of forms, from yeasts (single-celled
organisms which reproduce by budding) and moulds (which occur in long
filaments known as hyphae) to the dimorphic fungi which have a
chameleon-like ability to behave as yeasts in one environment and mould in
another.<p>

<IMG  WIDTH=148 HEIGHT=136 SRC="gifs/bud.gif" align=middle vspace=5 hspace=5><font size=3>The process of budding</font> <a href="../copy.html#fung">&copy;</a><br clear=left><p>

Of the many different types of fungi, only a few have the potential to
cause disease, and the severity of their effects varies widely.
Superficial mycoses, caused by a fungus such as
<cite>Epidermophyton</cite>, <cite>Microsporum</cite>,
<cite>Trichophyton</cite> or <cite>Sporothrix</cite> growing on the body
surface (skin, nails or hair) are unpleasant but usually mild infections.
<p>

Deep mycoses, involving the internal organs, are often life-threatening.
The fungi <a href="fungpix.html"><cite>Aspergillus</cite></a>,
<cite>Blastomyces</cite>, <a href="fungpix.html"><cite>Candida</cite></a>,
<cite>Coccidioides</cite>, <a
href="fungpix.html"><cite>Cryptococcus</cite></a>,
<cite>Histoplasma</cite> are responsible for deep mycoses, and pose
tremendous challenges for clinicians. <p>

Clinically, candidiasis and aspergillosis account for between 80% and 90%
of systemic fungal infections in immunocompromised patients. The
development of resistance to antifungal agents, together with the
emergence of new fungal pathogens such as <cite>Candida krusei</cite>,
<cite>Candida</cite> (formerly called <cite>Torulopsis</cite>)
<cite>glabrata</cite>, <cite>Fusarium</cite> and <cite>Trichosporon
beigelii</cite>, represent major new hazards to health. <p>

<a href="fung2.html">Forward to: Taking quick action</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-129</DOCNO>
<DOCOLDNO>IA057-000937-B009-274</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung2.html 193.128.22.20 19970109081444 text/html 2830
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:04:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 2639
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Taking quick action</font></h2><br>


<font size=5>Diagnosis of fungal infections is often problematic. Fungi
are often difficult to culture from readily accessible samples, such as a
patient's urine, blood or sputum. And because fungi are ubiquitous in
nature, a single positive culture from urine or sputum is of limited
clinical value. The possibility of contamination is always a very real
consideration when interpreting laboratory results.</font><p>

<IMG  WIDTH=146 HEIGHT=140 SRC="gifs/dish.gif" align=middle vspace=5 hspace=5><font size=3>Petri dish culture</font> <a href="../copy.html#fung">&copy;</a><br clear=left><p>

The current approach to diagnosing fungal disease involves blood cultures
and/or cultures from infected tissues, together with diagnostic imaging
techniques. Any patient in a serious clinical condition who has a
suspected fungal infection should therefore be directed to a specialist in
infectious diseases, a radiologist, a pathologist, and a
microbiologist.<p>

Any delay in diagnosing fungal infections and starting antifungal 
treatment means a poor prognosis for the victim. Therefore, in the early 
stages of suspected mycosis without definite diagnosis, antifungal 
therapy is usually given empirically.<p>

In neutropenic patients who have persistent fever without identifiable
cause, and who have undergone a five- to seven-day course of
broad-spectrum antibiotic therapy, administration of the antifungal
amphotericin B has been shown to be associated with a lower incidence of
infectious complications. <p>

After amphotericin B came onto the market in the late 1950s, very few new
antifungal drugs were developed until the early 1980s. Over the past five
years, however, pharmaceutical companies have become increasingly aware of
the expanding market for antifungal agents. Several companies have
recently developed new antifungals or have promising agents in the
pipeline, and expect demand to increase over the next decade.<p>

<p>
<a href="fung3.html">Forward to: Case scenarios</a><p>
<a href="fung1.html">Back to: Introduction</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>


</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-130</DOCNO>
<DOCOLDNO>IA057-000937-B009-287</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung3.html 193.128.22.20 19970109081454 text/html 3005
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:05:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 2814
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Case scenarios</font></h2><br>

<font size=5>Fungal infections may be manifested by a wide range of signs
and symptoms, which are often not specific. A clinician treating any
immunocompromised patient who has fever, organ infection, pulmonary
disease with cough, shortness of breath, chest pain or hemoptisis, or
hypoxemia, must consider mycosis a possibile cause and notify laboratory
staff of this possibility.</font><p>

Any organ may be involved: skin and soft tissues, oral cavity, nasal
sinuses, the gastrointestinal tract (oesophagitis), cardiovascular organs
and genito-urinary tract. Urinary tract infections may be caused by
indwelling catheters or disseminated fungal disease. Central nervous
system infections may occur through dissemination or through the spreading
of local infections in - for example the nasal sinuses. Specific case
scenarios may be helpful in reaching a diagnosis.<p>

<IMG  WIDTH=148 HEIGHT=136 SRC="gifs/spor.gif" align=middle vspace=5 hspace=5><font size=3><cite>Mucor spinosus</cite></font> <a href="../copy.html#fung">&copy;</a><br clear=left><p>

AIDS patients may suffer from candidiasis, which can cause oral thrush and
oesophagitis, or cryptococcosis, which results in meningitis. Clinical
specimens taken from haematological patients may contain a variety of
fungi, notably <cite>Aspergillus</cite> . Infections of the sinuses can be
caused by <cite>Mucor</cite> and <cite>Rhizopus</cite> (both a cause of
mucormycosis) as well as <cite>Aspergillus</cite>. Patients with a history
of travel to areas where fungal infections are endemic may suffer from coccidiodomycosis, histoplasmosis or blastomycosis.<p>

<IMG  WIDTH=170 HEIGHT=120 SRC="gifs/rhiz.gif" align=middle vspace=5 hspace=5><font size=3>The growth of <cite>Rhizopus sexualis</cite></font> <a href="../copy.html#fung">&copy;</a><br clear=left><p>

Patients receiving broad-spectrum antibiotics to counter bacterial
infection may become colonized by fungi, which gain a niche once bacteria
are eliminated. When the immune functions of the colonized patient are
depressed, these colonizing organisms may cause infection.<p>

<a href="fung4.html">Forward to: Pathogenesis of a fungal disease</a><p>
<a href="fung2.html">Back to: Taking quick action</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>


</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-131</DOCNO>
<DOCOLDNO>IA057-000937-B009-307</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung4.html 193.128.22.20 19970109081508 text/html 2191
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:05:21 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 2000
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Pathogenesis of a fungal disease</font></h2><br>

<font size=5>Very little is known about the mechanisms of fungal
pathogenicity, in contrast to the molecular mechanisms behind bacterial
infections.</font><p>

It is clear that fungi are most likely to colonize the body when bacterial
commensals are absent, and to cause disease when other host defences are
compromised. These other defences are phagocytes. White blood cells often
find fungi difficult to phagocytize because of their sheer biomass (with
all their hyphae, or cell extensions, they may be much larger than the
white blood cell itself) or because of their antiphagocytic products such
as capsular material.<p>

Macrophages, and to a lesser extent neutrophils, do, however, have an
important role in anti-fungal defence. This is evidenced by the
susceptibility of patients with leucopenia (extremely low white blood cell
count) or inherent defects in neutrophil function. Leucopenia may be
triggered in cancer patients after cytotoxic treatment, while neutrophil
disfunction can be seen in patients suffering from chronic granulomatous
disease. The fungicidal capacity of neutrophils is now known to be
limited, so host defence may largely rely on macrophages and T
lymphocytes. Indeed, defective T lymphocytes predispose for
<cite>Candida</cite> infections.<p>

<p>
<a href="fung5.html">Forward to: Laboratory diagnosis</a><p>
<a href="fung3.html">Back to: Case scenarios</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>


</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-132</DOCNO>
<DOCOLDNO>IA057-000937-B009-321</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung5.html 193.128.22.20 19970109081519 text/html 4607
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:05:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 4416
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Laboratory diagnosis</font></h2><br>

<font size=5>Once an appropriate specimen has been obtained, it should be
sent off for laboratory diagnosis, accompanied by adequate clinical
information. </font><p>

Because fungi are saprophytes - organisms that feed on decaying organic
matter - interpretation of the culture results is seldom straightforward.
A finding of <cite>Aspergillus</cite> in sputum, for example, is in
isolation of limited value and must be evaluated in the context of the
patient's clinical signs and symptoms. Often tissue biopsies (from lung or
brain) are needed for the definitive diagnosis.<p>

Blood cultures should, of course, be carried out for all patients.
Isolation of yeast - such as <cite>Candida</cite> - from blood is highly
predictive of invasive fungal disease. However <cite>Candida</cite> is
cultured from blood in less than 20% of patients with disseminated
candidiasis.<p>

Blood culturing may be carried out with the lysis centrifugation method
using the Dupont isolator. Because the detection time is determined by
fungal growth rate and inoculum size, concentrating the fungi in the
clinical specimen improves the overall rate of detection. This can be done
through centrifugation of blood and lysis of blood cells that may contain
fungal elements.<p>

<font size=5>Sero-diagnosis</font><p> Because of the limitations of
culture techniques many researchers have tried to find specific antibodies
against <cite>Candida</cite> and <cite>Aspergillus</cite> in serum by
using the titre of antibodies as diagnostic criterium. However, the
sensitivity of these attempts is very low - often less than 50% - as many
immunocompromised patients have difficulty raising an adequate immune
response.<p>

Because of its poor sensitivity, immunodiagnosis of fungal infection is
not cost-effective. It often gives a false negative result, and may also
lead to fungal infections being diagnosed where none exist, with the
consequence that antifungals are administered inappropriately.<p>

<font size=5>Antigens</font><p>

Because of the shortcomings of antibody detection, much attention has been
directed to tests which detect fungal antigens or metabolites in body
fluids. For diagnosis of <cite>Candida</cite> infections, tests have been
described to detect cell wall antigens such as mannans, metabolites such
as D-arabinitol, and cytoplasmic antigens such as enolase. The presence of
antibodies against immuno-dominant fungal antigens in some patients with
fungal diseases facilitates the selection of these antigens as targets for
detection.<p>

Several cell wall antigen detection methods are available. Most use latex
particles loaded with antibodies against cell wall antigens. In these
tests, serum is heated and treated with protease to free mannan from
antibodies to mannan. A major problem is the transient nature of antigens
in serum, which necessitates frequent testing. For most antigen detection
tests the overall sensitivity is unacceptably low, although multiple serum
sampling somewhat improves detection of antigenaemia. The predictive
values of such tests have not yet been determined in large trials, which
makes it difficult to estimate the clinical relevance of their results.
Until better methods of early detection are available, patients at high
risk of invasive candidiasis should continue to receive empirical
treatment with antifungal agents such as amphotericin B.<p>

The diagnostics of mycoses is an area where there is a great need for new
sophisticated techniques, such as DNA or RNA amplification systems. PCR
studies to diagnose fungal infection may prove useful, and may
revolutionize laboratory diagnosis and even management of patients with
serious fungal disease.<p> <p>

<a href="fung6.html">Forward to: Treatment</a><p>
<a href="fung4.html">Back to: Pathogenesis of a fungal disease</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>



</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-133</DOCNO>
<DOCOLDNO>IA057-000937-B009-337</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung6.html 193.128.22.20 19970109081530 text/html 5924
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:05:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 5733
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Treatment</font></h2><br>

<font size=5>The appropriate treatment for fungal infections depends on
the site of the infection. Superficial mycoses, such as oral thrush or
nail mycosis, can be effectively treated topically. Topical treatment
consists of either non-specific agents that diminish general fungal growth
by affecting the underlying skin - an example is Whitfield ointment, a
combination of salicylic and benzoic acid - or specific drugs that are
fungistatic or fungicidal for various fungi.</font><p>

The most important anti-fungal drug groups, polyenes and azoles, are
mainly used systemically, but are also available for topical use. Examples
of topical drugs are: nystatin and the oral suspension of amphotericin B,
which are applied mainly in patients with oral candidiasis (thrush). These
drugs are poorly absorbed after ingestion and therefore act only on the
mucous membranes of the gastrointestinal tract. The azoles (imidazoles and
the chemically closely related triazoles) are available for topical use as
cream or ointment and have proven to be clinically efficacious for
ringworm, <cite>Tinea versicolor</cite> and cutaneous candidiasis.<p>

Even in localized disease, however, systemic treatment is sometimes
needed, especially if the patient is immunocompromised. The systemic
medications available are amphotericin B, often combined with flucytosine,
and the azoles. Systemic therapy for persistent fungal infections of nails
and skin also includes the oral agents griseofulvin and the newer drug
terbinafine.  Amphotericin B is a bacterial product that increases fungal
cell membrane permeability by interfering with its lipid makeup. In low
dosages, amphotericin B acts as a fungistatic, in higher dosages it is
fungicidal. There is no absorption after oral ingestion, so systemic
application has to be parenteral (intravenously or intrathecally, that is
into the cerebrospinal fluid).<p>

After administration, amphotericin B binds highly to plasma proteins and
tissues and is stored in the liver, spleen and kidney, from which it is
released slowly into the circulation. Its elimination is mainly by (local)
degradation and only limited amounts are excreted in urine. Blood levels
are uninfluenced by hepatic or renal failure.<p>

The main side effects of amphotericin B are renal dysfunction, anaemia,
hypokalaemia, cardiac arrhythmia, nausea, vomiting, neuropathy and initial
fever with chills and hypotension, which subside with subsequent
administrations of the drug. Since toxicity, especially renal dysfunction,
frequently forces a dose reduction to suboptimal therapeutic levels,
alternative formulations are under investigation. One that looks promising
is the enveloping of amphotericin B in lipid vesicles called liposomes,
which seems to reduce renal toxicity, apparently without affecting the
efficacy. However the very high costs of this formulation are still a
serious disadvantage in clinical practice.<p>

Amphotericin B is known to be effective in patients with candidiasis,
aspergillosis, cryptococcosis, histoplasmosis, blastomycosis,
coccidioidomycosis, paracoccidioidomycosis, mucormycosis and
extracutaneous sporotrichosis. <p>

Flucytosine interferes with the fungal DNA-synthesis. It is rapidly
absorbed after oral ingestion and mainly excreted unchanged in the urine.
In patients with unimpaired renal, haematological and gastrointestinal
function, its toxicity is limited. However, there does appear to be a link
between high blood flucytosine levels and fatal bone marrow depression and
enterocolitis.<p>

Unlike amphotericin B, flucytosine is associated with a high risk of
secondary resistance, that is where fungal strains initially sensitive to
the drug lose their sensitivity. For this reason, flucytosine is mainly
used in combination with amphotericin B where it is responsible for an
amphotericin-sparing effect, thereby permitting a lower dose of
amphotericin B to be used for the same clinical effect.<p>

Flucytosine is mainly effective against cryptoccocosis, candidiasis and
chromomycosis. The imidazoles (containing two N-atoms) and the closely
related triazoles (three N-atoms) act through interference with enzyme
systems (cytochrome P-450) that are involved in the synthesis of the
fungal cytoplasmic membrane. Their effect results in increased
permeability and fragility of the fungal cell membrane. Those clinically
available are the imidazoles miconazole, clotrimazole (both for topical
use only), ketoconazole and the triazoles fluconazole and itraconazole.
All azoles are known for interactions with other drugs like antibiotics
(rifampicin), neuroleptics (phenytoin) and coumarines.<p>

All the azoles mentioned are efficacious in treating superficial
candidiasis in the non-immunocompromised patient. Fluconazole seems
effective in systemic candidiasis as well. Apart from itraconazole, the
azoles are ineffective for the treatment of aspergillosis. Fluconazole is
used in cryptococcal meningitis after pre-treatment with amphotericin B in
immunocompromised patients.<p>


<p>
<a href="fung7.html">Forward to: Fungi and the future</a><p>
<a href="fung5.html">Back to: Laboratory diagnosis</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-134</DOCNO>
<DOCOLDNO>IA057-000937-B009-350</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/fungi/fung7.html 193.128.22.20 19970109081539 text/html 1921
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:05:53 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 1730
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Fungi and the future</font></h2><br>


<font size=5>As the number of susceptible patients grows, fungal infection
is increasingly becoming a clinical problem. Such infections are difficult
to diagnose, with available tests short on predictive value and
sensitivity, and therefore only cost-effective in research settings. As
clinicians are often left with a presumptive diagnosis, at most, treatment
is in many cases given empirically without a definitive
diagnosis.</font><p>

All drugs available today have their limitations. They may be toxic, in
the case of amphotericin B, or have limited activity, and establishing a
balance between efficacy and side effects is a delicate business. All the
newer antifungal drugs are expensive, reflecting the costs to
pharmaceutical companies of complicated and costly clinical trials for
these new drugs. To make matters worse, there is growing evidence that the
newer drugs select for resistant fungi. Many laboratories are not equipped
to test for fungal resistance. Here is an area where we rapidly need
standardized tests.<p>


<a href="fung6.html">Back to: Treatment</a><p>
<a href="index.html">Return to: Mushrooming problems contents page</a><p>
<a href="../">Return to: Odyssey contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-135</DOCNO>
<DOCOLDNO>IA057-000937-B020-348</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/index.html 193.128.22.20 19970109095708 text/html 2597
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:47:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:40 GMT
Content-length: 2406
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>The process of new drug development</font></h2>


<font size=5>What goes on in the dozen years - on average - it takes to
turn a compound into a safe, marketable drug? And why do most prototype
pharmaceuticals never make it onto the pharmacy shelves? Odyssey follows
the long and winding road of drug development, and signals some new trends
along the way.</font><p>


by Kenneth I. Kaitin, PhD,<br>
<font size=3>Associate Director,<br>
Tufts Center For The Study of Drug Development,<br>
Tufts University, Boston, Massachusetts;</font><p>
and Huub Houben, MD,<br>
<font size=3> Publisher of Odyssey</font>
<p>

<a href="worth2.html">The drug development process</a><p>
<a href="worth3.html">The preclinical phase</a><p>
<a href="worth4.html">Clinical trials</a><p>
<a href="worth5.html">Weighing the application</a><p>
<a href="worth6.html">The results</a><p>
<a href="worth7.html">Contributors</a><p>
<a href="worth8.html">The macro environment</a><p>
<a href="worth9.html">Conclusion</a><p>
<a href="../index.html">Return to: Odyssey contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><IMG align=absmiddle ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body></html>


</DOC>
<DOC>
<DOCNO>WT14-B39-136</DOCNO>
<DOCOLDNO>IA057-000937-B008-444</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth2.html 193.128.22.20 19970109081032 text/html 2811
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:00:44 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 2620
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>The drug development process</font></h2>


<font size=5>The process of developing a new drug can only start after a compound which has potentially valuable medicinal properties has been discovered. But before this stage is reached, many years will have been invested in research to learn more about
 the aetiology and pathogenesis of the particular disease for which the drug is suited.</font><p>

Knowing the cause of a disease and the way in which it leads to particular
symptoms and/or complications creates the possibility of envisaging
several levels of intervention. Therapy could be targeted at either
eliminating the cause of the disease, restoring function, preventing
complications or alleviating symptoms.<p>

<IMG align=absmiddle  WIDTH=100 HEIGHT=109 SRC="gifs/doubx.gif" alt="chromosomes"><a href="../copy.html#worth">&copy;</a><p>

Over the course of the past few decades, advances in molecular and
cellular biology have contributed to a far better understanding of many
diseases.  Consequently, whereas in the past the main sources of new drugs
were often serendipity, folk medicine or trial and error, today drug
design has become more directed. Nevertheless the natural world will
continue to be an important source of medically useful substances.<p>

<IMG align=absmiddle  WIDTH=97 HEIGHT=120 SRC="gifs/flask.gif" alt="test tube and beaker"><a href="../copy.html#worth">&copy;</a><p>

The continuing accumulation of fundamental knowledge about diseases and
technological progress in molecular biology and biotechnology (such as the
genetic manipulation of bacteria) has led to the development of much
better animal and laboratory models for many diseases. This makes the drug
screening process more efficient, an d may also lead to a decrease in the
use of animals for research and pre-clinical development. For example, the
insertion of human genes into bacteria means that metabolic studies of
human enzymes can now be carried out in these organisms.<p>

<p>

<a href="worth3.html">Forward to: The preclinical phase</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a><p>

<p>
</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-137</DOCNO>
<DOCOLDNO>IA057-000937-B009-8</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth3.html 193.128.22.20 19970109081041 text/html 5539
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:00:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 5348
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>The preclinical phase</font></h2>

<font size=5>Several major stages can be distinguished in new drug
development. These include the preclinical phase (studies on animal or
laboratory models), the clinical phase (studies on people) and a number of
regulatory reviews.</font><p>

<IMG align=absmiddle  WIDTH=119 HEIGHT=108 SRC="gifs/dog.gif"><IMG align=absmiddle  WIDTH=108 HEIGHT=110 SRC="gifs/mouse.gif" alt="animal models"><a href="../copy.html#worth">&copy;</a><p>

In recent years, there has been a substantial effort to harmonize the 
requirements for each of these stages, and their associated tests, 
stipulated by the major regulatory authorities (particularly in the 
United States, Europe and Japan). This effort is referred to as the 
International Conference on Harmonization (ICH). Overall, the whole 
process by which new drugs are developed and approved for marketing is 
time consuming, risky and expensive.<p>

The aim of the preclinical development phase for a potential new medicine is to
explore the drug's efficacy and safety before it is administered to patients.
In this preclinical phase, varying drug doses are tested on animals and/or in
vitro systems (such as yeast and bacteria).<p>

<IMG align=absmiddle  WIDTH=83 HEIGHT=140 SRC="gifs/kidney.gif" alt="liver and kidneys"><a href="../copy.html#worth">&copy;</a><p>

Various types of safety studies are required: acute, subacute and chronic
toxicity tests to detect unwanted general and organ-specific effects; 
reproductive toxicity tests to reveal the
effects on fertilization, the developing embryo, the foetus, and the new-born
offspring; mutagenicity tests to identify any damaging effects on DNA, genes
and chromosomes; and prolonged carcinogenicity tests to discover whether the
drug causes any tumours. <p>

Biological studies are carried out in animals to investigate absorption 
from the site of administration into the bloodstream, subsequent
distribution to other parts of the body, drug metabolism and, finally,
excretion of the compound and its metabolic products. These studies of how the
drug and its metabolites behave in the body are called pharmacokinetic (PK)
studies. In contrast, pharmacodynamic (PD) studies investigate the
therapeutically intended effects on the targeted organs or systems. Most of the
preclinical tests have to be conducted in accordance with the standards
prescribed in the Good Laboratory Practice (GLP) guidelines. <p>

<IMG align=absmiddle  WIDTH=83 HEIGHT=140 SRC="gifs/heart.gif" alt="heart and brain"><a href="../copy.html#worth">&copy;</a><p>

The technical development of a new medicine also has to comply with Good
Manufacturing Practice (GMP) guidelines. Technical development starts in the
preclinical phase, and continues during the clinical phase. It includes
chemical development (which involves determining new manufacturing processes so
that production can be increased in scale, while at the same time limiting
impurities and degradation products), analytical development (quality assurance
of the compounds and their form of delivery, including stability under various
conditions and over time), and pharmaceutical development (the drug formulation
process) which includes making choices about the route of administration, the
dosage forms (tablets, soluble tablets, capsules, suspension forms; the use of
excipients - other substances mixed with the drug - and coatings) and finally,
packaging. Such choices are influenced by the preferences of patients and
doctors, and by the impact of the choice on the bioavailability and stability
of the substance.<p>

One area where significant progress has been made of late is that of drug
delivery devices and technologies. The drug delivery system involves the site
of drug administration, the speed at which the drug is released, and its
absorption and distribution rates. For a single route of administration (for
example the mucosa of the nose) the selected method of administration (such as
drops, a manually squeezed bottle, a metered pump spray or a metered aerosol)
may influence the drug's bioavailability, its efficiency and the occurrence of
side-effects. When and where in the body the drug is delivered can be regulated
using controlled-release techniques, or by using pro-drugs, which are drugs
ingested in inactive form and transformed by the body's metabolic processes
into active drugs.<p>

Furthermore, delivery systems can improve the uptake of the substance into the
body and, its subsequent penetration through various internal barriers (for
example, liposomes enable water-soluble molecules to pass lipid membranes). <p>
<p>

<a href="worth4.html">Forward to: Clinical trials</a><p>
<a href="worth2.html">Back to: The drug development process</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a>

<p>
</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>
</html>





































</DOC>
<DOC>
<DOCNO>WT14-B39-138</DOCNO>
<DOCOLDNO>IA057-000937-B009-23</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth4.html 193.128.22.20 19970109081053 text/html 6270
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:01:05 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 6079
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>Clinical trials</font></h2>

<font size=5>Compounds that survive the high attrition rate in the
preclinical phase then undergo clinical investigations involving human
subjects. In the United States, an Investigational New Drug (IND)
application must be filed with the FDA before human testing may commence.
Then, all clinical study protocols must first be approved by local ethical
committees (in the United States called Institutional Review Boards),
which evaluate the ethical issues involved. </font><p>

<IMG  WIDTH=139 HEIGHT=85 SRC="gifs/teach.gif" alt="Local ethical communities"><a href="../copy.html#worth">&copy;</a><p>

Furthermore, all subjects participating in the clinical trials must first 
be fully informed of
the nature and goals of the study, the potential risks and benefits, and their
right to withdraw at any time. The participants then sign a written informed
consent statement. This is just one of the many standards which apply to
clinical research on human subjects as they have been defined in the Good
Clinical Practice (GCP) guidelines.<p>

The clinical development period is usually divided into a number of phases,
with each phase progressively testing the safety and efficacy of the compound.
In Phase I, which lasts an average of one year, the drug is tested on a small
number of healthy (or non-patient) volunteers. These are usually male, since at
this stage it is unlikely that all reproductive toxicity tests have been
completed, and young, since the likelihood of ill-health increases with age.
The main goal of these trials is to obtain data on the compound's safety,
appropriate dosage range and pharmacokinetic properties.<p>

<IMG  WIDTH=121 HEIGHT=100 SRC="gifs/stantab.gif" alt="non-patient volunteers"> <a href="../copy.html#worth">&copy;</a><br clear=left><p>

Not all drugs are tested on non-patient volunteers during phase I. For example,
anti-cancer drugs are only tested on patients. Because of the correlation of
higher dose with better tumour response, higher levels of toxicity are accepted
for these compounds. The goal of the phase I study remains the same, however,
and any patients participating in a phase I study should be informed that the
study is conducted without real therapeutic intent.<p>

In phase II, which normally lasts about two years, the drug is tested in
controlled studies involving 100 to 300 patient volunteers. Controlled studies
have a high level of inbuilt rigidity, such as strict inclusion and exclusion
criteria and treatment protocols. An unfortunate consequence is that the
patient group may not be representative of the real patient population and this
issue needs to be addressed in the design of later clinical trials. The main
goals in Phase II are to assess the drug's effectiveness in patients, collect
dose-response information to establish the dose which produces the desired
effect, and collect additional information on safety. In some countries, a
conference with the regulatory authority is held at the end of phase II to
evaluate the progress of the study.<p>

<IMG  WIDTH=125 HEIGHT=94 SRC="gifs/beds.gif" alt="Patient volunteers"><a href="../copy.html#worth">&copy;</a><p>

Finally, phase III studies are undertaken. Lasting an average of three years,
they involve large-scale trials on a more heterogeneous patient population that
better reflects the actual population attending a physician's practice.
Typically, 1,000 to 3,000 patients are involved in these multicentre trials.<p>
In phase III the drug's effectiveness is defined more precisely (that is,
information about the optimum dosage and the indications for use are refined),
and the drug is generally compared with a placebo or an available alternative
drug. Ideally, this is done in a randomized clinical trial (RCT): only after a
patient has been admitted to the study will he or she be assigned at random to
receive one of the treatments being compared. If possible, such trials are
double-blind; that is, neither the physician nor the patient knows which of the
treatments is being given.<p>

<IMG  WIDTH=125 HEIGHT=94 SRC="gifs/bedtab.gif"><IMG  WIDTH=122 HEIGHT=95 SRC="gifs/bedred.gif" alt="double blind trials"><a href="../copy.html#worth">&copy;</a><p>

RCTs are the centrepiece of the clinical phase and have generally become
accepted as the method of choice for the evaluation of new therapeutic
remedies.<p>

Collecting further information on drug safety is also an aspect of phase III
studies. Because of the large number of patients involved, the more common
adverse effects should be detected at this stage. However, monitoring for rarer
side effects, which are unpredictable from the pharmacology, will continue in
subsequent development phases - and indeed after the medicine has been
launched.<p>

In general, clinical trials continue until enough evidence is obtained to file
a New Drug Application (NDA) with the regulatory authorities. (Outside the
United States, other terms are used; in the United Kingdom, for example, it is
called a Product Licence Application.) The NDA contains all the scientific
data, both preclinical and clinical, collected by the sponsor. This data
typically runs to 100,000 or more pages. Thus, not surprisingly,
computer-assisted NDAs (CANDAs) are now  being submitted. The NDA also includes
samples and the proposed labelling, with details of the text of the package
insert.<p>
<p>

<a href="worth5.html">Forward to: Weighing the application</a><p>
<a href="worth3.html">Back to: The preclinical phase</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a>
<p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-139</DOCNO>
<DOCOLDNO>IA057-000937-B009-38</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth5.html 193.128.22.20 19970109081105 text/html 2804
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:01:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 2613
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>Weighing the application</font></h2>


<font size=5>Next, it is up to the regulatory authority to review the NDA
and to balance the risks and benefits.  First, the application has to be
deemed eligible for review; then a review priority will be established. 
Drugs for life-threatening or serious diseases may be fast-tracked.  Under
strictly defined conditions, such drugs may even be given to selected
patients before all clinical trials have been completed. The application
is reviewed simultaneously by a number of different experts (scientists as
well as physicians). At various stages during the review process the
regulatory body may request additional information or visit manufacturing
and trial sites.</font><p>

After the NDA has been filed, phase IV studies aimed at providing data on
long-term safety and efficacy commence. This phase involves both follow-up of
earlier clinical trials and the initiation of new trials. Phase IV studies may
also be designed to collect new types of information, such as data on the
impact of the drug on quality-of-life parameters (functioning and well-being)
or pharmacoeconomic statistics (does the drug provide value for money compared
with the other therapies available?). Increasingly, however, such studies are
being conducted at an earlier stage, before the NDA is filed.<p>

<IMG align=absmiddle  WIDTH=106 HEIGHT=110 SRC="gifs/books.gif" alt="pile of books"><a href="../copy.html#worth">&copy;</a><p>

Once a new drug has been approved, new clinical phase II and III studies may be
initiated to develop new indications or formulations. <p>

The manufacturing company and the healthcare authorities will keep monitoring
the drug after it has been approved and is being marketed (post-marketing
surveillance, pharmacovigillance) in order to discover whether its use leads to
any adverse reactions or whether there is some incompatibility or interaction
with other drugs used simultaneously.
<p>

<a href="worth6.html">Forward to: The results</a><p>
<a href="worth4.html">Back to: Clinical trials</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a>
<p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-140</DOCNO>
<DOCOLDNO>IA057-000937-B009-59</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth6.html 193.128.22.20 19970109081120 text/html 3129
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:01:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 2938
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>The results</font></h2>


<font size=5>New drug development is, then, a lengthy process. According
to information collected by the Tufts Center for the Study of Drug
Development on the new drugs approved by the FDA from 1990 through 1994,
it took an average of 12 years from the preclinical development stage of a
new compound to the date on which it received marketing
approval.</font><p>

Pharmaceutical innovation is also associated with a high risk of failure.
Only about one drug in 1,000 tested in preclinical studies will survive to
the clinical phase. Failure can be due either to overly negative effects
(unacceptable toxicity or unwanted side effects) or to insufficient
therapeutic effects. Even for those drugs which do reach the clinical
testing phase, obtaining marketing approval is far from certain. Of every 
100 drugs which enter clinical studies, an average 30% are rejected 
during phase I, a further 37% during phase II, 6% in phase III and 7% 
during the regulatory review. In total, only 20% of the drugs which reach 
the stage of being tested on humans are eventually approved for marketing.
<p>

<IMG align=absmiddle WIDTH=110 HEIGHT=108 SRC="gifs/scales.gif" alt="weighing up the risks and benefits"><a href="../copy.html#worth">&copy;</a><p>

The substantial time and risk involved in guiding a new product from its
discovery or synthesis through to its appearance on the market are
reflected in the high cost of pharmaceutical research and development.
Joseph DiMasi and Louis Lasagna at Tufts University, along with colleagues
Ronald Hansen at the University of Rochester and Henry Grabowski at Duke
University, calculated that the average cost of developing a new drug is
US$291 million, up from US$130 million in 1976 (both figures converted to
1994 dollars).<p>

 Recently, the US Office of Technology Assessment, using data from the DiMasi
study, but applying a higher rate of cost discounting, determined that the cost
of drug development was US$400 million (in 1994 dollars per approved new drug).
These figures include both out-of-pocket costs and time costs (that is,
investment income forgone as a result of expending funds on R&amp;D before any
returns are realized). They also include the costs of failed projects.<p>
<p>


<a href="worth7.html">Forward to: Contributors</a><p>
<a href="worth5.html">Back to: Weighing the application</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a>
<p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-141</DOCNO>
<DOCOLDNO>IA057-000937-B009-74</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth7.html 193.128.22.20 19970109081130 text/html 2140
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:01:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 1949
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>Contributors</font></h2>

<font size=5>Of the 196 new drugs approved in the United States between 1981 and 1990, 181
(92.4%) originated from the pharmaceutical industry. Academia was the source of
seven new drugs (3.6%) and government of two (1%); the remaining six came from
miscellaneous sources.</font> <p>

These findings should not suggest that government and academia play an
insignificant role in biomedical research and new drug development. The basic
science contributions of academia, governmental (intramural) institutions and
government-funded (extramural) research centres often constitute essential
support for new drug discovery and development. <p>

Current investment in the Human Genome project, which generates much useful
data on genes and provides clues about the functioning of gene products, is a
good example of the contribution of basic science to drug research. The
pharmaceutical industry often collaborates with academic research centres, as
well as maintaining contacts and research agreements with university research
laboratories and clinical centres.<p>

There are other parties essential to the drug development process. These
include clinicians, other hospital and laboratory personnel, and - very
importantly - patients.<p>
<p>

<a href="worth8.html">Forward to: The macro environment</a><p>
<a href="worth6.html">Back to: The results</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a>
<p>
</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-142</DOCNO>
<DOCOLDNO>IA057-000937-B009-90</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth8.html 193.128.22.20 19970109081158 text/html 3982
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:01:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 3791
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>The macro environment</font></h2>


<font size=5>Drug development is influenced by changes in the political, economic,
regulatory and scientific environment, as well as by changes in the general
health of the population. Political and economic factors have placed
substantial pressure on drug firms to streamline their drug development
processes, reduce costs and focus on medical therapies with demonstrable
advantages over existing products or medical techniques.</font><p>

Whereas once drug development focused on product safety and 
efficacy, today other criteria play
an increasingly salient role. These include comparison with other drugs (or
other types of intervention) currently available for the same indication, value
for money (for which various pharmacoeconomic equations are in use), and impact
on patients' quality of life.<p>

<IMG align=absmiddle WIDTH=136 HEIGHT=86 SRC="gifs/parcel.gif" alt="safety leaflet with drugs"><a href="../copy.html#worth">&copy;</a><p>

In terms of the regulatory climate, requirements have become more stringent
over the years, which has contributed to longer development times and steeper
costs. This tightening up of regulations reflects events such as the
thalidomide disaster between 1959 and 1962, when use of this sedative led to
the birth of numerous deformed babies. There is no easy answer to the question
of what level of risk regulatory agencies should accept when approving new
drugs. <p>

The goal of preclinical and clinical safety studies is not to establish
that a drug is without any possible risk, since such a goal would be
unachievable, but rather to determine the likely nature and degree of
risk. There are, however, continuous efforts to validate the predictive
value of particular toxicity tests and other safety studies, and to
develop better alternatives - that is, tests with a higher predictive
value, tests that are quicker to carry out or cheaper, and tests which
eliminate the need to trial drugs on animals. <p>

Scientific progress has also influenced the direction of pharmaceutical
research and development. Advances in molecular and cellular biology (from
genome research to the elucidation of complex cellular and molecular
structures and functions) and other technologies (such as imaging) have
provided new insights into the aetiology and pathogenesis of such complex
diseases as Alzheimer's disease, AIDS, multiple sclerosis and cancer. The
process of developing drugs to treat these persistent and degenerative
diseases is typically longer, more expensive and more complicated than for
other diseases.<p>

From a population health perspective, the range of diseases responsible for
major morbidity and mortality has changed. Cancer and vascular diseases have
now replaced infectious diseases as the main causes of mortality in many
countries. That is not to say that infectious diseases no longer pose a threat,
however: tuberculosis, malaria and AIDS, among others, are exacting a heavy
toll on a worldwide scale. There is also the problem of drug resistance and the
shortage of adequate vaccines.<p>
<p>


<a href="worth9.html">Forward to: Conclusion</a><p>
<a href="worth7.html">Back to: Contributors</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a><p>

<br>

<p>
</ul></ul></ul></ul></ul>
</ul></ul></ul></ul></ul>

</basefont>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-143</DOCNO>
<DOCOLDNO>IA057-000937-B009-106</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/worth/worth9.html 193.128.22.20 19970109081213 text/html 2207
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:02:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:02 GMT
Content-length: 2016
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>Conclusion</font></h2>

<font size=5>Throughout the past few decades, the drug development process has increasingly
become more complex, lengthy and costly. These trends may be halted or even
reversed, however, by the new technologies and test methods now available or
being developed, and by pharmaceutical industry efforts to rationalize and
optimalize research and development programmes.</font> <p>

Furthermore, the International Conference of Harmonization might help to
prevent the duplication of preclinical and clinical studies which often occurs
at the moment because of the regulatory requirements in different countries.
European Union initiatives such as the European Medicines Evaluation Agency
(EMEA), which opened its office in London at the start of 1995, are aimed at
streamlining regulation within Europe. Finally, the regulatory agencies in most
countries are trying to shorten the time taken for their reviews.<p>

These are stimulating and turbulent times for those involved in all aspects of
new drug development. New therapies have made substantial contributions to
better health and healthcare. Yet there are still many illnesses that are
currently untreatable, or for which the existing treatment is inadequate. The
hope of meeting this challenge is reason enough to persist with the search for
new medicines and therapies.<p>
<p>

<a href="worth8.html">Back to: The macro environment</a><p>
<a href="index.html">Return to: Worthwhile persistence contents page</a><p>
<a href="../">Return to: Odyssey contents page</a>
<p>
</ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-144</DOCNO>
<DOCOLDNO>IA057-000937-B017-346</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/worth/index.html 193.128.22.20 19970109093426 text/html 2570
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:24:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:42 GMT
Content-length: 2379
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Worthwhile Persistence</title></head>

<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Worthwhile persistence</font></h1>
<hr size=4>
<br>

<h2><font size=6>The process of new drug development</font></h2>


<font size=5>What goes on in the dozen years - on average - it takes to
turn a compound into a safe, marketable drug? And why do most prototype
pharmaceuticals never make it onto the pharmacy shelves? Odyssey follows
the long and winding road of drug development, and signals some new trends
along the way.</font><p>


by Kenneth I. Kaitin, PhD,<br>
<font size=3>Associate Director,<br>
Tufts Center For The Study of Drug Development,<br>
Tufts University, Boston, Massachusetts;</font><p>
and Huub Houben, MD,<br>
<font size=3> Publisher of Odyssey</font>
<p>

<a href="worth2.html">The drug development process</a><p>
<a href="worth3.html">The preclinical phase</a><p>
<a href="worth4.html">Clinical trials</a><p>
<a href="worth5.html">Weighing the application</a><p>
<a href="worth6.html">The results</a><p>
<a href="worth7.html">Contributors</a><p>
<a href="worth8.html">The macro environment</a><p>
<a href="worth9.html">Conclusion</a><p>
<a href="../index.html">Return to: Odyssey contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><IMG align=absmiddle ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body></html>


</DOC>
<DOC>
<DOCNO>WT14-B39-145</DOCNO>
<DOCOLDNO>IA057-000937-B017-386</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/fungi/index.html 193.128.22.20 19970109093505 text/html 2637
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:25:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:40 GMT
Content-length: 2446
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Mushrooming Problems</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Mushrooming problems</font></h1>
<hr size=4>
<br>
<h2><font size=6>Responding to the rise of fungal infection</font></h2><br>


<font size=5>The incidence of bloodstream infection by <a
href="fungpix.html"><cite>Candida albicans</cite></a> increased by almost
50% in the last decade, and other fungal fellows are gaining ground as
well. Odyssey surveys the urgent challenges clinicians face as mycoses
proliferate and new resistant strains of fungi develop. </font><p>

by J. Verhoef, I.M. Hoepelman and M. Lipovsky,<br><font size=3>
Eijkman-Winkler Institute of Medical and Clinical Microbiology,<br>
University Hospital Utrecht, the Netherlands<br></font>

<IMG  WIDTH=120 HEIGHT=167 SRC="gifs/front.gif" align=absmiddle hspace=5 
vspace=5><font size=3><cite>Aspergillus flavus</cite></font> <a href="../copy.html#fung">&copy;</a><p>

<p>
<a href="fung1.html">Introduction</a><p>
<a href="fung2.html">Taking quick action</a><p>
<a href="fung3.html">Case scenarios</a><p>
<a href="fung4.html">Pathogenesis of a fungal disease</a><p>
<a href="fung5.html">Laboratory diagnosis</a><p>
<a href="fung6.html">Treatment</a><p>
<a href="fung7.html">Fungi and the future</a><p>
<a href="../">Return to: Odyssey contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>

</html>




</DOC>
<DOC>
<DOCNO>WT14-B39-146</DOCNO>
<DOCOLDNO>IA057-000937-B020-358</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/index.html 193.128.22.20 19970109095718 text/html 3127
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:47:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:39 GMT
Content-length: 2936
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>The return of an old nemesis</font></h2><br>



<font size=5>Tuberculosis - the captain of all the men of death, a romantic theme of 19th-century Europe, a terrifying memory for pre-war 
generations - has resurfaced as a public health concern in the industrialized world. How is it possible that we should be witnessing an 
apparent reversal of one of the great victories of the antibiotic revolution? The natural history of the tuberculosis bacterium is inextricably 
linked with the evolution of human society, and, as with all human stories, it is necessary to follow a number of threads in order to grasp the 
overall picture.<p></font> <p>

by Douglas B. Young,<br><font size=3>
Department of Medical Microbiology<br>
St Mary's Hospital Medical School<br>
London, UK</font><p>

  
<IMG  WIDTH=160 HEIGHT=128 SRC="gifs/tbgif1.gif" align=absmiddle hspace=5 vspace=5>
<font size=3>
<cite>Mycobacterium tuberculosis</cite>.</font><a href="../copy.html#tuber">&copy;</a><p>
<dl>
<dt><a href="tuberc1.html">Introduction</a><p>
<dt><a href="tuberc2.html">Reasons for resurgence</a><p>
<dt><a href="tuberc3.html">Strategies for combatting tuberculosis</a><p>
<dt><a href="tuberc4.html">Diagnosis and drug resistance</a><p>
<dt><a href="tuberc5.html">Priorities for strategic research</a><p>
<dt><a href="tuberc6.html">Tuberculosis and immune response</a><p>
<p>
<dt><a href="../../../science/actiontb/">Action TB</a>
<dt>An international research programme aimed at finding new targets for
anti-tuberculosis therapies. Action TB is a Glaxo Wellcome Research
Initiative.
<p>
<dt><a href="../">Return to: Odyssey contents page</a>
</dl><p>
    
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>

</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-147</DOCNO>
<DOCOLDNO>IA057-000937-B009-123</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuberc1.html 193.128.22.20 19970109081223 text/html 3264
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:02:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:00 GMT
Content-length: 3073
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Introduction</font></h2><br>

<font size=5>Tuberculosis can occur in a variety of clinical forms 
described by a historically diverse terminology. It is difficult to 
obtain more than crude estimates of the incidence of the disease in 
previous centuries. Tuberculosis is thought to have accounted for some 20 
per cent of all deaths in England and Wales in 1650, with a period of 
decline over the next century and a subsequent resurgence to peak levels 
in the early 1800s.<p></font> 

In both the US and Europe a progressive decline then set in, with the 
annual mortality dropping from about 500 per 100,000 of the population at 
the start of the century, to approximately 200 per 100,000 by the time 
Robert Koch announced the discovery of <cite>Mycobacterium 
tuberculosis</cite> (<cite>M. tuberculosis</cite>) in 1882. The gradual 
decline continued throughout the first half of the 20th century and was 
accelerated by the introduction of effective therapy in the 1950s. In the 
1960s and '70s the incidence of tuberculosis showed an annual decline of 
5-10 per cent in most developed countries, with cure rates approaching 
100 per cent. The pattern has changed over the past few years, however. 
Incidence rates reached a plateau level of about 10-20 per 100,000, and 
then started to increase: case rates in the United States, for example, 
rose by 20 per cent between 1985 and 1992.<p>

A particularly worrying aspect of the resurgence of tuberculosis in the US has
been the occurrence of a series of outbreaks caused by drug-resistant strains
of <cite>M. tuberculosis</cite>. Soon after the introduction of 
streptomycin therapy for
tuberculosis, it became clear that treatment with a single drug resulted in
selection and growth of drug-resistant strains of bacteria. With the subsequent
introduction of a range of new drugs, it was possible to design treatments
involving three or four drugs which, when delivered in combination, eliminated
the problem of drug-resistance.<p>

However, the recent US outbreaks have involved strains of <cite>M. 
tuberculosis</cite> which have developed resistance to a range of drugs 
and which can no longer be treated even by complex combination therapies. 
Infection with these multidrug-resistant (MDR) strains - generally 
defined as those resistant at least to isoniazid and rifampicin, the two 
most effective antituberculous drugs - is often fatal, with mortality 
rates comparable to those observed in the pre-antibiotic era. <p><p>


<a href="tuberc2.html">Forward to: Reasons for resurgence</a><p>
<a href="index.html">Return to: Tuberculosis contents page</a>
<p>


</ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-148</DOCNO>
<DOCOLDNO>IA057-000937-B009-139</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuberc2.html 193.128.22.20 19970109081232 text/html 4303
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:02:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:00 GMT
Content-length: 4112
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Reasons for resurgence</font></h2><br>

<font size=5>There is no single underlying cause for the resurgence of tuberculosis in developed countries.  There is a close association between 
tuberculosis and social deprivation, clearly evident by the marked increases in tuberculosis mortality in many European countries which accompanied 
the social upheavals of the first and second world wars.<p></font>
The most striking recent increases have been in inner city areas, most notably New York City, and may similarly reflect changing living conditions. 
More prosaically, the previous pattern of declining incidence may itself have contributed to the problem by promoting a withdrawal of funds from 
tuberculosis control programmes and a general decrease in expertise and awareness amongst clinicians.<p>

<IMG  WIDTH=170 HEIGHT=120 SRC="gifs/tbgif3.gif" align=absmiddle hspace=5 
vspace=5><font size=3>Inner city social deprivation</font> <a href="../copy.html#tuber">&copy;</a><br clear=left><p>


The AIDS epidemic represents an additional important contributory factor. In general, individuals who are infected by <cite>M. tuberculosis</cite> have a 10 per 
cent life-time risk of developing clinically significant disease. For individuals who are coinfected with the human immunodeficiency virus (HIV), 
however, this risk rises to around 10 per cent a year, along with greatly increased case fatality.  HIV-associated disease accounts for a major part of 
the tuberculosis resurgence in the US. In the UK, for example, HIV and tuberculosis are largely restricted to different population groups. The 
incidence of tuberculosis in the UK is particularly high in immigrant communities.<p>

For further information, follow the link to <a href="tuber21.html">Spitting blood</a>.<p>

It is important at this stage to turn from the industrialized West and to look at tuberculosis in developing countries. In an era of vastly increased 
air travel and population movement, it is no longer feasible to consider disease control strategies which are restricted to single countries or 
regions.   Tuberculosis is a worldwide problem requiring worldwide solutions.<p>
<IMG  WIDTH=200 HEIGHT=300 SRC="gifs/graph.gif" align=left vspace=5 hspace=5 alt="Rise in number of new TB cases: New York City 1980-1991. Source US Centres for Disease Control"><br clear=all><br><p>

While tuberculosis was brought under control in the West, a different pattern was emerging in the rest of the world. Although accurate figures are 
difficult to obtain, the World Health Organization (WHO) estimates that approximately three million people die from tuberculosis every year. No other 
single infectious agent claims as many lives as <cite>M. tuberculosis</cite> and, of all deaths in the 15- to 
59-year-old age group, almost 20 per cent are due to tuberculosis. With the spread of HIV in many developing countries, it is projected 
that the annual death toll from tuberculosis will rise to four million over the next decade. From a worldwide 
perspective, it is clear that the resurgence of tuberculosis in developed countries is the very small tip of a very large iceberg. It is staggering 
that, half a century after the successes of penicillin and streptomycin, and in spite of the accumulation of a 
detailed understanding of the biochemistry and genetics of bacteria, mankind is still losing so dramatically in the battle against a bacterial 
infection. <p>

<a href="tuberc3.html">Forward to: Strategies for combatting tuberculosis</a><p>
<a href="tuberc1.html">Back to: Introduction</a><p>
<a href="index.html">Return to: the Tuberculosis contents page</a><p>
<p>

<p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-149</DOCNO>
<DOCOLDNO>IA057-000937-B009-153</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuberc3.html 193.128.22.20 19970109081242 text/html 2710
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:02:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:00 GMT
Content-length: 2519
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Strategies for combatting tuberculosis</font></h2><br>

<font size=5>Most cases of tuberculosis can be cured using existing 
drugs. It seems likely that heightened public concern will increase 
awareness and budgets for tuberculosis control, and there is reason to be 
optimistic that this will translate into a reversal of the increased 
incidence in most developed countries over the next few years.</font><p>

Recent statistics for 1993 do indeed suggest the start of a decline in 
tuberculosis in the US. Isolation of existing MDR cases, along with 
improved monitoring of therapy, should also contribute to control of the 
current drug-resistance problems. Yet, even under this optimistic 
scenario, it is estimated that for the US alone the direct and indirect 
costs of the tuberculosis epidemic will total over two billion dollars by 
the year 2000.<p>

Turning back to the worldwide problem, the cost of the drugs required to 
cure a tuberculosis patient averages around $30. In addition to saving 
the life of the patient, early treatment has the effect of restricting 
spread of the disease within the community. Taking these factors into 
account, it was calculated in the World Development Report 1993 that 
every 90 cents spent on tuberculosis control `buys' one year of healthy 
life for an individual. This makes tuberculosis treatment one of the most 
cost-effective of all health intervention measures currently available, 
and there is no doubt that the first step in combating tuberculosis is to 
ensure that the existing treatment is made as widely available as 
possible. <p>

The WHO has estimated that an additional annual funding of $100 million 
for tuberculosis control would allow a reduction of 50 per cent in 
tuberculosis mortality over the next decade. Concerted efforts are being 
made to mobilize appropriate sources.<p> <p>

<a href="tuberc4.html">Forward to: Diagnosis and drug resistance</a><p>
<a href="tuberc2.html">Back to: reasons for resurgence</a><p>
<a href="index.html">Return to: the Tuberculosis contents page</a><p>
<p>

<p></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-150</DOCNO>
<DOCOLDNO>IA057-000937-B009-174</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuberc4.html 193.128.22.20 19970109081255 text/html 5165
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:03:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:01 GMT
Content-length: 4974
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Diagnosis and drug resistance</font></h2><br>

<font size=5>Implementation of current control measures would be facilitated by the development of improved techniques for the diagnosis of tuberculosis patients and for the early detection of drug-resistant strains of <cite>M. tuberculosis</cite>.<p></font><p>


Diagnosis of tuberculosis currently relies mainly on the detection of bacteria by microscopic analysis of smears prepared from sputum samples. A more 
sensitive technique involves laboratory culture of the bacteria but, because of the slow growth rate of <cite>M. tuberculosis</cite>, culture results may take as long as four to six weeks. By using the polymerase chain reaction (PCR) to amplify specific fragments of bacterial DNA it is now possible to detect 
the presence of small numbers of <cite>M. tuberculosis</cite> in clinical samples within a matter of hours, and commercial diagnostic kits based on such assays are currently under evaluation. The present technologies are likely to be prohibitively expensive for routine use in developing countries, but the 
potential for future development of simpler and cheaper DNA-based tests holds some promise for improved diagnosis of tuberculosis. An additional 
spin-off from the analysis of <cite>M. tuberculosis</cite> DNA has been the development of fingerprinting techniques which, for the first time, allow accurate differentiation between strains of the bacteria and provide a new tool for studying the epidemiology of tuberculosis.<p>

The monitoring of the skin reaction to the injection of a mycobacterial protein mixture (the `Heaf' or `Mantoux' test) has traditionally provided a 
tool for identifying individuals exposed to <cite>M. tuberculosis</cite>. On the basis of this test, it is estimated that approximately one third of the world's 
population has been exposed to tuberculosis. The current skin test cannot be used to distinguish healthy individuals exposed to infection from those 
at risk of developing clinical disease, and much research has been carried out to try and identify individual protein fractions for use as improved 
reagents. Recent promising results from a group at the Statens Seruminstitut in Copenhagen suggest that a specific protein secreted by <cite>M. tuberculosis</cite> may provide the basis for a test to distinguish tuberculosis exposure from Bacille Calmette-Gu&eacute;rin (BCG) vaccination.<p>

Clinical problems associated with MDR tuberculosis in the US have stimulated an active interest in the development of rapid tests for drug 
resistance.  Currently available techniques rely on monitoring the effect of drugs on bacterial growth in laboratory culture and, as noted above, 
this is a lengthy process. Using recombinant DNA techniques, scientists at the Albert Einstein School of Medicine in New York have developed a 
phage-based system which allows rapid assessment of the viability of <cite>M. tuberculosis</cite>, and optimization of this technique may provide a clinically useful tool for the assessment of drug susceptibility.  Taking an alternative approach, several groups have focussed on understanding the genetic mechanisms by which <cite>M. tuberculosis</cite> becomes resistant to the major drugs.  Genetic changes - generally involving mutation of single nucleotides in key genes - have been characterized for resistance to rifampicin, 
isoniazid, streptomycin and the fluoroquinolones. Again, efforts are under way to exploit this information in the development of clinically useful 
assays for the rapid identification of resistant strains. Genetic analysis of the strains responsible for MDR tuberculosis suggests that their 
drug-resistance profiles are the result of the acquisition of a series of mutations, each conferring resistance to a single drug. The most likely 
origin of such strains is that they are the result of poorly administered therapy, for example the treatment of patients sequentially with individual 
drugs rather than combination therapy.<p>

The evolution of MDR strains by alternative pathways - a genetic alteration with a generalized effect on drug uptake, for example - presents a 
frightening theoretical possibility, and it will be important to maintain detailed monitoring of drug-resistance outbreaks. 
<p>

<a href="tuberc5.html">Forward to: Priorities for strategic research</a><p>
<a href="tuberc3.html">Back to: Strategies for combatting tuberculosis</a><p>

<a href="index.html">Return to: the Tuberculosis contents page</a><p>
<p>

<p></ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-151</DOCNO>
<DOCOLDNO>IA057-000937-B009-193</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuberc5.html 193.128.22.20 19970109081308 text/html 3353
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:03:19 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:01 GMT
Content-length: 3162
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Priorities for strategic research</font></h2><br>

<font size=5>While the importance of the drug-resistance approach is
beyond question, it must be asked whether this is in itself sufficient in
light of the magnitude of the worldwide problem. Existing tuberculosis
therapy will undoubtedly save lives and has certainly proved a powerful
tool for disease control in the context of a declining disease incidence
in developed countries. But will such treatment alone be able to reverse
the increasing trends in developing countries?<p></font> <p>

Even in African countries with highly efficient control programmes in 
place - in Tanzania, for example - the current trend remains upwards. It 
is important that we do not restrict our efforts to what is currently 
possible, but that we also strive to identify new and improved strategies 
for tuberculosis control. The resurgence of tuberculosis has triggered a 
resurgence of interest in strategic research and also an increase in 
research funding - by the US National Institutes of Health, and other 
national and international agencies.<p>

The most effective `short-course chemotherapy' for tuberculosis requires 
administration of at least three drugs over a six-month period. 
Delivery of such treatment is problematic in developed countries and 
extremely difficult in developing countries lacking a well-organized 
healthcare infrastructure. The long treatment period is required to 
prevent relapse of disease and is thought to reflect the fact that some of 
the bacteria are able to persist in aquiescent or `dormant' phase in 
which they are refractory to drug action. An understanding of the molecular 
basis of dormancy might provide a foundation for developing new drugs 
with the potential for shortening the time required for tuberculosis therapy.<p>

The application of molecular genetic tools has been a major factor in 
stimulating research on bacterial pathogenesis and, over the past few 
years, considerable effort has been invested in developing genetic tools 
for mycobacteria. Techniques are available for the introduction of 
genes into mycobacteria, and projects to establish the nucleotide 
sequences of the genomes of <cite>M. tuberculosis</cite> and <cite>M. 
leprae</cite> are well under way. It is anticipated that these 
initiatives will allow fundamental insights into the basic biology of M. 
tuberculosis and its interaction with the infected host, and will provide 
new leads for rational drug design.<p>

<a href="tuberc6.html">Forward to: Tuberculosis and immune response</a><p>
<a href="tuberc4.html">Back to: Diagnosis and drug resistance</a><p>
<a href="index.html">Return to: the Tuberculosis contents page</a><p>
<p>

<p>
</ul></ul></ul></ul></ul></ul></ul>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-152</DOCNO>
<DOCOLDNO>IA057-000937-B009-206</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuberc6.html 193.128.22.20 19970109081325 text/html 4251
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:03:30 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:01 GMT
Content-length: 4060
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Tuberculosis and immune response</font></h2><br>

<font size=5>The outcome of infection with <cite>M. tuberculosis</cite> 
is critically
dependent on the individual immune response. Boosting the immune response
represents a very attractive strategy for preventing tuberculosis, and
also, perhaps, for augmenting treatment.<p></font> 
<p>
<IMG WIDTH=120 HEIGHT=167 SRC="gifs/tbgif7.gif" align=absmiddle hspace=5 
vspace=5>
<font size=3>Tuberculosis with fibrosis.</font> <a href="../copy.html#tuber">&copy;</a><br clear=left><br><p>

Throughout the past century scientists have strived to develop this
concept into a practical reality, but ultimately it is the HIV virus which
has been most successful in demonstrating the real power of immune
manipulation in tuberculosis - with the devastatingly negative effect
described above. The most extensively investigated tuberculosis vaccine
has been BCG - an isolate of <cite>Mycobacterium bovis</cite> attenuated 
by <cite>in vitro</cite>
passage, discovered by the French scientists Calmette and Gu&eacute;rin in
the early years of this century. BCG acts as an effective vaccine in a
range of experimental animal models and has shown protective efficacy of
more than 70 per cent in some human trials. In other trials, however, BCG
has been found to confer no protection whatsoever against the predominant
adult forms of tuberculosis. BCG trials have been discussed and analysed
at length but, in the end, the mechanisms underlying the failure of BCG -
and indeed the mechanisms underlying its success - remain the subject of
conjecture.<p>

The complex and frustrating history of BCG provides an object lesson in
the difficulties to be faced in attempts to develop tuberculosis vaccines.
Given the potential public health benefits, however, and in light of
current developments in understanding the basic biology of <cite>M. 
tuberculosis</cite>, a compelling case can be made for a renewed and concerted
effort in the area of tuberculosis vaccination. While a new vaccine would
ultimately have to be evaluated by its ability to prevent disease,
progress towards vaccine development will depend on the availability of
intermediate tests to assess likely protective efficacy of different
candidate vaccines in a range of human populations. Protection against
tuberculosis depends on regulation of the cell-mediated immune system - on
the balance between activation of particular T lymphocytes and release of
an appropriate blend of soluble mediators. While this regulation is
complex and understood only at the most rudimentary level, the problems
faced in tuberculosis are shared by a wide range of immune-mediated
diseases - including allergy and arthritis - and are currently being
addressed by a broad range of scientists.<p>

While the current resurgence of tuberculosis in developed countries may
be reversed by increased vigilance and the strengthening of existing
control programmes, global tuberculosis will only be controlled by a
renewed global effort. At the same time, strategic research to develop
improved means of tuberculosis control presents a formidable conceptual
challenge for microbiologists and immunologists. <p>

Mobilization of appropriate financial, human and scientific resources is
required to ensure that in the 21st century people are no longer allowed
to die in millions from a 19th-century disease such as tuberculosis.<p>
<p>

<a href="tuberc5.html">Back to: Priorities for strategic research</a><p>
<a href="index.html">Return to: Tuberculosis contents page</a><p>
<a href="../">Return to: Odyssey contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-153</DOCNO>
<DOCOLDNO>IA057-000937-B020-378</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/tuberc/tuber21.html 193.128.22.20 19970109095733 text/html 1382
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:47:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:00 GMT
Content-length: 1191
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Spitting blood</font></h2><br>

<font size=5>Tuberculosis is an infectious disease that is still increasing.  It thrives on overcrowding and poor nutrition.  Roughly one third of the world population alive today (two billion people) are, or have been, infected by tuberculosis. </font>
<p>

Although more than 95 per cent of people infected live in poor countries, recent outbreaks of tuberculosis have struck the impoverished inner cities of the US.  Increase of tuberculosis is also clearly related to the AIDS epidemic.  Approximately 10 million people are HIV positive.  About three million of these are estimated to be infected by tuberculosis.<p>
<p>


<a href="tuberc2.html">Back to: Reasons for resurgence</a><p>
<p>

<p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-154</DOCNO>
<DOCOLDNO>IA057-000937-B017-197</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/il5.html 193.128.22.20 19970109093217 text/html 4269
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:22:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:22 GMT
Content-length: 4078
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Interleukin-5</font></h2>

<p>
<font size=5>One of the key events in chronic asthma is the migration into the lungs of a set of leukocytes known as 
eosinophils.  Upon activation of these cells, a variety of protein, lipid and other small molecule mediators are released into the
 surrounding tissues, resulting in inflammation and the destruction of cells.  The normal function of this reaction <cite>in vivo</cite> is to 
combat and eliminate invading parasites.  The aberrant recruitment and activation of eosinophils in asthma may therefore be a 
misfiring of the body's natural defences.</font><p>

A variety of factors can recruit eosinophils into inflammatory sites.  However, only one of these, interleukin-5 (IL-5), has been shown to have the three-fold ability to enhance the 
production of eosinophils, as well as their recruitment and activation. IL-5 is a dimeric protein with a molecular weight of 26 000 Da. Studies using animal models of allergic asthma 
have shown that antibodies against IL-5 block the recruitment of inflammatory cells into the lung.  Therapeutically, it would be useful to have a molecule that is not a protein, but 
which blocks the interaction of IL-5 with its receptor. As part of a programme to obtain such a molecule, we are defining  the active regions (the pharmacophores) in both the IL-5 
molecule and its receptor, which control their interaction.  It is not simply a question of identifying which amino acids are important, but also of defining their precise three dimensional location.<p>

The project has two underlying themes:<p>
<ul  type=disc>
<li>  First, to study the structure of IL-5 and its receptor by X-ray crystallography and by site-directed mutagenesis, so that we can define a pharmacophore, and from this identify 
new molecules which will help reduce the chronic inflammation in asthma. 

<li> Second, to draw conclusions from this study that will be generally applicable to the rational design of small molecules which 
can block protein-protein interactions.</ul><p>

<b>Dimeric protein</b><p>

<IMG  WIDTH=337 HEIGHT=201 SRC="bioinf4.gif"><p>

Interleukin-5 is a dimeric protein; the two subunits are identical and joined together by a pair of disulphide bridges.  We produced the protein in E. coli, in which it forms insoluble 
aggregates (inclusion bodies).  The IL-5 was subsequently extracted, refolded and purified.  After careful adjustment of the conditions (protein concentration, reductant, etc.) our 
'scale-up' protein purification laboratory produced 100 mg batches of pure, active IL-5. This was crystallised by our colleagues at the  Glaxo Research Institute  in North Carolina.<P> 

<a href="il52.html">Forward to: Protein structure</a><p>
<a href="project.html">Return to: Research projects contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-155</DOCNO>
<DOCOLDNO>IA057-000937-B023-243</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/il52.html 193.128.22.20 19970109102238 text/html 5698
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:12:47 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:23 GMT
Content-length: 5507
Content-type: text/html
</DOCHDR>
<html><head><title>GBRI, Switzerland</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>
<h2><font size=6>Protein structure</font></h2>

<p>

<font size=5>One of the problems in using X-ray crystallography to solve the 
structures of proteins is that heavy atom derivatives 
are required to phase the diffraction spots.  Heavy metal salts are often used for this purpose, but this method is difficult 
to use with small proteins which sometimes do not contain distinct heavy atom binding sites.  We used a new approach (Graber et 
al., 1993) to obtain our derivatives.</font>
<p>

By growing an E. coli methionine auxotroph expressing IL-5 on seleno-methionine, we were able to produce a protein in which the 
sulphur atoms of the methionine were specifically replaced by the much heavier selenium.  This has the added advantage that we 
know exactly where the heavy atoms are located in  the protein sequence. <P> 

The structure of IL-5 has now been solved to a resolution of 2.4 angstroms (Milburn et al., 1993).  The protein is an intimate 
dimer, both sub-units being four helical bundles.  The 
individual subunits are coloured red and blue in the figure below.  It can be seen that there are two bundles or domains placed end to 
end, and that each domain contains secondary structure from 
both chains.  Starting with the N-terminus, the polypeptide chain of IL-5 forms three a-helices followed by a b-strand, all 
tightly packed together.  At this point (cysteine-86), the 
backbone crosses into the other half of the dimer to form a second b-strand and the final a-helix.  This sharing of one helix 
and a b-strand between the two domains is novel for 
cytokines.  It was not completely unexpected, since we had already demonstrated that the disulphide bonding pattern was "head 
to tail", in other words cysteine-86 from one subunit 
forms a disulphide bridge to cysteine-44 of the other subunit.  The reason why IL-5 is a dimer is also clear from the 
structure.  Many hydrophobic residues which are normally present 
in the core of the dimer would be exposed to solvent. By forming a dimer, some 7000 square angstroms of surface area is buried 
within the protein.<P>

<img src="bioinf4.gif"><p>

The topology of the four helical bundles of IL-5 is the same as that seen for many other cytokines such as IL-4, IL-2 and the 
colony stimulating factors.  This three dimensional 
similarity is all the more striking since there are no clear similarities between the primary sequences of the proteins. 
However IL-5 is unusual in that it is a dimer, and also that it 
is the only cytokine in which structural elements are shared between the two domains. <P> 
We are currently identifying the regions which are important in receptor binding.  Using site-directed mutagenesis we have 
already shown that, contrary to the published evidence, the 
fourth helix is not the essential one for interaction with the receptor.  This is important since it has been shown by other 
groups that antagonist variants of IL-4 can be made by 
mutating residues in the fourth helix.  This scenario does not appear to hold for IL-5; clearly cytokines are using a four 
helical bundle scaffold to hold together different 
pharmacophores. By using scanning mutagenesis techniques, we are refining our understanding of which amino acids are essential 
for binding and for the subsequent signalling events.  To 
address why the protein should exist as a dimer and whether residues from both halves of the molecule are really needed, we 
have developed a system for making heterodimers of mutant IL-5 molecules.<P> 

 
<b>Some recent publications:</b><p>

Graber, P., Bernard, A. R., Hassell, A. M., Milburn, M. V., Jordan, S. R., Proudfoot, A. E. I., Fattah, D. and T.N.C. Wells. 
(1993). Purification, characterisation and crystallisation of selenomethional recombinant human interleukin-5 from Escherichia coli. <i> Eur. J. Biochem.</i> 212:751-5.<P>

Milburn, M. V., Hassell, A. M., Lambert, M. H., Jordan, S. R., Proudfoot, A. E. I., Graber, P. and T.N.C. Wells. (1993). A novel dimer configuration revealed by the crystal structure at 2.4A resolution of human interleukin-5. <i> Nature </i>363: 172-6.<P>


 

<a href="il5.html">Back to: Interleukin-5</a><p>

<a href="project.html">Return to: Research projects contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-156</DOCNO>
<DOCOLDNO>IA057-000937-B020-323</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/index.html 193.128.22.20 19970109095653 text/html 2742
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:47:01 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:37 GMT
Content-length: 2551
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Cinderella's reversal of fortune</font></h2><br>



<font size=5>It is not uncommon today to see articles on cell biology in medical journals
that until recently were devoted exclusively to practical clinical medicine.
This is testimony to an increasing awareness and recognition of the growing
impact of cell biology in clinical medicine.</font><p>
<p>
by Jan James,<br> <font size=3>Professor Emeritus of Histology and Cell Biology,<br>Academic Medical Centre in Amsterdam</font><p>
<p>
  <IMG  WIDTH=88 HEIGHT=132 SRC="gifs/trancell.gif" align=absmiddle vspace=5 hspace=5><font size=3>General diagram of a cell</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>

<a href="cellb1.html">Introduction</a><p>
<a href="cellb2.html">The growth of cytology</a><p>
<a href="cellb3.html">Organelles with specific functions</a><p>   
<a href="cellb4.html">Ubiquitin, stress proteins and the cytoskeleton</a><p>
<a href="cellb5.html">Cell-membrane receptors and coatings</a><p>
<a href="cellb6.html">Cell-cell and cell-matrix interactions</a><p>
<a href="cellb7.html">Adhesion molecules and disease</a><p>
<a href="cellb8.html">Conclusions</a><p>
<p><p>
<a href="../">Return to: Odyssey contents page</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>

</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-157</DOCNO>
<DOCOLDNO>IA057-000937-B008-301</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb1.html 193.128.22.20 19970109080827 text/html 2761
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:58:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 2570
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Introduction</font></h2><br>

<font size=5>The cell as a form of life is the ultimate masterpiece of evolution. More than 60 years ago the zoologist and pioneer cytologist Edmund B. Wilson wrote: `The key to every biological problem must finally be sought in the cell.' Roughly 60 x 10

12 cells make up the adult human body. Each cell has the same hereditary information laid down in its DNA, but in the body's 200-odd cell types only a small and variable part of the total of more than 50,000 genes is active. 
Recent work in molecular genetics has provided considerable
insight into the complex regulatory mechanisms involved in the control of
selective gene expression. Genes encode proteins, and these determine the
character of a cell. Some proteins (enzymes) are involved in catalyzing
particular steps in the metabolic pathways, others contribute to the structures
of the cell.</font><p>

<IMG WIDTH=126 HEIGHT=164 SRC="gifs/prop.gif" align=absmiddle vspace=5 hspace=5 ><a href="prophase.html">See the process of cell division in 
action</a> <a href="../copy.html#cell">&copy;</a><br clear=left><p>


In Wilson's time, cell types could only be identified by careful microscopic
observation of shapes (morphology), usually in preparations contrasted by non-
specific stains. To study molecules in those days biochemists had to resort to
the destruction of the cell and its structures. Since then, newer tools have
become
available, starting with electron microscopy in the 1960s, which can be used
for the detection and analysis of macromolecules and for the localization and
even the  measurement of enzyme activities at the microscopic level without
tissue destruction. The integration of morphological and biochemical studies
has enabled much finer analysis and has led to the discovery of a multitude of
functionally different entities within each cell type, with corresponding
cellular structures and functions.<p>

<a href="cellb2.html">Forward to: The growth of cytology</a><p>
<a href="index.html">Return to: Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-158</DOCNO>
<DOCOLDNO>IA057-000937-B008-325</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb2.html 193.128.22.20 19970109080846 text/html 3586
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:58:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 3395
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>The growth of cytology</font></h2><br>



<font size=5>Less than 30 years ago, however, developments in the 
study of cells
(cytology) and other related sciences were generally considered of marginal
importance to clinical medicine. Basic scientists and clinical research workers
followed completely different agendas. This situation has since changed
dramatically.</font><p>
  
<IMG  WIDTH=178 HEIGHT=116 SRC="gifs/11top.gif" align=absmiddle vspace=5 hspace=5><font size=3>Pores in the nuclear envelope</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>
  
Fundamental biomedical research has become far more important in
the understanding of life and in the practice of medicine itself. Daily reports
of discoveries in cell biology, molecular biology and genetics, which have a
direct bearing on day-to-day
medical practice, and regular Nobel prizes for work in the basic sciences, are
testimony to an undeniable role reversal.<p>

Spectacular results have been achieved in the field of molecular biology and
molecular genetics, but these would be incomplete without a proper insight into
the orchestration of cellular functions and behaviour. Molecular biology
describes the structure and functioning of molecules operating in living
organisms, whereas cell biology studies the way in which these molecules
operate in concert to constitute the wondrous universe of the cell. Molecular
biology and cell biology have, in fact, become inseparable. The two disciplines
differ, however, in the tools they use and in their way of thinking.<p>

<IMG  WIDTH=178 HEIGHT=116 SRC="gifs/11bot.gif" align=absmiddle hspace=5 vspace=5><font size=3>Rough endoplasmic reticulum</font> <a 
href="../copy.html#cell">&copy;</a><br clear=left><p>

  As was pointed out recently in a paper by Albrecht-Buehler called `In defence
of non-molecular
cell biology', the orchestration of functions in larger compartments - among
which are included the membrane system that covers the nucleus (nuclear envelope), the spindle structure involved in dividing chromosomes during cell division
(mitotic spindle), and the Golgi complex (one of the particularly specialized
compartments called organelles), which contains millions of interacting
macromolecules - cannot be fully understood on a molecular basis alone. Though
genetics garners much attention in the popular press, the way in which the cell
is maintained as an organization is less well known both among research workers
in the basic sciences and within the circle of the clinical profession. A brief
outline of some of the tenets of cell biology will indicate the importance of
this field to the future of basic and clinical research.<p>
<p>


<a href="cellb3.html">Forward to: Organelles with specific functions</a><p>
<a href="cellb1.html">Back to: Introduction</a><p>
<a href="index.html">Return to: Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-159</DOCNO>
<DOCOLDNO>IA057-000937-B008-341</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb3.html 193.128.22.20 19970109080859 text/html 4609
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:59:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 4418
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Organelles with specific functions</font></h2><br>



<font size=5>Lysosomes are protein-containing sacs  produced by the
activity of the rough endoplasmatic reticulum (rough ER)
and the Golgi complex. In these two compartments, proteins, synthesized in the
ribosomes, are distributed or further chemically modified by the attachment of
groups, such as sulphates, and lipid or sugar units.</font><p>

<IMG WIDTH=166 HEIGHT=122 SRC="gifs/12bit.gif" align=absmiddle vspace=5 hspace=5><font size=3>Nerve cell image</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>  
  
Lysosomes have a set of
some 40 hydrolytic enzymes enabling the breakdown of all the major classes of
biological molecules. These molecules are digested to small fragments, which
then pass through the membrane of the lysosome to be re-utilized
in the cellular metabolic mill.<p>

Lipofuscin granules, `age pigment', are the slowly accumulated result of
incomplete digestive activity. They contain a complex of fatty macromolecular
substances. They may accumulate in long-lived
cells such as nerve or liver parenchyma cells, and do not seem to interfere
with their functioning. The term age pigment is misleading, as the granules may
be found in middle age yet fail to occur in octogenarians. More severe
accumulation occurs when the lysosomal set lacks an enzyme to break down a more
common substrate. This gives rise to a score of congenital storage diseases
such as Pompe's disease, which is characterized by greatly swollen lysosomes
resulting from the accumulation of glycogen caused by an  alpha-glucosidase
defect, and Gaucher's disease, caused by a glucocerebrosidase deficiency.
Therapeutic administration of the latter enzyme, which has recently become
available, has shown promising results and has achieved a reduction in the size
of the enlarged liver and spleen in some cases. A more causal treatment by gene
therapy is the subject of intense study and could well open new horizons before
the year 2000.<p>

Mitochondria are essential for maintaining a continuous supply of adenosine
triphosphate (ATP), the cell's fuel for all energy-consuming activities.
Cellular death following oxygen depletion (ischaemic necrosis) is usually
initiated by a collapse of mitochondrial function, leading to a deficiency of
the energy supply. Remarkably, mitochondria contain their own DNA (mtDNA)
encoding for a small but vital set of proteins. Several discrete mutations in
mtDNA and nuclear DNA have been described which affect the protein household of
mitochondria. While leaving the ATP supply at a certain level they may result
in various syndromes characterized by severe damage to the brain and muscles
(encephalomyopathies). Mutations of mtDNA are now often held responsible for
degenerative phenomena associated with senescence.<p>

Peroxisomes are a comparatively recent discovery in the cellular organelle
family. Unless special enzyme-histochemical techniques are employed, they
cannot be readily observed with a light
microscope. After it was established that the rare Zellweger's
cerebrohepatorenal syndrome is associated with the absence (or at least
dysfunction) of peroxisomes, the complex function of peroxisomes in dealing
with the toxic substance hydrogen peroxide and with etherphospholipid
synthesis, fatty acid oxidation and glyoxylate metabolism, was finally
correlated with congenital diseases. So far, research has led to the discovery
of no less than 14 peroxisomal diseases. The significance of peroxisomes in
cellular metabolism seems to have been greatly underestimated at first, and the
pathophysiology of their complex disorders is still only partly understood.<p>
<p>
	

<p>

<a href="cellb4.html">Forward to: Ubiquitin, stress proteins and the cytoskeleton</a><p>
<a href="cellb2.html">Back to: The growth of cytology</a><p>
<a href="index.html">Return to: Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-160</DOCNO>
<DOCOLDNO>IA057-000937-B008-366</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb4.html 193.128.22.20 19970109080917 text/html 6228
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:59:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 6037
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Ubiquitin, stress proteins and the cytoskeleton</font></h2><br>

<font size=5>Proteins are  continuously formed during the active life of a 
cell. The overall protein turnover has turned out to be much quicker than 
was previously thought,
a factor which may be functionally important. Likewise, many enzymes important
to regulatory functions have short half-lives so that their concentrations can
quickly be adapted to circumstances. </font><p>

Until recently the breakdown of proteins was thought to be exclusively an 
activity of the lysosomes. However, relatively short-lived proteins (with 
half-lives of up to only 30 minutes) were found to be degraded
in the cytoplasmic matrix. Before they meet their destiny, these proteins
receive a tag, a special small protein called ubiquitin. Ubiquitin, which also
has other functions, is among the most highly conserved proteins in the
evolution of life. Its sequence is almost identical in organisms as distantly
related as yeast, animals and higher plants. This indicates that the function
of ubiquitin is highly critical and that almost any alteration in its sequence
is likely to be lethal. This alternative breakdown mechanism of the cytoplasm
provides a means of quickly removing defective proteins, particularly those
with half-lives of the order of two minutes or less. These are often defective
because of errors in translation or due to oxidative damage.<p>

Another exciting development should be mentioned here. Certain aggressive
assaults on a cell such as heat, poisons or oxygen depletion induce most cells
of the body to synthesize stress proteins (formerly called heat-shock
proteins). The synthesis of stress proteins is induced by the denaturation
products of proteins. They act as protectants for the damaged cell and chaperon
newly formed proteins to replace the damaged ones. Medically, this is an
important phenomenon because it allows cellular damage to be reduced. But it is
also a danger, since the `strange' stress proteins have been shown to be a
source of autoimmune reactions.<p>

The supportive networks of the cell, which together form the cytoskeleton, are
responsible for both the cell's ability to adopt different shapes, for example
to execute movements, and the intracellular displacement of organelles.The name
cytoskeleton is too suggestive of a static framework; a more accurate name
would be cytomusculature. It consists of a complex protein network of
filamentous and tubular structures far beyond the reach of the light
microscope; as such they are typical of cellular systems belonging to the new
era of cell biology. All three components of the cytoskeleton are proteins. The
microfilaments consist of actin and the microtubules of tubulin, while the
intermediary filaments have a variable composition. The elements of the
cytoskeleton are continuously renewed although at different rates; the
hollow-centred microtubules can be formed from monomer tubulin units in less
than a minute.<p>

The two best-understood examples of cellular movement are the contractions of
muscle and non-muscle cells, which are actin-dependent,
and the beating of cilia and flagella, which depends exclusively on the
activity of microtubules. In the immotile cilia syndrome, a variety of minor
genetic defects in the accessory proteins of the ciliar and flagellar
microtubules leads to a combination of male infertility and recurrent upper and
lower airway infections. The sperm tail, a flagellum with a microtubular core
structure, is unable to move the sperm cell. The cilia in the respiratory
epithelium fail to clean the airways by their unidirectional beatings. The rare
and serious Kartagener syndrome, in which the normal asymmetry of the body is
reversed (situs inversus, with the heart on the right side and the liver on the
left), seems also to be caused by immotile cilia. This suggests that the
unidirectional beating of cilia during early development plays a role in
determining left-right asymmetry.<p>

Intermediary filaments, which are tissue-and cell-specific,
have primarily a supporting function in the cell. Their great diversity can
only be distinguished with immunocytochemical methods, using monoclonal
antibodies. Under the electron microscope, they all have virtually the same
appearance with a diameter of 7-11 nanometers. Twenty different types of
intermediary filaments (here called cytokeratins) can be identified in
epithelial tissues. In the liver, related epithelia, such as the bile ductules
and liver parenchyma, can now be distinguished on the basis of differences in
cytokeratins. In medicine such knowledge can be applied to identify the tissue
provenance of the original tumour after metastasis, on the basis of difference
in keratin types. Straightforward defects of intermediary filaments are found
in the brains of Alzheimer dementia patients is due to modified neurofibrils,
the intermediary filament type of nerve cells; Mallory bodies in cirrhotic 
livers, resulting from alcohol abuse, have recently been shown to be composed 
of aggregates of cytokeratin filaments.. Epidermolysis bullosa, a skin disease
characterized by blistering, can be correlated with an abnormal structure of 
the cytokeratins (and the related connected intercellular junctions) in the 
epidermal cells. <p><p>

<a href="cellb5.html">Forward to: Cell-membrane receptors and coating</a><p>
<a href="cellb3.html">Back to: Organelles with specific functions</a><p>
<a href="index.html">Return to: the Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-161</DOCNO>
<DOCOLDNO>IA057-000937-B008-386</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb5.html 193.128.22.20 19970109080946 text/html 3482
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:59:50 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 3291
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6> Cell-membrane receptors and coatings</font></h2><br>

<font size=5>The cell membrane, with its backbone structure of a bimolecular
lipid layer in which proteins are bound in a loose or
more integrated fashion, has been thoroughly investigated. The proteins
regulate cell permeability and act as receptors for a broad range of signal
molecules, such as hormones, growth factors and transmitters (so-called
first-messenger molecules). </font><p>

<IMG  WIDTH=144 HEIGHT=82 SRC="gifs/transpri.gif" align=absmiddle vspace=5 hspace=5><font size=3>Transmembrane protein image</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>

The binding of a signal molecule, or of a drug molecule, to a receptor results in either its activation or it merely occupies that position and prevents activation by another molecule. The activation of a receptor can have either a positive or a negative 
stimulatory effect on the cell's growth, differentiation or any other function; intracellularly, secondary messengers are often involved. All of the steps in these communication pathways offer opportunities for pharmacological intervention. This is an act
ive field of research.<p>

The outer surface of the cell membrane has a carbohydrate cell coating
(glycocalyx), which has a highly variable biochemical nature. The glycocalyx is
identifiable by electron microscopy. The carbohydrate (sugar-like)
portions of glycoproteins, glycolipids and other carbohydrate complexes, extend
outwards from the membrane, thus forming the glycocalyx. It has been found
recently that this coating is an important carrier of information. Because of
its complex structure, it can carry much more information per unit weight than
proteins. When the physical state of the cell changes or in an abnormal
condition such as disease, the coating conveys this information by emitting
signals, almost like a smell, which have an effect on the cell's social
relations. 

Carbohydrate-directed
interactions are also of primary importance for the operation of the immune
system. Signal molecules in the carbohydrate coating provide essential
landmarks, not only in helping immune system cells distinguish between self and
non-self, but also, for example, in the movement of lymphocytes from the
bloodstream into peripheral lymph nodes, a process which is started by the
adhesion of lymphocytes to vascular endothelial cells. This selective binding,
based on a protein-carbohydrate interaction, involves a novel protein family of
adhesion molecules, termed selectins.<p>


<p>

<a href="cellb6.html">Forward to: Cell-cell and cell-matrix interactions</a><p>
<a href="cellb4.html">Back to: Ubiquitin, stress proteins and the cytoskeleton</a><p>
<a href="index.html">Return to: the Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-162</DOCNO>
<DOCOLDNO>IA057-000937-B008-397</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb6.html 193.128.22.20 19970109081002 text/html 4815
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:00:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 4624
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Cell-cell and cell-matrix interactions</font></h2><br>






<FONT SIZE=5>Maintenance of the stability and integrity of body tissues 
depends on adhesion  between cells and the extracellular matrix. More permanent
cell attachments involve cellular junctions, such as desmosomes and adhesion
plates, which are all relatively large, complex structures in which many
different molecules cooperate. </font><p>

<IMG  WIDTH=164 HEIGHT=124 SRC="gifs/15top.gif" align=absmiddle vspace=5 hspace=5><font size=3>Desmosome image</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>
  
Cells in a stratified epithelium (such as the
skin) adhere to each other by means of full desmosomes, each apparently
contributing to the junction with a similar structure. Intracellularly,
cytokeratin filaments (here called tonofilaments) are connected to the
desmosomes and serve as cytoplasmic anchors for the junction. However, at the
base of the epithelium, cells adhere to the extracellular matrix (here the
basal lamina) by means of  half desmosomes. At the superficial layer, the fully
differentiated epithelial cells lose their mutual adhesion and are sloughed
off.<p>

<IMG  WIDTH=164 HEIGHT=124 SRC="gifs/15bot.gif" align=absmiddle hspace=5 vspace=5><font size=3>Long filaments in epithelial cells</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>
  
However, many cells in the body have quite another relation to each other and
to the extracellular matrix. Connective tissue cells adhere to each other or to
the extracellular matrix on a more or less temporary basis. In general, white
blood cells, such as granulocytes and lymphocytes, and blood platelets
circulate freely. But in an inflammatory reaction the granulocytes must adhere
to the blood vessel lining (endothelium) so as to penetrate into the tissue to
attack invading organisms. Lymphocytes adhere to specialized blood vessels,
called high endothelial venules, which enable them to leave the bloodstream and
enter the lymphatic system. Platelets adhere to sites with damaged or absent
endothelium. In all these temporary adhesion processes, interactions between
specific molecules play a crucial role.<p>

Two groups of transmembrane glycoproteins are of importance in cell-cell
adhesion: the calcium-dependent cadherins, which only connect in the presence
of calcium ions, and the calcium-independent cell adhesion molecules (CAMs).
Both groups have several tissue-specific forms, such as E- (for epithelial) 
cadherin and N- (for neural) CAM. Molecules of the same type recognize
each other and form
temporary connections (homotypical interaction). Cadherins are integrated in
the plasma membrane and their cellular domain is linked to the cytoskeleton via
specific proteins called catenins. CAMs are linked to, but not integrated
within, the plasma membrane. CAMs belong to the immunoglobulin superfamily, so
called because of their structural resemblance to antibodies. Several CAMs have
a role in the immune system, for example in antigen recognition and the
adhesion of T-lymphocytes,
and in the recognition of major histocompatibility complex molecules.<p>



Another family of adhesion molecules, the integrins, recognizes and binds to
proteins, such as the fibronectins and laminin, in the extracellular matrix.
These proteins are the most common linking elements in the extracellular
structures of the body (important constituents of which are collagens and
proteoglycans). Here too, the intracellular part of integrin binds to the
cytoskeleton, thereby linking the entire system into a framework that extends
from the inside to the outside of the cell. Another group of adhesion
molecules, the selectins, do not bind to proteins but, with varying degrees of
specificity, bind instead to carbohydrates. The selectins are involved in
different processes related to inflammatory and immunological responses.<p>

<a href="cellb7.html">Forward to: Adhesion molecules and disease</a><p>
<a href="cellb5.html">Back to: Cell-membrane receptors and coatings</a><p>
<a href="index.html">Return to: the Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-163</DOCNO>
<DOCOLDNO>IA057-000937-B008-414</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb7.html 193.128.22.20 19970109081013 text/html 3178
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:00:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 2987
Content-type: text/html
</DOCHDR>
<html><head><title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Adhesion molecules and disease</font></h2><br>

<FONT SIZE=5>The link between adhesion molecules and disease has given
rise to a new field of research embracing various disorders. In the inherited disease known as leukocyte adhesion deficiency, a defective form of integrin results in the
impaired adhesion of granulocytes and other white blood cells, which greatly
impairs their functioning and often leads to death from infections in
childhood. </font><p>


Cell-cell and cell-matrix
interactions play a crucial role in tumour invasion and tumour metastasis. In
both cases cell adhesion molecules play a role. In the growth of a tumour, the
interplay between cells and the matrix is much more complex than it was thought
to be a few years ago. The image of an aggressive invasion into a passive
interstitium is far too simplistic. In the invaded stroma, the growing tumour
induces a proliferation of fibroblasts and endothelial cells, which develop the
infrastructure in which the tumour is allowed to expand. On the other hand,
tumour cells have to break down certain structures such as the basal lamina and
its supporting basement membranes before they can invade a stromal compartment
or a parenchymal formation. To do this, tumour cells secrete proteinases such
as collagenases and cathepsins. Curiously enough, tumour cells also produce
basal lamina material (non-fibrous collagen type-IV laminin) and the prognosis
of a tumour is better when the cells produce a high amount of such materials.
Cadherins, particularly E-cadherin (uvomorulin), have an antimetastatic 
effect. The disappearance of E-cadherins
in cancer cells results in an increased tendency to detach and spread. This is
an exciting new development, the exploration of which has only just begun. <p>


One group of skin disorders arises as the consequence of adhesion molecule
malfunctioning. The blistering in pemphigus is caused by a defect of cadherin-
like glycoproteins in the epidermic cellular junctions. In bullous pemphigoid,
an autoimmune reaction develops against half desmosomes, causing the epidermis
to detach from its bedding in the basement membrane.  The role of cell adhesion
molecules in other inflammatory responses, for example in asthma, is currently
being investigated.<p>
<p>

<a href="cellb8.html">Forward to: Conclusions</a><p>
<a href="cellb6.html">Back to: Cell-cell and cell-matrix interactions</a><p>
<a href="index.html">Return to: the Cell biology in clinical medicine contents page</a><p>

</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-164</DOCNO>
<DOCOLDNO>IA057-000937-B008-431</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/cellb8.html 193.128.22.20 19970109081020 text/html 1959
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:00:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:57 GMT
Content-length: 1768
Content-type: text/html
</DOCHDR>
<html><head><title>Odysssey: Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Conclusions</font></h2><br>

<FONT SIZE=5>
The development of new technologies has resulted in spectacular advances in
biomedical research disciplines such as genetics, biochemistry, pharmacology
and cell biology. In the process, boundaries have faded and progress in these
fields has become interdependent. Modern cell biology has developed into a
meeting place for research workers from a range of different disciplines, all
concentrating on the study of cells in health and disease.</font><p>

In this overview, various examples have been briefly presented to illustrate
the scope, advances and current fields of active research of modern cell
biology. Not only have such advances increased the understanding of the
mechanisms involved in health and disease, but they have also contributed to
bridging the gap between basic biomedical research and patient care. One
conclusion can safely be drawn from the welter of facts: cell biology is no
longer the Cinderella of medical education, and preclinical science is now an
integral part of modern medicine.<p>

<p>

<a href="cellb7.html">Back to: Adhesion molecules and disease</a><p>
<a href="index.html">Return to: Cell biology in clinical medicine contents page</a><p>
<a href="../">Return to: the Odyssey contents page</a>
</ul></ul></ul></ul></ul></ul></ul>


</body>


</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-165</DOCNO>
<DOCOLDNO>IA057-000937-B020-301</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/prophase.html 193.128.22.20 19970109095637 text/html 831
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:46:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 641
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>
<h1><font size=7>Prophase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/prop.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="metaphas.html">Forward to: Metaphase</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-166</DOCNO>
<DOCOLDNO>IA057-000937-B024-224</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/metaphas.html 193.128.22.20 19970109103009 text/html 831
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:20:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 641
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>
<h1><font size=7>Metaphase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/meta.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="anaphase.html">Forward to: Anaphase</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-167</DOCNO>
<DOCOLDNO>IA057-000937-B025-65</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/anaphase.html 193.128.22.20 19970109103527 text/html 830
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:25:36 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:56 GMT
Content-length: 640
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>
<h1><font size=7>Anaphase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/ana.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="telophas.html">Forward to: Telophase</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-168</DOCNO>
<DOCOLDNO>IA057-000937-B025-138</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/health/odyssey/cellbio/telophas.html 193.128.22.20 19970109103650 text/html 834
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:26:24 GMT
Last-modified: Tuesday, 24-Dec-96 11:14:58 GMT
Content-length: 644
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>
<h1><font size=7>Telophase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/telo.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="cellb1.html">Back to: the introduction</a><p>

</ul></ul></ul></ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-169</DOCNO>
<DOCOLDNO>IA057-000937-B024-91</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/index.html 193.128.22.20 19970109102753 text/html 2617
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:18:03 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 2426
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB</font></h1>
<hr size=4>

<h2><font size=6>Action TB News</font></h2>

<font size=5>Articles from the first issue of Action TB News:</font>
<p>
<dl>
<dt><a href="artintro.html">Introduction</a><p>

<dt><a href="art1.html">TB reactivated, not acquired</a>
<dd>Dr Nulda Beyers, University of Stellenbosch<p>

<dt><a href="art2.html">Speeding diagnosis to save lives</a>
<dd>Professor Paul van Helden, University of Stellenbosch<p>

<dt><a href="art3.html">Apoptosis kills TB</a>
<dd>Dr DS Kumaratne, The Medical School, Edgbaston<p>

<dt><a href="art4.html">Test finds one in a million</a>
<dd>Dr Ken Duncan, Glaxo Wellcome Research and Development,
Stevenage<p>

<dt><a href="art5.html">TB's hidden door found</a>
<dd>Professor Mario Ehlers, University of Cape Town<p>

<dt><a href="art6.html">Clones identify target proteins</a>

<dd>Dr Francis Nano, University of Victoria, Canada<p>

<dt><a href="art7.html">Unusual DNA repair enzyme</a>
<dd>Professor Valerie Mizrahi, South African Institute for Medical Research<p>

<dt><a href="art8.html">Sugars point to new therapies</a>
<dd>Professor Douglas Young, St Mary's Hospital Medical School, Imperial College London

</dl>
<p>
<a href="../news.html">Return to: Action TB News contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-170</DOCNO>
<DOCOLDNO>IA057-000937-B019-189</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/artintro.html 193.128.22.20 19970109094930 text/html 2928
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:39:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 2737
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Introduction</font></h2>

<font size=5>

More than 150 scientists gathered in Cape Town last year to exchange research
news. This newsletter provides an overview of progress made by Action TB News.</font><p>
 This first issue includes results from an exciting epidemiology study
and details of a rapid test for identifying drug resistant TB in
patients. The research has also identified several potential targets
for novel anti-tuberculosis therapies, which may be incorporated into
Glaxo Wellcome's high throughput screening programme. Bioluminescent
mycobacteria are already being used by Glaxo Wellcome scientists to
find new active compounds.<p>

The failure to control TB with the available drugs illustrates the need for new
approaches to tackle this complex disease. Action TB News's fundamental research is
the first step in the quest for a novel TB therapy. Its outcome will determine
the direction we take in the pursuit of new more effective treatments. That
goal is still someway off, but the progress already made by Action TB News
researchers is encouraging.<p>

<img align="left" src="hands.gif" alt="Hands">
<br clear="full"><p>
<br>

Two hands can barely hold 18 days of treatment for
turberculosis. Since a typical course of therapy takes 6 months,
ensuring completion of the six month course places a major burden on
healthcare services.

<p>
<a href="art1.html">Forward to: TB reactivated, not acquired</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-171</DOCNO>
<DOCOLDNO>IA057-000937-B019-210</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art1.html 193.128.22.20 19970109094948 text/html 4162
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:39:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:52 GMT
Content-length: 3971
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB reactivated, not acquired</font></h2>

<font size=5>DNA fingerprinting pin-points source of epidemics<p>


DNA fingerprinting studies have brought into question the received wisdom that
TB epidemics result from recent transmission through direct contact with a
source of infection.</font><p>

Using DNA fingerprinting, it is possible to differentiate accurately
between various strains of mycobacteria. <i>Mycobacterium
tuberculosis</i> strains, for example, can be differentiated by using
the insertion element IS6110, a relatively stable DNA sequence which
occurs at various locations in the genome of <i>M. tuberculosis</i>,
and with a variable copy number (between 0 and &gt;20). By identifying
the strains of TB carried by patients and mapping their movements in
the community, it is possible to establish how TB infection spreads in
specific communities.  <p>

With an incidence of more than 1000 cases per 100,000 population,
Ravensmead and Uitsig, two adjacent suburbs of the Western Cape
Provence of South Africa, have amongst the highest recorded TB
incidences in the world, making them ideal communities for DNA
fingerprinting studies. Surprisingly few patients in this small, 2.42
km<sup>2</sup> area are infected with identical TB strains. Instead,
the majority of patients with active TB disease carry unique strains.
Only 46 out of 209 identified TB strains were shared by more than one
person, and in many of these cases no, or only very casual contact
could be established. Based on the theory that recent transmission
results in little strain diversity, it is more likely that the TB
epidemic in these Western Cape suburbs is caused by reactivation of
latent disease.  <p>

TB is not distributed evenly across the community and generally, the highest
number of cases are associated with the worst socio-economic conditions,
indicated by low per capita income, poor housing and overcrowding. When
considered by separate subdistricts the incidence of TB in Ravensmead and
Uitsig varies between 78 and 3150 per 100,000 people. In certain houses, TB
occurs repeatedly; a third of the houses had at least one case of TB over the
past ten years and 447 houses had 3 or more cases.
<p>

For more information contact:
<p>

Dr Nulda Beyers,<br>
Department of Paediatrics and Child Health University of Stellenbosch,<br>
Faculty of Medicine,<br>
PO Box 19063,<br>
Tygerberg 7505,<br>
South Africa.<p>

Tel: +27 21 938 9506,<br>
Fax: +27 21 931 7810,<br>
e-mail: <a href="mailto:nb@maties.sun.ac.za">nb@maties.sun.ac.za</a>
<p>
<a href="art2.html">Forward to: Speeding diagnosis to save lives </a><p>
<a href="artintro.html">Back to: Introduction</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-172</DOCNO>
<DOCOLDNO>IA057-000937-B019-223</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art2.html 193.128.22.20 19970109094958 text/html 5157
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:40:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:53 GMT
Content-length: 4966
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Speeding diagnosis to save lives</font></h2>

<font size=5>Molecular diagnostic for drug resistant TB<p>


Rapid screening for antibiotic-resistant strains of <i>M. tuberculosis</i>
may soon become a reality with the development of a new test that
provides results in only a few days.</font><p>

Using conventional culture methods, diagnosis and drug
susceptibility testing for tuberculosis can take up to twelve weeks, which  for
patients with drug-resistant infections, can be fatal. Such delays in diagnosis
can also substantially increase the risk of transmission of drug-resistant TB
within the community.
<p>

The primary cause of resistance to drugs such as rifampicin (RMP) is mutation
in structural genes encoding target enzymes. Researchers at the University of
Stellenbosch in South Africa have used single-stranded conformation
polymorphism (SSCP) technology to develop a test for the detection of drug
resistant strains of <i>M. tuberculosis</i>. This polymerase chain reaction (PCR)
based technique identifies single base substitutions, as well as small
deletions and insertions in specific genes.
<p>

The SSCP diagnostic test makes it possible to identify mutations in
the rpoB gene, a molecular marker for RMP resistance in
<i>M. tuberculosis</i>. Using this procedure, ninety-five per cent of
RMP-resistant isolates of <i>M. tuberculosis</i> were identified.  <p>

As there is a high probability (95%) in South Africa that RMP-resistant TB is
also resistant to isoniazid (INH), identifying mutations in the rpoB gene is a
way of identifying most multidrug-resistant (MDR) strains. Mutations in genes
leading to INH resistance are far more variable, making these genes less useful
for the development of a DNA-based test.
<p>

<strong>Developing resistance</strong><br>
Antibiotic resistance can develop within a patient, for example, because
chemotherapy treatment was not completed. However, in approximately half of
reported cases of drug resistant TB in the Western Cape Province of South
Africa, resistance was transmitted through contact with another drug-resistant
case, rather than resulting from de novo development of antibiotic resistance.
Drug resistance is considered to be one of the key underlying factors
responsible for the increase in TB recorded over the last few years in many
developing countries.
<p>

The rapid screening method described makes it possible to quickly identify
patients harbouring drug-resistant strains of TB, allowing appropriate
treatment to be initiated immediately. This may also help to contain and
substantially reduce the spread of MDR-TB cases. Presently, only hospital
laboratories have the capacity and expertise to use this test procedure.
However, further development  may provide a more robust screen suitable for a
wider range of healthcare laboratories.
<p>

The rapid test can be performed using either: 
<ul type=disc> 
<li> sputum sample taken directly from patients, or
<li><i>M. tuberculosis</i> isolates produced after a short culture period in
standard BACTEC culture medium.<p>
</ul>

For further information contact:<p>

Professor Paul van Helden,<br>
MRC Centre for Molecular and Cellular Biology<br>
(<a href="http://www.sun.ac.za/local/academic/med_biochem/mrc1.html">http://www.sun.ac.za/local/academic/med_biochem/mrc1.html</a>),
<p>

University of Stellenbosch,<br>
PO Box 19063,<br>
7505 Tygerberg,<br>
 South Africa.<p>
Tel: +27 21 938 9401,<br>
Fax: +27 21 931 7810,<br>
e-mail: <a href="mailto:pvh@maties.sun.ac.za">pvh@maties.sun.ac.za</a>
<p>
<a href="art3.html">Forward to: Apoptosis kills TB </a><p>
<a href="art1.html">Back to: TB reactivated, not acquired </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-173</DOCNO>
<DOCOLDNO>IA057-000937-B019-239</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art3.html 193.128.22.20 19970109095008 text/html 3678
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:40:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:53 GMT
Content-length: 3487
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Apoptosis kills TB</font></h2>

<font size=5>Only ATP-induced apoptosis is effective<p>


The key to the survival of <i>M. tuberculosis</i> is its invasiveness. The bacillus
rapidly invades host monocytes and macrophages and freely grows and replicates
in these cells. This occurs despite the fact that macrophages are a central
component of the host immune system.</font><p>

Induction of apoptosis, or programmed cell death, in infected macrophages
occurs <i>in vivo</i> through either cytokine or cytolytic T cell action, and usually
leads to the uptake of the apoptotic macrophage by its neighbours. Because
intracellular processing of infected apoptotic macrophages may occur in a
totally different manner to that of independent bacterial particles, further
studies are now underway to establish whether mycobacteria within the apoptotic
macrophages are killed by this cell-mediated destruction, or whether
phagocytosis of the apoptotic macrophage simply permits the bacteria to spread
from cell to cell.
<p>

BCG (bacille Calmette-Gu&eacute;rin) infection does not induce apoptosis of the
infected macrophage, but instead it makes the macrophages more susceptible to
the induction of apoptosis by other stimuli. However, recent studies  show that
macrophage apoptosis induced by ligation of the surface Fas antigen, or
following treatment with TNF-alpha, did not affect the viability of the
intracellular mycobacteria. Only when macrophage apoptosis was induced by ATP
was the survival rate of the intracellular mycobacteria reduced.
<p>

ATP-related apoptosis may prove to be an exciting target for a novel
immunotherapeutic strategy. Understanding the mechanism behind
ATP-induced apoptosis may lead to unique approaches to the treatment
of <i>M. tuberculosis</i> that involve specific stimulation of the
immune system.  <p>

For further information contact:<p>

Dr DS Kumaratne,<br>
 Department of Immunology,<br>
 The Medical School,<br>
 Edgbaston,<br>
 B15 2TT,<br>
 UK.<p>
 Tel: +44 121 414 6976,<br>
 Fax: +44 121 414 3599,<p>


<a href="art4.html">Forward to: Test finds one in a million </a><p>
<a href="art2.html">Back to: Speeding diagnosis to save lives</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-174</DOCNO>
<DOCOLDNO>IA057-000937-B019-256</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art4.html 193.128.22.20 19970109095018 text/html 3174
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:40:28 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:53 GMT
Content-length: 2983
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Test finds one in a million</font></h2>

<font size=5>High throughput screen for anti-mycobacterial drugs<p>

New high throughput screening technology now enables thousands of potential
antibiotics and biocides for TB to be screened each day. A recently developed
screen now rapidly identifies compounds which are specifically active against
mycobacteria.</font><p>

Using a fast growing, non-pathogenic mycobacterium, <i>Mycobacterium aurum</i>, this
bioluminescence-based assay allows compounds to be tested without the need for
complicated containment facilities. The luxA and luxB genes from Vibrio
harveyii were cloned into <i>M. aurum</i>. Recombinant bacteria now produce light
(bioluminescence) when a simple substrate is added. Thus, viability can be
measured in the presence of test compounds. Using microtitre format, many
thousands of compounds can be tested in one day and those with activity can
then be evaluated further in the more difficult and time consuming <i>M.
tuberculosis</i> assay.
<p>

Natural products are a potential source of new drugs. A compound with
antimycobacterial activity, magnolol, was isolated from a plant used in
traditional Chinese medicine, Magnolia officialis. Another compound,
ascididemin, was isolated from sponge.
<p>

For more information contact:<p>

Dr Ken Duncan,<br>
Glaxo Wellcome Research and Development,<br>
 Gunnels Wood Road,<br>

Stevenage,<br>
 Herts,<br>
 SG1 2NY,<br>
 UK.<p>

Tel: +44 1438 763841,<br>
Fax: +44 1438 764782<br>
e-mail: <a href="mailto:kd9430@ggr.co.uk">kd9430@ggr.co.uk</a>.
<p>
<a href="art5.html">Forward to: TB's hidden door found </a><p>
<a href="art3.html">Back to: Apoptosis kills TB </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-175</DOCNO>
<DOCOLDNO>IA057-000937-B019-280</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art5.html 193.128.22.20 19970109095037 text/html 3905
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:40:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:53 GMT
Content-length: 3714
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB's hidden door found</font></h2>

<font size=5>TB may use CR3 receptor to escape destruction<p>


Recent studies have identified a complement receptor that allows <i>M.
tuberculosis</i> to enter host cells, a key step in the establishment of infection.</font><p>

Once inside the cell, <i>M. tuberculosis</i> resides inside large membrane-bound
vacuoles, where it may escape detection by the immune system for many years.
<p>

Binding to the CR3 receptor was demonstrated using a non-phagocytic cell line
co-transfected with the cDNAs for the CR3 subunits CD11b and CD18. In these
studies, <i>M. tuberculosis</i> consistently bound to the co-transfected cell line 5
times more than to wild type cells, regardless of whether serum was present.
This is the first time that the CR3 receptor has been shown to promote uptake
of <i>M. tuberculosis</i> into a non-phagocytic cell by a presumably phagocytic
mechanism.
<p>

Similar studies have focused on identifying the cell wall components that allow
<i>M. tuberculosis</i> to bind to specific non-phagocytic cell types. Human serum and
20% Fetal Calf Serum (FCS) significantly enhanced binding of
<i>M. tuberculosis</i> to these cell lines. A panel of monoclonal antibodies to<i> M.
tuberculosis</i> surface antigens was tested for their ability to inhibit <i>M.
tuberculosis</i> binding to these cells. Two were found to reduce binding
significantly. Further analysis revealed that the <i>M. tuberculosis</i> antigen
recognised by the monoclonal antibody is a non-proteinaceous cell wall
component, possibly a phosphatidylinositol mannoside.
<p>

Macrophages usually ingest bacteria with a phagocytic mechanism which
induces a respiratory burst that kills the bacteria. Understanding the
route by which <i>M.  tuberculosis</i> enters cells may help
identify the mechanisms <i>M. tuberculosis</i> uses to evade normal
killing processes. This may lead to new targets and approaches to
promote host responses to <i>M. tuberculosis</i> and ultimately to new
immunotherapies.  <p>

For further information contact:<br>

Professor Mario Ehlers,<br>
 University of Cape Town,<br>
 Department of Medical
Biochemistry,<br>
 Observatory 7925,<br>
 Cape Town,<br>
 South Africa.<p>
 Tel: +27 21 406 6335,<br>

Fax: +27 21 477669<p>

<a href="art6.html">Forward to: Clones identify target proteins </a><p>
<a href="art4.html">Back to: Test finds one in a million </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-176</DOCNO>
<DOCOLDNO>IA057-000937-B019-295</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art6.html 193.128.22.20 19970109095046 text/html 3632
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:40:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:53 GMT
Content-length: 3441
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Clones identify target proteins</font></h2>

<font size=5>Efflux and immunostimulatory proteins found<p>


A number of <i>M. tuberculosis</i> membrane, cell wall and secreted
proteins that may include novel targets for new drugs or vaccines have
been identified using a novel expression cloning system.</font><p>

The expression system relies on randomly fusing the alkaline
phosphatase gene (PhoA) from <i>E. coli</i> to <i>M. tuberculosis</i>
DNA. Since alkaline phosphatase is only active when localised outside
the cytoplasmic membrane, this system specifically identifies
membrane, cell wall and secreted proteins. Once clones with alkaline
phosphatase activity have been identified, <i>M. tuberculosis</i>
proteins are located by anti-PhoA monoclonal antibody reactivity using
Western blot analysis.  <p>

The DNA from 350 clones has already been cloned, sequenced and the deduced
amino acid sequences compared with known protein sequences. Using this
procedure, three proteins with high sequence similarity to efflux proteins were
identified.
<p>

A further 76 recombinant fusion proteins that stimulate the immune system have
also been identified. Immunostimulatory activity was assessed by the ability of
the proteins to stimulate mouse TH1 cells to secrete interferon-g, an index of
the protective effect of the proteins. Studies are underway to sequence these
immunostimulatory proteins, some of which may already have known functions.
Over the next year, the proteins will be tested for reactivity with T cells
from tuberculin positive patients. This is the first step in the process of
identifying proteins that may be suitable for inclusion in a subunit vaccine.
<p>

For further information contact:<p>

Dr Francis Nano,<br>
 Department of Biochemistry and Microbiology<br>
(<a href="http://zeus.bioc.uvic.ca/BiocDept.Html">http://zeus.bioc.uvic.ca/BiocDept.Html</a>),<p>
 University of Victoria,<br>
 Victoria,<br>
 V8W 3P6,<br>
 Canada.<p>

 Tel: +1604 721 7074,<br>
 Fax: +1604 721 8855
<p>
<a href="art7.html">Forward to: Unusual DNA repair enzyme </a><p>
<a href="art5.html">Back to: TB's hidden door found </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-177</DOCNO>
<DOCOLDNO>IA057-000937-B019-313</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art7.html 193.128.22.20 19970109095109 text/html 4039
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:41:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:53 GMT
Content-length: 3848
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Unusual DNA repair enzyme</font></h2>

<font size=5>Repair polymerase is weak link<p>


Researchers in South Africa have confirmed that the DNA polymerase I from
 <i>M. tuberculosis</i> is unable to discriminate between natural
nucleotides and chain-terminating analogues during DNA
synthesis.</font><p>

 This finding agrees with the recent predictions of Tabor and
Richardson (Harvard) and makes the <i>M. tuberculosis</i> enzyme the
first one of its kind from bacteria to possess this unusual
property. This enzyme may make a potentially useful and novel target
for future anti-TB drug design.<p>


DNA polymerase I is important for DNA repair, a process essential for
the survival of all organisms. Recent results in
<i>M. tuberculosis</i> have shown that its DNA polymerase I
incorporates chain-terminating dideoxynucleotide analogues with even
greater efficacy than the benchmark non-discriminating DNA polymerase
from bacteriophage T7. Cloning and sequencing of
<i>M. tuberculosis</i> polA, the gene encoding DNA polymerase I, has
also shown that, although all the primary structural elements
necessary for DNA polymerase and 5' nuclease are present, the gene
lacks the motifs required for an associated 3'-5' exonuclease
(proof-reading) activity.  <p>

The role of DNA polymerase I in DNA repair has recently been confirmed
in <i>M.  smegmatis</i>. When DNA polymerase production was stopped by
disrupting polA, the resulting mutant's phenotype was
hypersensitivity to DNA damage caused by UV irradiation and by
hydrogen peroxide challenge. Disruption of the gene's function was
achieved by homologous recombination using a DNA fragment comprising a
partial polA gene that had been disrupted within the 3'- terminal
polymerase-encoding region by a drug resistance marker.  <p>

DNA polymerase I is almost certain to be involved in DNA repair in
<i>M.  tuberculosis</i>, and deactivating this enzyme, for example by
introducing chain terminating nucleoside analogues, may be a useful
way of reducing the chances of this mycobacterium's survival.  <p>

For further information contact:<p>

Professor Valerie Mizrahi,<br>
 Molecular Biology Unit,<br>
 South African Institute for
Medical Research,<br>
 PO Box 1038,<br>
 Joannesburg 2000,<br>
 South Africa.<p>
 Tel: +27 11 489 9370,<br>
 Fax: +27 11 489 9001,<br>
 e-mail: <a href="mailto:075val@chiron.wits.ac.za">075val@chiron.wits.ac.za</a>
<p>
<a href="art8.html">Forward to: Sugars point to new therapies</a><p>
<a href="art6.html">Back to: Clones identify target proteins </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-178</DOCNO>
<DOCOLDNO>IA057-000937-B019-329</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news1/art8.html 193.128.22.20 19970109095122 text/html 4024
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:41:31 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 3833
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Sugars point to new therapies</font></h2>

<font size=5>Trehalose and glycoprotein pathways targeted<p>


Factors that protect bacteria against environmental stress are a particularly
interesting target for anti-mycobacterial drugs, since mycobacteria are able to
survive for extended periods in a hostile environment.</font><p>

 Trehalose is thought to protect proteins and membranes in bacteria
and may play an analogous role in promoting mycobacterial survival.
<p>


Two enzymes involved in trehalose metabolism, trehalose-6-phosphate synthase
and trehalose-6-phosphate phosphatase, have recently been purified. The genes
corresponding to these proteins have been identified and sequence analysis
begun. Further research will focus on producing recombinant proteins that will
allow the trehalose metabolic pathway to be explored.
<p>

<strong>Glycoprotein research</strong><br>
Protein glycosylation has been considered as a potential target for anti-fungal
therapy and may prove an exciting target for anti-mycobacterial agents. Little
is currently known about bacterial glycoproteins, but glycosylation pathways
have been extensively characterised in eukaryotes.<p>

As a test system, the gene encoding the 19 kDa lipoprotein from <i>M. tuberculosis</i>
is being studied in the rapidly growing mycobacterium, <i>M. smegmatis</i>. This,
combined with the preparation of fusion proteins, has pinpointed glycosylation
to the N-terminal region of the 19 kDa protein. Site-directed mutagenesis
studies revealed that two threonine clusters play a key role.<p>

Functional studies, using amino acid replacement, indicate that
glycosylation protects the 19 kDa antigen from proteolysis and may
regulate conversion between a cell-associated and a soluble secreted
form of the protein. Strategies are also underway to develop assays
for the enzymes involved in protein glycosylation for incorporation
into high throughput screens.<p>


For further information contact:<p>

Professor Douglas Young,<br>
 Department of Medical Microbiology<br>

(<a href="http://www.sm.ic.ac.uk/medical_microbiology/home.htm">http://www.sm.ic.ac.uk/medical_microbiology/home.htm</a>),<p>
 Wright Fleming Institute,<br>
 St Mary's Hospital Medical School,<br>
 Imperial College of Science, Technology & Medicine,<br>
 London,<br>
 W2 1PG,<br>
 UK.<p>
 Tel: +44 171 725 1591,<br>
 Fax: +44 171 262 6299,<br>
 e-mail: <a href="mailto:d.young@imperial.ac.uk">d.young@imperial.ac.uk</a>
<p>


<a href="art7.html">Back to: Unusual DNA repair enzyme</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-179</DOCNO>
<DOCOLDNO>IA057-000937-B017-116</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/role.html 193.128.22.20 19970109093047 text/html 5551
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:20:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:24 GMT
Content-length: 5360
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>GBRI, Switzerland</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>
<h1><font size=7>Geneva Biomedical Research Institute</font></h1>
<hr size=4>
<br>
<h2><font size=6>The role of the Institute</font></h2>

<font size=5>The role of Geneva Biomedical Research Institute (GBRI) is to understand disease mechanisms at the molecular level  in order to identify selective and 
specific molecular targets for new drug development programmes. </font><p>

The identification  and validation of a new target provides an important interface between GBRI scientists and scientists at other Glaxo Wellcome R&amp;D sites who are using another set 
of rapidly developing technologies for designing, identifying and testing compounds that interact with targets to modify their activities. <P>

The Institute is  concentrating on  diseases of the immune and nervous systems 
where the advances in molecular biology and genetics  are creating major opportunities for developing new therapies.  Research on the immune system is focused on asthma, allergies and 
autoimmune diseases. Our studies on the nervous system concentrate on neurodegenerative conditions such as Alzheimer's disease. 
 <P>

In addition to our research on specific diseases,  we have projects aimed at understanding key biological mechanisms, particularly the functioning of receptors and ion channels as well 
as their signal transduction mechanisms. Much of the research at GBRI is driven by the creative interactions between the two kinds of project team - those with a specific disease 
focus and those aimed at understanding a particular biological mechanism. For example, the progress we have made towards understanding the signalling mechanisms of mammalian receptors 
expressed in yeast cells is of great value for dissecting the pathways that lead to the death of neurones. 
 <P>

The projects summarised on the following pages represent about half of all our ongoing 
research programmes.  In addition, we have projects on the structure and function of seven transmembrane receptors, ion channels and chemokines. The summaries illustrate some important 
themes common to all our projects, such as the interdisciplinary approach and the value placed on collaborations with leading researchers throughout the world, including those at other 
Glaxo Wellcome research laboratories.   <P>

We place particular emphasis on developing and maintaining  strong links with other top research groups around the world and our good publication record is evidence of this. The 
Universities of Geneva and Lausanne are obviously very important to us; several new research collaborations have started this year and we organise joint symposia. Another important 
trend is the increasing number of scientists from Glaxo Wellcome research centres in Europe, the U.S.A. and Japan who spend some  time working at the Institute.  This strengthens our ties with 
other Glaxo Wellcome laboratories and helps to ensure that the discoveries made  by GBRI scientists are translated into drug development programmes at other R&D sites. Our 
interactions with Glaxo Wellcome's strategic alliance partners  form an important part of several projects. <P>

Since its founding in 1987, GBRI's staff has grown to 140, not including the visiting scientists and students who make a significant contribution to the Institute's activities.  Our 
post-doctoral programme has developed very well; we currently have ten scientists who  have just received their PhDs and spend three years working with us on questions of fundamental 
importance.  Geneva has proved an ideal location for creating a truly international team of leading researchers; scientists from more than 20 countries work at GBRI. Geneva's many 
advantages include its international atmosphere, a central location in a very attractive part of Europe with excellent communications and all the benefits of the quality of life in 
Switzerland. <P> 

The Geneva Biomedical Research Institute, in Switzerland, looks forward to participating in the exciting developments taking place in molecular biology to understand the molecular 
mechanisms of disease and provide the basis for new therapies. 
 <P>
<a href="index.html">Return to: GBRI contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-180</DOCNO>
<DOCOLDNO>IA057-000937-B017-361</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/tuberc/index.html 193.128.22.20 19970109093438 text/html 3100
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:24:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:42 GMT
Content-length: 2909
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>The return of an old nemesis</font></h2><br>



<font size=5>Tuberculosis - the captain of all the men of death, a romantic theme of 19th-century Europe, a terrifying memory for pre-war 
generations - has resurfaced as a public health concern in the industrialized world. How is it possible that we should be witnessing an 
apparent reversal of one of the great victories of the antibiotic revolution? The natural history of the tuberculosis bacterium is inextricably 
linked with the evolution of human society, and, as with all human stories, it is necessary to follow a number of threads in order to grasp the 
overall picture.<p></font> <p>

by Douglas B. Young,<br><font size=3>
Department of Medical Microbiology<br>
St Mary's Hospital Medical School<br>
London, UK</font><p>

  
<IMG  WIDTH=160 HEIGHT=128 SRC="gifs/tbgif1.gif" align=absmiddle hspace=5 vspace=5>
<font size=3>
<cite>Mycobacterium tuberculosis</cite>.</font><a href="../copy.html#tuber">&copy;</a><p>
<dl>
<dt><a href="tuberc1.html">Introduction</a><p>
<dt><a href="tuberc2.html">Reasons for resurgence</a><p>
<dt><a href="tuberc3.html">Strategies for combatting tuberculosis</a><p>
<dt><a href="tuberc4.html">Diagnosis and drug resistance</a><p>
<dt><a href="tuberc5.html">Priorities for strategic research</a><p>
<dt><a href="tuberc6.html">Tuberculosis and immune response</a><p>
<p>
<dt><a href="../../../science/actiontb/">Action TB</a>
<dt>An international research programme aimed at finding new targets for
anti-tuberculosis therapies. Action TB is a Glaxo Wellcome Research
Initiative.
<p>
<dt><a href="../">Return to: Odyssey contents page</a>
</dl><p>
    
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>

</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-181</DOCNO>
<DOCOLDNO>IA057-000937-B024-107</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/index.html 193.128.22.20 19970109102810 text/html 2670
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:18:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:55 GMT
Content-length: 2479
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB</font></h1>
<hr size=4>

<h2><font size=6>Action TB News</font></h2>

<font size=5>Articles from the second issue of Action TB News:</font>
<p>
<dl>
<dt><a href="art1.html">Therapy made to measure</a>
<dd>Professor Paul van Helden, University of Stellenbosch<p>

<dt><a href="art2.html">Asp protects against killing</a>
<dd>Dr Ken Duncan, Glaxo Wellcome Research and Development, Stevenage<p>

<dt><a href="art3.html">Two to replicate</a>
<dd>Dr Neil Stoker, London School of Hygiene & Tropical Medicine<p>

<dt><a href="art4.html">Rapping out novel genes</a>
<dd>Dr Claire Spreadbury, University of Birmingham<p>

<dt><a href="art5.html">Stepping toward targeted drug design</a>
<dd>Dr Richard Stokes, University of British Columbia<p>

<dt><a href="art6.html">Communication as a protection strategy</a>
<dd>Dr Julian Davies, University of British Columbia<p>

<dt><a href="art7.html">TB protein holds prickly solutions</a>
<dd>Dr Lafras Steyn, University of Cape Town<p>

<dt><a href="art8.html">Host immune failure in tuberculosis</a>
<dd>Professor Stan Ress, Groote Shuur Hospital, Cape Town<p>

<dt><a href="art9.html">TB's sweet sites</a>
<dd>Dr Malcom Ward, Glaxo Wellcome Research & Development, Stevenage
<p>

</dl>
<p>
<a href="../news.html">Return to: Action TB News contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-182</DOCNO>
<DOCOLDNO>IA057-000937-B019-344</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art1.html 193.128.22.20 19970109095145 text/html 4560
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:41:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 4369
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Therapy made to measure</font></h2>

<font size=5>Screening for drug metabolism rate may lead to tailored therapy<p>Customising therapy for individual patients could, in future, reduce the number of drug resistant TB strains. A large number of multi-drug resistant (MDR) strains are only moderately resistant to current therapy and increasing the dose of antibiotic given could wipe out these TB strains. However, toxicity can be just as harmful to a patient as resistance.</font><p>

Using molecular biology techniques for genotyping, patients can be classified according to how quickly they metabolise isoniazid (INH) (e.g. fast, medium, slow).  Every time the drug is administered to a patient, the drug concentration found in the patient's serum initially rises, but this is followed by a decline at a rate dictated by the patient's metabolism. Understanding a patient's drug metabolic rate will, therefore, help predict the length of time the antibiotic remains in the system above the minimum inhibitory concentration (the level required to kill the mycobacteria). If the drug level is inadequate, treatment will be unsuccessful and the strain of TB will appear to be resistant.<p>


In some patients, considered to be infected with an INH-resistant strain of TB, the organism is found to be highly sensitive to INH. These patients have metabolised the antibiotic before it has killed the mycobacteria. This is a dangerous situation; not only is the patient receiving inadequate treatment, but the mycobacteria are being exposed to low levels of drug which may stimulate it to develop resistance, thereby making it more difficult to treat in the longer term.<p>
 

When it comes to combination therapy, this can be particularly dangerous. Consider a fast metaboliser of INH who is treated with INH and rifampicin (RIF). In this case, the mycobacteria are effectively only exposed to RIF as a monotherapy, which inevitably leads to RIF resistance. As treatment continues the RIF-resistant mycobacteria are then exposed to an inadequate dose of INH and develop additional INH resistance, effectively becoming multi-drug resistant, despite "correct" therapy. <p>


Screening patients could prevent an individual with a high metabolic rate receiving too low a dose of antibiotics. Similarly screening could prevent administration of high levels of drugs to slow metabolisers, potentially leading to unpleasant side effects. Genotyping provides metabolic classification in hours and initial studies have shown a greater than 97% success rate.<p>


In the future, molecular diagnostic tests could be used to identify drug-resistant TB strains rapidly. When combinined with metabolic genotyping of the patient, doctors may be able to customise treatment to an individual patient. This would help prevent further development of drug-resistant strains of TB.<p>

For more information contact:<p>

Professor Paul Van Helden <br>
University of Stellenbosch, South Africa.<p>

Tel: +27 21 938 9401<p>

<a href="art2.html">Forward to: Asp protects against killing</a><p>

<a href="index.html">Return to: Action TB News issue two contents page</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-183</DOCNO>
<DOCOLDNO>IA057-000937-B019-362</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art2.html 193.128.22.20 19970109095159 text/html 4251
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:42:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 4060
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Asp protects against killing</font></h2>

<font size=5>Key amino acid substitution protects mycobacteria<p>A recent study by researchers at Glaxo Wellcome is challenging our current understanding of the reaction mechanism of a key peptidoglycan enzyme.</font><p>


Peptidoglycan is essential for the integrity of the bacterial cell wall, and many antibiotics, including fosfomycin (fos), act by disrupting its synthesis. Fos targets the enzyme that catalyses the first committed step in peptidoglycan synthesis, UDP-N-acetylglucosamine enolpyruvyl transferase. Although active against many bacteria, including <i>E. coli</i>, fos is not active against <i>M. tuberculosis</i>.<p>


When isolated, UDP-N-acetylglucosamine enolpyruvyl transferase from <i>E. coli</i> has a molecule of the natural substrate, phosphoenol-pyruvate (PEP), tethered to the active site cysteine residue which suggests that the reaction pathway proceeds via this covalent intermediate. Fos inactivates the <i>E. coli</i> enzyme by covalently binding to the same cysteine residue preventing it from forming a complex with PEP.<p>


The Glaxo Wellcome team cloned the gene from <i>M. tuberculosis</i> that codes for this enzyme. After sequencing the gene, they found that the encoded protein has 45% overall similarity with its <i>E. coli</i> counter-part. However, the <i>M. tuberculosis</i> protein has an aspartate residue in the key position occupied by the cysteine residue in the <i>E. coli</i> protein. Fos cannot form a covalent complex with the aspartate residue, and this may explain why the antibiotic is not effective against mycobacteria.<p>


In collaboration, researchers at Harvard Medical School then constructed an 
<i>E. coli</i> mutant that would mimic the mycobacterial enzyme (i.e. with an aspartate residue in place of the cysteine residue); this mutant was active. As expected, when the mutant enzyme was isolated there was no PEP bound to the active site. This finding challenges the previous notion that a covalent intermediate is formed as part of the normal reaction pathway of the enzyme. In addition, detailed biochemical studies with the mutant protein suggest that the active site residue (aspartate or cysteine) is a general acid in catalysis, a role not previously proposed for this residue.<p>


Fos is a natural product produced by streptomyces, a soil organism. Since most mycobacteria live in soil, mycobacteria may have evolved the aspartate substitution as a protection mechanism.<p>


For more information contact:<p>


Dr Ken Duncan <br>

Glaxo Wellcome Research & Development<br>
Stevenage, UK<p>
 
Tel: +44 1438 763841<p>

<a href="art3.html">Forward to: Two to replicate</a><p>
<a href="art1.html">Back to: Therapy made to measure</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-184</DOCNO>
<DOCOLDNO>IA057-000937-B020-3</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art3.html 193.128.22.20 19970109095214 text/html 4706
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:42:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 4515
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Two to replicate</font></h2>

<font size=5>Plasmid replication studies may help target identification<p>Researchers at the London School of Hygiene &amp; Tropical Medicine in the UK have made significant progress in understanding how plasmids replicate in mycobacteria; until now, little had been known about the machinery involved.</font><p>


For many years, plasmids have been used as a means of delivering interrupted genes. This allowed the importance of individual gene products to be assessed. These so called "gene knock out studies" have allowed researchers to assess quickly the potential of novel targets for drug discovery. <p>


Such studies have not been possible in mycobacteria, greatly delaying the validation of potential drug targets. A better understanding of mycobacterial plasmids may lead to the development of better delivery systems for gene knock-out studies.<p>


The researchers identified two genes in the plasmid pAL5000, repA and repB, close to the origin of replication. The products of these genes, the RepA and RepB proteins, are required for plasmid replication. RepA is highly similar to a class of replication initiation proteins from plasmids found in other bacteria, such as <i>E. coli</i>. RepB, however, shows no significant similarity to any proteins of known function in the GenBank database. Further studies suggest that RepB may regulate its own transcription as well as regulating plasmid replication.<p>


The findings suggest a novel mechanism for triggering replication of pAL5000: so called "high affinity" binding sites on the plasmid molecule may sequester RepB, preventing it from triggering plasmid replication until all high affinity sites are full. Once these sites are full, RepB will bind to the low affinity site that initiates plasmid replication, thus generating a new set of high affinity sites. However, since RepB also seems to regulate its own synthesis, once all high affinity sites are full, there will be competition between RepB binding to its own transcription site and halting gene expression and RepB binding to the plasmid replication site and triggering replication. <p>


The researchers hope that these findings will enable techniques to be developed that will allow gene knock out studies to be undertaken in slow growing mycobacteria, such as <i>M. tuberculosis</i>.<p>


One possible approach would be to use a system whereby plasmid A contains the genes required for plasmid replication and plasmid B contains an antibiotic resistance gene but lacks one of the replication genes. Both plasmids are then required for mycobacterial growth in the presence of antibiotic. After recombination between the plasmid and host genome has occurred, antibiotic can be removed from the growth media and both plasmids will quickly disappear.<p>

For more information contact:<p>

Dr Neil Stoker<br>
London School of Hygiene & Tropical Medicine<br>
<a href="http://www.lshtm.ac.uk/">(http://www.lshtm.ac.uk)</a><p>

Tel: +44 171 927 2425<br>
e-mail: <a href="mailto:n.stoker@lshtm.ac.uk">n.stoker@lshtm.ac.uk</a><p>

<a href="art4.html">Forward to: Rapping out novel genes</a><p>
<a href="art2.html">Back to: Asp protects against killing</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-185</DOCNO>
<DOCOLDNO>IA057-000937-B020-21</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art4.html 193.128.22.20 19970109095228 text/html 3551
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:42:39 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:54 GMT
Content-length: 3360
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Rapping out novel genes</font></h2>

<font size=5>New technology identifies key genes<p>Identifying genes that are selectively expressed by mycobacteria during intracellular infection of macrophages could lead to novel approaches to drug therapy. Such genes could lead to the identification of virulence factors, approaches to blocking macrophage infection or to gene products that allow the mycobacteria to remain undetected by the host immune system. </font><p>

Research underway in the UK using a new technique has already identified genes induced during intracellular infection. The genes were identified by using the RNA arbitrarily primed polymerase chain reaction (RAP-PCR). Following a short culture period, researchers randomly amplify RNA from four samples: <p>

<ul type=disc>

<li>macrophages infected with <i>M. tuberculosis</i><p>

<li>macrophages infected with latex beads<p>

<li><i>M. tuberculosis</i> growing in tissue culture media <p>

<li><i>M. tuberculosis</i> growing in standard broth <p>
</ul>

This allows them to detect genes that are differentially expressed during infection. Genes expressed by the intracellular mycobacteria are identified by a process of elimination - they are the genes that are not expressed by the three groups of control cells.  <p>


A similar technique is also being used to detect macrophage genes that are selectively expressed during mycobacterial infection as well as identifying macrophage genes that appear to be down regulated during mycobacterial infection. Identifying these genes may lead to an understanding of how mycobacteria escape killing by the macrophage, thereby enabling them to reside for prolonged periods unaffected by the immune system. <p>


For more information contact:<p>


Dr Claire Spreadbury<br>
University of Birmingham, UK<p>

Tel: +44 121 414 6975<br>
e-mail: <a href="mailto:c.l.spreadbury@bham.ac.uk">c.l.spreadbury@bham.ac.uk</a><p>

<a href="art5.html">Forward to: Stepping toward targeted drug design</a><p>
<a href="art3.html">Back to: Two to replicate</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-186</DOCNO>
<DOCOLDNO>IA057-000937-B020-42</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art5.html 193.128.22.20 19970109095245 text/html 3861
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:42:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:55 GMT
Content-length: 3670
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Stepping toward targeted drug design</font></h2>

<font size=5>Homologous recombination in mycobacteria<p>Understanding the function of specific genes is an essential step on the road to finding and validating new targets for drug design. Until recently tools have not been available to study the function of individual genes in pathogenic myco-bateria - a crucial step in the process. </font><p>


Researchers in Canada have, for the first time, used homologous recombination to disrupt an <i>M. intracellulare</i> gene. Homologous recombination has previously proved extremely difficult in mycobacteria, particularly slow growing pathogenic species, such as <i>M. tuberculosis</i>, and a number of approaches are being investigated to develop systems for routinely carrying it out. <p>


The researchers subcloned a fragment of the katG gene and introduced a frameshift mutation by using a fill in reaction. The katG gene codes for an inducible catalase-peroxidase, which is involved in isoniazid (INH) sensitivity. Disruption of the katG gene will produce bacteria that are INH resistant.<p>


The plasmid was introduced into <i>M. intracellulare</i>. The plasmid
contains a gentamicin cassette for selection and is not able to
replicate in mycobacteria or integrate into the chromosome, except by
homologous recombination. Some of the bacteria able to grow in the
presence of gentamicin were found to have incorporated DNA by a single
crossover event. After further growth in the absence of gentamicin,
bacteria able to grow in the presence of high concentrations of INH
were identified and shown to contain the mutated katG gene, created by
a second crossover event.<p>


Southern hybridisation confirmed that the four base pair insertion was responsible for the loss of activity. This technique will now be used by other Action TB researchers to study the function of enzymes that are potential drug targets.<p>

For more information contact:

Dr Richard Stokes<br>
University of British Columbia<br>
Vancouver, Canada<br>
<a href="http://cod.microbiology.ubc.ca/stokes.html">(http://cod.microbiology.ubc.ca/stokes.html)</a><p>


Tel: +1 604 875 2466<br>
e-mail: <a href="mailto:rstokes@cbdn.ca">rstokes@cbdn.ca</a><p>

<a href="art6.html">Forward to: Communication as a protection strategy</a><p>
<a href="art4.html">Back to: Rapping out novel genes</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-187</DOCNO>
<DOCOLDNO>IA057-000937-B020-61</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art6.html 193.128.22.20 19970109095258 text/html 3350
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:43:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:55 GMT
Content-length: 3159
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Communication as a protection strategy</font></h2>

<font size=5>Phosphorylation may protect mycobacteria from macrophage killing<p>Communication between mycobacteria and host cells may not be as far fetched as it would at first appear. In fact, a simple communication mechanism based on protein phosphorylation may be one of the strategies mycobacteria use to protect themselves from macrophages. </font><p>

Canadian Action TB researchers have found that <i>M. tuberculosis</i> secretes phosphorylated proteins. In eukaryotic cells, protein phosphorylation is a major mechanism whereby cells transmit signals that control cellular functions and secreted phosphorylated proteins are known to be involved in signal transduction. In the case of <i>M. tuberculosis</i>, these phosphorylated proteins may stop the host macrophage from acidifying the vacuoles containing the mycobacteria, the normal process used to kill ingested microorganisms. <p>


To date, two protein kinases have been identified - one phosphorylates on a tyrosine residue (tyrosine kinase) and another phosphorylates on a serine residue (serine/threonine kinase). Tyrosine kinases have, so far, only been found in pathogenic mycobacteria. Researchers believe that protein phosphorylation plays a role in TB infection. It has been shown that in Yersinia bacterial infections, protein phosphorylation is essential for virulence. The Canadian researchers are now exploring the function of these two proteins, as well as searching for additional components of signal transduction in mycobacteria.<p>


For more information contact:<p>


Dr Julian Davies<br>
University of British Columbia<br>
Vancouver, Canada<p>

Tel: +1 604 822 2501<p>


<a href="art7.html">Forward to: TB protein holds prickly solutions</a><p>
<a href="art5.html">Back to: Stepping toward targeted drug design</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-188</DOCNO>
<DOCOLDNO>IA057-000937-B020-82</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art7.html 193.128.22.20 19970109095322 text/html 3689
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:43:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:55 GMT
Content-length: 3498
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB protein holds prickly solutions</font></h2>

<font size=5>Selective expression after host infection<p>Proteins that are selectively expressed by <i>M. tuberculosis</i> during or after invasion of the host may prove to be useful diagnostic tools and may eventually lead to a better skin prick test. The identification of such proteins will also contribute to our understanding of the way in which 
<i>M. tuberculosis</i> causes disease and to the rational design of new improved vaccines.  One such protein, MPB83, has recently been identified by collaborating research groups in South Africa and the UK.</font><p>


MPB83 is highly immunogenic and may make a suitable single component skin prick test.  Such a test would offer advantages over the current, multicomponent test in terms of specificity since MPB83 is present in <i>M. tuberculosis</i> and a number of related organisms but is not present in non-pathogenic mycobacteria.<p>


Studies have shown that MPB83 is only expressed by <i>M. tuberculosis</i> after infection of the host, which may make it a useful marker of active infection.  The current skin prick test cannot distinguish between patients with active infection and those vaccinated with BCG - presenting clinicians with a real problem when it comes to diagnosing tuberculosis in patients who have been vaccinated.  This is a particular problem in areas where vaccination is routine. Since some strains of BCG express MPB83 at all times in culture it may be possible to design a test using this protein that would differentiate between the immune response to active infection and vaccination. <p>


The South African researchers are working in collaboration with a group led by 
Dr Glyn Hewinson from the Central Veterinary Laboratories Weybridge, UK. The CVL group are working on the development of a TB vaccine for animals and have a particular interest in MPB83 from <i>M. bovis</i>.<p>

For more information contact:<p>


Dr Lafras Steyn<br>
University of Cape Town<br>
South Africa<p>

Tel: +27 21 406 6389<p>


<a href="art8.html">Forward to: Host immune failure in tuberculosis</a><p>
<a href="art6.html">Back to: Communication as a protection strategy</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-189</DOCNO>
<DOCOLDNO>IA057-000937-B020-107</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art8.html 193.128.22.20 19970109095335 text/html 4122
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:43:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:55 GMT
Content-length: 3931
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Host immune failure in tuberculosis</font></h2>

<font size=5>T cells suppress immune response<p>Research carried out in South Africa may lead to an alternative therapy that will specifically stimulate the immune system to combat <i>M. tuberculosis</i> infection better.</font><p>

Protective cell-mediated immunity against intracellular pathogens (including mycobacteria, fungi and viruses) is mediated by a type 1 helper CD4+ T cell response. Susceptibility to intracellular infections is often characterised by a type 2 helper CD4+ T cell response, which normally mediates antibody production and allergy. Type 2 helper T cells can suppress the function of type 1 helper T cells and they have also been shown to play a role in the immunosuppression which features prominently in diseases such as lepromatous leprosy. The extent of type 2 helper T cell involvement in immunosuppression in other diseases, including tuberculosis, is not known.<p>


The T cell proliferative response to stimulation by mycobacterial antigens was examined in the peripheral blood of patients with advanced tuberculosis. This revealed a diminished type 1 T cell response relative to uninfected individuals, but at the same time did not show the dominant characteristics of a type 2 response. However, when T cells were derived from the site of disease 
(e.g. the lung), there was evidence for suppressor T cell activity. <p>


A suppressor T cell clone was characterised and found not to be a classic type 2 helper CD4+ T cell, but rather a type 2-like CD8+ T cell (CD8+ T cells are best known for their cytotoxic function). Cytokines interleukin-4 and interferon-gamma are produced by this clone, and it suppresses the 
<i>M. tuberculosis</i>-specific responses of peripheral blood T cells as well as that of a type 1 CD4+ helper T cell clone isolated from the same patient. Further experiments are being carried out to investigate the mechanism of this suppression.<p>


Immunotherapy directed at combating immunosuppression and enhancing the host's own immune response is an attractive approach to supplement conventional therapy for tuberculosis. By understanding the molecular mechanism whereby T cells mediate immuno-suppression, targets for novel immuno-therapies may also be identified.<p>

For more information contact:<p>


Professor Stan Ress <br>
Groote Shuur Hospital<br>
Cape Town, South Africa<p>

Tel: +27 21 406 6201<br>
e-mail: <a href="mailto:sress@uctgsh1.uct.ac.za">sress@uctgsh1.uct.ac.za</a><p>

<a href="art9.html">Forward to: TB's sweet sites</a><p>
<a href="art7.html">Back to: TB protein holds prickly solutions</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-190</DOCNO>
<DOCOLDNO>IA057-000937-B020-120</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/actiontb/news2/art9.html 193.128.22.20 19970109095359 text/html 3716
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:44:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:55 GMT
Content-length: 3525
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB's sweet sites</font></h2>

<font size=5>First bacterial N-linked glycosylation site found<p>For the first time, N-linked glycosylation has been found on the surface of a mycobacterial protein. This has never been seen in bacteria before, though it is common in higher organisms, such as mammals. Glycosylation is thought to play a key part in the interaction between mycobacteria and the host immune cells. For this reason, the enzymes involved in glycosylation are prime targets for drug discovery. Knowing the pattern of glycosylation present on the surface of 
<i>M. tuberculosis</i> will help researchers identify these targets.</font><p>


A recombinant 19KDa antigen from 
<i>M. tuberculosis</i> protein was expressed in <i>M. vaccae</i> by researchers at St Mary's Hospital in London, UK and then passed on to Glaxo Wellcome researchers for characterisation. <p>


After sequencing the protein, the researchers cut a tiny amount into 10 fragments, using the protease trypsin. Based on the protein sequence, the researchers were able to predict the molecular weight of each fragment and compare these to the actual molecular weights found by mass spectroscopy. <p>


Only minute quantities of protein were required for this analysis because the researchers used the new nanoelectrospray technique. Using this highly sensitive technique researchers can virtually spray one molecule at a time onto the mass spectrometer, enabling studies to be carried out on protein samples taken directly from 2-D electrophoresis gels. <p>


Peptide fragments that were heavier than expected were found to be glycosylated and these were analysed further to discover the type of glycosylation. The 
N-linked glycosylation site was found on an asparagine residue near the C-terminus of the protein. Additional O-linked glycosylation sites, which had previously been identified by genetic studies, were found near the N-terminus of the protein. <p>

For more information contact:<p>


Dr Malcom Ward<br>
Glaxo Wellcome Research & Development<br>
Stevenage, UK<p>

Tel: +44 1438 764857<br>
e-mail: <a href="mailto:maw7109@ggr.co.uk">maw7109@ggr.co.uk</a><p>

<a href="art8.html">Back to: Host immune failure in tuberculosis</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-191</DOCNO>
<DOCOLDNO>IA057-000937-B017-230</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/yeast.html 193.128.22.20 19970109093238 text/html 8174
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:22:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:24 GMT
Content-length: 7983
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30"> <basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>
<h2><font size=6>Signal transduction in yeast</font></h2>
<p>

<font size=5>The power of yeast genetics provides unique opportunities 
for dissecting signal transduction pathways. We are taking full 
advantage of this to study signal transduction pathways that regulate cell wall synthesis. The components of such regulatory pathways are potential targets for developing new antifungal drugs.</font><p>

Yeast also provides the means for analysing mammalian signal transduction pathways. There are many yeast homologues of mammalian 
signal transduction components and, furthermore,  several mammalian receptors can function in yeast. This gives us exciting 
opportunities, working with members of the neurobiology group, to analyse the pathways that operate in neuronal outgrowth and 
survival.<p>

<b>Regulation of cell wall synthesis: protein kinase C1</b><p>

The regulation and timing of fungal cell wall synthesis must be intimately coupled to cell growth and progression through the cell 
cycle. The key enzymes involved in this process are likely to be important cell control proteins and may also be interesting 
regulatory targets for novel antifungal drugs.<P>

An opportunity for studying such an enzyme came when we identified a gene whose inactivation led to lysis of the Saccharomyces 
cerevisiae cell and which to our surprise was found to encode a yeast homologue of mammalian protein kinase C (PKC). In fact it 
proved to be the PKC1 gene that had been  previously identified by David Levin (Johns Hopkins University) on the basis of sequence 
similarity with mammalian homologues. Our subsequent research showed that the PKC1 gene product is a key player in a novel and 
complex pathway of signal transduction that regulates cell wall assembly in yeast. Homologues of mammalian kinases, MAP kinase 
(MPK) MAP kinase kinase (MEK) and MAP kinase kinase kinase (MEKKinase) were discovered to be part of this pathway. This has 
strengthened the view that such kinase cascades have been conserved in evolution, but have different functions in different 
cells, e.g. response to growth factor stimuli in human cells, but regulation of cell wall synthesis in yeast.<P>

In subsequent work, we have been analysing in detail the activity of the PKC1 gene product to discover the signals that tell a 
yeast cell when, and when not, to make cell wall.<P> 

<b>Mammalian receptors in yeast</b><p>

The conservation of signalling pathways between yeast and mammalian cells has been the springboard for another project, to use 
yeast as a host for  expressing components of mammalian signal transduction pathways. We are studying their interactions and 
regulation to derive insights about  how these pathways operate, particularly in neuronal development, and to determine their 
roles  in a variety of disease states.<P>

Mammalian signalling pathways respond to extracellular stimuli largely through ligands that bind to cell surface receptors which 
trigger intracellular signalling cascades. Broadly speaking, receptors fall into three families: those with seven transmembrane 
spanning domains (7TMs); growth factor receptors 
(tyrosine kinase or TK receptors) that, upon activation, often have the intrinsic ability to phosphorylate  tyrosine residues 
on key downstream effector molecules;  and ion channels which may or may not be activated by external ligands.<P>

We have expressed several types of receptor on the yeast cell surface. For example, a ligand gated ion channel, the 5HT3 receptor 
which responds to the ligand serotonin, can be expressed in a correct orientation at the cell surface of S. cerevisiae  and is 
pharmacologically indistinguishable from the same 
receptor found on  mammalian cells.  Both S. cerevisiae and the fission yeast Schizosaccharomyces pombe  can express several 
members of the 7TM class of receptor, in a functional 
form,  at the cell surface. We have developed a new range of S. pombe secretion vectors using the highly regulated promoter nmt 
to drive the synthesis of these recombinant proteins. <P>

<b>TK receptors.</b><p>

However, by far the most difficult class of receptor to express at the cell surface has been the TK receptors. Yeast cells do 
not appear to have endogeneous TK receptors;  this gives 
us the possibility of rebuilding mammalian signalling pathways in an otherwise naive host to allow detailed studies of 
regulatory mechanisms.  We have successfully produced an active 
form of the platelet-derived growth factor (PDGF) receptor in S. pombe. Although the receptor is probably not expressed at the 
cell surface, it is nevertheless able to phosphorylate <cite>in 
vivo</cite> known downstream effectors such as phospholipase-Cg and to activate them, a process which mimics that found in a mammalian 
growth factor-activated cascade. <P>

Through a number of important collaborations with groups outside Glaxo, we are studying the downstream events in neuronal growth 
factor signalling. Our plans are to couple activation of mammalian receptors to a visible change in yeast cells which would 
allow us to tell if the receptor is activated or regulated. 
One way of doing this is to activate yeast PKCs by receptor activation and to this end we have extended our studies on yeast PKCs to include the cloning of PKCs from yeasts other than 
S. cerevisiae, including C. albicans and S. pombe. The discovery of PKCs in yeast is surprising  since in mammalian cells they 
respond to 
extracellular signals. In yeast, these receptors might respond to intracellular signals, such as cell cycle checkpoints, or 
perhaps  
there are extracellular signals to which yeasts respond and for which they may have as yet undiscovered receptors. The study of  
yeast signalling pathways and their similarities to analogous pathways in mammals is a very exciting area of research which 
should give important insights into the regulation of mammalian signal transduction pathways in health and disease.<P>


<b>Some recent publications:</b><p>

Paravicini G., Cooper, M., Friedli, L., Smith, D.J., Carpentier, J.-L. , Klig, L.S. and M.A. Payton. (1992). 
The osmotic integrity of the yeast cell requires a functional PKC1 gene 
product. <i> Mol. Cell. Biol.</i>  12:4896-905.<P>

Mazzei, G.J., Schmid, E.M.,  Knowles, J.K.C., Payton, M.A. and K.G. Maundrell.
(1993). 
 A Ca2+ - independent protein kinase C from fission yeast. <i> J. Biol. Chem.</i> 268:7401-6.<P>

Antonsson, B., Montessuit, S., Friedli, L., Payton, M.A. and G. Paravicini.  (1994). 
Protein kinase C in yeast: characteristics of the S.cerevisiae PKC1 gene product. <i>  
J.Biol. Chem.</i> (in press).<P>

<a href="project.html">Return to: Research projects contents page</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-192</DOCNO>
<DOCOLDNO>IA057-000937-B014-297</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/zap.html 193.128.22.20 19970109090209 text/html 746
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:52:19 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:32 GMT
Content-length: 556
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Zap</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont size=4> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Zap</font></h2><p>
<pre>
Syntax:  zap
</pre><p>
Deletes the contents of the current database and resets parameter
variables to their initial default state.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-193</DOCNO>
<DOCOLDNO>IA057-000937-B014-179</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/set.html 193.128.22.20 19970109085948 text/html 1869
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:49:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1678
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Set</font></h2><p>
<pre>
Syntax:  set &lt;parameter&gt; {&lt;option&gt;}
</pre><p>
The RasMol
<tt><b>set</b></tt>
command allows the user to alter various internal program parameters
such as those controlling rendering options. Each parameter has its
own set or permissible parameter options. Typically, ommiting the
paramter option resets that parameter to its default value. A list of
valid parameter names is given below.
<p>
<pre>
    <a href="setamb.html">Ambient</a>         <a href="setaxes.html">Axes</a>            <a href="setbackg.html">Background</a>
    <a href="setbond.html">BondMode</a>        <a href="setbound.html">BoundBox</a>        <a href="setdisp.html">Display</a>
    <a href="setfont.html">FontSize</a>        <a href="sethbd.html">HBonds</a>          <a href="sethet.html">Hetero</a>
    <a href="sethour.html">HourGlass</a>       <a href="sethyd.html">Hydrogen</a>        <a href="setkine.html">Kinemage</a>
    <a href="setmenus.html">Menus</a>           <a href="setmouse.html">Mouse</a>           <a href="setrad.html">Radius</a>
    <a href="setshad.html">Shadow</a>          <a href="setslab.html">SlabMode</a>        <a href="setsol.html">Solvent</a>
    <a href="setspecu.html">Specular</a>        <a href="setspecp.html">SpecPower</a>       <a href="setssbd.html">SSBonds</a>
    <a href="setstr.html">Strands</a>         <a href="setunit.html">UnitCell</a>        <a href="setvec.html">VectPS</a>
</pre>

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-194</DOCNO>
<DOCOLDNO>IA057-000937-B022-226</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setamb.html 193.128.22.20 19970109101208 text/html 1365
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:02:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1174
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Ambient</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont size=4>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Ambient</font></h2><p>
<pre>
Syntax:  set ambient {&lt;value&gt;}
</pre><p>
The RasMol
<tt><b>ambient</b></tt>
parameter is used to control the amount of ambient (or surrounding)
light in the scene. The
<tt><b>ambient</b></tt>
value must be between 0 and 100 that controls the percentage intensity
of the darkest shade of an object. For a solid object, this is the
intensity of surfaces facing away from the light source or in shadow.
For depth-cued objects this is the intensity of objects furthest from
the viewer.
<p>
This parameter is commonly used to correct for monitors with different
"gamma values" (brightness), to change how light or dark a hardcopy
image appears when printed or to alter the feeling of depth for
wireframe or ribbon representations.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-195</DOCNO>
<DOCOLDNO>IA057-000937-B022-236</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setaxes.html 193.128.22.20 19970109101217 text/html 1005
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:02:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 815
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Axes</font></h2><p>
<pre>
Syntax:  set axes &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>axes</b></tt>
parameter controls the display of orthogonal co-ordinate axes on
the current display. The co-ordinate axes are those used in the
molecule data file, and the origin is the centre of the molecule's
bounding box. The
<tt><b>set axes</b></tt>
command is similar the the commands
<a href="setbound.html"><tt><b>set boundbox</b></tt></a>
and
<a href="setunit.html"><tt><b>set unitcell</b></tt></a>
that display the bounding box and the crystallographic unit cell
respectively.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-196</DOCNO>
<DOCOLDNO>IA057-000937-B022-141</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setbackg.html 193.128.22.20 19970109101040 text/html 1298
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:00:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1107
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Background</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Background</font></h2><p>
<pre>
Syntax:  set background {&lt;colour&gt;}
</pre><p>
The RasMol
<tt><b>background</b></tt>
parameter is used to set the colour of the "canvas" background. The
colour may be given as either a colour name or a comma separated
triple of Red, Green, Blue (RGB) components enclosed in square
brackets. Typing the command
<a href="help.html"><tt><b>help colours</b></tt></a>
will give a list of the predefined colour names recognised by RasMol.
When running under X Windows, RasMol also recognises colours in the
X server's colour name database.
<p>
The command
<tt><b>set background</b></tt>
is synonymous with the RasMol command
<a href="backg.html"><tt><b>background.</b></tt></a>

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-197</DOCNO>
<DOCOLDNO>IA057-000937-B022-247</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setbond.html 193.128.22.20 19970109101225 text/html 1286
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:02:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1095
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set BondMode</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set BondMode</font></h2><p>
<pre>
Syntax:  set bondmode and
         set bondmode or
</pre><p>
The RasMol
<tt><b>set bondmode</b></tt>
command controls the mechanism used to select individual bonds. When
using the
<a href="select.html"><tt><b>select</b></tt></a>
and
<a href="restrict.html"><tt><b>restrict</b></tt></a>
commands, a given bond will be selected if i) the bondmode is
<tt><b>or</b></tt>
and either of the connected atoms is selected, or ii) the bondmode is
<tt><b>and</b></tt>
and both atoms connected by the bond are selected. Hence an individual
bond may be uniquely identified by using the command
"<tt><b>set bondmode and</b></tt>"
and then uniquely selecting the atoms at both ends.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-198</DOCNO>
<DOCOLDNO>IA057-000937-B022-286</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setbound.html 193.128.22.20 19970109101302 text/html 1121
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:03:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 931
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set BoundBox</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set BoundBox</font></h2><p>
<pre>
Syntax:  set boundbox &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>boundbox</b></tt>
parameter controls the display of the current molecules bounding box
on the display. The bounding box is orthogonal to the data file's
original co-ordinate axes. The
<tt><b>set boundbox</b></tt>
command is similar the the commands
<a href="setaxes.html"><tt><b>set axes</b></tt></a>
and
<a href="setbound.html"><tt><b>set unitcell</b></tt></a>
that display orthogonal co-ordinate axes and the bounding box
respectively.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-199</DOCNO>
<DOCOLDNO>IA057-000937-B022-318</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setdisp.html 193.128.22.20 19970109101351 text/html 1479
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:03:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1288
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Display</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont size=4> <a href="../"><img src="../icon.gif" border=0 align=left></a> <br clear=
left>
<ul><ul><ul><ul><ul><ul type=disc>
<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Display</font></h2><p>
<pre>
Syntax:  set display selected
         set display normal
</pre><p>
This command controls the display mode within RasMol. By default,
<tt><b>set display normal,</b></tt>
RasMol displays the molecule in the representation specified by the
user. The command
<tt><b>set display selected</b></tt>
changes the display mode such that the molecule is temporarily drawn
so as to indicate currently selected portion of the molecule. The
user specified colour scheme and representation remains unchanged.
In this representation all selected atoms are shown in yellow and
all non selected atoms are shown in blue. The colour of the background
is also changed to a dark grey to indicate the change of display mode.
This command is typically only used by external Graphical User
Interfaces (GUIs).

<p>
<a href="chsetopt.html">Internal parameters</a>
</ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
	
</DOC>
<DOC>
<DOCNO>WT14-B39-200</DOCNO>
<DOCOLDNO>IA057-000937-B022-196</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setfont.html 193.128.22.20 19970109101146 text/html 1030
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:01:58 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 840
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set FontSize</font></h2><p>
<pre>
Syntax:  set fontsize {&lt;boolean&gt;}
</pre><p>
The RasMol
<tt><b>set fontsize</b></tt>
command is used to control the size of the characters that
form atom labels. This value corresponds to the height of
the displayed character in pixels. The maximum value of
<tt><b>fontsize</b></tt>
is 32 pixels, and the default value is 8 pixels high. To
display atom labels on the screen use the RasMol
<a href="label.html"><tt><b>label</b></tt></a>
command and to change the colour of displayed labels, use
the
<a href="colour.html"><tt><b>colour labels</b></tt></a>
command.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-201</DOCNO>
<DOCOLDNO>IA057-000937-B022-178</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/sethbd.html 193.128.22.20 19970109101130 text/html 1429
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:01:31 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1238
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set HBonds</font></h2><p>
<pre>
Syntax:  set hbonds backbone
         set hbonds sidechain
</pre><p>
The RasMol
<tt><b>hbonds</b></tt>
parameter determines whether hydrogen bonds are drawn between
the donor and acceptor atoms of the hydrogen bond,
<tt><b>set hbonds sidechain</b></tt>
or between the alpha carbon atoms of the protein backbone and between
the phosphorous atoms of the nucleic acid backbone,
<tt><b>set hbonds backbone.</b></tt>
The actual display of hydrogen bonds is controlled by the
<a href="hbonds.html"><tt><b>hbonds</b></tt></a>
command. Drawing hydrogen bonds between protein alpha carbons or
nucleic acid phosphorous atoms is useful when the rest of the molecule
is shown in only a schematic representation such as
<a href="backbone.html"><tt><b>backbone,</b></tt></a>
<a href="ribbons.html"><tt><b>ribbons</b></tt></a>
or
<a href="strands.html"><tt><b>strands.</b></tt></a>
his parameter is similar to the RasMol
<a href="setssbd.html"><tt><b>ssbonds</b></tt></a>
parameter.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-202</DOCNO>
<DOCOLDNO>IA057-000937-B022-212</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/sethet.html 193.128.22.20 19970109101157 text/html 1534
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:02:09 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1343
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Hetero</font></h2><p>
<pre>
Syntax:  set hetero &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>hetero</b></tt>
parameter is used to modify the `default' behaviour of the RasMol
<a href="select.html"><tt><b>select</b></tt></a>
command, i.e. the behaviour of
<tt><b>select</b></tt>
without any parameters. When this value is
<tt><b>false,</b></tt>
the default
<a href="select.html"><tt><b>select</b></tt></a>
region does not include an heterogenous atoms (refer to the
predefined set
<a href="hetero.html"><tt><b>hetero</b></tt></a>
). When this value is
<tt><b>true,</b></tt>
the default
<a href="select.html"><tt><b>select</b></tt></a>
region may contain hetero atoms. This parameter is similar to
the RasMol
<a href="sethyd.html"><tt><b>hydrogen</b></tt></a>
parameter which determines whether hydrogen atoms should be
included in the default set. If both
<tt><b>hetero</b></tt>
and
<a href="sethyd.html"><tt><b>hydrogen</b></tt></a>
are
<tt><b>true,</b></tt>
<a href="select.html"><tt><b>select</b></tt></a>
without any parameters is equivalent to
<a href="select.html"><tt><b>select all.</b></tt></a>

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-203</DOCNO>
<DOCOLDNO>IA057-000937-B022-329</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/sethour.html 193.128.22.20 19970109101402 text/html 1095
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:04:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 905
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set HourGlass</font></h2><p>
<pre>
Syntax:  set hourglass &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>hourglass</b></tt>
parameter allows the user to enable and disable the use of the `hour
glass' cursor used by RasMol to indicate that the program is currently
busy drawing the next frame. The command
<tt><b>set hourglass on</b></tt>
enable the indicator, whilst
<tt><b>set hourglass off</b></tt>
prevents RasMol from changing the cursor. This is useful when spinning
the molecule, running a sequence of commands from a script file or
using interprocess communication to execute complex sequences of
commands. In these cases a `flashing' cursor may be distracting.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-204</DOCNO>
<DOCOLDNO>IA057-000937-B022-347</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/sethyd.html 193.128.22.20 19970109101418 text/html 1711
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:04:30 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1520
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Hydrogen</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Hydrogen</font></h2><p>
<pre>
Syntax:  set hydrogen &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>hydrogen</b></tt>
parameter is used to modify the `default' behaviour of the RasMol
<a href="select.html"><tt><b>select</b></tt></a>
command, i.e. the behaviour of
<tt><b>select</b></tt>
without any parameters. When this value is
<tt><b>false,</b></tt>
the default
<a href="select.html"><tt><b>select</b></tt></a>
region does not include any hydrogen or deuterium atoms (refer
to the predefined set
<a href="hydrog.html"><tt><b>hydrogen</b></tt></a>
). When this value is
<tt><b>true,</b></tt>
the default
<a href="select.html"><tt><b>select</b></tt></a>
region may contain hydrogen atoms. This parameter is similar to
the RasMol
<a href="sethet.html"><tt><b>hetero</b></tt></a>
parameter which determines whether heterogenous atoms should be
included in the default set. If both
<tt><b>hydrogen</b></tt>
and
<a href="sethet.html"><tt><b>hetero</b></tt></a>
are
<tt><b>true,</b></tt>
<a href="select.html"><tt><b>select</b></tt></a>
without any parameters is equivalent to
<a href="select.html"><tt><b>select all.</b></tt></a>

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-205</DOCNO>
<DOCOLDNO>IA057-000937-B022-363</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setkine.html 193.128.22.20 19970109101433 text/html 1299
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:04:44 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1108
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Kinemage</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Kinemage</font></h2><p>
<pre>
Syntax:  set kinemage &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>set kinemage</b></tt>
command controls the amount of detail stored in a Kinemage output
file generated by the RasMol
<a href="write.html"><tt><b>write kinemage</b></tt></a>
command. The output kinemage files are intended to be displayed by
David Richardson's Mage program.
<tt><b>set kinemage false,</b></tt>
the default, only stores the currently displayed representation in
the generated output file. The command
<tt><b>set kinemage true,</b></tt>
generates a more complex Kinemage that contains both the wireframe
and backbone representations as well as the co-ordinate axes,
bounding box and crystal unit cell.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-206</DOCNO>
<DOCOLDNO>IA057-000937-B022-386</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setmenus.html 193.128.22.20 19970109101448 text/html 741
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:04:58 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 551
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Menus</font></h2><p>
<pre>
Syntax:  set menus &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>set menus</b></tt>
command enables the canvas window's menu buttons or menu bar. This
command is typically only used by graphical user interfaces or to
create as large as image as possible when using Microsoft Windows.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-207</DOCNO>
<DOCOLDNO>IA057-000937-B022-406</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setmouse.html 193.128.22.20 19970109101505 text/html 1433
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:05:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:29 GMT
Content-length: 1242
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Mouse</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Mouse</font></h2><p>
<pre>
Syntax:  set mouse rasmol
         set mouse insight
         set mouse quanta
</pre><p>
The RasMol
<tt><b>set mouse</b></tt>
command sets the rotation, translation, scaling and zooming mouse
bindings. The default value is
<tt><b>rasmol</b></tt>
which is suitable for two button mice (for three button mice the
second and third buttons are synonymous); X-Y rotation is controlled
by the first button, and X-Y translation by the second. Additional
functions are controlled by holding a modifier key on the keyboard.
[Shift] and the first button performs scaling, [shift] and the second
button performs Z-rotation, and [control] and the first mouse button
controls the clipping plane. The
<tt><b>insight</b></tt>
and
<tt><b>quanta</b></tt>
provide the same mouse bindings as other packages for experienced
users.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-208</DOCNO>
<DOCOLDNO>IA057-000937-B022-421</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setrad.html 193.128.22.20 19970109101515 text/html 1618
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:05:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 1427
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Radius</font></h2><p>
<pre>
Syntax:  set radius {&lt;value&gt;}
</pre><p>
The RasMol
<tt><b>set radius</b></tt>
command is used to alter the behaviour of the RasMol
<a href="dots.html"><tt><b>dots</b></tt></a>
command depending upon the value of the
<a href="setsol.html"><tt><b>solvent</b></tt></a>
parameter.
When
<a href="setsol.html"><tt><b>solvent</b></tt></a>
is
<tt><b>true,</b></tt>
the
<tt><b>radius</b></tt>
parameter controls whether a true Van der Waal's surface
is generated by the
<a href="dots.html"><tt><b>dots</b></tt></a>
command. If the value of
<tt><b>radius</b></tt>
is anything other than zero, that value is used as the
radius of each atom instead of it true VdW value. When
the value of
<a href="setsol.html"><tt><b>solvent</b></tt></a>
is
<tt><b>true,</b></tt>
this parameter determines the `probe sphere' (solvent) radius.
The parameter may be given as an integer in rasmol units or
containing a decimal point in Angstroms. The default value of
this parameter is determined by the value of
<a href="setsol.html"><tt><b>solvent</b></tt></a>
and changing
<a href="setsol.html"><tt><b>solvent</b></tt></a>
resets
<tt><b>radius</b></tt>
to its new default value.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-209</DOCNO>
<DOCOLDNO>IA057-000937-B022-453</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setshad.html 193.128.22.20 19970109101605 text/html 1124
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:06:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 934
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Shadow</font></h2><p>
<pre>
Syntax:  set shadow &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>set shadow</b></tt>
command enables and disables raytracing of the currently rendered image.
Currently only the spacefilling representation is shadowed or can cast
shadows. Enabling shadowing will automatically disable the Z-clipping
(slabbing) plane using the command
<a href="slab.html"><tt><b>slab off.</b></tt></a>
Raytracing typically takes about 10s for a moderately sized protein.
It is recommended that shadowing is normally disabled whilst the
molecule is being transformed or manipulated, and only enabled once
an appropiate viewpoint is selected, to provide a greater impression
of depth.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-210</DOCNO>
<DOCOLDNO>IA057-000937-B022-512</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setslab.html 193.128.22.20 19970109101721 text/html 954
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:06:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 764
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set SlabMode</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set SlabMode</font></h2><p>
<pre>
Syntax:  set slabmode &lt;slabmode&gt;
</pre><p>
The RasMol
<tt><b>slabmode</b></tt>
parameter controls the rendering method of objects cut by the
slabbing (z-clipping) plane. Valid slabmode parameters are
"<tt><b>reject</b></tt>", "<tt><b>half</b></tt>",
"<tt><b>hollow</b></tt>", "<tt><b>solid</b></tt>" and
"<tt><b>section</b></tt>".

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-211</DOCNO>
<DOCOLDNO>IA057-000937-B023-6</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setsol.html 193.128.22.20 19970109101751 text/html 1490
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:07:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 1299
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Solvent</font></h2><p>
<pre>
Syntax:  set solvent &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>set solvent</b></tt>
command is used to control the behaviour of the RasMol
<a href="dots.html"><tt><b>dots</b></tt></a>
command. Depending upon the value of the
<tt><b>solvent</b></tt>
parameter, the
<a href="dots.html"><tt><b>dots</b></tt></a>
command either generates a Van der Waal's or a solvent
acessible surface around the currently selected set of
atoms. Changing this parameter automatically resets the
value of the RasMol
<a href="setrad.html"><tt><b>radius</b></tt></a>
parameter.
The command
<tt><b>set solvent false,</b></tt>
the default value, indicates that a Van der Waal's surface
should be generated and resets the value of
<a href="setrad.html"><tt><b>radius</b></tt></a>
to zero. The command
<tt><b>set solvent true</b></tt>
indicates that a `Connolly' or `Richards' solvent
accessible surface should be drawn and sets the
<a href="setrad.html"><tt><b>radius</b></tt></a>
parameter, the solvent radius, to 1.2 Angstroms (or 300
RasMol units).

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-212</DOCNO>
<DOCOLDNO>IA057-000937-B023-22</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setspecu.html 193.128.22.20 19970109101817 text/html 1218
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:08:28 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 1027
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set Specular</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Specular</font></h2><p>
<pre>
Syntax:  set specular &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>set specular</b></tt>
command enables and disables the display of specular highlights on
solid objects drawn by RasMol. Specular highlights appear as white
reflections of the light source on the surface of the object. The
current RasMol implementation uses an approximation function to
generate this highlight.
<p>
The specular highlights on the surfaces of solid objects may be
altered by using the specular reflection coefficient, which is
altered using the RasMol
<a href="setspecp.html"><tt><b>set specpower</b></tt></a>
command.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-213</DOCNO>
<DOCOLDNO>IA057-000937-B023-53</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setspecp.html 193.128.22.20 19970109101845 text/html 1172
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:08:58 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 982
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Set SpecPower</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set SpecPower</font></h2><p>
<pre>
Syntax:  set specpower {&lt;value&gt;}
</pre><p>
The
<tt><b>specpower</b></tt>
parameter determines the shininess of solid objects rendered by
RasMol. This value between 0 and 100 adjusts the reflection
coeffient used in specular highlight calculations. The specular
highlights are enabled and disabled by the RasMol
<a href="setspecu.html"><tt><b>set specular</b></tt></a>
command. Values around 20 or 30 produce plastic looking surfaces.
High values represent more shiny surfaces such as metals, while
lower values produce more diffuse/dull surfaces.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-214</DOCNO>
<DOCOLDNO>IA057-000937-B023-71</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setssbd.html 193.128.22.20 19970109101904 text/html 1281
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:09:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 1090
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set SSBonds</font></h2><p>
<pre>
Syntax:  set ssbonds backbone
         set ssbonds sidechain
</pre><p>
The RasMol
<tt><b>ssbonds</b></tt>
parameter determines whether disulphide bridges are drawn between
the sulphur atoms in the sidechain (the default) or between the alpha
carbon atoms in the backbone of the cysteines residues. The actual
display of disulphide bridges is controlled by the
<a href="ssbonds.html"><tt><b>ssbonds</b></tt></a>
command. Drawing disulphide bridges between alpha carbons is useful
when the rest of the protein is shown in only a schematic
representation such as
<a href="backbone.html"><tt><b>backbone,</b></tt></a>
<a href="ribbons.html"><tt><b>ribbons</b></tt></a>
or
<a href="strands.html"><tt><b>strands.</b></tt></a>
his parameter is similar to the RasMol
<a href="sethbd.html"><tt><b>hbonds</b></tt></a>
parameter.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-215</DOCNO>
<DOCOLDNO>IA057-000937-B023-87</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setstr.html 193.128.22.20 19970109101917 text/html 997
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:09:28 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 807
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set Strands</font></h2><p>
<pre>
Syntax:  set strands {&lt;value&gt;}
</pre><p>
The RasMol
<tt><b>strands</b></tt>
parameter controls the number of parallel strands that are displayed
in the ribbon representations of proteins. The permissible values for
this parameter are 1, 2, 3, 4, 5 and 9. The default value is 5. The
number of strands is constant for all ribbons being displayed.
However, the ribbon width (the separation between strands) may be
controlled on a residue by residue basis using the RasMol
<a href="ribbons.html"><tt><b>ribbons</b></tt></a>
command.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-216</DOCNO>
<DOCOLDNO>IA057-000937-B023-97</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setunit.html 193.128.22.20 19970109101925 text/html 1150
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:09:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 960
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set UnitCell</font></h2><p>
<pre>
Syntax:  set unitcell &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>unitcell</b></tt>
parameter controls the display of the crystallographic unit cell on
the current display. The crystal cell is only enabled if the appropriate
crystal symmetry information is contained in the PDB data file. The
RasMol command
<a href="show.html"><tt><b>show symmetry</b></tt></a>
display details of the crystal's space group and unit cell axes. The
<tt><b>set unitcell</b></tt>
command is similar the the commands
<a href="setaxes.html"><tt><b>set axes</b></tt></a>
and
<a href="setbound.html"><tt><b>set boundbox</b></tt></a>
that display orthogonal co-ordinate axes and the bounding box
respectively.

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body> 
</html> 

</DOC>
<DOC>
<DOCNO>WT14-B39-217</DOCNO>
<DOCOLDNO>IA057-000937-B023-111</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/setvec.html 193.128.22.20 19970109101941 text/html 1166
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:09:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 976
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Set VectPS</font></h2><p>
<pre>
Syntax:  set vectps &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>vectps</b></tt>
parameter is use to control the way in which the RasMol
<a href="write.html"><tt><b>write</b></tt></a>
command generates vector PostScript output files. The command
<tt><b>set vectps on</b></tt>
enables to use of black outlines around spheres and cylinder bonds
producing `cartoon-like' high resolution output. However, the current
implementation of RasMol incorrectly cartoons spheres that are intersected
by more than one other sphere. Hence `ball and stick' models are rendered
correctly by not large spacefilling spheres models. Cartoon outlines
can be disabled, the default, by the command
<tt><b>set vectps off</b></tt>

<p>
<a href="chsetopt.html">Internal parameters</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-218</DOCNO>
<DOCOLDNO>IA057-000937-B013-451</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/help.html 193.128.22.20 19970109085404 text/html 640
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:44:16 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 450
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Help</font></h2><p>
<pre>
Syntax:  help {&lt;topic&gt; {&lt;subtopic&gt;}}
         ? {&lt;topic&gt; {&lt;subtopic&gt;}}
</pre><p>
The RasMol
<tt><b>help</b></tt>
command provides on-line help on the given topic.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-219</DOCNO>
<DOCOLDNO>IA057-000937-B013-294</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/backg.html 193.128.22.20 19970109085139 text/html 1133
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:41:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 943
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Background</font></h2><p>
<pre>
Syntax:  background &lt;colour&gt;
</pre><p>
The RasMol
<tt><b>background</b></tt>
command is used to set the colour of the "canvas" background. The
colour may be given as either a colour name or a comma separated
triple of Red, Green and Blue (RGB) components enclosed in square
brackets. Typing the command
<a href="help.html"><tt><b>help colours</b></tt></a>
will give a list of the predefined colour names recognised by RasMol.
When running under X Windows, RasMol also recognises colours in the
X server's colour name database.
<p>
The
<tt><b>background</b></tt>
command is synonymous with the RasMol
<a href="setbackg.html"><tt><b>set background</b></tt></a>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-220</DOCNO>
<DOCOLDNO>IA057-000937-B014-168</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/select.html 193.128.22.20 19970109085935 text/html 1566
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:49:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1375
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Select</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" 
link="#1a1afa" vlink="30aa30"> <basefont size=4>
<a href="../"><img src="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6><font size=6>Select</font></font></h2><p>
<pre>
Syntax:  select {&lt;expression&gt;}
</pre><p>
Define the currently selected region of the molecule. All subsequent RasMol
commands that manipulate a molecule or modify its colour or representation,
only affects the currently selected region. The parameter of a
<tt><b>select</b></tt>
command is a RasMol expression that is evaluated for every atom of the
current molecule. The currently selected (active) region of the molecule
are those atoms that cause the expression to evaluate true. To select
the whole molecule use the RasMol command
<tt><b>select all.</b></tt>
The behaviour of the
<tt><b>select</b></tt>
command without any parameters is determined by the RasMol
<a href="sethet.html"><tt><b>hetero</b></tt></a>
and
<a href="set.html"><tt><b>hydrogen</b></tt></a>
parameters.
<p>
Type "help expression" for more information on RasMol atom expressions.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-221</DOCNO>
<DOCOLDNO>IA057-000937-B014-70</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/restrict.html 193.128.22.20 19970109085736 text/html 1535
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:47:48 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1344
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Restrict</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Restrict</font></h2><p>
<pre>
Syntax:  restrict {&lt;expression&gt;}
</pre><p>
The RasMol
<tt><b>restrict</b></tt>
command both defines the currently selected region of the
molecule and disables the representation of (most of) those parts of the
molecule no longer selected.  All subsequent RasMol commands that modify
a molecule's colour or representation effect only the currently selected
region. The parameter of a
<tt><b>restrict</b></tt>
command is a RasMol atom expression that is evaluated for every atom
of the current molecule. This command is very similar to the RasMol
<a href="select.html"><tt><b>select</b></tt></a>
command, except restrict disables the
<a href="wire.html"><tt><b>wireframe,</b></tt></a>
<a href="space.html"><tt><b>spacefill</b></tt></a>
and
<a href="backbone.html"><tt><b>backbone</b></tt></a>
representations in the non-selected region.
<p>
Type "help expression" for more information on RasMol atom expressions.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-222</DOCNO>
<DOCOLDNO>IA057-000937-B013-504</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/label.html 193.128.22.20 19970109085502 text/html 2020
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:44:33 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 1829
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Label</font></h2><p>
<pre>
Syntax:  label {&lt;string&gt;}
         label &lt;boolean&gt;
</pre><p>
The RasMol
<tt><b>label</b></tt>
command allows an arbitrary formatted text string to be
associated with each currently selected atom.  This string may contain
embedded `expansion specifiers' which display properties of the atom
being labelled. An expansion specifier consists of a `%' character
followed by a single alphabetic character specifying the property to be
displayed (similar to C's printf syntax).
An actual '%' character may be displayed by using the expansion
specifier `%%'.
<p>
Atom labelling for the currently selected atoms may be turned off with
the command
<tt><b>label off.</b></tt>
By default, if no string is given as a parameter RasMol uses labels
appropriate for the current molecule.
RasMol uses the label "%n%r:%c.%a" if the molecule contains more than
one chain, "%e%i" if the molecule has only a single residue (a small
molecule) and "%n%r.%a" otherwise.
<p>
The colour of each label may be changed using the
<a href="colour.html"><tt><b>colour label</b></tt></a>
command. By default, each label is drawn in the same colour as the atom
to which it is attached. The size of the displayed text may be changed
using the
<a href="setfont.html"><tt><b>set fontsize</b></tt></a>
command.
<p>
The following table lists the current expansion specifiers:
<p>
<pre>
    %a      Atom Name
    %b %t   B-factor/Temperature
    %c %s   Chain Identifier
    %e      Element Atomic Symbol
    %i      Atom Serial Number
    %n      Residue Name
    %r      Residue Number
</pre>

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-223</DOCNO>
<DOCOLDNO>IA057-000937-B013-345</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/colour.html 193.128.22.20 19970109085224 text/html 2612
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:42:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 2421
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Colour</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Colour</font></h2><p>
<pre>
Syntax:  colour {&lt;object&gt;} &lt;colour&gt;
         color {&lt;object&gt;} &lt;colour&gt;
</pre><p>
Colour the atoms (or other objects) of the selected region. The colour may
be given as either a colour name or a comma separated triple of Red, Green
and Blue (RGB) components enclosed in square brackets. Typing the command
<a href="help.html"><tt><b>help colours</b></tt></a>
will give a list of all the predefined colour names recognised
by RasMol.
<p>
Allowed objects are
<tt><b>atoms,</b></tt>
<tt><b>bonds,</b></tt>
<a href="backbone.html"><tt><b>backbone,</b></tt></a>
<a href="ribbons.html"><tt><b>ribbons</b></tt></a>
<a href="labels.html"><tt><b>labels</b></tt></a>
<a href="dots.html"><tt><b>dots,</b></tt></a>
<a href="hbonds.html"><tt><b>hbonds,</b></tt></a>
and
<a href="ssbonds.html"><tt><b>ssbonds.</b></tt></a>
If no object is specified, the default keyword
<tt><b>atom</b></tt>
is assumed.
Some colour schemes are defined for certain object types. The colour scheme
<tt><b>none</b></tt>
can be applied all objects accept atoms and dots, stating that the selected
objects have no colour of their own, but use the colour of their associated
atoms (i.e. the atoms they connect).
<tt><b>Atom</b></tt>
objects can also be coloured by
<a href="cpkcol.html"><tt><b>cpk,</b></tt></a>
<a href="aminocol.html"><tt><b>amino,</b></tt></a>
<a href="chain.html"><tt><b>chain,</b></tt></a>
<a href="group.html"><tt><b>group,</b></tt></a>
<a href="shapcol.html"><tt><b>shapely,</b></tt></a>
<a href="struccol.html"><tt><b>structure,</b></tt></a>
<a href="tempcol.html"><tt><b>temperature</b></tt></a>
<a href="charcol.html"><tt><b>charge</b></tt></a>
and
<a href="usercol.html"><tt><b>user</b></tt></a>. Hydrogen bonds can also be coloured by
<a href="hbondtyp.html"><tt><b>type</b></tt></a>
and dot surfaces can also be coloured by
<a href="potent.html"><tt><b>electrostatic potential.</b></tt></a>
For more information type
<a href="chcolour.html"><tt><b>help colour <colour>.</b></tt></a>

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-224</DOCNO>
<DOCOLDNO>IA057-000937-B013-442</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/hbonds.html 193.128.22.20 19970109085350 text/html 1673
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:43:58 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1482
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>HBonds</font></h2><p>
<pre>
Syntax:  hbonds {&lt;boolean&gt;}
         hbonds &lt;value&gt;
</pre><p>
The RasMol
<tt><b>hbond</b></tt>
command is used to represent the hydrogen bonding of the protein
molecule's backbone. This information is useful in assessing the
protein's secondary structure. Hydrogen bonds are represented as
either dotted lines or cylinders between the donor and acceptor
residues. The first time the
<tt><b>hbond</b></tt>
command is used, the program searches the structure of the
molecule to find hydrogen bonded residues and reports the number of bonds
to the user. The command
<tt><b>hbonds on</b></tt>
displays the selected `bonds' as dotted lines, and the
<tt><b>hbonds off</b></tt>
turns off their display. The colour of hbond objects may be changed
by the
<a href="colour.html"><tt><b>colour hbond</b></tt></a>
command. Initially, each hydrogen bond has the colours of its connected
atoms.
<p>
By default the dotted lines are drawn between the accepting oxygen and
the donating nitrogen. By using the
<a href="sethbd.html"><tt><b>set hbonds</b></tt></a>
command the alpha carbon positions of the appropriate residues may be
used instead. This is especially useful when examining proteins in
backbone representation.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-225</DOCNO>
<DOCOLDNO>IA057-000937-B013-272</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/backbone.html 193.128.22.20 19970109085114 text/html 1847
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:41:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 1656
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Backbone</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../"><img src="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Backbone</font></h2><p>
<pre>
Syntax:  backbone {&lt;boolean&gt;}
         backbone &lt;value&gt;
</pre><p>
The RasMol
<tt><b>backbone</b></tt>
command permits the representation of a polypeptide
backbone as a series of bonds connecting the adjacent alpha carbons of
each amino acid in a chain. The display of these backbone `bonds' is
turned on and off by the command parameter the same as the
<a href="wire.html"><tt><b>wireframe</b></tt></a>
command. The command
<tt><b>backbone off</b></tt>
turns off the selected `bonds', and
<tt><b>backbone on</b></tt>
or with a number turns them on. The number can be used
to specify the cylinder radius of the representation in either angstrom
or rasmol units. A parameter value of 500 (2.0 angstroms) or above
results in a "Parameter value too large" error. Backbone objects may be
coloured using the RasMol
<a href="colour.html"><tt><b>colour backbone</b></tt></a>
command.
<p>
The reserved word
<tt><b>backbone</b></tt>
is also used as a predefined set and as a parameter to the
<tt><b>set hbond</b></tt>
and
<tt><b>set ssbond</b></tt>
commands. The RasMol command
<tt><b>trace</b></tt>
is synonymous with the command
<tt><b>backbone.</b></tt>

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-226</DOCNO>
<DOCOLDNO>IA057-000937-B014-108</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/ribbons.html 193.128.22.20 19970109085837 text/html 1795
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:48:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1604
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Ribbons</font></h2><p>
<pre>
Syntax:  ribbons {&lt;boolean&gt;}
         ribbons &lt;value&gt;
</pre><p>
The RasMol
<tt><b>ribbons</b></tt>
command displays the currently loaded protein or nucleic acid as a
smooth solid "ribbon" surface passing along the backbone of the protein.
The ribbon is drawn between each amino acid whose alpha carbon is
currently selected. The colour of the ribbon is changed by the RasMol
<a href="colour.html"><tt><b>colour ribbon</b></tt></a>
command. If the current ribbon colour is
<tt><b>none</b></tt>
(the default), the colour is taken from the alpha carbon at each
position along its length.
<p>
The width of the ribbon at each position is determined by the optional
parameter in the usual RasMol units. By default the width of the ribbon
is taken from the secondary structure of the protein or a constant value
of 720 (2.88 Angstroms) for nucleic acids.
The default width of protein alpha helices and beta sheets is 380 (1.52
Angstroms) and 100 (0.4 Angstroms) for turns and random coil. The
secondary structure assignment is either from the PDB file or calculated
using the DSSP algorithm as used by the
<a href="struct.html"><tt><b>structure</b></tt></a>
command. This command is similar to the RasMol command
<a href="strands.html"><tt><b>strands</b></tt></a>
which renders the biomolecular ribbon as parallel depth-cued curves.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-227</DOCNO>
<DOCOLDNO>IA057-000937-B014-234</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/strands.html 193.128.22.20 19970109090103 text/html 2308
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:51:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 2117
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Strands</font></h2><p>
<pre>
Syntax:  strands {&lt;boolean&gt;}
         strands &lt;value&gt;
</pre><p>
The RasMol
<tt><b>strands</b></tt>
command displays the currently loaded protein or nucleic acid as a
smooth "ribbon" of depth-cued curves passing along the backbone of the
protein. The ribbon is composed of a number of strands that run parallel
to one another along the peptide plane of each residue. The ribbon is
drawn between each amino acid whose alpha carbon is currently selected.
The colour of the ribbon is changed by the RasMol
<a href="colour.html"><tt><b>colour ribbon</b></tt></a>
command. If the current ribbon colour is
<tt><b>none</b></tt>
(the default), the colour is taken from the alpha carbon at each
position along its length. The colour of the central and outermost
strands may be coloured independently using the
<a href="colour.html"><tt><b>colour ribbon1</b></tt></a>
and
<a href="colour.html"><tt><b>colour ribbon2</b></tt></a>
commands respectively. The number of strands in the ribbon may be
altered using the RasMol
<a href="setstr.html"><tt><b>set strands</b></tt></a>
command.
<p>
The width of the ribbon at each position is determined by the optional
parameter in the usual RasMol units. By default the width of the ribbon
is taken from the secondary structure of the protein or a constant value
of 720 for nucleic acids (which produces a ribbon 2.88 Angstroms wide).
The default width of protein alpha helices and beta sheets is 380 (1.52
Angstroms) and 100 (0.4 Angstroms) for turns and random coil. The
secondary structure assignment is either from the PDB file or calculated
using the DSSP algorithm as used by the
<a href="struct.html"><tt><b>structure</b></tt></a>
command. This command is similar to the RasMol command
<a href="ribbons.html"><tt><b>ribbons</b></tt></a>
which renders the biomolecular ribbon as a smooth shaded surface.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-228</DOCNO>
<DOCOLDNO>IA057-000937-B015-123</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/hetero.html 193.128.22.20 19970109090746 text/html 1024
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:57:53 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 834
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Hetero Set</font></h2><p>
This set contains all the heterogenous atoms in the molecule. These
are the atoms described by HETATM entries in the PDB file. These
typically contain water, cofactors and other solvents and ligands. All
<tt><b>hetero</b></tt>
atoms are classified as either
<a href="ligand.html"><tt><b>ligand</b></tt></a>
or
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms. These heterogenous
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms are further classified as either
<a href="water.html"><tt><b>water</b></tt></a>
or
<a href="ionsset.html"><tt><b>ions.</b></tt></a>

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-229</DOCNO>
<DOCOLDNO>IA057-000937-B015-137</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/hydrog.html 193.128.22.20 19970109090756 text/html 632
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:58:09 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 442
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Hydrogen Set</font></h2><p>
This predefined set contains all the hydrogen and deuterium atoms
of the current molecule. This predefined set is equivalent to the
RasMol atom expression
"<tt><b>elemno=1</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-230</DOCNO>
<DOCOLDNO>IA057-000937-B014-284</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/write.html 193.128.22.20 19970109090157 text/html 1995
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:52:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:32 GMT
Content-length: 1804
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Write</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Write</font></h2><p>
<pre>
Syntax:  write {&lt;format&gt;} &lt;filename&gt;
</pre><p>
Write the current image to a file in a standard raster format. Currently
supported image file formats include
"<tt><b>gif</b></tt>"
(Compuserve GIF),
"<tt><b>ppm</b></tt>"
(Portable Pixmap),
"<tt><b>ras</b></tt>"
(Sun rasterfile),
"<tt><b>ps</b></tt>"
and
"<tt><b>epsf</b></tt>"
(Encapsulated PostScript),
"<tt><b>monops</b></tt>"
(Monochrome Encapsulated PostScript),
"<tt><b>bmp</b></tt>"
(Microsoft bitmap) and
"<tt><b>pict</b></tt>"
(Apple PICT). The
<tt><b>write</b></tt>
command may also be used to generate command scripts for other graphics
programs. The format
<tt><b>script</b></tt>
writes out a file containing the RasMol
<a href="script.html"><tt><b>script</b></tt></a>
commands to reproduce the current image. The format
<tt><b>molscript</b></tt>
writes out the commands required to render the current view of the
molecule as ribbons in Per Kraulis' Molscript program and the format
<tt><b>kinemage</b></tt>
the commands for David Richardson's program Mage.
<p>
The distinction between this command and the RasMol
<a href="save.html"><tt><b>save</b></tt></a>
command has been dropped. The only difference is that without a format
specifier the
<a href="save.html"><tt><b>save</b></tt></a>
command generates a
<tt><b>PDB</b></tt>
file and the
<tt><b>write</b></tt>
command generates a
<tt><b>GIF</b></tt>
image.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-231</DOCNO>
<DOCOLDNO>IA057-000937-B013-394</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/dots.html 193.128.22.20 19970109085303 text/html 1713
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:43:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1522
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Dots</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Dots</font></h2><p>
<pre>
Syntax:  dots {&lt;boolean&gt;}
         dots &lt;value&gt;
</pre><p>
The RasMol
<tt><b>dots</b></tt>
command is used to generate a Van der Waal's dot surface around the
currently selected atoms. Dot surfaces display regularly spaced points
on a sphere of Van der Waals' radius about each selected atom. Dots that
would are `buried' within the Van der Waal's radius of any other atom
(selected or not) are not displayed.
The command
<tt><b>dots on</b></tt>
deletes any existing dot surface and generates a dots surface around
the currently selected atom set with a default dot density of 100. The
command
<tt><b>dots off</b></tt>
deletes any existing dot surface. The dot density may be
specified by providing a numeric parameter between 1 and 1000. This
value approximately corresponds to the number of dots on the surface
of a medium sized atom.
<p>
By default, the colour of each point on a dot surface is the colour
of it's closest atom at the time the surface is generated. The colour
of the whole dot surface may be changed using the
<a href="colour.html"><tt><b>colour dots</b></tt></a>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-232</DOCNO>
<DOCOLDNO>IA057-000937-B014-208</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/slab.html 193.128.22.20 19970109090028 text/html 927
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:50:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 737
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Slab</font></h2><p>
<pre>
Syntax:  slab {&lt;boolean&gt;}
         slab &lt;value&gt;
</pre><p>
The RasMol
<tt><b>slab</b></tt>
command enables, disables or positions the z-clipping plane of the
molecule. The program only draws those portions of the
molecule that are further from the viewer than the slabbing plane.
Values range  from zero at the very back of the molecule to
100 which is completely in front of the molecule. Intermediate values
determine the percentage of the molecule to be drawn.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-233</DOCNO>
<DOCOLDNO>IA057-000937-B014-220</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/ssbonds.html 193.128.22.20 19970109090052 text/html 1758
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:50:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 1567
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>SSBonds</font></h2><p>
<pre>
Syntax:  ssbonds {&lt;boolean&gt;}
         ssbonds &lt;value&gt;
</pre><p>
The RasMol
<tt><b>ssbonds</b></tt>
command is used to represent the disulphide bridges of the protein
molecule as either dotted lines or cylinders between the connected
cysteines. The first time that the
<tt><b>ssbonds</b></tt>
command is used, the program searches the structure of the protein to
find half-cysteine pairs (cysteines whose sulphurs are within 3 angstroms
of each other) and reports the number of bridges to the user. The command
<tt><b>ssbonds on</b></tt>
displays the selected `bonds' as dotted lines, and the command
<tt><b>ssbonds off</b></tt>
disables the display of ssbonds in the currently selected area. Selection
of disulphide bridges is identical to normal bonds, and may be adjusted
using the RasMol
<a href="setbond.html"><tt><b>set bondmode</b></tt></a>
command. The colour of disulphide bonds may be changed using the
<a href="colour.html"><tt><b>colour ssbonds</b></tt></a>
command. By default, each disulphide bond has the colours of its connected
atoms.
<p>
By default disulphide bonds are drawn between the sulphur atoms within
the cysteine groups. By using the
<a href="setssbd.html"><tt><b>set ssbonds</b></tt></a>
command the position of the cysteine's alpha carbons may be used instead.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-234</DOCNO>
<DOCOLDNO>IA057-000937-B014-190</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/show.html 193.128.22.20 19970109090001 text/html 1066
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:50:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 876
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Show</font></h2><p>
<pre>
Syntax:  show information
         show sequence
         show symmetry
</pre><p>
The RasMol
<tt><b>show</b></tt>
command display details of the status of the currently
loaded molecule. The command
<tt><b>show information</b></tt>
lists the molecule's name,
classification, PDB code and the number of atoms, chains, groups it contains.
If hydrogen bonding, disulphide bridges or secondary structure have been
determined, the number of hbonds, ssbonds, helices, ladders and turns
are also displayed respectively. The command
<tt><b>show sequence</b></tt>
lists the residues that compose each chain of the molecule.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-235</DOCNO>
<DOCOLDNO>IA057-000937-B014-264</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/wire.html 193.128.22.20 19970109090132 text/html 1390
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:51:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:32 GMT
Content-length: 1199
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Wireframe</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Wireframe</font></h2><p>
<pre>
Syntax:  wireframe {&lt;boolean&gt;}
         wireframe &lt;value&gt;
</pre><p>
The RasMol
<tt><b>wireframe</b></tt>
command represents each bond within the selected region of the molecule
as either a cylinder, a line or depth-cued vector. The display of bonds
as depth-cued vectors (drawn darker the further away from the viewer)
is turned on by the command
<tt><b>wireframe</b></tt>
or
<tt><b>wireframe on.</b></tt>
The selected bonds are displayed as cylinders by specifying a radius
either as an integer in RasMol units or containing a decimal point as
a value in Angstroms.  A parameter value of 500 (2.0 angstroms) or
above results in an "Parameter value too large" error. Bonds may be
coloured using the
<a href="colour.html"><tt><b>colour bonds</b></tt></a>
command.

<p>
</UL><a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-236</DOCNO>
<DOCOLDNO>IA057-000937-B013-379</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/space.html 193.128.22.20 19970109085251 text/html 1916
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:42:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 1725
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Spacefill</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4> <a href="../"><img 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Spacefill</font></h2><p>
<pre>
Syntax:  spacefill {&lt;boolean&gt;}
         spacefill temperature
         spacefill user
         spacefill &lt;value&gt;
</pre><p>
The RasMol
<tt><b>spacefill</b></tt>
command is used to represent all of the currently selected atoms as solid
spheres. This command is used to produce both union-of-spheres and
ball-and-stick models of a molecule. The command,
<tt><b>spacefilll true,</b></tt>
the default, represents each atom as a sphere of Van der Waals radius.
The command
<tt><b>spacefill off</b></tt>
turns off the representation of the selected atom as spheres. A sphere
radius may be specified as an integer in RasMol units (1/250th Angstrom)
or a value containing a decimal point. A value of 500 (2.0
Angstroms) or greater results in a "Parameter value too large" error.
<p>
The
<tt><b>temperature</b></tt>
option sets the radius of each sphere to the value stored in its temperature
field. Zero or negative values causes have no effect and values greater than
2.0 are truncated to 2. The
<tt><b>user</b></tt>
option allows the radius of each spheres to be specified by additional lines
in the molecule's PDB file using Raster 3D's COLOR record extension.
<p>
The RasMol command
<tt><b>cpk</b></tt>
is synonymous with the
<tt><b>spacefill</b></tt>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-237</DOCNO>
<DOCOLDNO>IA057-000937-B015-476</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/cpkcol.html 193.128.22.20 19970109091412 text/html 1355
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:04:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1164
Content-type: text/html
</DOCHDR>
<html><head>
<title>RasMol Manual: CPK Colours</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 

<basefont size=4> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>CPK Colours</font></h2><p>
The RasMol
<tt><b>cpk</b></tt>
colour scheme is based upon the colours of the popular plastic
spacefilling models which were developed by Corey, Pauling and later
improved by Kultun. This colour scheme colour `atom' objects by the
atom (element) type. This is the scheme conventionally used by chemists.
The assignment of element type to colours is given below.
<p>
<pre>
    Carbon       light grey       Chlorine         green
    Oxygen       red              Bromine, Zinc    brown
    Hydogen      white            Sodium           blue
    Nitrogen     light blue       Iron             purple
    Sulphur      yellow           Calcium, Metals  dark grey
    Phosphorous  orange           Unknown          deep pink
</pre>

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-238</DOCNO>
<DOCOLDNO>IA057-000937-B015-495</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/aminocol.html 193.128.22.20 19970109091430 text/html 1496
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:04:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 1305
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Amino Colours</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont size=4> <a 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<h2><font size=6>Amino Colours</font></h2><p>
The RasMol
<tt><b>amino</b></tt>
colour scheme colours amino acids according to traditional amino acid
properties. The purpose of colouring is to identify amino acids in an
unusual or surprising environment. The outer parts of a protein that are
polar are visible (bright) colours and non-polar residues darker. Most
colours are hallowed by tradition. This colour scheme is similar to the
<a href="shapcol.html"><tt><b>shapely</b></tt></a>
scheme.
<p>
<pre>
   ASP,GLU bright red [230,10,10]     CYS,MET     yellow [230,230,0]
   LYS,ARG blue       [20,90,255]     SER,THR     orange [250,150,0]
   PHE,TYR mid blue   [50,50,170]     ASN,GLN     cyan   [0,220,220]
   GLY     light grey [235,235,235]   LEU,VAL,ILE green  [15,130,15]
   ALA     dark grey  [200,200,200]   TRP         pink   [180,90,180]
   HIS     pale blue  [130,130,210]   PRO         flesh  [220,150,130]
</pre>

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-239</DOCNO>
<DOCOLDNO>IA057-000937-B015-539</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/chain.html 193.128.22.20 19970109091529 text/html 846
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:05:02 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 656
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Chain Colours</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Chain Colours</font></h2><p>
The RasMol
<tt><b>chain</b></tt>
colour scheme assigns each macromolecular chain a unique colour. This
colour scheme is particularly useful for distinguishing the parts of
multimeric structure or the individual `strands' of a DNA chain.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-240</DOCNO>
<DOCOLDNO>IA057-000937-B015-556</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/group.html 193.128.22.20 19970109091621 text/html 1128
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:06:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 938
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Group Colours</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Group Colours</font></h2><p>
The RasMol
<tt><b>group</b></tt>
colour scheme colour codes residues by their position in a macromolecular
chain. Each chain is drawn as a smooth spectrum from blue through green,
yellow and orange to red. Hence the N terminus of proteins and 5' terminus
of nucleic acids are coloured red and the C terminus of proteins and 3'
terminus of nucleic acids are drawn in blue. If a chain has a large number
of heterogenous molecules associated with it, the macromolecule may not be
drawn in the full `range' of the spectrum.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-241</DOCNO>
<DOCOLDNO>IA057-000937-B015-571</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/shapcol.html 193.128.22.20 19970109091636 text/html 1022
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:06:48 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 832
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Shapely Colours</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Shapely Colours</font></h2><p>
The RasMol
<tt><b>shapely</b></tt>
colour scheme colour codes residues by amino acid property. This scheme
is based upon Bob Fletterick's "Shapely Models". Each amino acid and
nucleic acid residue is given a unique colour. The
<tt><b>shapely</b></tt>
colour scheme is used by David Bacon's Raster3D program. This colour
scheme is similar to the
<a href="aminocol.html"><tt><b>amino</b></tt></a>
colour scheme.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-242</DOCNO>
<DOCOLDNO>IA057-000937-B015-584</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/struccol.html 193.128.22.20 19970109091646 text/html 1027
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:06:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 837
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Structure Colours</font></h2><p>
The RasMol
<tt><b>structure</b></tt>
colour scheme colours the molecule by protein secondary structure.
Alpha helices are coloured magenta, [240,0,128], beta sheets are
coloured yellow, [255,255,0], turns are coloured pale blue, [96,128,255]
and all other residues are coloured white. The secondary structure
is either read from the PDB file (HELIX and SHEET records), if available,
or determined using Kabsch and Sander's DSSP algorithm. The RasMol
<a href="struct.html"><tt><b>structure</b></tt></a>
command may be used to force DSSP's structure assignment to be used.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-243</DOCNO>
<DOCOLDNO>IA057-000937-B016-4</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/tempcol.html 193.128.22.20 19970109091656 text/html 1213
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:07:08 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 1022
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Temperature Colours</font></h2><p>
The RasMol
<tt><b>temperature</b></tt>
colour scheme colour codes each atom according to the anisotropic
temperature (beta) value stored in the PDB file. Typically this gives
a measure of the mobility/uncertainty of a given atom's position. High
values are coloured in warmer (red) colours and lower values in colder
(blue) colours. This feature is often used to associate a "scale" value
[such as amino acid variability in viral mutants] with each atom in a
PDB file, and colour the molecule appropriately.
<p>
The difference between the
<tt><b>temperature</b></tt>
and
<a href="charcol.html"><tt><b>charge</b></tt></a>
colour schemes is that increasing temperature values proceed from blue
to red, whereas increasing charge valuse go from red to blue.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-244</DOCNO>
<DOCOLDNO>IA057-000937-B016-26</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/charcol.html 193.128.22.20 19970109091713 text/html 1474
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:07:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 1283
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Charge Colours</font></h2><p>
The RasMol
<tt><b>charge</b></tt>
colour scheme colour codes each atom according to the charge value
stored in the input file (or beta factor field of PDB files). High
values are coloured in blue (positive) and lower values coloured in
red (negative). Rather than use a fixed scale this scheme determines
the maximum and minimum values of the charge/temperature field and
interpolates from red to blue appropriately. Hence, green cannot be
assumed to be `no net charge' charge.
<p>
The difference between the
<a href="charcol.html"><tt><b>charge</b></tt></a>
and
<tt><b>temperature</b></tt>
colour schemes is that increasing temperature values proceed from blue
to red, whereas increasing charge valuse go from red to blue.
<p>
If the charge/temperature field stores reasonable values it is possible
to use the RasMol
<a href="potent.html"><tt><b>colour dots potential</b></tt></a>
command to colour code a dot surface (generated by the
<a href="dots.html"><tt><b>dots</b></tt></a>
command) by electrostatic potential.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-245</DOCNO>
<DOCOLDNO>IA057-000937-B016-37</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/usercol.html 193.128.22.20 19970109091722 text/html 863
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:07:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 673
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: User Colours</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>User Colours</font></h2><p>
The RasMol
<tt><b>user</b></tt>
colour scheme allows RasMol to use the colour scheme stored in the
PDB file. The colours for each atom are stored in COLO records placed
in the PDB data file. This convention was introduced by David Bacon's
Raster3D program.

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-246</DOCNO>
<DOCOLDNO>IA057-000937-B016-50</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/hbondtyp.html 193.128.22.20 19970109091730 text/html 1324
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:07:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1133
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>HBond Type Colours</font></h2><p>
The RasMol
<tt><b>type</b></tt>
colour scheme applies only to hydrogen bonds, hence is used in the command
"<tt><b>colour hbonds type</b></tt>"
This scheme colour codes each hydrogen bond according to the
distance along a protein chain between hydrogen bond donor and acceptor.
This schematic representation was introduced by Belhadj-Mostefa and
Milner-White. This representation gives a good insight into protein
secondary structure (hbonds forming alpha helices appear red, those
forming sheets appear yellow and those forming turns appear magenta).
<p>
<pre>
      Offset    Colour    Triple
        +2      white     [255,255,255]
        +3      magenta   [255,0,255]
        +4      red       [255,0,0]
        +5      orange    [255,165,0]
        -3      cyan      [0,255,255]
        -4      green     [0,255,0]
      default   yellow    [255,255,0]
</pre>

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-247</DOCNO>
<DOCOLDNO>IA057-000937-B016-65</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/potent.html 193.128.22.20 19970109091746 text/html 2946
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:07:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 2755
Content-type: text/html
</DOCHDR>
<html><head>
<title>RasMol Manual: Potential Colours</title></head>
<body 
background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont size=4> <a href="../"><img src="../icon.gif" border=0 align=left></a> <br 
clear=left>
<ul><ul><ul><ul>
<ul><ul type=disc>
<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br> 

<h2><font size=6>Potential Colours</font></h2><p>
The RasMol
<tt><b>potential</b></tt>
colour scheme applies only to dot surfaces, hence is used in the command
"<tt><b>colour dots potential</b></tt>"
This scheme colours each currently displayed dot by the electrostatic 
potential at that point in space. This potential is calculated using   
Coulomb's law taking the temperature/charge field of the input file to 
be the charge assocated with that atom. This is the same interpretation
used by the
<a href="charcol.html"><tt><b>colour charge</b></tt></a>
command. Like the
<a href="charcol.html"><tt><b>charge</b></tt></a>
colour scheme low values are blue/white and high values are red.
The table below shows the static assignment of colours using a
dielectric constant value of 10.
<p>  
<pre>
     25 < V          red       [255,0,0]  
     10 < V <  25    orange    [255,165,0]
      3 < V <  10    yellow    [255,255,0]
      0 < V <   3    green     [0,255,0]  
     -3 < V <   0    cyan      [0,255,255] 
    -10 < V <   3    blue      [0,0,255]    
    -25 < V < -10    purple    [160,32,240] 
          V < -25    white     [255,255,255]
</pre>

 <h2><font size=6>Potential Colours</font></h2><p>
The RasMol
<tt><b>potential</b></tt>
colour scheme applies only to dot surfaces, hence is used in the command
"<tt><b>colour dots potential</b></tt>"
This scheme colours each currently displayed dot by the electrostatic
potential at that point in space. This potential is calculated using
Coulomb's law taking the temperature/charge field of the input file to
be the charge assocated with that atom. This is the same interpretation
used by the
<a href="charcol.html"><tt><b>colour charge</b></tt></a>
command. Like the
<a href="charcol.html"><tt><b>charge</b></tt></a>
colour scheme low values are blue/white and high values are red.
The table below shows the static assignment of colours using a
dielectric constant value of 10.
<p>
<pre>
     25 < V          red       [255,0,0]
     10 < V <  25    orange    [255,165,0]
      3 < V <  10    yellow    [255,255,0]
      0 < V <   3    green     [0,255,0]
     -3 < V <   0    cyan      [0,255,255]
    -10 < V <   3    blue      [0,0,255]
    -25 < V < -10    purple    [160,32,240]
          V < -25    white     [255,255,255]
</pre>
<p>

<p>
<a href="chcolour.html">Colour schemes</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-248</DOCNO>
<DOCOLDNO>IA057-000937-B014-243</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/struct.html 193.128.22.20 19970109090112 text/html 977
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:51:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 787
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Structure</font></h2><p>
<pre>
Syntax:  structure
</pre><p>
The RasMol
<tt><b>structure</b></tt>
command calculates secondary structure assignments
for the currently loaded protein. If the original PDB file contained
structural assignment records (HELIX and SHEET) these are discarded.
Initially, the hydrogen bonds of the current molecule are found, if this
hasn't been done already. The secondary structure is the determined using
Kabsch and Sander's DSSP algorithm. Once finished the program reports the
number of helices, strands and turns found.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-249</DOCNO>
<DOCOLDNO>IA057-000937-B015-196</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/ligand.html 193.128.22.20 19970109090846 text/html 829
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:58:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 639
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Ligand Set</font></h2><p>
This set contains all the heterogenous cofactor and ligand moieties that
are contained in the current molecule data file. At this set is defined
to be all
<a href="hetero.html"><tt><b>hetero</b></tt></a>
atoms that are not
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms. Hence this set is equivalent to the RasMol atom expression
"<tt><b>hetero and not solvent</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-250</DOCNO>
<DOCOLDNO>IA057-000937-B015-387</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/solvent.html 193.128.22.20 19970109091219 text/html 1047
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:02:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 857
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Solvent Set</font></h2><p>
This set contains the solvent atoms in the molecule co-ordinate file.
These are the heterogenous water molecules, phosphate and sulphate
ions. All
<a href="hetero.html"><tt><b>hetero</b></tt></a>
atoms are classified as either
<a href="ligand.html"><tt><b>ligand</b></tt></a>
or
<tt><b>solvent</b></tt>
atoms. All
<tt><b>solvent</b></tt>
atoms are classified as either
<a href="water.html"><tt><b>water</b></tt></a>
or
<a href="ionsset.html"><tt><b>ions.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>hetero and not ligand</b></tt>"
and
"<tt><b>water or ions</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-251</DOCNO>
<DOCOLDNO>IA057-000937-B015-456</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/water.html 193.128.22.20 19970109091332 text/html 1227
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:03:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 1036
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Water Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Water Set</font></h2><p>
This set contains all the heterogenous water molecules in the current
database. A large number of water molecules are sometimes associated
with protein and nucleic acid structures determined by X-ray
crystallography. These atoms tend to clutter an image.
All
<a href="hetero.html"><tt><b>hetero</b></tt></a>
atoms are classified as either
<a href="ligand.html"><tt><b>ligand</b></tt></a>
or
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms. The
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms are further classified as either
<tt><b>water</b></tt>
or
<a href="ionsset.html"><tt><b>ions.</b></tt></a>

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-252</DOCNO>
<DOCOLDNO>IA057-000937-B015-160</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/ionsset.html 193.128.22.20 19970109090818 text/html 1232
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:58:30 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 1041
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Ions Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Ions Set</font></h2><p>
This set contains all the heterogenous phosphate and sulphate ions in
the current molecule data file. A large number of these ions are
sometimes associated with protein and nucleic acid structures determined
by X-ray crystallography. These atoms tend to clutter an image. All
<a href="hetero.html"><tt><b>hetero</b></tt></a>
atoms are classified as either
<a href="ligand.html"><tt><b>ligand</b></tt></a>
or
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms. All
<a href="solvent.html"><tt><b>solvent</b></tt></a>
atoms are classified as either
<a href="water.html"><tt><b>water</b></tt></a>
or
<tt><b>ions.</b></tt>

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-253</DOCNO>
<DOCOLDNO>IA057-000937-B014-145</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/script.html 193.128.22.20 19970109085912 text/html 1757
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:49:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1566
Content-type: text/html
</DOCHDR>
<html><head>
<title>RasMol Manual: Script</title>

</head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">

<basefont size=4>
<a href="../"><img src="../icon.gif" border=0 align=left></a> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Script</font></h2><p>
<pre>
Syntax:  script &lt;filename&gt;
</pre><p>
The RasMol
<tt><b>script</b></tt>
command reads a set of RasMol commands sequentially from a
text file and executes them. This allows sequences of commonly used
commands to be stored and performed by single command. A RasMol script
file may contain a further script command up to a maximum "depth" of 10,
allowing compilicated sequences of actions to be executed. RasMol
ignores all characters after the first '#' character on each line
allowing the scripts to be annotated. Script files are often also
annotated using the RasMol
<a href="echo.html"><tt><b>echo</b></tt></a>
command.
<p>
The most common way to generate a RasMol script file is to use the
<a href="write.html"><tt><b>write script</b></tt></a>
or
<a href="write.html"><tt><b>write rasmol</b></tt></a>
commands to output the sequence of commands that are needed to
regenerate the current view, representation and colouring of the
currently displayed molecule.
<p>
The RasMol command
<tt><b>source</b></tt>
is synonymous with the
<tt><b>script</b></tt>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-254</DOCNO>
<DOCOLDNO>IA057-000937-B014-135</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/save.html 193.128.22.20 19970109085859 text/html 1005
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:49:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 815
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Save</font></h2><p>
<pre>
Syntax:  save {pdb} &lt;filename&gt;
         save alchemy &lt;filename&gt;
</pre><p>
Save the currently selected set of atoms in either a Brookhaven Protein
Database (PDB) or Alchemy(tm) format file.
The distinction between this command and the RasMol
<a href="write.html"><tt><b>write</b></tt></a>
command has been dropped. The only difference is that without a format
specifier the
<tt><b>save</b></tt>
command generates a
<tt><b>PDB</b></tt>
file and the
<a href="write.html"><tt><b>write</b></tt></a>
command generates a
<tt><b>GIF</b></tt>
image.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-255</DOCNO>
<DOCOLDNO>IA057-000937-B013-417</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/echo.html 193.128.22.20 19970109085321 text/html 1053
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:43:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 863
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Echo</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Echo</font></h2><p> <pre>
Syntax:  echo {&lt;string&gt;}
</pre><p>
The RasMol
<tt><b>echo</b></tt>
command is used to display a message in the RasMol command/terminal
window. The string parameter may optionally be delimited in double
quote characters. If no parameter is specified, the
<tt><b>echo</b></tt>
command displays a blank line. This command is particularly useful
for displaying text from within a RasMol
<a href="script.html"><tt><b>script</b></tt></a>
file.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-256</DOCNO>
<DOCOLDNO>IA057-000937-B023-152</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/index.html 193.128.22.20 19970109102049 text/html 2654
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:11:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:58 GMT
Content-length: 2463
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB</font></h1>
<hr size=4>

<h2><font size=6>Action TB News</font></h2>

<font size=5>Articles from the second issue of Action TB News:</font>
<p>
<dl>
<dt><a href="art1.html">Therapy made to measure</a>
<dd>Professor Paul van Helden, University of Stellenbosch<p>

<dt><a href="art2.html">Asp protects against killing</a>
<dd>Dr Ken Duncan, Glaxo Wellcome Research and Development, Stevenage<p>

<dt><a href="art3.html">Two to replicate</a>
<dd>Dr Neil Stoker, London School of Hygiene & Tropical Medicine<p>

<dt><a href="art4.html">Rapping out novel genes</a>
<dd>Dr Claire Spreadbury, University of Birmingham<p>

<dt><a href="art5.html">Stepping toward targeted drug design</a>
<dd>Dr Richard Stokes, University of British Columbia<p>

<dt><a href="art6.html">Communication as a protection strategy</a>
<dd>Dr Julian Davies, University of British Columbia<p>

<dt><a href="art7.html">TB protein holds prickly solutions</a>
<dd>Dr Lafras Steyn, University of Cape Town<p>

<dt><a href="art8.html">Host immune failure in tuberculosis</a>
<dd>Professor Stan Ress, Groote Shuur Hospital, Cape Town<p>

<dt><a href="art9.html">TB's sweet sites</a>
<dd>Dr Malcom Ward, Glaxo Wellcome Research & Development, Stevenage
<p>

</dl>
<p>
<a href="../news.html">Return to: Action TB News contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-257</DOCNO>
<DOCOLDNO>IA057-000937-B016-532</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art1.html 193.128.22.20 19970109092623 text/html 4544
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:16:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:57 GMT
Content-length: 4353
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Therapy made to measure</font></h2>

<font size=5>Screening for drug metabolism rate may lead to tailored therapy<p>Customising therapy for individual patients could, in future, reduce the number of drug resistant TB strains. A large number of multi-drug resistant (MDR) strains are only moderately resistant to current therapy and increasing the dose of antibiotic given could wipe out these TB strains. However, toxicity can be just as harmful to a patient as resistance.</font><p>

Using molecular biology techniques for genotyping, patients can be classified according to how quickly they metabolise isoniazid (INH) (e.g. fast, medium, slow).  Every time the drug is administered to a patient, the drug concentration found in the patient's serum initially rises, but this is followed by a decline at a rate dictated by the patient's metabolism. Understanding a patient's drug metabolic rate will, therefore, help predict the length of time the antibiotic remains in the system above the minimum inhibitory concentration (the level required to kill the mycobacteria). If the drug level is inadequate, treatment will be unsuccessful and the strain of TB will appear to be resistant.<p>


In some patients, considered to be infected with an INH-resistant strain of TB, the organism is found to be highly sensitive to INH. These patients have metabolised the antibiotic before it has killed the mycobacteria. This is a dangerous situation; not only is the patient receiving inadequate treatment, but the mycobacteria are being exposed to low levels of drug which may stimulate it to develop resistance, thereby making it more difficult to treat in the longer term.<p>
 

When it comes to combination therapy, this can be particularly dangerous. Consider a fast metaboliser of INH who is treated with INH and rifampicin (RIF). In this case, the mycobacteria are effectively only exposed to RIF as a monotherapy, which inevitably leads to RIF resistance. As treatment continues the RIF-resistant mycobacteria are then exposed to an inadequate dose of INH and develop additional INH resistance, effectively becoming multi-drug resistant, despite "correct" therapy. <p>


Screening patients could prevent an individual with a high metabolic rate receiving too low a dose of antibiotics. Similarly screening could prevent administration of high levels of drugs to slow metabolisers, potentially leading to unpleasant side effects. Genotyping provides metabolic classification in hours and initial studies have shown a greater than 97% success rate.<p>


In the future, molecular diagnostic tests could be used to identify drug-resistant TB strains rapidly. When combinined with metabolic genotyping of the patient, doctors may be able to customise treatment to an individual patient. This would help prevent further development of drug-resistant strains of TB.<p>

For more information contact:<p>

Professor Paul Van Helden <br>
University of Stellenbosch, South Africa.<p>

Tel: +27 21 938 9401<p>

<a href="art2.html">Forward to: Asp protects against killing</a><p>

<a href="index.html">Return to: Action TB News issue two contents page</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-258</DOCNO>
<DOCOLDNO>IA057-000937-B016-559</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art2.html 193.128.22.20 19970109092650 text/html 4235
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:17:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:57 GMT
Content-length: 4044
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Asp protects against killing</font></h2>

<font size=5>Key amino acid substitution protects mycobacteria<p>A recent study by researchers at Glaxo Wellcome is challenging our current understanding of the reaction mechanism of a key peptidoglycan enzyme.</font><p>


Peptidoglycan is essential for the integrity of the bacterial cell wall, and many antibiotics, including fosfomycin (fos), act by disrupting its synthesis. Fos targets the enzyme that catalyses the first committed step in peptidoglycan synthesis, UDP-N-acetylglucosamine enolpyruvyl transferase. Although active against many bacteria, including <i>E. coli</i>, fos is not active against <i>M. tuberculosis</i>.<p>


When isolated, UDP-N-acetylglucosamine enolpyruvyl transferase from <i>E. coli</i> has a molecule of the natural substrate, phosphoenol-pyruvate (PEP), tethered to the active site cysteine residue which suggests that the reaction pathway proceeds via this covalent intermediate. Fos inactivates the <i>E. coli</i> enzyme by covalently binding to the same cysteine residue preventing it from forming a complex with PEP.<p>


The Glaxo Wellcome team cloned the gene from <i>M. tuberculosis</i> that codes for this enzyme. After sequencing the gene, they found that the encoded protein has 45% overall similarity with its <i>E. coli</i> counter-part. However, the <i>M. tuberculosis</i> protein has an aspartate residue in the key position occupied by the cysteine residue in the <i>E. coli</i> protein. Fos cannot form a covalent complex with the aspartate residue, and this may explain why the antibiotic is not effective against mycobacteria.<p>


In collaboration, researchers at Harvard Medical School then constructed an 
<i>E. coli</i> mutant that would mimic the mycobacterial enzyme (i.e. with an aspartate residue in place of the cysteine residue); this mutant was active. As expected, when the mutant enzyme was isolated there was no PEP bound to the active site. This finding challenges the previous notion that a covalent intermediate is formed as part of the normal reaction pathway of the enzyme. In addition, detailed biochemical studies with the mutant protein suggest that the active site residue (aspartate or cysteine) is a general acid in catalysis, a role not previously proposed for this residue.<p>


Fos is a natural product produced by streptomyces, a soil organism. Since most mycobacteria live in soil, mycobacteria may have evolved the aspartate substitution as a protection mechanism.<p>


For more information contact:<p>


Dr Ken Duncan <br>

Glaxo Wellcome Research & Development<br>
Stevenage, UK<p>
 
Tel: +44 1438 763841<p>

<a href="art3.html">Forward to: Two to replicate</a><p>
<a href="art1.html">Back to: Therapy made to measure</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-259</DOCNO>
<DOCOLDNO>IA057-000937-B016-570</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art3.html 193.128.22.20 19970109092659 text/html 4690
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:17:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:57 GMT
Content-length: 4499
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Two to replicate</font></h2>

<font size=5>Plasmid replication studies may help target identification<p>Researchers at the London School of Hygiene &amp; Tropical Medicine in the UK have made significant progress in understanding how plasmids replicate in mycobacteria; until now, little had been known about the machinery involved.</font><p>


For many years, plasmids have been used as a means of delivering interrupted genes. This allowed the importance of individual gene products to be assessed. These so called "gene knock out studies" have allowed researchers to assess quickly the potential of novel targets for drug discovery. <p>


Such studies have not been possible in mycobacteria, greatly delaying the validation of potential drug targets. A better understanding of mycobacterial plasmids may lead to the development of better delivery systems for gene knock-out studies.<p>


The researchers identified two genes in the plasmid pAL5000, repA and repB, close to the origin of replication. The products of these genes, the RepA and RepB proteins, are required for plasmid replication. RepA is highly similar to a class of replication initiation proteins from plasmids found in other bacteria, such as <i>E. coli</i>. RepB, however, shows no significant similarity to any proteins of known function in the GenBank database. Further studies suggest that RepB may regulate its own transcription as well as regulating plasmid replication.<p>


The findings suggest a novel mechanism for triggering replication of pAL5000: so called "high affinity" binding sites on the plasmid molecule may sequester RepB, preventing it from triggering plasmid replication until all high affinity sites are full. Once these sites are full, RepB will bind to the low affinity site that initiates plasmid replication, thus generating a new set of high affinity sites. However, since RepB also seems to regulate its own synthesis, once all high affinity sites are full, there will be competition between RepB binding to its own transcription site and halting gene expression and RepB binding to the plasmid replication site and triggering replication. <p>


The researchers hope that these findings will enable techniques to be developed that will allow gene knock out studies to be undertaken in slow growing mycobacteria, such as <i>M. tuberculosis</i>.<p>


One possible approach would be to use a system whereby plasmid A contains the genes required for plasmid replication and plasmid B contains an antibiotic resistance gene but lacks one of the replication genes. Both plasmids are then required for mycobacterial growth in the presence of antibiotic. After recombination between the plasmid and host genome has occurred, antibiotic can be removed from the growth media and both plasmids will quickly disappear.<p>

For more information contact:<p>

Dr Neil Stoker<br>
London School of Hygiene & Tropical Medicine<br>
<a href="http://www.lshtm.ac.uk/">(http://www.lshtm.ac.uk)</a><p>

Tel: +44 171 927 2425<br>
e-mail: <a href="mailto:n.stoker@lshtm.ac.uk">n.stoker@lshtm.ac.uk</a><p>

<a href="art4.html">Forward to: Rapping out novel genes</a><p>
<a href="art2.html">Back to: Asp protects against killing</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-260</DOCNO>
<DOCOLDNO>IA057-000937-B016-604</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art4.html 193.128.22.20 19970109092749 text/html 3535
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:17:53 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:57 GMT
Content-length: 3344
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Rapping out novel genes</font></h2>

<font size=5>New technology identifies key genes<p>Identifying genes that are selectively expressed by mycobacteria during intracellular infection of macrophages could lead to novel approaches to drug therapy. Such genes could lead to the identification of virulence factors, approaches to blocking macrophage infection or to gene products that allow the mycobacteria to remain undetected by the host immune system. </font><p>

Research underway in the UK using a new technique has already identified genes induced during intracellular infection. The genes were identified by using the RNA arbitrarily primed polymerase chain reaction (RAP-PCR). Following a short culture period, researchers randomly amplify RNA from four samples: <p>

<ul type=disc>

<li>macrophages infected with <i>M. tuberculosis</i><p>

<li>macrophages infected with latex beads<p>

<li><i>M. tuberculosis</i> growing in tissue culture media <p>

<li><i>M. tuberculosis</i> growing in standard broth <p>
</ul>

This allows them to detect genes that are differentially expressed during infection. Genes expressed by the intracellular mycobacteria are identified by a process of elimination - they are the genes that are not expressed by the three groups of control cells.  <p>


A similar technique is also being used to detect macrophage genes that are selectively expressed during mycobacterial infection as well as identifying macrophage genes that appear to be down regulated during mycobacterial infection. Identifying these genes may lead to an understanding of how mycobacteria escape killing by the macrophage, thereby enabling them to reside for prolonged periods unaffected by the immune system. <p>


For more information contact:<p>


Dr Claire Spreadbury<br>
University of Birmingham, UK<p>

Tel: +44 121 414 6975<br>
e-mail: <a href="mailto:c.l.spreadbury@bham.ac.uk">c.l.spreadbury@bham.ac.uk</a><p>

<a href="art5.html">Forward to: Stepping toward targeted drug design</a><p>
<a href="art3.html">Back to: Two to replicate</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-261</DOCNO>
<DOCOLDNO>IA057-000937-B016-640</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art5.html 193.128.22.20 19970109092822 text/html 3845
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:18:31 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:57 GMT
Content-length: 3654
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Stepping toward targeted drug design</font></h2>

<font size=5>Homologous recombination in mycobacteria<p>Understanding the function of specific genes is an essential step on the road to finding and validating new targets for drug design. Until recently tools have not been available to study the function of individual genes in pathogenic myco-bateria - a crucial step in the process. </font><p>


Researchers in Canada have, for the first time, used homologous recombination to disrupt an <i>M. intracellulare</i> gene. Homologous recombination has previously proved extremely difficult in mycobacteria, particularly slow growing pathogenic species, such as <i>M. tuberculosis</i>, and a number of approaches are being investigated to develop systems for routinely carrying it out. <p>


The researchers subcloned a fragment of the katG gene and introduced a frameshift mutation by using a fill in reaction. The katG gene codes for an inducible catalase-peroxidase, which is involved in isoniazid (INH) sensitivity. Disruption of the katG gene will produce bacteria that are INH resistant.<p>


The plasmid was introduced into <i>M. intracellulare</i>. The plasmid
contains a gentamicin cassette for selection and is not able to
replicate in mycobacteria or integrate into the chromosome, except by
homologous recombination. Some of the bacteria able to grow in the
presence of gentamicin were found to have incorporated DNA by a single
crossover event. After further growth in the absence of gentamicin,
bacteria able to grow in the presence of high concentrations of INH
were identified and shown to contain the mutated katG gene, created by
a second crossover event.<p>


Southern hybridisation confirmed that the four base pair insertion was responsible for the loss of activity. This technique will now be used by other Action TB researchers to study the function of enzymes that are potential drug targets.<p>

For more information contact:

Dr Richard Stokes<br>
University of British Columbia<br>
Vancouver, Canada<br>
<a href="http://cod.microbiology.ubc.ca/stokes.html">(http://cod.microbiology.ubc.ca/stokes.html)</a><p>


Tel: +1 604 875 2466<br>
e-mail: <a href="mailto:rstokes@cbdn.ca">rstokes@cbdn.ca</a><p>

<a href="art6.html">Forward to: Communication as a protection strategy</a><p>
<a href="art4.html">Back to: Rapping out novel genes</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-262</DOCNO>
<DOCOLDNO>IA057-000937-B017-12</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art6.html 193.128.22.20 19970109092904 text/html 3334
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:18:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:57 GMT
Content-length: 3143
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Communication as a protection strategy</font></h2>

<font size=5>Phosphorylation may protect mycobacteria from macrophage killing<p>Communication between mycobacteria and host cells may not be as far fetched as it would at first appear. In fact, a simple communication mechanism based on protein phosphorylation may be one of the strategies mycobacteria use to protect themselves from macrophages. </font><p>

Canadian Action TB researchers have found that <i>M. tuberculosis</i> secretes phosphorylated proteins. In eukaryotic cells, protein phosphorylation is a major mechanism whereby cells transmit signals that control cellular functions and secreted phosphorylated proteins are known to be involved in signal transduction. In the case of <i>M. tuberculosis</i>, these phosphorylated proteins may stop the host macrophage from acidifying the vacuoles containing the mycobacteria, the normal process used to kill ingested microorganisms. <p>


To date, two protein kinases have been identified - one phosphorylates on a tyrosine residue (tyrosine kinase) and another phosphorylates on a serine residue (serine/threonine kinase). Tyrosine kinases have, so far, only been found in pathogenic mycobacteria. Researchers believe that protein phosphorylation plays a role in TB infection. It has been shown that in Yersinia bacterial infections, protein phosphorylation is essential for virulence. The Canadian researchers are now exploring the function of these two proteins, as well as searching for additional components of signal transduction in mycobacteria.<p>


For more information contact:<p>


Dr Julian Davies<br>
University of British Columbia<br>
Vancouver, Canada<p>

Tel: +1 604 822 2501<p>


<a href="art7.html">Forward to: TB protein holds prickly solutions</a><p>
<a href="art5.html">Back to: Stepping toward targeted drug design</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-263</DOCNO>
<DOCOLDNO>IA057-000937-B017-35</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art7.html 193.128.22.20 19970109092946 text/html 3673
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:19:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:58 GMT
Content-length: 3482
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB protein holds prickly solutions</font></h2>

<font size=5>Selective expression after host infection<p>Proteins that are selectively expressed by <i>M. tuberculosis</i> during or after invasion of the host may prove to be useful diagnostic tools and may eventually lead to a better skin prick test. The identification of such proteins will also contribute to our understanding of the way in which 
<i>M. tuberculosis</i> causes disease and to the rational design of new improved vaccines.  One such protein, MPB83, has recently been identified by collaborating research groups in South Africa and the UK.</font><p>


MPB83 is highly immunogenic and may make a suitable single component skin prick test.  Such a test would offer advantages over the current, multicomponent test in terms of specificity since MPB83 is present in <i>M. tuberculosis</i> and a number of related organisms but is not present in non-pathogenic mycobacteria.<p>


Studies have shown that MPB83 is only expressed by <i>M. tuberculosis</i> after infection of the host, which may make it a useful marker of active infection.  The current skin prick test cannot distinguish between patients with active infection and those vaccinated with BCG - presenting clinicians with a real problem when it comes to diagnosing tuberculosis in patients who have been vaccinated.  This is a particular problem in areas where vaccination is routine. Since some strains of BCG express MPB83 at all times in culture it may be possible to design a test using this protein that would differentiate between the immune response to active infection and vaccination. <p>


The South African researchers are working in collaboration with a group led by 
Dr Glyn Hewinson from the Central Veterinary Laboratories Weybridge, UK. The CVL group are working on the development of a TB vaccine for animals and have a particular interest in MPB83 from <i>M. bovis</i>.<p>

For more information contact:<p>


Dr Lafras Steyn<br>
University of Cape Town<br>
South Africa<p>

Tel: +27 21 406 6389<p>


<a href="art8.html">Forward to: Host immune failure in tuberculosis</a><p>
<a href="art6.html">Back to: Communication as a protection strategy</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-264</DOCNO>
<DOCOLDNO>IA057-000937-B017-66</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art8.html 193.128.22.20 19970109093012 text/html 4106
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:20:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:58 GMT
Content-length: 3915
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Host immune failure in tuberculosis</font></h2>

<font size=5>T cells suppress immune response<p>Research carried out in South Africa may lead to an alternative therapy that will specifically stimulate the immune system to combat <i>M. tuberculosis</i> infection better.</font><p>

Protective cell-mediated immunity against intracellular pathogens (including mycobacteria, fungi and viruses) is mediated by a type 1 helper CD4+ T cell response. Susceptibility to intracellular infections is often characterised by a type 2 helper CD4+ T cell response, which normally mediates antibody production and allergy. Type 2 helper T cells can suppress the function of type 1 helper T cells and they have also been shown to play a role in the immunosuppression which features prominently in diseases such as lepromatous leprosy. The extent of type 2 helper T cell involvement in immunosuppression in other diseases, including tuberculosis, is not known.<p>


The T cell proliferative response to stimulation by mycobacterial antigens was examined in the peripheral blood of patients with advanced tuberculosis. This revealed a diminished type 1 T cell response relative to uninfected individuals, but at the same time did not show the dominant characteristics of a type 2 response. However, when T cells were derived from the site of disease 
(e.g. the lung), there was evidence for suppressor T cell activity. <p>


A suppressor T cell clone was characterised and found not to be a classic type 2 helper CD4+ T cell, but rather a type 2-like CD8+ T cell (CD8+ T cells are best known for their cytotoxic function). Cytokines interleukin-4 and interferon-gamma are produced by this clone, and it suppresses the 
<i>M. tuberculosis</i>-specific responses of peripheral blood T cells as well as that of a type 1 CD4+ helper T cell clone isolated from the same patient. Further experiments are being carried out to investigate the mechanism of this suppression.<p>


Immunotherapy directed at combating immunosuppression and enhancing the host's own immune response is an attractive approach to supplement conventional therapy for tuberculosis. By understanding the molecular mechanism whereby T cells mediate immuno-suppression, targets for novel immuno-therapies may also be identified.<p>

For more information contact:<p>


Professor Stan Ress <br>
Groote Shuur Hospital<br>
Cape Town, South Africa<p>

Tel: +27 21 406 6201<br>
e-mail: <a href="mailto:sress@uctgsh1.uct.ac.za">sress@uctgsh1.uct.ac.za</a><p>

<a href="art9.html">Forward to: TB's sweet sites</a><p>
<a href="art7.html">Back to: TB protein holds prickly solutions</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-265</DOCNO>
<DOCOLDNO>IA057-000937-B017-80</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news2/art9.html 193.128.22.20 19970109093021 text/html 3700
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:20:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:58 GMT
Content-length: 3509
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB's sweet sites</font></h2>

<font size=5>First bacterial N-linked glycosylation site found<p>For the first time, N-linked glycosylation has been found on the surface of a mycobacterial protein. This has never been seen in bacteria before, though it is common in higher organisms, such as mammals. Glycosylation is thought to play a key part in the interaction between mycobacteria and the host immune cells. For this reason, the enzymes involved in glycosylation are prime targets for drug discovery. Knowing the pattern of glycosylation present on the surface of 
<i>M. tuberculosis</i> will help researchers identify these targets.</font><p>


A recombinant 19KDa antigen from 
<i>M. tuberculosis</i> protein was expressed in <i>M. vaccae</i> by researchers at St Mary's Hospital in London, UK and then passed on to Glaxo Wellcome researchers for characterisation. <p>


After sequencing the protein, the researchers cut a tiny amount into 10 fragments, using the protease trypsin. Based on the protein sequence, the researchers were able to predict the molecular weight of each fragment and compare these to the actual molecular weights found by mass spectroscopy. <p>


Only minute quantities of protein were required for this analysis because the researchers used the new nanoelectrospray technique. Using this highly sensitive technique researchers can virtually spray one molecule at a time onto the mass spectrometer, enabling studies to be carried out on protein samples taken directly from 2-D electrophoresis gels. <p>


Peptide fragments that were heavier than expected were found to be glycosylated and these were analysed further to discover the type of glycosylation. The 
N-linked glycosylation site was found on an asparagine residue near the C-terminus of the protein. Additional O-linked glycosylation sites, which had previously been identified by genetic studies, were found near the N-terminus of the protein. <p>

For more information contact:<p>


Dr Malcom Ward<br>
Glaxo Wellcome Research & Development<br>
Stevenage, UK<p>

Tel: +44 1438 764857<br>
e-mail: <a href="mailto:maw7109@ggr.co.uk">maw7109@ggr.co.uk</a><p>

<a href="art8.html">Back to: Host immune failure in tuberculosis</a><p>
<a href="index.html">Return to: Action TB News issue two contents page</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-266</DOCNO>
<DOCOLDNO>IA057-000937-B017-213</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/trans.html 193.128.22.20 19970109093229 text/html 6440
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:22:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:24 GMT
Content-length: 6249
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30"> <basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Transcription</font></h2>

<p>
<font size=5>The goals of our research on gene regulation are to understand the mechanisms that lead to the specificity 
of gene regulation, how these different mechanisms interact and to determine the points of potential therapeutic intervention in gene transcription.</font><p>
One part of our work is focused on understanding the mechanisms of induction of the cellular adhesion molecule E-selectin.  By studying the molecular events that regulate expression of 
this gene we have identified several targets for modulating its production.  Modulating E-selectin expression would significantly affect the pathological inflammatory events seen in 
important diseases such as asthma, allergy and arthritis. <p>

In a second approach we are studying a particular class of transcription factors. Novel members of the family have been identified and we have obtained evidence about their potential 
roles.<p>

The biological basis for our research on E-selectin is the discovery that circulating leukocytes are selected by contact with blood vessel cells (endothelial cells) to perform their 
tasks.  The problem of selecting the appropriate circulating cells to participate in the inflammatory response is complex.   The endothelial cells must have mechanisms for signalling a 
site of inflammation and for recruiting  the appropriate circulating cells. <p>
A potent and selective mechanism that is used is the induction by inflammatory mediators (e.g., cytokines) of cellular adhesion molecules on endothelial cells.  These adhesion proteins 
interact with their counterparts on the circulating cells to select and adhere the correct cell types to the endothelial cells.  E-selectin is one of three similar adhesion proteins 
(selectins) which, by virtue of their lectin (or sugar affinity) structure, select leukocytes that express proteins carrying the counterpart carbohydrate molecules. <p>

Cells selected by E-selectin include neutrophils, monocytes, and some memory T-cells.  This is a critical group of cells in the inflammatory response; they provide both an immediate 
defence (neutrophils/monocytes) and a longer term response (memory T-cells).  Moreover E-selectin is the only adhesion molecule to be both exclusively expressed on endothelial cells 
and to be highly regulated.   E-selectin is found on the surface of endothelial cells, only following induction by an inflammatory signal.<P>

We found that treatment of endothelial cells with cytokines IL-1 or TNFa results in a dramatic increase (approximately 1000-fold) 
in the amount of E-selectin mRNA in the cells. This massive increase results from an equally impressive increase in the rate 
of transcription of the gene. We have identified four regions of the E-selectin promoter which bind proteins that control  its 
activity (Fig. 1).  Three of the four protein complexes that bind to the promoter have been extensively characterised.  Most important to the induction of transcription is the binding 
of the inducible transcription factor, NF-kB. <p>

In the absence of cytokine induction, NF-kB does not bind to its consensus binding sequence in the E-selectin promoter.  However, 
nuclear extracts from cells induced by cytokines have NF-kB that binds to this site.  Thus, IL-1 causes the NF-kB complex to migrate to the nucleus and bind the E-selectin promoter.  
In contrast to the inducible binding of NF-kB to the E-selectin promoter, we have identified a complex of ATF transcription factors which bind constitutively.  This complex is most 
probably a hete rodimer composed of two members of the ATF family (e.g. ATFa/ATF2) that bind to a sequence similar to the binding sequence of the 
CREB transcription factor.  <P>

Our demonstration that the NF-kB and ATF complexes physically interact with one another is particularly interesting because this protein/protein interaction may account for our 
observations on the interdependence of the two sites in promoting transcription; the amount of transcription when only one site is functional is much less than when both sites are 
active.  A third complex that we have recently identified is composed of the DNA binding protein HMG-I and most probably NF-kB.  HMG-I has been shown to bind DNA specifically and to 
interact with both ATFs and NF-kB.<P>

In summary, our data indicate that the dramatic induction of E-selectin expression by inflammatory signals such as IL-1 results from the following series of events. NF-kB is released 
from its complex with inhibitor and migrates to the nucleus where it binds to both its consensus sequence and to several other sites where it is stabilized by HMG-I.  The ATFs and the 
multiple NF-kBs then interact to form a potent transcription initiation complex which binds and activates the RNA polymerase complex.<P>

<a href="trans2.html">Forward to: Intracellular receptors</a><p>
<a href="project.html">Return to: Research projects contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-267</DOCNO>
<DOCOLDNO>IA057-000937-B023-258</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/trans2.html 193.128.22.20 19970109102301 text/html 4914
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:13:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:24 GMT
Content-length: 4723
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30"> <basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Intracellular receptors</font></h2>
<p>

This important class of receptors includes the steroid hormone receptors, which are ligand-activated transcription factors.  
Most intracellular receptors are transcriptional regulators 
that are themselves regulated by ligands. Small molecules that antagonize or agonize these receptors may be useful as 
therapeutics. Certain steroids analogues, for example,  are used to 
control inflammatory and immune reactions. Identification of new members of this family of receptors as well as a greater 
understanding of how they work, may well provide novel targets for regulating gene expression and for treating  diseases.<P>

The unifying and conserved feature of intracellular receptors is the presence of a DNA binding domain which is made up of two 
protein loops, each stablized by a zinc ion that gives them the name "zinc fingers".  Based on the conservation of amino acid 
residues in the DNA binding domain we have identified 
several novel intracellular receptors. The two most intriguing receptors are members of a new subfamily.  We have named these 
the Retinoid Z Receptors (RZRa and b) because of the high 
degree of homology of their DNA binding domains to those of the retinoid binding receptors, RAR and RXR.<P>

Both RZRs bind to DNA sequences that contain an extended retinoid response element.  The need for additional nucleotides allows 
a clear distinction to be made between the binding 
requirements of RZR and RAR/RXR.  Although RZRa and RZRb function similarly on the same response element, they differ markedly 
in their tissue distribution.  RZRa mRNA is found in many 
different tissues although the highest levels are found in skin and leukocytes.  In contrast, RZRb mRNA is highly localized.  
RZBb expression is primarily found in the brain. The particular location of RZRb-mRNA within the brain provides some clues as 
to its role in processing light input.<P>

Our research is now focused on understanding the functions of RZRs: which genes do they regulate; how are they regulated during 
development or differentiation; do they have roles in pathological states as well as in normal cell functioning?<P>

<b>Some recent publications:</b><p>

Hooft van Huijsduijnen, R., Whelan, J., Pescini, R., Becker-Andre, M., Schenk, A.-M. and J.F. DeLamarter (1992).  A T-cell enhancer cooperates with NF-kB to yield cytokine induction of E-selectin gene transcription in endothelial cells.
 <i> J. Biol. Chem.</i> 267:22385-91.<P>

Kaszubska, W., Hooft van Huijsduijnen, R., Ghersa, P., DeRaemy-Schenk, A.-M.,
Chen, B.P.C., Hai, T., DeLamarter, J.F. and J. Whelan (1993). Cyclic AMP-independent ATF family members interact with NFkB and function in the activation of the E-selectin promoter in response to cytokines. <i> Mol. Cell. Biol.</i> 13: 7180-90.<P>

Carlberg, C., Hooft van Huijsduijnen, R., Staple, J., DeLamarter, J.F. and M. Becker-Andre  (1993). RZRs, a new family of retinoid-related orphan receptors that function as both monomes and homodimers. <i> Mol. Endo.</i>  8:757-70. <P>

Lewis, H., Kaszubska, W., DeLamarter, J.F. and J. Whelan, J. (1994). Cooperativity between two NFkB complexes, mediated by HMG-I(Y), is essential for cytokine induced expression of the E-selectin promoter. <i> Mol. Cell. Biol. </i> (in press).<P>

<a href="trans.html">Back to: Transcription</a><p>
<a href="project.html">Return to: Research projects contents page</a>

<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-268</DOCNO>
<DOCOLDNO>IA057-000937-B017-157</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/neuro.html 193.128.22.20 19970109093128 text/html 4834
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:21:39 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:23 GMT
Content-length: 4643
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Neurodegeneration</font></h2>

<font size=5>Our goal is to understand the molecular basis of neuronal  cell death. Neuronal death has been recognized for many years as an essential feature of nervous system development; more than half of the neurones that are generated die during the, 

so-called,  naturally occurring cell death period. Massive neuronal death 
is also an obvious feature of pathologies in the adult nervous system, 
including Alzheimer's, Parkinson's and motorneurone diseases. </font>
<p>
The causes of these neurodegenerative diseases are largely unknown. Our 
hypothesis is that neuronal survival or death, both during development 
and in adults, is determined by the balance of expression of positive and 
negative regulatory genes. Several such regulatory genes have been 
identified; their mechanisms of action are providing important 
information about how neuronal survival and death is controlled.<p>

During development, the tips of growing axons are guided to their targets
where they establish connections. Typically, half of the neurones form
synapses and differentiate further, while the rest are eliminated during
the naturally occurring cell death pe riod. Although the mechanisms that
lead either to the death or to the differentiation of neurones are
unknown, appropriate cell-cell interactions, electrical activity and gene
expression play important roles in both pathways.  The same mechanisms may
also contribute to the remodelling of nerve terminals that occurs in the 
adult brain as a morphological corollary to memory and learning. Our 
strategy for identifying novel genes associated with synapse formation 
and neuronal selection is based on cloning genes that are specifically 
expressed during 
synaptogenesis and which are regulated by electrical activity.<P>

<b>Stathmin is involved in the transduction of signals induced by NGF</b><p>

We cloned the stathmin cDNA by screening for genes that were more highly
expressed at particular stages of development. Stathmin is a
phosphoprotein enriched in the nervous system. The regulation of its
expression and phosphorylation during development co ntrols cell
proliferation and differentiation. We found that treatment of PC12 cells
with stathmin antisense oligonucleotides prevented the nerve growth factor
(NGF)-induced differentiation of these cells <cite>in vitro</cite> and
also prevented the effec ts of NGF on cell survival in serum free 
conditions.  Thus stathmin appears to form part of the NGF signal 
transduction pathways that control both differentiation and survival. <P>

Both stathmin and a neurone-specific homologue, SCG-10, show a strong 
peak of expression during developmental cell death and synapse formation. 
At this stage, however, neurones express different levels of both 
proteins, suggesting that the level of expression may correlate with the 
fate (death or survival) of the cell.<P>

Our research on stathmin and SCG-10 indicate that the mechanisms 
regulating the
expression of such proteins, which transmit neurotrophic factor signals, 
may have important roles in neuronal survival and in successful sprouting 
during developmental cell death, ageing or disease. <P>

<a href="neuro2.html">Forward to: SNAP-25 and the bcl-2a protooncogene</a><p>
<a href="project.html">Return to: Research projects contents page</a>

<p>

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-269</DOCNO>
<DOCOLDNO>IA057-000937-B023-221</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/neuro2.html 193.128.22.20 19970109102210 text/html 5908
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:12:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:23 GMT
Content-length: 5717
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" 
vlink="30aa30">
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>
<h2><font size=6>SNAP-25</font></h2>

<font size=5>SNAP-25 is involved in axonal growth and transmitter release, processes that form the basis of cognition-related 
plasticity.</font><p>

The cDNA encoding SNAP-25 was also cloned by screening for genes that are differentially expressed during development. SNAP-25 is 
expressed in axonal growth cones during late stages of elongation. When we selectively inhibited SNAP-25 expression, by 
antisense oligonucleotides, we found that it prevented the 
elongation of neurites that were produced by rat cortical neurones and PC12 cells <cite>in vitro</cite> as well as those produced by 
amacrine cells of the developing chick retina <cite>in vivo</cite>. The results show that SNAP-25 plays a key role in axonal growth. They also suggest that the high levels of SNAP-25 expression that are found in 
specific areas of the adult brain may contribute to nerve terminal plasticity.<P>
SNAP-25 is also involved in regulating the release of neurotransmitters. In collaboration with scientists at the University of 
Padova, we showed that botulinum neurotoxins act as zinc-endoproteases that are specific for SNAP-25 (Schiavo et al. <cite>J. Biol. Chem.</cite> 268:23784-7. 1993). These toxins dramatically block 
transmitter release, indicating that SNAP-25 is involved in controlling 
transmitter release as well as axonal growth. Both mechanisms are known to be involved in the functional and morphological 
plasticity of nerve terminals that relate to cognitive events 
in the brain. Alterations of these mechanisms may therefore play important roles in cognitive decline during ageing and 
neurodegenerative diseases. <P>

<b>The proto-oncogene Bcl-2a blocks neuronal death in vivo.</b><p>
Bcl-2a blocks apoptosis in non-neuronal cells and we had previously found that it could also rescue neurones from apoptosis 
that was induced by depriving them of neurotrophic factor <cite>in 
vitro</cite>. (Garcia, I., Martinou, I., Tsujimoto, Y. and J.-C. Martinou.  Science 258:302-4, 1992). To find out whether bcl-2a could 
also rescue neurones <cite>in vivo</cite>, we generated, in 
collaboration with scientists at the University of Geneva, transgenic mice overexpressing bcl-2a under the control of the 
neurone-specific enolase promoter. The transgenic had 30-40% 
more neurones in the facial motor nucleus and in the ganglion cell layer of the retina, indicating that bcl-2a reduces the 
extent of naturally occurring neuronal death during 
development.<p> 

Bcl-2a overexpression also increases the survival of facial motorneurones whose axons have been cut. In wild type animals, the 
lesioned nerve and the corresponding 
motorneurone cell bodies underwent rapid degeneration, as expected. However, in transgenic mice, the facial motorneurones 
survived axotomy. bcl-2a also protects neurones from ischaemia 
induced by permanent middle cerebral artery occlusion; in transgenic mice the infarct area was reduced by approximately 50%.<p>

Regions of the bcl-2a protein that are required for subcellular localization, activity and interaction with other proteins are 
being determined by creating deletions, truncations and point mutations in regions that are most conserved between the different
 bcl-2 species. We found that membrane attachment is not required for the effects of bcl-2a on neurone survival.<P>
The mechanisms regulated by bcl-2a and other novel genes involved in neuronal survival are giving important insights that should 
lead to the development of novel strategies to treat neurodegenerative disease. Our goal therefore is to obtain a greater 
understanding of these mechanisms, for example by identifying 
proteins that interact with gene products that control neuronal survival and that transmit the signals for survival or death. <P>

<b>Some recent publications:</b><p>

Osen-Sand, A., Catsicas, S., Staple, J.K., Jones, K.A. and G. Ayala. (1993). 
Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. <i> Nature</i> 
364: 445-8.<P>
Dubois-Dauphin, M., Frankowski, H., Tsuijimoto, Y., Huarte, J. and J.-C. Martinou. (1994). 
Neonatal motoneurons overexpressing the bcl-2 protooncogene in transgenic mice are 
protected from axotomy-induced cell death. <i> Proc.Natl. Acad. Sci. U.S.A.</i> 91:3309-13.<p><p>

<a href="neuro.html">Back to: Neurodegeneration</a><p>
<a href="project.html">Return to: Research projects contents page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-270</DOCNO>
<DOCOLDNO>IA057-000937-B023-127</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/index.html 193.128.22.20 19970109102020 text/html 2601
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:10:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:56 GMT
Content-length: 2410
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB</font></h1>
<hr size=4>

<h2><font size=6>Action TB News</font></h2>

<font size=5>Articles from the first issue of Action TB News:</font>
<p>
<dl>
<dt><a href="artintro.html">Introduction</a><p>

<dt><a href="art1.html">TB reactivated, not acquired</a>
<dd>Dr Nulda Beyers, University of Stellenbosch<p>

<dt><a href="art2.html">Speeding diagnosis to save lives</a>
<dd>Professor Paul van Helden, University of Stellenbosch<p>

<dt><a href="art3.html">Apoptosis kills TB</a>
<dd>Dr DS Kumaratne, The Medical School, Edgbaston<p>

<dt><a href="art4.html">Test finds one in a million</a>
<dd>Dr Ken Duncan, Glaxo Wellcome Research and Development,
Stevenage<p>

<dt><a href="art5.html">TB's hidden door found</a>
<dd>Professor Mario Ehlers, University of Cape Town<p>

<dt><a href="art6.html">Clones identify target proteins</a>

<dd>Dr Francis Nano, University of Victoria, Canada<p>

<dt><a href="art7.html">Unusual DNA repair enzyme</a>
<dd>Professor Valerie Mizrahi, South African Institute for Medical Research<p>

<dt><a href="art8.html">Sugars point to new therapies</a>
<dd>Professor Douglas Young, St Mary's Hospital Medical School, Imperial College London

</dl>
<p>
<a href="../news.html">Return to: Action TB News contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-271</DOCNO>
<DOCOLDNO>IA057-000937-B016-323</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/artintro.html 193.128.22.20 19970109092209 text/html 2912
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:11:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:56 GMT
Content-length: 2721
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Introduction</font></h2>

<font size=5>

More than 150 scientists gathered in Cape Town last year to exchange research
news. This newsletter provides an overview of progress made by Action TB News.</font><p>
 This first issue includes results from an exciting epidemiology study
and details of a rapid test for identifying drug resistant TB in
patients. The research has also identified several potential targets
for novel anti-tuberculosis therapies, which may be incorporated into
Glaxo Wellcome's high throughput screening programme. Bioluminescent
mycobacteria are already being used by Glaxo Wellcome scientists to
find new active compounds.<p>

The failure to control TB with the available drugs illustrates the need for new
approaches to tackle this complex disease. Action TB News's fundamental research is
the first step in the quest for a novel TB therapy. Its outcome will determine
the direction we take in the pursuit of new more effective treatments. That
goal is still someway off, but the progress already made by Action TB News
researchers is encouraging.<p>

<img align="left" src="hands.gif" alt="Hands">
<br clear="full"><p>
<br>

Two hands can barely hold 18 days of treatment for
turberculosis. Since a typical course of therapy takes 6 months,
ensuring completion of the six month course places a major burden on
healthcare services.

<p>
<a href="art1.html">Forward to: TB reactivated, not acquired</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-272</DOCNO>
<DOCOLDNO>IA057-000937-B016-398</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art1.html 193.128.22.20 19970109092358 text/html 4146
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:12:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:55 GMT
Content-length: 3955
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB reactivated, not acquired</font></h2>

<font size=5>DNA fingerprinting pin-points source of epidemics<p>


DNA fingerprinting studies have brought into question the received wisdom that
TB epidemics result from recent transmission through direct contact with a
source of infection.</font><p>

Using DNA fingerprinting, it is possible to differentiate accurately
between various strains of mycobacteria. <i>Mycobacterium
tuberculosis</i> strains, for example, can be differentiated by using
the insertion element IS6110, a relatively stable DNA sequence which
occurs at various locations in the genome of <i>M. tuberculosis</i>,
and with a variable copy number (between 0 and &gt;20). By identifying
the strains of TB carried by patients and mapping their movements in
the community, it is possible to establish how TB infection spreads in
specific communities.  <p>

With an incidence of more than 1000 cases per 100,000 population,
Ravensmead and Uitsig, two adjacent suburbs of the Western Cape
Provence of South Africa, have amongst the highest recorded TB
incidences in the world, making them ideal communities for DNA
fingerprinting studies. Surprisingly few patients in this small, 2.42
km<sup>2</sup> area are infected with identical TB strains. Instead,
the majority of patients with active TB disease carry unique strains.
Only 46 out of 209 identified TB strains were shared by more than one
person, and in many of these cases no, or only very casual contact
could be established. Based on the theory that recent transmission
results in little strain diversity, it is more likely that the TB
epidemic in these Western Cape suburbs is caused by reactivation of
latent disease.  <p>

TB is not distributed evenly across the community and generally, the highest
number of cases are associated with the worst socio-economic conditions,
indicated by low per capita income, poor housing and overcrowding. When
considered by separate subdistricts the incidence of TB in Ravensmead and
Uitsig varies between 78 and 3150 per 100,000 people. In certain houses, TB
occurs repeatedly; a third of the houses had at least one case of TB over the
past ten years and 447 houses had 3 or more cases.
<p>

For more information contact:
<p>

Dr Nulda Beyers,<br>
Department of Paediatrics and Child Health University of Stellenbosch,<br>
Faculty of Medicine,<br>
PO Box 19063,<br>
Tygerberg 7505,<br>
South Africa.<p>

Tel: +27 21 938 9506,<br>
Fax: +27 21 931 7810,<br>
e-mail: <a href="mailto:nb@maties.sun.ac.za">nb@maties.sun.ac.za</a>
<p>
<a href="art2.html">Forward to: Speeding diagnosis to save lives </a><p>
<a href="artintro.html">Back to: Introduction</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-273</DOCNO>
<DOCOLDNO>IA057-000937-B016-420</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art2.html 193.128.22.20 19970109092418 text/html 5141
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:14:30 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:55 GMT
Content-length: 4950
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Speeding diagnosis to save lives</font></h2>

<font size=5>Molecular diagnostic for drug resistant TB<p>


Rapid screening for antibiotic-resistant strains of <i>M. tuberculosis</i>
may soon become a reality with the development of a new test that
provides results in only a few days.</font><p>

Using conventional culture methods, diagnosis and drug
susceptibility testing for tuberculosis can take up to twelve weeks, which  for
patients with drug-resistant infections, can be fatal. Such delays in diagnosis
can also substantially increase the risk of transmission of drug-resistant TB
within the community.
<p>

The primary cause of resistance to drugs such as rifampicin (RMP) is mutation
in structural genes encoding target enzymes. Researchers at the University of
Stellenbosch in South Africa have used single-stranded conformation
polymorphism (SSCP) technology to develop a test for the detection of drug
resistant strains of <i>M. tuberculosis</i>. This polymerase chain reaction (PCR)
based technique identifies single base substitutions, as well as small
deletions and insertions in specific genes.
<p>

The SSCP diagnostic test makes it possible to identify mutations in
the rpoB gene, a molecular marker for RMP resistance in
<i>M. tuberculosis</i>. Using this procedure, ninety-five per cent of
RMP-resistant isolates of <i>M. tuberculosis</i> were identified.  <p>

As there is a high probability (95%) in South Africa that RMP-resistant TB is
also resistant to isoniazid (INH), identifying mutations in the rpoB gene is a
way of identifying most multidrug-resistant (MDR) strains. Mutations in genes
leading to INH resistance are far more variable, making these genes less useful
for the development of a DNA-based test.
<p>

<strong>Developing resistance</strong><br>
Antibiotic resistance can develop within a patient, for example, because
chemotherapy treatment was not completed. However, in approximately half of
reported cases of drug resistant TB in the Western Cape Province of South
Africa, resistance was transmitted through contact with another drug-resistant
case, rather than resulting from de novo development of antibiotic resistance.
Drug resistance is considered to be one of the key underlying factors
responsible for the increase in TB recorded over the last few years in many
developing countries.
<p>

The rapid screening method described makes it possible to quickly identify
patients harbouring drug-resistant strains of TB, allowing appropriate
treatment to be initiated immediately. This may also help to contain and
substantially reduce the spread of MDR-TB cases. Presently, only hospital
laboratories have the capacity and expertise to use this test procedure.
However, further development  may provide a more robust screen suitable for a
wider range of healthcare laboratories.
<p>

The rapid test can be performed using either: 
<ul type=disc> 
<li> sputum sample taken directly from patients, or
<li><i>M. tuberculosis</i> isolates produced after a short culture period in
standard BACTEC culture medium.<p>
</ul>

For further information contact:<p>

Professor Paul van Helden,<br>
MRC Centre for Molecular and Cellular Biology<br>
(<a href="http://www.sun.ac.za/local/academic/med_biochem/mrc1.html">http://www.sun.ac.za/local/academic/med_biochem/mrc1.html</a>),
<p>

University of Stellenbosch,<br>
PO Box 19063,<br>
7505 Tygerberg,<br>
 South Africa.<p>
Tel: +27 21 938 9401,<br>
Fax: +27 21 931 7810,<br>
e-mail: <a href="mailto:pvh@maties.sun.ac.za">pvh@maties.sun.ac.za</a>
<p>
<a href="art3.html">Forward to: Apoptosis kills TB </a><p>
<a href="art1.html">Back to: TB reactivated, not acquired </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-274</DOCNO>
<DOCOLDNO>IA057-000937-B016-434</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art3.html 193.128.22.20 19970109092442 text/html 3662
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:14:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:55 GMT
Content-length: 3471
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Apoptosis kills TB</font></h2>

<font size=5>Only ATP-induced apoptosis is effective<p>


The key to the survival of <i>M. tuberculosis</i> is its invasiveness. The bacillus
rapidly invades host monocytes and macrophages and freely grows and replicates
in these cells. This occurs despite the fact that macrophages are a central
component of the host immune system.</font><p>

Induction of apoptosis, or programmed cell death, in infected macrophages
occurs <i>in vivo</i> through either cytokine or cytolytic T cell action, and usually
leads to the uptake of the apoptotic macrophage by its neighbours. Because
intracellular processing of infected apoptotic macrophages may occur in a
totally different manner to that of independent bacterial particles, further
studies are now underway to establish whether mycobacteria within the apoptotic
macrophages are killed by this cell-mediated destruction, or whether
phagocytosis of the apoptotic macrophage simply permits the bacteria to spread
from cell to cell.
<p>

BCG (bacille Calmette-Gu&eacute;rin) infection does not induce apoptosis of the
infected macrophage, but instead it makes the macrophages more susceptible to
the induction of apoptosis by other stimuli. However, recent studies  show that
macrophage apoptosis induced by ligation of the surface Fas antigen, or
following treatment with TNF-alpha, did not affect the viability of the
intracellular mycobacteria. Only when macrophage apoptosis was induced by ATP
was the survival rate of the intracellular mycobacteria reduced.
<p>

ATP-related apoptosis may prove to be an exciting target for a novel
immunotherapeutic strategy. Understanding the mechanism behind
ATP-induced apoptosis may lead to unique approaches to the treatment
of <i>M. tuberculosis</i> that involve specific stimulation of the
immune system.  <p>

For further information contact:<p>

Dr DS Kumaratne,<br>
 Department of Immunology,<br>
 The Medical School,<br>
 Edgbaston,<br>
 B15 2TT,<br>
 UK.<p>
 Tel: +44 121 414 6976,<br>
 Fax: +44 121 414 3599,<p>


<a href="art4.html">Forward to: Test finds one in a million </a><p>
<a href="art2.html">Back to: Speeding diagnosis to save lives</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>




<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-275</DOCNO>
<DOCOLDNO>IA057-000937-B016-451</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art4.html 193.128.22.20 19970109092507 text/html 3158
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:15:09 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:55 GMT
Content-length: 2967
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Test finds one in a million</font></h2>

<font size=5>High throughput screen for anti-mycobacterial drugs<p>

New high throughput screening technology now enables thousands of potential
antibiotics and biocides for TB to be screened each day. A recently developed
screen now rapidly identifies compounds which are specifically active against
mycobacteria.</font><p>

Using a fast growing, non-pathogenic mycobacterium, <i>Mycobacterium aurum</i>, this
bioluminescence-based assay allows compounds to be tested without the need for
complicated containment facilities. The luxA and luxB genes from Vibrio
harveyii were cloned into <i>M. aurum</i>. Recombinant bacteria now produce light
(bioluminescence) when a simple substrate is added. Thus, viability can be
measured in the presence of test compounds. Using microtitre format, many
thousands of compounds can be tested in one day and those with activity can
then be evaluated further in the more difficult and time consuming <i>M.
tuberculosis</i> assay.
<p>

Natural products are a potential source of new drugs. A compound with
antimycobacterial activity, magnolol, was isolated from a plant used in
traditional Chinese medicine, Magnolia officialis. Another compound,
ascididemin, was isolated from sponge.
<p>

For more information contact:<p>

Dr Ken Duncan,<br>
Glaxo Wellcome Research and Development,<br>
 Gunnels Wood Road,<br>

Stevenage,<br>
 Herts,<br>
 SG1 2NY,<br>
 UK.<p>

Tel: +44 1438 763841,<br>
Fax: +44 1438 764782<br>
e-mail: <a href="mailto:kd9430@ggr.co.uk">kd9430@ggr.co.uk</a>.
<p>
<a href="art5.html">Forward to: TB's hidden door found </a><p>
<a href="art3.html">Back to: Apoptosis kills TB </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-276</DOCNO>
<DOCOLDNO>IA057-000937-B016-468</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art5.html 193.128.22.20 19970109092530 text/html 3889
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:15:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:56 GMT
Content-length: 3698
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>TB's hidden door found</font></h2>

<font size=5>TB may use CR3 receptor to escape destruction<p>


Recent studies have identified a complement receptor that allows <i>M.
tuberculosis</i> to enter host cells, a key step in the establishment of infection.</font><p>

Once inside the cell, <i>M. tuberculosis</i> resides inside large membrane-bound
vacuoles, where it may escape detection by the immune system for many years.
<p>

Binding to the CR3 receptor was demonstrated using a non-phagocytic cell line
co-transfected with the cDNAs for the CR3 subunits CD11b and CD18. In these
studies, <i>M. tuberculosis</i> consistently bound to the co-transfected cell line 5
times more than to wild type cells, regardless of whether serum was present.
This is the first time that the CR3 receptor has been shown to promote uptake
of <i>M. tuberculosis</i> into a non-phagocytic cell by a presumably phagocytic
mechanism.
<p>

Similar studies have focused on identifying the cell wall components that allow
<i>M. tuberculosis</i> to bind to specific non-phagocytic cell types. Human serum and
20% Fetal Calf Serum (FCS) significantly enhanced binding of
<i>M. tuberculosis</i> to these cell lines. A panel of monoclonal antibodies to<i> M.
tuberculosis</i> surface antigens was tested for their ability to inhibit <i>M.
tuberculosis</i> binding to these cells. Two were found to reduce binding
significantly. Further analysis revealed that the <i>M. tuberculosis</i> antigen
recognised by the monoclonal antibody is a non-proteinaceous cell wall
component, possibly a phosphatidylinositol mannoside.
<p>

Macrophages usually ingest bacteria with a phagocytic mechanism which
induces a respiratory burst that kills the bacteria. Understanding the
route by which <i>M.  tuberculosis</i> enters cells may help
identify the mechanisms <i>M. tuberculosis</i> uses to evade normal
killing processes. This may lead to new targets and approaches to
promote host responses to <i>M. tuberculosis</i> and ultimately to new
immunotherapies.  <p>

For further information contact:<br>

Professor Mario Ehlers,<br>
 University of Cape Town,<br>
 Department of Medical
Biochemistry,<br>
 Observatory 7925,<br>
 Cape Town,<br>
 South Africa.<p>
 Tel: +27 21 406 6335,<br>

Fax: +27 21 477669<p>

<a href="art6.html">Forward to: Clones identify target proteins </a><p>
<a href="art4.html">Back to: Test finds one in a million </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-277</DOCNO>
<DOCOLDNO>IA057-000937-B016-478</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art6.html 193.128.22.20 19970109092539 text/html 3616
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:15:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:56 GMT
Content-length: 3425
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Clones identify target proteins</font></h2>

<font size=5>Efflux and immunostimulatory proteins found<p>


A number of <i>M. tuberculosis</i> membrane, cell wall and secreted
proteins that may include novel targets for new drugs or vaccines have
been identified using a novel expression cloning system.</font><p>

The expression system relies on randomly fusing the alkaline
phosphatase gene (PhoA) from <i>E. coli</i> to <i>M. tuberculosis</i>
DNA. Since alkaline phosphatase is only active when localised outside
the cytoplasmic membrane, this system specifically identifies
membrane, cell wall and secreted proteins. Once clones with alkaline
phosphatase activity have been identified, <i>M. tuberculosis</i>
proteins are located by anti-PhoA monoclonal antibody reactivity using
Western blot analysis.  <p>

The DNA from 350 clones has already been cloned, sequenced and the deduced
amino acid sequences compared with known protein sequences. Using this
procedure, three proteins with high sequence similarity to efflux proteins were
identified.
<p>

A further 76 recombinant fusion proteins that stimulate the immune system have
also been identified. Immunostimulatory activity was assessed by the ability of
the proteins to stimulate mouse TH1 cells to secrete interferon-g, an index of
the protective effect of the proteins. Studies are underway to sequence these
immunostimulatory proteins, some of which may already have known functions.
Over the next year, the proteins will be tested for reactivity with T cells
from tuberculin positive patients. This is the first step in the process of
identifying proteins that may be suitable for inclusion in a subunit vaccine.
<p>

For further information contact:<p>

Dr Francis Nano,<br>
 Department of Biochemistry and Microbiology<br>
(<a href="http://zeus.bioc.uvic.ca/BiocDept.Html">http://zeus.bioc.uvic.ca/BiocDept.Html</a>),<p>
 University of Victoria,<br>
 Victoria,<br>
 V8W 3P6,<br>
 Canada.<p>

 Tel: +1604 721 7074,<br>
 Fax: +1604 721 8855
<p>
<a href="art7.html">Forward to: Unusual DNA repair enzyme </a><p>
<a href="art5.html">Back to: TB's hidden door found </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-278</DOCNO>
<DOCOLDNO>IA057-000937-B016-493</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art7.html 193.128.22.20 19970109092552 text/html 4023
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:16:02 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:56 GMT
Content-length: 3832
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Unusual DNA repair enzyme</font></h2>

<font size=5>Repair polymerase is weak link<p>


Researchers in South Africa have confirmed that the DNA polymerase I from
 <i>M. tuberculosis</i> is unable to discriminate between natural
nucleotides and chain-terminating analogues during DNA
synthesis.</font><p>

 This finding agrees with the recent predictions of Tabor and
Richardson (Harvard) and makes the <i>M. tuberculosis</i> enzyme the
first one of its kind from bacteria to possess this unusual
property. This enzyme may make a potentially useful and novel target
for future anti-TB drug design.<p>


DNA polymerase I is important for DNA repair, a process essential for
the survival of all organisms. Recent results in
<i>M. tuberculosis</i> have shown that its DNA polymerase I
incorporates chain-terminating dideoxynucleotide analogues with even
greater efficacy than the benchmark non-discriminating DNA polymerase
from bacteriophage T7. Cloning and sequencing of
<i>M. tuberculosis</i> polA, the gene encoding DNA polymerase I, has
also shown that, although all the primary structural elements
necessary for DNA polymerase and 5' nuclease are present, the gene
lacks the motifs required for an associated 3'-5' exonuclease
(proof-reading) activity.  <p>

The role of DNA polymerase I in DNA repair has recently been confirmed
in <i>M.  smegmatis</i>. When DNA polymerase production was stopped by
disrupting polA, the resulting mutant's phenotype was
hypersensitivity to DNA damage caused by UV irradiation and by
hydrogen peroxide challenge. Disruption of the gene's function was
achieved by homologous recombination using a DNA fragment comprising a
partial polA gene that had been disrupted within the 3'- terminal
polymerase-encoding region by a drug resistance marker.  <p>

DNA polymerase I is almost certain to be involved in DNA repair in
<i>M.  tuberculosis</i>, and deactivating this enzyme, for example by
introducing chain terminating nucleoside analogues, may be a useful
way of reducing the chances of this mycobacterium's survival.  <p>

For further information contact:<p>

Professor Valerie Mizrahi,<br>
 Molecular Biology Unit,<br>
 South African Institute for
Medical Research,<br>
 PO Box 1038,<br>
 Joannesburg 2000,<br>
 South Africa.<p>
 Tel: +27 11 489 9370,<br>
 Fax: +27 11 489 9001,<br>
 e-mail: <a href="mailto:075val@chiron.wits.ac.za">075val@chiron.wits.ac.za</a>
<p>
<a href="art8.html">Forward to: Sugars point to new therapies</a><p>
<a href="art6.html">Back to: Clones identify target proteins </a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-279</DOCNO>
<DOCOLDNO>IA057-000937-B016-513</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/science/actiontb/news1/art8.html 193.128.22.20 19970109092609 text/html 4008
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:16:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:56 GMT
Content-length: 3817
Content-type: text/html
</DOCHDR>
<html><head>
<title>Action TB News</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Action TB News</font></h1>
<hr size=4>

<h2><font size=6>Sugars point to new therapies</font></h2>

<font size=5>Trehalose and glycoprotein pathways targeted<p>


Factors that protect bacteria against environmental stress are a particularly
interesting target for anti-mycobacterial drugs, since mycobacteria are able to
survive for extended periods in a hostile environment.</font><p>

 Trehalose is thought to protect proteins and membranes in bacteria
and may play an analogous role in promoting mycobacterial survival.
<p>


Two enzymes involved in trehalose metabolism, trehalose-6-phosphate synthase
and trehalose-6-phosphate phosphatase, have recently been purified. The genes
corresponding to these proteins have been identified and sequence analysis
begun. Further research will focus on producing recombinant proteins that will
allow the trehalose metabolic pathway to be explored.
<p>

<strong>Glycoprotein research</strong><br>
Protein glycosylation has been considered as a potential target for anti-fungal
therapy and may prove an exciting target for anti-mycobacterial agents. Little
is currently known about bacterial glycoproteins, but glycosylation pathways
have been extensively characterised in eukaryotes.<p>

As a test system, the gene encoding the 19 kDa lipoprotein from <i>M. tuberculosis</i>
is being studied in the rapidly growing mycobacterium, <i>M. smegmatis</i>. This,
combined with the preparation of fusion proteins, has pinpointed glycosylation
to the N-terminal region of the 19 kDa protein. Site-directed mutagenesis
studies revealed that two threonine clusters play a key role.<p>

Functional studies, using amino acid replacement, indicate that
glycosylation protects the 19 kDa antigen from proteolysis and may
regulate conversion between a cell-associated and a soluble secreted
form of the protein. Strategies are also underway to develop assays
for the enzymes involved in protein glycosylation for incorporation
into high throughput screens.<p>


For further information contact:<p>

Professor Douglas Young,<br>
 Department of Medical Microbiology<br>

(<a href="http://www.sm.ic.ac.uk/medical_microbiology/home.htm">http://www.sm.ic.ac.uk/medical_microbiology/home.htm</a>),<p>
 Wright Fleming Institute,<br>
 St Mary's Hospital Medical School,<br>
 Imperial College of Science, Technology & Medicine,<br>
 London,<br>
 W2 1PG,<br>
 UK.<p>
 Tel: +44 171 725 1591,<br>
 Fax: +44 171 262 6299,<br>
 e-mail: <a href="mailto:d.young@imperial.ac.uk">d.young@imperial.ac.uk</a>
<p>


<a href="art7.html">Back to: Unusual DNA repair enzyme</a><p>
<a href="index.html">Return to: Action TB News issue one contents page</a>
<p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-280</DOCNO>
<DOCOLDNO>IA057-000937-B017-319</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/cellbio/index.html 193.128.22.20 19970109093406 text/html 2715
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:24:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:40 GMT
Content-length: 2524
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Cell biology in clinical medicine</font></h1>
<hr size=4>
<br>
<h2><font size=6>Cinderella's reversal of fortune</font></h2><br>



<font size=5>It is not uncommon today to see articles on cell biology in medical journals
that until recently were devoted exclusively to practical clinical medicine.
This is testimony to an increasing awareness and recognition of the growing
impact of cell biology in clinical medicine.</font><p>
<p>
by Jan James,<br> <font size=3>Professor Emeritus of Histology and Cell Biology,<br>Academic Medical Centre in Amsterdam</font><p>
<p>
  <IMG  WIDTH=88 HEIGHT=132 SRC="gifs/trancell.gif" align=absmiddle vspace=5 hspace=5><font size=3>General diagram of a cell</font> <a href="../copy.html#cell">&copy;</a><br clear=left><p>

<a href="cellb1.html">Introduction</a><p>
<a href="cellb2.html">The growth of cytology</a><p>
<a href="cellb3.html">Organelles with specific functions</a><p>   
<a href="cellb4.html">Ubiquitin, stress proteins and the cytoskeleton</a><p>
<a href="cellb5.html">Cell-membrane receptors and coatings</a><p>
<a href="cellb6.html">Cell-cell and cell-matrix interactions</a><p>
<a href="cellb7.html">Adhesion molecules and disease</a><p>
<a href="cellb8.html">Conclusions</a><p>
<p><p>
<a href="../">Return to: Odyssey contents page</a><p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>

</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-281</DOCNO>
<DOCOLDNO>IA057-000937-B009-381</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/uk.html 193.128.22.20 19970109081621 text/html 1838
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:06:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:36 GMT
Content-length: 1647
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-UK</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>UK addresses</font></h2>

<p><br>

<a href="gw.html">Glaxo Wellcome plc</a><p>

<a href="gwuk.html">Glaxo Wellcome UK Ltd</a><p>
        
<a href="rd.html">Glaxo Wellcome Research &amp; Development</a><p>
 
<a href="gwops.html">Glaxo Wellcome Operations</a><p>
 
<hr>

<p>

<a href="../index.html">Return to: Glaxo Wellcome contacts page</a>

<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-282</DOCNO>
<DOCOLDNO>IA057-000937-B020-411</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwuk.html 193.128.22.20 19970109095815 text/html 1671
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:48:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:29 GMT
Content-length: 1480
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome UK Ltd</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome UK Ltd</font>
</h2> 
<p>

<a href="gwuk1.html">Stockley Park West, Middlesex</a><p>

<p>
<hr>
<p>

<a href="uk.html">Return to: Main UK addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-283</DOCNO>
<DOCOLDNO>IA057-000937-B020-428</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/rd.html 193.128.22.20 19970109095842 text/html 1818
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:48:54 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:33 GMT
Content-length: 1627
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; Development</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

<a href="rd1.html">Greenford, Middlesex</a><p>
<a href="rd2.html">Glaxo Wellcome Medicines Research Centre, Stevenage</a><p>
<a href="rd3.html">Ware, Hertfordshire</a><p>
<P>
<hr>
<p>

<a href="uk.html">Return to: Main UK addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-284</DOCNO>
<DOCOLDNO>IA057-000937-B020-464</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops.html 193.128.22.20 19970109095907 text/html 2184
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:49:19 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:27 GMT
Content-length: 1993
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations (Head office and production sites)</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Operations (Head office and production sites)</font></h2>
<p>

<a href="gwops1.html">Head Office, Stockley Park West</a><p>
<strong>Production sites</strong><p>
<ul type=disc>
<li><a href="gwops2.html">Ulverston, Cumbria</a><p>
<li><a href="gwops3.html">Newbie, Annan, Dumfriesshire</a><p>
<li><a href="gwops4.html">Barnard Castle, County Durham</a><p>
<li><a href="gwops5.html">Ware, Hertfordshire</a><p>
<li><a href="gwops6.html">Dartford, Kent</a><p>
<li><a href="gwops7.html">Speke, Liverpool</a><p>
<li><a href="gwops8.html">Montrose, Angus</a><p>
</ul>
<p>
<hr>
<p>

<a href="uk.html">Return to: Main UK addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-285</DOCNO>
<DOCOLDNO>IA057-000937-B024-237</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwuk1.html 193.128.22.20 19970109103018 text/html 1746
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:20:30 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:29 GMT
Content-length: 1555
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome UK Ltd</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome UK Ltd</font>
</h2>

Stockley Park West,<br>
Uxbridge,<br>
Middlesex.<br>
UB11 1BT<p>
Tel: (0181) 990 9000<br>
Telex: 22134<br>
Fax No: (0181) 990 4321

<p>

<a href="gwuk.html">Return to: Glaxo Wellcome UK Ltd addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-286</DOCNO>
<DOCOLDNO>IA057-000937-B024-256</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/rd1.html 193.128.22.20 19970109103036 text/html 1892
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:20:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:33 GMT
Content-length: 1701
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; DevelopmentGlaxo Research and Development Ltd.</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

891-995 Greenford Road,<br>
Greenford,<br>
Middlesex.<br>
UB6 0HE<p> 

Tel: (0181) 422 3434<br>
Telex: 22134<br>
Telex: 8951942   - When Using Computer<br>
Fax No: (0181) 423 4401 <br>
<p>

<a href="rd.html">Return to: Glaxo Wellcome Research &amp; Development addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-287</DOCNO>
<DOCOLDNO>IA057-000937-B024-292</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/rd2.html 193.128.22.20 19970109103122 text/html 1834
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:21:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:34 GMT
Content-length: 1643
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; Development</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

Glaxo Wellcome Medicines Research Centre,<br>
Gunnels Wood Road,<br>
Stevenage,<br>
Hertfordshire.<br>
SG1 2NY<p>
Tel: (01438) 745745<br>
Fax No: (01438) 764502

<p>

<a href="rd.html">Return to: Glaxo Wellcome Research &amp; Development addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-288</DOCNO>
<DOCOLDNO>IA057-000937-B024-323</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/rd3.html 193.128.22.20 19970109103153 text/html 1837
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:21:54 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:34 GMT
Content-length: 1646
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; Development</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

Park Road,<br>
Ware,<br>
Hertfordshire.<br>
SG12 0DP<p> 
Tel: (01920) 469469<br>
Telex: 817877<br>
Telex: 817073   - When Using Computer<br>
Fax No: (01920) 463172

<p>

<a href="rd.html">Return to: Glaxo Wellcome Research &amp; Development addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-289</DOCNO>
<DOCOLDNO>IA057-000937-B024-359</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops1.html 193.128.22.20 19970109103219 text/html 1775
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:22:16 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:27 GMT
Content-length: 1584
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations (Head Office)</font></h2>

Bide Building<br>
Stockley Park West,<br>
Uxbridge,<br>
Middlesex.<br>
UB11 1BU<p>
Tel: (0181) 990 9100<br>

Fax  No: (0181) 990 4321
<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-290</DOCNO>
<DOCOLDNO>IA057-000937-B024-385</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops2.html 193.128.22.20 19970109103241 text/html 1756
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:22:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:28 GMT
Content-length: 1565
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

North Lonsdale Road,<br>
Ulverston,<br>
Cumbria.<br>
LA12 9DR<p>
Tel: (01229) 582261<br>
Telex: 65169<br>
Fax No: (01229) 482282
<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-291</DOCNO>
<DOCOLDNO>IA057-000937-B024-398</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops3.html 193.128.22.20 19970109103249 text/html 1770
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:23:03 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:28 GMT
Content-length: 1579
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Three Trees Road,<br>
Newbie,<br>
Annan,<br>
Dumfriesshire.<br>
DG12 5QH<p>
Tel: (01461) 203661<br>
Telex: 777489 <br>
Fax No: (01461) 207354

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-292</DOCNO>
<DOCOLDNO>IA057-000937-B024-423</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops4.html 193.128.22.20 19970109103314 text/html 1761
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:23:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:28 GMT
Content-length: 1570
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Harmire Road,<br>
Barnard Castle,<br>
County Durham.<br>
DL12 8DT<p>
Tel: (01833) 690600<br>
Telex: 58539<br>
Fax No: (01833) 692300

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-293</DOCNO>
<DOCOLDNO>IA057-000937-B024-443</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops5.html 193.128.22.20 19970109103337 text/html 1737
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:23:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:28 GMT
Content-length: 1546
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Priory Street,<br>
Ware,<br>  
Hertfordshire.<br>
SG12 0DJ<p>
Tel: (01920) 463993<br>
Fax No: (01920) 463899

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-294</DOCNO>
<DOCOLDNO>IA057-000937-B024-456</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops6.html 193.128.22.20 19970109103358 text/html 1750
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:24:01 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:28 GMT
Content-length: 1559
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Temple Hill<br>
Dartford<br>
Kent<br>
DA1 5AH<p>
Tel: (01322) 223488<br>
Telex: (01322) 913770<br>
Fax: (01322) 291840<p>

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-295</DOCNO>
<DOCOLDNO>IA057-000937-B024-472</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops7.html 193.128.22.20 19970109103414 text/html 1752
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:24:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:28 GMT
Content-length: 1561
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Speke Boulevard,<br>
Speke,<br>
Liverpool.<br>
L24 4JD<p>
Tel: (0151) 486 1881<br>
Telex: 629673<br>
Fax No: (0151) 486 1058
<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-296</DOCNO>
<DOCOLDNO>IA057-000937-B025-24</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gwops8.html 193.128.22.20 19970109103447 text/html 1760
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:24:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:29 GMT
Content-length: 1569
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Cobden Street,<br>
Montrose,<br>
Angus,<br>
Scotland.<br>
DD10 8EA<p>
Tel: (01674) 672606<br>
Telex: 76125<br>
Fax No: (01674) 674558
<p>
<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-297</DOCNO>
<DOCOLDNO>IA057-000937-B013-235</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/oz.html 193.128.22.20 19970109085049 text/html 1796
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:40:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1605
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Australasia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Australia</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Australia Ltd</font></h2>

P.O. Box 168<br>
        Boronia<br>
        Victoria 3155<br>
        AUSTRALIA<p>
        
Tel:    (613) 97295100<br>
Telex:  30287<br>
Fax No: (613) 97295319<p>




<hr><p>
<a href="aus.html">Return to: Australasian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-298</DOCNO>
<DOCOLDNO>IA057-000937-B014-401</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/acid.html 193.128.22.20 19970109090356 text/html 1007
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:54:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 817
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Acidic Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Acidic Set</font></h2><p>

The set of acidic amino acids.
These are the residue types Asp and Glu.
All amino acids are classified as either
<tt><b>acidic,</b></tt>
<a href="basicset.html"><tt><b>basic</b></tt></a>
<tt><b>or</b></tt>
<a href="neutral.html"><tt><b>neutral.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>asp, glu</b></tt>"
and
"<tt><b>amino and not (basic or neutral)</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-299</DOCNO>
<DOCOLDNO>IA057-000937-B015-23</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/basicset.html 193.128.22.20 19970109090550 text/html 817
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:56:01 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 627
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Basic Set</font></h2><p>
The set of basic amino acids.
These are the residue types Arg, His and Lys.
All amino acids are classified as either
<a href="acid.html"><tt><b>acidic,</b></tt></a>
<tt><b>basic</b></tt>
or
<a href="neutral.html"><tt><b>neutral.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>arg, his, lys</b></tt>"
and
"<tt><b>amino and not (acidic or neutral)</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-300</DOCNO>
<DOCOLDNO>IA057-000937-B015-224</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/neutral.html 193.128.22.20 19970109090946 text/html 745
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:59:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 555
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Neutral Set</font></h2><p>
The set of neutral amino acids.
All amino acids are classified as either
<a href="acid.html"><tt><b>acidic,</b></tt></a>
<tt><b>basic</b></tt>
or
<a href="neutral.html"><tt><b>neutral.</b></tt></a>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not (acidic or basic)</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-301</DOCNO>
<DOCOLDNO>IA057-000937-B017-182</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/geneva/immuno.html 193.128.22.20 19970109093207 text/html 9578
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:22:13 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:23 GMT
Content-length: 9387
Content-type: text/html
</DOCHDR>
<html><head>
<title>GBRI, Switzerland</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../project.html"><IMG  WIDTH=75 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>
<ul><ul><ul><ul type=disc>

<H1><font size=7> Geneva Biomedical Research Institute </font></H1>
<HR size=4><br>

<h2><font size=6>Immunoregulation</font></h2><p>

<font size=5>Our goal is to understand the molecular and cellular mechanisms that regulate human IgE production. IgE is the key 
immunoglobulin that is involved in more than 90% of cases of allergic diseases such as allergic asthma, allergic rhinitis, hay 
fever and food allergies. IgE binds to the high affinity receptor for IgE on basophils and mast cells. Crosslinking of the 
bound IgE by allergens leads to the release of various inflammatory mediators from these cells. </font><p>

IgE is produced by B cells in response to two sets of signals. The first signal is given by cytokines IL-4 and IL-13, which are 
produced by the Th2 class of T lymphocyte and by basophils. This signal induces the e germline sterile transcript (a precursor 
mRNA for IgE synthesis). The second signal is provided by the physical interaction of B cells with T 
cells which results in the synthesis of the mature e transcript and hence to IgE secretion. <p>
We have identified two pairs of leukocyte surface molecules that have critical roles in IgE synthesis. By interacting with CD21 
(Aubry et al., 1992), the CD23 molecule regulates the 
antigen-specific IgE response in an isotype-selective manner (Flores-Romo et al., 1993), i.e. the CD23/CD21 interaction 
stimulates synthesis of the IgE isotype but not the production 
of other immunoglobulin isotypes, such as IgG. Another cell surface molecule, CD40L, is also necessary for IgE synthesis and is 
involved in general isotype switching as well, through 
its interaction with CD40 (Di Santo et al., 1993). Moreover, functional CD40L was identified on the surfaces of basophils and 
mast cells, enabling these cells to directly regulate IgE production independently of T cells (Gauchat et al., 1993).<p>

Immunoglobulin E (IgE) is central to the induction of allergic diseases through its binding to the high affinity receptor 
(Fc*R1) on mast cells and basophils. Cross-linking of the bound IgE by allergens leads to the release of inflammatory 
mediators. IgE production by B cells requires a physical interaction with T cells, involving a number of surface adhesion 
molecules, as well as the soluble factors (IL-4) and IL-13 that are produced by T cells, basophils and mast cells. <P>

The first indication that the interaction between CD40 and CD40L is a key event in the Ig switching that is required for IgE 
synthesis came from studies using anti-CD40 monoclonal 
antibodies and CD40L transfectants. Several factors that are known to control IgE production have also been shown to regulate 
CD40L expression. Furthermore,  T cell-mediated 
stimulation of IgE synthesis can be inhibited by soluble forms of CD40. Finally, we provided direct evidence for the importance 
of CD40L in Ig switching through our collaborative 
research with the INSERM U132 research unit in Paris; patients with hyper-IgM syndrome, were shown to have  mutations in the 
gene for CD40L (Di Santo et al., 1993).<P>

<b>Mast cells and basophils.</b><p>

Our subsequent studies on CD40L brought to light a potentially very important role of mast cells and basophils in controlling 
IgE synthesis. To identify new cellular mechanisms that 
control IgE production, we tested whether, in the absence of T cells, other cell types could induce IgE synthesis by purified B 
cells that have been stimulated with IL-4. Freshly isolated 
mast cells, purified from human lung, and blood basophils were shown to express CD40L and to induce IgE production.  Basophils 
were able to induce IgE synthesis even in the absence of exogenous IL-4. This suggests that mast cells and basophils may play key 
roles in allergy not only by producing inflammatory mediators, but also by directly regulating IgE production independently of 
T cells. Thus, Ig switching which was previously thought to take place only in the germinal centres of lymph nodes, may also 
occur in peripheral organs such as the lung or the skin.<P>

The immunosupressive drug cyclosporin A has recently been shown to be of therapeutic benefit in the treatment of certain atopic 
diseases. We found that cyclosporin A inhibited the increase in CD40L mRNA synthesis that was induced by treating mast cells 
with calcium ionophore and phorbol ester. There was a corresponding decrease in the expression of the CD40L protein (Gauchat et 
al., 
1993). The inhibition of CD40L synthesis by mast cells might therefore contribute to the beneficial action of cyclosporin A. <P>

<b>CD23 and CD21</b><p>

The observation that IL-4 and IL-13, which induce IgE-switching, were able to increase CD23 expression, suggested that CD23 is 
also involved in the specific control of IgE production. 
This was confirmed by studies using anti-CD23 antibodies and recombinant soluble CD23, which were shown to regulate 
IL-4-induced IgE production. CD23 is a 45 kDa type II transmembrane 
glycoprotein that is expressed in many cell types. It was originally defined as a low affinity IgE receptor. Based on our 
observation that CD23 interacts with a ligand other than IgE, 
namely CD21, we have proposed a model whereby CD23/CD21 molecules facilitate the T cell/B cell interaction that is necessary 
for IgE production. CD23 is one of several molecules that 
are involved in the T cell/B cell interaction, along with LFA-1/ICAM-1, CD2/LFA-3, CD28/B7 and CD5/CD72. However, the 
particular characteristic of the CD21/CD23 pair, when compared to 
the others, is that this pairing specifically controls IgE synthesis; it does not affect the synthesis of other immunoglobulin 
isotypes.<P>

Studies on induction of the IgE response <cite>in vivo</cite>, in the rat, confirmed the crucial role played by CD23 (Flores-Romo et al., 
1993). A rabbit polyclonal antiserum, Rb55, raised against 
a truncated version of recombinant human CD23, was found to inhibit IL-4-induced IgE production by human mononuclear cells <cite>in 
vitro</cite> in an isotype-specific manner. Rb55  apparently also 
recognizes the rat homologue of CD23 since it binds to a cell surface molecule that is expressed on the surface of splenic B 
cells of rats that have been stimulated with IgE, a process 
known to induce a low affinity IgE receptor. Administration of Rb55 antibody to rats when  an allergen (ovalbumin)-specific IgE 
response was induced resulted in up to 90% inhibition of 
ovalbumin-specific IgE synthesis. The mechanism of inhibition is believed to be the prevention of T cell/B cell interaction, 
which is known to be essential for IgE production. Rb55 Fab 
fragments as well as intact Rb55 IgG both inhibited IgE production, <cite>in vitro</cite> and <cite>in vivo</cite>, and were also shown to prevent T 
cell/B cell conjugate formation. These results show for the 
first time that CD23 plays a central role in the regulation of IgE synthesis <cite>in vivo</cite> and may therefore be important in a number 
of allergic diseases. The identification of these new 
molecular and cellular pathways has greatly increased our understanding of human IgE regulation.<P>

<b>Some recent publications:</b><p>

Aubry, J.-P., Pochon, S., Graber, P., Jansen, K. and J.-Y. Bonnefoy. (1992).
CD21 is a ligand for CD23 and regulates IgE 
production. <i>Nature</i> 358: 505-7.<P>

Flores-Romo, L., Shields, J., Humbert, Y., Graber, P., Aubry, J.-P., Gauchat, J.-F., Ayala, G., Allet, B., Chavez, M., Bazin, H., 
Capron, M. and J.-Y. Bonnefoy. (1993).
Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. 
<i>Science</i> 261:1038-41.<P>

Di Santo, J.-P., Bonnefoy, J.-Y., Gauchat, J.-F., Fischer, A. and G. de Saint-Basile. (1993).
CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM.
<i>Nature</i> 361: 541-3.<P>

Gauchat, J.-F., Henchoz, S., Mazzei, G., Aubry, J.-P., Brunner, T., Blasey, H., Life, P., Talabot, D., Flores-Romo, L., Thompson, J., Kishi, K., Butterfield, J., Dahinden, C. and J.-Y. 
Bonnefoy. (1993).
Induction of human IgE synthesis in B cells by mast cells and basophils. <i>Nature</i> 365: 340-3. <P>

<a href="project.html">Return to: Research projects contents page</a><p>

<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-302</DOCNO>
<DOCOLDNO>IA057-000937-B014-306</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/zoom.html 193.128.22.20 19970109090217 text/html 926
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:52:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:32 GMT
Content-length: 736
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Zoom</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Zoom</font></h2><p>
<pre>
Syntax:  zoom {&lt;boolean&gt;}
         zoom &lt;value&gt;
</pre><p>
Change the magnification of the currently displayed image. Boolean
parameters either magnify or reset the scale of current molecule. An
integer parameter between 10 and 200 specifies the desired magnification
as a percentage of the default scale.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-303</DOCNO>
<DOCOLDNO>IA057-000937-B013-516</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/load.html 193.128.22.20 19970109085516 text/html 1558
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:45:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 1367
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Load</font></h2><p>
<pre>
Syntax:  load {&lt;format&gt;} &lt;filename&gt;
</pre><p>
Load a molecule co-ordinate file into RasMol2. Valid molecule file
formats are
<tt><b>pdb</b></tt>
(Brookhaven Protein Databank),
<tt><b>mdl</b></tt>
(Molecular Design Limited's MOL file format),
<tt><b>alchemy</b></tt>
(Tripos' Alchemy file format),
<tt><b>mol2</b></tt>
(Tripos' Sybyl Mol2 file format),
<tt><b>charmm</b></tt>
(CHARMm file format) or
<tt><b>xyz</b></tt>
(MSC's XMol XYZ file format). If no file format is specified,
<tt><b>pdb</b></tt>
is assumed by default. Only a single molecule may be loaded at a time.
To delete a molecule prior to loading another use the RasMol
<a href="zap.html"><tt><b>zap</b></tt></a>
command.
<p>
The
<tt><b>load</b></tt>
command selects all the atoms in the molecule, centres it on the
screen and renders it as a CPK coloured wireframe model. If the molecule
contains no bonds (i.e. contains only alpha carbons), it is drawn as
an alpha carbon backbone. If the file specifies less bonds than atoms,
RasMol determines connectivity using the
<a href="connect.html"><tt><b>connect</b></tt></a>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-304</DOCNO>
<DOCOLDNO>IA057-000937-B013-359</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/connect.html 193.128.22.20 19970109085236 text/html 1430
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:42:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1239
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br> 
<h2><font size=6>Connect</font></h2><p>
<pre>
Syntax:  connect {&lt;boolean&gt;}
</pre><p>
The RasMol
<tt><b>connect</b></tt>
command is used to force RasMol to (re)calculate the connectivity
of the current molecule. If the original input file contained
connectivity information, this is discarded. The command
<tt><b>connect false</b></tt>
uses an extremely fast heuristic algorithmm that is suitable for
determing bonding in large bio-molecules such as proteins and
nucleic acids.  The command
<tt><b>connect true</b></tt>
uses a slower more accurate algorithm based upon covalent radii
that is more suitable for small molecules containing inorganic
elements or strained rings. If no parameters are given, RasMol
determines which algorithm to use based on the number of atoms
in the file. Greater than 255 atoms causes RasMol to use the
faster implementation. This is the method used to determine
bonding, if necessary, when a molecule is first read in using
the
<a href="load.html"><tt><b>load</b></tt></a>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-305</DOCNO>
<DOCOLDNO>IA057-000937-B013-430</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/quit.html 193.128.22.20 19970109085329 text/html 759
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:43:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 569
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Quit</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Quit</font></h2><p>
<pre>
Syntax:  quit
         exit
</pre><p>
Exit from the RasMol program. The RasMol commands
<tt><b>exit</b></tt>
and
<tt><b>quit</b></tt>
are synonymous.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-306</DOCNO>
<DOCOLDNO>IA057-000937-B013-533</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/print.html 193.128.22.20 19970109085531 text/html 1383
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:45:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1192
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Print</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Print</font></h2><p>
<pre>
Syntax:  print
</pre><p>
The RasMol
<tt><b>print</b></tt>
command sends the currently displayed image to the local default printer
using the operating system's native printer driver. Note: this command
is not yet supported under UNIX or VMS. It is intended to take advantage
of Microsoft Windows and Apple Macintosh printer drivers. For example,
allowing images to be printed directly on a dot matrix printer.
<p>
When using RasMol on a UNIX or VMS system this functionality may be
achieved by either generating a PostScript file using the RasMol
<a href="write.html"><tt><b>write ps</b></tt></a>
or
<a href="write.html"><tt><b>write vectps</b></tt></a>
commands and printing that or generating a raster image file and using a
utility to dump that to the local printer.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-307</DOCNO>
<DOCOLDNO>IA057-000937-B014-56</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/reset.html 193.128.22.20 19970109085724 text/html 1119
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:47:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 929
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Reset</font></h2><p>
<pre>
Syntax:  reset
</pre><p>
The RasMol
<tt><b>reset</b></tt>
command restores the original viewing transformation
and centre of rotation. The scale is set to it's default value,
<a href="zoom.html"><tt><b>zoom 100,</b></tt></a>
the centre of rotation is set to the geometric centre of the currently
loaded molecule,
<a href="centre.html"><tt><b>centre all,</b></tt></a>
this centre is translated to the middle of the screen and
the viewpoint set to the default orientation.
<p>
This command should not be mistaken for the RasMol
<a href="zap.html"><tt><b>zap</b></tt></a>
command which deletes the currently stored molecule, returning the
program to its initial state.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-308</DOCNO>
<DOCOLDNO>IA057-000937-B013-306</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/centre.html 193.128.22.20 19970109085154 text/html 1200
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:42:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 1009
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Centre</font></h2><p>
<pre>
Syntax:  center {&lt;expression&gt;}
         centre {&lt;expression&gt;}
</pre><p>
The RasMol
<tt><b>centre</b></tt>
command defines the point about which the
<a href="rotate.html"><tt><b>rotate</b></tt></a>
command and the scroll bars rotate the current molecule. Without a
parameter the centre command resets the centre of rotation to be the
centre of gravity of the molecule. If an atom expression is specified,
RasMol rotates the molecule about the centre of gravity of the set of
atoms specified by the expression. Hence, if a single atom is specified
by the expression, that atom will remain `stationary' during rotations.
<p>
Type
<a href="help.html"><tt><b>help expression</b></tt></a>
for more information on RasMol atom expressions.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-309</DOCNO>
<DOCOLDNO>IA057-000937-B014-123</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/rotate.html 193.128.22.20 19970109085851 text/html 963
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:49:02 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 773
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Rotate</font></h2><p>
<pre>
Syntax:  rotate &lt;axis&gt; {-} &lt;value&gt;
</pre><p>
Rotate the molecule about the specified axis.
Permited values for the axis parameter are
"<tt><b>x</b></tt>", "<tt><b>y</b></tt>" and "<tt><b>z</b></tt>".
The integer parameter states the angle in degrees for the structure to
be rotated. For the X and Y axes, positive values move the closest point
up and right, and negative values move it down and left respectively. For
the Z axis, a positive rotation acts clockwise and a negative angle
anti-clockwise.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-310</DOCNO>
<DOCOLDNO>IA057-000937-B014-390</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/atset.html 193.128.22.20 19970109090345 text/html 1022
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:53:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 832
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: AT Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../"><img src="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>AT Set</font></h2><p>
This set contains the atoms in the complementary nucleotides
adenosine and thymidine (A and T respectively). All nucleotides
are classified as either the set
<tt><b>at</b></tt>
or the set
<a href="cgset.html"><tt><b>cg</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>a,t</b></tt>"
and
"<tt><b>nucleic and not cg</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-311</DOCNO>
<DOCOLDNO>IA057-000937-B015-62</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/cgset.html 193.128.22.20 19970109090621 text/html 792
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:56:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 602
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>CG Set</font></h2><p>
This set contains the atoms in the complementary nucleotides
cytidine and guanoine (C and G respectively). All nucleotides
are classified as either the set
<a href="atset.html"><tt><b>at</b></tt></a>
or the set
<tt><b>cg</b></tt>
This set is equivalent to the RasMol atom expressions
"<tt><b>c,g</b></tt>"
and
"<tt><b>nucleic and not at</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-312</DOCNO>
<DOCOLDNO>IA057-000937-B008-125</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/workshop/progwed.html 193.128.22.20 19970109080537 text/html 3013
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:55:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:51 GMT
Content-length: 2822
Content-type: text/html
</DOCHDR>
 
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Conference announcement</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Conference announcement</font></h1>
<hr size=4>
<p>
<h2><font size=6>Transient gene expression in animal cells</font></h2>

<font size=5>Preliminary programme</font><p>

<strong>Wednesday, 14 May 1997: Non-Viral Expression Strategies</strong><p>



<table width="70%" border=0 cellpadding=1 cellspacing=2>
<tr>
<th colspan=2><font size=4>Chair:  Florian Wurm<p></td></tr>
<tr><td>8:30-9:10</td>
<td>Introduction - Florian Wurm</td></tr>	 
<tr><td>9:10-9:50<p></td>
<td>Applied and scale-up - Horst Blasey<p></td></tr>	 
<tr><td><em>9:50-10:20</em><p></td>
<td><em>Break</em><p></td></tr>	

<tr><td>10:20-10:40</td><td>Calcium phosphate transfection - Martin Jordan</td></tr>
<tr><td>10:40-11:00</td><td><br></td></tr>
<tr><td>11:00-11:20</td><td>Dirk Gheysen</td></tr>
<tr><td>11:20-11:40<br>
11:40-12:00<br>
12:00-12:20<p></td><td><p></td></tr>
<tr><td><em>12:30-2:00</em><p></td><td><em>Lunch</em><p></td></tr>

<th colspan=2><font size=4>Chair: Matt Cotten<p></td></tr>
<tr><td>2:00-2:40</td><td>Inducible promoters - Herman Bujard<p></td></tr>
<tr><td>2:40-3:20<p></td><td>Receptor-mediated transfection - Matt Cotten<p></td></tr>
<tr><td><em>3:20-3:50</em><p></td>
<td><em>Break</em><p></td></tr>
<tr><td>3:50-4:10</td><td><br></td></tr>
<tr><td>4:10-4:30</td><td>Liposomes - Joel Jessee</td></tr>
<tr><td>4:30-4:50</td><td>HSV/VP16 - Paul Hippenmeyer</td></tr>
<tr><td>4:50-5:10<br>
5:10-5:30<br>
5:30-5:50</td><td><br></td></tr>
</table>

<p>


<a href="progtue.html">Back to: Tuesday's programme</a><p>
<a href="prog.html">Return to: Preliminary programme index page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-313</DOCNO>
<DOCOLDNO>IA057-000937-B008-103</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/workshop/progtue.html 193.128.22.20 19970109080517 text/html 3098
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:55:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:51 GMT
Content-length: 2907
Content-type: text/html
</DOCHDR>
 
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Conference announcement</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Conference announcement</font></h1>
<hr size=4>
<p>
<h2><font size=6>Transient gene expression in animal cells</font></h2>

<font size=5>Preliminary programme</font><p>

<strong>Tuesday, 13 May 1997: Mammalian Virus Expression</strong><p>



<table width="70%" border=0 cellpadding=1 cellspacing=2>
<tr>
<th colspan=2><font size=4>SFV and Sindbis Chair: Peter Liljestr&ouml;m<p></td></tr>
<tr><td>8:30-9:10</td>
<td>General Overview - Sondra Schlesinger</td></tr>	 
<tr><td>9:10-9:50<p></td>
<td>Applications/Scale-up - Ken Lundstr&ouml;m<p></td></tr>	 
<tr><td><em>9:50-10:20</em><p></td>
<td><em>Break</em><p></td></tr>	

<tr><td>10:20-10:40</td><td>Vaccines technology - Cristian Smerdou</td></tr>
<tr><td>10:40-11:00</td><td>Sindbis - Tom Dubensky</td></tr>
<tr><td>11:00-11:20</td><td>Robert Johnston</td></tr>
<tr><td>11:20-11:40<br>
11:40-12:00<br>
12:00-12:20<p></td><td><p></td></tr>
<tr><td><em>12:30-2:00</em><p></td><td><em>Lunch</em><p></td></tr>
<tr>
<th colspan=2><font size=4>Other Viral Systems Chair:  Marie-Paule Kieny<p></td></tr>
<tr><td>2:00-2:40<p></td><td>Vaccinia - Marie-Paule Kieny<p></td></tr>
<tr><td><em>2:40-3:10</em><p></td>
<td><em>Break</em><p></td></tr>
<tr><td>3:10-3:50</td><td>Retroviruses - Chris Petropoulos</td></tr>
<tr><td>3:50-4:30</td><td>Adenovirus - Michel Perricaudet</td></tr>
<tr><td>4:30-5:10<br>
5:10-5:30</td><td><br></td></tr>
</table>

<p>

<a href="progwed.html">Forward to: Wednesday's programme</a><p>
<a href="progmon.html">Back to: Monday's programme</a><p>
<a href="prog.html">Return to: Preliminary programme index page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-314</DOCNO>
<DOCOLDNO>IA057-000937-B008-90</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/news/workshop/progmon.html 193.128.22.20 19970109080447 text/html 2887
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:54:58 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:51 GMT
Content-length: 2696
Content-type: text/html
</DOCHDR>
 
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Conference announcement</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Conference announcement</font></h1>
<hr size=4>
<p>
<h2><font size=6>Transient gene expression in animal cells</b></font></h2>

<font size=5>Preliminary programme</font><p>

<strong>Monday 12 May 1997: Baculovirus Expression</strong><p>



<table width="70%" border=0 cellpadding=1 cellspacing=2>
<tr>
<th colspan=2><font size=4>Chair: Verne Luckow<p></td></tr>
<tr><td>8:30-8:40</td>
<td>Opening - Alain Bernard / Bob Possee</td></tr>	 
<tr><td>8:40-9:20</td>
<td>Introduction - Verne Luckow</td></tr>	 
<tr><td>9:20-10:00<p></td>
<td>Michael Dennis<p></td></tr>
<tr><td><em>10:00-10:30</em><p></td>
<td><em>Break</em><p></td></tr>	

<tr><td>10:30-10:50<br>
10:50-11:10<br>
11:10-11:30<br>
11:30-11:50<br>
11:50-12:10<br>
12:10-12:30<p></td><td><p></td></tr>
<tr><td><em>12:30-2:00</em><p></td><td><em>Lunch</em><p></td></tr>




<tr>
<th colspan=2><font size=4>Chair: Bob Possee<p></td></tr>
<tr><td>2:00-2:40</td>
<td>George Rohrmann</td></tr>
<tr><td>2:40-3:20<p></td>
<td>Johannes Tramper<p></td></tr>
<tr><td><em>3:20-3:50</em><p></td>
<td><em>Break</em><p></td></tr>



<tr><td>3:50-4:10<br>
4:10-4:30<br>
4:30-4:50<br>	
4:50-5:10<br>
5:10-5:30<br>
5:30-5:50<br></td><td><br></td></tr>
<tr><td>6:00-8:00<p></td><td>Posters<p></td></tr> 
<tr><td><em>8:00-10:00</em><p><td><em>Dinner</em><p></td></tr>
</table>

<p>

<a href="progtue.html">Forward to: Tuesday's programme</a><p>

<a href="prog.html">Return to: Preliminary programme index page</a>
<p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-315</DOCNO>
<DOCOLDNO>IA057-000937-B015-332</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/sheet.html 193.128.22.20 19970109091103 text/html 817
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:01:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 627
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Sheet Set</font></h2><p>
This set contains all atoms that form part of a protein beta
sheet as determined by either the PDB file author or Kabsch and
Sander's DSSP algorithm. By default, RasMol uses the secondary
structure determination given in the PDB file if it exists.
Otherwise, it uses the DSSP algorithm as used by the RasMol
<a href="struct.html"><tt><b>structure</b></tt></a>
command.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-316</DOCNO>
<DOCOLDNO>IA057-000937-B012-304</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/uar.html 193.128.22.20 19970109084037 text/html 1729
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:30:48 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:36 GMT
Content-length: 1538
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: United Arab Emirates</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Gulf & North Arabia</font></h2>
<p>
P. O. Box 50199<br>
                  Dubai<br>
                  UNITED ARAB EMIRATES<p>


<hr><p>


<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-317</DOCNO>
<DOCOLDNO>IA057-000937-B014-427</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/aliph.html 193.128.22.20 19970109090416 text/html 822
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:54:27 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 632
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Aliphatic Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont size=4> <a 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><BR>
<h2><font size=6>Aliphatic Set</font></h2><p>
This set contains the aliphatic amino acids.
These are the amino acids Ala, Gly, Ile, Leu and Val.
This set is equiavlent to the RasMol atom expression
"<tt><b>ala, gly, ile, leu, val</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-318</DOCNO>
<DOCOLDNO>IA057-000937-B015-181</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/large.html 193.128.22.20 19970109090833 text/html 246
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:58:44 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 57
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

</DOC>
<DOC>
<DOCNO>WT14-B39-319</DOCNO>
<DOCOLDNO>IA057-000937-B015-366</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/small.html 193.128.22.20 19970109091157 text/html 876
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:02:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 686
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Small Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Small Set</font></h2><p>
All amino acids are classified as either
<tt><b>small,</b></tt>
<a href="medium.html"><tt><b>medium</b></tt></a>
or
<a href="large.html"><tt><b>large.</b></tt></a>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not (medium or large)</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-320</DOCNO>
<DOCOLDNO>IA057-000937-B015-208</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/medium.html 193.128.22.20 19970109090910 text/html 713
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:59:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 523
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Medium Set</font></h2><p>
All amino acids are classified as either
<a href="small.html"><tt><b>small,</b></tt></a>
<tt><b>medium</b></tt>
or
<a href="large.html"><tt><b>large.</b></tt></a>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not (large or small)</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-321</DOCNO>
<DOCOLDNO>IA057-000937-B009-365</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gw1.html 193.128.22.20 19970109081552 text/html 1770
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:06:04 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:27 GMT
Content-length: 1579
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-UK</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome plc</font></h2>

Glaxo Wellcome House<br>
Berkeley Avenue,<br>
Greenford,<br>
Middlesex.<br>
UB6 0NN<p>
Tel: (0171) 493 4060<br>
Telex: 25456<br>
Fax No: (0181) 966 8330 / (0181) 966 8228

<p>
<a href="gw.html">Return to: Glaxo Wellcome plc addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-322</DOCNO>
<DOCOLDNO>IA057-000937-B014-255</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/trans.html 193.128.22.20 19970109090122 text/html 1484
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:51:33 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 1293
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Translate</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Translate</font></h2><p>
<pre>
Syntax:  translate &lt;axis&gt; {-} &lt;value&gt;
</pre><p>
The RasMol
<tt><b>translate</b></tt>
command moves the position of the centre of the molecule on the
screen. The axis parameter specifies along which axis the molecule
is to be moved and the integer parameter specifies the absolute
position of the molecule centre from the middle of the screen.
Permited values for the axis parameter are
"<tt><b>x</b></tt>", "<tt><b>y</b></tt>" and "<tt><b>z</b></tt>".
Displacement values must be between -100 and 100 which correspond to
moving the current molecule just off the screen. A positive
"<tt><b>x</b></tt>"
displacement moves the molecule to the right, and a positive
"<tt><b>y</b></tt>"
displacement moves the molecule down the screen. The pair of commands
<tt><b>translate x 0</b></tt>
and
<tt><b>translate y 0</b></tt>
centres the molecule on the screen.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-323</DOCNO>
<DOCOLDNO>IA057-000937-B017-429</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/rd.html 193.128.22.20 19970109093543 text/html 1792
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:25:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:36 GMT
Content-length: 1601
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; Development</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

<a href="rd1.html">Greenford, Middlesex</a><p>
<a href="rd2.html">Glaxo Wellcome Medicines Research Centre, Stevenage</a><p>
<a href="rd3.html">Ware, Hertfordshire</a><p>
<P>
<hr>
<p>

<a href="uk.html">Return to: Main UK addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-324</DOCNO>
<DOCOLDNO>IA057-000937-B023-337</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/rd1.html 193.128.22.20 19970109102422 text/html 1865
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:14:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:36 GMT
Content-length: 1674
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; DevelopmentGlaxo Research and Development Ltd.</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

891-995 Greenford Road,<br>
Greenford,<br>
Middlesex.<br>
UB6 0HE<p> 

Tel: (0181) 422 3434<br>
Telex: 22134<br>
Telex: 8951942   - When Using Computer<br>
Fax No: (0181) 423 4401<br>
<p>

<a href="rd.html">Return to: Glaxo Wellcome Research &amp; Development addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-325</DOCNO>
<DOCOLDNO>IA057-000937-B023-354</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/rd2.html 193.128.22.20 19970109102447 text/html 1808
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:14:47 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:36 GMT
Content-length: 1617
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; Development</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

Glaxo Wellcome Medicines Research Centre,<br>
Gunnels Wood Road,<br>
Stevenage,<br>
Hertfordshire.<br>
SG1 2NY<p>
Tel: (01438) 745745<br>
Fax No: (01438) 764502

<p>

<a href="rd.html">Return to: Glaxo Wellcome Research &amp; Development addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-326</DOCNO>
<DOCOLDNO>IA057-000937-B023-367</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/rd3.html 193.128.22.20 19970109102502 text/html 1811
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:15:16 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:36 GMT
Content-length: 1620
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Research &amp; Development</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Research &amp; Development</font>
</h2>

Park Road,<br>
Ware,<br>
Hertfordshire.<br>
SG12 0DP<p> 
Tel: (01920) 469469<br>
Telex: 817877<br>
Telex: 817073   - When Using Computer<br>
Fax No: (01920) 463172

<p>

<a href="rd.html">Return to: Glaxo Wellcome Research &amp; Development addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-327</DOCNO>
<DOCOLDNO>IA057-000937-B013-327</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/clipb.html 193.128.22.20 19970109085211 text/html 1035
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:42:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 845
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Clipboard</font></h2><p>
<pre>
Syntax:  clipboard
</pre><p>
The RasMol
<tt><b>clipboard</b></tt>
command places a copy of the currently displayed image on the local
graphics `clipboard'. Note: this command is not yet supported on
UNIX or VMS machines. It is intended to make transfering images
between applications easier under Microsoft Windows or on an Apple
Macintosh.
<p>
When using RasMol on a UNIX or VMS system this functionality may be
achieved by generating a raster image in a format that can be read
by the receiving program using the RasMol
<a href="write.html"><tt><b>write</b></tt></a>
command.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-328</DOCNO>
<DOCOLDNO>IA057-000937-B015-262</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/polar.html 193.128.22.20 19970109091015 text/html 870
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:00:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 680
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Polar Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Polar Set</font></h2><p>
This set contains the polar amino acids.
All amino acids are classified as either
<a href="hydroph.html"><tt><b>hydrophobic</b></tt></a>
or
<tt><b>polar.</b></tt>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not hydrophobic</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-329</DOCNO>
<DOCOLDNO>IA057-000937-B015-149</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/hydroph.html 193.128.22.20 19970109090806 text/html 1004
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:58:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 814
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Hydrophobic Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Hydrophobic Set</font></h2><p>
This set contains all the hydrophobic amino acids.
These are the amino acids Ala, Leu, Val, Ile, Pro, Phe, Met and Trp.
All amino acids are classified as either
<tt><b>hydrophobic</b></tt>
or
<a href="polar.html"><tt><b>polar.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>ala, leu, val, ile, pro, phe, met, trp</b></tt>"
and
"<tt><b>amino and not polar</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-330</DOCNO>
<DOCOLDNO>IA057-000937-B010-487</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/aust.html 193.128.22.20 19970109082533 text/html 1738
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:15:47 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:24 GMT
Content-length: 1547
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Austria</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Pharmazeutica G.m.b.H.</font></h2>

Albert-Schweitzer-Gasse<br>
A-1140 Wien<br>
AUSTRIA<br>
<p> 

Tel: (431) 970 750<br>
Fax No: (431) 970 75 170<p>
<hr><p>
<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-331</DOCNO>
<DOCOLDNO>IA057-000937-B011-179</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/neth.html 193.128.22.20 19970109082845 text/html 1725
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:18:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:31 GMT
Content-length: 1534
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Netherlands</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome B.V.</font></h2>


P. O. Box 780<br>
3700 AT Zeist<br>
NETHERLANDS<p>

  
Tel:	(31) (3069) 38100<br>
Fax No:	(31) (3069) 38471<br>
<p>
<hr><p>


<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-332</DOCNO>
<DOCOLDNO>IA057-000937-B011-344</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/swit.html 193.128.22.20 19970109083151 text/html 2406
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:22:02 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 2215
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information: Switzerland</font></h1>
<hr size=4>
<p>
<font size=5><a href="swexit.html">Glaxo Wellcome Switzerland WWW</a></font>
<p>
<h2><font size=6>Adechsa S.A.</font></h2>

Baarerstrasse 18<br>
Postfach<br>
6304 Zug<br>
SWITZERLAND<p> 

Tel:	(4141) 7102566<br>
Fax No:	(4141) 7102159<p>
<hr><p>

<h2><font size=6>Glaxo Wellcome AG</font></h2>

Bahnhofstrasse 5<br>
Postfach<br>
CH-3322 Schonb&uuml;hl/Berne<br>
SWITZERLAND<p> 

Tel: (4131) 8596100<br>
Telex: 911279<br>
Fax No:	(4131) 8596330<p>

With effect  from 7  September 1996 the telephone and fax numbers of Glaxo Wellcome AG will change as follows:<p>

Tel: (4131) 8501111<br>
Fax: (4131) 8501100 (General)<p>

<hr><p>

<h2><font size=6>Geneva Biomedical Research Institute</font></h2>

14 Chemin des Aulx<br>
1228-Plan-les-ouates<br>
Geneva<br>
SWITZERLAND<p> 


Tel: (4122) 7069666 <br>
Telex: 421744<br>
Fax No: (4122) 7946965 (General) <p>

<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-333</DOCNO>
<DOCOLDNO>IA057-000937-B022-129</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/swexit.html 193.128.22.20 19970109101029 text/html 2330
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:00:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 2139
Content-type: text/html
</DOCHDR>
<html><head>
<title>You are leaving the Glaxo Wellcome global web site</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>You are leaving the Glaxo Wellcome global web site</font></h1>
<hr size=4>


<p>

<font size=5>Thank you for visiting the Glaxo Wellcome global Web site, maintained by <a href="gw.html">Glaxo Wellcome plc in London, UK.</a></font><p>

You are about to reach pages created by Glaxo Wellcome Switzerland for
Swiss residents only. Not all the information it contains will be
applicable outside Switzerland.  Your <a href="../">local Glaxo Wellcome company</a> will always be happy to respond to your enquiries.<p>

Please remember that medical practice varies from country to country.
Always seek the advice of your doctor.<p>

<img src="ch.gif" align=left hspace=5>Forward to: Glaxo Wellcome Switzerland<br>
 <a href="http://www.glaxowellcome.ch/gw/gw_fr.html">en Fran&ccedil;aise</a> or
<a href="http://www.glaxowellcome.ch/gw/gw_dt.html">in Deutsch</a>
<br clear=left><p>


<a href="swit.html">Return to: Swiss contacts page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-334</DOCNO>
<DOCOLDNO>IA057-000937-B011-284</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/russ.html 193.128.22.20 19970109083051 text/html 1806
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:21:03 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:34 GMT
Content-length: 1615
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Russia</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Export Branch Office</font></h2>


ul. Novocheremushkinskaya<br>
                  117418 Moscow<br>
                  RUSSIA<p>

Tel: (7095) 258 6722<br>
Fax: (7095) 258 6723 <br>
Satellite Tel: (7095) 258 6722<p>
<hr><p>



<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-335</DOCNO>
<DOCOLDNO>IA057-000937-B012-181</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/paki.html 193.128.22.20 19970109083834 text/html 1814
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:28:44 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1623
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Pakistan</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Laboratories (Pakistan) Limited</font></h2>
<p>
P.O. Box 4674<br>
Dockyard Road<br>
West Wharf<br>
        Karachi 74000<br>
        PAKISTAN<p>

Tel:    (9221) 200151 (8 lines)<br>
Telex:  24070 GLXKF PK<br>
Fax No: (9221) 2310364<p>

<hr><p>
<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-336</DOCNO>
<DOCOLDNO>IA057-000937-B013-204</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/vene.html 193.128.22.20 19970109085029 text/html 1913
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:40:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:37 GMT
Content-length: 1722
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Venezuela</font></h1>
<hr size=4>
<br>
<h2><font size=6>Laborotorios Glaxo de Venezuela C.A.</font></h2>

As the postal service is poor in Venezuela it is recommended that all communications should be sent by courier or fax.<p>


Postal Address:<br>
Apartado Postal 4641<br>
Caracas 1010<br>
VENEZUELA<p>

Tel: (582) 932122<br>
Telex: 28056 GLAXO VC<br>
Fax No: (582) 9417909<p>
<hr><p>

<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-337</DOCNO>
<DOCOLDNO>IA057-000937-B013-95</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/chil.html 193.128.22.20 19970109084850 text/html 1794
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:38:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:25 GMT
Content-length: 1603
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Chile</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Farmaceutica Chilena Limitada</font></h2>

Av. Andr&eacute;s Bello 2687<br>
Piso 19 - Edificio del Pacifico<br>
Las Condes<br>
Santiago<br>
CHILE<p> 

Tel: (562) 203 9020<br>
Fax No: (562) 203 9030<p>

<hr><p>

<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-338</DOCNO>
<DOCOLDNO>IA057-000937-B011-154</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/ital.html 193.128.22.20 19970109082825 text/html 1760
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:18:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1569
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Italy</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome S.p.A.</font></h2>

Via Alessandro Fleming 2<br>
37155 Verona<br>
ITALY<br>
<p> 

Tel:	(3945) 9218111 (18 lines)<br>
Telex:	481418 GLAXO I<br>
Fax No:	(3945) 9218388<p>



<hr><p>
<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-339</DOCNO>
<DOCOLDNO>IA057-000937-B012-211</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/saud.html 193.128.22.20 19970109083903 text/html 1740
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:29:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:34 GMT
Content-length: 1549
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Saudi Arabia</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Saudi Arabia Limited</font></h2>
<p>
P. O. Box 22617<br>
        Jeddah 21416<br>
        SAUDI ARABIA<p>

Tel: (9662) 6445872<br>
Fax No: (9662) 6440701<p>

<hr><p>
<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-340</DOCNO>
<DOCOLDNO>IA057-000937-B011-215</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/pola.html 193.128.22.20 19970109082923 text/html 1766
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:19:36 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:33 GMT
Content-length: 1575
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Poland</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Polska Sp. z o.o.</font></h2>


AL. Jana Pawla 11 34 Apt 6<br>
00141 Warsaw<br>
POLAND<br>
<p> 

Tel:	(4822) 624 74 24<br>
Telex:	817497 GXMW PL<br>
Fax No:	(4822) 624 71 29<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-341</DOCNO>
<DOCOLDNO>IA057-000937-B012-40</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/nige.html 193.128.22.20 19970109083614 text/html 1958
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:26:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:31 GMT
Content-length: 1767
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Africa</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Nigeria</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Nigeria Limited</font></h2>
<p>
<font size=5>It is
recommended that all communications to Nigeria should be sent by courier or fax.</font>
<p>
        41 Creek Road<br>
        PMB 1401  <br>
        Apapa<br>
        NIGERIA<p>

Tel:    (2341)5872050<br>
Telex:  22256<br>
Fax No: (2341) 5872054<br>
Satellite<br>
Tel:    (871) 1772174<br>
Fax No: (871) 1772175<p>
<hr><p>


<a href="afri.html">Return to: African contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-342</DOCNO>
<DOCOLDNO>IA057-000937-B013-81</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/braz.html 193.128.22.20 19970109084839 text/html 1771
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:38:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:25 GMT
Content-length: 1580
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Brazil</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A.</font></h2>

Rua Viuva Claudio, 300<br>
20970-030 - Jacare<br>
Rio de Janeiro<br>
BRAZIL<p> 

Tel: (5521) 2010122<br>
Telex: 2123082<br>
Fax No: (5521) 5818558<p>


<hr><p>
<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-343</DOCNO>
<DOCOLDNO>IA057-000937-B012-156</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/kore.html 193.128.22.20 19970109083812 text/html 1772
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:28:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1581
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Korea</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Korea Limited</font></h2>
<p>

P. O. Box 63<br>
Seoul Regional Communication Office<br>
Seoul 140-600<br>
        KOREA<p>
        
Tel:    (822) 7094100<br>
Fax No: (822) 7964710<p>



<hr><p>


<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-344</DOCNO>
<DOCOLDNO>IA057-000937-B013-116</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/colo.html 193.128.22.20 19970109084906 text/html 1785
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:39:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:25 GMT
Content-length: 1594
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Colombia</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome de Colombia S.A.</font></h2>

Carrera 8A No 99-51<br>
Torre A, Piso 9<br>
Santafe de Bogota<br>
COLOMBIA<p> 

Tel:(571) 2186911<br>
Telex:	42615 GLAXO C<br>
Fax No:	(571) 2184752<p>
<hr><p>
<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-345</DOCNO>
<DOCOLDNO>IA057-000937-B012-251</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/taiw.html 193.128.22.20 19970109083931 text/html 1822
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:29:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 1631
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Taiwan</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Taiwan Limited</font></h2>
<p>
        7th Floor, IBM Building<br>
        No. 2, Tun Hwa South Road, Sec. 1.<br>
        Taipei,    <br>
        Republic of China<br>
TAIWAN<p>

Tel:    (8862) 7311836<br>
Fax No: (8862) 7718228<p>

  
<hr><p>

<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-346</DOCNO>
<DOCOLDNO>IA057-000937-B012-168</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/maly.html 193.128.22.20 19970109083821 text/html 1771
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:28:32 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:31 GMT
Content-length: 1580
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Malaysia</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Malaysia Sdn Berhad</font></h2>
<p>

P. O. Box 11<br>
46700 Petaling Jaya<br>
MALAYSIA<p>

 
        
Tel:    (603) 7552633<br>

Telex:  37308 GLXMA <br>
Fax No: (603) 7556830<br>




<hr><p>
<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-347</DOCNO>
<DOCOLDNO>IA057-000937-B011-125</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/icel.html 193.128.22.20 19970109082804 text/html 1751
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:18:02 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:29 GMT
Content-length: 1560
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Iceland</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome hf</font></h2>

Thverholt 14,<br>
105 Reykjavik<br>
P O Box 5499,<br>
125 Reykjavik<br>
ICELAND<br>
<p> 

Tel:	(354) 561 6930<br>
Fax No:	(354) 561 6933<br>
<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-348</DOCNO>
<DOCOLDNO>IA057-000937-B011-42</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/finl.html 193.128.22.20 19970109082610 text/html 1924
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:16:19 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:26 GMT
Content-length: 1733
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information: Finland</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome OY</font></h2>


P.O. Box 32<br>
02170 Espoo 17<br>
FINLAND<p>

 
Tel: (3580) 5024240<br>
Telex: 122054<br>
Fax Nos: (3580) 422264
<p>

With  effect  from 12 October 1996 the area  codes  for  Glaxo
Wellcome OY will change from 3580 to 3589.  The telephone  and
fax numbers will be as follows:
<p>

Tel: 3589 5024240<br>
Fax No: 3589 422264<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-349</DOCNO>
<DOCOLDNO>IA057-000937-B011-410</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/turk.html 193.128.22.20 19970109083322 text/html 1818
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:23:33 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:36 GMT
Content-length: 1627
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Turkey</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome I.S.A.S</font></h2>
<p>
        Yildiz Posta Caddesi No 52/8<br>
        80700 Esentepe<br>
        Istanbul<br>
        TURKEY  <p>
        
Tel:    (90) (212) 2753474<br>
Telex:  26043 glax tr<br>
Fax No: (90) (212)  2723581<p>

<hr><p>


<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-350</DOCNO>
<DOCOLDNO>IA057-000937-B011-140</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/irel.html 193.128.22.20 19970109082815 text/html 1789
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:18:27 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1598
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Ireland</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Limited</font></h2>

P.O.Box No. 700<br>
Grange Road<br>
Rathfarnham<br>
Dublin 16<br>
REPUBLIC OF IRELAND<p> 

Tel:	(3531) 2984733 (10 lines)<br>
Telex:	93660 GLAXO EI<br>
Fax No:	(3531) 4934405<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-351</DOCNO>
<DOCOLDNO>IA057-000937-B013-143</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/pana.html 193.128.22.20 19970109084945 text/html 1745
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:39:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1554
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Panama</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Centro America S.A.</font></h2>

Apartado Postal 742<br>
Zona 9A<br>
REPUBLIC OF PANAMA<p>



Tel: (507) 2636711<br>
Fax: (507) 263 7774<p>


<hr><p>


<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-352</DOCNO>
<DOCOLDNO>IA057-000937-B012-93</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/hong.html 193.128.22.20 19970109083715 text/html 1871
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:27:28 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:29 GMT
Content-length: 1680
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Hong Kong</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Hong Kong Limited</font></h2>
<p>
        18th Floor West<br>
        Warwick House<br>
        Taikoo Place<br>
        979 King's Road<br>
        Quarry Bay<br>
        HONG KONG<p>



Tel:    (852) 25650524<br>
Telex:  66341 GLAXO HX<br>
Fax No's:       (852) 25659302/0910<p>

<hr><p>

<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-353</DOCNO>
<DOCOLDNO>IA057-000937-B011-84</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gree.html 193.128.22.20 19970109082654 text/html 1727
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:17:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:27 GMT
Content-length: 1536
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Greece</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome A.E.B.E.</font></h2>

266 Kifisias Avenue<br>
152 32 Halandri<br>
Athens<br>
GREECE<br>
<p> 
Tel: (301) 6882100<br>
Fax: (301) 6847144<p>

<hr><p>
<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-354</DOCNO>
<DOCOLDNO>IA057-000937-B015-291</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/purine.html 193.128.22.20 19970109091033 text/html 778
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:00:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 588
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Purine Set</font></h2><p>
The set of purine nucleotides.
These are the bases adenosine and guanosine (A and G respectively).
All nucleotides are either
<tt><b>purines</b></tt>
or
<a href="pyrimid.html"><tt><b>pyrimidines.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>a,g</b></tt>"
and
"<tt><b>nucleic and not purine</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-355</DOCNO>
<DOCOLDNO>IA057-000937-B015-308</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/pyrimid.html 193.128.22.20 19970109091045 text/html 945
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:00:56 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 755
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Pyrimidine Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Pyrimidine Set</font></h2><p>
The set of pyrimidine nucleotides.
These are the bases cytidine and thymidine (C and T respectively).
All nucleotides are either
<a href="purine.html"><tt><b>purines</b></tt></a>
or
<tt><b>pyrimidines.</b></tt>
This set is equivalent to the RasMol atom expressions
"<tt><b>c,t</b></tt>"
and
"<tt><b>nucleic and not pyrimidine</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-356</DOCNO>
<DOCOLDNO>IA057-000937-B013-133</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/ecua.html 193.128.22.20 19970109084935 text/html 1740
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:39:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:26 GMT
Content-length: 1549
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Ecuador</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A.</font></h2>


Casilla 1701-3733<br>
Quito<br>
ECUADOR<p>


Tel: (5932) 459887<br>
Telex:	21166<br>
Fax No:	(5932) 434523<P>






<hr><p>


<a href="sam.html">Return to: South American contacts page</a>

<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-357</DOCNO>
<DOCOLDNO>IA057-000937-B012-222</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/sing.html 193.128.22.20 19970109083914 text/html 2049
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:29:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:34 GMT
Content-length: 1858
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Singapore</font></h1>
<hr size=4>
<br>


<h2><font size=6>Glaxo Pharmaceuticals PTE Ltd</font></h2>
<p>
        1 Pioneer Sector 1<br>
        Jurong<br>
        SINGAPORE 628413<p>
        
Tel:    (65) 8612111<br>
Telex:  RS34164  GLAXEM<br>
Fax No: (65) 8611806<p>

<hr><p>

<h2><font size=6>Glaxo Wellcome Singapore PTE Ltd</font></h2>
<p>
Twenty First Floor<br>
Gateway West<br>
        150 Beach Road<br>
        SINGAPORE 189720<p>
        
Tel:    (65) 2916070<br>
Telex:  RS 25374 GLAXOR<br>
Fax No: (65) 2919737   <br>

<hr><p>


<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-358</DOCNO>
<DOCOLDNO>IA057-000937-B012-328</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/cana.html 193.128.22.20 19970109084054 text/html 1819
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:31:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:25 GMT
Content-length: 1628
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - North America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Canada</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Inc</font></h2>
<p>

        7333 Mississauga Road North<br>
        Mississauga<br>
        Ontario <br>
        CANADA, L5N 6L4<p>
        
Tel:    (1905) 8193000<br>
Telex:  3690119<br>
Fax No: (1905) 8193099<p>

<hr><p>

<a href="nam.html">Return to: North American contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-359</DOCNO>
<DOCOLDNO>IA057-000937-B011-10</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/czec.html 193.128.22.20 19970109082545 text/html 1767
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:15:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:26 GMT
Content-length: 1576
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Czech Republic</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome s.r.o.</font></h2>

K Zizkovu 5<br>
19000 Prague 9<br>
CZECH REPUBLIC<br>
<p> 

Tel: (422) 66122571  (422) 66122572<br>
Telex: 121510 GLCS-C<br>
Fax No: (422) 6844113<p>
<hr><p>


<a href="euro.html">Return to European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-360</DOCNO>
<DOCOLDNO>IA057-000937-B011-197</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/norw.html 193.128.22.20 19970109082858 text/html 1736
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:19:08 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1545
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Norway</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome AS</font></h2>


Postboks 4312<br>
Torshov<br>
0402 Oslo<br>
NORWAY<p>


Tel:	(4722) 151945<br>
Telex:	72575 GLAXO N<br>
Fax No:	(4722) 152741<p>
<hr><p>


<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-361</DOCNO>
<DOCOLDNO>IA057-000937-B014-358</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/within.html 193.128.22.20 19970109090321 text/html 1583
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:53:33 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:32 GMT
Content-length: 1392
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Within Expressions</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Within Expressions</font></h2><p>
A RasMol
<tt><b>within</b></tt>
expression allows atoms to be selected on their proximity to
another set of atoms. A
<tt><b>within</b></tt>
expression takes two parameters separated by a comma and surrounded
by parenthesis. The first argument is an integer value called the
"cut-off" distance of the within expression and the second argument
is any  valid atom expression. The cut-off distance is expressed in
either integer RasMol units or Angstroms containing a decimal point.
An atom is selected if it is within the cut-off distance of any of
the atoms defined by the second argument. This allows complex
expressions to be constructed containing nested
<tt><b>within</b></tt>
expressions.
<p>
For example, the command
<tt><b>select within(3.2,backbone)</b></tt>
selects any atom within a 3.2 Angstrom radius of any atom in a
protein or nucleic acid backbone.
<tt><b>Within</b></tt>
expressions are particularly useful for selecting the atoms
around an active site.

<p>
<a href="chexprs.html">Atom expressions</a></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-362</DOCNO>
<DOCOLDNO>IA057-000937-B015-350</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/sidech.html 193.128.22.20 19970109091123 text/html 1198
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:01:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:30 GMT
Content-length: 1007
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Sidechain Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Sidechain Set</font></h2><p>
This set contains the functional sidechains of any amino acids
and the base of each nucleotide. These are the atoms not part of
the polypeptide N-C-C-O backbone of proteins or the sugar
phosphate backbone of nucleic acids.
Use the RasMol predefined sets
<tt><b>protein</b></tt>
and
<tt><b>nucleic</b></tt>
to distinguish between the two forms of sidechain.
Atoms in nucleic acids and proteins are either
<a href="backset.html"><tt><b>backbone</b></tt></a>
or
<tt><b>sidechain.</b></tt>
This set is equivalent to the RasMol expression
"<tt><b>(protein or nucleic) and not backbone</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-363</DOCNO>
<DOCOLDNO>IA057-000937-B015-3</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/backset.html 193.128.22.20 19970109090537 text/html 1244
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:55:47 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 1053
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Backbone Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Backbone Set</font></h2><p>
This set contains the four atoms of each amino acid that form the
polypeptide N-C-C-O backbone of proteins, and the atoms the sugar
phosphate backbone of nucleic acids.
Use the RasMol predefined sets
<tt><b>protein</b></tt>
and
<tt><b>nucleic</b></tt>
to distinguish between the two forms of backbone.
Atoms in nucleic acids and proteins are either
<tt><b>backbone</b></tt>
or
<a href="sidech.html"><tt><b>sidechain.</b></tt></a>
This set is equivalent to the RasMol expression
"<tt><b>(protein or nucleic) and not sidechain</b></tt>"
<p>
The predefined set
<tt><b>mainchain</b></tt>
is synonymous with the set
<tt><b>backbone.</b></tt>

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-364</DOCNO>
<DOCOLDNO>IA057-000937-B011-318</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/swed.html 193.128.22.20 19970109083132 text/html 1723
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:21:43 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 1532
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Sweden</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome AB</font></h2>

P.O. Box 263<br>
S-431 23 Molndal<br>
SWEDEN<p>


Tel: (4631) 670900<br>
Telex: 20092<br>
Fax No: (4631) 274745<p>




<hr><p>
<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-365</DOCNO>
<DOCOLDNO>IA057-000937-B012-502</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/puer.html 193.128.22.20 19970109084452 text/html 1702
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:34:53 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:33 GMT
Content-length: 1511
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - North America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Puerto Rico</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Puerto Rico Inc.</font></h2>
<p>

P. O. Box 363461<br>
San Juan<br>
PUERTO RICO 00936-3461<p>

<hr><p>
<a href="nam.html">Return to: North American contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-366</DOCNO>
<DOCOLDNO>IA057-000937-B013-187</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/urug.html 193.128.22.20 19970109085015 text/html 1705
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:40:26 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:36 GMT
Content-length: 1514
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information: Uruguay</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A.</font></h2>
<p>

Salto 1105<br>
Montevideo<br>
URUGUAY<p>

Tel:(5982) 498333<br>
Fax No: (5982) 488063<p>

<hr><p>

<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-367</DOCNO>
<DOCOLDNO>IA057-000937-B011-24</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/denm.html 193.128.22.20 19970109082556 text/html 1720
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:16:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:26 GMT
Content-length: 1529
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Denmark</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome A/S</font></h2>

Nykaer 68<br>
DK-2605 Brondby<br>
DENMARK<p> 

Tel: (45) 36759000<br>
Telex: 19906<br>
Fax Nos: (45) 36753008<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-368</DOCNO>
<DOCOLDNO>IA057-000937-B013-160</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/para.html 193.128.22.20 19970109084956 text/html 1737
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:40:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1546
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Paraguay</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A.</font></h2>

Sargento Gauto esq. Zurbaran<br>
Asuncion<br>
PARAGUAY<p> 

Tel: (595) 21 208518 <br>
Fax No:	(595) 21 210020<p>

<hr><p>


<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-369</DOCNO>
<DOCOLDNO>IA057-000937-B011-458</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/cdiv.html 193.128.22.20 19970109083446 text/html 1764
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:24:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:25 GMT
Content-length: 1573
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Africa</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: C&ocirc;te d'Ivoire</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Export Ltd</font></h2>
<p>
       O1 BP 8111<br>
                  Abidjan 01<br>
                  COTE D'IVOIRE<p>

Tel: (225) 216337<br>
Fax: (225) 211114<p>

<hr><p>
<a href="afri.html">Return to: African contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-370</DOCNO>
<DOCOLDNO>IA057-000937-B014-323</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/primit.html 193.128.22.20 19970109090251 text/html 2545
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:52:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 2354
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Primitive Expressions</font></h2><p>
RasMol primitive expressions are the fundamental building blocks
of atom expressions. There are two types of primitive expression.
The first type is used to identify a given residue number or range
of residue numbers. A single residue is identified by its number
(position in the sequence), and a range is specified by lower and
upper bounds separated by a hyphen character. For example
<tt><b>select 5,6,7,8</b></tt>
is also
<tt><b>select 5-8.</b></tt>
Note that this selects the given residue numbers in all macromolecule
chains.
<p>
The second type of primitive expression specifies a sequence of fields
that must match for a given atom. The first part specifies a residue
(or group of residues) and an optional second part specifies the atoms
within those residues. The first part consists of a residue name,
optionally followed by a residue number and/or chain identifier.
<p>
A residue name typically consists of up to three alphabetic characters,
which are case insensitive. Hence the primitive expressions
<tt><b>SER</b></tt>
and
<tt><b>ser</b></tt>
are equivalent, identifying all serine residues.
Residue names that contain non-alphabetic characters, such as
sulphate groups, may be delimited using square brackets, i.e.
<tt><b>[SO4]</b></tt>
<p>
The residue number is the residue's position in the macromolecule
sequence. Negative sequence numbers are permited. For example,
<tt><b>SER70</b></tt>
Care must be taken when specifying both residue name and number,
it the group at the specified position isn't the specified residue
no atoms are selected.
<p>
The chain identifier is typically a single case-insensitive
alphabetic or numeric character. Numeric chain identifiers must
be distinguished or separated from residue numbers by a colon
character. For example,
<tt><b>SER70A</b></tt>
or
<tt><b>SER70:1</b></tt>
<p>
The second part consists of a period character followed by an atom
name.
An atom name may be up to four alphabetic or numeric characters.
<p>
An asterisk may be used as a wild card for a whole field and a
question mark as a single character wildcard.

<p>
<a href="chexprs.html">Atom expressions</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-371</DOCNO>
<DOCOLDNO>IA057-000937-B012-81</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/chin.html 193.128.22.20 19970109083707 text/html 2159
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:27:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:25 GMT
Content-length: 1968
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: China</font></h1>
<hr size=4>
<br>
<h2><font size=6>ChongQuing Glaxo Pharmaceuticals Limited</font></h2>
<p>
        Gong Nong Cun, Long Xi Zhen<br>   
        Jiangbei<br>
        Chongqing<br>
        Sichuan Province 631147<br>
        CHINA<p>
        
Tel:    (852) 2565 0524<br>
Telex:  62274 CGPL CN<br>
Fax No: (86) 811-7856688<p>

<hr><p>

<h2><font size=6>Glaxo Wellcome China Limited</font></h2>
<p>
 Glaxo Wellcome China Ltd<br>
 18th Floor West<br>
 Warwick House  <br>
 Taikoo Place   <br>
 979 King's Road<br>
 Quarry Bay<br>
 HONG KONG<p>



Tel:    (852) 2565 0524<br>
Telex:  66341 GLAXO HX<br>
Fax No: (852) 256 59302<p>

<hr><p>

<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-372</DOCNO>
<DOCOLDNO>IA057-000937-B011-70</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/germ.html 193.128.22.20 19970109082637 text/html 2023
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:16:51 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:27 GMT
Content-length: 1832
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information: Germany</font></h1>
<hr size=4>
<p>
<font size=5><a href="gexit.html">Glaxo Wellcome Deutschland WWW</a></font>
<p>

<h2><font size=6>Glaxo Wellcome GmbH &amp; Co.</font></h2>


Alsterufer 1<br>
20354 Hamburg<br>
GERMANY<p>

Tel:	(4940) 415230 (32 lines)<br>
Telex:	2166422 glxod.<br>
Fax Nos: (4940) 41523123<p>


<hr><p>
<h2><font size=6>Cascan GmbH &amp; Co. KG</font></h2>

Hohenstaufenstrasse 7<br>
65189 Wiesbaden<br>
GERMANY<p> 

Tel:	(49) 61171010<br>
Telex:	4186980 CAS D<br>
Fax No:	(49) 6117101172<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-373</DOCNO>
<DOCOLDNO>IA057-000937-B022-108</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/gexit.html 193.128.22.20 19970109101010 text/html 2249
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:00:24 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:27 GMT
Content-length: 2058
Content-type: text/html
</DOCHDR>
<html><head>
<title>You are leaving the Glaxo Wellcome global web site</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>You are leaving the Glaxo Wellcome global web site</font></h1>
<hr size=4>


<p>

<font size=5>Thank you for visiting the Glaxo Wellcome global web site, maintained by <a href="gw.html">Glaxo Wellcome plc in London, UK.</a></font><p>

You are about to reach pages created by Glaxo Wellcome Germany for German
residents only. Not all the information it contains will be applicable
outside Germany. Your <a href="../">local Glaxo Wellcome company</a> will always be happy to respond to your enquiries.<p>

Please remember that medical practice varies from country to country.
Always seek the advice of your doctor.<p>

<a href="http://www.Glaxowellcome.de/"><img src="de.gif" align=center hspace=5>Forward to: Willkommen bei Glaxo Wellcome Deutschland im World Wide Web</a>
<br clear=left><p>

<a href="germ.html">Return to: German contacts page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-374</DOCNO>
<DOCOLDNO>IA057-000937-B011-486</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/egyp.html 193.128.22.20 19970109083502 text/html 1792
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:25:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:26 GMT
Content-length: 1601
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Africa</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Egypt</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Egypt S.A.E.</font></h2>
<p>
        El Salam City - 11491<br>
        P O Box 3001<br>
        Cairo<br>
        EGYPT<p>

Tel:    (202) 2807000<br>
Telex:  23665 GLAXO UN<br>
Fax No: (202) 2806031<br>

<hr><p>
<a href="afri.html">Return to: African contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-375</DOCNO>
<DOCOLDNO>IA057-000937-B012-64</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/bang.html 193.128.22.20 19970109083641 text/html 1854
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:26:48 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:24 GMT
Content-length: 1663
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Bangladesh</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Bangladesh Limited</font></h2>

<p>
        Fouzderhat Industrial Area<br>
        Dhaka Trunk Road<br>
        P.O. North Kattali<br>
        Chittagong<br>
        BANGLADESH<p>


Tel:    880 31 752071-9<br>
Telex:  633022 Glaxo Bj<br>
Fax No: 880 31 751051<p>

<hr><p>

<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-376</DOCNO>
<DOCOLDNO>IA057-000937-B013-404</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/define.html 193.128.22.20 19970109085310 text/html 1053
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:43:23 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 863
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Define</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Define</font></h2><p>
<pre>
Syntax:  define &lt;identifier&gt; &lt;expression&gt;
</pre><p>
The RasMol
<tt><b>define</b></tt>
command allows the user to associate an arbitrary set of atoms with a
unique identifier. This allows the definition of user-defined sets. These
sets are declared statically, i.e. once defined the contents of the set
do not change, even if the expression defining them depends on the
current transformation and representation of the molecule.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-377</DOCNO>
<DOCOLDNO>IA057-000937-B011-57</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/fran.html 193.128.22.20 19970109082627 text/html 1753
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:16:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:26 GMT
Content-length: 1562
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: France</font></h1>
<hr size=4>
<br>
<h2><font size=6>Laborotoire Glaxo Wellcome S.A.S.</font></h2>


B. P. 166-16<br>
75764<br>
Paris Cedex 16<br>
FRANCE<p> 



Tel:	(331) 47553300<br>
Telex:	645645<br>
Fax No:	(331) 47046375<p>




<hr><p>
<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-378</DOCNO>
<DOCOLDNO>IA057-000937-B012-137</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/japa.html 193.128.22.20 19970109083749 text/html 2015
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:27:59 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1824
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Japan</font></h1>
<hr size=4>
<br>
<h2><font size=6>Nippon Glaxo Limited</font></h2>
<p>
Shinjuko Mayuds Tower<br>
  1-1 Yoyogi 2-chome<br>
  Shibuyu-ku<br>
Tokyo 151<br>
JAPAN<p>
Tel: (813) 5352 2600<br>
Fax No: (813) 5352 2609<br>
<hr><p>



<h2><font size=6>Nippon Wellcome K.K.</font></h2>
<p>
        Kobe Crystal Tower<br>
        1-3, Higashi-Kawasaki-cho 1-chome<br>
        Chuo-ku<br>
        Kobe 650<br>
        JAPAN<p>
        
Tel:    (8178) 360 8900<br>
Fax No: (8178) 360 8980<p>

<hr><p>
<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-379</DOCNO>
<DOCOLDNO>IA057-000937-B013-66</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/arge.html 193.128.22.20 19970109084829 text/html 1762
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:38:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:24 GMT
Content-length: 1571
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Argentina</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome S.A.</font></h2>

J J Castelli 6701<br>
(1605) Munro<br>
Buenos Aires<br>
ARGENTINA<p> 

Tel:	(541) 7660021<br>
Telex:	26204<br>
Fax No:	(541) 721 8134<p>
<hr><p>


<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-380</DOCNO>
<DOCOLDNO>IA057-000937-B012-343</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/mexi.html 193.128.22.20 19970109084124 text/html 1859
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:31:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:31 GMT
Content-length: 1668
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - North America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Mexico</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A. de C.V.</font></h2>

<p>
        Calzada Mexico-Xochimilco 4900<br>
        Colonia San Lorenzo Huipulco<br>
        Delegacion Tlalpan 14370<br>

        MEXICO DF<p>  
        
Tel:    (525) 7285200<br>
Fax No: (525) 7285297<br>
        (525) 7285288<p>

<hr><p>
<a href="nam.html">Return to: North American contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-381</DOCNO>
<DOCOLDNO>IA057-000937-B012-51</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/safr.html 193.128.22.20 19970109083627 text/html 1814
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:26:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:34 GMT
Content-length: 1623
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Africa</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: South Africa</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome South Africa (Pty) Limited</font></h2>
<p>
P. O. Box 3388<br>
      Halfway House<br>
       Gauteng 1685<br>
        SOUTH AFRICA<p>

Tel:    (2711) 3136000<br>
Telex:  420144<br>
Fax No: (2711) 3136111<p>
        

<hr><p>


<a href="afri.html">Return to: African contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-382</DOCNO>
<DOCOLDNO>IA057-000937-B013-252</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/nzea.html 193.128.22.20 19970109085100 text/html 1859
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:41:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1668
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Australasia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: New Zealand</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Holdings NZ Limited</font></h2>

<p>
        Private Bag 106600
<br>        Downtown, Quay Tower
<br>        Cnr Albert & Customs St.
<br>        Auckland 1
<br>        NEW ZEALAND
<p>

Tel:    (649) 3672900<br>
Telex:  32095<br>
Fax No: (649) 3672910<p>
<hr><p>

<a href="aus.html">Return to: Australasian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-383</DOCNO>
<DOCOLDNO>IA057-000937-B012-237</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/sril.html 193.128.22.20 19970109083923 text/html 1736
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:29:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 1545
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Sri Lanka</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Ceylon Limited</font></h2>
<p>

P. O. Box 80<br>
Mt Lavinia<br>
SRI LANKA<p>
                
Tel No: (941) 636341-2<br>
Fax No: (941) 635000<p>


<hr><p>

<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-384</DOCNO>
<DOCOLDNO>IA057-000937-B013-171</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/peru.html 193.128.22.20 19970109085005 text/html 1740
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:40:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:32 GMT
Content-length: 1549
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - South America</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Peru</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A.</font></h2>


P. O. Box 4239<br>
Lima 100<br>
PERU<p>




Tel: (5114) 425520 <br>
Telex:	20330 PE CP Lima<br>
Fax No:	(5114) 424866<p>
<hr><p>

<a href="sam.html">Return to: South American contacts page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-385</DOCNO>
<DOCOLDNO>IA057-000937-B012-121</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/indo.html 193.128.22.20 19970109083739 text/html 1902
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:27:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1711
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Indonesia</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Orient Pte Ltd</font></h2>
<p>
        JL. Pulobuaran Raya Kav III DD/2,3,4<br>
        Kawasan Industri Pulogadung<br>
        Jakarta 13930<br>
        INDONESIA<p>

Tel:    (6221) 4603292 (GLAXO)<br>
        (6221) 4615166 (WELLCOME)<br>
Fax No: (6221) 4603293 (GLAXO)<br>
        (6221) 4615164 (WELLCOME)<p>

<hr><p>
<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-386</DOCNO>
<DOCOLDNO>IA057-000937-B012-8</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/moro.html 193.128.22.20 19970109083532 text/html 1780
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:25:40 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:31 GMT
Content-length: 1589
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Africa</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Morocco</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Maroc S.A.</font></h2>
<p>
        28, Bd Al Massira Al Khadra<br>
        Casablanca<br>
        MOROCCO<p>
        

Tel:    (2122) 396930<br>
Telex:  45962<br>
Fax No: (2122) 396935<p>


<hr><p>
<a href="afri.html">Return to: African contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-387</DOCNO>
<DOCOLDNO>IA057-000937-B011-300</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/spai.html 193.128.22.20 19970109083111 text/html 1753
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:21:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 1562
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Spain</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome S.A.</font></h2>

Apartado de Correos 146<br>
28760 Tres Cantos<br>
Madrid<br>
  SPAIN<p> 

Tel:	(341) 8070301<br>
Telex:	23770 GLXOE<br>
Fax No:	(341) 8070310 <p>

<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-388</DOCNO>
<DOCOLDNO>IA057-000937-B012-104</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/indi.html 193.128.22.20 19970109083725 text/html 1773
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:27:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1582
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: India</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo India Limited</font></h2>
<p>
        Dr Annie Besant Road<br>
        Mumbai 400 025<br>
        INDIA  <p>

Tel:    (9122) 4933871<br>
Telex:  1174410 GLXO IN<br>
       
Fax No: (9122) 4935358<p>

<hr><p>



<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-389</DOCNO>
<DOCOLDNO>IA057-000937-B011-506</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/keny.html 193.128.22.20 19970109083519 text/html 1862
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:25:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:30 GMT
Content-length: 1671
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Africa</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Kenya</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome (Kenya) Limited</font></h2>

<p>
        P.O. Box 18288<br>
        Dakar Road<br>
        Nairobi<br>
        KENYA<p>
        
Tel:    (2542) 532461<br>
Telex:  24279 Answerback GLAXO NBI<br>
Cables: GLAXO NAIROBI<br>
Fax No: (2542) 542689<br>
        (2542) 543550<p>



<hr><p>
<a href="afri.html">Return to: African contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-390</DOCNO>
<DOCOLDNO>IA057-000937-B015-83</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/cyclic.html 193.128.22.20 19970109090645 text/html 1213
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:56:57 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1022
Content-type: text/html
</DOCHDR>
<html><head>
<title>RasMol Manual: Cyclic Set</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Cyclic Set</font></h2><p>
The set of atoms in amino acids containing a cycle or rings.
All amino acids are classified as either
<tt><b>cyclic</b></tt>
or
<a href="acyclic.html"><tt><b>acyclic.</b></tt></a>
This set consists of the amino acids His, Phe, Pro, Trp and Tyr.
The members of the predefined set
<a href="aromatic.html"><tt><b>aromatic</b></tt></a>
are members of this set.
The only cyclic but non-aromatic amino acid is proline.
This set is equivalent to the RasMol atom expressions
"<tt><b>his, phe, pro, trp, tyr</b></tt>"
and
"<tt><b>aromatic or pro</b></tt>"
and
"<tt><b>amino and not acyclic</b></tt>"

<p>
<a href="predef.html">Predefined sets</a>
</ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-391</DOCNO>
<DOCOLDNO>IA057-000937-B014-414</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/acyclic.html 193.128.22.20 19970109090406 text/html 956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:54:17 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 766
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Acyclic Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../"><img src="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Acyclic Set</font></h2><p>
The set of atoms in amino acids not containing a cycle or
ring. All amino acids are classified as either
<a href="cyclic.html"><tt><b>cyclic</b></tt></a>
or
<tt><b>acyclic.</b></tt>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not cyclic</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-392</DOCNO>
<DOCOLDNO>IA057-000937-B014-474</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/aromatic.html 193.128.22.20 19970109090517 text/html 1071
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:55:29 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 881
Content-type: text/html
</DOCHDR>
<html><head>
<title>RasMol Manual: Aromatic Set</title>

</head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>
<a href="../"><img src="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Aromatic Set</font></h2><p>
The set of atoms in amino acids containing aromatic rings.
These are the amino acids His, Phe, Trp and Tyr.
Because they contain aromatic rings all members of this
set are member of the predefined set
<a href="cyclic.html"><tt><b>cyclic.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>his, phe, trp, tyr</b></tt>"
and
"<tt><b>cyclic and not pro</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-393</DOCNO>
<DOCOLDNO>IA057-000937-B011-265</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/port.html 193.128.22.20 19970109083037 text/html 1814
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:20:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:33 GMT
Content-length: 1623
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Portugal</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Farmaceutica, Limitada</font></h2>

Rua Dr. Ant&oacute;nio Loureiro Borges, No. 3<br>
Arquiparque - Miraflores - Alg&eacute;s<br>
1495 Lisbon<br>
PORTUGAL<p> 

Tel:	(3511) 4129500<br>
Telex:	13601 GLAXO P<br>
Fax No:	(3511) 4120438<p>
<hr><p>



<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-394</DOCNO>
<DOCOLDNO>IA057-000937-B012-277</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/thai.html 193.128.22.20 19970109083955 text/html 1767
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:29:58 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:35 GMT
Content-length: 1576
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Thailand</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome (Thailand) Limited</font></h2>
<p>
G. P. O. Box 955<br>
Bangkok 10501<br>
THAILAND<p>

Tel:    (662) 2373666/73<br>

Telex:  20934 GLAXOTHTH<br>
Fax No: (662) 2373674/75<p>

        
<hr><p>


<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-395</DOCNO>
<DOCOLDNO>IA057-000937-B011-94</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/hung.html 193.128.22.20 19970109082713 text/html 1742
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:17:25 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:29 GMT
Content-length: 1551
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses-Europe</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" align=left border=0></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Hungary</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome kft</font></h2>

Revay Utca 10.<br>
2nd Floor<br>
1065 Budapest<br>
HUNGARY<br>
<p> 

Tel:	(361) 2691155<br>
Telex:	227851<br>
Fax No:	(361) 2691161<p>
<hr><p>

<a href="euro.html">Return to: European contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-396</DOCNO>
<DOCOLDNO>IA057-000937-B015-241</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/nucleic.html 193.128.22.20 19970109090957 text/html 1117
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:00:09 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:27 GMT
Content-length: 927
Content-type: text/html
</DOCHDR>
<html><head>
<title>RasMol Manual: Nucleic Set</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<a href="../"><img src="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Nucleic Set</font></h2><p>
The set of all atoms in nucleic acids, which consists of the four
nucleotide bases adenosine, cytidine, guanosine and thymidine (A,
C, G and T respectively). All neucleotides are classified as either
<a href="purine.html"><tt><b>purine</b></tt></a>
or
<a href="pyrimid.html"><tt><b>pyrimidine.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>a,c,g,t</b></tt>"
and
"<tt><b>purine or pyrimidine</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-397</DOCNO>
<DOCOLDNO>IA057-000937-B015-278</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/protein.html 193.128.22.20 19970109091024 text/html 620
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:00:35 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 430
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Protein Set</font></h2><p>
The set of all atoms in proteins. This consists of the RasMol
predefined set
<a href="aminoset.html"><tt><b>amino</b></tt></a>
and common post-translation modifications.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-398</DOCNO>
<DOCOLDNO>IA057-000937-B014-449</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/aminoset.html 193.128.22.20 19970109090445 text/html 639
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:54:45 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 449
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Amino Set</font></h2><p>
This set contains all the atoms contained in amino acid residues.
This is useful for distinguishing the protein from the nucleic
acid and heterogenous atoms in the current molecule database.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-399</DOCNO>
<DOCOLDNO>IA057-000937-B012-287</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/aturk.html 193.128.22.20 19970109084012 text/html 1818
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:30:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:24 GMT
Content-length: 1627
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Turkey</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome I.S.A.S</font></h2>
<p>
        Yildiz Posta Caddesi No 52/8<br>
        80700 Esentepe<br>
        Istanbul<br>
        TURKEY  <p>
        
Tel:    (90) (212) 2753474<br>
Telex:  26043 glax tr<br>
Fax No: (90) (212)  2723581<p>

<hr><p>


<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-400</DOCNO>
<DOCOLDNO>IA057-000937-B017-264</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/affymax/affymax3.html 193.128.22.20 19970109093302 text/html 3344
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:23:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:20 GMT
Content-length: 3153
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>

<h2><font size=6>Entrepreneurial culture</font></h2>

<font size=5>"The hallmark of technological invention comes from
having people with different backgrounds and perspectives looking at
the same problem from their own local vantage point and together
figuring out how to solve it," says Dr Ringold.</font><p>

Such approaches are already being developed by the rest of the Glaxo
Wellcome organisation. When the company recently reorganised its research
structure in the UK the advantages were recognised and adopted at the new
Medicines Research Centre at Stevenage.<p>

The entrepreneurial company culture encourages individual Affymax
scientists to have ideas and develop them through to working models.
Another mark of the company's flexibility has been the opportunity to
launch "spin off" companies, using outside finance, based on technology
whose applications are regarded as peripheral to Affymax's core interests.<p>

<strong>Interesting ideas</strong><br>
"If you put good ideas on the shelf there's a danger that you take away the
incentive of your most creative people, making it increasingly difficult to
attract and retain them," says Dr Ringold.<p>

To this end, 1993 saw the launch of Affymetrix, a company that is
developing the chip technology originally created for drug discovery to
produce diagnostic tests to screen for genetic diseases such as cystic
fibrosis.<p>

Owning Affymax has also allowed Glaxo Wellcome to establish a physical
presence in the high tech environment of the west coast of the USA.<p>

Dr Ringold: "We can serve as Glaxo Wellcome's eyes and ears to California's
academic and biotech community and provide the company with a technology
magnet that attracts people with interesting ideas to us."<p>

<a href="affyfile.html">Forward to: Affymax fact file</a><p>
<a href="affymax2.html">Back to: Automated drug research</a><p>
<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>


<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-401</DOCNO>
<DOCOLDNO>IA057-000937-B023-286</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/world/affymax/affyfile.html 193.128.22.20 19970109102331 text/html 2626
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:13:38 GMT
Last-modified: Tuesday, 24-Dec-96 11:31:19 GMT
Content-length: 2435
Content-type: text/html
</DOCHDR>
<html><head>
<title>Affinity for Affymax</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>Affinity for Affymax</font></h1>
<hr size=4>



<h2><font size=6>Affymax fact file</font></h2>

<ul type=disc>

<li>The name Affymax is a distillation of the term affinity matrix,
which occurs when many disease targets are mixed with lots of molecules,
producing compounds with an affinity for each other in the combinatorial
process.<p>

<li>In December 1991 the first public offering of Affymax raised $92
million, the third largest in biotechnology. This allowed rapid growth in
1992 from 65 employees to 200.<p>

<li>In 1993, Affymetrix Inc, a subsidiary of Affymax, was created.
Glaxo Wellcome now owns about 48 per cent of the equity of Affymetrix.<p>

<li>In March 1995, Affymax was acquired by Glaxo, now Glaxo Wellcome.
Structurally, within Glaxo Wellcome, Affymax reports to Dr Barry Ross,
director of Research Strategy and Alliances. Functionally, it reports to
all Glaxo Wellcome research centres.<p>

<li>Affymax currently employs 215 people. Of these, 80 are biologists,
66 chemists and 13 engineers, with the remainder being support staff.
Affymax has two sites - Palo Alto and, not far away, Santa Clara.

</ul>
<p>
<a href="affymax3.html">Back to: Entrepreneurial culture</a><p>

<a href="../research.html">Return to: Glaxo Wellcome research centres</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-402</DOCNO>
<DOCOLDNO>IA057-000937-B015-37</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/bondset.html 193.128.22.20 19970109090601 text/html 556
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:56:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 366
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Bonded Set</font></h2><p>
This set contain all the atoms in the current molecule database that
are bonded to atleast one other atom.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-403</DOCNO>
<DOCOLDNO>IA057-000937-B015-72</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/charged.html 193.128.22.20 19970109090635 text/html 889
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:56:46 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 699
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Charged Set</font></h2><p>
This set contains the charged amino acids. These are the amino
acids that are either
<a href="acid.html"><tt><b>acidic</b></tt></a>
or
<a href="basicset.html"><tt><b>basic.</b></tt></a>
Amino acids are classified as being either
<tt><b>charged</b></tt>
or
<a href="neutral.html"><tt><b>neutral.</b></tt></a>
This set is equivalent to the RasMol atom expressions
"<tt><b>acidic or basic</b></tt>"
and
"<tt><b>amino and not neutral</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-404</DOCNO>
<DOCOLDNO>IA057-000937-B012-197</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/contact/addresses/phili.html 193.128.22.20 19970109083848 text/html 1746
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:29:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:29:33 GMT
Content-length: 1555
Content-type: text/html
</DOCHDR>
<html><head>
<title>Addresses - Asia</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Glaxo Wellcome contact information: Philippines</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Philippines Inc</font></h2>


2266 Chino Roces Avenue<br>
City of Makati 1231<br>
Philippines<p>

Tel:    (632) 8104806<br>
Fax No: (632) 8164585 <p> 





<hr><p>
<a href="asia.html">Return to: Asian contacts index</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-405</DOCNO>
<DOCOLDNO>IA057-000937-B008-248</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/nature/nature5c.html 193.128.22.20 19970109080751 text/html 4519
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:58:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:03 GMT
Content-length: 4328
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Redesigning drug discovery</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Redesigning drug discovery</font></h1>
<hr size=4>
<h2><font size=6>Combinatorial chemistry</font></h2>


<font size=5>Directed primary libraries<p>

When chemists have some idea of what kind of molecule might interact with a
target, such as X-ray data relating to the target, a different approach can
be pursued. Then the likely choice will be afocused or directed primary
library. Such libraries may be an order of magnitude smaller than in RPLS.</font><p>

<img align="left" src="glaxo4.gif" alt="[Affymax ESL synthesizers]" hspace=5>

If the target is a metalloproteinase, for example, a zinc chelating group
would be a good starting point. Prior knowledge is thus used to increase
the chances of success in a focused library. Libraries for focused primary
screening may contain only a few thousand members, often all containing a
common pharmacophore that has historically yielded compounds active against
related targets. Beyond the shared pharmacophore, maximum chemical
diversity can be generated in a way that is believed to be compatible with
retention of the pharmacophore's activity.<p>

It is now over a year since Glaxo Wellcome acquired Affymax, and the
benefits are already apparent. The parent company's chemists from Research
Triangle Park, Stevenage and Verona are being trained in solid-phase
chemistry andautomation at the Affymax sites in Palo Alto and Santa Clara.
Stevenage chemists have already built two Affymax ESL synthesizers, which
are now producing libraries; a similar technology transfer is also under
way at Research Triangle Park. In addition, many Glaxo Wellcome biological
screens have been transferred to Affymax.<p>

One of Affymax's major attractions to Glaxo Wellcome was that its approach
goes beyond organic chemistry: it integrates combinatorial chemistry with
engineering and instrumentation associated with novel assay formats.
Affymax is now charged with inventing enabling technologies for efficient
drug discovery and transferring them to the rest of Glaxo Wellcome for
exploitation. The combinatorial revolution has shaken up traditional
approaches to the final stages of lead optimization, and the Group's
Combinatorial Lead Optimisation Programme is testing just how far down the
drug discovery and development pathway the new tech-nologies can be
applied.<p>

Lead optimization has traditionally relied on using single-compound
synthesis, but this technique is rapidly being replaced by parallel
synthesis of discrete compounds. One approach is array chemistry, a system
involving dozens of parallel reactions for establishing structure/activity
relationships. Glaxo Wellcome has developed proprietary parallel reactors,
with efficient heating, cooling and stirring capability, and these are
spreading rapidly throughout the labs. Automated, and therefore faster,
purification equipment has also been developed. Automated HPLC means that
large batches of compounds can be purified each day, apreviously
unthinkable feat.<p>


<a href="nature5b.html">Back to: Tagging beads</a><p>
<a href="nature5.html">Return to: Combinatorial chemistry</a><p>




<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-406</DOCNO>
<DOCOLDNO>IA057-000937-B008-226</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/nature/nature5b.html 193.128.22.20 19970109080730 text/html 4950
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:57:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:03 GMT
Content-length: 4759
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Redesigning drug discovery</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Redesigning drug discovery</font></h1>
<hr size=4>
<h2><font size=6>Combinatorial chemistry</font></h2>


<font size=5>Tagging beads<p>

To permit smaller beads, Affymax has developed an approach which gives each
bead a unique code describing its history during the synthesis. Clearly the
chemistry used to generate the code must be inert to the chemistries used
to generate the combinatorial library. An early example used
oligonucleotides, produced by a route that had no effect on the synthesis
of the library and vice versa, each building block in the library being
associated with a unique codon in the oligonucleotide attached to the bead.
Following screening, the oligonucleotide attached to the active bead could
then be amplified by PCR and sequenced, identifying the structure of the
active compound.</font><p>

Some chemistries, however, are incompatible with oligonucleotide synthesis.
To cope with these situations, Affymax has developed an alternative
approach, called a hard tag protocol, using robust chemistries that are
resistant to degradation. The process involves building a polymeric tag
which forms secondary amines reactive towards dansyl groups when degraded
by acid. These can then be identified by their retention times on HPLC. In
this case, the building blocks used are encoded by the particular secondary
amine used. Whatever the encryption scheme used, however, its presence
means that huge libraries can be made and screened in small volumes,
greatly reducing chemical consumption and providing a significant advantage
over simpler combinatorial technologies.<p>

Using this principle, Glaxo Wellcome can create encoded synthetic libraries
(ESL) in one of two ways. With tethered ESL (tESL), compounds remain on the
beads throughout, and the active compound is identified by separating and
decoding its bead. Although this is a rapid screening method, it does
require that the active compound can bind its target (which must be in
solution) while attached to its bead.<p>

<img align="left" src="glaxo2.gif" alt="[combinational library synthesis on beads]" hspace=5>

To overcome these limitations, Affymax has developed soluble ESL (sESL), a
further variation on the theme with much broader applications. In this
case, the compound is cleaved from the bead to yield an aqueous solution of
the molecule, making it accessible to any pharmaceutical assay. One version
of this approach uses a photochemically cleavable linker between each bead
and its compound, allowing precise cleavage to release only the desired
fraction of the chosen compounds.
<br clear=left><br><p>
Using the split-pool approach with beads on an instrument with 36 reaction
vessels, 46,656 compounds can be made in three chemical steps from three
classes of building block. Such a library can then be screened by
aliquoting pools of, say, 100 beads, each bearing a unique compound,
cleaving 50% of the compound from each bead using UV light, and removing
the resulting solution for screening. Beads from any pool that gives a
positive result can then be redistributed individually, using special
bead-dispensing equipment designed by Affymax, before cleaving the
remaining compound from each bead and repeating the assay. Active beads can
then be decoded, and the compound resynthesized to validate the result.
<p>

<a href="nature5c.html">Forward to: Directed primary libraries</a><p>
<a href="nature5a.html">Back to: Solution- and solid-phase libraries</a><p>
<a href="nature5.html">Return to: Combinatorial chemistry</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-407</DOCNO>
<DOCOLDNO>IA057-000937-B008-198</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/science/nature/nature5a.html 193.128.22.20 19970109080644 text/html 4612
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 07:56:55 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:02 GMT
Content-length: 4421
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html><head>
<title>Redesigning drug discovery</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Redesigning drug discovery</font></h1>
<hr size=4>
<h2><font size=6>Combinatorial chemistry</font></h2>


<font size=5>Solution- and solid-phase libraries<p>

At Stevenage, Glaxo Wellcome's chemists lead the world in solution-phase
libraries. The attraction of solution-phase synthesis is that it
capitalizes on the vast range of solution chemistry available in the
chemical literature.</font><p>

But solid-phase synthesis, too, has its strengths, in particular facile
purification and easier automation. At Research Triangle Park, the strategy
is thus to investigate how to construct novel pharmacophores and building
blocks with which to make drug-like organic compounds, using solid-phase
supports.<p>

A major challenge is finding what these large libraries contain, and Glaxo
Wellcome is making rapid advances in methodology for monitoring solid-phase
chemistry. Affymax has developed a method for obtaining high-quality 1H NMR
spectra of organic molecules covalently attached to beads using magic angle
spinning in a conventional spectrometer, which allows the non-destructive
monitoring of solid-phase reactions. An alternative approach entails the
use of 13C-enriched building blocks coupled with 13C NMR spectroscopy,
which again permits very rapid analyses of the reaction during synthesis
without destruction of precious samples.<p>

Glaxo Wellcome is also looking at the opportunities created by the various
uses of combinatorial chemistry. Large libraries, such as those based on
beads, are appropriate for initial screening to identify lead compounds,
while smaller libraries can be used for project-specific optimization of
leads.<p>

At Affymax, researchers are tailoring systems to particular needs. If, for
example, there is no information on compounds interacting with a target of
interest, such as the protein encoded by a gene sequence from the human
genome programme, then the best approach would be random primary library
screening (RPLS). For RPLS, high chemical diversity is required, so
multiple libraries, each with 50,000 or more molecules, may be needed.<p>

To produce such libraries, automated equipment controlled by
custom-designed software is used to perform many reactions in parallel,
maximizing the number of compounds produced by using a split-pool synthesis
with bead supports. Once a particular chemistry has been adequately
rehearsed, one chemist may be able to synthesize a library of 50,000
compounds in a day.<p>

The task is then to isolate the few hits in such a library. If the target
can bind to a library molecule while still attached to the bead, then
extracting the desired bead and compound from the library should be
relatively easy. Some companies are already taking this approach, using
fluorescent targets, picking out the fluorescent bead-ligand combination,
and analysing it by mass spectroscopy. This may require a fairly large
bead, however, necessitating large quantities of reagents, and thus
increased costs, as well as limiting the number of molecules that can be
synthesized in a particular library.<p>

<a href="nature5b.html">Forward to: Tagging beads</a><p>
<a href="nature5.html">Return to: Combinatorial chemistry</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/intexpl/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/intexpl/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/intexpl/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/intexpl/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul></ul></ul></ul>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT14-B39-408</DOCNO>
<DOCOLDNO>IA057-000937-B017-404</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwuk.html 193.128.22.20 19970109093518 text/html 1645
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:25:28 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:31 GMT
Content-length: 1454
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome UK Ltd</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome UK Ltd</font>
</h2> 
<p>

<a href="gwuk1.html">Stockley Park West, Middlesex</a><p>

<p>
<hr>
<p>

<a href="uk.html">Return to: Main UK addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-409</DOCNO>
<DOCOLDNO>IA057-000937-B023-323</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwuk1.html 193.128.22.20 19970109102401 text/html 1720
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:14:12 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:31 GMT
Content-length: 1529
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome UK Ltd</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome UK Ltd</font>
</h2>

Stockley Park West,<br>
Uxbridge,<br>
Middlesex.<br>
UB11 1BT<p>
Tel: (0181) 990 9000<br>
Telex: 22134<br>
Fax No: (0181) 990 4321

<p>

<a href="gwuk.html">Return to: Glaxo Wellcome UK Ltd addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-410</DOCNO>
<DOCOLDNO>IA057-000937-B015-50</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/buriset.html 193.128.22.20 19970109090612 text/html 908
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:56:24 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:25 GMT
Content-length: 718
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>

<h2><font size=6>Buried Set</font></h2><p>
This set contains the atoms in those amino acids that tend
(prefer) to buried inside protein, away from contact with
solvent molecules. This set refers to the amino acids
preference and not the actual solvent acessibility for
the current protein.
All amino acids are classified as either
<a href="surface.html"><tt><b>surface</b></tt></a>
or
<tt><b>buried.</b></tt>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not surface</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-411</DOCNO>
<DOCOLDNO>IA057-000937-B015-428</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/surface.html 193.128.22.20 19970109091258 text/html 909
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:03:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 719
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Surface Set</font></h2><p>
This set contains the atoms in those amino acids that tend
(prefer) to be on the surface of proteins, in contact with
solvent molecules. This set refers to the amino acids
preference and not the actual solvent accessibility for
the current protein.
All amino acids are classified as either
<tt><b>surface</b></tt>
or
<a href="buriset.html"><tt><b>buried.</b></tt></a>
This set is equivalent to the RasMol atom expression
"<tt><b>amino and not buried</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-412</DOCNO>
<DOCOLDNO>IA057-000937-B014-375</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/example.html 193.128.22.20 19970109090331 text/html 1244
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:53:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1053
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Example Expressions</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Example Expressions</font></h2><p>
The following table gives some useful examples of RasMol
atom expressions.
<p>
<pre>
    <b>Expression</b>      <b>Interpretation</b>

    *               All atoms
    cys             Atoms in cysteines
    hoh             Atoms in heterogenous water molecules
    as?             Atoms in either asparagine or aspartic acid
    *120            Atoms at residue 120 of all chains
    *p              Atoms in chain P
    *.n?            Nitrogen atoms
    cys.sg          Sulphur atoms in cysteine residues
    ser70.c?        Carbon atoms in serine-70
    hem*p.fe        Iron atoms in the Heme groups of chain P
</pre>

<p>
<a href="chexprs.html">Atom expressions</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-413</DOCNO>
<DOCOLDNO>IA057-000937-B015-96</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/cystine.html 193.128.22.20 19970109090717 text/html 898
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:57:15 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 708
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Cystine Set</font></h2><p>
This set contains the atoms of cysteine residues that form part
of a disulphide bridge, i.e. half cystines. RasMol automatically
determines disulphide bridges, if neither the predefined set
<tt><b>cystine</b></tt>
nor the RasMol
<a href="ssbonds.html"><tt><b>ssbonds</b></tt></a>
command have been used since the molecule was loaded. The set of
free cysteines may be determined using the RasMol atom expression
"<tt><b>cys and not cystine</b></tt>"

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-414</DOCNO>
<DOCOLDNO>IA057-000937-B015-441</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/turnset.html 193.128.22.20 19970109091308 text/html 971
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:03:18 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:31 GMT
Content-length: 781
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Turn Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Turn Set</font></h2><p>
This set contains all atoms that form part of a protein turns
as determined by either the PDB file author or Kabsch and
Sander's DSSP algorithm. By default, RasMol uses the secondary
structure determination given in the PDB file if it exists.
Otherwise, it uses the DSSP algorithm as used by the RasMol
<a href="struct.html"><tt><b>structure</b></tt></a>
command.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-415</DOCNO>
<DOCOLDNO>IA057-000937-B015-106</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/helixset.html 193.128.22.20 19970109090729 text/html 1152
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:57:41 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 962
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Helix Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Helix Set</font></h2><p>
This set contains all atoms that form part of a protein alpha
helix as determined by either the PDB file author or Kabsch and
Sander's DSSP algorithm. By default, RasMol uses the secondary
structure determination given in the PDB file if it exists.
Otherwise, it uses the DSSP algorithm as used by the RasMol
<a href="struct.html"><tt><b>structure</b></tt></a>
command.
<p>
This predefined set should not be confused with the predefined set
<a href="alphaset.html"><tt><b>alpha</b></tt></a>
which contains the alpha carbon atoms of a protein.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-416</DOCNO>
<DOCOLDNO>IA057-000937-B014-438</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/alphaset.html 193.128.22.20 19970109090425 text/html 769
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:54:37 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:24 GMT
Content-length: 579
Content-type: text/html
</DOCHDR>
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>Rasmol Manual</font></h1>
<hr size=4><br>

<h2><font size=6>Alpha Set</font></h2><p>
The set of alpha carbons in the protein molecule. This set is
approximately equivalent to the RasMol atom expression
"<tt><b>*.CA</b></tt>"
This command should not be confused with the predefined set
<a href="helixset.html"><tt><b>helix</b></tt></a>
which contains the atoms in the amino acids of the protein's
alpha helices.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-417</DOCNO>
<DOCOLDNO>IA057-000937-B019-40</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gexit.html 193.128.22.20 19970109094646 text/html 2233
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:36:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:29 GMT
Content-length: 2042
Content-type: text/html
</DOCHDR>
<html><head>
<title>You are leaving the Glaxo Wellcome global web site</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>You are leaving the Glaxo Wellcome global web site</font></h1>
<hr size=4>


<p>

<font size=5>Thank you for visiting the Glaxo Wellcome global web site, maintained by <a href="gw.html">Glaxo Wellcome plc in London, UK.</a></font><p>

You are about to reach pages created by Glaxo Wellcome Germany for German
residents only. Not all the information it contains will be applicable
outside Germany. Your <a href="../">local Glaxo Wellcome company</a> will always be happy to respond to your enquiries.<p>

Please remember that medical practice varies from country to country.
Always seek the advice of your doctor.<p>

<a href="http://www.Glaxowellcome.de/"><img src="de.gif" align=center hspace=5>Forward to: Willkommen bei Glaxo Wellcome Deutschland im World Wide Web</a>
<br clear=left><p>

<a href="germ.html">Return to: German contacts page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-418</DOCNO>
<DOCOLDNO>IA057-000937-B014-38</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/renumber.html 193.128.22.20 19970109085659 text/html 1203
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:47:07 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 1012
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Renumber</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> <basefont 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Renumber</font></h2><p>
<pre>
Syntax:  renumber {{-} &lt;value&gt;}
</pre><p>
The RasMol
<tt><b>renumber</b></tt>
command sequentially numbers the residues in a macromolecular chain.
The optional parameter specifies the value of the first residue in the
sequence. By default, this value is one. For proteins,
each amino acid is numbered consecutively from the N terminus to the C
terminus. For nucleic acids, each base is numbered from the 5' terminus
to 3' terminus. All chains in the current database are renumbered and gaps
in the original sequence are ignored. The starting value for numbering may
be negative.

<p>
<a href="chcomref.html">Command reference</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-419</DOCNO>
<DOCOLDNO>IA057-000937-B014-347</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/comparis.html 193.128.22.20 19970109090312 text/html 1770
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 08:53:11 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:26 GMT
Content-length: 1579
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Comparison Operators</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Comparison Operators</font></h2><p>
Parts of a molecule may also be distinguished using equality,
inequality and ordering operators on their properties. The format
of such comparison expression is a property name, followed by a
comparison operator and then an integer value.
<p>
The atom properties that may be used in RasMol are
<tt><b>atomno</b></tt>
for the atom serial number,
<tt><b>elemno</b></tt>
for the atom's atomic number (element),
<tt><b>resno</b></tt>
for the residue number,
<tt><b>radius</b></tt>
for the spacefill radius in RasMol units (or zero if not represented
as a sphere) and
<tt><b>temperature</b></tt>
for the PDB anisotropic temperature value.
<p>
The equality operator is denoted either
"<tt><b>=</b></tt>" or "<tt><b>==</b></tt>".
The inequality operator as either
"<tt><b>&lt;&gt;</b></tt>", "<tt><b>!=</b></tt>" or
"<tt><b>/=</b></tt>".
The ordering operators are
"<tt><b>&lt;</b></tt>"
for less than,
"<tt><b>&lt;=</b></tt>"
for less than or equal to,
"<tt><b>&gt;</b></tt>"
for greater than, and
"<tt><b>&gt;=</b></tt>"
for greater than or equal to.
<p>
<pre>
Examples:    resno < 23
             temperature >= 900
             atomno == 487
</pre>

<p>
<a href="chexprs.html">Atom expressions</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-420</DOCNO>
<DOCOLDNO>IA057-000937-B017-445</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops.html 193.128.22.20 19970109093609 text/html 2158
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:26:06 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1967
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations (Head office and production sites)</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>
<h2><font size=6>Glaxo Wellcome Operations (Head office and production sites)</font></h2>
<p>

<a href="gwops1.html">Head Office, Stockley Park West</a><p>
<strong>Production sites</strong><p>
<ul type=disc>
<li><a href="gwops2.html">Ulverston, Cumbria</a><p>
<li><a href="gwops3.html">Newbie, Annan, Dumfriesshire</a><p>
<li><a href="gwops4.html">Barnard Castle, County Durham</a><p>
<li><a href="gwops5.html">Ware, Hertfordshire</a><p>
<li><a href="gwops6.html">Dartford, Kent</a><p>
<li><a href="gwops7.html">Speke, Liverpool</a><p>
<li><a href="gwops8.html">Montrose, Angus</a><p>
</ul>
<p>
<hr>
<p>

<a href="uk.html">Return to: Main UK addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-421</DOCNO>
<DOCOLDNO>IA057-000937-B023-404</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops1.html 193.128.22.20 19970109102536 text/html 1749
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:15:42 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1558
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations (Head Office)</font></h2>

Bide Building<br>
Stockley Park West,<br>
Uxbridge,<br>
Middlesex.<br>
UB11 1BU<p>
Tel: (0181) 990 9100<br>

Fax  No: (0181) 990 4321
<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-422</DOCNO>
<DOCOLDNO>IA057-000937-B023-419</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops2.html 193.128.22.20 19970109102549 text/html 1730
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:16:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1539
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

North Lonsdale Road,<br>
Ulverston,<br>
Cumbria.<br>
LA12 9DR<p>
Tel: (01229) 582261<br>
Telex: 65169<br>
Fax No: (01229) 482282
<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-423</DOCNO>
<DOCOLDNO>IA057-000937-B023-431</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops3.html 193.128.22.20 19970109102559 text/html 1744
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:16:10 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1553
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Three Trees Road,<br>
Newbie,<br>
Annan,<br>
Dumfriesshire.<br>
DG12 5QH<p>
Tel: (01461) 203661<br>
Telex: 777489 <br>
Fax No: (01461) 207354

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-424</DOCNO>
<DOCOLDNO>IA057-000937-B023-447</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops4.html 193.128.22.20 19970109102612 text/html 1735
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:16:22 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1544
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Harmire Road,<br>
Barnard Castle,<br>
County Durham.<br>
DL12 8DT<p>
Tel: (01833) 690600<br>
Telex: 58539<br>
Fax No: (01833) 692300

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-425</DOCNO>
<DOCOLDNO>IA057-000937-B024-17</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops5.html 193.128.22.20 19970109102639 text/html 1711
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:16:49 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1520
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Priory Street,<br>
Ware,<br>  
Hertfordshire.<br>
SG12 0DJ<p>
Tel: (01920) 463993<br>
Fax No: (01920) 463899

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-426</DOCNO>
<DOCOLDNO>IA057-000937-B024-37</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops6.html 193.128.22.20 19970109102712 text/html 1724
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:17:20 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:30 GMT
Content-length: 1533
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Temple Hill<br>
Dartford<br>
Kent<br>
DA1 5AH<p>
Tel: (01322) 223488<br>
Telex: (01322) 913770<br>
Fax: (01322) 291840<p>

<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-427</DOCNO>
<DOCOLDNO>IA057-000937-B024-50</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops7.html 193.128.22.20 19970109102726 text/html 1726
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:17:34 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:31 GMT
Content-length: 1535
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Speke Boulevard,<br>
Speke,<br>
Liverpool.<br>
L24 4JD<p>
Tel: (0151) 486 1881<br>
Telex: 629673<br>
Fax No: (0151) 486 1058
<p>

<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-428</DOCNO>
<DOCOLDNO>IA057-000937-B024-68</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/gwops8.html 193.128.22.20 19970109102740 text/html 1734
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:17:50 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:31 GMT
Content-length: 1543
Content-type: text/html
</DOCHDR>
<html><head>
<title>Glaxo Wellcome Operations</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../"><IMG  WIDTH=76 HEIGHT=76 SRC="../icon.gif" border=0 align=left></a>
<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Glaxo Wellcome contact information</font></h1>
<hr size=4>
<br>

<h2><font size=6>Glaxo Wellcome Operations</font></h2>

Cobden Street,<br>
Montrose,<br>
Angus,<br>
Scotland.<br>
DD10 8EA<p>
Tel: (01674) 672606<br>
Telex: 76125<br>
Fax No: (01674) 674558
<p>
<a href="gwops.html">Return to: Glaxo Wellcome Operations addresses page</a>
<p>
<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-429</DOCNO>
<DOCOLDNO>IA057-000937-B015-319</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/intexpl/software/rasmol/selected.html 193.128.22.20 19970109091053 text/html 922
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:01:05 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:28 GMT
Content-length: 732
Content-type: text/html
</DOCHDR>
<html><head><title>RasMol Manual: Selected Set</title></head><body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30"> 
<br clear=left>

<ul><ul><ul><ul><ul><ul><ul type=disc>

<h1><font size=7>RasMol manual</font></h1>
<hr size=4><br>
<h2><font size=6>Selected Set</font></h2><p>
This set contains the set of atoms in the currently selected
region. The currently selected region is defined by the preceding
<a href="select.html"><tt><b>select</b></tt></a>
or
<a href="restrict.html"><tt><b>restrict</b></tt></a>
command and not the atom expression containing the
<tt><b>selected</b></tt>
keyword.

<p>
<a href="predef.html">Predefined sets</a></ul></ul></ul></ul></ul></ul></ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-430</DOCNO>
<DOCOLDNO>IA057-000937-B019-69</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/contact/addresses/swexit.html 193.128.22.20 19970109094719 text/html 2314
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:37:31 GMT
Last-modified: Tuesday, 24-Dec-96 11:30:38 GMT
Content-length: 2123
Content-type: text/html
</DOCHDR>
<html><head>
<title>You are leaving the Glaxo Wellcome global web site</title></head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000" link="#1a1afa" vlink="30aa30">
<basefont size=4>

<img src="icon.gif" align=left border=0>
<br clear=left>

<ul><ul><ul><ul type=disc>

<h1><font size=7>You are leaving the Glaxo Wellcome global web site</font></h1>
<hr size=4>


<p>

<font size=5>Thank you for visiting the Glaxo Wellcome global Web site, maintained by <a href="gw.html">Glaxo Wellcome plc in London, UK.</a></font><p>

You are about to reach pages created by Glaxo Wellcome Switzerland for
Swiss residents only. Not all the information it contains will be
applicable outside Switzerland.  Your <a href="../">local Glaxo Wellcome company</a> will always be happy to respond to your enquiries.<p>

Please remember that medical practice varies from country to country.
Always seek the advice of your doctor.<p>

<img src="ch.gif" align=left hspace=5>Forward to: Glaxo Wellcome Switzerland<br>
 <a href="http://www.glaxowellcome.ch/gw/gw_fr.html">en Fran&ccedil;aise</a> or
<a href="http://www.glaxowellcome.ch/gw/gw_dt.html">in Deutsch</a>
<br clear=left><p>


<a href="swit.html">Return to: Swiss contacts page</a><p>



<hr><p><a href="http://www.glaxowellcome.co.uk/netscape/map/bar.map"><img ismap src="http://www.glaxowellcome.co.uk/netscape/gifs/bar.gif" border=0></a>
<br>
<p>
<font size=2>
<a href="http://www.glaxowellcome.co.uk/netscape/world/">GW World</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/contact/">Contact</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/news/">News</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/health/">Healthcare</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/whatnew/">What's new</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/science/">Science</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/software/">Download</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/bookmark/">Bookmarks</a> |
<a href="http://www.glaxowellcome.co.uk/netscape/index.html">GW Homepage</a>
</font>
</ul></ul></ul></ul>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT14-B39-431</DOCNO>
<DOCOLDNO>IA057-000937-B017-376</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/tuberc/tuber21.html 193.128.22.20 19970109093448 text/html 1355
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:25:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:53 GMT
Content-length: 1164
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Tuberculosis</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>

<h1><font size=7>Tuberculosis</font></h1>
<hr size=4>
<br>
<h2><font size=6>Spitting blood</font></h2><br>

<font size=5>Tuberculosis is an infectious disease that is still increasing.  It thrives on overcrowding and poor nutrition.  Roughly one third of the world population alive today (two billion people) are, or have been, infected by tuberculosis. </font>
<p>

Although more than 95 per cent of people infected live in poor countries, recent outbreaks of tuberculosis have struck the impoverished inner cities of the US.  Increase of tuberculosis is also clearly related to the AIDS epidemic.  Approximately 10 million people are HIV positive.  About three million of these are estimated to be infected by tuberculosis.<p>
<p>


<a href="tuberc2.html">Back to: Reasons for resurgence</a><p>
<p>

<p>

</ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-432</DOCNO>
<DOCOLDNO>IA057-000937-B025-42</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/cellbio/anaphase.html 193.128.22.20 19970109103502 text/html 803
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:25:14 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:49 GMT
Content-length: 613
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>
<h1><font size=7>Anaphase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/ana.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="telophas.html">Forward to: Telophase</a><p>

</ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-433</DOCNO>
<DOCOLDNO>IA057-000937-B025-85</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/cellbio/telophas.html 193.128.22.20 19970109103550 text/html 807
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:26:00 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:50 GMT
Content-length: 617
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>
<h1><font size=7>Telophase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/telo.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="cellb1.html">Back to: the introduction</a><p>

</ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-434</DOCNO>
<DOCOLDNO>IA057-000937-B023-305</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/cellbio/metaphas.html 193.128.22.20 19970109102347 text/html 804
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 10:13:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:50 GMT
Content-length: 614
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>
<h1><font size=7>Metaphase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/meta.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="anaphase.html">Forward to: Anaphase</a><p>

</ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-435</DOCNO>
<DOCOLDNO>IA057-000937-B017-302</DOCOLDNO>
<DOCHDR>
http://ukweb1.glaxowellcome.co.uk:80/netscape/health/odyssey/cellbio/prophase.html 193.128.22.20 19970109093340 text/html 804
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Thursday, 09-Jan-97 09:23:52 GMT
Last-modified: Tuesday, 24-Dec-96 11:15:50 GMT
Content-length: 614
Content-type: text/html
</DOCHDR>
<html><head>
<title>Odyssey - Cell biology in clinical medicine</title>
</head>
<body background="back1.gif" bgcolor="#ffffff" text="#000000"
link="#1a1afa" alink="#" vlink="#30aa30">
<basefont size=4>

<a href="../../"><IMG align=absmiddle  WIDTH=76 HEIGHT=77 SRC="../../icon.gif" border=0 align=left></a>

<br clear=left>

<ul><ul><ul><ul>
<h1><font size=7>Prophase stage</font></h1>
<hr size=4><br>

<IMG align=absmiddle  WIDTH=126 HEIGHT=164 SRC="gifs/prop.gif"> <a href="../copy.html#cell">&copy;</a><p>
<a href="metaphas.html">Forward to: Metaphase</a><p>

</ul></ul></ul></ul>

</basefont>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-436</DOCNO>
<DOCOLDNO>IA012-000130-B042-70</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/main.htm 196.26.82.193 19970217022626 text/html 4253
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:30:03 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>CHAMBER OF MINES OF SOUTH AFRICA</title>
</head>

<body background="images/Pat1.gif" bgcolor="#F2F2F2"
text="#0000A0" link="#0000FF" vlink="#800000">

<p align="center"><font size="6"><b>Chamber of Mines of South
Africa</b></font><br>
<font size="3"><i>Serving South Africa's Private Sector Mining
Industry Since 1889</i></font></p>
<div align="center"><center>

<table border="0" cellspacing="1">
    <tr>
        <td align="right" valign="top"><img
        src="images/hedger.jpg"
        alt="Welcome to our showcase on the South African mining industry"
        align="middle" width="158" height="232"><br>
        </td>
        <td align="center"><a href="/new.htm"><img
        src="images/spare2.gif" alt="What's New?" border="0"
        width="200" height="46"></a><br>
        <a href="org1.htm"><img src="images/spare3.gif"
        alt="Our Organisation" border="0" width="200" height="46"></a><br>
        <a href="res1.htm"><img src="images/spare4.gif"
        alt="Online Resources" border="0" width="200" height="46"></a><br>
        <a href="/kruger.htm"><img src="images/spare5.gif"
        alt="Krugerrand" border="0" width="200" height="46"></a><br>
        <a href="/info.htm"><img src="images/spare6.gif"
        alt="Contacting Us" border="0" width="200" height="46"></a> </td>
        <td valign="top"><img src="images/welc3.JPG"
        alt="The Chamber of Mines Online" align="middle"
        width="158" height="232"></td>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="0" cellpadding="4" width="71%" bgcolor="#FCDE32">
    <tr>
        <th><font color="#EC0000" size="2"><em> 1995, 1996
        Chamber of Mines of South Africa<br>
        </em></font><font color="#800040" size="2">Web Design and
        Management: </font><a href="mailto:twood@bullion.org.za"><font
        color="#800040" size="2">Timothy Wood</font></a></th>
    </tr>
</table>
</center></div>

<p align="center"><font color="#800080"><strong>This site is best
viewed with:<br>
</strong></font><a href="http://www.microsoft.com"><font
color="#008040" face="Arial Narrow"><strong><img
src="images/bestwith.gif" alt="MS Explorer" align="middle"
border="0" width="94" height="35"></strong></font></a><font
color="#008040" face="Arial Narrow"><strong> </strong></font><font
color="#0080FF" size="3" face="Arial"><em><strong>800x600x256</strong></em></font><a
href="http://www.netscape.com/comprod/mirror/client_download.html"><font
color="#0080FF" size="3" face="Arial"><em><strong><img
src="images/Netnow3.gif" alt="Netscape 3" align="middle"
border="0" width="95" height="35"></strong></em></font></a></p>
<div align="center"><center>

<table border="6" cellpadding="4" cellspacing="0"
bordercolor="#800000" bordercolorlight="#FF9D9D">
    <tr>
        <td align="center" bgcolor="#FF0000"><font
        color="#FFFFFF" size="4"><strong>DISCLAIMER</strong></font></td>
    </tr>
</table>
</center></div>

<p align="center"><font color="#000000" size="3">By entering any
of the resources on this site, you have accepted this disclaimer.
Whilst every effort has been made to ensure that information
contained herein is accurate, the Chamber of Mines of South
Africa disclaims all liability for any loss, damage, injury or
expense however caused, arising from the use of, or reliance
upon, in any manner, the information provided through this
service and does not warrant the truth, accuracy or completeness
of the content.</font></p>

<p align="center"><font color="#800080"><strong>Powered by The
Internet Solution<br>
</strong></font><a href="http://www.is.co.za"><font
color="#008040" face="Arial Narrow"><strong><img
src="images/islogo.gif" alt="Interne Solution" border="0"
width="82" height="37"></strong></font></a><font color="#008040"
face="Arial Narrow"><strong><br>
</strong></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-437</DOCNO>
<DOCOLDNO>IA012-000121-B038-73</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/new.htm 196.26.82.193 19970217003103 text/html 6841
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:34:32 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines: What's new on our site.</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><img src="../images/LOGO1.gif" width="300"
height="160"></p>

<p align="center"><img src="images/New2.JPG" alt="What's New?"
width="200" height="46"></p>
<div align="center"><center>

<table border="1" cellpadding="2">
    <tr>
        <td align="center" width="150"><a href="#UPDATEDDAILY"><strong>Updated
        Daily</strong></a></td>
        <td align="center" width="150"><a href="#THEVERYLATEST"><strong>The
        Very Latest</strong></a></td>
        <td align="center" width="150"><a href="#Search"><strong>Search</strong></a></td>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="1">
    <tr>
        <td align="center" width="16%"><font
        color="#800080" size="2"><a href="#January">January</font></a></td>
        <td align="center" width="16%"><font
        color="#800080" size="2"><a href="#THEVERYLATEST">February</a></font></a></td>
        <td align="center" width="17%"><font
        color="#800080" size="2">March</font></a></td>
        <td align="center" width="17%"><font
        color="#800080" size="2">April</font></a></td>
        <td align="center" width="17%"><font
        color="#800080" size="2">May</font></a></td>
        <td align="center" width="17%"><font
        color="#800080" size="2">June</font></a></td>
    </tr>
    <tr>
        <td align="center" width="16%"><font
        color="#800080" size="2">July</font></a></td>
        <td align="center" width="16%"><font color="#800080"
        size="2">August</font></td>
        <td align="center" width="17%"><font color="#800080"
        size="2">September</font></td>
        <td align="center" width="17%"><font color="#800080"
        size="2">October</font></td>
        <td align="center" width="17%"><font color="#800080"
        size="2">November</font></td>
        <td align="center" width="17%"><font color="#800080"
        size="2">December</font></td>
    </tr>
</table>
</center></div>

<p align="left">&nbsp;</p>

<p align="left"><a name="UPDATEDDAILY"><font color="#008000"
size="3"><b>UPDATED DAILY</b></font></a></p>

<p><font size="3"><img src="purple.gif" width="14" height="14"> </font><a
href="../news/home.htm"><font size="3">Daily Mining News</font></a><font
size="3"><br>
<img src="purple.gif" width="14" height="14"> </font><a
href="prices.htm"><font size="3">Daily Economic Indicators and
Precious Metal Prices</font></a><font size="3"><br>
</font></p>

<p><a name="THEVERYLATEST"><font color="#008000" size="3"><b>THE
VERY LATEST</b></font></a></p>

<p><a name="February"><font color="#800040" size="4"><em><strong>February</strong></em></font></a><font
color="#800040" size="4"><em><strong> 1997</strong></em></font></p>

<img src="purple.gif" width="14" height="14"> </font><a href="http://www.bullion.org.za/statistics/cmp96p12.pdf"><font
size="3">Gold Quarterly Analysis - January to December 1996</font></a><font size="3"> </font><font color="#FF0000" size="2"><b>[PDF file - 8k]</b></font><font size="3"> (14 February 1997)<br>
<img src="purple.gif" width="14" height="14"> </font><a href="http://www.bullion.org.za/statistics/g-output.htm#December"><font size="3">Gold Production for December 1996</font></a><font size="3"> (12 February 1997)<br>


<p><a name="January"><font color="#800040" size="4"><em><strong>January</strong></em></font></a><font
color="#800040" size="4"><em><strong> 1997</strong></em></font></p>


<p><img src="purple.gif" width="14" height="14"><a href="#Search"> <font
size="3">Search the Chamber of Mines Online</font></a> (20
January 1997)<br>
<img src="purple.gif" width="14" height="14"><a
href="releases/1997/comnum97.htm"><font size="3">Joint Media
Statement by the National Union of Mineworkers and the Chamber of
Mines on their Agreement Relating to the new Mine Health &amp;
Safety Act</font></a><font size="3"> (9 January 1997)<br>
</font></p>

<p align="center"><a href="http://www.bullion.org.za/new1996.htm"><font
size="2" face="Arial"><em><strong>What was new in 1996?</strong></em></font></a></p>

<p align="center">&nbsp;</p>

<p align="center"><a name="Search"><font size="2" face="Arial">Search</font></a><font
size="2" face="Arial"> the Chamber of Mines Online using
AltaVista! To search for information about<b> Gold Mining</b> type <b>gold
mining</b> in the search box. <br>
</font><font size="1" face="Arial">(Please leave a hard space
after .za before entering your search text)</font></p>

<form action="http://www.altavista.digital.com/cgi-bin/query"
method="GET">
    <input type="hidden" name="pg" value="q"><p align="center"><font
    size="2"><strong>Search</strong></font><select name="what"
    size="1">
        <option selected value="web">the Web</option>
    </select><font size="2"><strong>and Display the Results</strong></font> <select
    name="fmt" size="1">
        <option selected value=".">in Standard Form</option>
        <option value="c">in Compact Form</option>
        <option value="d">in Detailed Form</option>
    </select> <br>
    <input type="text" size="45" maxlength="200" name="q"
    value="host:www.bullion.org.za "> <input type="submit"
    value="Submit"><br>
    </p>
</form>

<p align="center"><a href="org1.htm"><font size="3"><img
src="tb101.gif" alt="organisation" border="0" width="101"
height="17"></font></a><font size="3"> </font><a href="res1.htm"><font
size="3"><img src="tb102.gif" alt="Resources" border="0"
width="101" height="17"></font></a><font size="3"> </font><a
href="kruger.htm"><font size="3"><img src="tb104.gif"
alt="Krugerrand" border="0" width="101" height="17"></font></a><font
size="3"> </font><a href="new.htm"><font size="3"><img
src="tb105.gif" alt="What's New?" border="0" width="101"
height="17"></font></a><font size="3"> </font><a href="info.htm"><font
size="3"><img src="tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></font></a><font size="3"> </font></p>

<hr size="3">

<address>
    <font size="2"> 1995 - 97 Chamber of Mines of South Africa<br>
    HTML Coding by Andrew Parsons : </font><a
    href="mailto:aparsons@bullion.org.za"><font size="2">aparsons@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-438</DOCNO>
<DOCOLDNO>IA012-000121-B038-145</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/org1.htm 196.26.82.193 19970217003201 text/html 3786
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:35:21 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Minesof South Africa: Our Organisation</title>
<base href="http://www.bullion.org.za">
</head>

<body bgcolor="#FFFFFF" text="#0000A0" vlink="#0000A0">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><img src="http://www.bullion.org.za./LOGO1.gif"
width="300" height="160"></p>

<p align="center"><img src="http://www.bullion.org.za./images/spare3.gif"
alt="our organisation" width="200" height="46"></p>
<div align="center"><center>

<table border="1" cellpadding="2">
    <tr>
        <th><a href="/organisation/members.htm">Members of the
        Chamber</a></th>
        <th><a href="/organisation/manage.htm">Principal
        Committees</a></th>
        <th><a href="/organisation/manage.htm#manpol">Chamber
        Management</a></th>
    </tr>
    <tr>
        <th><a href="/organisation/work2.htm">Services and
        Functions</a></th>
        <th><a href="/organisation/other.htm">Associates of the
        Chamber</a></th>
        <th><a href="file:///W:/info.htm#info1">General
        Information</a></th>
    </tr>
    <tr>
        <td colspan="3"><p align="center"><a
        href="/publications/constitution.htm"><b><i>Constitution
        of the Chamber of Mines of South Africa</i></b></a> </p>
        </td>
    </tr>
</table>
</center></div>
<center>
<p align="center"><font size="2" face="Arial">Search the Chamber
of Mines Online using AltaVista! To search for information about<b>
Gold Mining</b> type <b>gold mining</b> in the search box. <br>
</font><font size="1" face="Arial">(Please leave a hard space
after .za before entering your search text)</font></p>

<form action="http://www.altavista.digital.com/cgi-bin/query"
method="GET">
    <input type="hidden" name="pg" value="q"><p align="center"><font
    size="2"><strong>Search</strong></font><select name="what"
    size="1">
        <option selected value="web">the Web</option>
    </select><font size="2"><strong>and Display the Results</strong></font> <select
    name="fmt" size="1">
        <option selected value=".">in Standard Form</option>
        <option value="c">in Compact Form</option>
        <option value="d">in Detailed Form</option>
    </select> <br>
    <input type="text" size="45" maxlength="200" name="q"
    value="host:www.bullion.org.za "> <input type="submit"
    value="Submit"><br>
    </p>
</form>

<p align="center"><a href="/org1.htm"><img
src="http://www.bullion.org.za./tb101.gif" alt="organisation"
border="0" width="101" height="17"></a><a
href="/res1.htm"><img
src="http://www.bullion.org.za./tb102.gif" alt="Resources"
border="0" width="101" height="17"></a><a
href="/kruger.htm"><img
src="http://www.bullion.org.za./tb104.gif" alt="Krugerrand"
border="0" width="101" height="17"></a><a
href="/new.htm"><img
src="http://www.bullion.org.za./tb105.gif" alt="What's New?"
border="0" width="101" height="17"></a><a
href="/info.htm"><img
src="http://www.bullion.org.za./tb106.gif" alt="Contacting us"
border="0" width="101" height="17"></a> </p>

<hr>
<div align="center"><center>

<address>
    <font size="2"> 1996, 1997 Chamber of Mines of South Africa<br>
    HTML Coding by Andrew Parsons : </font><a
    href="mailto:aparsons@bullion.org.za"><font size="2">aparsons@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</center></div>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-439</DOCNO>
<DOCOLDNO>IA012-000121-B039-4</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/res1.htm 196.26.82.193 19970217003311 text/html 3969
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:36:11 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa: Online Resources</title>
<base href="http://www.bullion.org.za/RES1.HTM">
</head>

<body bgcolor="#FFFFFF" text="#000080" vlink="#0000A0">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><img src="/images/LOGO1.gif" width="300"
height="160"></p>

<p align="center"><img src="/images/Res1.jpg"
alt="Online Resources" width="200" height="46"></p>
<div align="center"><center>

<table border="1" cellpadding="2" width="520">
    <tr>
        <th><a href="/policy/discuss.htm">Policy Documents</a></th>
        <th><a href="/releases/releases.htm">Press Releases</a></th>
        <th><a href="/publications/comnl.htm">Publications &amp; Texts</a></th>
    </tr>
    <tr>
        <th><a href="/speeches/speech.htm">Speeches</a></th>
        <th><a href="/agreements/agree.htm">Industry Agreements</a></th>
        <th><a href="/statistics/statsd01.htm">Facts &amp;
        Figures</a></th>
    </tr>
    <tr>
        <th><a href="/samlnks.htm">SA Mining Directory</a></th>
        <th><a href="/mining.htm">World Mining Directory</a></th>
        <th><a href="/images.htm">Image Library</a></th>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="1" cellpadding="4" width="520">
    <tr>
        <th><a href="/news/home.htm">Daily News</a></th>
        <th><a href="/prices.htm">Daily Economic Indicators</a></th>
        <td align="center"><a href="visit.htm"><strong>Mine
        Visits</strong></a></td>
    </tr>
</table>
</center></div>

<p align="center"><font size="2" face="Arial">Search the Chamber
of Mines Online using AltaVista! To search for information about<b>
Gold Mining</b> type <b>gold mining</b> in the search box. <br>
</font><font size="1" face="Arial">(Please leave a hard space
after .za before entering your search text)</font></p>

<form action="http://www.altavista.digital.com/cgi-bin/query"
method="GET">
    <input type="hidden" name="pg" value="q"><p align="center"><font
    size="2"><strong>Search</strong></font><select name="what"
    size="1">
        <option selected value="web">the Web</option>
    </select><font size="2"><strong>and Display the Results</strong></font> <select
    name="fmt" size="1">
        <option selected value=".">in Standard Form</option>
        <option value="c">in Compact Form</option>
        <option value="d">in Detailed Form</option>
    </select> <br>
    <input type="text" size="45" maxlength="200" name="q"
    value="host:www.bullion.org.za "> <input type="submit"
    value="Submit"><br>
    </p>
    <p align="center"><a href="org1.htm"><img
    src="/images/tb101.gif" alt="organisation" border="0"
    width="101" height="17"></a><a href="res1.htm"><img
    src="/images/tb102.gif" alt="Resources" border="0"
    width="101" height="17"></a><a href="kruger.htm"><img
    src="tb104.gif" alt="Krugerrand" border="0" width="101"
    height="17"></a><a href="new.htm"><img
    src="/images/tb105.gif" alt="What's New?" border="0"
    width="101" height="17"></a><a href="info.htm"><img
    src="/images/tb106.gif" alt="Contacting us" border="0"
    width="101" height="17"></a> </p>
    <hr size="3" width="500">
    <div align="center"><center><address>
        <font size="2"> 1996 Chamber of Mines of South Africa<br>
        HTML Coding by Timothy Wood : </font><a
        href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
        size="2"> </font>
    </address>
    </center></div>
</form>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-440</DOCNO>
<DOCOLDNO>IA012-000121-B039-52</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/kruger.htm 196.26.82.193 19970217003347 text/html 23686
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:37:07 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>The Chamber of Mines of South Africa - Krugerrand Marketing</title>
</head>

<body bgcolor="#FFFFFF" text="#000080" vlink="#001F76">

<p align="center"><img src="images/Kgrnd.jpg"
alt="Incredible pic of a set of Krugerrands" width="470"
height="225"><br>
<img src="images/nkrhead.gif" alt="KRUGERRAND" width="532"
height="69"><br>
<font color="#400040" size="5">The World's Favourite Gold Bullion
Coin</font><font color="#400040"><br>
</font><font color="#400040" size="4" face="Arial"><i>Generation
to Generation</i></font></p>

<p align="center"><a name="top"><img src="images/line3.gif"
align="middle" width="590" height="2"></a></p>
<div align="center"><center>

<table border="2" cellspacing="4" width="560">
    <tr>
        <td align="center" width="50%"><a href="#general"><font
        size="3"><b>General Information</b></font></a></td>
        <td align="center" width="50%"><a href="#specs"><font
        size="3"><b>Technical Description of Krugerrands</b></font></a></td>
    </tr>
    <tr>
        <td align="center" width="50%"><a href="#DEALERS"><font
        size="3"><b>International Krugerrand Distributors</b></font></a></td>
        <td align="center" width="50%"><a href="#COINS"><font
        size="3"><b>Pictures of Krugerrands</b></font></a></td>
    </tr>
    <tr>
        <td align="center" colspan="2"><a href="#CONTACT"><font
        size="3"><b>Contact Information</b></font></a></td>
    </tr>
</table>
</center></div>

<p align="center"><a name="top"><img src="images/line3.gif"
align="middle" width="590" height="2"></a></p>

<h3 align="center"><a name="general">General Information</a></h3>

<p>The South African Krugerrand was first mass-produced in 1970.
Since then more than 46,2 million ounces (1440 tons) or 54,3
million coins of all four sizes have been sold world-wide, making
it the most successful in the history of gold bullion coins. In
1978 sales reached a peak of more than 6 million ounces. Each
Krugerrand contains an exact amount of pure gold, added to which
is a small amount of copper to provide durability. Thus the coins
are made of 22 carat alloy and their mass is a little more than
that of the fine gold contained as indicated on the reverse. </p>

<p>The obverse depicts Paul Kruger, President of the original
South African Republic from 1883 to 1902, and the reverse shows the
springbok, the national animal of South Africa. Krugerrand is now well
established as the only South African world brand. Behind this
remarkable achievement is an innovative concept allied to
effective marketing. </p>

<p>The Chamber of Mines of South Africa, a voluntary association
of private sector South African mining companies, evolved the
concept in the 1960's - the striking of a gold coin containing exactly one
ounce of gold without a face value, the price of which would move
in accord with the daily gold price on world markets. </p>

<p>For this concept to realise its potential, it was essential
that the coin be accorded legal tender status. After negotiation,
the government amended the South African Mint and Coinage Act in October 1966,
to include a one ounce gold coin - the Krugerrand - in the
official coinage of South Africa. The coin was first struck by
the South African Mint in July 1967, in small numbers as a proof
coin of interest primarily to collectors. </p>

<p>However, the gold mining industry's objective was to place
gold into as many private hands as possible by making it
available in a convenient and easily negotiable form at
relatively low premium over the international price of bullion. </p>

<p>Accordingly, arrangements were made for the Mint, while
continuing the production of proof coins in limited numbers, to mass-produce
the coin in uncirculated quality for sale at a low premium above its
gold content. </p>

<p>Availability of the coin in large numbers from 1970 onwards
was followed by an explosion of demand for a tangible asset on a
scale that could not have been foreseen, as a hedge against the erosion
of assets through rampant inflation arising from political and
economic uncertainty. </p>

<p>The rapid increase in the gold price in the late 1970's
created a situation in which many people could no longer afford
to buy the one ounce Krugerrand. But it was the man-on-the-street
who was most vulnerable to inflation and who needed to find a counter
to the erosion of his savings. Action was once again taken to
place gold ownership within the reach of those for whom the price
of the one ounce coin had risen too high. Agreement was obtained
from the South African authorities to strike in addition to the
one ounce coin a half ounce Krugerrand, a quarter ounce Krugerrand
and a one tenth ounce Krugerrand which were also accorded the
status of legal tender of the world's largest gold producing
country. </p>

<p>To maintain the high recognition value created on world gold
markets by the original one ounce coin the smaller units were struck
with the same design as their &quot;parents&quot;. In addition to
the huge potential of the consumer savings market for bullion coins
at popular prices, it was envisaged that the popularity of the
coins would extend into jewellery or as gifts for special occasions.
The new coins were launched internationally on 23 September 1980.
Thus a &quot;family&quot; of Krugerrands had been created
covering all facets of consumer demand. </p>

<p>The Chamber of Mines continues today with these same
objectives. The Krugerrand gives the man-on-the-street convenient access
to gold; illustrates that gold is an economic asset, a store of value
and a form of money all combined together in one coin; and adds
value locally to South African gold. <br>
</p>

<hr size="6" noshade width="600">

<h3 align="center"><a name="specs"><font color="#800040">Technical
Description of Krugerrands</font></a></h3>

<h4 align="center"><font color="#0080C0"><i>As per Schedule 2 of
the South African Reserve Bank Act(1989)</i></font></h4>

<table border="1" cellpadding="2" width="100%">
    <tr>
        <th><font color="#FF0000">Measurement</font></th>
        <th><font color="#FF0000">1oz<br>
        Krugerrand</font></th>
        <th><font color="#FF0000">0.5oz<br>
        Krugerrand</font></th>
        <th><font color="#FF0000">0.25oz<br>
        Krugerrand</font></th>
        <th><font color="#FF0000">0.1oz<br>
        Krugerrand</font></th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Gold Content<br>
        </font></th>
        <th align="right">1,000oz<br>
        31,103g</th>
        <th align="right">0,500oz<br>
        15,552g</th>
        <th align="right">0,250oz<br>
        7,776g</th>
        <th align="right">0,100oz<br>
        3,110g</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Standard Mass</font></th>
        <th align="right">33,930g</th>
        <th align="right">16,965g</th>
        <th align="right">8,482g</th>
        <th align="right">3,393g</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Maximum Mass</font></th>
        <th align="right">34,000g</th>
        <th align="right">17,000g</th>
        <th align="right">8,502g</th>
        <th align="right">3,403g</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Minimum Mass</font></th>
        <th align="right">33,930g</th>
        <th align="right">16,965g</th>
        <th align="right">8,482g</th>
        <th align="right">3,393g</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Standard Fineness<br>
        </font></th>
        <th align="right">11/12Au<br>
        1/12 Cu</th>
        <th align="right">11/12Au<br>
        1/12 Cu</th>
        <th align="right">11/12Au<br>
        1/12 Cu</th>
        <th align="right">11/12Au<br>
        1/12 Cu</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Millesimal
        Fineness</font></th>
        <th align="right">916,7</th>
        <th align="right">916,7</th>
        <th align="right">916,7</th>
        <th align="right">916,7</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Diameter<br>
        - maximum<br>
        - minimum</font></th>
        <th align="right"><br>
        27,07mm<br>
        26,93mm</th>
        <th align="right"><br>
        32,77mm<br>
        32,61mm</th>
        <th align="right"><br>
        22,06mm<br>
        21,94mm</th>
        <th align="right"><br>
        16,55mm<br>
        16,45mm</th>
    </tr>
    <tr>
        <th align="left"><font color="#800080">Thickness<br>
        - maximum<br>
        - minimum</font></th>
        <th align="right"><br>
        **2,84mm<br>
        **2,74mm</th>
        <th align="right"><br>
        2,215mm<br>
        2,115mm</th>
        <th align="right"><br>
        1,888mm<br>
        1,788mm</th>
        <th align="right"><br>
        1,35mm<br>
        1,25mm</th>
    </tr>
</table>

<table border="1" cellpadding="2" width="100%">
    <tr>
        <th align="left"><font size="2"><tt>**Prior to 1976 these
        measurements were: Max 2,972mm; Min 2,870mm. From 1976 to
        February 1979, these measurements were: Max 2,800; Min
        2,740mm. <br>
        </tt></font><p><font size="2"><tt>Minimum Mass: the least
        mass that a coin may reach through wear in circulation
        before it is no longer acceptable as legal tender. </tt></font></p>
        </th>
    </tr>
</table>

<p><br>
<br>
</p>

<p align="center"><a href="tmain.htm"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
<br>
</p>

<p align="center"><a name="DEALERS"><font face="Arial Narrow"><b>KRUGERRAND
DISTRIBUTORS</b></font> </a></p>

<p align="center"><font size="2" face="Arial Narrow"><b>(including
branches where applicable)<br>
</b></font></p>

<p align="center"><font size="2" face="Arial Narrow"><b>(Updated
March 1996) <br>
<br>
</b></font></p>
<div align="center"><center>

<table border="1">
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>AUSTRALIA</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>SCB The
        Mocatta Group Australia</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 61
        - 2 - 224 - 8588</font> <br>
        <font face="Arial Narrow">Fax No.: + 61 - 2 - 224 - 8690</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>FRANCE</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>CPR-Or </b></font></td>
        <td width="306"><font face="Arial Narrow">Tel. No.: +33 -
        1 - 4970 - 5507</font> <br>
        <font face="Arial Narrow">Fax. No.:+33 - 1 - 4596 - 0141</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>GERMANY</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Bayerische
        Landesbank Girozentrale</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 49
        - 911 - 235 - 9350</font> <br>
        <font face="Arial Narrow">Fax No.: + 49 - 911 - 244 -
        7540</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Deutsche
        Bank AG</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 49
        - 69 - 971 - 3410</font> <br>
        <font face="Arial Narrow">Fax No.: + 49 - 69 - 910 -
        35099</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Dresdner
        Bank AG</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 49
        - 69 - 263 - 2211</font> <br>
        <font face="Arial Narrow">Fax No.: + 49 - 69 - 263 - 5228</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>HONG KONG</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>SCB The
        Mocatta Group Hong Kong</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 852
        - 573 - 3238</font> <br>
        <font face="Arial Narrow">Fax No.: + 852 - 573 - 7869</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>JAPAN</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Mitsubishi
        Corporation</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 81
        - 3 - 3210 - 3796</font> <br>
        <font face="Arial Narrow">Fax No.: + 81 - 3 - 3210 - 3994</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Sumitomo
        Corporation</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel No.: + 81 -
        3 - 3217 - 5000</font> <br>
        <font face="Arial Narrow">Fax No.: + 81 - 3 - 3294 - 6176</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Tanaka
        Kikinzoku Kogyo K. K.</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 81
        - 3 - 3669 - 8422</font> <p><font face="Arial Narrow">Fax
        No.: + 81 - 3 - 3669 - 1460</font> <br>
        <font face="Arial Narrow">+ 81 - 3 - 3667 - 6479</font> </p>
        </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>SWITZERLAND</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Bank Leu</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 41
        - 1 - 219 - 2233</font> <br>
        <font face="Arial Narrow">Fax No.: + 41 - 1 - 219 - 3094</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Credit
        Suisse</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel No.: + 41 -
        1 - 333 - 5391</font> <br>
        <font face="Arial Narrow">Fax No.: + 41 - 1 - 333 - 5515</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Swiss Bank
        Corporation</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 41
        - 1 - 239 - 2286</font> <br>
        <font face="Arial Narrow">Fax No.: + 41 - 1 - 239 - 2625</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Union Bank
        of Switzerland</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel No.: + 41 -
        1 - 234 - 3424</font> <br>
        <font face="Arial Narrow">Fax No.: + 41 - 1 - 234 - 3725</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>TAIWAN ( REPUBLIC OF
        CHINA)</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Central
        Trust of China</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 886
        - 2 - 331 - 3695</font> <br>
        <font face="Arial Narrow">Fax No.: + 886 - 2 - 382 - 1047</font> <br>
        <font face="Arial Narrow">+ 886 - 2 - 375 - 2139</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>UNITED KINGDOM</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Deutsche
        Bank Sharps Pixley</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 44
        - 171 - 626 - 6191</font> <br>
        <font face="Arial Narrow">Fax No.: + 44 - 171 - 971 -
        7183</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Mitsubishi
        Corporation (UK) PLC</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel No.: + 44 -
        171 - 822 - 0245</font> <br>
        <font face="Arial Narrow">Fax No.: + 44 - 171 - 822 -
        0228</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Montagu
        Precious Metals</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel No.: + 44 -
        171 - 336 - 3773</font> <br>
        <font face="Arial Narrow">Fax No.: + 44 - 171 - 336 -
        3510</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>N M
        Rothschild &amp; Sons Limited</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 44
        - 171 - 280 - 5000</font> <br>
        <font face="Arial Narrow">Fax No.: + 44 - 171 - 280 -
        5095</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Republic
        Mase Bank Limited</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 44
        - 171 - 621 - 7800</font> <br>
        <font face="Arial Narrow">Fax No.: + 44 - 171 - 621 -
        7878</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>SCB The
        Mocatta Group London</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 44
        - 171 - 628 - 2825</font> <br>
        <font face="Arial Narrow">Fax No.: + 44 - 171 - 588 -
        9768</font> </td>
    </tr>
    <tr>
        <td colspan="2" width="612">&nbsp;</td>
    </tr>
    <tr>
        <td colspan="2" width="612"><font color="#800000"
        size="4" face="Arial Narrow"><b><i>UNITED STATES OF
        AMERICA</i></b></font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>A-Mark
        Precious Metals, Inc</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 1 -
        310 - 319 - 0200</font> <br>
        <font face="Arial Narrow">Fax No.: + 1 - 310 - 319 - 0279</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>J Aron &amp;
        Company</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 1 -
        212 - 902 - 7709</font> <br>
        <font face="Arial Narrow">Fax No.: + 1 - 212 - 509 - 1084</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>MTB Bank</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 1 -
        212 - 858 - 3300</font> <br>
        <font face="Arial Narrow">Fax No.: + 1 - 212 - 858 - 3449</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Imperial
        Bank</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.:+ 1 -
        310 - 417 - 5600</font> <br>
        <font face="Arial Narrow">Fax No.: + 1 - 310 - 417 - 5781</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>Republic
        National Bank of New York</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.: + 1 -
        212 - 525 - 6338</font> <br>
        <font face="Arial Narrow">Fax No.: + 1 - 212 - 525 - 6860</font> </td>
    </tr>
    <tr>
        <td width="306"><font face="Arial Narrow"><b>SCB The
        Mocatta Group New York</b></font> </td>
        <td width="306"><font face="Arial Narrow">Tel. No.:+ 1 -
        212 - 912 - 8500</font> <br>
        <font face="Arial Narrow">Fax No.: + 1 - 212 - 912 - 8415</font> </td>
    </tr>
</table>
</center></div>

<p><br>
</p>

<p align="center"><a href="tmain.htm"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
<a name="COINS"><br>
</a></p>

<p align="center"><a href="/images/k-rand1.gif"><img
src="../images/krand1_9.gif" border="0" width="65" height="64">
One ounce Krugerrand (20k) </a><a href="/images/k-rand3.gif"><img
src="images/krand3_9.gif" border="0" width="64" height="27"> Full
set of Kruggerrands (138k)</a></p>

<p><br>
</p>

<p align="center"><img src="line3.gif" align="middle" width="590"
height="2"><br>
<a name="CONTACT"><font color="#800040">For more information
contact</font></a></p>

<p align="center"><br>
<a href="mailto:dpollnow@bullion.org.za"><b>Dr Daniel Pollnow</b></a><b>,
Gold Marketing Consultant</b><br>
or <br>
<a href="mailto:gmoncur@bullion.org.za"><b>Ms Gillian Moncur</b></a><b>,
Gold Marketing Assistant</b></p>

<blockquote>
    <blockquote>
        <p align="left"><br>
        <img src="../images/phone.gif" align="middle" width="50"
        height="50"> <strong>Phone</strong>: +27 11 498-7100 <br>
        <img src="../images/faxphone.gif" align="middle"
        width="50" height="50"> <strong>Facsimile</strong>: +27
        11 838-4255 <br>
        <img src="../images/pobox.gif" align="middle" width="50"
        height="50"> <strong>Postal Address</strong>: PO Box
        61809, MARSHALLTOWN, 2107, SOUTH AFRICA<br>
        </p>
    </blockquote>
</blockquote>

<p align="center"><br>
<a href="org1.htm"><img src="tb101.gif" alt="organisation"
border="0" width="101" height="17"></a> <a href="res1.htm"><img
src="tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="kruger.htm"><img src="tb104.gif"
alt="Krugerrand" border="0" width="101" height="17"></a> <a
href="new.htm"><img src="tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="info.htm"><img
src="tb106.gif" alt="Contacting us" border="0" width="101"
height="17"></a> <br>
</p>

<hr>

<address>
    <font size="2"> 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-441</DOCNO>
<DOCOLDNO>IA012-000121-B039-146</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/info.htm 196.26.82.193 19970217003520 text/html 23699
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:38:04 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines Information</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="../images/LOGO1.gif" width="300"
height="160"></b></p>

<p align="center"><b><img src="../images/Con1.jpg" width="200"
height="46"></b>&nbsp;</p>
<div align="center"><center>

<table border="1" cellpadding="4" width="72%" border>
    <tr>
        <th><a href="#info1"><b>About Us: FAQ</b></a></th>
        <th><a href="#enq"><b>Enquiries</b></a></th>
        <th><a href="#JHB"><b>Johannesburg</b></a></th>
        <th><a href="#CT"><b>Cape Town</b></a></th>
        <th><a href="mail.htm"><b>E-Mail</b></a></th>
    </tr>
</table>
</center></div>

<p>&nbsp;</p>

<hr size="3" noshade>

<h3 align="center"><a name="info1"><b>ABOUT THE CHAMBER OF MINES
- FREQUENTLY ASKED QUESTIONS</b></a></h3>
<div align="center"><center>

<table border="1" cellpadding="2" border>
    <tr>
        <th><a
        href="http://www.cs.wits.ac.za/faq/safrica/safrica.html"><font
        color="#800080" size="3"><b>FAQ on South Africa</b></font></a></th>
        <th><a href="/images/SAMAP.gif"><font color="#FF8000"
        size="3"><b>Map of South Africa</b></font></a></th>
    </tr>
    <tr>
        <td colspan="2"><a href="/images/cmine5.jpg"><em><b>Picture
        of the Chamber of Mines Building, 5 Hollard Street,
        Marshalltown</b></em></a></td>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="0" cellspacing="4" width="80%">
    <tr>
        <td width="100%"><a href="#Why">Why is our web address<i>
        bullion.org.za</i>?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#What">What is the Chamber of
        Mines of South Africa?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#old">How old is the Chamber of
        Mines?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#established">Why was the
        Chamber of Mines established?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#name">Has the Chamber of Mines
        ever changed its name?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#Who">Who does the Chamber of
        Mines Represent?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#President">Who was the first
        President of the Chamber of Mines?</a></td>
    </tr>
    <tr>
        <td width="100%"><a href="#founding">Which were the
        founding companies?</a></td>
    </tr>
    <tr>
        <td><a href="#oldest">Which is the oldest operating mine
        which is a member of the Chamber of Mines?</a></td>
    </tr>
    <tr>
        <td><a href="#first">Which were the first Chamber of
        Mines members to declare gold?</a></td>
    </tr>
    <tr>
        <td><a href="#history">Has a history of the Chamber of
        Mines been written?</a></td>
    </tr>
</table>
</center></div>

<h4><a name="Why"><b>Why</b></a><b> is our web address</b><b><i>
bullion.org.za</i></b><b>?</b></h4>

<p><i>Bullion Johannesburg</i> was the telegraphic address of the
Chamber of Mines and its identity has now been transferred to the Internet's
World Wide Web. ZA is the international digraph identifying South
Africa and is derived from the Dutch name for South Africa - <i>Zuid
Afrika</i>.</p>

<h4><a name="What"><b>What</b></a><b> is the Chamber of Mines of
South Africa?</b></h4>

<p>The Chamber of Mines of South Africa is a prominent industry
employers' organisation which exists to serve its <a
href="organisation/members.htm">members</a> and promote their
interests in the South African mining industry. It does this through
a variety of activities and programmes undertaken in areas where
it is deemed desirable for members to consult with one another on
matters of common concern or to co-operate in specific industry-level
policy responses and joint initiatives.</p>

<p>With this scope defining its role, the Chamber exists as an
important strategic partner to its member mines and mining
finance houses who are active in some nine distinct mining
industries. These are the gold, coal, diamond, platinum,
antimony, asbestos, manganese, lead and copper mining industries.</p>

<p>In recent years the Chamber&#146;s role and functions have
undergone substantial change in view of developments unfolding in
the external environment. This redirection of the organisation
has been undertaken with a view to :&nbsp;</p>

<ul>
    <li>refocusing the Chamber to position it as the principal
        advocate to government of major policy positions endorsed
        by mining employers;</li>
    <li>ending the Chamber&#146;s direct involvement in (and
        financial subsidisation of) various industry services;
        and</li>
    <li>extended the membership base of the organisation.</li>
</ul>

<p>Consequently, the Chamber exists today primarily to provide
strategic support and advisory input to its members. It
facilitates interaction among mine employers to examine and
deliberate policy issues and other matters which are of mutual
concern In order to define desirable industry-level stances. Consultation
and co-operation within the Chamber system occur on a voluntary
basis and do not encroach on the managerial powers or
prerogatives of individual member mines and mining groups.</p>

<p>A key activity is the Chamber&#146;s representation of the
formalised policy position of its membership to various organs of
South Africa&#146;s national and provincial governments, and to
other relevant policy-making and opinion-forming entities inside
the country, and internationally.</p>

<p>A range of professional resources is maintained to support the
Chamber&#146;s policy review and advocacy functions and to equip it
to render advice to its members. Specialist resource areas include mining
health and safety, education and training, communication,
research, environmental management, economics, industrial
relations and gold marketing.</p>

<p>Chamber influence over member affairs is, however, regulated
by an approach to industry policy direction and formulation that
is founded on the striking of consensus among members, all of
whom associate within the Chamber system on a voluntary basis.
Consensus is defined via the deliberations of a number of Chamber <a
href="organisation/manage.htm">principal committees</a>, headed
by an <a href="organisation/manage.htm#EXCOM">Executive Committee</a>. The
principal committees are representative of South Africa's <a
href="/speeches/trn2.htm#miningfinancehouses">major mining
finance houses</a>, or mining groups. Senior industry executives
serving on these committees as representatives of their respective
groups oversee various portfolios and provide valuable guidance
to aid decision-making and the implementation of strategy by
Chamber <a href="organisation/work2.htm">departments</a> and <a
href="organisation/other.htm">associated business units and companies</a>.</p>

<p>Principal committees are, in turn, advised by a number of
expert committees actively engaged in the major spheres of Chamber
activity. Within the <a href="organisation/work2.htm">core
Chamber</a>, a <a href="organisation/manage.htm#manpol">management
policy committee</a>, headed by the <a
href="organisation/cvs/main.htm">Chief Executive</a>, directs Chamber
operations and implements policy.</p>

<h4><b>How </b><a name="old"><b>old</b></a><b> is the Chamber of
Mines?</b></h4>

<p>The first Chamber of Mines was formed on 7 December 1887 in
the Central Hotel in Johannesburg and was succeeded by the modern
Chamber on 5 October 1889. On that day, the first meeting of members
of the modern Chamber was held and was attended by
representatives of the following mines: Aurora, Balmoral, City
and Suburban, Crown Reef, Driefontein, Eclipse, Geldenhuis
Estate, George Goch, Langlaagte Block B, Langlaagte Estate,
Langlaagte Western, Luipaard's Vlei, Nigel, Odessa, Randfontein,
Riet Vlei, Robinson, Stanhope Geldenhuis, Transvaal Montana,
White Reef and Witwatersrand.</p>

<p><strong>Why was the Chamber of Mines </strong><a
name="established"><strong>established</strong></a><strong>?</strong></p>

<p>The Chamber of Mines was established to disseminate
authoritative statistical information about the Transvaal gold
fields and to validate prospectuses. Other objectives included:</p>

<ul>
    <li>the promotion and protection of mining interests;</li>
    <li>the promotion of public discussion on mining industry
        issues;</li>
    <li>the promotion of favourable legislative measures; and</li>
    <li>the exchange of information with other public and private
        mining bodies within and outside of South Africa.</li>
</ul>

<p><b>Has the Chamber of Mines ever changed its </b><a
name="name"><b>name</b></a><b>?</b></p>

<p>The Chamber of Mines has undergone a number of name changes in
its history which coincide with mining and political developments
in South Africa. The Chamber of Mines' predecessor was formed in
1887 - one year after an Australian gold-digger, George Harrison,
discovered gold on the farm Langlaagte - and was named the
Chamber of Mines in Johannesburg. The name changes and the applicable
periods are as follows:</p>

<ul>
    <li>Witwatersrand Chamber of Mines: <br>
        1889-1896</li>
    <li>Chamber of Mines of the South African Republic:<br>
        1897-1901</li>
    <li>Transvaal Chamber of Mines: <br>
        1902-1952</li>
    <li>Transvaal and Orange Free State Chamber of Mines:<br>
        1953-1967</li>
    <li>Chamber of Mines of South Africa: <br>
        1968-</li>
</ul>

<h4><a name="Who"><b>Who</b></a><b> does the Chamber of Mines
Represent?</b></h4>

<p>It is an association of six major mining finance houses and
other major financial corporations, 36 gold mines and 22 coal mines
and 16 diamond, platinum, antimony, asbestos, lead and copper mines,
as well as a number of other members, including various
associated bodies.</p>

<p><strong>Who was the first </strong><a name="President"><strong>President</strong></a><strong>
of the Chamber of Mines?</strong></p>

<p>The first President was Mr Hermann Eckstein of the Corner
House mining company, who held the position from 1889 to 1892.
The first two vice presidents were Mr RR Hollins and Mr Carl
Hanau.</p>

<p><strong>Which were the </strong><a name="founding"><strong>founding</strong></a><strong>
companies?</strong></p>

<ul>
    <li>The Corner House (later Rand Mines and now <a
        href="http://www.mbendi.co.za/orgs/cb4c.htm">Randgold and
        Exploration Limited</a>) representing Wernher, Beit, London
        and led by H Eckstein and JB Taylor;</li>
    <li>Consolidated Gold Fields (now <a
        href="http://www.mbendi.co.za/orgs/caau.htm">Gold Fields
        of South Africa</a>) led by Cecil Rhodes;</li>
    <li>The Robinson Group led by JB Robinson; and</li>
    <li>Johannesburg Consolidated Investment Company (now <a
        href="http://www.jci.co.za/DivCorp/hi15/hi15.htm">JCI
        Limited</a>) led by Barney Barnato.</li>
</ul>

<p><strong>Which is the </strong><a name="oldest"><strong>oldest</strong></a><strong>
operating mine which is a member of the Chamber of Mines?</strong></p>

<p>East Rand Proprietary Mines (ERPM) first declared gold in
September 1894 and has produced 1&nbsp;431&nbsp;228 kilograms of
gold at an average grade of 7,23 grams per metric ton to date.
ERPM has milled 197&nbsp;972&nbsp;000 metric tons of ore to
obtain this gold. The next oldest member mine is Grootvlei Gold
Mine which first declared gold in September 1938 and has produced 612&nbsp;681 kilograms
of gold at an average grade of 6,03 grams per ton. The youngest
member mine of the Chamber is Kloof Gold Mine which first
declared gold in January 1992 and has produced 36&nbsp;595 kilograms
at an average grade of 6,68 grams per ton.</p>

<p><strong>Which were the </strong><a name="first"><strong>first</strong></a><strong>
Chamber of Mines members to declare gold?</strong></p>

<p>They were Jubilee Mine and Salisbury Mine. &nbsp;Both declared
gold for the first time in September 1887. They both ceased production
in early 1912, producing 11&nbsp;908 and 12&nbsp;458 kilograms of gold respectively.</p>

<h4><b>Has a </b><a name="history"><b>history</b></a><b> of the
Chamber of Mines been written?</b></h4>

<p>John Lang published a book in the centenary year of the
Chamber of Mines entitled: <font color="#FF0000" size="3"><i>Bullion Johannesburg:
Men, Mines and the Challenge of Conflict</i> </font><font
color="#004080" size="3">(Jonathan Ball Publishers,Johannesburg,
1986). He was also commissioned to write a history of the coal
mining industry which was published in 1995 and entitled: </font><font
color="#FF0000" size="3"><i>Power Base: Coal Mining in the Life
of South Africa</i></font><font color="#004080" size="3"> (Jonathan
Ball Publishers, Johannesburg, 1995).</font></p>

<p><font color="#FF0000" size="3"><strong><i>Bullion Johannesburg</i></strong></font><br>
Bullion Johannesburg, named after the telegraphic address of the
Chamber of Mines, tells the story of the Chamber from its foundation
soon after the proclamation of the Rand gold-fields in 1886, up to
the year of its centenary. The book gives the first full account
of the genesis of the Chamber, and goes on to record the conflict
that arose between mining men and the Kruger regime as the mining industry
endeavoured to establish itself in a rural wilderness. It
discusses the involvement of mining personalities in the
conspiracy that led to the Jameson Raid and the Johannesburg
Rising of 1895, and analyses the events that followed, leading to
war between the Transvaal and Britain.</p>

<p>Bullion Johannesburg covers the reconstruction after the war,
and the relationship between the Chamber and the Milner Administration.
As the escalating demand for new capital and technology to mine
the deep levels confirmed the essential function of the mining
houses, so did the need for men to work the mines institute the
Chamber&#146;s enduring preoccupation with labour. The book examines
the interlude in which 50 000 labourers from China filled gaps in
the black labour force, and describes the political storms that
led to their repatriation. It give&#146;s fresh perspective of
the political drama that saw the resurgence of Afrikaner
nationalism and the increasing disunity among the British
population of the Transvaal, on which Botha and Smuts were swept
to power in 1907 to begin the long Afrikaner dominance of
government in South Africa.</p>

<p>The book recalls the tensions and the patterns of protest that
quickly emerged in the new Union of South Africa, and shows how a
structure of labour relations, long to endure, was hammered out
on the Rand. IT casts new light on the course of events that
resulted in the 1922 Strike on the Rand and the Revolution that
followed, and discusses the aftermath of this violent clash: the
coming to power of the Nationalist/Labour Pact Government, headed
by General Hertzog, and the fateful entrenchment in South Africa
of segregation and the colour bar. It goes on to describe the aftermath
of the country&#146;s departure from the gold standard at the end
of 1932, and the rapid economic progress, based on the higher
gold price, which made possible expansion into new mining areas,
an advance interrupted, but not halted, by World War 2 and the
turbulent days that followed.</p>

<p>John Lang brings his story up to the present, illuminating the
technological and social advances that took place. He describes the
confidential background to the gold crises of the 60&#146;s, when
the Chamber in its most secret council&#146;s faced the prospect that
the Unites States was prepared to force down the gold price below
the $35 which had reigned since 1934. And it outlines the onward
march of the mineral industry, creating for the West a new
position of critical dependence on South Africa as the source of
strategic materials. Against this background, the book mirrors
the impact on mining of the mounting political unrest that led to
the pressure for reform, and opened the way to the abolition of
the colour bar so long imposed on the industry by Government
decree.</p>

<p>In a foreword, Professor Burridge Spies, Professor of History
at the University of South Africa, comments that the author has not
avoided controversy, but has sought to balance the Chamber&#146;s role against
other forces, telling his story against the background of the
political, social and economic framework of the last 100 years.
He writes, </p>

<blockquote>
    <p>&quot;This is no dull institutional history. Many
    remarkable, colourful personalities, who have been prominent
    in the mining world and who have helped shape the developments
    of their time, are vividly portrayed.&quot; </p>
</blockquote>

<p><b>About the Author</b><br>
John Lang was born in Secunderabad, India, the son of an Indian
Army officer. He grew up in England and was educated there,
entering the Royal Military College, Sandhurst, on 27 August 1939.
He took part in the Norwegian Campaign of 1940, and in the Burma
Campaigns of 1943 - 1945. Post-war, he was appointed to the staff
of the Director of Infantry, at the War Office, Whitehall. In
1948 he decided against peace-time soldering in favour of a
writing career. He emigrated to South Africa and joined the Natal
Daily News. He became its political correspondent, and, as a
parliamentary lobby correspondent, served Argus Group newspapers. At
the end of 1957, he joined the Chamber of Mines and was Public
Relations Adviser (1966-1980). Since then, he has been an
independent writer and editorial consultant. He is married and
has two daughters.</p>

<p align="center"><a><img src="../images/nb1.gif" alt="Main Menu"
align="middle" hspace="20" width="60" height="17"></a> <a
href="#top"><img src="../images/nb2.gif" alt="Top of Page"
align="middle" border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
<br>
</p>

<hr size="3" noshade>

<h3 align="center"><a name="enq">ENQUIRIES</a></h3>

<p align="center"><font color="#FF0000" size="3" face="Arial"><b>PLEASE
NOTE</b></font><font size="1" face="Arial"><br>
</font><font size="2" face="Arial">Please ensure that you are
using a valid e-mail address when making an enquiry. We have
received a number of enquiries that have outdated or incorrect IP
addresses and as a result have been unable to respond.</font></p>
<div align="center"><center>

<table border="2" cellpadding="2">
    <caption align="top"><font color="#FF0000" size="4"><b>GENERAL
    ENQUIRIES</b></font></caption>
    <tr>
        <td bgcolor="#FFEEFF">Web Comments</td>
        <td bgcolor="#FFEEFF">Commercial Enquiries</td>
        <td bgcolor="#FFEEFF">Media Enquiries</td>
        <td align="center" valign="top" bgcolor="#FFEEFF">World
        Mining Directory</td>
        <td align="center" valign="top" bgcolor="#FFEEFF">Staff
        Addresses</td>
    </tr>
    <tr>
        <td align="center"><a
        href="mailto:aparsons@bullion.org.za">Andrew Parsons</a></td>
        <td align="center"><a href="mailto:rboers@bullion.org.za">Reinoud
        Boers</a></td>
        <td align="center"><a href="mailto:lkriel@bullion.org.za">Llewellyn
        Kriel</a></td>
        <td align="center" valign="top"><a
        href="mailto:cjones@bullion.org.za">Cheryl Jones</a></td>
        <td align="center" valign="top"><a href="mail.htm">E-Mail
        Listing</a></td>
    </tr>
</table>
</center></div>

<p align="center">&nbsp;</p>

<hr size="3" noshade>

<h3 align="center"><a name="JHB"><b>JOHANNESBURG</b></a></h3>

<pre><b>
<img src="../images/build.gif" align="middle" width="50"
height="50"> Physical Address: 5 Hollard Street, Marshalltown, Johannesburg
<img src="../images/phone.gif" align="middle" width="50"
height="50"> Telephone +27 11 498-7100 
<img src="../images/faxphone.gif" align="middle" width="50"
height="50"> Facsimile +27 11 834-1884
<img src="../images/pobox.gif" align="middle" width="50"
height="50"> Postal Address: PO Box 61809, MARSHALLTOWN, 2107, SOUTH AFRICA
<img src="../images/emm.gif" align="middle" width="50"
height="50"> Internet E-Mail </b><a
href="mailto:aparsons@bullion.org.za"><b>aparsons@bullion.org.za</b></a><b>
</b></pre>

<p align="center"><br>
<a><img src="../images/nb1.gif" alt="Main Menu" align="middle"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<hr size="3" noshade>

<h3 align="center"><a name="CT"><b>CAPE TOWN</b></a></h3>

<pre><b>
<img src="../images/build.gif" align="middle" width="50"
height="50"> Physical Address: Rhodes Building, 150 St Georges Mall, Cape Town
<img src="../images/phone.gif" align="middle" width="50"
height="50"> Telephone +27 21 23-5266/7
<img src="../images/faxphone.gif" align="middle" width="50"
height="50"> Facsimile +27 21 24-7039
<img src="../images/pobox.gif" align="middle" width="50"
height="50"> Postal Address: PO Box 762, CAPE TOWN, 8000, SOUTH AFRICA
<img src="../images/emm.gif" align="middle" width="50"
height="50"> Internet E-Mail </b><a href="mailto:jlieb@is.co.za"><b> jlieb@is.co.za</b></a><b> or </b><a
href="mailto:francois@bullion.co.za"><b>francois@bullion.co.za</b></a><b>
</b></pre>

<p align="center"><br>
<a><img src="../images/nb1.gif" alt="Main Menu" align="middle"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p align="center"><br clear="left">
<a href="org1.htm"><img src="../images/tb101.gif"
alt="organisation" border="0" width="101" height="17"></a><a
href="res1.htm"><img src="tb102.gif" alt="Resources" border="0"
width="101" height="17"></a><a href="kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a><a href="new.htm"><img src="../images/tb105.gif"
alt="What's New?" border="0" width="101" height="17"></a><a
href="info.htm"><img src="tb106.gif" alt="Contacting us"
border="0" width="101" height="17"></a> <br>
</p>

<address>
    <font size="2"><br>
     1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-442</DOCNO>
<DOCOLDNO>IA012-000121-B045-18</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/news/home.htm 196.26.82.193 19970217005509 text/html 16248
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:57:59 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="News" content="Daily Mining News">
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa: Daily Mining News</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="../LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><b><i>Daily Mining News</i></b></h2>
<div align="center"><center>

<table border="1" cellpadding="2">
    <tr>
        <td align="center"><a href="#today"><strong><i>Latest
        News</i></strong></a></td>
        <td align="center"><a href="#month"><strong><i>This
        Month's News</i></strong></a></td>
        <td align="center"><a href="#arch"><strong><i>News
        Archive</i></strong></a></td>
    </tr>
    <tr>
        <td align="center" bgcolor="#EFEEFF"><a href="#other1"><font
        size="2" face="Arial"><strong>Other Mining News</strong></font></a></td>
        <td align="center" bgcolor="#EFEEFF"><a href="#other"><font
        size="2" face="Arial"><strong>Other SA News</strong></font></a></td>
        <td align="center" bgcolor="#EFEEFF"><a
        href="../../prices.htm"><font size="2" face="Arial"><strong>Economic
        Indicators</strong></font></a></td>
    </tr>
    <tr>
        <td align="center" colspan="3"><a href="#Search"><font
        size="2" face="Arial"><strong>SEARCH THE DAILY NEWS
        ARCHIVES</strong></font></a></td>
    </tr>
</table>
</center></div>

<p align="center">&nbsp;</p>

<p align="center"><i><br>
</i><font color="#008040" size="5"><b><i>Latest</i></b></font><a
name="today"><font color="#008040" size="5"><b><i> News</i></b></font></a></p>

<p align="center"><font size="4"><strong>THURSDAY, 13 FEBRUARY
1997 -13h00 GMT +2</strong></font></p>


GOLD FIXES AT $337,70 IN LONDON, ITS LOWEST AFTERNOON FIXING SINCE 1993<I>(Business Report, Johannesburg)</I><BR>
Gold fixed at $337,70 in London yesterday afternoon, from $339,40 on Tuesday.<BR><P>
ANGLO EDGES CLOSER TO ZAMBIAN COPPER COUP<I>(Business Report, Johannesburg)</I><BR>
A consortium led by Anglo American has signed a memorandum of understanding with the Zambian government, which gives the group the exclusive right to conduct a feasibility study on the Konkola copper mining project.<BR><P>
SA JEWELLER SEIZES GOLDEN OPPORTUNITY<I>(Business Report, Johannesburg)</I><BR>
The Reserve Bank has given a Durban jeweller the go-ahead to export sculptures of big game in precious metals to Hollywood stars and other rich overseas collectors.<BR><P>
BALANCING THE RAND Editorial Comment <I>(Business Day, Johannesburg)</I><BR>
Reserve Bank governor Chris Stals did not intend his off-the-cuff remark to Reuters that the rand may have rebounded a little too far to have the dramatic impact it did in the market on Tuesday - a seven cent plunge before clawing back half of that after he clarified his views.  But if the unintended effect of the governor's intervention is to return to a more stable course for the rand, it will have served a useful purpose.<BR><P>
EMPLOYMENT<I>(Business Day, Johannesburg)</I><BR>
Employment rose from 4,95-million in March 1994 to 5,24-million in Sept last year, an increase of 290 000, Labour Minister Tito Mboweni said yesterday.<BR><P>
ZWELITHINI LISTS POSSIBLE JOINT VENTURES WITH US<I>(Business Day, Johannesburg)</I><BR>
More than 40 proposed joint venture agreements with US companies, expected to inject tens of millions of rands into rural KwaZulu-Natal and significantly reduce unemployment, were announced by Zulu king Goodwill Zwelithini last night.<BR><P>
AN RDP BY ANY OTHER NAME WILL HAVE THE SAME BASIC PRINCIPLES<I>(Business Day, Johannesburg)</I><BR>
In March last year, President Mandela closed the reconstruction and development programme (RDP) office amid concern about its effective delivery.  At the time, there seemed to be few linkages in place to ensure the effective management of programmes.  But are there any now?  Has a change of location made a difference and has the RDP remained at the centre of government's activities?<BR><P>
GOVT 'UNLIKELY TO LET SAA GO TO FOREIGNERS'<I>(Business Day, Johannesburg)</I><BR>
Government was unlikely to give foreign buyers the opportunity to acquire a majority stake in SA Airways (SAA), following its decision to give offshore investors access to up to 49% of a privatised Sun Air, Public Enterprises Ministry spokesman Wandile Zote said yesterday.<BR><P>
COMMONWEALTH DEVELOPMENT CORPORATION TO INVEST R400M IN SA<I>(Business Report, Johannesburg)</I><BR>
The Commonwealth Development Corporation, Britain's overseas finance institution, will invest about R400 million in development projects in SA over the next three years, David Morley, the SA director of the corporation said yesterday.<BR><P>

<p align="center"><a href="/Welcome.html"><i><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></i></a><i> </i><a href="#top"><i><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></i></a><i> </i><a
href="#toolbar"><i><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></i></a><i> <br>
</i><br>
</p>

<p align="center"><a name="month"><font color="#008040" size="5"><b><i>This
Month's News</i></b></font></a></p>

<blockquote>
    <p>
<A HREF="http://www.bullion.org.za/news/1997/130297.htm">13 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/120297.htm">12 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/110297.htm">11 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/100297.htm">10 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/070297.htm"> 7 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/060297.htm">6 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/050297.htm">5 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/040297.htm">4 FEBRUARY 1997</A><BR>
<A HREF="http://www.bullion.org.za/news/1997/030297.htm"> 3 FEBRUARY 1997</A><BR>
    </p>
</blockquote>

<p align="center"><a href="/Welcome.html"><i><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></i></a><i> </i><a href="#top"><i><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></i></a><i> </i><a
href="#toolbar"><i><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></i></a><i> <br>
</i><br>
</p>


<p align="center"><a name="arch"><font color="#008040" size="5"><b><i>1997
News Archive</i></b></font></a></p>
<div align="center"><center>
<table border="1" cellpadding="2" width="60%">
    <tr>
        <th><a href="arch97.htm#jan"> January</a></th>
        <th><a href=>February</a></th>
        <th><a href=>March</a></th>
        <th><a href=>April</a></th>
        <th><a href=>May</a></th>
        <th><a href=>June</a></th>
    </tr>
    <tr>
        <th><a href=>July</a></th>
        <th><a href=>August</a></th>
        <th><a href=>September</a></th>
        <th><a href=>October</a></th>
        <th><a href=>November</a></th>
        <th><a href=>December</th>
    </tr>
</table>
</center></div>


<p align="center"><a name="arch"><font color="#008040" size="5"><b><i>1996
News Archive</i></b></font></a></p>
<div align="center"><center>

<table border="1" cellpadding="2" width="60%">
    <tr>
        <th>January</th>
        <th><a href="/news/arch.htm#feb">February</a></th>
        <th><a href="/news/arch.htm#mar">March</a></th>
        <th><a href="/news/arch.htm#apr">April</a></th>
        <th><a href="/news/arch.htm#may">May</a></th>
        <th><a href="/news/arch.htm#jun">June</a></th>
    </tr>
    <tr>
        <th><a href="/news/arch.htm#jul">July</a></th>
        <th><a href="/news/arch.htm#aug">August</a></th>
        <th><a href="/news/arch.htm#sep">September</a></th>
        <th><a href="/news/arch.htm#oct">October</a></th>
        <th><a href="/news/arch.htm#nov">November</a></th>
        <th><a href="/news/arch.htm#dec">December</th>
    </tr>
</table>
</center></div>

<p align="center"><a href="/Welcome.html"><i><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></i></a><i> </i><a href="#top"><i><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></i></a><i> </i><a
href="#toolbar"><i><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></i></a><i> <br>
<br>
</i></p>

<p align="center"><a name="other1"><font color="#008040" size="5"><b><i>Other
Mining News Sources<br>
</i></b></font></a><img src="../images/Starred.gif" width="18"
height="13"><font color="#800080" size="2" face="Arial"><b>Editor's
Choice</b></font></p>
<div align="center"><center>

<table border="1" cellpadding="4" cellspacing="4" width="500">
    <tr>
        <th>
        <a href="http://www.mining.co.za">African Mining</a> <br>
        <a href="http://www.mintek.ac.za/IEPD/BusInfo.htm">Mintek
        Business Information</a><br>
        <a href="http://www.csn.net/mbd/wkbrf.htm">Mining
        Business Digest Weekly Briefing</a><img
        src="../images/Starred.gif" width="18" height="13"><br>
        <a href="http://www.info-mine.com/daily.news/">Info-Mine
        Daily Prospector</a><br>
        <a
        href="http://www.info-mine.com/minpubs/minjournal/weeklysum.html">Mining
        Journal Weekly Summaries</a> <br>
        <a href="http://www.woza.co.za/mining.htm">Woza: Mining
        News</a><img src="../images/Starred.gif" width="18"
        height="13"></th>
    </tr>
</table>
</center></div>

<p align="center"><a href="/Welcome.html"><i><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></i></a><i> </i><a href="#top"><i><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></i></a><i> </i><a
href="#toolbar"><i><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></i></a><i> <br>
<br>
</i></p>

<p align="center"><a name="other"><font color="#008040" size="5"><b><i>Other
South African News Sources<br>
</i></b></font></a><img src="../images/Starred.gif" width="18"
height="13"><font color="#800080" size="2" face="Arial"><b>Editor's
Choice</b></font></p>
<div align="center"><center>

<table border="1" cellpadding="4" cellspacing="4" width="500">
    <tr>
        <th align="left" colspan="2" width="500"><blockquote>
            <blockquote>
                <p><a
                href="gopher://gopher.anc.org.za:70/11/anc/newsbrief/"><br>
                ANC Daily News Briefings</a><br>
                <a href="http://www.naspers.co.za/beeld/">Beeld</a><br>
                <a href="http://www.bday.co.za/">Business Day </a><a
                href="http://www.bday.co.za/">Online</a> <img
                src="../images/Starred.gif" width="18"
                height="13"><a href="http://www.btimes.co.za/"><br>
                Business Times Online</a><img
                src="../images/Starred.gif" width="18"
                height="13"><a href="http://www.btimes.co.za/"><br>
                </a><a href="http://www.cbn.co.za/">Cape </a><a
                href="http://www.cbn.co.za/">Business News</a> <br>
                <a
                href="http://www.sabc.co.za/units/chanafr/index.html">Channel
                Africa (SABC)</a><br>
                <a href="news:clari.world.africa.south_africa">ClariNet
                SA News Group</a><br>
                <a href="http://www.naspers.co.za/die_burger/">Die
                Burger</a> <br>
                <a
                href="http://www.ru.ac.za/departments/journ/ecna/welcome.html">Eastern
                Cape News Agency</a><br>
                <a href="http://africa.com/mags/finweek">Finance
                Week</a><br>
                <a href="http://www.atd.co.za/fm/">Financial Mail</a><img
                src="../images/Starred.gif" width="18"
                height="13"><br>
                <a href="http://www.inc.co.za/">Independent
                On-line</a><br>
                <a href="http://www.mg.co.za/mg/">Mail and
                Guardian</a><img src="../images/Starred.gif"
                width="18" height="13"><br>
                <a
                href="http://www.mainstreet.t5.com/index~1.htm">Main
                Street South Africa</a><img
                src="../images/Starred.gif" width="18"
                height="13"><br>
                <a href="http://www.naspers.co.za/rapport/">Rapport</a><br>
                <a href="http://www.sacs.org.za/level2/sacs.htm">SA
                Communication Service</a><br>
                <a href="http://www.satimes.press.net/">The Star
                and SA Times<br>
                </a><a href="http://www.woza.co.za">Woza: E-News</a><img
                src="../images/Starred.gif" width="18"
                height="13"><br>
                <a
                href="http://pubweb.is.co.za/mg/news/96may/news1.html">ZA
                Now: M&amp;G Daily</a></p>
            </blockquote>
        </blockquote>
        </th>
    </tr>
</table>
</center></div>

<p align="center"><a name="Search"><font size="2" face="Arial">Search</font></a><font
size="2" face="Arial"> the Chamber of Mines Online using
AltaVista! To search for information about<b> Gold Mining</b> type <b>gold
mining</b> in the search box. <br>
</font><font size="1" face="Arial">(Please leave a hard space
after .za before entering your search text)</font></p>

<form action="http://www.altavista.digital.com/cgi-bin/query"
method="GET">
    <input type="hidden" name="pg" value="q"><p align="center"><font
    size="2"><strong>Search</strong></font><select name="what"
    size="1">
        <option selected value="web">the Web</option>
    </select><font size="2"><strong>and Display the Results</strong></font> <select
    name="fmt" size="1">
        <option selected value=".">in Standard Form</option>
        <option value="c">in Compact Form</option>
        <option value="d">in Detailed Form</option>
    </select> <br>
    <input type="text" size="45" maxlength="200" name="q"
    value="host:www.bullion.org.za "> <input type="submit"
    value="Submit"><br>
    </p>
</form>

<p align="center"><i><img src="../images/line3.gif" width="590"
height="2"><br>
</i></p>

<p align="center"><a href="/org1.htm"><i><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></i></a><i> </i><a href="/res1.htm"><i><img
src="../images/tb102.gif" alt="Resources" border="0" width="101"
height="17"></i></a><i> </i><a href="/kruger.htm"><i><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"height="17"></i></a><i> </i><a href="/new.htm"><i><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></i></a><i> </i><a href="/info.htm"><i><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></i></a><i> <br>
</i></p>

<hr>
<div align="left">

<address>
    <font size="2"><i> 1995-1997 Chamber of Mines of South
    Africa<br>
    </i>Last updated: 13 February 1997 <br>
    HTML Coding by Llewellyn Kriel </font><a
    href="mailto:lkriel@bullion.org.za"><font size="2">lkriel@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</div>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-443</DOCNO>
<DOCOLDNO>IA012-000121-B040-96</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/prices.htm 196.26.82.193 19970217003743 text/html 28157
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:40:02 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Daily Economic Indicators</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><b><i>Daily Economic Indicators</i></b><b><br>
</b></h2>
<div align="center"><center>

<table border="1" width="90%">
    <tr>
        <th><b>Friday 14  February 1997<br>
        15h32 South African Standard Time [UST+2]</b> </th>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="1" cellpadding="4" width="90%">
    <tr>
        <th><a href="#SPOT">International Gold Prices</a></th>
        <th><a href="#PRECIOUS">Other Precious Metals</a></th>
        <th><a href="#LONDON">LME Prices</a></th>
        <th><a href="#KRUGERRAND">Krugerrand</a></th>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="1" cellpadding="4" width="90%">
    <tr>
        <th><a href="#CROSS-RATES"><b>Currency Crosses</b></a></th>
        <th><a href="#INTERNATIONAL"><b>International Exchange Indices</b></a></th>
        <th><a href="#JOHANNESBURG">Johannesburg SE</a></th>
        <th><a href="#GENERAL"><b>Related SA Resources</b></a></th>
    </tr>
</table>
</center></div>

<hr size="4" noshade width="90%">

<blockquote>
    <p align="center"><a href="http://www.kitco.com/index.html"><img
    src="http://www.kitco.com/image/quote.gif"></a> <font
    size="3"><br>
    </font><font color="#FF0000" size="3" face="Arial Narrow"><em><tt>Please
    press reload to view the latest precious metals prices</tt></em></font></p>
</blockquote>
<div align="left">

<pre><font size="3">
</font><a name="SPOT"><font color="#008000" size="4" face="Arial"><b><i>SPOT</i></b></font></a><font
color="#008000" size="4" face="Arial"><b><i> GOLD </i></b></font><font
color="#008000" size="3" face="Arial"><b><i>(closing prices from previous trading day)</i></b></font></pre>
</div>

<blockquote>
    <table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD LONDON AM FIX US$/OZ</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">343.00 </font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD LONDON PM FIX US$/OZ</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">342.65 </font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD LONDON PM RAND PER OZ </font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">1512.69</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD PARIS FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">342.39</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD FRANKFURT FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">342.54</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD ZURICH FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">342.10</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">GOLD HONG KONG CLOSE</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">343.85</font></td>
        </tr>
    </table>
</blockquote>

<p align="left"><font color="#008000" size="3" face="Arial"><b><i>OTHER </i></b></font><a
name="PRECIOUS"><font color="#008000" size="3" face="Arial"><b><i>PRECIOUS</i></b></font></a><font
color="#008000" size="3" face="Arial"><b><i> METALS</i></b></font><font
color="#008000" size="2" face="Arial"><b><i> (closing prices from
previous trading day)</i></b> </font></p>

<blockquote>
    <table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">SILVER US$ FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">5.1300</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">PLATINUM US$/OZ FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">366.00</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">PALLADIUM US$/OZ FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">137.00</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">ANTIMONY US$/OZ FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">2300 - 2400</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">IRIDIUM US$/OZ FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">180 - 200 </font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">RHODIUM US$/OZ FIX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">190 - 200 </font></td>
        </tr>
    </table>
</blockquote>

<blockquote>
    <p align="left"><a
    href="http://www.stockixchange.com/commodities.htm"><font
    color="#FF0000" size="2" face="Arial"><img
    src="images/Stx1.gif" border="0" width="55" height="35"></font></a><a
    href="http://www.stockixchange.com/commodities.htm"><font
    color="#FF0000" size="2" face="Arial"> </font><font
    color="#0000A0" size="3" face="Arial">Graphs of commodities</font></a><font
    color="#0000A0" size="3" face="Arial"> from </font><a
    href="http://www.stockixchange.com/"><font color="#0000A0"
    size="3" face="Arial">Stock IXchange</font></a><font
    color="#0000A0" size="3" face="Arial"> </font></p>
    <p align="center"><a
    href="http://www.stockixchange.com/stxlite.htm"><font
    color="#0000A0" size="3" face="Arial"><img
    src="images/Stxfree.gif" align="middle" border="0"
    width="113" height="31"></font><font color="#0000A0"
    face="Arial"> </font><font size="1" face="Arial"><em>Download
    IXCHANGE plug-in to view charts</em></font></a></p>
</blockquote>

<p align="left"><a href="http://www.lme.co.uk"><font
color="#008000" size="3" face="Arial"><em><b>LONDON METAL
EXCHANGE</b></em></font></a><font color="#008000" size="3"
face="Arial"><em><b> </b></em></font><a name="LONDON"><font
color="#008000" size="3" face="Arial"><em><b>PRICES</b></em></font></a><font
color="#008000" size="2" face="Arial"><em><b> (closing middle
prices from previous trading day)</b></em></font></p>

<p align="left">&nbsp;</p>

<blockquote>
    <table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">COPPER A CASH</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">2371.0 - 72.0</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">LEAD CASH</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">652.00 - 3.00</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">ZINC SPECIAL HIGH CASH</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">1194.0 - 95.0</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">ALUMINIUM HIGH CASH</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">1532.0 - 33.0</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">NICKEL CASH</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">7795 - 7800</font></td>
        </tr>
    </table>
</blockquote>

<p align="left"><a name="KRUGERRAND"><font color="#008000"
size="4" face="Arial"><b><i>KRUGERRAND</i></b></font></a><font
size="3" face="Arial"> </font></p>

<blockquote>
    <table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">1 OUNCE KRUGERRAND (RANDS) </font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">1555.00 </font></td>
        </tr>
    </table>
</blockquote>

<h4 align="left"><a name="CURRENCIES"><font color="#008000"
size="4" face="Arial"><em><b>CURRENCIES</b></em></font></a><font
color="#008000" size="4" face="Arial"><em><b> </b></em></font></h4>

<blockquote>
    <table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">SA RAND PER US DOLLAR</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">4.4110 </font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">SA RAND PER GB POUND</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">7.1643 </font></td>
        </tr>
    </table>
</blockquote>

<blockquote>
    <div align="left"><pre><font color="#FF0000" size="3"
face="Times New Roman"><img src="images/Stx1.gif" width="55"
height="35"> </font><a
href="http://www.stockixchange.com/charts/RAND.stx"><font
color="#0000A0" size="4" face="Times New Roman">Graph of the Rand against the US Dollar</font></a><font
color="#0000A0" size="4" face="Times New Roman"> from </font><a
href="http://www.stockixchange.com/"><font color="#0000A0"
size="4" face="Times New Roman">Stock IXchange</font></a><font
color="#0000A0" size="4" face="Times New Roman"> </font></pre>
    </div><div align="center"><center><pre><a
href="http://www.stockixchange.com/stxlite.htm"><font
color="#0000A0" size="3" face="Arial"><img
src="images/Stxfree.gif" align="middle" border="0" width="113"
height="31"></font><font color="#0000A0" face="Arial"> </font><font
size="2" face="Arial"><em>Download IXCHANGE plug-in to view charts</em></font></a></pre>
    </center></div>
</blockquote>
<div align="left">

<pre><font color="#008000" size="5" face="Arial"><em><b>CURRENCY </b></em></font><a
name="CROSS-RATES"><font color="#008000" size="5" face="Arial"><em><b>CROSS-RATES</b></em></font></a><font
color="#008000" size="4" face="Arial"><em><b> </b></em></font><font
size="3" face="Arial"><b> </b></font><font color="#FF0000"
size="4" face="Arial"><em><b>14/02/97 07h00</b></em></font><font
color="#FF0000" size="3" face="Arial"><b> </b></font></pre>
</div>

<blockquote>
    <table border="0">
        <tr>
            <td align="center"><font size="2" face="Arial"><strong>&nbsp;</strong></font></td>
            <td align="center"><font size="2" face="Arial"><strong>&nbsp;</strong></font></td>
            <td align="center"><font size="2" face="Arial"><strong>&nbsp;</strong></font></td>
            <td align="center" width="80" bgcolor="#F2EEFF"><font
            size="2" face="Arial"><strong>USD </strong></font></td>
            <td align="center" width="80" bgcolor="#F0F0F0"><font
            size="2" face="Arial"><strong>ZAR </strong></font></td>
            <td align="center" width="80" bgcolor="#F2EEFF"><font
            size="2" face="Arial"><strong>DEM </strong></font></td>
            <td align="center" width="80" bgcolor="#F0F0F0"><font
            size="2" face="Arial"><strong>YEN </strong></font></td>
            <td align="center" width="80" bgcolor="#F2EEFF"><font
            size="2" face="Arial"><strong>CHF </strong></font></td>
            <td align="center" width="80" bgcolor="#F0F0F0"><font
            size="2" face="Arial"><strong>GBP </strong></font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>1</strong></font></td>
            <td bgcolor="#F2EEFF"><font size="2" face="Arial"><strong>USD</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80" bgcolor="#000000"><font
            size="2" face="Arial">**</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">4.4110</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1.6852</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">124.32</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1.4565</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.6157</font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>1</strong></font></td>
            <td bgcolor="#EAEAEA"><font size="2" face="Arial"><strong>ZAR</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.2267</font></td>
            <td align="right" width="80" bgcolor="#000000"><font
            size="2" face="Arial">**</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.3820</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">28.18</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.3302</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.1396</font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>1</strong></font></td>
            <td bgcolor="#F2EEFF"><font size="2" face="Arial"><strong>DEM</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.5934</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">2.6175</font></td>
            <td align="right" width="80" bgcolor="#000000"><font
            size="2" face="Arial">**&nbsp;</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">73.86</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.8634</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.3652</font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>100</strong></font></td>
            <td bgcolor="#F0F0F0"><font size="2" face="Arial"><strong>YEN</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.8044</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">3.5481</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1.3540</font></td>
            <td align="right" width="80" bgcolor="#000000"><font
            size="2" face="Arial">**&nbsp;</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1.1680</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.4956</font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>1</strong></font></td>
            <td bgcolor="#F2EEFF"><font size="2" face="Arial"><strong>CHF</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.6866</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">3.0285</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1.1610</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">85.62</font></td>
            <td align="right" width="80" bgcolor="#000000"><font
            size="2" face="Arial">**&nbsp;</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">0.4232</font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>1</strong></font></td>
            <td bgcolor="#F0F0F0"><font size="2" face="Arial"><strong>GBP</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1.6242</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">7.1643</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">2.7380</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">201.92</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">2.3632</font></td>
            <td align="right" width="80" bgcolor="#000000"><font
            size="2" face="Arial">&nbsp;**</font></td>
        </tr>
        <tr>
            <td bgcolor="#C1D7C4"><font size="2" face="Arial"><strong>1</strong></font></td>
            <td bgcolor="#F2EEFF"><font size="2" face="Arial"><strong>GOLD</strong></font></td>
            <td><font size="2" face="Arial">=</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">341.500</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">1506.35</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">575.495</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">42455.2</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">497.394</font></td>
            <td align="right" width="80"><font size="2"
            face="Arial">210.257</font></td>
        </tr>
    </table>
</blockquote>
<div align="left">

<pre><font color="#FF0000" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|ZAR=SA RAND|DEM=DMARK|CHF=SWISS FRANC|YEN=JAPANESE YEN|USD=US DOLLAR|GBP=BRITISH POUNDS
</font></pre>
</div>

<h4 align="left"><font color="#008000" size="4" face="Arial"><em><b>STOCK </b></em></font><a
name="MARKET"><font color="#008000" size="4" face="Arial"><em><b>MARKET</b></em></font></a><font
color="#008000" size="4" face="Arial"><em><b> INDICES </b></em></font><font
color="#008000" size="3" face="Arial"><em><b>(closing prices from
previous trading day)</b></em></font></h4>

<blockquote>
    <div align="left"><pre><a name="JOHANNESBURG"><font size="4"
face="Times New Roman"><b><i>JOHANNESBURG</i></b></font></a></pre>
    </div><table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">JSE ALL SHARE</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">7041.5</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">JSE INDUSTRIAL</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">8332.8</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">JSE ALL GOLD</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">1390.4</font></td>
        </tr>
    </table>
    <p align="left"><font size="3" face="Arial"><img
    src="../images/orange.gif" align="top" width="14" height="14"></font><a
    href="http://www.jse.co.za"><font size="3" face="Arial"><b>Johannesburg
    Stock Exchange</b></font></a><font size="3" face="Arial"><br>
    </font><a href="http://www.stockixchange.com/saindices.htm"><font
    color="#FF0000" size="2" face="Arial"><img
    src="images/Stx1.gif" border="0" width="55" height="35"></font></a><a
    href="http://www.stockixchange.com/saindices.htm"><font
    color="#FF0000" size="2" face="Arial"> </font><font
    color="#0000A0" size="3" face="Arial">Graphs of the JSE
    Indices</font></a><font color="#0000A0" size="3" face="Arial">
    from </font><a href="http://www.stockixchange.com/"><font
    color="#0000A0" size="3" face="Arial">Stock IXchange</font></a><font
    color="#0000A0" size="3" face="Arial"> </font></p>
    <p align="center"><a
    href="http://www.stockixchange.com/stxlite.htm"><font
    color="#0000A0" size="3" face="Arial"><img
    src="images/Stxfree.gif" align="middle" border="0"
    width="113" height="31"></font><font color="#0000A0" size="2"
    face="Arial"> </font><font size="1" face="Arial"><em>Download
    IXCHANGE plug-in to view charts</em></font></a></p>
    <p align="left"><a name="INTERNATIONAL"><font size="3"
    face="Arial"><b><i>INTERNATIONAL</i></b></font></a></p>
    <table border="0">
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">FT-SE 100</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">4327.1</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">DAX</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">3229.48</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">NIKKEI 50</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">18688.06</font></td>
        </tr>
        <tr>
            <td width="300" bgcolor="#DFDFDF"><font size="2"
            face="Arial">DOW JONES INDUSTRIAL</font></td>
            <td align="right" width="100" bgcolor="#F4F2FF"><font
            size="2" face="Arial">7022.44</font></td>
        </tr>
    </table>
</blockquote>

<blockquote>
    <p align="left"><a
    href="http://www.stockixchange.com/intindices.htm"><font
    color="#FF0000" size="2" face="Arial"><img
    src="images/Stx1.gif" border="0" width="55" height="35"></font></a><a
    href="http://www.stockixchange.com/intindices.htm"><font
    color="#FF0000" size="2" face="Arial"> </font><font
    color="#0000A0" size="3" face="Arial">Graphs of International
    Indices</font></a><font color="#0000A0" size="3" face="Arial">
    from </font><a href="http://www.stockixchange.com/"><font
    color="#0000A0" size="3" face="Arial">Stock IXchange</font></a><font
    color="#0000A0" size="3" face="Arial"> </font></p>
    <p align="center"><a
    href="http://www.stockixchange.com/stxlite.htm"><font
    color="#0000A0" size="3" face="Arial"><img
    src="images/Stxfree.gif" align="middle" border="0"
    width="113" height="31"></font><font color="#0000A0"
    face="Arial"> </font><font size="1" face="Arial"><em>Download
    IXCHANGE plug-in to view charts</em></font></a></p>
</blockquote>

<blockquote>
    <p align="left">&nbsp;</p>
</blockquote>

<p align="left"><a name="GENERAL"><font color="#008000" size="4"
face="Arial"><b><i>RELATED</i></b></font></a><font
color="#008000" size="4" face="Arial"><b><i> SOUTH AFRICAN
RESOURCES</i></b></font></p>

<blockquote>
    <p align="left"><font size="3" face="Arial"><img
    src="purple.gif" width="14" height="14">&nbsp;</font><a
    href="http://www.resbank.co.za"><font size="3" face="Arial">South
    African Reserve Bank</font></a><font size="3" face="Arial"><br>
    <img src="purple.gif" width="14" height="14"> </font><a
    href="http://africa.com/pages/jse/page1.htm"><font size="3"
    face="Arial">South African Investors Guide</font></a><font
    size="3" face="Arial"><br>
    <img src="purple.gif" width="14" height="14"> </font><a
    href="http://www.is.co.za/absa/economic/daily.html"><font
    size="3" face="Arial">Absa Bank</font></a><font size="3"
    face="Arial">: Daily Economic Report<br>
    <img src="purple.gif" width="14" height="14"> </font><a
    href="http://www.ixchange.com/premcor/news.htm"><font
    size="3" face="Arial">Premcor Asset Management</font></a><font
    size="3" face="Arial"><br>
    <img src="purple.gif" width="14" height="14"> </font><a
    href="http://rmb.co.za/"><font size="3" face="Arial">Rand
    Merchant Bank</font></a><font size="3" face="Arial">: </font><a
    href="http://rmb.co.za/market.html"><font size="3"
    face="Arial">Weekly Market Report</font></a><font size="3"
    face="Arial"> / </font><a href="http://rmb.co.za/report.html"><font
    size="3" face="Arial">Economic Report and Econmic Calender</font></a><font
    size="3" face="Arial"><br>
    <img src="purple.gif" width="14" height="14"> </font><a
    href="http://www.southernlife.com/sla/pubs/slpbhome.htm"><font
    size="3" face="Arial">Southern Life</font></a><font size="3"
    face="Arial">: Economic Comment<br>
    </font></p>
    <p align="center"><a href="/org1.htm"><font size="2"
    face="Arial"><img src="tb101.gif" alt="organisation"
    border="0" width="101" height="17"></font></a><font size="2"
    face="Arial"> </font><a href="/res1.htm"><font size="2"
    face="Arial"><img src="tb102.gif" alt="Resources" border="0"
    width="101" height="17"></font></a><font size="2"
    face="Arial"> </font><a href="/kruger/kruger.htm"><font
    size="2" face="Arial"><img src="tb104.gif" alt="Krugerrand"
    border="0" width="101" height="17"></font></a><font size="2"
    face="Arial"> </font><a href="/new.htm"><font size="2"
    face="Arial"><img src="tb105.gif" alt="What's New?"
    border="0" width="101" height="17"></font></a><font size="2"
    face="Arial"> </font><a href="/info.htm"><font size="2"
    face="Arial"><img src="tb106.gif" alt="Contacting us"
    border="0" width="101" height="17"> </font></a><font size="2"
    face="Arial"><br>
    </font></p>
    <hr>
</blockquote>
<div align="left">

<address>
    <font size="2" face="Arial"> 1996 Chamber of Mines of South
    Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2"
    face="Arial">twood@bullion.org.za</font></a><font size="2"
    face="Arial"> </font>
</address>
</div>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-444</DOCNO>
<DOCOLDNO>IA012-000121-B040-160</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/1997/comnum97.htm 196.26.82.193 19970217003830 text/html 8802
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:41:49 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Press Release</title>
<base href="http://www.bullion.org.za/">
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font size="5"><strong><img
src="http://www.bullion.org.za/images/logo2.gif" width="102"
height="64"></strong></font></p>

<p align="center"><font color="#008000" size="5"><em><strong>Press
Release</strong></em></font></p>

<p align="center"><font color="#FF0000" size="3"
face="Courier New"><b><u>EMBARGO: NONE</u></b></font></p>

<p align="center"><font size="4" face="Arial"><strong><u>JOINT
MEDIA STATEMENT BY THE<br>
NATIONAL UNION OF MINEWORKERS<br>
AND THE CHAMBER OF MINES<br>
ON THEIR AGREEMENT RELATING TO THE<br>
NEW MINE HEALTH &amp; SAFETY ACT</u></strong></font></p>

<p align="center"><font color="#800040" size="2"><strong>DATE:
Thursday, 9 January 1997</strong></font></p>

<p align="left"><font color="#0000A0">The Chamber of Mines and
the National Union of Mineworkers (NUM) today signed an agreement
regarding a proposed amendment of the new Mine Health and Safety
Act to establish a system of administrative penalties (fines) for
breaches of statutory health and safety standards.<br>
</font></p>

<p><font color="#0000A0">Chamber President Nick Segal said the
agreement was an affirmation of both parties&#146; commitment to
creating a safer working environment for South Africa&#146;s more
than 500,000 mining industry employees.<br>
</font></p>

<p><font color="#0000A0">&quot;It also demonstrates,&quot; Segal
added, &quot;the willingness and capacity possessed by both the Chamber
and the NUM to find a common approach to complicated issues
fundamental to the future of mining. The negotiations that have
led to this agreement have been conducted in a constructive and forward-looking
spirit that bodes well for effective implementation of the Act,
and for the future of the industry more generally.&quot;<br>
</font></p>

<p><font color="#0000A0">The President of the NUM, James Motlatsi
said: &quot;Both parties have found an effective solution to
ensuring enforcement of the Mine Health and Safety Act. The Union
was concerned that the controversy surrounding sections 86(2) and
(3) of the Act would obscure the importance of the new
legislation in improving health and safety on the mines.<br>
</font></p>

<p><font color="#0000A0">&quot;There is general recognition in
both the South African mining industry and internationally that criminal
prosecution in the context of occupational health and safety is
not the most effective means of obtaining compliance with law. A
system of administrative penalties is a superior system of enforcement.
The Union is confident that a system of administrative penalties
will evoke the behaviour necessary to improve health and safety for
all mineworkers.<br>
</font></p>

<p><font color="#0000A0">&quot;During 1996, more than 500
mineworkers lost their lives. This agreement is the start of
labour and employers critically working together to address this
problem.&quot;<br>
</font></p>

<p><font color="#0000A0">Passed by Parliament in June 1996, the
Mine Health and Safety Act is to be implemented by government
later this month (January 1997). Since the Act was passed, the
NUM and the Chamber have engaged in protracted discussions
regarding the most appropriate and effective form of enforcement
of the Act. These discussions addressed both -<br>
</font></p>

<p><font color="#0000A0"><The NUMs concerns regarding the ineffectiveness of the criminal prosecution system in dealing with failures by mine owners and managers to provide and maintain healthy and safe working conditions at mines; and<BR></font></p>

<p><font color="#0000A0">The Chamber&#146;s view that, in effect,
by sections 86(2) and (3) of the Act a mine manager or owner must
be convicted of criminal negligence in any case where serious
injury occurs or where health or safety are endangered at a mine.
To avoid conviction, the manager or owner would have to prove that
he had taken reasonably practicable measures to provide and maintain
a working environment that was safe and without risk to the health
of employees.<br>
</font></p>

<p><font color="#0000A0">During negotiations it was agreed that
the Act could most effectively be enforced through a system of
administrative penalties, involving fines for violations of
statutory health and safety standards. The authority to impose fines
would be vested in the Mine Health and Safety Inspectorate.<br>
</font></p>

<p><font color="#0000A0">In terms of today&#146;s agreement both
the Chamber and the NUM propose that appropriate administrative
penalties should be introduced into the Act in the course of 1997
to replace the current system of criminal sanctions for breaches
of health and safety standards, including sections 86(2) and (3)
of the Act. <br>
</font></p>

<p><font color="#0000A0">What the parties have not yet been able
to achieve, however, is agreement on whether administrative
penalties should be imposed only on mining companies or should
also be extended to individual employees, including managers and
other categories of employee.<br>
</font></p>

<p><font color="#0000A0">It is the view of NUM that
administrative penalties should apply to mining companies, and
not individual employees, as the Union believes that-<br>
</font></p>

<p><font color="#0000A0">Mining companies (and their managers)
design the systems, allocate the requisite resources, manage and
have ultimate responsibility for health and safety; and <br>
</font></p>

<p><font color="#0000A0">The overwhelming majority of unsafe and
unhealthy conditions at mines arise from circumstances over which
only the company and its senior management have control; and that<br>
</font></p>

<p><font color="#0000A0">Criminal sanctions should continue to
apply to individual employees.<br>
</font></p>

<p><font color="#0000A0">While recognising NUM&#146;s argument,
the Chamber believes that precisely in the spirit of the Act, a
culture has to be created on every mine in which there is a fully
shared sense of responsibility and accountability and that, if an
individual employee violates the requirements of the Act, he
should also be liable to an administrative penalty, and, in the
event of his action being negligent, to criminal prosecution.<br>
</font></p>

<p><font color="#0000A0">The parties have agreed on a process for
resolving this difference. The process involves obtaining expert
opinion on experiences relating to both options in other
countries. Once opinion has been obtained, there is to be appropriate
tripartite discussion followed by Government finalisation of the matter
if disagreement persists.<br>
</font></p>

<p><font color="#0000A0">The Chamber and the NUM have now agreed
to approach Government with a view to having the Act implemented
as soon as possible, and to delay the implementation of Sections
86(2) and (3) until January 1998. During this time the Chamber
and NUM will endeavour to have the agreed amendments regarding
the envisaged system of administrative penalties introduced to the Act.<br>
</font></p>

<p>&nbsp;</p>

<p align="center"><font color="#008000" size="2">&nbsp;</font><font
color="#008000" size="5"><b>ends ...</b></font></p>

<p align="center">&nbsp;</p>

<p align="center"><font color="#E30000"><strong>Please direct
enquiries to Llewellyn Kriel, <br>
Communication Manager: Media, Chamber of Mines of SA </strong></font><a
href="mailto:lkriel@bullion.org.za"><font color="#E30000"><strong>lkriel@bullion.org.za</strong></font></a></p>

<p align="center"><a href="/org1.htm"><img
src="http://www.bullion.org.za./tb101.gif" alt="organisation"
border="0" width="101" height="17"></a> <a href="/res1.htm"><img
src="http://www.bullion.org.za./tb102.gif" alt="Resources"
border="0" width="101" height="17"></a> <a href="/kruger.htm"><img
src="http://www.bullion.org.za./tb104.gif" alt="Krugerrand"
border="0" width="101" height="17"></a> <a href="/new.htm"><img
src="http://www.bullion.org.za./tb105.gif" alt="What's New?"
border="0" width="101" height="17"></a> <a href="/info.htm"><img
src="http://www.bullion.org.za./tb106.gif" alt="Contacting us"
border="0" width="101" height="17"></a> </p>

<p align="left"><font size="2"><em> 1997, Chamber of Mines of
South Africa</em></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-445</DOCNO>
<DOCOLDNO>IA012-000121-B041-2</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/members.htm 196.26.82.193 19970217003919 text/html 35058
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:42:29 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>The Chamber of Mines of South Africa Members</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080">
<p align=center><font color="#0000A0"><font size=5><b>Chamber of Mines of South Africa</b></font></font></p>
<p align=center><b><img src="/images/LOGO1.gif" align=bottom width=300 height=160></b></p>
<h2 align=center><b><i>Members</i></b></h2>
<p align=center>&nbsp;</p>
<div align=center><center>
<table border=1 cellpadding=2 cellspacing=3 width=100%>
<tr><td align=center width=20%><a href="#Financial"><strong>Financial 
Corporations</strong></a><strong></strong></td><td align=center width=20%><a href="#Gold"><strong>Gold Mining</strong></a></td><td align=center width=20%><a href="#Coal"><strong>Coal Mining</strong></a></td><td align=center width=20%><a href="#Diamond"><strong>Diamond Mining</strong></a></td><td align=center width=20%><a href="#Platinum"><strong>Platinum Mining</strong></a></td></tr>
<tr><td align=center width=20%><a href="#Antimony"><strong>Antimony Mining</strong></a></td><td align=center width=20%><a href="#Asbestos"><strong>Asbestos Mining</strong></a></td><td align=center width=20%><a href="#Lead"><strong>Lead Mining</strong></a></td><td align=center width=20%><a href="#Copper"><strong>Copper Mining</strong></a></td><td align=center width=20%><a href="#Other"><strong>Other Members</strong></a></td></tr>
</table>
</center></div>
<p align=center><br>
</p>
<hr>
<h3 align=center><a name="Financial">Financial Corporation Members </a></h3>
<ul>
<li><a href="#African">African Exploration Company Limited</a></li>
<li><a href="#Anglo">Anglo American Corporation of South Africa Limited</a></li>
<li><a href="#AV">Anglovaal Limited</a></li>
<li><a href="#DeBeers">De Beers Consolidated Mines Limited</a></li>
<li><a href="#Gencor">Gencor Limited</a> </li>
<li><a href="#GFSA">Gold Fields of South Africa Limited</a> </li>
<li><a href="#Hanova">Hanova Mining Holdings Limited</a> </li>
<li><a href="#JCI">JCI Limited</a> </li>
<li><a href="#Kangra">Kangra Group Limited</a> </li>
<li><a href="#Lonrho">Lonrho South Africa Limited</a> </li>
<li><a href="#Messina">Messina Investments Limited</a> </li>
<li><a href="#Msauli">Msauli Asbestos Limited</a> </li>
<li><a href="#Randgold">Randgold Limited</a> </li>
</ul>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Other">Other</a> Members </h3>
<ul>
<li><a href="#Anglo">Anglo American Platinum Corporation Limited</a></li>
<li><a href="#Cementation">Cementation (Africa Contracts) (Pty) Limited</a></li>
<li><a href="#Eskom">Eskom </a></li>
<li><a href="#Gengold">Gengold Limited</a></li>
<li><a href="#GFSATraining">Gold Fields Training Services (Pty) Limited </a></li>
<li><a href="#Griqualand">Griqualand Exploration and Finance Company Limited </a></li>
<li><a href="#Hanova">Hanover Mining Holding (Pty) Limited </a></li>
<li><a href="#Ingwe">Ingwe Coal Corporation Limited </a></li>
<li><a href="#Iscor">Iscor Limited </a></li>
<li><a href="#Kangra">Kangra Group (Pty) Limited </a></li>
<li><a href="#Lonrho">Lonrho South Africa Limited </a></li>
<li><a href="#Messina">Messina Limited </a></li>
<li><a href="#RMP">Rand Mines Properties </a></li>
<li><a href="#ShaftSinkers">Shaft Sinkers (Pty) Limited </a></li>
<li><a href="#Transvaal">Transvaal Gold Mining Estates Limited </a></li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Gold">Gold</a> Mining Members</h3>
<ul>
<li>Barberton Mines Limited </li>
<li>Blyvooruitzicht Gold Mining Company Limited </li>
<li>Buffelsfontein Gold Mining Company Limited </li>
<li>City Deep Limited (operations suspended) </li>
<li>Consolidated Main Reefs Mines and Estate Limited (operations suspended) </li>
<li>Crown Mines Limited (operations suspended) </li>
<li>Deelkraal Gold Mining Company Limited </li>
<li>Doornfonein Gold Mining Company Limited </li>
<li>Driefontein Consolidated Limited </li>
<li>Durban Roodepoort Deep Limited </li>
<li>East Rand Proprietary Mines Limited </li>
<li>Elandsrand Gold Mining Company Limited </li>
<li>Free State Consolidated Gold Mines [Freegold] (Operations) Limited </li>
<li>Grootvlei Proprietary Mines Limited </li>
<li>HJ Joel Gold Mining Company Limited </li>
<li>Harmony Gold Mining Company Limited </li>
<li><a href="http://www.anglovaal.co.za/hgm.html">Hartebeestfontein Gold Mining Company Limited</a> </li>
<li>Kinross Mines Limited </li>
<li>Leslie Gold Mines Limited </li>
<li>Loraine Gold Mines Limited </li>
<li>Luipaards Vlei Estates Limited (operations suspended) </li>
<li>Oryx Gold Mine </li>
<li>Randfontein Estates Gold Mining Company, Witwatersrand Limited </li>
<li>St Helena Gold Mines Limited </li>
<li>South African Land and Exploration Company Limited (operations suspended) </li>
<li>Stilfontein Gold Mining Company Limited (operations suspended) </li>
<li>Unisel Gold Mines Limited </li>
<li>Vaal Reefs Exploration and Mining Company Limited </li>
<li>Weltevreden Mines Limited (operations suspended) </li>
<li>Western Areas Gold Mining Company Limited </li>
<li>Winkelhaak Mines Limited </li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Coal">Coal</a> Mining Members</h3>
<ul>
<li>AMCOAL Collieries and Industrial Operations Limited <ul>
<li>Arnot Colliery </li>
<li>Bank Colliery </li>
<li>Goedehoop Colliery </li>
<li>Kriel Colliery </li>
<li>New Denmark Colliery </li>
<li>New Vaal Colliery </li>
</ul>
</li>
<li>SA Coal Estates Division </li>
<li>Vryheid Coronation Colliery </li>
<li>Annandale Colliery (Pty) Limited </li>
<li>Douglas Colliery Limited </li>
<li>Duiker Exploration Limited <ul>
<li>Alpha Anthracite Colliery </li>
<li>Piet Retief Colliery </li>
<li>Tweefontein Colliery </li>
<li>Witbank Consolidated Colliery </li>
</ul>
</li>
<li>Durban Navigation Collieries (Pty) Limited </li>
<li>Gold Fields Coal Limited <ul>
<li>Coalbrook Colliery </li>
<li>Greenside Colliery </li>
<li>New Clydesdale Colliery </li>
</ul>
</li>
<li>Ingagane Colliery (Pty) Limited (operations suspended) </li>
<li>Ingwe Coal Corporation (Pty) Limited <ul>
<li>Delmas Colliery </li>
<li>Koornfontein Mines </li>
<li>Optimum Colliery </li>
</ul>
</li>
<li>Khutala Mining Services (Pty) Limited </li>
<li>Longridge Colliery </li>
<li>Matla Coal Limited </li>
<li>Spitzkop Colliery </li>
<li>Strathrae Colliery </li>
<li>JCI Coal Limited <ul>
<li>Tavistock Collieries Limited <ul>
<li>Tavistock Colliery </li>
<li>Arthur Taylor Colliery </li>
<li>Phoenix Colliery </li>
<li>South Witbank Colliery </li>
</ul>
</li>
</ul>
</li>
<li>The Natal Navigation Collieries and Estate Company (Pty) Limited </li>
<li>Tweewaters Fuel (Pty) Limited <ul>
<li>Springlake Colliery </li>
</ul>
</li>
<li>Vryheid (Natal) Railway Coal and Iron Company Limited <ul>
<li>Hlobane Colliery </li>
</ul>
</li>
<li>Welgedacht Exploration Company Limited <ul>
<li>Utrecht Colliery </li>
</ul>
<p><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Diamond">Diamond</a> Mining Members </h3>
</li>
<li><a href="#DeBeers">De Beers Consolidated Mines Limited</a> <ul>
<li>Kimberley Mines </li>
<li>Finsch Mine </li>
<li>Koffiefontein Mine </li>
<li>Namaqualand Mines </li>
<li>Premier Mine </li>
<li>Venetia Mine</li>
</ul>
</li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Platinum">Platinum</a> Mining Members</h3>
<ul>
<li>Barplats Mines Limited <ul>
<li>Crocodile River Mine </li>
</ul>
</li>
<li>Eastern Platinum Limited </li>
<li><A HREF="HTTP://www.implats.co.za">Impala Platinum Limited</A> <ul>
<li>Bafokeng North Mine </li>
<li>Impala Services </li>
<li>Mineral Processes </li>
<li>Refineries </li>
<li>Wildebeestfontein North Mine </li>
<li>Wildebeestfontein South Mine </li>
</ul>
</li>
<li>Northam Platinum Limited <ul>
<li>Zondereinde Division </li>
</ul>
</li>
<li>Rustenburg Platinum Mines Limited <ul>
<li>Amandelbult Section </li>
<li>Rustenburg Section </li>
<li>Union Section </li>
</ul>
</li>
<li>Western Platinum Limited <ul>
<li>Karee Mine</li>
</ul>
</li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Antimony">Antimony</a> Mining Members</h3>
<ul>
<li>Consolidated Murchison Limited </li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Asbestos">Asbestos</a> Mining Members</h3>
<ul>
<li>African Chrysotile Asbestos Limited </li>
<li>Griqualand Exploration and Finance Company Limited </li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Lead">Lead</a> Mining Members</h3>
<ul>
<li>Black Mountain Mineral Development Company (Pty) Limited </li>
</ul>
<p align=center><a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p><br>
<br>
<br>
</p>
<hr>
<h3 align=center><a name="Copper">Copper</a> Mining Members</h3>
<ul>
<li>O'Kiep Copper Company Limited </li>
<li>Prieska Copper Mines (Pty) Limited (operations suspended) </li>
</ul>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<hr>
<p align=center><br>
<br>
<br>
<img src="/images/line3.gif" align=middle width=590 height=2> </p>
<h1 align=center>MEMBERS: <a name="CONTACT">CONTACT</a> REFERENCES</h1>
<p><br>
</p>
<h2><a name="African">African</a> Exploration Company Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 61661, Marshalltown, 2107, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 403 2930.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 339 3694.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
</p>
<p><a name="DeBeers"><font size=5><b><a href="http://www.debeers.co.za">De Beers Consolidated Mines Limited</a></b></font> </a></p>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 616, Kimberley, 8300, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 0531 22 171.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 0531 24 611.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Anglo"> <a href="http://www.edata.co.za/Anglo/anglostart.html">Anglo American Corporation of South Africa Limited</a></a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box  61587, Marshalltown, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 638 9111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 638 3221.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
<a name="AV"></a></p>
<p><a name="AV"></a><a href="http://www.avmin.co.za"><H2>Anglovaal Limited</H2></a> </p>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail : <a href="mailto:juliang@avmin.co.za">juliang@avmin.co.za</a>
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 62379, Marshalltown, 2107, South Africa;
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 634 9111
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 634 0038.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Amplats"><A HREF="HTTP://www.amplats.co.za">Anglo American Platinum Corporation Limited</A></a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 62179, Marshalltown, 2107, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 373 6111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 838 5537.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Cementation">Cementation</a> (Africa Contracts) (Pty) Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 1128, Johannesburg, 200, South Africa;
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 493 3400.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 493 8283.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
</p>
<h2><a name="Gencor">Gencor</a> Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 61820, Marshalltown, 2107, South Africa;
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 376 9111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 838 4716.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="Eskom"><a href="http://www.eskom.co.za">Eskom</a></a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 1091, Johannesburg, 200, South Africa;
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 800 4122.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 800 5555.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Gengold">Gengold</a> Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 61820, Marshalltown, 2107, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 376 9111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 834 2889.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="GFSATraining">Gold Fields Training Services (Pty) Limited</a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 3146, Valblum, 1783, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 725 1145.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 639 2101.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="GFSA">Gold Fields of South Africa Limited</a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 61525, Marshalltown, 2107, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 639 9111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 639 2101.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Griqualand">Griqualand</a> Exploration and Finance Company Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 10505, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 339 5458.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 339 3722.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
</p>
<h2><a name="Hanova">Hanova</a> Mining Holdings Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 10505, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 339 5458.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 339 3722.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="Iscor">Iscor</a> Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 450, Pretoria, 0001, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 12 298 1111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 12 62 1800.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Ingwe">Ingwe</a> Coal Corporation Limited</h2>
<pre>
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 61820, Marshalltown, 2107, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 376 9111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 834 2889.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
<a name="JCI"></a></p>
<p><a name="JCI"><H2>JCI Limited</H2><a href="http://www.jci.co.za"></a></a></p>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail : <A HREF="MAILTO:webmaster@jci.co.za">webmaster@jci.co.za</A>
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 590, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 373 9111
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 834 4961.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Kangra">Kangra</a> Group (Pty) Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 2465, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 643 7371.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 484 3024.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="Lonrho">Lonrho</a> South Africa Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 1146, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 642 7691.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 642 9717.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="Messina">Messina</a> Investments Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 132, Maraisburg, 1700, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 674 1270.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 672 8724.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="MessinaLimited">Messina</a> Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 61386, Marshalltown, 2107, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 376 2800.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 836 0729.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="Msauli">Msauli</a> Asbestos Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 10505, Johannesburg, 2000, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 376 9111.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 376 3216.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="Randgold">Randgold</a> Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 82291, Southdale, 2135, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 496 1722
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 835 3513.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p><br>
<br>
</p>
<h2><a name="RMP">Rand Mines Properties</a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 839-2411.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 837-8714.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="ShaftSinkers">Shaft Sinkers (Pty) Limited</a></h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 783501, Sandton, 2146, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 11 444 5600.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 11 444 4410.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
<br>
</p>
<h2><a name="Transvaal">Transvaal</a> Gold Mining Estates Limited</h2>
<pre>
<img src="/images/emm.gif" align=middle width=50 height=50> Public Affairs e-mail :
<img src="/images/pobox.gif" align=middle width=50 height=50> Postal Address: P O Box 21, Pilgrims Rest, 1290, South Africa.
<img src="/images/phone.gif" align=middle width=50 height=50> Telephone +27 135 81 271.
<img src="/images/faxphone.gif" align=middle width=50 height=50> Facsimile +27 135 81 271 ask for fax.
</pre>
<p align=center><br>
<a><img src="/images/nb1.gif" alt="Main Menu" align=middle hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> </p>
<p align=center><br>
<A NAME="toolbar"><img src="/images/line3.gif" align=middle width=590 height=2></p>
</A><p align=center><a href="/org1.htm"><img src="/tb101.gif" alt="organisation" align=bottom border=0 width=101 height=17></a> <a href="/res1.htm"><img src="/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></a><a href="/kruger.htm"><img src="/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></a> <a href="/new.htm"><img src="/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></a> <a href="/info.htm"><img src="/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></a> <br>
</p>
<hr>
<address><font size=2><br>
&#169; 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </font><a href="mailto:twood@bullion.org.za"><font size=2>twood@bullion.org.za</font></a><font size=2> </font></address>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-446</DOCNO>
<DOCOLDNO>IA012-000121-B041-82</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/manage.htm 196.26.82.193 19970217004054 text/html 10559
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:43:32 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>The Chamber of Mines of South Africa Management</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0" vlink="#0000A0">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="../images/LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><a name="top"><b><i>Decision</i></b></a><b><i>
Making and Management Structures</i></b> </h2>
<div align="center"><center>

<table border="1" cellpadding="3">
    <tr>
        <td align="center"><a href="#Council"><font size="3"><strong>Council</strong></font></a></td>
        <td align="center"><a href="#EXCOM"><font size="3"><strong>Executive
        Committee</strong></font></a></td>
        <td align="center"><a href="#gpcom"><font size="3"><strong>Gold
        Producers' Committee</strong></font></a></td>
        <td align="center"><a href="#colcom"><font size="3"><strong>Collieries
        Committee</strong></font></a></td>
    </tr>
    <tr>
        <td align="center" colspan="4"><a href="#manpol"><font
        size="3"><strong>Senior Management</strong></font></a></td>
    </tr>
</table>
</center></div>

<p align="center">&nbsp;</p>

<h2><a name="Council"><font size="4">Council</font></a><font
size="4"> of the Chamber of Mines of South Africa</font></h2>

<ul>
    <li>Mr BC Alberts, <a href="members.htm#Iscor">Iscor Limited</a></li>
    <li>Dr JW Campbell, <a
        href="http://www.bullion.org.za/organisation/members.htm#Anglo">Anglo
        American Coal Corporation Limited</a></li>
    <li>Mr TG Dale, <a href="members.htm#Gencor">Gengold Limited</a></li>
    <li>Mr BE Davison, <a
        href="http://www.bullion.org.za/organisation/members.htm#Anglo">Anglo
        American Platinum Corporation Limited</a></li>
    <li>Mr AJ Du Plessis, <a href="members.htm#Gencor">Gencor
        Limited</a> </li>
    <li>Mr JJ Geldenhuys, <a href="members.htm#AV">Anglovaal
        Limited</a> </li>
    <li>Mr BP Gilbertson, <a href="members.htm#Gencor">Gencor
        Limited</a> </li>
    <li>Mr RM Godsell, <a href="members.htm#Anglo">Anglo American
        Corporation of South Africa Limited</a> </li>
    <li>Mr JvdM Grimes, <a href="members.htm#Iscor">Iscor Limited</a> </li>
    <li>Mr EP Gush, <a
        href="http://www.bullion.org.za/organisation/members.htm#DeBeers">De
        Beers Consolidated Mines Limited</a></li>
    <li>Mr BE Hersov, <a href="members.htm#AV">Anglovaal Limited</a> </li>
    <li>Mr PR Janisch, <a href="members.htm#GFSA">Gold Fields of
        South Africa Limited</a></li>
    <li>Mr RP Menell, <a href="members.htm#AV">Anglovaal Limited</a></li>
    <li>Mr AH Munro, <a href="members.htm#GFSA">Gold Fields of
        South Africa Limited</a></li>
    <li>Mr DJK Murray, <a
        href="http://www.bullion.org.za/organisation/members.htm#Ingwe">Ingwe
        Coal Corporation Limited</a></li>
    <li>Mr WA Nairn, <a href="members.htm#JCI">JCI Limited</a></li>
    <li>Mr J Ogilvie Thompson, <a href="members.htm#Anglo">Anglo
        American Corporation of South Africa Limited</a> </li>
    <li>Dr NS Segal, <a href="members.htm#JCI">JCI Limited,</a> </li>
    <li>Mr AJ Wright, <a href="members.htm#GFSA">Gold Fields of
        South Africa Limited</a> </li>
</ul>

<p align="center"><br>
<a><img src="../images/nb1.gif" alt="Main Menu" align="middle"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p><a name="EXCOM"></a></p>

<h3>Executive Committee</h3>

<ul>
    <li><a href="/images/persimages/segal.gif">Dr NS Segal</a>, <a
        href="members.htm#JCI">JCI Limited</a>, (President)</li>
    <li><a href="/images/persimages/gods.gif">Mr RM Godsell</a>, <a
        href="members.htm#Anglo">Anglo American Corporation of
        South Africa Limited</a>, (Vice President) </li>
    <li><a href="/images/persimages/mun.gif">Mr AH Munro</a>, <a
        href="members.htm#GFSA">Gold Fields of South Africa
        Limited</a>, (Vice President)</li>
    <li><a href="/images/persimages/atdu.gif">Mr AJ Du Plessis</a>, <a
        href="members.htm#Gencor">Gencor Limited</a>, </li>
    <li><a href="/images/persimages/geld.gif">Mr JJ Geldenhuys</a>, <a
        href="members.htm#AV">Anglovaal Limited</a> </li>
    <li><a href="/images/persimages/grime.gif">Mr JvdM Grimes</a>, <a
        href="members.htm#Iscor">Iscor Limited</a> </li>
    <li><a href="/images/persimages/robin.gif">Mr PDK Robinson</a>, <a
        href="members.htm#Gencor">Gencor Limited</a></li>
</ul>

<p align="center"><a><img src="../images/nb1.gif" alt="Main Menu"
align="middle" hspace="20" width="60" height="17"></a> <a
href="#top"><img src="../images/nb2.gif" alt="Top of Page"
align="middle" border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p><a name="gpcom"></a></p>

<h3>Gold Producers' Committee</h3>

<ul>
    <li><a href="/images/persimages/robin.gif">Mr PDK Robinson</a>, <a
        href="members.htm#Gencor">Gencor Limited</a>, (Chairman) </li>
    <li><a href="/images/persimages/ash.gif">Mr D Ashworth</a>, <a
        href="members.htm#Randgold">Randgold Limited </a></li>
    <li><a href="/images/persimages/brow.gif">Mr JF Brownrigg</a>, <a
        href="members.htm#JCI">JCI Limited</a> </li>
    <li><a href="/images/persimages/spind.gif">Mr TV Spindler</a>, <a
        href="members.htm#AV">Anglovaal Limited</a> </li>
    <li>Mr KC Spencer, <a href="members.htm#GFSA">Gold Fields of
        South Africa Limited</a> </li>
    <li><a href="/images/persimages/wil.gif">Mr KH Williams, </a><a
        href="members.htm#Anglo">Anglo American Corporation of
        South Africa Limited</a> </li>
</ul>

<p align="center"><a><img src="../images/nb1.gif" alt="Main Menu"
align="middle" hspace="20" width="60" height="17"></a> <a
href="#top"><img src="../images/nb2.gif" alt="Top of Page"
align="middle" border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p><a name="colcom"></a></p>

<h3>Collieries Committee </h3>

<ul>
    <li><a href="/images/persimages/grime.gif">Mr JvdM Grimes</a>, <a
        href="members.htm#Iscor">Iscor Limited</a>, (Chairman)</li>
    <li>Mr D Groenewald, <a href="members.htm#Gencor">Gencor
        Limited</a> </li>
    <li><a href="/images/persimages/bar.gif">Mr GD Bartholomew</a>, <a
        href="members.htm#Lonrho">Lonrho South Africa Limited</a> </li>
    <li><a href="/images/persimages/beck.gif">Mr GJ Beck</a>, <a
        href="members.htm#Kangra">Kangra Group (Pty) Limited</a> </li>
    <li>Mrs BA Day, <a href="members.htm#GFSA">Gold Fields of
        South Africa Limited</a> </li>
    <li><a href="/images/persimages/roger.gif">Mr MR Rogers</a>, <a
        href="members.htm#JCI">JCI Limited</a> </li>
    <li>Mr A Martin, <a href="members.htm#Anglo">Anglo American
        Corporation of South Africa Limited</a> </li>
</ul>

<p align="center"><a><img src="../images/nb1.gif" alt="Main Menu"
align="middle" hspace="20" width="60" height="17"></a> <a
href="#top"><img src="../images/nb2.gif" alt="Top of Page"
align="middle" border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p><a name="manpol"></a></p>

<h3>Senior Management</h3>

<p>Senior management is based at the Chamber of Mines Building in
Hollard Street, Marshalltown, Johannesburg. An office also operates
in Cape Town from the Rhodes Building, 150 St Georges Mall, Cape
Town. Click <a href="work2.htm">HERE</a> for more information on the
core Management Structure. </p>

<ul>
    <li><a href="/organisation/cvs/main.htm">Mr TRN Main, Chief
        Executive</a> </li>
    <li><a href="/organisation/cvs/liebenb.htm">Mr J Liebenberg,
        Public Policy Consultant</a> </li>
    <li><a href="/organisation/cvs/pollnow.htm">Dr DLB Pollnow,
        Gold Marketing Consultant</a> </li>
    <li><a href="/images/persimages/mou.gif">Mr KC Mourant, Human
        Resources Consultant</a> </li>
    <li><a href="/organisation/cvs/stewart.htm">Dr JM Stewart,
        Mining Consultant</a> </li>
    <li><a href="/images/persimages/botha.gif">Mr JPJ Botha,
        General Manager: Corporate and Industry Services</a> </li>
</ul>

<p align="center"><br>
<a><img src="../images/nb1.gif" alt="Main Menu" align="middle"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
<img src="/images/line3.gif" align="middle" width="590"
height="2"> </p>

<p align="center"><a href="/org1.htm" name="toolbar"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../images/tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
</p>

<hr>

<address>
    <font size="2"> 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-447</DOCNO>
<DOCOLDNO>IA012-000121-B041-165</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/work2.htm 196.26.82.193 19970217004212 text/html 26685
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:44:54 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines Core Functions and Services</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font color="#0000A0" size="4"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="/images/LOGO1.gif"></b></p>

<h2 align="center"><b><i>Core Functions and Services</i></b></h2>

<table border="0">
    <tr>
        <td align="center" bgcolor="#0000A0"><font
        color="#FFFFFF" size="3" face="Arial"><strong></strong></font></td>
        <td align="center" valign="top" bgcolor="#0000A0"><font
        color="#FFFFFF" size="3" face="Arial"><strong>TEL</strong></font></td>
        <td align="center" valign="top" bgcolor="#0000A0"><font
        color="#FFFFFF" size="3" face="Arial"><strong>E-MAIL</strong></font></td>
    </tr>
    <tr>
        <td><a href="/cvs/main.htm" name="TomMain"><b>Chief
        Executive: Mr Tom Main</b></a></td>
        <td align="center" valign="top">&nbsp;498-7302&nbsp;</td>
        <td valign="top"><a href="mailto:tmain@bullion.org.za">tmain@bullion.org.za</a></td>
    </tr>
    <tr>
        <td><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personal
        Assistant</em>: Ms Amber Morrison<i>&nbsp;&nbsp;</i><p><i></i>&nbsp;</p>
        </td>
        <td align="center" valign="top">&nbsp;498-7305&nbsp;</td>
        <td valign="top"><a href="mailto:amorriso@bullion.org.za">amorriso@bullion.org.za</a></td>
    </tr>
    <tr>
        <td bgcolor="#E4E3FF">&nbsp;</td>
        <td align="center" valign="top" bgcolor="#E4E3FF">&nbsp;</td>
        <td valign="top" bgcolor="#E4E3FF">&nbsp;</td>
    </tr>
    <tr>
        <td><a href="/images/persimages/mou.gif"
        name="Ken Mourant"><b>Human Resources Consultant: Mr Ken
        Mourant<br>
        </b></a><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><em>Secretary</em><strong>: </strong>Ms
        Shirley Barry<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;&nbsp;498-7311&nbsp;<br>
        498-7300</td>
        <td valign="top"><a href="mailto:kmourant@bullion.org.za">kmourant@bullion.org.za<br>
        </a><a href="mailto:sbarry@bullion.org.za">sbarry@bullion.org.za</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="Finance"><b>Finance</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Manager</i>:
        Mr John Winson <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary</i>:
        Ms Peta Harris<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7476<br>
        498-7468</td>
        <td valign="top">&nbsp;<br>
        </td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information </b><a
        name="Technology"><b>Technology</b></a>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr
        Sinisa Tucakovic<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7219</td>
        <td valign="top">&nbsp;<br>
        </td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/departments/infv.htm" name="Information"><b>Information</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Manager</i>:
        Ms Jeannette Hofsajer-van Wyk <p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7214</td>
        <td valign="top">&nbsp;<br>
        <a href="mailto:jhofsaje@bullion.org.za">jhofsaje@bullion.org.za</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="Personnel"><b>Personnel</b></a><p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;</td>
        <td valign="top">&nbsp;</td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="ActuarialServices"><b>Actuarial Services</b></a> <br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actuary</i>:
        Mr Reno Blake<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;</td>
        <td valign="top">&nbsp;</td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="CompanySecretariat"><b>Company Secretariat</b></a> <br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
        Secretary</i>: Mr Simon Orchardson<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>&nbsp;Acting
        Principal Committees Administrator</em>: Mr Timothy Wood<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Assistant</em>:
        Ms Cheryl Jones<p>&nbsp; </p>
        </td>
        <td align="center" valign="top"><br>
        <br>
        498-7309<br>
        498-7306&nbsp;</td>
        <td valign="top">&nbsp;<br>
        <br>
        <a href="mailto:twood@bullion.org.za"><u>twood@bullion.org.za</u></a><br>
        <a href="mailto:cjones@bullion.org.za"><u>cjones@bullion.org.za</u></a></td>
    </tr>
    <tr>
        <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a
        name="IndustrialRelations"><b>Industrial Relations</b></a> <br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/images/persimages/adri.gif"><i>Industrial
        Relations Adviser</i>: Mr Adrian du Plessis</a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Pauline Mitchell<br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/cvs/barker.htm"><i>Deputy Industrial Relations
        Adviser</i>: Dr Frans Barker</a><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Anne Waldek<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>&nbsp;Manager:
        Industrial Relations Services</em>: Mr Vic Esselaar<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>&nbsp;Manager:
        Industrial Relations Services</em>: Mr Richard Ryan<em><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manager:
        Industrial Relations Services</em>: Mr Nick Smythe<em><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manager:
        Industrial Relations Administration</em>: Ms Susan
        Whybrow<em><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assistant
        Manager: Industrial Relations Services</em>: Mr Sig
        Hannig<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>
        Industrial Relations Practitioner</em>: Mr Mike Spowart<p>&nbsp; </p>
        </td>
        <td align="center" valign="top"><br>
        498-7630<br>
        498-7371<br>
        498-7290<br>
        498-7291<br>
        498-7555<br>
        498-7409<br>
        498-7420<br>
        498-7657<br>
        498-7462<br>
        498-7413</td>
        <td valign="top"><br>
        <br>
        <br>
        <a href="mailto:fbarker@bullion.org.za"><u>fbarker@bullion.org.za</u></a><br>
        <br>
        <a href="mailto:vesselaa@bullion.org.za"><u>vesselaa@bullion.org.za</u></a><br>
        <br>
        <br>
        <br>
        <a href="mailto:shannig@bullion.org.za">shannig@bullion.org.za</a><br>
        <a href="mailto:mspowart@bullion.org.za">mspowart@bullion.org.za</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/departments/edtr.htm" name="Education"><b>Education
        and Training</b> <br>
        </a><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/images/persimages/dip.gif"><i>Education Adviser</i>:
        Dr Andr Dippenaar</a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Erica Gous<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Manager</em>: <em>MIETTB</em>:
        Ms Stella Carthy<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Projects
        Leader: Education Services</em>: Ms Brenda Timp<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7278<br>
        498-7277<br>
        498-7646<br>
        498-7652</td>
        <td valign="top"><br>
        <a href="mailto:adippena@bullion.org.za&nbsp;">adippena@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a name="Health"><b>Health</b></a> <br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/images/persimages/letti.gif"><i>Deputy Health
        Adviser</i>: Dr Lettie La Grange</a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary</em>:
        Ms Christine Palos<p>&nbsp; </p>
        </td>
        <td align="center" valign="top"><br>
        498-7331&nbsp;<br>
        498-7390</td>
        <td valign="top"><br>
        <a href="mailto:llagrang@bullion,org,za">llagrang@bullion,org,za<br>
        </a><a href="mailto:cpalos@bullion.org.za&nbsp;">cpalos@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/statistics/statsd01.htm" name="Stats"><b>Statistics</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Manager</i>:
        Ms Diann Owen-Thomas <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Mineral
        Analyst</em>: Ms Madhu Vythilingam<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7501<br>
        498-7365</td>
        <td valign="top"><br>
        <a href="mailto:dowentho@bullion.org.za&nbsp;">dowentho@bullion.org.za&nbsp;</a><br>
        <a href="mailto:mvythili@bullion.org.za">mvythili@bullion.org.za</a></td>
    </tr>
    <tr>
        <td bgcolor="#E4E3FF">&nbsp;</td>
        <td align="center" valign="top" bgcolor="#E4E3FF">&nbsp;</td>
        <td valign="top" bgcolor="#E4E3FF">&nbsp;</td>
    </tr>
    <tr>
        <td><a href="/cvs/stewart.htm" name="Stewart"><b>Mining
        Consultant: Dr John Stewart</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary</i>:<em> </em>Ms
        Glenda Barlow-Jones<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Technical
        Assistant</i>: Dr Andrew Parsons<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">498-7312<br>
        498-7330<br>
        498-7394&nbsp;</td>
        <td valign="top"><a href="mailto:jstewart@bullion.org.za">jstewart@bullion.org.za<br>
        </a><a href="mailto:gbarlowj@bullion.org.za">gbarlowj@bullion.org.za<br>
        </a><a href="mailto:aparsons@bullion.org.za">aparsons@bullion.org.za</a>&nbsp;</td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="Technology"><b>Technology</b></a><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a
        href="/images/persimages/hume.gif"><i>Technology Adviser</i>:
        Dr Howard Hume</a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:<em> </em>Ms
        Veronica Quinn<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Assistant Technology Aviser</em>: Dr Denis Wymer<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7522<br>
        498-7525<br>
        498-7335</td>
        <td valign="top"><br>
        <a href="mailto:hhume@bullion.org.za">hhume@bullion.org.za</a><br>
        <br>
        <a href="mailto:dwymer@bullion.org.za&nbsp;">dwymer@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a name="Safety"><b>Safety</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;Safety
        Projects Manager</i>: Dr Mike Gouws&nbsp;<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Beryl Anwaruddin<p>&nbsp; </p>
        </td>
        <td align="center" valign="top"><br>
        498-7423<br>
        498-7424</td>
        <td valign="top"><br>
        <a href="mailto:mgouws@bullion.org.za&nbsp;">mgouws@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="Environment"><b>Environment</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Environmental
        Adviser</i>: Dr John Kilani<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary</em>:
        Ms Beryl Anwaruddin<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7421<br>
        498-7424</td>
        <td valign="top"><br>
        <a href="mailto:jkilani@bullion.org.za&nbsp;">jkilani@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="TechnicalSupport"><b>Technical Support</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a
        href="/images/persimages/greef.gif"><i>General Manager</i>:
        Mr Johann Greeff</a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>
        &nbsp;&nbsp;&nbsp;Technical Support Manager</i>: Mr Dick
        Kruger<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Manager:
        Technical Administration</em>:<em> </em>Ms Jill Watson<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7361<br>
        498-7275<br>
        498-7527</td>
        <td valign="top"><br>
        <br>
        <a href="mailto:dkruger@bullion.org.za">dkruger@bullion.org.za</a>&nbsp;</td>
    </tr>
    <tr>
        <td bgcolor="#E4E3FF">&nbsp;</td>
        <td align="center" valign="top" bgcolor="#E4E3FF">&nbsp;</td>
        <td valign="top" bgcolor="#E4E3FF">&nbsp;</td>
    </tr>
    <tr>
        <td><a href="/cvs/liebenb.htm" name="PPU"><b>Public
        Policy Consultant: Mr Johann Liebenberg</b></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Sandra Lopes<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p>
        </td>
        <td align="center" valign="top">(012)235266</td>
        <td valign="top"><a href="mailto:jlieb@is.co.za">jlieb@is.co.za</a><br>
        <a href="mailto:sandra@bullion.co.za&nbsp;">sandra@bullion.co.za&nbsp;</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/departments/comm.htm" name="Communications"><b>Communications</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>
        &nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/images/persimages/bunk.gif"><i>Communications
        Adviser</i>: Mr Peter Bunkell</a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary</em>:
        Ms Geneva Ontong<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Media Manager</i>:
        Mr Llewellyn Kriel<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International
        Liaison Manager</i>: Mr Reinoud Boers<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Manager</em>:
        Mr Geoff Behrent<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Publications
        Manager</em>: Mr Al Smit<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Publications
        Editor</em>: Ms Theresa Onderstal<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7205<br>
        498-7345<br>
        498-7316<br>
        498-7212<br>
        498-7200<br>
        498-7272<br>
        498-7217</td>
        <td valign="top"><br>
        <a href="mailto:pbunkell@bullion.org.za">pbunkell@bullion.org.za</a><br>
        <br>
        <a href="mailto:lkriel@bullion.org.za">lkriel@bullion.org.za<br>
        </a><a href="mailto:rboers@bullion.org.za">rboers@bullion.org.za<br>
        </a><a href="mailto:gbehrent@bullion.org.za&nbsp;">gbehrent@bullion.org.za&nbsp;</a><br>
        <a href="mailto:alsmit@bullion.org.za">alsmit@bullion.org.za</a><br>
        <a href="mailto:tonderst@bullion.org.za">tonderst@bullion.org.za</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/departments/econ.htm" name="Economics"><b>Economics</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>
        &nbsp;&nbsp;&nbsp;Senior Economist</i> / Head of
        Department: Mr Roger Baxter<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Economist</em>:<em> </em>Mr
        Bongi Gasa<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>
        Trainee Economist</em>: Ms Firoza Adam<p><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="../../cvs/grant.htm"><i>Economic Research
        Consultant</i>: Dr Richard Grant </a><br>
        </p>
        <p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7663<br>
        498-7459<br>
        498-7456<br><br>
        498-7457</td>
        <td valign="top">&nbsp;<br>
        <a href="mailto:rbaxter@bullion.org.za">rbaxter@bullion.org.za<br>
        </a><br><br><br>
        <p><a href="mailto:rgrant@bullion.org.za">rgrant@bullion.org.za</a></p>
        </td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/departments/legal.htm" name="Legal"><b>Legal<br>
        </b></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/images/persimages/ans.gif"><i>Legal Adviser</i>:
        Mr Peter Anscombe</a><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Jean Hutton<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assistant Legal
        Adviser</i>: Mr Anton van Achterbergh<br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        &nbsp;Assistant Legal Adviser</i>: Ms Sandy Oberholzer<br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        &nbsp; Assistant Legal Adviser</i>: Mr Paul Henderson<br>
        <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal
        Counsellor</i>: Mr Barry Shipman<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        498-7376<br>
        498-7377<br>
        498-7378<br>
        498-7381<br>
        498-7370<br>
        498-7382</td>
        <td valign="top">&nbsp;<font size="1"><br>
        </font>
        <a href="mailto:panscomb@bullion.org.za">panscomb@bullion.org.za</a><br>
        <br>
        <a href="mailto:avanacht@bullion.org.za">avanacht@bullion.org.za</a><br>
        <a href="mailto:soberhol@bullion.org.za">soberhol@bullion.org.za<br>
        </a><a href="mailto:phenders@bullion.org.za">phenders@bullion.org.za</a><br>
        </td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        href="/departments/ppu1.htm"><b>Public Policy</b></a>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Office
        Manager, Cape Town</i>: Mr Franois Basson<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;<br>
        (021)235266</td>
        <td valign="top">&nbsp;&nbsp;<br>
        <a href="mailto:francious@bullion.co.za">francious@bullion.co.za</a></td>
    </tr>
    <tr>
        <td bgcolor="#E4E3FF">&nbsp;</td>
        <td align="center" valign="top" bgcolor="#E4E3FF">&nbsp;</td>
        <td valign="top" bgcolor="#E4E3FF">&nbsp;</td>
    </tr>
    <tr>
        <td><a href="/cvs/pollnow.htm" name="Pollnow"><b>Gold
        Marketing Consultant: Dr Dan Pollnow</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Secretary</em>:
        Ms Rose de Freitas<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;498-7332<br>
        498-7206</td>
        <td valign="top"><a
        href="mailto:dpollnow@bullion.org.za&nbsp;">dpollnow@bullion.org.za&nbsp;</a><br>
        &nbsp;</td>
    </tr>
    <tr>
        <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a
        href="/gold1.htm"><strong>Gold Marketing</strong><br>
        </a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;Gold
        Marketing Assistant</i>: Ms Gillian Moncur <br>
        </td>
        <td align="center" valign="top">&nbsp;&nbsp;<br>
        498-7560</td>
        <td valign="top">&nbsp;<br>
        <a href="mailto:gmoncur@bullion.org.za&nbsp;">gmoncur@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td bgcolor="#E4E3FF">&nbsp;</td>
        <td align="center" valign="top" bgcolor="#E4E3FF">&nbsp;</td>
        <td valign="top" bgcolor="#E4E3FF">&nbsp;</td>
    </tr>
    <tr>
        <td><a href="/images/persimages/botha.gif"
        name="ServicesCompany"><b>Manager: Chamber of Mines
        Services Company (Pty.) Ltd. Mr Johann Botha<br>
        </b></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;</i><em>Secretary</em>:
        Ms Maureen Wood<p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;&nbsp;<br>
        498-7611&nbsp;<br>
        498-7611</td>
        <td valign="top">&nbsp;<br>
        <a href="mailto:jbotha@bullion.org.za&nbsp;">jbotha@bullion.org.za&nbsp;</a><br>
        <a href="mailto:mwood@bullion.org.za&nbsp;">mwood@bullion.org.za&nbsp;</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a
        name="CentresforHumanDevelopment"><b>Centres for Human
        Development</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;</i><a
        href="/associates/gauteng.htm"><i>Johannesburg: Manager</i>:
        Mr Andre Beugger</a><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;Klerksdorp:
        Manager</i>: Dr Coetzee Badenhorst <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;Rustenburg:
        Manager</i>: Mr Jan MacLachlan <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;Witbank:
        Manager</i>: Dr Andre van Jaarsveld <p>&nbsp; </p>
        </td>
        <td align="center" valign="top">&nbsp;&nbsp;<br>
        834-1611&nbsp;<br>
        </td>
        <td valign="top">&nbsp;&nbsp;<br>
        <a href="mailto:abeugger@bullion.org.za">abeugger@bullion.org.za</a></td>
    </tr>
    <tr>
        <td><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><a name="MPAS"><b>Mines
        Professional Association Secretariat</b></a> <br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manager</i>:
        Mr Simon Orchardson </td>
        <td align="center" valign="top">&nbsp;&nbsp;<br>
        498-7327
        </td>
        <td valign="top">&nbsp;</td>
    </tr>
</table>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p align="center"><a><img src="/images/nb1.gif" alt="Main Menu"
align="middle" hspace="20"></a> <a href="#top"><img
src="/images/nb2.gif" alt="Top of Page" align="middle" border="0"
hspace="20"></a> <a href="#toolbar"><img src="/images/nb3.gif"
alt="Toolbar" align="middle" border="0" hspace="20"></a> <br>
</p>

<p align="center"><img src="/images/line3.gif" align="middle"></p>

<p align="center"><a href="/org1.htm"><img
src="/images/tb101.gif" alt="organisation" border="0"></a> <a
href="/res1.htm"><img src="/images/tb102.gif" alt="Resources"
border="0"></a><a href="/kruger.htm"><img src="/images/tb104.gif"
alt="Krugerrand" border="0"></a> <a href="/new.htm"><img
src="/images/tb105.gif" alt="What's New?" border="0"></a> <a
href="/info.htm"><img src="/images/tb106.gif" alt="Contacting us"
border="0"></a> <br>
</p>

<address>
    <font size="2">Last Updated: 11 February 1997<br>
     1996, 1997 Chamber of Mines of South Africa<br>
    HTML Coding by Andrew Parsons : </font><a
    href="mailto:aparsons@bullion.org.za"><font size="2">aparsons@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-448</DOCNO>
<DOCOLDNO>IA012-000121-B042-14</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/other.htm 196.26.82.193 19970217004308 text/html 2495
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:46:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>The Chamber of Mines Functions and Services</TITLE>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<center><FONT SIZE=5 COLOR=0000A0><b>Chamber of Mines of South Africa</FONT></FONT><p>
<IMG SRC="/images/LOGO1.gif"><p></center>
<p><h2><CENTER><b><i>Associated Organisations and Companies</i></b>
</h2>
</CENTER>
<UL>
<LI> <a href="/associates/teba.htm">The Employment Bureau of Africa Limited (TEBA)</a> </EM>
<LI> <a href="/associates/tcash.htm">TEBA Savings Fund</a> (trading as TEBA-CASH)</EM>
<LI> <a href="/associates/rma.htm">The Rand Mutual Assurance Company Limited</a> </EM>
<LI> The Rand Mutual Life Assurance Company Limited</EM>
<LI> The Rand Mutual Hospital</EM>
<LI> <a href="/associates/rr.htm">Rand Refinery Limited</a> </EM>
<LI>Mines Rescue Training (Pty) Limited
<LI>Environmental Management Services
<LI><a href="/associates/nufcor.htm">Nuclear Fuels Corporation of South Africa (Pty) Limited</a></EM>
<LI> Colliery Training College (Pty) Limited</EM>
<LI> <a href="/associates/igc.htm">International Gold Corporation Limited</a></EM>
<LI> Far West Rand Dolomitic Water Association</EM>
<LI> Chamber of Mines Pension Fund</EM>
<LI> Chamber of Mines Medical Aid Scheme</EM>
<LI> Chamber of Mines Services Company</EM>
</UL>
<center>
<a href=""> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br><br><p>
<IMG SRC="/images/line3.gif" ALIGN=MIDDLE></center>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  5 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT14-B39-449</DOCNO>
<DOCOLDNO>IA012-000121-B042-115</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/publications/constitution.htm 196.26.82.193 19970217004450 text/html 68391
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:47:33 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Constitution</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#0000A0" link="#800040" vlink="#008000" alink="#808080">
<p align=center><a name="top"><font size=5><b>Chamber of Mines of South Africa</b></font></a><font size=2> </font></p>
<p align=center><img src="/images/LOGO1.gif" alt="constitution of the Chamber of Mines of South Africa" align=bottom width=300 height=160> </p>
<p align=center><font color="#008000"><font size=7><strong>CONSTITUTION</strong></font></font></p>
<div align=center><center>
<table border=1>
<tr><td width=340><p align=center><font FACE="Arial"><font size=1><b><u>NOTE<font FACE="Arial"></u></b></font> <br>
<font size=1>The most recent amendments to the Constitution of the Chamber of 
Mines of South Africa reflected in this copy are those agreed to at the 
special general meeting of members held on 7 November 1995 and 
approved by the Industrial Registrar with effect from 4 December 1995. </font></p>
</td></tr>
</table>
</center></div>
<p align=center><img src=" /images/linegr.gif" align=middle> <br>
</p>
<p align=center><img src="/images/save.gif" align=bottom width=16 height=16> <L1> <a href="const.pdf"><font size=2><b>Download &quot;Chamber of Mines of South Africa Constitution&quot; </b></font></a><font size=1>(ACROBAT .PDF 197KB) <img src="/images/save.gif" align=bottom width=16 height=16></font> <br>
<br>
</p>
<p align=center><img src="/images/wd1.gif" align=middle width=32 height=31><br>
<font FACE="Century Schoolbook"><font size=2><b>CONTENTS</font></b></font> </p>
<hr>
<div align=center><center>
<table border=1>
<tr><td width=527></td><td width=63><font FACE="Arial"> 
<font size=2><i>Article</font></i></font> </td></tr>
<tr><td width=527><a href="#name"><b>Name</b></a></td><td width=63><font FACE="Arial"><b>1 
</font></b> </td></tr>
<tr><td width=527><a href="#objects"><b>Objects and powers</b></a> </td><td width=63><font FACE="Arial"><b>2 
</font></b> </td></tr>
<tr><td width=527><a href="#membership"><b>Membership</b></a> </td><td width=63><font FACE="Arial"><b>3-7 
</font></b> </td></tr>
<tr><td width=527><a href="#appointment"><b>Appointment of representatives</b></a> </td><td width=63><font FACE="Arial"><b>8-11 
</font></b> </td></tr>
<tr><td width=527><a href="#provisions"><b>General provisions applicable to members</b></a> </td><td width=63><font FACE="Arial"> 
<a name="provisions"><b>12-19</font></b></a> </td></tr>
<tr><td width=527><a href="#register"><b>Register of members</b></a> </td><td width=63><font FACE="Arial"><b>20 
</font></b> </td></tr>
<tr><td width=527><a href="#council"><b>Constitution and powers of the Council</b></a> </td><td width=63><b>21-29</b></td></tr>
<tr><td width=527><a href="#president"><b>President and Vice-President</b></a> </td><td width=63><font FACE="Arial"> 
<b>30-32</font></b> </td></tr>
<tr><td width=527><a href="#exco"><b>Constitution and powers of the Executive Committee</b></a> </td><td width=63><font FACE="Arial"> 
<b>33-36</font></b> </td></tr>
<tr><td width=527><a href="#principal"><b>Constitution and powers of principal committees of the Chamber</b></a> </td><td width=63><font FACE="Arial"> 
<b>37-38</font></b> </td></tr>
<tr><td width=527><a href="#committees"><b>General provisions applicable to committees</b></a> </td><td width=63><font FACE="Arial"> 
<b>39-46</font></b> </td></tr>
<tr><td width=527><a href="#agms"><b>Annual general meetings</b></a> </td><td width=63><font FACE="Arial"> 
<b>47-49</font></b> </td></tr>
<tr><td width=527><a href="#specials"><b>Special general meetings</b></a> </td><td width=63><font FACE="Arial"><b>50 
</font></b> </td></tr>
<tr><td width=527><a href="#general"><b>General provisions applicable to general meetings</b></a> </td><td width=63><font FACE="Arial"> 
<b>51-63</font></b> </td></tr>
<tr><td width=527><a href="#ballots"><b>Ballots on lock outs</b></a> </td><td width=63><font FACE="Arial"> 
<b>63A-B</font></b> </td></tr>
<tr><td width=527><a href="#ceo"><b>Chief Executive</b></a></td><td width=63><font FACE="Arial"><b>64 
</font></b> </td></tr>
<tr><td width=527><a href="#subs"><b>Subscriptions</b></a></td><td width=63><font FACE="Arial"> 
<b>65-67</font></b> </td></tr>
<tr><td width=527><a href="#financials"><b>Financial year, funds and accounts</b></a> </td><td width=63><font FACE="Arial"> 
<b>68-74</font></b> </td></tr>
<tr><td width=527><a href="#auditors"><b>Auditors</b></a></td><td width=63><font FACE="Arial"><b>75 
</font></b> </td></tr>
<tr><td width=527><a href="#minutes"><b>Minutes and records</b></a> </td><td width=63><font FACE="Arial"><b>76 
</font></b> </td></tr>
<tr><td width=527><a href="#proceedings"><b>Proceedings</b></a> </td><td width=63><font FACE="Arial"><b>77 
</font></b> </td></tr>
<tr><td width=527><a href="#property"><b>Property</b></a></td><td width=63><font FACE="Arial"><b>78 
</font></b> </td></tr>
<tr><td width=527><a href="#signature"><b>Signature of documents</b></a> </td><td width=63><font FACE="Arial"><b>79 
</font></b> </td></tr>
<tr><td width=527><a href="#notices"><b>Notices</b></a></td><td width=63><font FACE="Arial"> 
<b>80-81</font></b> </td></tr>
<tr><td width=527><a href="#indemnity"><b>Indemnity</b></a></td><td width=63><font FACE="Arial"><b>82 
</font></b> </td></tr>
<tr><td width=527><a href="#articles"><b>Alteration of Articles</b></a> </td><td width=63><font FACE="Arial"><b>83 
</font></b> </td></tr>
<tr><td width=527><a href="#winding"><b>Winding up</b></a></td><td width=63><font FACE="Arial"><b>84 
</font></b> </td></tr>
</table>
</center></div>
<hr>
<p><a name="name"><b>NAME<br>
</b></a></p>
<p>1. The name of the Organisation shall be <br>
</p>
<p>CHAMBER OF MINES OF SOUTH AFRICA <br>
</p>
<p>(hereinafter referred to as the &quot;Chamber&quot;). <br>
<br>
</p>
<p><a name="objects"><b>OBJECTS AND POWERS<br>
</b></a></p>
<p>2. The objects and powers of the Chamber shall be<br>
</p>
<p>(a) to advance, promote and protect the mining and other interests of its members; to consider, discuss and make 
recommendations on matters connected therewith or incidental thereto; to collect, circulate and publish information, and to 
investigate and conduct research into matters concerning its members, their interests or activities; to represent its members and 
to act on their behalf or as their agent in matters affecting their common interests; and to assist technically, financially or 
otherwise in the prosecution or defence of actions involving questions the decision whereof is likely to affect the common 
interests of its members;<br>
</p>
<p>(b) to regulate relations between its members and their employees; to represent its members and act on their behalf in matters 
connected with the regulation of such relations; to negotiate and conclude, on behalf of its members, agreements with any or 
all of their employees, or with any association, associations, trade union or trade unions representing any or all of such 
employees, relating to wages or other conditions of employment; to represent its members and act on their behalf in industrial 
disputes in which they or any of them are concerned and in all matters arising under or in connection with industrial legislation 
affecting them;<br>
</p>
<p>(c) to petition or make representations or submit evidence to the State President, Parliament, any Premier of a province or 
Executive Council of a province, any Municipality, any other legislative or administrative body or any commission on matters 
concerning its members, their interests or activities and to promote or oppose legislative measures affecting them; <br>
</p>
<p>(d) to form, or participate in the formation of, and to support, or grant subsidies to associations, institutions, companies, 
committees and other organisations or bodies associated or connected with the mining industry or calculated to benefit the 
industry, gratuity funds, provident and pension funds, and medical aid and sick benefit funds for the benefit, wholly or partly, 
of persons employed in the mining industry; to provide scholarships and endowments; to provide facilities for the training in 
first aid, rescue operations and safety, of persons employed in the mining industry; to establish and maintain a mining exhibit or 
exhibits at any exhibition or public show; to subscribe money for charitable or benevolent objects, for exhibitions or for public, 
general or useful objects; and to guarantee the payment of the liabilities or the fulfilment of the contracts or undertakings of any 
person, company, association or institution; <br>
</p>
<p>(e) to examine and report upon applications for patents or other monopolies which affect or may affect the interests of its 
members; to promote or oppose such applications and to acquire, hold and dispose of any patents or other monopolies for 
the purposes of the Chamber;<br>
</p>
<p>(f) to establish, or participate in the establishment of pension, gratuity, medical aid or sick funds for the benefit, wholly or 
partly of the Chamber's employees and to contribute to any such fund;<br>
</p>
<p>(g) to acquire and hold, to improve, sell, lend, let, hire, mortgage, donate, dispose of or deal in any other way with any 
property, movable or immovable, for the purposes of the Chamber;<br>
</p>
<p>(h) to invest or lend any moneys of the Chamber with or without security and on such terms and conditions as may be decided 
from time to time and to realise or vary any such investment or loan; <br>
</p>
<p>(i) to borrow or raise moneys for the purposes of the Chamber, whether by means of debenture bonds, mortgages or 
otherwise howsoever and to pledge as security for the repayment of such moneys all or any of the property or assets of the 
Chamber; <br>
</p>
<p>(j) to open and operate a banking account and to make, draw, accept, endorse, discount, execute, issue or otherwise dispose 
of bills of exchange, promissory notes, bills of lading and other negotiable or transferable instruments or securities;<br>
</p>
<p>(k) to employ or appoint and remunerate attorneys, advisers, agents and other persons for the purposes of the Chamber;<br>
</p>
<p>(l) to establish and maintain a library and museum embracing collections of books and articles of interest to its members;<br>
</p>
<p>(m) to act as secretaries or managers of associations, institutions, funds, companies, committees and other organisations or 
bodies associated or connected with the mining industry and to charge fees for so acting; and<br>
</p>
<p>(n) generally to do all such other things as are necessary, conducive or incidental to the attainment of the above objects.<br>
<br>
</p>
<p><a name="membership"><b>MEMBERSHIP</b></a> </p>
<p>3. The following may be admitted as ordinary members of the Chamber: <br>
</p>
<p>(a) any company registered with limited liability and engaged in the Republic of South Africa in the business of mining;<br>
</p>
<p>(b) any company registered with limited liability and engaged in the Republic of South Africa in the business of promoting or 
financing mining ventures or in the business of providing administrative, secretarial, technical or other services to companies 
engaged in the business of mining; <br>
</p>
<p>(c) any company registered with limited liability and engaged in the Republic of South Africa in the business of extracting any 
mineral (as defined in the Minerals Act No. 50 of 1991, or any law in substitution thereof) from any tailings, slimes, waste 
rock or other residues produced in the course of mining if such company is provided with administrative, secretarial, technical 
or other services by a member of the Chamber; and<br>
</p>
<p>(d) any association whose members include a significant number of companies contemplated in paragraph (a), (b) or (c) of this 
Article 3.<br>
</p>
<p>For the purposes of this Article &quot;mining&quot; means the operation of any mine as defined in the Minerals Act No. 50 of 1991 or 
any law in substitution thereof.<br>
</p>
<p>4. Any company desirous of becoming an ordinary member of the Chamber shall lodge with the Chief Executive a written 
application to the Executive Committee for admission as such; and, for the purposes of the application, the company 
concerned shall provide the Committee with the company's full name or names and registered address and such further 
information as the Committee may require. The application shall be considered at the next ordinary meeting of the Executive 
Committee or, if the President so directs, at a special meeting of the Committee convened for the purpose and that Committee 
shall then decide whether or not the applicant shall be admitted and the terms and conditions upon which it shall be admitted 
which shall not be subject to review in terms of this Article; provided that such an application, if received less than fourteen 
days before the next ordinary meeting of the Executive Committee, shall be considered at that meeting, or at the meeting 
following, as the President may direct. <br>
</p>
<p>After the meeting of the Executive Committee at which such an application is considered, the applicant shall be notified, in 
writing, by the Chief Executive whether or not the applicant has been admitted and of the terms and conditions imposed by the 
Committee. If within thirty days of the date of a notification from the Chief Executive that an application for admission as an 
ordinary member has been refused, the applicant lodges with the Chief Executive a request, in writing, that the Executive 
Committee's decision be reviewed by the Chamber, in general meeting, the application shall be considered at the next annual 
general meeting of the Chamber, or if the Executive Committee so decides, at a special general meeting of the Chamber 
convened for the purpose; and if the meeting then decides to admit the applicant by a two-thirds majority of the 
representatives present and entitled to vote, the applicant shall be admitted to ordinary membership, but not otherwise.<br>
</p>
<p>5. Any person may be elected by the Executive Committee, on such terms and conditions as that Committee may decide, as 
an honorary member of the Chamber.<br>
</p>
<p>6. The liability of ordinary members shall be limited to the amount, if any, payable by way of subscription or otherwise to the 
Chamber by such members. Any such liability may be waived in whole or in part by resolution of the Executive Committee on 
behalf of the Chamber. <br>
</p>
<p>7. The Council may establish two or more classes of ordinary members according to the nature or extent of the business 
carried on by members of the Chamber or according to any other criterion as may be determined by the Council and in such 
event the Executive Committee shall allocate every ordinary member to one or more of such classes. In making such allocation 
the Executive Committee shall be guided, but not bound, by the member's principal business or businesses. The Executive 
Committee may at any time re-allocate an ordinary member to any class or classes.<br>
<br>
</p>
<p><a name="appointment"><b>APPOINTMENT OF REPRESENTATIVES </b></a></p>
<p>8. Within fourteen days of admission to membership of the Chamber, each ordinary member shall appoint a representative, by 
notice, in writing, lodged with the Chief Executive. Such notice shall contain the full names, occupation and address of the 
representative concerned.<br>
</p>
<p>9. An ordinary member may, at any time, appoint an alternate representative, by notice, in writing, lodged with the Chief 
Executive. Such notice shall contain the full names, occupation and address of the alternate representative concerned.<br>
</p>
<p>10. An ordinary member may withdraw the appointment of a representative or alternate representative, by notice in writing, 
lodged with the Chief Executive and, in the case of the withdrawal of the appointment of an alternate representative, may then 
or at any time thereafter appoint, in the manner prescribed by Article 9, another in his place. If the appointment of a 
representative is so withdrawn or if a representative ceases for any other reason, to be such, the ordinary member concerned 
shall appoint, within fourteen days thereafter and in the manner prescribed by Article 8, another in his place.<br>
</p>
<p>11. The representative or alternate representative of an ordinary member shall cease to be such<br>
</p>
<p>(a) if he resigns;<br>
</p>
<p>(b) if his appointment is withdrawn by the member by whom he was appointed; or<br>
</p>
<p>(c) if the member by whom he was appointed ceases to be a member. <br>
<br>
</p>
<p><a name="provisions"><b>GENERAL PROVISIONS APPLICABLE TO MEMBERS</b></a> </p>
<p>12. Six months' notice in writing (or such lesser period of notice as may be allowed by resolution of the Executive Committee) 
shall be given to the Chief Executive of any ordinary member's intention to withdraw from the Chamber. Upon expiry of the 
financial year of the Chamber in which the period of such notice expires, the member concerned shall cease to be a member. </p>
<p>13. Any ordinary member who ceases to be eligible, in terms of Article 3, for ordinary membership, shall withdraw from the 
Chamber within three months of ceasing to be eligible for membership. One month's notice, in writing, shall be given to the 
Chief Executive of such member's intention so to withdraw from the Chamber, and, upon the expiry of the notice, the member 
concerned shall cease to be a member. Any member who, having ceased to be eligible for ordinary membership, does not so 
withdraw from the Chamber may be excluded from the Chamber by resolution of the Executive Committee and shall 
thereupon cease to be a member.<br>
</p>
<p>14. Any member who, having been given notice, in writing, by the Chief Executive of the amount of any subscription due by 
such member and of the date on which such subscription is payable, fails to pay the amount concerned within six months of 
that date, may be excluded from the Chamber by resolution of the Executive Committee and shall thereupon cease to be a 
member; provided that the provisions of this Article shall not apply to any ordinary member who has failed to pay the amount 
of any such subscription by reason of the fact that a request, lodged in terms of Article 66, that the basis on which such 
subscription has been calculated or the amount of such subscription, be reviewed, has not yet been considered and disposed 
of by the Chamber in general meeting. <br>
</p>
<p>15. Any member who has been placed in liquidation or is under judicial management, may be excluded from the Chamber by 
resolution of the Executive Committee and shall thereupon cease to be a member. <br>
</p>
<p>16. Any member who has infringed the provisions of these Articles or of any by-laws passed in terms of Article 36, or being, 
in the opinion of the Executive Committee, guilty of any practice or proceeding likely to bring discredit upon the Chamber, 
may be excluded from the Chamber by resolution of the Executive Committee. <br>
</p>
<p>17. Any member who has been excluded from the Chamber by resolution of the Executive Committee, in terms of Articles 
13, 14, 15 or 16, shall be notified immediately by the Chief Executive, in writing, of the Committee's decision and the ground, 
with such particularity as the Chairman shall decide, on which such member has been excluded. <br>
</p>
<p>18. If a member who has been excluded from the Chamber by resolution of the Executive Committee, in terms of Article 16 
lodges with the Chief Executive, within fourteen days of the date of the notification referred to in Article 17, a request, in 
writing, that the decision of the Executive Committee be reviewed by the Chamber, in general meeting, the matter shall be 
considered at the next annual general meeting of the Chamber or, if the Executive Committee so decides, at a special general 
meeting of the Chamber convened for the purpose; and the member concerned shall not be excluded from the Chamber if the 
meeting then decides accordingly by a majority of not less than two-thirds of the representatives present and entitled to vote. 
Unless it is so decided that the member concerned shall not be excluded from the Chamber, such member shall cease to be a 
member at the conclusion of the meeting. If such a written request that the Executive Committee's decision to exclude a 
member, in terms of Article 16, be so reviewed, is not received by the Chief Executive within fourteen days of the date of the 
notification referred to in Article 17, the member concerned shall thereupon cease to be a member.<br>
</p>
<p>19. Cessation of membership in terms of these Articles shall not release the member concerned from liability for any 
subscription or other amount due by the member to the Chamber or from any other obligation to the Chamber. <br>
</p>
<p><a name="register"><b>REGISTER OF MEMBERS</b></a> </p>
<p>20. There shall be kept a register of members in which there shall be recorded<br>
</p>
<p>(a) the full name or names and the address of each member and a statement whether the member is an ordinary member or an 
honorary member;<br>
</p>
<p>(b) the full names of the representative and alternate representative, if any, of each ordinary member; and<br>
</p>
<p>(c) the date on which each member is admitted to membership of the Chamber, the class or classes to which each ordinary 
member has been allocated or re-allocated in terms of Article 7 together with the date of such allocation or re-allocation, and 
the date on which any member ceases to be a member and the reason therefor. <br>
<br>
</p>
<p><a name="council&lt;B&gt;CONSTITUTION AND POWERS OF THE COUNCIL&lt;/B&gt;&lt;/A&gt;
&lt;P&gt;
21. There shall be a Council of the Chamber which shall consist
of not less than seven and not more than twenty persons as may
be determined from time to time at a general meeting of the Chamber.
&lt;BR&gt;

&lt;P&gt;
22. The members of the Council shall be elected at each annual
general meeting of the Chamber by the representatives of ordinary
members present and entitled to vote. Each member of the Council
shall hold office until the next annual general meeting after
his election when he shall retire but be eligible for re-election.
Each candidate for election to the Council other than a retiring
member shall be nominated by the representative of an ordinary
member and such nomination shall be lodged with the Chief Executive
at least fourteen days prior to the date on which the election
is to take place. The representatives of ordinary members shall
be the only persons eligible for election to the Council.&lt;BR&gt;

&lt;P&gt;
23. The President shall be the Chairman of the Council and shall
take the chair at all meetings of the Council. If the President
is not present at any such meeting the members present shall elect
one of their number to be Chairman of that meeting.&lt;BR&gt;

&lt;P&gt;
24. Five members of the Council shall form a quorum at any meeting
of the Council.&lt;BR&gt;

&lt;P&gt;
25. The Council shall meet at as soon as practicable after each
annual general meeting of the Chamber. At least seven days' notice
in writing of each meeting of the Council or such shorter period
of notice as the President or the Council itself may decide shall
be given to members thereof by the Chief Executive provided that
such shorter period of notice, if given, shall not be less than
is reasonably necessary to permit the members to attend the meeting
concerned. &lt;BR&gt;

&lt;P&gt;
The President may convene a meeting of the Council at any time
and the Chief Executive shall convene a meeting of the Council
if requested in writing to do so by at least five members thereof.
The Council may act notwithstanding any vacancy or vacancies in
its number, but if and so long as the number of continuing members
of the Council is reduced below the number fixed as the quorum,
such continuing members of the Council may act for the purpose
of increasing the number of members to that number, but for no
other purpose. 
&lt;P&gt;
Notwithstanding Articles 21 and 22, the Council may at any time
and from time to time in its discretion, appoint any representative
of an ordinary member as an additional member of the Council provided
that the maximum number of additional members of the Council so
appointed at any one time shall not exceed three and provided
further that the total number of members of the Council shall
not be more than twenty persons. Each member so appointed to the
Council shall hold office until the next annual general meeting
after his appointment when he shall retire but be eligible for
re-election or re-appointment.&lt;BR&gt;

&lt;P&gt;
The Council may at any time co-opt the services of the representative
or the alternate representative of any ordinary member to such
extent and for such purposes as the Council may decide. Such a
representative or alternate representative may attend, by invitation,
any meeting of the Council and may take part in discussion, but
may not vote.&lt;BR&gt;

&lt;P&gt;
26. The Council shall have power to appoint at any time a representative
of an ordinary member to fill a casual vacancy in the Council.
Any representative so appointed shall hold office as a member
of the Council until the next annual general meeting of the Chamber
when he shall retire but shall then be eligible for re-election.
&lt;BR&gt;

&lt;P&gt;
27. Any member of the Council shall cease to hold office as such
if he resigns by giving notice in writing to the Chief Executive
of his resignation or if he ceases to be a representative of an
ordinary member.&lt;BR&gt;

&lt;P&gt;
28. At any meeting of the Council a decision shall be taken by
a majority of the members present voting by a show of hands. The
Chairman shall have a deliberative vote but no casting vote. The
conduct of a meeting of the Council shall be the responsibility
of the Chairman who, subject to the provisions of these Articles,
shall determine the procedure to be followed at the meeting. 
&lt;BR&gt;

&lt;P&gt;
28(A). A resolution in writing signed by all the members of the
Council who may at the time be present in Johannesburg and being
not fewer in number than are sufficient to form a quorum shall
be as valid as if it had been passed at a meeting of the Council
duly called and constituted. Such resolution may consist of several
documents in like form each signed by one or more members of the
Council. &lt;BR&gt;

&lt;P&gt;
29. The Council shall have the power generally to direct and control
the functioning of the Executive Committee and the policy adopted
by it in the management and administration of the Chamber. Further,
and without prejudice to its general powers, the Council shall
have power to do all acts required to be done by it in terms of
these Articles and shall have all the specific and general powers
conferred by these Articles upon the Executive Committee. &lt;BR&gt;
&lt;BR&gt;

&lt;P&gt;
&lt;A NAME=" president"><b>PRESIDENT AND VICE-PRESIDENTS </b></a></p>
<p>30. The President and Vice-Presidents of the Chamber in office when this provision comes into operation shall remain in office 
until the next ensuing annual general meeting of the Chamber at which, and at each annual general meeting thereafter, one of 
the members of the Council then elected in terms of Article 22 shall be elected President and two or more representatives of 
ordinary members (whether or not members of the Council) shall be elected Vice-Presidents of the Chamber by the 
representatives of ordinary members present at the meeting and entitled to vote. The President and Vice-Presidents shall hold 
office until the next annual general meeting when they shall retire, but shall be eligible for re-election. <br>
</p>
<p>31. The President or any Vice-President shall cease to hold office as such if he resigns from that office or if he ceases to be a 
representative of an ordinary member. <br>
</p>
<p>32. If the office of the President or a Vice-President becomes vacant for any reason such vacancy shall be filled for the 
unexpired term of the current period of office by the Council, or, if the Council so decides, at a special general meeting of the 
Chamber convened for the purpose. <br>
<br>
</p>
<p><a name="exco"><b>CONSTITUTION AND POWERS OF THE EXECUTIVE COMMITTEE</b></a> </p>
<p>33. There shall be an Executive Committee of the Chamber which shall consist of six members of the Council or such other 
number as the Council may determine from time to time. The President shall be a member of the Executive Committee and the 
remaining members shall be appointed by the Council at its first meeting after this Article has come into operation and 
thereafter at its first meeting after each annual general meeting of the Chamber. The Council may at any time and from time to 
time in its discretion appoint any member of the Council as an additional member of the Executive Committee. Each member 
of the Executive Committee shall hold office until the first meeting of the Council held after the annual general meeting of the 
Chamber next following his appointment. <br>
</p>
<p>34. The President shall be the Chairman of the Executive Committee and shall take the Chair at all meetings of that 
Committee. If the President is not present at any such meeting the members present shall elect one of their number to be 
Chairman of that meeting. <br>
</p>
<p>35. Three members of the Executive Committee shall form a quorum at any meeting of that Committee. <br>
</p>
<p>36. Subject to the direction and control of the Council the general administration and management of the Chamber shall be 
vested in the Executive Committee which in addition to the powers expressly conferred upon it by these Articles may exercise 
all such powers and do all such acts and things in the name of and on behalf of the Chamber as may be exercised or done by 
the Chamber. <br>
</p>
<p>Without prejudice to its general powers or to the powers, acts and things which by these Articles it may exercise or is 
required to do, the Executive Committee shall have power<br>
</p>
<p>(a) to enter into such contracts in the name and on behalf of the Chamber as it thinks expedient for the purpose of the 
Chamber; <br>
</p>
<p>(b) to pass by-laws for the regulation of the business of the Chamber not inconsistent with the provisions of these Articles or 
of any law;<br>
</p>
<p>(c) to appoint at such remuneration and on such terms as the Committee may decide and to remove employees or agents of 
the Chamber;<br>
</p>
<p>(d) to acquire and hold, to improve, sell, rent, let, hire, mortgage, donate, dispose of or deal with in any other way, any 
property, movable or immovable for the purposes of the Chamber;<br>
</p>
<p>(e) to determine and change at its discretion, the place at which the head office of the Chamber shall be situated;<br>
</p>
<p>(f) to appoint representatives on any industrial council or conciliation board in which the Chamber or any member is 
concerned; </p>
<p>(g) to institute, conduct, defend, compound or abandon any proceedings by or against the Chamber in any court of law or 
before any arbitrator, wage board or other body constituted according to law and, without prejudice to any other provision 
contained herein, to recover by legal proceedings or otherwise any amount due to the Chamber; <br>
</p>
<p>(h) to appoint sub-committees to act in an advisory and/or specialist capacity and any other standing committees, ad-hoc 
committees or ad-hoc working parties which the Executive Committee in its discretion deems necessary, and to regulate the 
number of such committees or working parties, the nature of the business to be conducted by each of them and their 
composition, to establish procedural rules and guidelines to be followed by them, and for the purposes of any such 
appointment, to authorise the co-option of the services of any person; and <br>
</p>
<p>(i) to delegate any of its functions or powers to any member of the Executive Committee or to any principal committee 
established by the Council, or to any employee of the Chamber upon such terms and conditions as the Executive Committee 
may decide. <br>
<br>
</p>
<p><a name="principal">CONSTITUTION AND POWERS OF PRINCIPAL COMMITTEES OF THE CHAMBER </a></p>
<p>37. The Council may establish one or more principal committees of the Chamber specifically to promote the interests of and 
to deal with matters concerning any class of members established by the Council in terms of Article 7. Every principal 
committee shall consist of such number of members as the Council shall determine, who shall be appointed by the Council 
from the representatives of members of the class for which the principal committee has been established. Each member of a 
principal committee shall hold office until the first meeting of the Council held after the annual general meeting next following his 
appointment. The Council shall appoint a member of each principal committee as Chairman and shall fix a quorum for each 
such committee. If the Chairman of a principal committee is not present at a meeting of the committee, the members present 
shall elect one of their number to be Chairman of that meeting.<br>
</p>
<p>38. Subject to the direction and control of the Executive Committee every principal committee appointed by the Council shall 
be empowered to deal with all matters concerning members of the Chamber of the class in respect of which the committee 
was appointed and with all matters arising within the mining industry which affect their interests and to that end may exercise all 
such powers and do all such acts and things in the name and on behalf of the Chamber as may be done by the Chamber by 
virtue of paragraphs (a), (b), (c), (d), (e) and (n) of Article 2; and, without prejudice to such general powers and such further 
powers that may be delegated to it by the Executive Committee, a principal committee shall have power<br>
</p>
<p>(a) to appoint representatives on any industrial council or conciliation board in which any member of the class for which the 
committee has been established or the Chamber acting on behalf of any or all of such members, is concerned; and<br>
</p>
<p>(b) to appoint sub-committees to act in an advisory and/or specialist capacity, and any other standing committees, ad-hoc 
committees, or ad-hoc working parties which such principal committee may in its discretion deem necessary, and to regulate 
the number of such committees or working parties, the nature of the business to be conducted by each of them and their 
composition, to establish procedural rules and guidelines to be followed by them, and for the purposes of any such 
appointment, to authorise the co-option of the services of any person. <br>
<br>
</p>
<p><a name="committees"><b>GENERAL PROVISIONS APPLICABLE TO COMMITTEES</b></a> </p>
<p>39. The Executive Committee and every principal committee shall each meet at least once every three months on such dates 
and at such times as shall be decided by the committee concerned. All matters on which a decision has to be taken at any 
meeting of any such committee (including the election of Chairman where necessary) shall be decided by the majority of 
members present voting by a show of hands. <br>
</p>
<p>40. The Chairman of a meeting of the Executive Committee or a principal committee shall have a deliberative vote but not a 
casting vote. <br>
</p>
<p>41. Subject to the provisions of Article 42 the Executive Committee and any principal committee of the Chamber may make 
such regulations as it thinks appropriate as to the summoning and holding of its meetings and the transaction of business 
thereat; provided that the Chairman of such committee may convene a special meeting of such committee at any time. No 
business may be transacted at any meeting of any such committee unless a quorum is present except that the Executive 
Committee may, despite the absence of a quorum, convene a general meeting in terms of Article 50. Each such committee 
may also at any time co-opt the services of the representative or the alternate representative of any ordinary member to such 
extent and for such purposes as the committee concerned may decide. Such a representative or alternate representative may 
attend by invitation any meeting of the committee by which he was co-opted and may take part in discussion but may not 
vote.<br>
</p>
<p>41(A). Any member of the Executive Committee or of any principal committee shall have the power at any time to appoint, by 
notice in writing to the Chief Executive, any person to act as alternate member in his place at any meeting of the committee 
concerned at which he shall not be present and to act on his behalf for the purpose of signing any resolution contemplated in 
Article 44(a) whenever he is not present in Johannesburg. Any alternate member so appointed shall, whilst so acting in the 
place of the member who appointed him, hold office as a member of the committee concerned. The appointment of any 
alternate member by the Chairman of the Executive Committee or of any principal committee shall not entitle the person so 
appointed to act as Chairman at any meeting of the committee concerned and the Chairman of such meeting shall be elected in 
accordance with Article 34 or 37 as the case may be. The appointment of an alternate member shall cease whenever the 
member who appointed him shall cease to be a member of the committee concerned, or shall give notice in writing to the 
Chief Executive that the alternate member representing him has ceased to do so. <br>
</p>
<p>42. At least three days' notice in writing of each meeting of the Executive Committee or a principal committee, as the case 
may be, or such shorter period of notice as the Chairman of the committee concerned, or the committee itself shall decide, 
shall be given to the members thereof by the Chief Executive, provided that such shorter period of notice, if given, shall not be 
less than is reasonably necessary to permit the members to attend the meeting concerned. <br>
</p>
<p>43. The Council shall have power to appoint at any time a member of the Council or a representative of an ordinary member 
in the appropriate class, as the case may be, to fill a casual vacancy in the Executive Committee or a principal committee. Any 
person so appointed shall hold office as a member of the committee concerned until the first meeting of the Council held after 
the annual general meeting next following his appointment. <br>
</p>
<p>44. The Chairman of any meeting of the Executive Committee or of a principal committee shall be responsible for the conduct 
of the meeting and shall, subject to the provisions of these Articles, determine the procedure to be followed at the meeting. </p>
<p>44(A). A resolution in writing signed by all the members of the Executive Committee or of a principal committee who may at 
the time be present in Johannesburg and being not fewer in number than are sufficient to form a quorum shall be as valid as if it 
had been passed at a meeting of the committee concerned duly called and constituted. Such resolution may consist of several 
documents in like form each signed by one or more members of the committee concerned. <br>
</p>
<p>45. A member of the Executive Committee or of a principal committee shall be entitled to resign at any time from membership 
of the committee concerned by giving notice of his resignation in writing to the Chief Executive.<br>
</p>
<p>46. A member of the Executive Committee or of a principal committee shall cease to hold office as a member of the 
committee concerned <br>
</p>
<p>(a) if he resigns;<br>
</p>
<p>(b) if he ceases to hold the qualification necessary in terms of these Articles for appointment to the committee concerned; or<br>
</p>
<p>(c) if he is absent without leave of absence duly granted by the committee concerned from three consecutive meetings of the 
committee concerned.<br>
<br>
</p>
<p><a name="agms"><b>ANNUAL GENERAL MEETINGS</b></a> <br>
</p>
<p>47. The annual general meeting of the Chamber shall be held in each calendar year before the first day of December, on such 
day and at such time and place as the Executive Committee shall decide. The Chief Executive shall give at least thirty days' 
notice, in writing, of such meeting to each member. <br>
</p>
<p>48. At each annual general meeting the Chairman shall review the activities of the Chamber and refer to any other matters 
which he considers to be relevant to the occasion and the Executive Committee shall submit an audited statement of income 
and expenditure for the past financial year, an audited balance sheet as at the date to which such statement is made up, and 
the report of the Chamber's auditors thereon.<br>
</p>
<p>49. At least fourteen days before the date for which each annual general meeting is originally called, the Chief Executive shall 
send to each member true copies of the audited statement of income and expenditure, the audited balance sheet and the 
report of the Chamber's auditor or auditors thereon, which are to be submitted to the meeting in terms of Article 48. <br>
<br>
</p>
<p><a name="specials"><b>SPECIAL GENERAL MEETINGS</b></a> </p>
<p>50. The Executive Committee may convene a special general meeting of the Chamber, at any time, for the consideration of 
special business and shall do so within thirty days of the date on which a request, in writing, by the representatives of at least 
seven ordinary members, that a special general meeting be convened, is lodged with the Chief Executive. Subject to the 
provisions of Articles 83 and 84, the Chief Executive shall give to each member at least seven days' notice, in writing, of each 
special general meeting or such shorter period of notice as the Executive Committee may decide; provided such shorter 
period of notice, if given, shall not be less than is reasonably necessary to permit the representatives of members to attend the 
meeting concerned. <br>
</p>
<p><a name="general"><b>GENERAL PROVISIONS APPLICABLE TO GENERAL MEETINGS</b></a> </p>
<p>51. Each ordinary member shall be represented at general meetings of the Chamber by the representative of such member or, 
in his absence, by the alternate representative of such member, duly appointed in terms of these Articles. <br>
</p>
<p>52. An honorary member may be present, in person, at general meetings of the Chamber. <br>
</p>
<p>53. The representative or, in his absence, the alternate representative of any ordinary member, and any honorary member shall 
be entitled to take part in the discussions at all general meetings of the Chamber. If the representative of an ordinary member 
is present at any general meeting, the alternate representative of that member may also be present and may take part in the 
discussions, but shall not vote at the meeting on behalf of the member concerned. An alternate representative of an ordinary 
member, while acting in the place of the representative of that member, shall exercise all the duties, powers and functions of 
such representative. <br>
</p>
<p>54. Any person who has been invited by the Executive Committee to be present and take part in the discussion at any general 
meeting, may do so, but shall have no right of voting. <br>
</p>
<p>55. The President shall take the Chair at all general meetings of the Chamber. If the President is not present at any general 
meeting, the representatives of ordinary members present and entitled to vote shall elect one or other of the Vice-Presidents to 
be Chairman of that meeting. If neither the President nor a Vice-President is present at a general meeting, the representatives 
of ordinary members present and entitled to vote shall elect one of their number to be Chairman of the meeting. The Chairman 
of a general meeting shall be responsible for the conduct of the meeting. <br>
</p>
<p>56. The representatives of seven ordinary members shall form a quorum at any general meeting of the Chamber. If a quorum 
is not present ten minutes after the time for which any such meeting is called, the meeting shall stand adjourned until the same 
day in the next week at the same time and place, or if such day is a public holiday, until the day following, and the 
representatives then present shall constitute a quorum and may transact the business for which the meeting was originally 
called. <br>
</p>
<p>57. If any ordinary member, having been given notice, in writing, by the Chief Executive of the amount of any subscription due 
by such member and the date on which such subscription is payable, has failed to pay the amount concerned within six months 
of that date and the subscription is still outstanding on the date for which any general meeting of the Chamber is originally 
called, the representative of that member shall not be entitled to be present at or take part in the proceedings of the meeting or 
any adjournment thereof nor to vote thereat; provided that the provisions of this Article shall not apply to any representative of 
any ordinary member who has failed to pay the amount of any such subscription by reason of the fact that a request, lodged in 
terms of Article 66, that the basis on which such subscription has been calculated or the amount of such subscription be 
reviewed, has not yet been considered and disposed of by the Chamber in general meeting. <br>
</p>
<p>58. If any member has been excluded from the Chamber by resolution of the Executive Committee in terms of Articles 13, 14, 
15 or 16, neither the member concerned nor any representative of that member shall be entitled to be present at or to take 
part in the proceedings of any general meeting of the Chamber or any adjournment thereof or, in the case of an ordinary 
member, to vote thereat, except for the purposes of the review of such member's exclusion in terms of Article 18. </p>
<p>59. The representative or, in his absence, the alternate representative of each ordinary member present at a general meeting 
shall be entitled on a show of hands, to one vote on behalf of the member concerned. On a ballot other than a ballot on a 
lock-out referred to in Article 63(A), the representative or, in his absence, the alternate representative of each ordinary 
member present at a general meeting shall be entitled, on behalf of the member concerned, to one vote in respect of each one 
hundred rand (R100) or part thereof paid by such member by way of subscription in respect of the immediately preceding 
financial year, provided that such representative or, in his absence, such alternate representative shall be entitled to at least one 
vote. <br>
</p>
<p>An honorary member shall not be entitled to vote any general meeting of the Chamber. <br>
</p>
<p>60. All matters on which a decision has to be taken at any general meeting (including the election of Chairman, where 
necessary, the election of the President and the Vice-Presidents, and the election of members of the Council) shall be decided 
on a show of hands, unless a ballot is required to be taken by virtue of this or any other Article, and, unless a ballot is so 
required to be taken, a declaration by the Chairman that a resolution has or has not been carried, on a show of hands, shall be 
final. <br>
</p>
<p>At any general meeting, the Chairman or the representatives of seven ordinary members present and entitled to vote may 
demand a ballot on any matter, on which a decision has to be taken either before or on a declaration of the result of a show of 
hands, except on the matter of the election of a Chairman or of the appointment of scrutineers or of the adjournment of the 
meeting. If a ballot is so demanded, it shall be taken at once or at such other time during the meeting as the Chairman shall 
decide. <br>
</p>
<p>A ballot which is required to be taken by virtue of this or any other Article, shall be conducted in accordance with and shall be 
governed by the following provisions: <br>
</p>
<p>(a) two scrutineers shall be appointed by the Chairman to supervise the taking of the ballot at the meeting; <br>
</p>
<p>(b) the representative of each ordinary member present at the meeting shall be given, in the presence of the scrutineers, one 
ballot paper which he shall thereupon complete, fold and deposit in a container provided for the purpose; <br>
</p>
<p>(c) a ballot paper shall not be endorsed or marked in any away apart from any endorsement required to show the number of 
votes to which a representative is entitled and the mark or marks required to be made by a representative in recording his vote 
or votes. Papers bearing any other endorsements or marks shall be regarded as spoiled and shall not be counted; <br>
</p>
<p>(d) on completion of the taking of the ballot the result of the voting thereat shall be ascertained by the scrutineers and 
communicated to the Chairman, by whom the outcome of the ballot shall be declared to the meeting;<br>
</p>
<p>(e) in computing the majority on a ballot, regard shall be had to the number of votes to which the representative of each 
ordinary member present at the meeting is entitled;<br>
</p>
<p>(f) for the purposes of ascertaining the representatives who are entitled to vote, on a ballot, at any general meeting and the 
votes to which they are or any of them is entitled, the scrutineers shall have a right of access to the register of members and to 
the books of account and other records of the Chamber; </p>
<p>(g) for the purposes of enabling the scrutineers to ascertain the result of the voting at any ballot and to communicate such result 
to the Chairman, the Chairman may adjourn the meeting to a place, date and time to be fixed by him, in which case the 
outcome of the ballot shall be declared at such adjourned meeting; <br>
</p>
<p>(h) the result of a ballot shall be deemed to be the decision of the meeting at which the ballot was required to be taken on the 
matter concerned;<br>
</p>
<p>(i) a demand for a ballot shall not prevent the continuance of the meeting for the transaction of any business, other than the 
matter on which the ballot was demanded;<br>
</p>
<p>(j) the decision of the Chairman on any matter arising in connection with the taking of a ballot shall be final.<br>
</p>
<p>61. At the instance and on the direction of the Chairman of any general meeting of the Chamber, any question which, in the 
opinion of the Chairman, directly affects one class of ordinary members shall be dealt with, at the meeting, by the 
representatives present of the ordinary members within the class affected and entitled to vote and, for such purpose, the 
Chairman shall confine the proceedings on the question concerned at the meeting to the representatives of that class; and all 
the provisions of these Articles shall apply, <i>mutatis mutandis</i>, for the purpose of ascertaining the decision of such class on 
that question. <br>
</p>
<p>62. Members wishing to bring business before the Chamber at any annual general meeting shall lodge notice in writing, with 
the Chief Executive of intention to move the discussion of such business, at least fourteen days before the date of the meeting 
at which such business is proposed to be brought forward.<br>
</p>
<p>The only business which shall be dealt with at a special general meeting shall be the business for the consideration of which the 
meeting was convened. <br>
</p>
<p>63. The Chairman of a general meeting, may, with the consent of the meeting, adjourn the same from time to time and from 
place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the 
meeting from which the adjournment took place.<br>
<br>
</p>
<p><a name="ballots"><b>BALLOTS ON LOCK-OUTS</b></a> </p>
<p>63(A). A ballot shall be taken on a proposal by any member concerning calling or taking part in a lock-out as defined in the 
Labour Relations Act, No. 28 of 1956, or any law in substitution thereof. Should the President, or in his absence one of the 
Vice-Presidents, decide that the proposal shall be considered at a general meeting of the Chamber, the ballot thereon shall be 
conducted in accordance with the provisions of Article 60; provided that the representative or, in his absence, the alternate 
representative of each ordinary member present and entitled to vote shall have only one vote and the proposal shall be 
deemed to have been carried if a majority of all the members concerned have voted in favour of it.<br>
</p>
<p>63(B). In the event that it is decided that a proposal referred to in Article 63(A) should not be considered at a general 
meeting, the following procedure shall apply:<br>
</p>
<p>(a) the Chief Executive shall forthwith submit the proposal to the Executive Committee, which shall determine which members 
or class or classes of members are directly affected by the proposal. Voting in the ballot shall be confined to such members or 
class or classes of members; <br>
</p>
<p>(b) after the Executive Committee has determined who shall participate in the ballot the Chief Executive shall give written 
notice of the ballot to the members concerned in good standing;<br>
</p>
<p>(c) such notice shall be given at least three days before the ballot is to be conducted or within such shorter period as the 
Executive Committee may decide; provided that such shorter period of notice shall not be less than is reasonably necessary to 
permit the members concerned to vote in the ballot. The notice shall specify the date, place and time for voting in the ballot;<br>
</p>
<p>(d) a ballot paper shall be sent with each notice and each ordinary member concerned shall have one vote;<br>
</p>
<p>(e) before voting in the ballot commences, the Chief Executive shall appoint two scrutineers to supervise the taking of the 
ballot and to ascertain the result thereof;<br>
</p>
<p>(f) a ballot paper shall not be marked in any way apart from the mark or marks required to be made by a member in 
recording its vote. Papers bearing any other marks shall be regarded as spoiled and shall not be counted;<br>
</p>
<p>(g) voting shall take place by a representative of a member, his alternate or another person authorised by the member 
depositing the marked and folded ballot paper in a container provided for this purpose;<br>
</p>
<p>(h) upon the expiry of the time fixed for voting in the ballot the scrutineers shall ascertain the result thereof and inform the Chief 
Executive who shall make it known to all ordinary members; <br>
</p>
<p>(i) the proposal shall be deemed to have been carried if the majority of all the members concerned have voted in favour of it.<br>
<br>
</p>
<p><a name="ceo"><b>CHIEF EXECUTIVE</b></a> </p>
<p>64. There shall be a Chief Executive of the Chamber who shall be appointed by the Executive Committee on such terms and 
conditions as the Committee shall decide; provided that such appointment shall at all times be subject to the condition that it 
may be terminated at any time by the Committee or the Chief Executive on giving not less than one month's notice, in writing, 
of the Committee's or the Chief Executive's intention to do so or may be terminated summarily by the Committee on any 
ground which at common law justifies summary dismissal.<br>
</p>
<p>Subject to the direction and control of the Executive Committee, it shall be the duty of the Chief Executive<br>
</p>
<p>(a) to keep or cause to be kept the register of members for which provision is made in Article 20;<br>
</p>
<p>(b) to keep or cause to be kept the records and accounts for which provision is made in Article 69;<br>
</p>
<p>(c) to keep or cause to be kept the minutes and records for which provision is made in Article 76;<br>
</p>
<p>(d) to compile annually or at such other interval as the Executive Committee may decide, a report on the activities of the 
Chamber, for the information of its members; and<br>
</p>
<p>(e) to perform such other duties and functions as he is required to perform by these Articles or as may be required of him by 
the Executive Committee in accordance with the terms and conditions of his appointment.<br>
<br>
</p>
<p><a name="subs"><b>SUBSCRIPTIONS</b></a> </p>
<p>65. The aggregate subscriptions payable for each financial year by each class of members established in terms of Article 7 
shall be determined by the Council from time to time. Such aggregate subscriptions shall be allocated amongst the members of 
each particular class by the principal committee established in terms of Article 37 to deal with matters concerning each class 
or in the absence of such a committee, by the Executive Committee. The subscriptions payable by ordinary members in 
respect of each financial year shall be paid in advance or in arrear at such time or times or in such amount or amounts as the 
Executive Committee in its discretion may decide. An ordinary member admitted after the commencement of a financial year 
shall pay as a subscription for such year such amount, not exceeding the subscription that would have been payable by such 
member for the whole year, as the Executive Committee may decide. <br>
</p>
<p>66. Within thirty days of the date of any notice, in writing, from the Chief Executive giving the amount of any subscription due 
by any ordinary member and the date on which such subscription is payable, the ordinary member concerned may lodge with 
the Chief Executive a request, in writing, that the basis on which such subscription has been calculated and/or the amount of 
such subscription be reviewed by the Chamber, in general meeting. Such a request, if lodged within the period prescribed by 
this Article but not otherwise, shall be considered at the next annual general meeting of the Chamber or, if the Executive 
Committee so decides, at a special general meeting of the Chamber convened for the purpose; and the meeting shall then 
either confirm or determine anew the basis on which the subscription concerned shall be fixed and/or the amount of the 
subscription which the ordinary member concerned shall be required to pay, as the case may be. Any decision taken by the 
Chamber, in general meeting, in terms of this Article, shall be final in respect of the subscription which is the subject of such 
decision. <br>
</p>
<p>67. No subscription shall be payable by honorary members.<br>
<br>
</p>
<p><a name="financials"><b>FINANCIAL YEAR, FUNDS AND ACCOUNTS </b></a></p>
<p>68. The financial year of the Chamber shall be the period from 1 July to 30 June.<br>
</p>
<p>69. A record shall be kept of the subscriptions, if any, due by each member of the Chamber and the periods to which such 
subscriptions relate as also the subscriptions paid by each such member and the periods to which such payments relate. 
Proper accounts shall be kept of all moneys received and expended by the Chamber, of all the matters in respect of which 
such receipts and expenditure take place and of the assets, credits and balances of the Chamber. <br>
</p>
<p>70. All moneys received by the Chamber, from time to time, shall be banked in the name of the Chamber, within seven 
ordinary business days of receipt, with such bank as the Executive Committee shall, from time to time, appoint. <br>
</p>
<p>71. All cheques and other negotiable instruments drawn in the name of the Chamber shall be signed by one or more 
employees of the Chamber duly appointed for the purpose either by the Executive Committee or by such employee or 
employees of the Chamber as the Executive Committee shall decide. </p>
<p>72. All expenditure incurred by or on behalf of the Chamber shall be duly authorised by the Executive Committee or a 
principal committee as the case may be, acting in terms of the powers conferred upon such committee by these Articles, or by 
the Chief Executive or such other employee of the Chamber, acting in terms of such authority as shall have been conferred 
upon him by any of such committees. <br>
</p>
<p>73. Any profits or gains which may accrue to the Chamber shall not be distributed to any person, but shall be employed solely 
for the purpose of investment or for the carrying out of the Chamber's objects.<br>
</p>
<p>74. The Chamber's accounts shall be audited annually and reported upon by the auditor or auditors appointed in terms of 
Article 75.<br>
<br>
</p>
<p><a name="auditors"><b>AUDITORS</b></a> </p>
<p>75. An auditor or auditors shall be appointed to the Chamber at each annual general meeting, when the remuneration for the 
past year's audit shall also be fixed; provided that, if so authorised by resolution of the meeting, such remuneration may be 
fixed by the Executive Committee. The auditor or auditors appointed at each annual general meeting shall hold office until the 
next annual general meeting, when he or they shall retire, but shall be eligible for re-appointment. Casual vacancies in the office 
of auditor shall be filled by the Executive Committee and any person so appointed shall hold office until the next annual general 
meeting, when he shall retire, but shall be eligible for re-appointment.<br>
<br>
</p>
<p><a name="minutes"><b>MINUTES AND RECORDS</b></a> </p>
<p>76. Minutes shall be kept of proceedings of general meetings of the Chamber and of the meetings of the Council, the 
Executive Committee and the principal committees of the Chamber, as also records of the correspondence and transactions of 
the Chamber. <br>
<br>
</p>
<p><a name="proceedings"><b>PROCEEDINGS</b></a> </p>
<p>77. All legal or other proceedings by or against the Chamber shall be instituted, conducted or defended in its name.<br>
<br>
</p>
<p><a name="property"><b>PROPERTY</b></a> </p>
<p>78. All movable property belonging to or acquired by the Chamber shall vest in the Chamber and all immovable property 
belonging to or acquired by the Chamber shall be registered in its name. <br>
<br>
</p>
<p><a name="signature"><b>SIGNATURE OF DOCUMENTS</b></a> </p>
<p>79. All powers of attorney, bonds, deeds and other similar instruments shall be signed and executed on behalf of the Chamber 
by such member or members of the Executive Committee or by such employee or employees of the Chamber as the 
Executive Committee shall decide; provided that any such instrument which may be signed and executed on behalf of the 
Chamber by a principal committee in pursuance of the powers conferred in terms of these Articles on any such principal 
committee may be signed and executed by such member or members of the principal committee concerned and by such 
employee or employees of the Chamber as the principal committee concerned shall decide. <br>
</p>
<p><a name="notices"><b>NOTICES</b></a> </p>
<p>80. Any notice, written notification or document required by these Articles to be given or sent to any member shall be deemed 
to have been given or sent if it has been delivered, by hand, at such member's registered address or has been sent through the 
post addressed to such member at the member's registered address. <br>
</p>
<p>The date on which any such notice, written notification or document is so delivered or is so posted shall be deemed to be the 
date on which it was given or sent. <br>
</p>
<p>81. The notice convening any general meeting of the Chamber shall state the date, time and place of the meeting and the 
general nature of the business to be transacted; provided that, in the case of a notice convening a special general meeting at 
which any amendment or alteration of or any addition to these Articles is to be considered, the notice shall be accompanied by 
a copy of the proposed amendment, alteration or addition.<br>
</p>
<p><a name="indemnity"><b>INDEMNITY</b></a> </p>
<p>82. Each office-bearer and employee of the Chamber shall be indemnified by the Chamber against all costs, losses and 
expenses which any such office-bearer or employee may incur or become liable to by reason of any contract entered into or 
act or deed done by him in his capacity as such or in any way in the discharge of his duties.<br>
</p>
<p><a name="articles"><b>ALTERATION OF ARTICLES</b></a> </p>
<p>83. These Articles shall not be amended, altered or added to except by resolution of a majority of not less than two-thirds of 
the representatives of ordinary members present and entitled to vote at a special general meeting of the Chamber called for 
that purpose, of which at least fourteen days' notice, in writing, has been given by the Chief Executive to each member.<br>
</p>
<p>Upon any such alteration, amendment or addition being made in terms of this Article, the same shall be deemed to be 
incorporated in and form part of these Articles, in the same manner in all respects as though originally inserted herein, and shall 
be binding upon all members of the Chamber without any further act of assent thereto, subject, however, to the provisions of 
the Labour Relations Act, No. 28 of 1956, or any law in substitution thereof. <br>
</p>
<p><a name="winding"><b>WINDING UP</b></a> </p>
<p>84. The Chamber shall be wound up if, at a special general meeting of the Chamber of which at least thirty days' notice, in 
writing, has been given by the Chief Executive to each member and at which voting has taken place by ballot, a resolution to 
wind up the Chamber has been passed by a majority of two-thirds of the representatives of ordinary members present and 
entitled to vote. Upon the passing of such a resolution, the liquidator or liquidators, who shall be appointed by the meeting, 
shall realise the assets of the Chamber, in such manner as he or they think fit, liquidate the debts and liabilities of the Chamber 
and distribute any surplus assets among the then ordinary members, proportionately to the subscriptions payable by such 
members for the financial year immediately preceding the year in which the decision to wind up the Chamber was taken; but 
subject at all times and in all respects to such directions as may be given to the liquidator or liquidators by the Chamber, in 
general meeting, either at the time the decision to wind up the Chamber is taken or thereafter. <br>
</p>
<p align=center><img src="/images/line3.gif" align=middle width=590 height=2><br>
<br>
</p>
<p align=center><a href="/org1.htm"><img src="/images/tb101.gif" alt="Organisation" align=bottom border=0 width=101 height=17></a> <a href="/res1.htm"><img src="/images/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></a> <a href="/ess1.htm"><img src="/images/tb103.gif" alt="Essentials" align=bottom border=0 width=101 height=17></a> <a href="/kruger.htm"><img src="/images/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></a> <a href="/new.htm"><img src="/images/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></a> <a href="/info.htm"><img src="/images/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></a> <br>
<br>
</p>
<hr>
<address>&#169; 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <a href="mailto:twood@bullion.org.za">twood@bullion.org.za</a> </address>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-450</DOCNO>
<DOCOLDNO>IA012-000121-B042-241</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/policy/discuss.htm 196.26.82.193 19970217004625 text/html 30239
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:48:52 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>The Chamber of Mines Policy Library</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><b><i>Policy Documents</i></b></h2>

<p align="center"><font color="#FF0000"><strong>Please Note<br
clear="all">
</strong></font><font size="2" face="Arial"><em>Copyright
subsists in this work. Any unauthorised reproduction, adaptation,
distribution or</em><em><strong><br clear="all">
</strong></em><em>commercial exploitation of the work is an act
of copyright infringement.<br>
</em></font></p>

<blockquote>
    <blockquote>
        <p><img src="purple.gif" width="14" height="14">&nbsp;<a
        href="http://www.bullion.org.za/policy/trade.htm"><strong>Trade
        and the Environment</strong></a></p>
        <p><img src="purple.gif" width="14" height="14">&nbsp;<a
        href="http://www.bullion.org.za/policy/Environment.htm"><strong>Environmental
        Policy</strong></a></p>
        <p><img src="purple.gif" width="14" height="14">&nbsp;<a
        href="http://www.bullion.org.za/policy/water.htm"><strong>Water
        Law Principles</strong></a></p>
        <p><img src="purple.gif" width="14" height="14"> <a
        href="#MINING"><strong>Mining and Minerals Policy</strong></a></p>
        <p><img src="purple.gif" width="14" height="14">&nbsp;<a
        href="/agreements/educat1.htm"><strong>Education
        Partnership Policy</strong></a></p>
        <p><img src="purple.gif" width="14" height="14">&nbsp;<a
        href="/policy/saf/saf.htm"><strong>Other Policy Documents</strong></a></p>
    </blockquote>
</blockquote>

<p>&nbsp;</p>

<hr size="4" noshade width="90%">

<p>&nbsp;</p>

<p align="center"><a name="MINING"><font color="#800080" size="6"><strong>MINING
AND MINERALS POLICY</strong></font><font color="#800080" size="4"><strong> </strong></font></a></p>
<div align="center"><center>

<table border="1" cellpadding="4">
    <tr>
        <th><a href="/policy/MINPOLICY/compol3.htm">Chamber
        Vision Statement</a></th>
        <th><a href="/policy/MINPOLICY/compol1.htm">Chamber
        Policy Document</a></th>
        <th><a href="/policy/MINPOLICY/compol2.htm">Chamber
        Submission</a></th>
    </tr>
    <tr>
        <th><a href="/policy/MINPOLICY/mpolwshp.htm"><blink>Policy
        Workshops</blink></a></th>
        <th><a href="#TRIPARTITE">Tripartite Discussion Document</a></th>
        <th><a href="#link">Other Documents</a></th>
    </tr>
</table>
</center></div>

<p align="center"><br>
</p>

<hr>

<p align="center">&nbsp;</p>

<p><strong><u>Overview of the national policy formulation process <br>
</u></strong>The discussion document<a href="#policy2"><i> (A
Minerals and Mining Policy for South Africa) </i></a>constitutes
a first step in the process of arriving at a White Paper on
mining and minerals policy. It was compiled jointly by the <a
href="http://www.polity.org.za/lists/govdepts.html#DOMEA">Department
of Mineral and Energy Affairs (DMEA) </a>and the Minerals and
Energy Policy Centre (MEPC), and was released to the general
public for comment on 15 November 1995. The document brings
together background information, perceptions, issues, arguments
and views expressed on proposals which ought to be included in
South Africa&#146;s new mining and minerals policy from four base
documents:<br>
</p>

<ul>
    <li>a discussion document prepared by the African National
        Congress, <a
        href="gopher://gopher.anc.org.za:70/00/anc/policy/minen.anc"><i>Draft
        ANC Minerals and Energy Discussion Document</i></a>
        (November 1994) </li>
    <li>a discussion document prepared by the Department of
        Mineral and Energy Affairs, <i>Principles on which a
        Minerals and Mining Policy Should Be Based</i> (November
        1994) </li>
    <li>a document prepared by the Chamber of Mines, <a
        href="http://www.bullion.org.za/policy/compol1.htm"><i>Mining
        and Minerals Policy in the New South Africa</i></a> (June
        1995) </li>
    <li>a document prepared by the National Union of Mineworkers, <a
        href="http://www.anc.org.za/num/mining.html"><i>Mining
        and Minerals Policy for a Non-discriminatory, Efficient
        and Prosperous Mining Industry in South Africa</i></a> (August
        1995). </li>
</ul>

<p>The discussion document makes no attempt at placing any of the
views expressed in context, seeking merely to list a range of divergent
and often opposing statements under a series of policy headings.</p>

<p>Submissions have been invited from interested parties on
specific points, or alternatively, such parties may wish to
prepare a statement encapsulating their vision of a minerals and
mining policy for South Africa. The deadline for comment is 15
January 1996. Interested parties are referred to pages 8 and 9 of
the document for details on how to make their submissions.</p>

<p>Responses from the public to the discussion document, together
with a series of open workshops around identified themes to be
held during April and May 1996, will inform the contents of a Green Paper
outlining a broad policy for minerals and mining in South Africa.
It is anticipated that this will be published towards the end of
July. Parliamentary hearings on the contents of the Green Paper
are expected to take place during August, and a White Paper
published in October.<br>
</p>

<hr size="6" noshade width="550">

<h2 align="center"><a name="TRIPARTITE">TRIPARTITE DISCUSSION
DOCUMENT</a></h2>

<h2 align="center">A Minerals and Mining Policy for South Africa</h2>

<p align="center"><font color="#FF0000"><strong><blink>Please
Note</blink></strong><strong><br>
</strong></font><i>This is an abridged version of the discussion
document</i>.</p>

<h4 align="center">An unabridged version is available on the <a
href="http://www.polity.org.za/govdocs/discuss/minen.html"><b>GNU
Web Site</b></a></h4>
<div align="center"><center>

<table border="0" cellspacing="18" width="550">
    <tr>
        <td align="center" valign="top" width="250"><hr noshade
        width="250">
        <p><img src="save.gif" width="16" height="16"><a
        href="http://www.bullion.org.za/policy/dmeapol.txt"><b>DOWNLOAD</b></a><img
        src="save.gif" width="16" height="16"> <br>
        <i>A Minerals and Mining Policy</i><b><i><br>
        </i></b><i>for South Africa</i><b><i><br>
        </i></b><font size="2"><tt>(.TXT 220k)</tt></font><tt> <br>
        </tt></p>
        <hr noshade width="250">
        </td>
        <td align="center" valign="top" width="250"><hr noshade
        width="250">
        <p><img src="green.gif" width="14" height="14"><a
        href="#CONTENTS"><b>CONTENTS</b></a><img src="green.gif"
        width="14" height="14"><br>
        <i>A Minerals and Mining Policy</i><b><i><br>
        </i></b><i>for South Africa</i><b><i><br>
        </i></b><font size="2"><tt>Abridged Text</tt></font><tt> <br>
        </tt></p>
        <hr noshade width="250">
        </td>
    </tr>
</table>
</center></div>

<h4 align="center"><a name="Related">Related</a> Documents</h4>

<ul>
    <li>Chamber of Mines, <a href="/policy/MINPOLICY/compol3.htm"><i>Vision
        Statement</i></a> (February 1996) </li>
    <li>Chamber of Mines, <a href="/policy/MINPOLICY/compol1.htm"><i>Mining
        and Minerals Policy in the New South Africa</i></a> (June
        1995) </li>
    <li>National Union of Mineworkers, <a
        href="http://www.anc.org.za/num/minpolb.html%22"><i>Vision
        Statement</i></a> (February 1996) </li>
    <li>National Union of Mineworkers, <a
        href="http://www.anc.org.za/num/mining.html"><i>Mining
        and Minerals Policy for a Non-discriminatory, Efficient
        and Prosperous Mining Industry in South Africa</i></a>
        (August 1995). </li>
    <li>African National Congress, <a
        href="gopher://gopher.anc.org.za:70/00/anc/policy/minen.anc"><i>Draft
        ANC Minerals and Energy Discussion Document</i></a> (November
        1994) </li>
</ul>

<p>&nbsp;</p>

<p align="center"><a
href="http://www.bullion.org.za/policy/main.htm"><img
src="nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="nb2.gif" alt="Top of Page" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#toolbar"><img
src="nb3.gif" alt="Toolbar" align="middle" border="0" hspace="20"
width="80" height="17"></a> <br>
</p>

<h4 align="center"><a name="CONTENTS"><font color="#008000"
size="4">CONTENTS<br>
</font></a><font size="3" face="Arial">A Minerals and Mining
Policy for South Africa</font></h4>

<p align="center"><i>November 1995</i><br>
<img src="wd1.gif" align="middle" width="32" height="31"><br>
</p>

<ul>
    <li><a href="#PREAMBLE"><b>Preamble</b></a> </li>
    <li><a href="#MINERALPOLICYPROCESS "><b>Mineral policy
        process</b> </a></li>
    <li><a href="#WHITEPAPER"><b>How to make a submission</b></a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss2.htm#intro"><b>Introduction</b></a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss2.htm#climate">1.
        Business climate </a><ul>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#depart"><i>1.1
                points of departure</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#investreg"><i>1.2
                investment and regulatory environment</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#tax"><i>1.3
                taxation</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#elec"><i>1.4
                electricity</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#trans"><i>1.5
                transport</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#compet"><i>1.6
                competition</i></a> </li>
        </ul>
    </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss2.htm#access">2.
        Access and ownership</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss2.htm#resource">3.
        Resource management</a> <ul>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#minrights"><i>3.1
                mineral rights</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss2.htm#tenure"><i>3.2
                security of tenure</i></a> </li>
        </ul>
    </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss3.htm#explore">4.
        Exploration</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss3.htm#environ">5.
        Environmental management</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss3.htm#small">6.
        Small-scale mining and mineral development</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss3.htm#exploit">7.
        Exploitation</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss3.htm#down">8.
        Downscaling</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss3.htm#safety">9.
        Mining safety and health</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss4.htm#resource">10.
        Human resources </a><ul>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#develop"><i>10.1
                human resource development</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#housing"><i>10.2
                housing and living conditions</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#migrant"><i>10.3
                migrant labour</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#ir"><i>10.4
                industrial relations and employment conditions</i></a> </li>
        </ul>
    </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss4.htm#benfic">11.
        Mineral beneficiation</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss4.htm#market">12.
        Mineral marketing</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss4.htm#research">13.
        Research and development</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss4.htm#regional">14.
        Regionalisation and internationalisation</a> </li>
    <li><a
        href="http://www.bullion.org.za/policy/discuss4.htm#govern">15.
        Governance </a><ul>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#promo"><i>15.1
                Management and promotion</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#auth"><i>15.2
                National, provincial and local authority</i></a> </li>
            <li><a
                href="http://www.bullion.org.za/policy/discuss4.htm#stake"><i>15.3
                Stakeholder consultation</i></a> </li>
        </ul>
    </li>
</ul>

<p><br>
</p>

<p align="center"><a
href="http://www.bullion.org.za/policy/main.htm"><img
src="nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="nb2.gif" alt="Top of Page" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#toolbar"><img
src="nb3.gif" alt="Toolbar" align="middle" border="0" hspace="20"
width="80" height="17"></a> <br>
<br>
</p>

<hr size="6" noshade width="600">

<h4 align="center"><img src="wd1.gif" align="middle" width="32"
height="31"><br>
A Minerals and Mining Policy for South Africa </h4>

<h4 align="center"><font color="#FF0000" size="6">Tripartite
Discussion Document</font></h4>

<h5 align="center"><i>November 1995</i></h5>

<p align="center"><img src="linegr.gif" align="middle"
width="402" height="5"><br>
</p>

<p><a name="PREAMBLE"><b>PREAMBLE</b></a></p>

<p>South Africa's mining industry is facing major challenges as
it prepares to enter the twenty-first century. Supported by an extensive
and diversified resource base, the mineral industry has since its inception
been a cornerstone of South Africa's economy. To continue playing
its rightful role in the reconstruction and development of the
country, the industry must be developed, optimised and sustained,
especially in earning foreign exchange, creating jobs, and acting
as a base for further industrial development.</p>

<p>This initiative aims to create a dynamic process to address
the present and future challenges to the industry. It further proposes
to bring about change within the context of a dedication to partnerships, social
commitment, and environmental responsibility. It aims to seek a
prosperous and enduring mining industry within the framework of
an evolving and sustainable South African society.</p>

<p>The problems confronting the South African industry are many
and varied. In the gold sector, where the price has remained static
for a long time, a number of mines are nearing the end of their working lives
and are having to contend with rising operation costs, increasing
depths and actual or potential retrenchments. The industry as a
whole is responding to the far-reaching recommendations of the Leon
Commission on Health and Safety, as well as adapting in all areas of socio-economic
life to the country&#146;s new policy and institutional
environment. Environmental pressures are becoming increasingly
potent in respect of individual mining projects, with prospectively
direct implications for cost. Externally, there is increasing
competition, both in commodity markets and for investment, from
countries that have significantly lower cost structures and that
arguably are ahead of South Africa in terms of economic reform.</p>

<p>The overall picture is far from gloomy, however. South Africa
remains by far the largest producer (and holder of reserves) of many
of the world's principal minerals. There are, even in the
troubled gold sector, major new capital projects being implemented.
Further, fresh approaches to the organisation of work, including
but not confined to the introduction of so-called &quot;full
calendar operations&quot;, offer the prospect of major advances
in the utilisation of labour and capital; if realised, such improvements
could transform the outlook for the gold mines. In addition,
certain sectors - notably coal, ferro-alloys and some base metals
- are currently enjoying very favourable world market conditions,
which are enabling the companies to commit to sizeable investment programmes and
to position themselves well in relation to future price
fluctuations.</p>

<p>Against this complex background, the industry's principal
stakeholders - Government, business and labour - have concluded that
a consultative and non-adversarial process is needed to develop a strategic
vision and policy framework for the industry to take it into the
next century.</p>

<p>It is the intention, through this document, to provide
information and to stimulate debate on a mining and minerals
policy for South Africa in a process that is transparent and
accessible to all stakeholders in the mineral industry. In this
regard, ample opportunity will be given for participation through
public and plenary meetings, bilateral discussions, workshops,
and by means of written comment.<br>
</p>

<p><a name="MINERALPOLICYPROCESS "><b>MINERAL POLICY PROCESS </b></a></p>

<p align="center">[<a href="#background">background</a>] [<a
href="#reportback">report back</a>] [<a href="#pubcons">public
consultation</a>] [<a href="#working">working group</a>]<br>
[<a href="#steering">steering committee</a>] [<a href="#pubmeet">plenary</a>]
[<a href="#role">role of steering committee</a>] [<a href="#pub">public
meeting</a>] </p>

<p><a name="BACKGROUND"><em>1. BACKGROUND</em></a></p>

<p>South Africa's mineral industry is operating in a dynamic
milieu which necessitates adapting the country's mineral policy
in order to cope with changing circumstances, not least being
those in the country's political and social dimensions. With a
view to arriving at consensus over a process to re-evaluate South
Africa's mineral policy, Minister R F Botha, Minister of Mineral and
Energy Affairs, convened a plenary of stakeholders in the mining
industry on 24 April 1995.The meeting appointed a Working Group
to investigate the alternatives and to make appropriate recommendations.</p>

<p>The Working Group comprised of two representatives from each
of the following constituencies: Mining business, organised labour,
the Department of Mineral and Energy Affairs and the Parliamentary
Portfolio Committee on Mineral and Energy Affairs.
NEDLACdeclinedto participate in the Working Group, but the Trade
and Industry Chamber of the Council took the view that the draft
policy document should be tabled with NEDLAC.</p>

<p>The Working Group had the following mandate:</p>

<p>To work out a mechanism and the time-frame whereby minerals
policy formulation can proceed urgently, by means of an open and
transparent process, allowing for full participation by all stakeholders.To
report back to the full meeting of the stakeholders on the
proposed mechanism.<br>
</p>

<p>The Mineral and Energy Policy Centre (MEPC) acted as a
secretariat to the Working Group, which met on eight occasions.</p>

<p><a name="STAKEHOLDERS">2.1 REPORT BACK TO DIRECT STAKEHOLDERS<br>
</a>The process recommendations should be reported to the direct
stakeholders (Government, labour, business) in the mining industry.<br>
</p>

<p><a name="CONSULTATION">2.2 PUBLIC CONSULTATION ABOUT THE
PROCESS<br>
</a>Once the direct stake holders have given their approval, a
public meeting will be convened (via media advertising as well as by
direct invitation, where feasible) for presentation of the
process recommendations. The meeting should be chaired by the Minister
of Mineral and Energy Affairs.<br>
</p>

<p>The Working Group will, in the light of the public meeting,
formulate final proposals for the policy development process.<br>
</p>

<p>2.3 <a name="WORKING">WORKING</a> GROUP<br>
The Working Group should be dissolved as soon as the Steering
Committee (see below) comes into being.<br>
</p>

<p>2.4 CREATION OF A <a name="STEERING">STEERING</a> COMMITTEE<br>
2.4.1 A Steering Committee should be established to finalise and
oversee implementation of the Working Group's proposals.<br>
</p>

<p>The Steering Committee should be a tripartite committee
comprising representatives of business, labour and Government (from
both the legislative and executive branches). The number of representatives,
to be appointed by their respective constituencies, should be:<br>
Minimum / Maximum<br>
* Mining Business 2 / 4<br>
* Organised labour 2 / 4<br>
* DMEA 2 / 4<br>
* Parliamentary portfolio committee 2 / 4<br>
</p>

<p>2.4.2 Decision making: The Steering Committee will seek
consensus. Where this is not achieved, the guideline should be
that the differing views are recorded and to go forward to the
next step. This guideline is not applicable to the White Paper
which is Government's responsibility.<br>
</p>

<p>2.4.3 The Chairman of the Steering Committee should be drawn
from Government.<br>
</p>

<p>2.5 PUBLIC <a name="MEETING/PLENARY">MEETING/PLENARY</a> OF
STAKEHOLDERS<br>
</p>

<p>2.5.1 At the public meeting, the Minister as chairman will
seek broad consensus on the formation of a public forum which
will represent all interested and affected parties to the
process.committee<br>
</p>

<p>The forum contemplated may take the form of a public meeting
or a representative plenary of direct stakeholders and all other interested
parties.committee<br>
</p>

<p>2.5.2 Meetings of this forum will be convened at appropriate
intervals. The Steering Committee will report back to the forum for
the purpose of:committee<br>
* keeping all parties informed of progress;<br>
* soliciting the views of all parties;<br>
* seeking broad endorsement of policy proposals.<br>
</p>

<p>2.6 <a name="ROLE">ROLE</a> OF THE STEERING COMMITTEE<br>
</p>

<p>2.6.1 The Steering Committee will take receipt of a chopping
block document, which will be jointly prepared by the DMEA and
the MEPC. It will be based on the DMEA policy principles document (November
1994);the ANC draft mineral and energy policy discussion document (November1994);and
the industry (June 1995), National Union of Mineworkers (August1995) and other
responses to these documents.<br>
</p>

<p>This document will have the following characteristics:<br>
</p>

<p>i)The Drafting Committee will have some licence in identifying
the key themes, in a way which makes intellectual sense, based on
the source documents noted earlier.<br>
</p>

<p>ii) Where feasible, the format will follow that of a White
Paper. Accordingly, where principles are agreed, it will be
possible to draft policy guidelines. But where there are
materially different views, these will be set out.<br>
</p>

<p>iii) It will concern itself with principles but will include
sufficient detail to substantiate the positions presented.<br>
</p>

<p>iv) The target date for production of the initial document by
the drafting committee is end-August 1995.<br>
</p>

<p>v)The Steering Committee will be responsible for revising the
chopping block document to a point where it is suitable for public
discussion.<br>
</p>

<p>2.6.2 The Steering Committee will manage the Working Group's
plan to take the process forward to a Green Paper by the target
date of end July 1996.This plan will include soliciting the views
of interested and affected parties as set out in the accompanying
document Proposed Process for Preparation of a Minerals and
Mining White Paper.<br>
</p>

<p>3. <a href="#pub" name="PUBLICMEETING">PUBLIC MEETING</a><br>
</p>

<p>At the public meeting on the mineral policy process held on 29
September 1995, chaired by Minister R F Botha, the stakeholders
present endorsed the measures proposed by the Working Group, but
made an appeal to the Steering Committee to attempt to shorten
the process.<br>
</p>

<p><a name="WHITEPAPER"><strong>PROCESS FOR PREPARATION OF A
MINERALS AND MINING WHITE PAPER<br>
</strong></a><a name="WHITEPAPER"></a></p>

<p>HOW TO MAKE A <a name="SUBMISSION">SUBMISSION</a> FOR THE
GREEN PAPER ON A MINERALS AND MINING POLICY FOR SOUTH AFRICA<br>
</p>

<p align="center">[<a href="#BASICINFORMATION">basic information</a>]
[<a href="#VISION">option 1</a>] [<a href="#option2">option 2</a>]
[<a href="#DEADLINE">submission deadline</a>]<br>
</p>

<p align="left">Individuals and organisations wishing to make a
submission to the mineral policy process are invited to do so.
Please follow the format set out below, as this will make it
easier to process the comments. Submissions do not have to
include both options.<br>
</p>

<p><a name="BASICINFORMATION">1. BASIC INFORMATION<br>
</a></p>

<p>Name<br>
Title (position)<br>
Company or Organisation<br>
Postal address<br>
Telephone number<br>
Fax number<br>
</p>

<p><a name="VISION">2. OPTION 1: STATEMENT OF A VISION FOR THE
MINERALS AND MINING POLICY<br>
</a></p>

<p>Interested parties are invited to prepare a statement
encapsulating their vision of a minerals and mining policy for
South Africa. This statement may include an appraisal of
problems; fundamental principles on which to base policy;
mechanisms to implement policy; goals for minerals and mining policy;
goals for the minerals and mining industry; or targets for
successful policy results. The length of this statement may not
exceed 1200 words.</p>

<p>It is envisaged that these statements of vision for a minerals
and mining policy for South Africa will afford interested parties
an opportunity to present the key issues and solutions as they
see them. Similarly, it will afford all concerned an opportunity
to learn how others approach the matter and so contribute to
developing a common strategic vision among all stakeholders.</p>

<p>All such submissions will be circulated unabridged in a
separate volume to supplement this discussion document.</p>

<p>Statements of vision should include the name of the party
making the submission and be separate from other comments made in
their submission.</p>

<p><a name="OPTION2">3. OPTION 2: COMMENT ON THE DISCUSSION
DOCUMENT</a></p>

<p>Interested parties are invited to make submissions on specific
points contained in the points of departure; background information
and perceptions; issues and arguments; and policy proposals - views
expressed, supporting, disagreeing, or proposing additional
issues for consideration. Submissions should clearly refer to the
number of the point and section concerned. In addition to expressing
a motivated opinion, suggested new or additional wording for the
specific point would be valuable. Submissions on mineral policy
issues not covered in the Discussion Document are also welcome.<br>
</p>

<p>Submissions on specific points should, therefore, be formatted
thus:<br>
</p>

<p>Section number:<br>
Motivated comment:<br>
Suggested new wording:<br>
</p>

<p>4. <a name="DEADLINE">DEADLINE</a> FOR SUBMISSIONS<br>
</p>

<p>All submissions should be made by 30 January 1996. Post or fax
these to the following address:<br>
</p>

<blockquote>
    <p>Mineral Policy Discussion Document<br>
    Private Bag X4<br>
    Braamfontein<br>
    2017<br>
    </p>
    <p>Fax: (011) 403 2061<br>
    E-mail: <a href="mailto:submit@polity.org.za">submit@polity.org.za</a> </p>
</blockquote>

<p>Enquiries can be addressed to:<br>
</p>

<blockquote>
    <p>The Director<br>
    Minerals Bureau<br>
    Tel: (011) 339 4414<br>
    </p>
</blockquote>

<p align="center"><a
href="http://www.bullion.org.za/policy/main.htm"><img
src="nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="nb2.gif" alt="Top of Page" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#toolbar"><img
src="nb3.gif" alt="Toolbar" align="middle" border="0" hspace="20"
width="80" height="17"></a> </p>

<p align="center"><br>
<br>
<a href="/org1.htm"><img alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
alt="Resources" border="0" width="101" height="17"></a> <a
href="/kruger.htm"><img alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img alt="What's New?"
border="0" width="101" height="17"></a> <a href="/info.htm"><img
alt="Contacting us" border="0" width="101" height="17"></a> <br>
</p>

<hr>

<address>
    <font size="2"> 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-451</DOCNO>
<DOCOLDNO>IA012-000121-B043-41</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/releases.htm 196.26.82.193 19970217004715 text/html 23216
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:50:32 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa: Press Releases</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="../images/LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><b><i>Press Releases</i></b></h2>
<div align="center"><center>

<table border="1" cellpadding="2" width="80%">
    <tr>
        <td align="center" colspan="5" bgcolor="#ECECEC"><font
        color="#0000A0" face="Arial"><strong>Unless otherwise
        stated, all Releases are issued by:<br>
        </strong></font><a href="mailto:lkriel@bullion.org.za"><font
        color="#0000A0" face="Arial"><strong>Llewellyn Kriel</strong></font></a><font
        color="#0000A0" face="Arial"><strong>, Communication
        Manager: Media<br>
        </strong><em><strong>For further information, please
        call:</strong></em></font></td>
    </tr>
    <tr>
        <th><font color="#EA0000" size="2" face="Arial"><strong>Telephone</strong>:<br>
        +27 11<br>
        498-7316 [W]</font></th>
        <th><font color="#EA0000" size="2" face="Arial"><strong>Telephone</strong>:<br>
        +27 11<br>
        807-6193 [H]</font></th>
        <th><font color="#EA0000" size="2" face="Arial">Pager: <br>
        +27 11<br>
        650-5050 Code: LK25</font></th>
        <th><font color="#EA0000" size="2" face="Arial">Fax:<br>
        +27 11<br>
        838-4251</font></th>
        <th><font color="#EA0000" size="2" face="Arial">E-Mail:<br>
        </font><a href="mailto:lkriel@bullion.org.za"><font
        color="#EA0000" size="2" face="Arial">lkriel@bullion.org.za</font></a></th>
    </tr>
</table>
</center></div>

<ul>
     <li><a href="1997/comnum97.htm"><font size="3">Joint Media Statement by the National Union of Mineworkers and the
       Chamber of Mines on their Agreement Relating to the new Mine Health & Safety Act</font></a><font size="3"> (9 
       January 1997)</font></li>
     <li><a href="deplabor.htm"><font size="3">Chamber President
        responds to a negative report on conditions in the SA mining industry
        issued by the Department of Labour</font></a><font
        size="3"> (19 December 1996)</font></li>
    <li><a href="1996address_3.htm"><font size="3">Chamber
        Restructured to Meet Mining's Advocacy Needs</font></a><font
        size="3"> (5 November 1996)</font></li>
    <li><a href="1996address_2.htm"><font size="3">Chamber
        President Confident Despite Some Mining Sector Woes</font></a><font
        size="3"> (5 November 1996)</font></li>
    <li><a href="1996address.htm"><font size="3">Press Release:
        Chamber Aims to Face Challenges Constructively &amp;
        Transparently</font></a><font size="3"> (5 November 1996)</font></li>
    <li><a href="/releases/myburgh2.htm">Chamber supports wider
        probe into mine violence<font size="3"> <em>(14 October
        1996)</em></font></a></li>
    <li><a href="/releases/krugrnew.htm">Krugerrand readies for
        end of exchange controls<font size="3"> <em>(11 October
        1996)</em></font></a></li>
    <li><a href="/releases/wages96.htm">Chamber &amp; NUM sign
        1996/97 Wage Agreement<font size="3"> <em>(11 September
        1996)</em></font></a></li>
    <li><a href="dsput96.htm">NUM Declares Wage Dispute with
        Chamber on Wage Negotiations<i> (2 August 1996)</i></a> </li>
    <li><a href="constit1.htm">Chamber Comment on the Omission of
        the Lockout Clause <i>(9 May 1996)</i></a> </li>
    <li><a href="unctad.htm">Margin for error greatly reduced
        says Chamber CEO<i> (2 May 1996)</i></a> </li>
    <li><a href="krparis.htm">Krugerrand launched on Paris Bourse<i>
        (26 April 1996)</i></a> </li>
    <li><a href="nostrike.htm">Cosatu's strike call shows
        preference for threat over negotiation<i> (25 April 1996)</i></a> </li>
    <li><a href="fincttee.htm">Chamber critical of 96/97 Budget<i>
        (20 March 1996)</i></a> </li>
    <li><a href="96budcom.htm">Chamber reaction to the budget<i>
        (14 March 1996)</i></a> </li>
    <li><a href="safebill.htm">Chamber submission on draft Mine
        Health &amp; Safety Bill<i> (10 March 1996)</i></a> </li>
    <li><a href="mdbaparl.htm">Chamber welcomes Mandela's
        &quot;restructure&quot; call <i>(12 Feb. 1996)</i></a> </li>
    <li><a href="petlsign.htm">Chamber &amp; NUM sign PETL
        agreement <i>(8 Feb. 1996)</i></a> </li>
    <li><a href="nrsgrad1.htm">Nurse Clinicians gain 29
        distinctions <i>(12 Dec. 1995)</i></a> </li>
    <li><a href="#flexibility">Chamber President calls for
        flexibility <i>(28 Nov. 1995)</i> </a></li>
    <li><a href="#Information">Chamber of Mines on the Net <i>(22
        Nov. 1995)</i> </a></li>
    <li><a href="#petrol">Petrol Levy could threaten mining
        industry<i> (20 Nov. 1995)</i> </a></li>
    <li><a href="#crime">Chamber President says &quot;Stop
        Crime&quot; after payroll heist<i> (20 Nov. 1995)</i> </a></li>
    <li><a href="#munro95">Presidential address to 105th AGM <i>(7
        Nov. 1995)</i></a> </li>
    <li><a href="/speeches/stateof.htm">Chamber CE outlines state
        of SA mining industry<i> (6 Oct. 1995) </i></a></li>
</ul>

<p>&nbsp;</p>

<p align="center"><a href="/org1.htm"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
<br>
</p>

<address>
    <font size="2"> 1995, 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Llewellyn D. Kriel, Communication Manager :
    Media : </font><a href="mailto:lkriel@bullion.org.za"><font
    size="2">lkriel@bullion.org.za</font></a><font size="2"> </font>
</address>

<p>&nbsp;</p>

<p>&nbsp;</p>

<h3 align="center">Chamber president calls for <a
name="flexibility">flexibility</a> in formulating new mining dispensation
in SA </h3>

<p>PRESIDENT OF THE CHAMBER of Mines, At du Plessis, has urged
groups involved in tri-partite discussions on the future of
mining in SA to exercise flexibility and compromise and not &quot;enter
discussions with immovable or fixed positions&quot;.<br>
</p>

<p>Opening the <a href="dupcon95.htm">1995 Mine Safety and Health
Congress</a>, the quadrennial event recognised as the foremost
health and safety in mines congress in the country, Du Plessis
said it was time to adopt a problem-solving attitude &quot;to
ensure we end up with effective, practical and implementable laws that will
... prevent accidents and injuries without closing down our
business&quot;.<br>
</p>

<p>&quot;Since the last Safety and Health Congress, events in our
industry have attracted the attention of the country and the international
world,&quot; he told the more than 500 delegates to the congress
in Pretoria. &quot;The underground explosion at Middelbult coal
mine, and the horrendous accident at Vaal Reefs are tragedies
that the mining industry will never forget. However, there was
also the incident at Kloof gold mine where every one of over 100
trapped workers was taken to safety - surely one of the most
successful rescues in our country's history.&quot;<br>
</p>

<p>He said this &quot;clearly demonstrated that, though accidents
do happen, there are certainly more events that largely go unheralded
and ignored by the media.&quot;<br>
</p>

<p>Du Plessis said he regarded research and development as
critical for the future of mining. &quot;I ask myself if we have
paid sufficient attention to research and development in the
past. My view is &quot;No&quot;, but I look to our academics and
the Safety In Mines Research Advisory Committee (SIMRAC), and
challenge them not to measure their progress in the number of intellectual
reports generated, but rather in the successful implementation of
research findings.<br>
</p>

<p>&quot;Change is upon us, and if we do not adapt to the altered
circumstances, we will flounder and fail,&quot; he warned.<br>
</p>

<p>He added that Adult Basic Education had now become a
requirement on mines. It was no longer acceptable that managements
unilaterally lay down safety and health guidelines. Safety and
health committees had to be established and guidelines drawn up
with full involvement of workers.<br>
</p>

<p>&quot;Changes will, however, not succeed unless messages are
properly conveyed. This makes the education and training of our work-force
of paramount importance if we are to hope to improve our accident
rates. Understanding will bring comprehension and this will
prevent people from taking short cuts and ignoring instructions.<br>
</p>

<p>&quot;There is nothing stopping us from integrating safety
into our production systems to an even greater degree, neither is
there anything preventing us from creating small, focused,
empowered work-teams to tackle complex issues,&quot; Du Plessis
concluded.<br>
</p>

<p align="center"><a href="/main.htm"><img src="/nb1.gif"
alt="Main Menu" align="middle" border="0" hspace="20"></a> <a
href="#top"><img src="/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20"></a> <a href="#toolbar"><img
src="/nb3.gif" alt="Toolbar" align="middle" border="0"
hspace="20"></a> <br>
<br>
</p>

<h3 align="center">Chamber of Mines joins the <a
name="Information">Information</a> Superhighway </h3>

<p>IN A VIGOROUS attempt to provide easily accessible,
comprehensive, credible and useful information on South Africa's mining
industry, the Chamber of Mines has joined the Internet global information
highway.<br>
</p>

<p>The Chamber's homepage is located at <i>http://www.bullion.org.za</i>
and is already attracting global attention from mining analysts,
international news media, businesses, researchers, students,
tourists planning to visit SA and a host of casual visitors.<br>
</p>

<p>The 106-year-old organisation, whose members represent the
bulk of SA's private-sector mining interests, aims to provide topical
and useful information to make the industry more accessible.<br>
</p>

<p>&quot;Too many skewed or false perceptions exist about the
mining industry in South Africa, and we hope this service will contribute
to correcting these misconceptions, while providing comprehensive, up-to-date
and trustworthy information to everyone from the professional to
the casual enquirer,&quot; says Chris Westinghouse, the Chamber's
Communication Manager : Planning.<br>
</p>

<p>He says the WEB site is &quot;deliberately designed as a
public service, high on topical information, but low on `Wow!'
appeal - however, we intend keeping it lively and useful&quot;.
It is anticipated the major mining houses will soon be following
suit.<br>
</p>

<p>Visitors to the Chamber's homepage can now access:<br>
* Policy documents<br>
* Recent Press releases<br>
* Important speeches &amp; presentations<br>
* Information on mine visits<br>
* Gold production figures<br>
* Daily mining news<br>
* Daily economic indicators<br>
* A small image library<br>
* Mining-related WEBlinks<br>
* The Chamber's E-Mail directory<br>
* Information on Chamber members and associates<br>
* Information on the Chamber's management and core services<br>
</p>

<p>With the exception of one publication, <i>In Session</i>, the
Chamber's information is free of charge. &quot;We will be growing considerably
in the next few months and have some cutting-edge ideas in the pipeline,&quot;
says Westinghouse.<br>
</p>

<p align="center"><a href="/main.htm"><img src="/nb1.gif"
alt="Main Menu" align="middle" border="0" hspace="20"></a> <a
href="#top"><img src="/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20"></a> <a href="#toolbar"><img
src="/nb3.gif" alt="Toolbar" align="middle" border="0"
hspace="20"></a> <br>
<br>
</p>

<h3 align="center">Chamber warns 3c/l <a name="petrol">petrol</a>
levy could further<br>
threaten beleaguered mining industry </h3>

<p>THE CHAMBER OF MINES has warned that the proposed 3c/litre
petrol levy could further jeopardise prospects for South Africa's
embattled gold mining industry, have serious effects on the country's
GDP and send the wrong signals to potential foreign investors.<br>
</p>

<p>Chamber president At du Plessis said yesterday the Chamber was
opposed, in principle, to any forms of taxation, levies or imposts
on input costs that force operating costs of gold and coal mines up
and could lead to sterilising gold ore underground. This would
have the effect of jeopardising even more jobs, because the gold
industry cannot pass on working cost increases to the final consumer,
since the gold price is set on international markets.<br>
</p>

<p>&quot;This has serious negative consequences for employment,
Gross Domestic Product, foreign exchange earnings and the South African
economy in general. Minerals below the earth's surface do not
represent mineral wealth unless they can be profitably mined,&quot;
Du Plessis says.<br>
</p>

<p>&quot;Furthermore,&quot; he said, &quot;the Chamber of Mines
is opposed to the use of taxation, levies or imposts on input
costs for cross- subsidy purposes.&quot; The majority of vehicles
used by mines operate on private premises, not on public roads.
&quot;The use of this levy to cross-subsidise other users is inappropriate
and adds to working cost on mines.&quot;<br>
</p>

<p>&quot;The Chamber is also opposed to this kind of sudden
imposition of ad hoc levies which create uncertainty and
discourage investment. The Minister of Transport should focus on
the effective restructuring of the MMVA fund to be more cost effective,
rather than short-term raising of levies to temporarily roll-over
the mismanagement of the MMVA fund,&quot; Du Plessis said.<br>
</p>

<p align="center"><a href="/main.htm"><img src="/nb1.gif"
alt="Main Menu" align="middle" border="0" hspace="20"></a> <a
href="#top"><img src="/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20"></a> <a href="#toolbar"><img
src="/nb3.gif" alt="Toolbar" align="middle" border="0"
hspace="20"></a> <br>
<br>
</p>

<h3 align="center">Chamber President calls on government <br>
to stop <a name="crime">crime</a> following R1-m payroll heist</h3>

<p>CHAMBER OF MINES President At du Plessis has called on
government to take &quot;urgent, immediate and firm steps&quot;
to curb escalating crime following a R1-million hold-up of a mine payroll on
the East Rand.<br>
</p>

<p>Armed robbers last week held up an armoured car carrying more
than R1-million in miners' wages at a TEBA Savings pay point at
Leslie Mine. No-one was injured in the attack.<br>
</p>

<p>Du Plessis said that even the highly skilled security forces
employed by the mining industry were hard-pressed when confronted
by well-organised gangs armed with semi- automatic weapons. He said
that the 14 attempted robberies the industry had experienced this
year to date - of which four were successful - amounted to a 180%
increase on the 1994 statistics.<br>
</p>

<p>&quot;The mining industry is currently upgrading its internal
security measures , but incidents such as these are fast becoming
a way of life, rather than the exception. South Africa cannot
afford such rampant lawlessness. Unless something is done, and
done quickly by the Government, the reputation the country is
fast gaining as the `crime capital of the world' will be
justifiably earned,&quot; Du Plessis concluded.<br>
</p>

<p align="center"><a href="/main.htm"><img src="/nb1.gif"
alt="Main Menu" align="middle" border="0" hspace="20"></a> <a
href="#top"><img src="/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20"></a> <a href="#toolbar"><img
src="/nb3.gif" alt="Toolbar" align="middle" border="0"
hspace="20"></a> <br>
<br>
</p>

<h3 align="center">Translate <a name="democratic">democratic</a>
transition into economic success:<br>
Chamber president </h3>

<p>SOUTH AFRICA needs to show it has successfully eclipsed the
transition to democracy and translate into economic success the
&quot;euphoria and disruption which accompanied that momentous event&quot;,
outgoing Chamber of Mines president Alan Munro told the
organisation's <a href="speech.htm#top">105th Annual General
Meeting </a>in Johannesburg today.<br>
</p>

<p>He said the mining industry was &quot;the primary component of
the country's economic and wealth creation matrix&quot;, but it
could only fulfil its destiny, &quot;by increasing levels of
profitability and ensuring - specifically insofar as gold mining
is concerned - that costs are not elevated to the extent that valuable
deposits of gold are sterilised underground because their
extraction is not commercially viable&quot;.<br>
</p>

<p>Citing a recent survey of some of the world's top investment
fund managers, Munro said it had revealed that investment opportunities
in SA are currently not favoured. Instead investment is going to
Taiwan, Brazil, China, India and South Korea.<br>
</p>

<p>He said, the managers were concerned about SA's high labour
costs relative to productivity, and the unacceptable levels of civil
disorder reflected in ongoing and seemingly unstoppable violent crime, combined
with all-too frequent industrial action, which persuade investors
not to &quot;take the plunge in SA&quot;.<br>
</p>

<p>&quot;Achievement of acceptable levels of return in the mining
industry is going to require the development of new
understandings with employees and other important stakeholders. Productivity enhancement
measures like full calendar operations will not be completely
successful unless they go hand in hand with a realisation that
increased individual prosperity cannot be separated from increased
individual output,&quot; Munro told the meeting.<br>
</p>

<p>&quot;The confrontational employer/employee relationships of
the past need to be replaced by more co-operative partnerships which
have as their primary purpose the maximisation of industry growth and
profitability. The partnership will never totally eliminate
conflict between labour and capital. That would be abnormal. <br>
</p>

<p>&quot;What it should attempt to achieve however, is an
eradication of the ideological and racial divisions that have
bedevilled relationships in the mining industry for far too long.
Those conflicts are a feature of yesterday's debate. Today's
dynamic demands a different agenda. It requires an environment - untainted
by political difference - in which there is acceptance that diligent workplace
commitment is the only certain itinerary for personal and
national prosperity,&quot; said Munro.<br>
</p>

<p>Echoing a recent nation-wide call by President Nelson Mandela
following the local government elections, that South Africans should
&quot;all get down to work!&quot;, Munro added, &quot;South
Africa's celebrated transition to democracy has yet fully to
deliver the anticipated surge in industrial and commercial
prosperity&quot;.<br>
</p>

<p>Focusing on government's role in creating an environment
conducive to building prosperity, Munro said it &quot;must accept
the mining industry for what it truly is: a priceless national
asset which, far from some suggestions that it is moribund, still possesses
vast potential to enrich South Africa and all its people&quot;.<br>
</p>

<p>It was vital, he added, that all mining industry stakeholders
&quot;understand the principle that minerals in the ground do not constitute
wealth. Wealth is only generated when they are extracted, refined and sold
on local and international markets at a profit. Successful
completion of that process is also the only way that individual
and institutional mining industry investors receive a return on
their investment.&quot;<br>
</p>

<p>Acknowledging the seriousness of prevailing circumstances in
SA's mining industry, Munro ascribed its less than satisfactory performance
&quot;to the fact that in the aftermath of the 1994 internationally acknowledged
political miracle, the required commitment to realise full
potential remains to be engendered on many mines. Considering
that the transformation terminated decades of unrepresentative
rule in South Africa, it is hardly surprising that its effects
have been so long lasting.<br>
</p>

<p>&quot;But,&quot; he said, &quot;that does not mean that their
longevity has been tenable. Their impact on gold mining activity
- compounded by a static gold price, declining grades linked in
part to increased tonnages of low grade surface accumulations
being milled and wage increases above 10% - has been profoundly negative.<br>
</p>

<p>&quot;Still acutely reliant on labour intensive production
methods, the gold mining industry has a sharp further decline in
productivity over the past year. An increased number of public
holidays has exacerbated the malaise.&quot;<br>
</p>

<p>Munro said his observations were not &quot;intended to imply
that SA's democratisation was a disagreeable occurrence. Quite
the opposite. In fact, it was without doubt one of the most significant and
welcome events in our country's history.<br>
</p>

<p>&quot;Yet it gave rise to a workplace apathy which urgently
needs to be overcome if South Africa, and the mining industry in particular,
is to realise its maximum potential to foster domestic prosperity and at
the same time remain a prominent player in the highly competitive
international arena,&quot; Munro said.<br>
</p>

<p align="center"><br>
</p>

<p align="center"><a href="/org1.htm"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
<br>
</p>

<address>
    <font size="2"> 1995, 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Llewellyn D. Kriel, Communication Manager :
    Media : </font><a href="mailto:lkriel@bullion.org.za"><font
    size="2">lkriel@bullion.org.za</font></a><font size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-452</DOCNO>
<DOCOLDNO>IA012-000121-B043-162</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/publications/comnl.htm 196.26.82.193 19970217004917 text/html 12783
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:52:32 GMT
Content-type: text/html
</DOCHDR>
<!doctype html public "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines Publications</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font color="#0000A0" size="4"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="../images/LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><b><i>Chamber of Mines Publications</i></b></h2>
<div align="center"><center>

<table border="1" cellpadding="2">
    <tr>
        <td align="center" valign="top" width="100"><a href="#REGULAR"><strong>Regular
        Publications</strong></a></td>
        <td align="center" valign="top" width="100"><a href="#MINERAL"><strong>Mineral<br>
        Series</strong></a></td>
        <td align="center" valign="top" width="100"><a href="#OTHER"><strong>Other
        Publications</strong></a></td>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="0">
    <tr>
        <td align="center" width="80%"><font color="#EA0000"><strong><br
        clear="all">
        Please Note<br>
        </strong></font><font face="Arial Narrow">Copyright
        subsists in this work. Please refer to individual
        publication files for detail concerning conditions
        governing the permitted reproduction of published
        articles and information.</font></td>
    </tr>
</table>
</center></div>

<p align="center">&nbsp;</p>
<div align="center"><center>

<table border="0">
    <tr>
        <td align="center" valign="top" width="250"><div
        align="center"><center><table border="1">
            <tr>
                <td align="center" width="100%" bgcolor="#FF0000"><font
                color="#FFFFFF" size="4" face="Arial"><strong><tt>Subscription
                Information</tt></strong></font></td>
            </tr>
        </table>
        </center></div></td>
        <td align="center" valign="top" width="250"><div
        align="center"><center><table border="1">
            <tr>
                <td align="center" width="100%" bgcolor="#FF0000"><font
                color="#FFFFFF" size="4" face="Arial"><strong><tt>Downloading
                &amp; Reading Files</tt></strong></font></td>
            </tr>
        </table>
        </center></div></td>
    </tr>
    <tr>
        <td align="center" valign="top" width="250"><font
        color="#0000A0">To subscribe to <i>In Session</i> (not
        free), please contact </font><a
        href="mailto:jliebenb@bullion.org.za"><font
        color="#0000A0">Johann Liebenberg</font></a><font
        color="#0000A0"> . </font></td>
        <td align="center" valign="top" width="250">You will need
        the Adobe Acrobat Viewer to read these files.<br>
        <a href="http://www.adobe.com"><font size="3"><img
        src="../images/Getacro.gif" border="0" width="88"
        height="31"></font></a></td>
    </tr>
</table>
</center></div>
<br>

<a name="REGULAR"><font color="#008000"
size="4"><strong><CENTER>REGULAR PUBLICATIONS</CENTER></strong></font></a>
<div align="center"><center>
<table border="0" width="50%" align="center">
<tr>
<td><br></td>
</tr>
<tr>
        <td align="center" width="60%" bgcolor="#EBEBEB"><font
        color="#008040" size="2" face="Arial"><em><strong>ANNUAL
        REPORT</strong></em></font><font face="Arial"><em><br
        clear="all">
        </em></font><font size="2">Published in November</font></td>
    </tr>
    <tr>
        
        <td valign="top" width="60%"><font size="3"><img
        src="../images/pink.gif" width="14" height="14"> </font><a
        href="1996/ar1996.zip"><font size="3">1996 Annual
        Report</font></a><font size="3"> </font><font
        size="1">(PDF) [ZIP 1.13 MB]</font><font size="3">
        </td>
    </tr>    
<tr>
<td><font  color=#ffffff>.</font></td>
</tr>

<tr>
        <td align="center" width="60%" bgcolor="#EBEBEB"><font
        color="#008040" size="2" face="Arial"><em><strong>IN
        SESSION</strong></em></font><font face="Arial"><em><br
        clear="all">
        </em></font><font size="2">Weekly Parliamentary Report</font></td>
    </tr>
    <tr>
        
        <td valign="top" width="60%"><font size="3"><img
        src="../images/pink.gif" width="14" height="14"> </font><a
        href="/ppu1.htm#In Session"><font size="3">In
        Session</font></a><font size="3"> </font><font
        size="3">Parliamentary Review Publication</font><font size="3">
        </td>
    </tr>    
<tr>
<td><font  color=#ffffff>.</font></td>
</tr>
<tr>
        <td align="center" width="60%" bgcolor="#EBEBEB"><font
        color="#008040" size="2" face="Arial"><em><strong>CHAMBER&nbsp;NEWSLETTERS</strong></em></font><font
        face="Arial"><em><br clear="all">
        </em></font><font size="2">Published every quarter</font></td>
</tr>

<tr>
	<td valign="top" width="60%"><font size="3"><img
        src="../images/pink.gif" width="14" height="14"> </font><a
        href="/publications/NL296.ZIP"><font size="3">Newsletter,
        No.2 1996</font><font size="2"> </font></a><font size="1">(PDF)
        [ZIP 946k]</font><font size="2"><br>
		<font size="3"><img
        src="../images/pink.gif" width="14" height="14"> </font><a
        href="/publications/NL196.ZIP"><font size="3">Newsletter,
        No.1 1996</font><font size="2"> </font></a><font size="1">(PDF)
        [ZIP 452k]</font><font size="2"><br>
        </font><font size="3"><img src="../images/pink.gif"
        width="14" height="14"> </font><a
        href="/publications/nl595.zip"><font size="3">Newsletter,
        No.5 1995</font><font size="2"> </font></a><font size="1">(PDF)
        [ZIP 399k]</font></td></tr>
<tr>
<td><font  color=#ffffff>.</font></td>
</tr>
<tr>
        <td align="center" width="60%" bgcolor="#EBEBEB"><font
        color="#008040" size="2" face="Arial"><em><strong>STATISTICAL
        TABLES</strong></em></font><font face="Arial"><em><br
        clear="all">
        </em></font><font size="2">Annual Reference Publication</font></td>
    </tr>    
<tr>
        
        <td valign="top" width="60%"><font size="3"><img
        src="../images/pink.gif" width="14" height="14"> </font><a
        href="/publications/95stats.zip"><font size="3">1995
        Statistical Tables</font></a><font size="3"> </font><font
        size="1">(PDF) [ZIP 500k]</font><font size="3"><br>
        <img src="../images/pink.gif" width="14" height="14"> </font><a
        href="/publications/94stats.zip"><font size="3">1994
        Statistical Tables</font></a><font size="3"> </font><font
        size="1">(PDF) [ZIP 720k]</font><font size="2"><br>
        </font></td>
    </tr>
</table>
</div></center>

<blockquote>
    <p align="center">&nbsp;</p>
    <p align="center"><a name="MINERAL"><font color="#008000"
    size="4"><strong>MINERAL</strong></font></a><font
    color="#008000" size="4"><strong> SERIES</strong></font></p>
</blockquote>

<blockquote>
    <p align="left"><font size="3"><img
    src="../images/orange.gif" width="14" height="14"> </font><a
    href="basemetals.htm"><font size="3">Base Metals and Minerals
    Mining in South Africa</font></a><font size="3"> <br>
    <img src="../images/orange.gif" width="14" height="14"> </font><a
    href="/publications/AUextrac.htm"><font size="3">The Science
    of Gold Extraction: A Brief South African History</font></a><a
    href="/statistics/g-output.htm#GOLDPRODAUG96"><font size="3"><br>
    </font></a><font size="3"><img src="../images/orange.gif"
    width="14" height="14"> </font><a
    href="/publications/diamonds.htm"><font size="3">Diamond
    Mining in South Africa</font></a><a
    href="/publications/NUMMEMO.htm"><font size="3"><br>
    </font></a><font size="3"><img src="../images/orange.gif"
    width="14" height="14"> </font><a
    href="/publications/coal.htm"><font size="3">Coal Mining in
    South Africa</font></a><a href="/publications/NUMMEMO.htm"><font
    size="3"><br>
    </font></a><font size="3"><img src="../images/orange.gif"
    width="14" height="14"> </font><a
    href="/publications/coalfacts.htm"><font size="3">Coal Facts</font></a><a
    href="/publications/Platinum.htm"><font size="3"><br>
    </font></a><font size="3"><img src="../images/orange.gif"
    width="14" height="14"> </font><a
    href="/publications/Platinum.htm"><font size="3">The Platinum
    Group Metals in South Africa</font></a><font size="3"><br>
    <img src="../images/orange.gif" width="14" height="14"> </font><a
    href="/publications/nbgold96.htm"><font size="3">The
    Importance of Gold Mining to South Africa</font></a><font
    size="2"><br>
    </font><font size="3"><img src="../images/orange.gif"
    width="14" height="14">&nbsp;</font><a
    href="/publications/howgold.htm"><font size="3">How Gold is
    Mined in South Africa</font></a><font size="3"><br>
    </font></p>
</blockquote>

<blockquote>
    <p align="center">&nbsp;</p>
    <p align="center"><a name="OTHER"><font color="#008000"
    size="4"><strong>OTHER</strong></font></a><font
    color="#008000" size="4"><strong> PUBLICATIONS</strong></font></p>
    <p><font size="3"><img src="../images/green.gif" width="14"
    height="14"> </font><a href="/publications/career.htm"><font
    size="3">Career Opportunities in the Mining Industry</font></a><font
    size="3"><br>
    <img src="../images/green.gif" width="14" height="14"> </font><a
    href="http://www.woza.co.za/minenet.htm"><font size="3">Mining
    Companies Join the Cyber Rush</font></a><font size="3">: What
    the electronic press said about us<br>
    <img src="../images/green.gif" width="14" height="14"> </font><a
    href="/publications/sacoalresearch96.htm"><font size="3">South
    African Coal Research and Development: 1995-1996</font></a><font
    size="3"> </font><a
    href="/statistics/g-output.htm#GOLDPRODAUG96"><font size="3"><br>
    </font></a><font size="3"><img src="../images/green.gif"
    width="14" height="14"> </font><a
    href="/publications/Centenary.htm"><font size="3">Celebrating
    the Centenary of the University of the Witwatersrand School
    of Mines</font></a><font size="3"><br>
    <img src="../images/green.gif" width="14" height="14"> </font><a
    href="/associates/rescue.htm"><font size="3">Advanced Rescue
    Drilling Unit for South African Collieries</font></a><font
    size="2"><br>
    </font><font size="3"><img src="../images/green.gif"
    width="14" height="14"> </font><a
    href="/publications/constitution.htm"><font size="3">Constitution
    of the Chamber of Mines<br>
    </font></a></p>
</blockquote>

<p align="center"><font size="3"><img src="line3.gif"
align="middle" width="590" height="2"></font></p>

<p align="center"><a href="/main.htm"><font size="3"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></font></a><font size="3"> </font><a
href="#top"><font size="3"><img src="../images/nb2.gif"
alt="Top of Page" align="middle" border="0" hspace="20"
width="60" height="17"></font></a><font size="3"> </font><a
href="#toolbar"><font size="3"><img src="../images/nb3.gif"
alt="Toolbar" align="middle" border="0" hspace="20" width="80"
height="17"></font></a><font size="3"> </font></p>

<p align="center"><a href="/org1.htm"><font size="3"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></font></a><font size="3"> </font><a
href="/res1.htm"><font size="3"><img src="../images/tb102.gif"
alt="Resources" border="0" width="101" height="17"></font></a><font
size="3"> </font><a href="/kruger.htm"><font size="3"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></font></a><font size="3"> </font><a href="/new.htm"><font
size="3"><img src="../images/tb105.gif" alt="What's New?"
border="0" width="101" height="17"></font></a><font size="3"> </font><a
href="/info.htm"><font size="3"><img src="../images/tb106.gif"
alt="Contacting us" border="0" width="101" height="17"></font></a><font
size="3"> </font></p>

<address>
    <font size="2"> 1996 Chamber of Mines of South Africa<br>
    HTML coding by Timothy Wood:</font><a
    href="mailto:twood@bullion.org.za"><font size="2">
    twood@bullion.org.za</font></a> 
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-453</DOCNO>
<DOCOLDNO>IA012-000121-B044-18</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/speeches/speech.htm 196.26.82.193 19970217005105 text/html 38970
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:53:25 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>The Chamber of Mines Speeches</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><font color="#0000A0" size="5"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="../LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><font size="6"><b><i>Speeches</i></b></font></h2>

<h4 align="center"><font color="#FF0000">Please Note</font></h4>

<p align="center">Where applicable, copyright subsists in this
work. Any unauthorised reproduction, adaptation, distribution or
commercial exploitation of the work is an act of copyright
infringement.<br>
<br>
<font color="#E10000" size="3"><b>To view or print downloadable
information</b><br>
</font><font size="3" face="Arial Narrow"><em><tt>You will need
the Adobe Acrobat viewer to read these files <br>
</tt></em></font><a href="http://www.adobe.com"><font size="3"><img
src="../images/Getacro.gif" border="0" width="88" height="31"></font></a></p>
<div align="center"><center>

<table border="1" width="70%">
    <tr>
        <td align="center" width="50%"><a href="#GENERAL "><strong>General </strong></a></td>
        <td align="center" width="50%"><a href="#ANNUAL"><strong>Annual
        General Meetings</strong></a></td>
    </tr>
</table>
</center></div>

<p align="left">&nbsp;</p>

<p align="left"><a name="GENERAL "><font color="#FF0000"><strong>GENERAL </strong></font></a><font
color="#FF0000"><strong>SPEECHES BY CHAMBER OFFICIALS AND
INDUSTRY PERSONALITIES</strong></font></p>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <td align="center" width="80%"><font color="#008000"
        size="4"><strong>1996</strong></font></td>
    </tr>
</table>
</center></div>

<p><img src="../images/red.gif" width="14" height="14"><a
href="1996/Atnwma.htm"><font size="3"><strong>South Africa,
Rainbow Nation of Mineral Wealth.</strong><br>
</font></a><font size="3">&nbsp;&nbsp;&nbsp;&nbsp;A paper
presented by Mr At du Plessis, outgoing President, to the 102nd
annual<br>
&nbsp;&nbsp;&nbsp;&nbsp;North West Mining Association Convention
in Spokane, Washington, USA.<br>
<br>
</font><img src="../images/red.gif" width="14" height="14"><a
href="/speeches/istanbul.htm"><font size="3"><strong>Gold as a
Hedge Within Risk Diversification</strong></font></a><font
size="3"><br>
&nbsp;&nbsp;&nbsp;&nbsp;Speech by Mr TRN Main, Chief Executive,
at the Istanbul Gold Conference</font></p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="SAIMM.htm"><font size="3"><strong>Internet
in the Mining Industry</strong></font></a> Address by Mr Timothy
Wood at an SAIMM Seminar.</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/96wagsgn.htm"><font size="3"><strong>1996
Wage Agreement Signing Ceremony</strong></font></a> <br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by the President of the Chamber
of Mines </p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/amhrp96.htm"><strong>Annual
General Meeting of the Association of Mine Human Resource
Practitioners</strong></a><br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by the President of the Chamber
of Mines </p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/wits100.htm"><strong>Wits
University Department of Mining Engineering Centenary</strong></a><br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by Mr E. P. Gush, Deputy
Chairman, Anglo American Corporation</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/trn2.htm"><strong>New Initiatives
to the Year 2000 in South African Mining</strong></a><br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by Mr Tom Main, CEO of the
Chamber of Mines&nbsp;of &nbsp;SA<br>
&nbsp;&nbsp;&nbsp; at the 1996 FT World Gold Conference</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/TOMSUBSA.HTM"><b>Management,
Labour and Productivity</b></a><br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by Mr Tom Main, CEO of the
Chamber of Mines of SA<br>
&nbsp;&nbsp;&nbsp;&nbsp;at the 1996 Sub-Saharan Oil and Minerals
Conference</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/atsubsa.htm"><b>People and
Profits: Safety and Quality</b></a><br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by Mr At du Plessis, President of
the Chamber of Mines of SA<br>
&nbsp;&nbsp;&nbsp; at the 1996 &nbsp;Sub-Saharan Oil and Minerals
Conference</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/piksnate.htm"><b>Budget Speech</b></a><br>
&nbsp;&nbsp;&nbsp; Address by the Minister of Minerals &amp;
Energy, Pik Botha, to SA Senate</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="../../speeches/Africa_Connect.htm"><b>UNCTAD/AfricaConnect</b></a> <br>
&nbsp;&nbsp;&nbsp;Address by Mr Tom Main, CEO of the Chamber of
Mines of &nbsp;SA<br>
&nbsp;&nbsp; at the Official Opening of the UNCTAD / Africa
Connect Conference</p>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="../../speeches/bourse.htm"><strong>Quotation
of the 1oz. Krugerrand coin on the Paris Bourse</strong></a><br>
&nbsp;&nbsp;&nbsp;&nbsp;Address by Mr Kelvin Williams, Gold
Producers' Committee Chairman</p>

<p align="left">&nbsp;</p>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <td align="center" width="80%"><font color="#008000"
        size="4"><strong>1995</strong></font></td>
    </tr>
</table>
</center></div>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a href="/speeches/trnm1.htm"><strong>Financing
Mining Projects in Emerging Markets</strong></a><br>
&nbsp;&nbsp;&nbsp; Keynote address by Mr Tom Main, CEO of the
Chamber of Mines of &nbsp;SA<br>
&nbsp;&nbsp;&nbsp;&nbsp;at the 1995 FT World Gold Conference<br>
<br>
<img src="../images/red.gif" width="14" height="14"><a
href="/speeches/stateof.htm"><strong>State of the South African
Mining Industry</strong></a><br>
&nbsp;&nbsp;&nbsp;Address by Mr Tom Main, CEO of the Chamber of
Mines of SA.<br>
<br>
<img src="../images/red.gif" width="14" height="14"><a
href="http://www.anc.org.za/num/ibc.html"><font size="3"><strong>The
Political, Economic and Social Influences on South African Mining</strong></font></a><font
size="3">: <br>
&nbsp;&nbsp;&nbsp;Address by Mr M Golding, MP, Address to the
International Precious Metals Forum, London<br>
</font><br>
<img src="../images/red.gif" width="14" height="14"><a
href="http://www.bullion.org.za/speeches/dupamm96.htm"><b>Address</b></a>,
AGM, Association of Mine Managers, by Mr At du Plessis, President
of the Chamber of Mines of SA<br>
<br>
<img src="../images/red.gif" width="14" height="14"><a
href="coalsafe.htm"><b>Address</b></a>, 1996 Coal Safety and
Health Seminar, by Mr At du Plessis, President of the Chamber of
Mines of SA<br>
<br>
<img src="../images/red.gif" width="14" height="14"><a
href="http://www.bullion.org.za/speeches/atsacma.htm"><b>Address</b></a>,
AGM, Colliery Managers' Association, by Mr At du Plessis,
President of the Chamber of Mines of SA<br>
<br>
<img src="../images/red.gif" width="14" height="14"><a
href="http://www.bullion.org.za/speeches/dupcon95.htm"><b>Opening
Address</b></a>, 1995 Mine Safety and Health Congress, by Mr At
du Plessis, President of the Chamber of Mines <br>
&nbsp;&nbsp;&nbsp;of SA<br>
</p>

<p align="left"><br>
<a name="ANNUAL"><font color="#FF0000"><strong>ANNUAL</strong></font></a><font
color="#FF0000"><strong> GENERAL MEETINGS</strong></font></p>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <td align="center" width="80%"><font color="#008000"
        size="4"><strong>1996</strong></font></td>
    </tr>
</table>
</center></div>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><a
href="../../speeches/1996/PresidentialAddress_1996.htm"><b>Presidential
Address</b></a>, <a
href="http://www.bullion.org.za/persimages/atdu.gif">Mr JA du
Plessis</a>, Chamber of Mines President, 1996 Annual General Meeting.</p>

<p align="left">&nbsp;</p>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <td align="center" width="80%"><font color="#008000"
        size="4"><strong>1995</strong></font></td>
    </tr>
</table>
</center></div>

<p align="left"><img src="../images/red.gif" width="14"
height="14">&nbsp;<a
href="http://www.bullion.org.za/speeches/munro1.htm"><b>Presidential
Address</b></a>, <a
href="http://www.bullion.org.za/persimages/mun.gif">Mr AH Munro</a>,
Chamber of Mines President, 1995 Annual General Meeting.</p>

<p align="left"><img src="../images/blue.gif" width="14"
height="14"><b>&nbsp;</b><a
href="http://www.bullion.org.za/speeches/hersov.htm"><b>Address
by Mr B Hersov</b></a> in reply to the 1995 Presidential Address. </p>

<p align="left">&nbsp;</p>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <td align="center" width="80%"><font color="#008000"
        size="4"><strong>1994</strong></font></td>
    </tr>
</table>
</center></div>

<p align="left"><img src="../images/red.gif" width="14"
height="14"><b>&nbsp;</b><a href="#JJG"><b>Presidential Address</b></a>, <a
href="http://www.bullion.org.za/persimages/geld.gif">Mr JJ
Geldenhuys</a>, Chamber of Mines President, 1994 Annual General Meeting. </p>

<p align="left"><img src="../images/blue.gif" width="14"
height="14"><b>&nbsp;</b><a
href="http://www.bullion.org.za/speeches/mandela1.htm" nrmandela><b>Address
by Mr Nelson Mandela</b></a>, 1994 Chamber of Mines Annual
General Meeting. <br>
</p>

<p align="center"><img src="../images/line3.gif" align="middle"
width="590" height="2"><br>
</p>

<p><br>
</p>

<p align="center"><img src="../images/save.gif" width="16"
height="16"> <a href="padd94.pdf"><font size="2" face="Arial">Download</font></a><font
size="2" face="Arial"> 1994 Presidential Address</font> <font
size="2">(PDF 31k)</font> <img src="../images/save.gif"
width="16" height="16"><br>
</p>

<p align="center">&nbsp;</p>

<p align="center"><font color="#008000" size="5" face="Arial"><b>Presidential
Address by </b></font><a href="/persimages/geld.gif"><font
size="5" face="Arial"><strong>Mr JJ Geldenhuys</strong></font></a><font
color="#008000" size="7" face="Arial"><strong> </strong></font></p>

<p align="center"><font color="#0000A0" size="4">on the Occassion
of the One Hundred and Fifth <br>
Annual General Meeting of the <br>
Chamber of Mines of South Africa</font></p>

<p align="center"><font color="#FF0000" size="3" face="Arial"><em><strong>Tuesday,
8 November 1994</strong></em></font></p>

<p align="center"><img src="../images/wd1.gif" align="middle"
width="32" height="31"><br>
</p>

<p align="center"><img src="../images/linegr.gif" align="middle"
width="402" height="5"><br>
</p>

<p align="center">This one hundred and fourth annual general
meeting of the Chamber of Mines takes place as we approach the
end of a truly remarkable year. The momentous events that have
dramatically reshaped the fundamental structure of South African
society will compel future generations to recognise 1994 as one
of the most critical years in our country's history.<br>
</p>

<p>To describe as miraculous the social and political
transformation South Africa has so recently undergone, can in
nobody's mind be dispelled as exaggerated or extravagant. What is
more, it is a miracle that has finally enabled our country to
jettison the odious baggage of a universally denounced political
chimera and we are now poised, for the first time, to develop to
their full potential our abundant human and natural resources and
to pursue the many benefits of international acceptability.<br>
</p>

<p>In these activities the mining industry has a pivotal role to
play. It is an industry with a considerable capacity to
contribute to the vital process of domestic upliftment while at
the same time consolidating and enhancing its competency as a
global business participant and primary industrial procurer of foreign
exchange.<br>
</p>

<p>Not yet functioning in the most favourable circumstances to
achieve maximum progress, there is nevertheless good reason for the
mining industry to be more than cautiously optimistic about its capability
to foster and promote the indispensable determinants of stability
and growth in South Africa.<br>
</p>

<p>Although not perfect, the April election which preceded the
miracle I referred to earlier, was demonstrably unhampered by the
eruptions of widespread violence and bloodshed foreseen by some
local and foreign political analysts. On the contrary it was a
palpably peaceful event. One for which all South Africans have
good reason to feel proud. Even more significantly it beamed a signal to
the outside world which transparently illustrated the resolve of
South Africa's people to consign to oblivion the hurtful
depravities of the past and focus instead on the vital
imperatives of reconciliation and peace.<br>
</p>

<p>As a microcosm of the wider South African society, the mining
industry and its hundreds of thousands of employees were naturally
drawn into what most certainly must have been the country's most
important electoral happening. In identical vein to the wider
national election process, voting on the mines passed without
major incident. The industry was called upon to ensure that as
many of its employees who were eligible to vote, were afforded
unfettered access to the ballot boxes. The industry effort - not
concluded in the easiest of circumstances - was a resounding
success and with minimal exception, our employees deserve
acknowledgement and thanks for their dignified conduct during the
three days set aside for polling.<br>
</p>

<p>Predictably South African voters - the vast majority of them
exercising their right to the franchise for the first time - demonstrated
overwhelmingly their support for the African National Congress. True to
a pre-election commitment, President Mandela formed a government
of national unity which once again - contrary to the gloomy
predictions of some political commentators - has functioned both effectively
and harmoniously. Indeed, in just six months South Africa has emerged
as an example to the world of how bitterness and conflict can be
alleviated in the far greater interest of national appeasement.<br>
</p>

<p>For the mining industry the activities of the new Government
have given little reason for major concern. By establishing a co-operative
alliance - an issue I shall refer to in greater detail presently
- there is much we believe we can achieve together.<br>
</p>

<p>The industry is particularly comforted by the fact that there
has thus far been no attempt by Government to evolve an interventionist
approach to the private sector. Pre-election rhetoric by some ANC
representatives caused apprehension and fears were compounded by
threats to revise the existing mineral rights regime in a manner
not targeted to serve the best interests of the mining industry.
The mineral rights argument remains unresolved and it is in the
interests of government, the mining industry and the investor
community that it be sensibly settled.<br>
</p>

<p>We urge Government to resist the promulgation of any measures
which place inhibitions on the industry's capacity effectively to
pursue its identified objectives. Already, the industry operates under a
severe regulatory burden and there are current concerns
surrounding the possible imposition of controls which will
deliver costly and unrealistic standards in the areas of radiological
and environmental protection.<br>
</p>

<p>Additionally, the industry is alarmed by the Public Holiday
proposals produced by the Buthelezi Commission. This sense of alarm
is well founded for these are just some of the detrimental implications
that confront us if no work takes place on the twelve days
stipulated in the draft bill:<br>
</p>

<ul>
    <li>R1 478 million in foreign exchange earnings will be lost. </li>
    <li>The State will forego tax revenue of R208 million. </li>
    <li>The mining industry will lose profits amounting to R829
        million. </li>
    <li>In the gold mining sector 24 tons of production will be
        lost. </li>
    <li>Almost 15 000 jobs in gold mining alone will be
        jeopardised. </li>
</ul>

<p>Proposed legislation of this kind is indicative of how the
State - in some instances quite inadvertently - can unilaterally
create conditions which critically threaten our industry's
capability to meaningfully contribute to South Africa's
development imperatives.<br>
</p>

<p>It is the mining industry's profound conviction that
government's task insofar as mining is concerned be confined to
the construction of the best possible domain in which the
industry can maximise its productive capacity to most competently serve
the diverse interests of all its stakeholders. As it has demonstrated
consistently and convincingly for more than 100 years the mining
industry - left alone to conduct the business it knows best -
will contribute substantially to South Africa's socio-political and
economic well-being.<br>
</p>

<p>Recent suggestions seeking to minimise the mining sector's
importance to the national interest need to be considered with a great
deal of circumspection. Last year, through the export of primary
and beneficiated mineral products, the industry generated more
than 60 per cent of South Africa's foreign exchange earnings. In
spite of the protracted world recession and generally depressed mineral
markets, the value of mineral sales increased by almost 11 per
cent to R46,7 billion in 1993. The mining industry's direct
contribution to GDP amounted to 8,7 per cent or, if the so-called indirect
backward and forward linkages are included, a more significant 18
per cent. Total export sales rose by almost 15 per cent in 1993,
an increase attributed to bigger exports of gold, platinum group
metals, iron ore and miscellaneous minerals, among them diamonds.<br>
</p>

<p>As in previous years, at a level of more than R23 billion,
gold was the dominant earner in total mineral export sales of R38 billion
during 1993. Chamber member gold mines produced 578 tons of gold
- a nominal increase on the output during 1992. The rise in gold
production for the year came in spite of a 2,9 per cent reduction
in tons milled. Added to the output of non Chamber producers, South
African gold production in 1993 totalled slightly more than 619
tons which is the highest annual gold production figure since
1986.<br>
</p>

<p>1994 has seen a decline in South African gold production.
After nine months of the year gold output stood at 437,9 tons - five
per cent below the corresponding period in 1993. Towards the end
of the 1994 third quarter, the gold price seriously tested the
400 dollar per ounce level and with fabrication demand set to
recover and increased inflationary expectations fuelled by a
strong international demand for goods and services, there is good
reason to believe there will be further impetus for the gold
price.<br>
</p>

<p>Increasing working costs remain a serious problem for South
African gold producers and in 1993 the industry was not able to
contain costs to the low levels achieved in 1992. Annualised comparison
shows that working cost per kilogram, offset to some extent by an
improvement in yield, increased 4,5 per cent from R26 373 to R27
547 over the period. This was way above the less than 1 per cent
increase in 1992 over the 1991 figure but well within the 9,7 per
cent increase in the consumer price index.<br>
</p>

<p>In the first nine months of 1994 mediocre labour productivity,
five official public holidays and random work stoppages associated
with the transitional process forced up the cost of producing gold
to R31 559 per kilogram. This represents an increase of 16 per
cent when compared with the first nine months of 1993.<br>
</p>

<p>Cost increases of this magnitude are unsustainable and unless
they are timeously arrested will lead unavoidably to additional mine
closures and accompanying loss of jobs. They will also
precipitate the sterilisation of a sizeable proportion of South Africa's
remaining mineable gold because extracting and refining it will
not be a commercially viable exercise.<br>
</p>

<p>Fortunately, and in spite of the high working cost increases,
a higher gold price, mainly the result of a depreciating Rand,
has enabled the gold mining industry to improve working profit
during 1994. For the first three quarters of the year working
profit increased, in nominal terms, by more than 20 per cent on
the same period for 1993.<br>
</p>

<p>Improvements in the profitability of mining operations have
made it possible for the industry to reassess levels of capital expenditure.
By September 1994 total Capex exceeded R1,8 billion - more than
14 per cent up on the corresponding period in 1993.<br>
</p>

<p>Increased levels of capital expenditure are demonstrative of
the major mining companies' commitment to the future of both the
industry and the country.<br>
</p>

<p>After gold and platinum group metals, coal was South Africa's
next biggest export commodity in 1993. Despite difficult trading
conditions on the international coal market and poor economic conditions
at home, coal producers were able to consolidate their positions
in both markets. Last year South Africa produced 182,2 million
tons or about 5,3 per cent of total international coal production.
This made it the world's sixth largest producer. Domestic coal
sales of 131,7 million tons in 1993 were valued at R5,2 billion
while exports of 51,7 million tons realised almost R4,5 billion
in foreign exchange.<br>
</p>

<p>The 51 million tons of coal exported through the Richards Bay
Coal Terminal in 1993 eclipsed any previous annual export tonnage.
Current indications point to an even higher quantity in 1994.<br>
</p>

<p>Improvements in spot prices in the first six months of 1994 -
the result of declining international stock levels and enhanced economic
growth in industrialised countries - have not yet brought substantial
benefit to South African producers. The majority of export
commitments are locked into contracts with 1994 prices settled in
1993.<br>
</p>

<p>With Japan and Europe struggling to shake off economic
recession, the 1993 platinum price remained below 400 dollars an ounce
for most of the year. However, the opening months of 1994 saw the
price advance to its highest level since the first quarter of
1991. By the second quarter prices held close to 400 dollars to
average 397 dollars per ounce for the first half of 1994. Since then
the metal has traded between 400 and 428 dollars per fine ounce.
In 1993 South African sales of platinum surged by 610 000 ounces
to 3,36 million ounces. With the effect of emission control legislation
beginning to be felt, European car sales up some 5,8 per cent in
the first half of 1994 and sustained demand for platinum
jewellery, particularly in Japan, it is expected that global
platinum sales this year will be in the region of 4,6 million
ounces.<br>
</p>

<p>As one of the world's largest mining industries and South
Africa's cardinal export business the mining sector now, more
than ever before because of the opportunities being presented as
a consequence of the removal of barriers imposed during the isolation
era, must ensure that it is well geared to meet the new
challenges it will encounter in the competitive global arena. Doors
are being opened and for that we must pay tribute to a very large
extent to President Mandela. During his punishing international
schedule - and his recent visit to the United States is a good example
- the President has made impressive progress in convincing not
only heads of Government, but also prominent members of the
World's business community, that South Africa has genuinely bid
farewell to the discriminatory inequities of the past and has
earned the right to full membership of the international family
of Nations. Neither our country nor our business community could
have chosen a more capable or engaging agent. He has done an
outstanding job.<br>
</p>

<p>To enable the mining industry to fully take advantage of new
opportunities in the international marketplace it will become essential
to examine, and in some cases improve, a number of internal aspects
of our business. In an intensely competitive arena the industry
must be free to make unrestricted use of its human resources and
high cost capital equipment. It is opposed to the introduction of
a compulsory 40 hour working week. Furthermore, it regards as an
archaic anachronism regulatory restraints which prohibit a seven
day working week and which are not found on the statutes of any
of the countries whose mining industries vigorously compete with ours
for international market share. Their existence makes no sense.
They undermine our competitiveness and they demand urgent
abolition.<br>
</p>

<p>As a further consideration in consolidating its position as a
global operator, the industry will also need to clearly
demonstrate to many potential overseas customers its dedicated
approach to matters like environmental protection and employee
safety. Powerful pressure groups in the world's industrialised
democracies have ample capacity to bring embarrassment and discomfort
to enterprises which trade with countries or organisations
perceived to have an indifferent attitude to these and several
other issues.<br>
</p>

<p>A wealth of evidence is available to prove the industry's
commitment to rehabilitation programmes and campaigns to enhance the
safety of the workplace. Nevertheless, fatality and reportable injury statistics
for South African mines remain an area of justifiable concern. In
1993, 483 people lost their lives on Chamber member mines. Just
under 7 700 suffered reportable injuries. By the end of September
1994 there had been 308 deaths and 6 064 reportables. In the
first nine months of last year, 378 mining industry employees
were killed and 6 537 suffered reportable injuries. While we are
obviously gratified by this reduction it certainly gives no cause
for celebration.<br>
</p>

<p>Accepting that mining - particularly when discharged at the
exceptional depths that typify South African gold mining operations
- takes place in a hostile environment, it is nonetheless
imperative that additional energy be employed in the fundamental
quest to substantially reduce, indeed attempt to eliminate, the
tragic accidents which bring death to our mines. It is
unconscionable that any other task should command greater
attention.<br>
</p>

<p>In July this year, with the explicit support of the Chamber, a
Commission of Inquiry undertook an examination of various aspects
of health and safety in South African mines. Under the chairmanship of
Mr Justice R N Leon, assisted by three assessors, the Commission
sat for more than a month and heard evidence from a wide variety
of expert witnesses. With a report due before year end, it is the Chamber's
sincere wish that the Commission's recommendations will provide a meaningful
and practical contribution to industry efforts to ensure better
protection for the lives of all employees.<br>
</p>

<p>Concerted promotion of health and safety is crucial to an
industry which provides jobs for more than 500 000 people. The mining
industry's employee complement is exceeded only by the agricultural sector
and is representative of 4,5 per cent of the country's
economically active population. The positive economic
consequences of mining industry employment rates are considerable.
Last year, almost R12 billion was paid in salaries and wages to
the industry workforce. A sizeable portion of this amount would
have been ploughed back into the economy through consumer
spending.<br>
</p>

<p>Furthermore, it is estimated that for every three people
employed on a mine, one is employed by industries either directly
or indirectly serving the mining sector. The industry reach into
the wider South African community is additionally demonstrated by
the calculation which testifies that every mining industry worker
supports between seven and 10 dependants.<br>
</p>

<p>These facts add force to the argument that mining remains the
most important industrial socio-economic linchpin in South Africa.
They are also a compelling affirmation of the enduring vitality
and vigour of the industry.<br>
</p>

<p>In what has been a potentially disruptive period the industry
has also managed to pursue its operational activities in an atmosphere
of comparative tranquillity. The rampant violence which for so
long has traumatised so many of our country's people, although
disruptive from time to time, has thankfully not been a
significant industry problem. This is not a situation which has
evolved without effort but is rather the product of the sound and
healthy relationship formulated by employers and employees over a
considerable period.<br>
</p>

<p>The positive nature of the rapport between employees and
management is additionally exhibited in the successful - though
not easy - conclusion of negotiations on wages and other
conditions of employment with all mining industry representative
trade unions and other employee organisations earlier this year.
The negotiations, conducted in a constructive spirit, were completed
without workplace disruption.<br>
</p>

<p>Through the Chamber of Mines, agreement was also reached with
the National Union of Mineworkers on a plan to promote basic
adult education and training. The agreement is a conspicuous
illustration of the mining industry's commitment to the essential
process of upliftment conceived to bring enhanced opportunities
to all South Africans.<br>
</p>

<p>The positive association the mining industry has so
successfully forged with its employees - its most valuable asset
- is one it seeks to duplicate with other important stakeholders,
among them Government. Although the industry has no major
concerns about its existing relationship with the government of
national unity, it firmly believes there is good reason to
construct a co-operative alliance which will effectively enable
both Government and the industry to achieve their separate yet inter-related
aspirations and goals.<br>
</p>

<p>Careful scrutiny of Government policy statements - most
notably those contained in the Reconstruction and Development Programme
and the State of the Nation Address delivered by President
Mandela to Parliament on 24 May - convinces the mining industry
that what Government wants for South Africa finds comfortable
accommodation in the strategic objectives of our industry. We
believe we should blend our common goals in the creation of a
synergistic and mutually beneficial relationship which will best
serve the multiple interests of our industry, our country and all its
people.<br>
</p>

<p>Meeting the basic needs of the people is classified in the RDP
as Government's first priority. These needs embrace the provision
of a variety of fundamental human necessities - jobs, land, housing, water,
electricity, telecommunications, transport, a clean and healthy
environment, nutrition, health care and social welfare. The
mining industry - for some considerable time - has been providing
these RDP identified needs to hundreds of thousands of employees
and many of their dependants.<br>
</p>

<p>In the past few years members of the Chamber of Mines have
become dominant players in the Joint Educational Trust providing
some 60 per cent of the R500 million budgeted to fund this pioneering private
sector initiative designed to restructure black education. In
fact, the industry is an undisputed leader in the process of
delivering social infrastructure and it encourages Government,
the rest of the private sector and all individuals to get to work
so that the RDP visions can rapidly be transformed into reality.<br>
</p>

<p>President Mandela in his 24 May speech augmented the RDP
vision by eloquently identifying six specific freedoms essential to
the realisation of human dignity. As part of the commitment to create
a people-centred society, the President bound Government to the
pursuit of the goals of freedom from want, freedom from hunger,
freedom from deprivation, freedom from ignorance, freedom from suppression
and freedom from fear.<br>
</p>

<p>He urged all South Africans of goodwill to join together to
provide a better life for all. The mining industry endorses and upholds
these laudable ideals. It offers assistance to Government in its quest to
accomplish them. There is no single industry better equipped to
play this vitally important supportive role. Clearly, a visible
mining industry commitment could have a decisive catalytic effect and
encourage other industries, communities and individuals to
embrace a similarly positive approach.<br>
</p>

<p>Since the discovery of gold on the Witwatersrand more than 100
years ago, the mining industry has made an incalculable contribution
to the national economy. We are in no doubt that our achievements
in the past can be repeated in the future and that with
Government's indispensable assistance, the mining industry will
produce many of the imperatives critical to the creation of a peaceful
and prosperous South Africa.<br>
</p>

<p>What lies beyond our domain of control and competence is the
facilitation of the most favourable conditions - the best enabling
environment - in which the industry can most effectively play a nation-building
role.<br>
</p>

<p>This is a responsibility lodged in the hands of Government.
And it is in shaping the correct and most facilitative enabling environment
that the mining industry looks to Government to fulfil its role in
the proposed synergistic alliance.<br>
</p>

<p>Briefly stated, to perform to its best possible capability,
the mining industry needs to operate in a political environment unencumbered
by the destructive eruptions of violence which bring alarm to investors.
It also requires an economic environment which, among other
considerations, ensures a commitment to the principles of the
free market; adheres to a predictable and internationally competitive
taxation system; and imposes centralised taxation on profits, not
an imposition of levies and indirect taxes - national or
provincial - that increase industry costs and erode its international competitiveness. Finally,
the industry seeks a social environment in which the state refrains
from interfering in the collective bargaining process. The role
of Government should be confined to that of creating an effective
legislative framework and being a neutral facilitator.<br>
</p>

<p>The simple logic being unfolded here is that the mining
industry needs Government to enable it to perpetuate and
hopefully surpass the positive inputs it has made to the
development and growth of South Africa. The opposite side of the
coin suggests that Government also needs the mining industry. The
industry must be performing optimally so that it can contribute
to the achievement of the policy objectives identified in the
RDP.<br>
</p>

<p>What is emphatically certain is that provided it is allowed to
function in the correct operational circumstances, the mining industry
will create wealth, both nationally and regionally; it will
create jobs; it will build and sustain communities, and; it will earn
foreign exchange. However, neither Government nor the mining
industry can realise their individual but inter-related objectives
in isolation. A synergistic and co-operative relationship is
cardinal.<br>
</p>

<p>With that in place the industry and Government will be well
positioned to build a proud, prosperous and people-centred nation
together.<br>
</p>

<p>In conclusion, ladies and gentlemen, I should like to express
thanks to my two vice presidents, Mr Alan Munro and Mr At du Plessis,
for their indispensable support during my term of office. To Mr Munro
my sincere good wishes as he begins his tenure as President of
the Chamber of Mines.<br>
</p>

<p>My sincere thanks are also extended to my Executive Committee
colleagues, Mr Deric Wiggill, Chairman of the Collieries Committee,
and Mr Tom Main, Chamber Chief Executive and his staff, for the
valuable assistance they have given me over the past year.<br>
</p>

<p>Finally, to my wife Liz for her constant support during the
performance of my official duties.<br>
</p>

<p align="center"><img src="../images/linegr.gif" align="middle"
width="402" height="5"><br>
</p>

<p align="center"><a href="/main.htm"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> </p>

<p align="center"><br>
<br>
<a href="/org1.htm"><img src="../images/tb101.gif"
alt="organisation" border="0" width="101" height="17"></a> <a
href="/res1.htm"><img src="../images/tb102.gif" alt="Resources"
border="0" width="101" height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
</p>

<hr size="3" width="80%">

<address>
    <font size="2"><br>
     1995, 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-454</DOCNO>
<DOCOLDNO>IA012-000121-B044-61</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/agreements/agree.htm 196.26.82.193 19970217005139 text/html 4308
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:55:14 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Minesof South Africa: Negotiated Agreements</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font color="#0000A0" size="4"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><b><img src="/images/LOGO1.gif" width="300"
height="160"></b></p>

<h2 align="center"><b><i>Mining Industry Agreements</i></b></h2>

<p align="left"><b></b>&nbsp;</p>
<div align="center"><center>

<table border="1" cellpadding="2" cellspacing="3">
    <tr>
        <td align="center"><a href="#Wages"><font color="#008040"
        size="3"><b>Wages and Other Conditions of Employment</b></font></a></td>
        <td align="center"><a href="#Wages"><font color="#008040"
        size="3"><b>Other Agreements</b></font></a></td>
    </tr>
</table>
</center></div>

<p align="left"><b><br>
</b><font color="#008040" size="3"><b>Agreements on </b></font><a
name="Wages"><font color="#008040" size="3"><b>Wages</b></font></a><font
color="#008040" size="3"><b> and Other Conditions of Employment</b></font></p>

<blockquote>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="/agreements/wage96.htm"><font size="3"><b>1996 Review
    of Wages &amp; Other Conditions of Employment </b></font></a></p>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="/agreements/wage95.htm"><font size="3"><b>1995 Review
    of Wages &amp; Other Conditions of Employment</b></font></a><font
    size="3"><b> </b></font></p>
</blockquote>

<p align="left">&nbsp;</p>

<p align="left"><a name="Other"><font color="#008040" size="3"><b>Other</b></font></a><font
color="#008040" size="3"><b> Agreements</b></font></p>

<blockquote>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="/agreements/eap.htm"><font size="3"><b>Employee
    Assistance Programme Policy</b></font></a> </p>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="aids.htm"><font size="3"><b>AIDS Agreement</b></font></a><font
    size="3"><b> </b></font></p>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="/agreements/mqa.htm"><font size="3"><b>Mining
    Qualifications Forum Agreement</b></font></a><font size="3"><b> </b></font></p>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="/agreements/petl.htm"><font size="3"><b>Paid Education
    and Training Leave (PETL) Agreement</b></font></a><font
    size="3"><b> </b></font></p>
    <p align="left"><font size="3"><b><img
    src="../images/purple.gif" width="14" height="14"></b></font><a
    href="/agreements/abet.htm"><font size="3"><b>Adult Basic
    Education and Training (ABET) Agreement</b></font></a><font
    size="3"><b> </b></font></p>
</blockquote>

<p align="center"><b><br>
</b><a href="/org1.htm"><b><img src="/images/tb101.gif"
alt="Organisation" border="0" width="101" height="17"></b></a><a
href="/res1.htm"><b><img src="/images/tb102.gif" alt="Resources"
border="0" width="101" height="17"></b></a><a href="/kruger.htm"><b><img
src="/images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></b></a><a href="/new.htm"><b><img src="/tb105.gif"
alt="What's New?" border="0" width="101" height="17"></b></a><a
href="/info.htm"><b><img src="/images/tb106.gif" alt="Contacting us"
border="0" width="101" height="17"></b></a><b> <br>
</b></p>

<hr>

<address>
    <font size="2"> 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-455</DOCNO>
<DOCOLDNO>IA012-000121-B044-97</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/statistics/statsd01.htm 196.26.82.193 19970217005204 text/html 6112
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:55:38 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa : Statistics</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="brnpapr.gif" bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font size=3><b>Chamber of Mines of South Africa <br>
<img src="logo_stats.gif" align=bottom width=300 height=160></b></font></h1>
<h2 align=center><b><i>Core Services and Functions<br>
</i></b><IMG SRC="/images/line3.gif" align=middle width=590 height=2><br>
<font color="#800040"><font size=4><strong>STATISTICAL SERVICES</strong></font></font></h2>
<div align=center><center>
<table border=1 cellpadding=8>
<tr><th><a href="#Staff"><b>STAFF</b></a></th><th><a href="#About"><b>INFORMATION</b></a></th><th><a href="#Statistical"><b>STATISTICAL RESOURCES</b> </a></th></tr>
</table>
</center></div>
<h2><a name="Staff"><font size=4><b>Staff</b></font></a></h2>
<ul>
<li><font color="#000000"><font size=3>Diann Owen-Thomas, <i>Chief Statistician</i> </font></font></li>
<li><font color="#000000"><font size=3>Ashley East, <i>Analyst Programmer</i> </font></font></li>
<li><font color="#000000"><font size=3>Brian Ntshingila, <i>Statistical Officer</i> </font></font></li>
<li><font color="#000000"><font size=3>Shanaaz Omar, <i>Statistical Officer / Presentation Graphics Designer</i> </font></font></li>
<li><font color="#000000"><font size=3>Madhu Vythilingam, <i>Mineral Analyst</i> </font></font></li>
</ul>
<p>&#160;</p>
<hr size=3 noshade width=500>
<p align=center><a name="About"><font size=4><b>About Statistical Services</b></font></a></p>
<p><font color="#000000"><font size=3>Statistical Services receives and reports statistical information for the members of the Chamber of Mines of South Africa in the 
general areas of Mineral statistics, Labour and Earnings data, Safety statistics and Health and Occupational Disease statistics. </font></font></p>
<hr size=3 noshade width=500>
<p align=center><a name="Statistical"><font color="#800040"><font size=6><b>Statistical Resources</b></font></font></a></p>
<p align=center><font color="#E10000"><strong>Please Note<br>
</strong></font>Copyright subsists in this work. Any unauthorised reproduction, adaptation, distribution<br>
or commercial exploitation of the work is an act of copyright infringement.<br>
<br>
<font color="#E10000"><font size=3><b>To view or print this information</b><br>
</font></font><font size=3><em><tt>You will need the Adobe Acrobat viewer to read these files <br>
</tt></em></font><a href="http://www.adobe.com/prodindex/acrobat/readstep.html"><font size=3><img src="../images/Getacro.gif" align=bottom border=0 width=88 height=31></font></a></p>
<ol>
<li><font size=4>Mineral Statistics</font><ul>
<li><a href="g-output.htm"><font color="#400040"><font size=3><strong>Monthly Gold Production in S.A</strong></font></font></a></li>
<li><a href="analysis.htm"><font color="#400040"><font size=3><strong>Gold Comparative Analyses</strong></font></font><font size=2><strong> </strong></font></a></li>
<li><a href="analysis2.htm"><font color="#400040"><font size=3><strong>Analyses of Working Results for Chamber Member Gold Mines</strong></font></font></a></li>
<li><a href="his-awr.pdf"><font color="#400040"><font size=3><strong>Yearly Working Results for Chamber Member Gold Mines (1985-1996)</strong></font></font></a><font color="#400040"><font size=3><strong> </strong></font></font><font size=3><tt>[PDF File,9KB]</tt></font><font size=4><strong><tt> </tt></strong></font><a href="his-awr.pdf"><font color="#400040"><font size=3><strong><br>
</strong><br clear=all>
</font></font></a></li>
</ul>
</li>
<li><font size=4>Chamber of Mines Statistical Tables</font><ul>
<li><a href="/publications/stat94.pdf"><font color="#400040"><font size=3><strong>Statistical Tables 1994</strong></font></font></a><font size=4><tt>&#160;</tt></font><font size=3><tt>[PDF File,900KB]</tt></font><a href="/publications/stat94.pdf"><font color="#400040"><font size=3><br>
<li><a href="/publications/95stats.pdf"><font color="#400040"><font size=3><strong>Statistical Tables 1995</strong></font></font></a><font size=4><tt>&#160;</tt></font><font size=3><tt>[PDF File,625B]</tt></font><a href="/publications/95stats.pdf"><font color="#400040"><font size=3><br>

</font></font></a><a href="his-awr.pdf"><font color="#400040"><font size=3><br clear=all>
</font></font></a></li>
</ul>
</li>
<li><p align=left><a href="fact.htm"><font size=4>Facts &amp; Figures</font></a>: Charts and Tables, interesting facts about the mining industry. <a href="his-awr.pdf"><font color="#400040"><font size=3><br clear=all>
</font></font></a></p>
</li>
<li><font size=4>Labour and Earnings </font>(coming soon) </li>
<li><font size=4><a href="Safety01.htm"><font color="#400040"><font size=3><strong>Safety Statistics</strong></font></font><font size=2><strong> </strong></font></a></li>
<li><font size=4>Health &amp; Occupational Disease Statistics</font> (coming soon) </li>
</ol>
<p align=center>&#160;</p>
<p align=center><a href="/org1.htm"><IMG SRC="/images/tb101.gif" alt="organisation" align=bottom border=0 width=101 height=17></a><a href="/res1.htm"><IMG SRC="/images/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></a><a href="/kruger.htm"><IMG SRC="/images/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></a><a href="/new.htm"><IMG SRC="/images/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></a><a href="/info.htm"><IMG SRC="/images/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></a> </p>
<p align=left><b><u><br>
</u></b><font size=2><i>&#169; 1995, 1996 Chamber of Mines of South Africa<br>
HTML Coding by Madhu Vythilingam: </i></font><a href="mailto:mvythili@bullion.org.za"><font size=2><i>mvythili@bullion.org.za</i></font></a><font size=2><i> </i></font></p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-456</DOCNO>
<DOCOLDNO>IA012-000121-B044-136</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/samlnks.htm 196.26.82.193 19970217005240 text/html 27466
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:56:10 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="South African Mining and Minerals Links"
content="Mining and Minerals Resources Online in South Africa">
<meta name="South African Mining and Minerals Links"
content="Mining and Minerals Resources Online in South Africa">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Minesof South Africa: South African Mining and Minerals Links</title>
</head>

<body bgcolor="#000000" text="#FFFFFF" link="#0080FF"
vlink="#0080FF" alink="#0080FF">

<p align="center"><font color="#00FF00" size="1"><b>Chamber of
Mines of South Africa</b></font></p>

<p align="center"><font color="#FFFF00" size="5"><b>SOUTH AFRICAN<br>
</b></font><font color="#F9FF09" size="6"><b><i>Online Mining and
Minerals Directory</i></b></font></p>

<p align="center"><a href="/mining.htm"><img
src="images/Earth.gif" alt="WORLD MINING DIRECTORY"
align="middle" border="0" width="56" height="60"></a><a
href="/mining.htm"> <br>
<font size="4"><strong><tt>WORLD MINING DIRECTORY</tt></strong></font></a></p>
<div align="center"><center>

<table border="0" cellpadding="20">
    <tr>
        <td><img src="images/rdrf5.gif" width="170" height="170"></td>
        <td><p align="center"><a href="/associates/rr.htm"><font
        size="5"><b>RAND REFINERY LIMITED</b></font></a> </p>
        <p align="left">A private enterprise service
        organisation, Rand Refinery is an associated company of the <a
        href="http://www.bullion.org.za">Chamber of Mines of
        South Africa</a> and refines gold and silver on a co-operative basis
        for mines which are <a href="/members.htm">members of the Chamber</a>.
        Co-operation ensures the efficiencies and economies
        associated with a large-scale enterprise, a consistent assay
        mark and the security essential for such a valuable end
        product. </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/aac1.gif" width="160" height="60"></td>
        <td valign="top"><p align="center"><a
        href="http://www.aac.co.za"><font size="5"><b>ANGLO
        AMERICAN CORPORATION</b></font> </a></p>
        <p align="left"><font color="#FFFFFF" size="3">The </font><a
        href="http://www.edata.co.za/Anglo/anglostart.html"><font
        color="#FFFFFF" size="3">Corporation</font></a><font
        color="#FFFFFF" size="3"> is best known for its
        substantial gold and diamond interests, but it also has
        interests in companies with investments which cover a
        wide range of metals and minerals, including coal,
        chrome, copper, ferro-alloys, manganese, nickel, platinum
        and vanadium. Companies in which the Corporation is invested together produce
        more gold than any other enterprise in the world, while
        major diamond producer De Beers has been synonymous with
        the world diamond industry for over a century. Anglo
        American Coal Corporation is one of South Africa's
        largest coal producers and exporters and one of the
        larger private sector coal producers in the world. The
        Corporation's Platinum investments held largely through
        Anglo American Platinum Corporation include a major interest
        in the world's leading producer of platinum group metals,
        Rustenburg Platinum Mines. </font></p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a
        href="mailto:jduncan@goldho.anglo.co.za"><font size="4">jduncan@goldho.anglo.co.za</font></a></p>
        </td>
    </tr>
    <tr>
        <td><img src="images/aac2.gif" width="160" height="182"></td>
        <td valign="top"><p align="center"><a
        href="http://www.aac.co.za/gold/goldhome.htm"><font
        size="5"><b>ANGLO GOLD</b></font> </a></p>
        <p align="center"><font color="#FFFF00"><em><strong>The
        Gold and Uranium Division of Anglo American Corporation</strong></em></font></p>
        <p align="left">Anglo American Corporation of South
        Africa Limited&#146;s Gold and Uranium Division, known as
        Anglogold, is a service division of the Corporation,
        providing technical, financial, administrative and other
        services on a contractual basis to five South African
        gold producing companies.</p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a
        href="mailto:jduncan@goldho.anglo.co.za"><font size="4">jduncan@goldho.anglo.co.za</font></a></p>
        </td>
    </tr>
    <tr>
        <td><img src="images/Avl2.gif" width="61" height="70"></td>
        <td><p align="center"><a
        href="http://www.anglovaal.co.za/avl/"><font size="5"><b>ANGLOVAAL
        GROUP LIMITED</b></font></a> </p>
        <p align="left"><font color="#FFFFFF" size="3">Anglovaal
        Limited was incorporated in South Africa on 1 June 1933.</font><font
        color="#FFFFFF"> </font><font color="#FFFFFF" size="3">The company was
        originally structured as a <u>mining house</u>, a concept
        developed in South Africa to enable access by companies
        within the <u>mining house</u> to a central pool of
        scarce resources of skilled manpower, advanced technical
        capability and finance. This structure also facilitated
        the raising of capital for large new ventures.</font><font
        color="#FFFFFF"> </font><font color="#FFFFFF" size="3">Anglovaal
        today is an industrial, mining and investment holding and
        management company with a market capitalisation of R10
        billion, with its shares listed on the Johannesburg and London
        Stock Exchanges. The company establishes, finances, invests in
        and provides a range of services to companies which comprise
        its strategic investments, collectively known as the
        Anglovaal Group</font> </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:juliang@avmin.co.za"><font
        size="4">juliang@avmin.co.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/avming3.gif" width="160"
        height="57"></td>
        <td><p align="center"><a href="http://www.avmin.co.za/"><font
        size="5"><b>ANGLOVAAL MINERALS - AVMIN</b></font></a> </p>
        <p align="left"><font size="3">AVMIN which is located in
        Johannesburg, Gauteng, South Africa, is the Minerals Division
        of Anglovaal Limited, and was formed in 1994 when
        Anglovaal formalised an autonomous minerals divsion with
        an enhanced managerial and operation focus. AVMIN's operations
        and investments are located principally in the major
        mineral provinces of South Africa and range from mature
        gold and ferrous metals producers to strategic
        investments in the mining industry, including a major diamond
        investment to new projects currently under investigation. </font></p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:juliang@avmin.co.za"><font
        size="4">juliang@avmin.co.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/deb.gif" width="160" height="159"></td>
        <td><p align="center"><a href="http://www.debeers.co.za"><font
        size="5"><b>DE BEERS CONSOLIDATED MINES </b></font></a></p>
        <p align="left">De Beers is the world's premier diamond
        mining and marketing company. Its shares are traded on
        eight stock exchanges in South Africa and Europe and the company has
        a market capitalisation of about US$10 billion. Sales by
        the Central Selling Organisation, De Beers' marketing and
        trading arm, were US$4,5 billion in 1995. </p>
        <p align="center"><font color="#FF0000"><strong>SOUTH
        AFRICAN E-MAIL:<br>
        </strong></font><a href="mailto:ddiigb@db.co.za"><font
        size="4"><strong>ddiigb@db.co.za</strong></font></a> </p>
        </td>
    </tr>
    <tr>
        <td align="center"><img src="images/jci.gif" width="107"
        height="112"></td>
        <td><p align="center"><a href="http://www.jci.co.za/"><font
        size="5"><strong>JCI LIMITED</strong></font></a> </p>
        <p>JCI Limited is one of South Africa's largest mining finance
        companies, with managed assets in chrome, coal, <a
        href="/publications/howgold.htm">gold</a> and base metals
        as well as over 106 years of mining experience. Our
        business, which is being conducted on an increasingly international scale,
        is to identify, acquire, extract and process mineral resources. </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:webmaster@is.jci.co.za"><font
        size="4">webmaster@is.jci.co.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/implats.gif" width="55" height="56"></td>
        <td><p align="center"><a href="http://www.implats.co.za/"><font
        size="5"><strong>IMPALA PLATINUM HOLDINGS LIMITED<br>
        </strong></font></a><em>IMPLATS</em> </p>
        <p>Implats is in the business of mining, beneficiating
        and marketing<a href="/publications/platinum.htm">
        platinum group metals (pgm)</a>, nickel and copper. We
        also engage in downstream activities and secondary
        sourcing where our core competencies bring us a
        competitive advantage. Impala Platinum Holdings Limited
        (Implats) is the ultimate holding company of Impala
        Platinum Limited (Impala), the second largest producer of platinum
        in the western world, as well as Messina Limited
        (Messina) and Barplats Investments Limited (Barplats). It
        has an investment in Western Platinum Limited (WPL) and Eastern
        Platinum Limited (EPL), which together constitute the
        third largest platinum producer in southern Africa. </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a
        href="mailto:adunn@imphomrkt.implats.co.za"><font
        size="4">adunn@imphomrkt.implats.co.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/drasic.gif" align="absmiddle"
        width="160" height="85"></td>
        <td><p align="center"><a
        href="http://minotaur.marques.co.za/clients/drasic/drasic.htm"><font
        size="5"><b>DRASIC MINING</b></font></a> </p>
        <p align="left">Mining Equipment Suppliers and Brokers. </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/FALCONIMAGE.jpg" align="middle"
        width="100" height="91"></td>
        <td><p align="center"><a
        href="http://www.noranda.com/mining/falconbridge.html"><font
        size="5"><strong>FALCONBRIDGE LIMITED</strong></font> </a></p>
        <p>Falconbridge is the second largest producer of primary nickel
        products, the third largest producer of cobalt and one of
        the top ten copper producers in the Western world. The
        company employs over 6,000 people in 11 countries around
        the world. Headquartered in Toronto, Ontario,
        Falconbridge is 46% owned by Noranda Inc. It is publicly
        traded on major Canadian stock exchanges under the symbol
        FL. </p>
        <p align="center"><font color="#FF0000"><strong>SOUTH
        AFRICAN E-MAIL:<br>
        </strong></font><a href="mailto:bmex@iafrica.com"><font
        size="3"><strong>FALCONBRIDGE VENTURES OF AFRICA</strong></font></a><font
        size="2"><strong> </strong></font></p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/keeley.gif" align="absmiddle"></td>
        <td><p align="center"><a href="http://www.pix.za/keeley/"><font
        size="5"><b>KEELEY GRANITE</b></font></a> </p>
        <p align="left">Kelgran limited is the world's largest
        exporter of dimensional granite. The quarrying and
        exporting of a wide variety of granite blocks are
        complemented by the group's own granite processing
        plants, producing tiles and customised kitchen tops and furniture
        and its own dedicated granite terminal in Durban harbour. </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/VENMYN.gif" width="91" height="81"></td>
        <td><p align="center"><a href="http://www.venmyn.co.za/"><font
        size="5"><b>VENMYN RAND</b></font></a> </p>
        <p align="left"><font size="3">Venmyn Rand specialises in
        conducting mineral project evaluations in an interactive manner,
        presenting the critical linkages between technical
        assumptions and market-related economic issues. This in
        turn enable us to calculate the following: Project NPV's,
        Balance sheet NAV's, Sensitivity analyses of key
        variables, Market related valuations of companies and
        projects. The quantification of these criteria is then
        used to determine specific discount rates as ameans of comparing appropriate options.
        In addition to these services, Venmyn Rand also conducts strategic evaluations
        for privateand public companies, as well as for investors
        in such companies. Venmyn Rand is frequently called upon
        to act as independent technical experts for mergers and
        acquisitions.</font> </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:anc@rmb.co.za"><font
        size="4">anc@rmb.co.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/wrcons.jpg" align="middle"
        width="101" height="132"></td>
        <td><p align="center"><a
        href="http://mbendi.co.za/wrcons/index.htm"><font
        size="5"><strong>WEST RAND CONSOLIDATED<br>
        MINES LIMITED</strong></font> </a></p>
        <p>WRCons is a diversified gold exploration, development and
        mining organisation with interests in various parts of Gauteng,
        Mpumalanga, Northwest Province and the Northern Province
        of South Africa. The company is listed on the
        Johannesburg Stock Exchange, the London Stock Exchange
        and the Paris Bourse. </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:wrcpty01@cis.co.za"><font
        size="3"><strong>wrcpty01@cis.co.za</strong></font></a><font
        size="2"><strong> </strong></font></p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/geo.gif" align="absmiddle"> </td>
        <td><p align="center"><a
        href="http://www.geoscience.org.za/"><font size="5"><b>COUNCIL
        FOR GEOSCIENCE<br>
        GEOLOGICAL SURVEY OF SOUTH AFRICA</b></font></a> </p>
        <p align="left">The Council for Geoscience is a statutory
        body established in terms of the Geoscience Act. The
        Council is the successor to the Geological Survey of
        South Africa, which had its origins in the Geological
        Commission of the Cape of Good Hope (1895), the
        Geological Survey of the Transvaal Republic (1898) and
        the Geological Survey of Natal and Zululand (1899). The
        functions of the council are: </p>
        <ol>
            <li><p align="left">Geoscientific research in South
                Africa and the publication of information as maps
                and books, or in national and international
                journals. </p>
            </li>
            <li><p align="left">Development and management of a
                national geoscience database. </p>
            </li>
            <li><p align="left">Supply of technical information
                to the State and the public. </p>
            </li>
        </ol>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a
        href="mailto:webmaster@geosciences.org.za"><font size="4">webmaster@geosciences.org.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/mb.gif" align="absmiddle"></td>
        <td><p align="center"><a href="http://www.gov.za/mineral"><font
        size="5"><b>MINERALS BUREAU</b></font></a> </p>
        <p align="left">The Minerals Bureau, a Government
        Organization, which falls under the Department of Mineral
        and Energy Affairs is responsible for the following: </p>
        <ul>
            <li><p align="left">Collection, classification and
                analysis of mineral data. </p>
            </li>
            <li><p align="left">Advise Government and the Private
                Sector on matters relating to international mineral-economic
                developments. </p>
            </li>
            <li><p align="left">Provide assistance to the
                industry by way of mineral intelligence. </p>
            </li>
        </ul>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:alan@mejhb.pwv.gov.za"><font
        size="4">alan@mejhb.pwv.gov.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/mintek.gif" align="absmiddle"></td>
        <td><p align="center"><a href="http://www.mintek.ac.za"><font
        size="5"><b>MINTEK</b></font></a> </p>
        <p align="left">for more than 60 years, Mintek has been
        developing metallurgical and minerals-processing
        technology for one of the world's richest mining regions. Southern Africa
        has an exceptional wealth of mineral resources, including world-class
        deposits of gold, the platinum-group metals, diamonds,
        chromium and iron ores, the base metals, coal, and
        industrial minerals. Through innovative R&amp;D, Mintek
        aims to develop new and improved methods for extracting
        minerals and metals from ores, refining them, and
        processing them into value-added products. </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:ajc@info.mintek.ac.za"><font
        size="4">ajc@info.mintek.ac.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/csir.gif" align="absmiddle"></td>
        <td><p align="center"><a
        href="http://miningtek.csir.co.za/"><font size="5"><b>CSIR:
        MINING TECHNOLOGY</b></font></a> </p>
        <p align="left">CSIR: Mining Technology works in close
        collaboration and strategic partnership with the mining
        industry, employee organizations and government
        institutions by acquiring, developing and transferring
        technologies to improve the health, safety and wellbeing
        of their employees, and improve the profitability of the
        mining industry. </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:nmacnult@csir.co.za"><font
        size="4">nmacnult@csir.co.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/uct.gif" align="absmiddle"
        width="100" height="135"> </td>
        <td><p align="center"><a
        href="http://emma.sea.uct.ac.za/cms/mining.html"><font
        size="5"><b>UNIVERSITY OF CAPE TOWN:<br>
        MARINE MINING</b></font></a> </p>
        <ul>
            <li><p align="left">Consultancy service which draws
                on the tremendous resource of highly skilled specialists in
                marine and coastal sciences amongst its teaching
                and research staff to provide multidisciplinary
                marine expertise to the broader community. </p>
            </li>
            <li><p align="left">Co-ordinator and facilitator of
                inter-disciplinary and inter-departmental networking
                among marine researchers. </p>
            </li>
            <li><p align="left">Promoter of marine, maritime and
                coastal studies and job creation in southern Africa. </p>
            </li>
        </ul>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:bilski@physci.uct.ac.za"><font
        size="4">bilski@physci.uct.ac.za </font></a></p>
        </td>
    </tr>
    <tr>
        <td><img src="../images/tuks.gif" align="absmiddle"> </td>
        <td><p align="center"><a
        href="http://www.ee.up.ac.za/mmi/intro.html"><font
        size="5"><b>UNIVERSITY OF PRETORIA:<br>
        DEPT. OF METALLURGY</b></font></a> </p>
        <p align="left">The Department of Materials Science and
        Metallurgical Engineering is part of the Engineering
        Faculty which caters all the major engineering
        disciplines. The Departments of Materials Science and
        Metallurgical Engineering, Mining Engineering and Geology
        are housed together in the Minerals Science Building on the main campus
        of the University and are affiliated to the School for
        Mining and Mineral Science. Three centres of expertise
        are located in the Department, namely the Centre for
        Corrosion Engineering, the Centre for High Temperature
        Studies and the Centre for Welding Engineering. An
        interdisciplinary approach is followed. The Centre for
        Corrosion Engineering is a collaboration with the
        Department of Chemical and Environmental Engineering. The
        Centre for High Temperature Studies combines the
        disciplines of pyrometallurgy, refractory materials and
        high temperature mineralogy and collaboration exists with
        the Department of Geology. </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/wits.gif" align="absmiddle"
        width="100" height="138"> </td>
        <td><p align="center"><a
        href="http://www-eng.wits.ac.za/min/min_home.html"><font
        size="5"><b>WITS UNIVERSITY:<br>
        DEPT. OF MINING ENGINEERING</b></font></a> </p>
        <p align="left">The Department of Mining Engineering,
        which was one of the founding departments of the
        University of the Witwatersrand, can trace its origins
        back to the <a href="/publications/centenary.htm">Kimberley School
        of Mines</a>. Throughout its existence the reputation of
        the Department has been based on the quality of our
        graduates, many of whom have risen to hold senior positions
        in the South African Mining Industry and have made significant contributions
        to its growth and technological development. </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a
        href="mailto:inquiry@egoli.min.wits.ac.za"><font size="4">inquiry@egoli.min.wits.ac.za</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/new-2.jpg" width="170" height="170"></td>
        <td><p align="center"><a href="http://www.mining.co.za"><font
        size="5"><b>AFRICAN MINING</b></font></a> </p>
        <p align="left">In response to Africa's mining renaissance a new, independent bi-monthly magazine was launched in January 1996  - African Mining - a regular source of focused, concise business information relevant to mining executives, prospectors, investors, governments and equipment suppliers alike. 
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a
        href="mailto:pcran@icon.co.za"><font size="4">pcran@icon.co.za</font></a> </p>
<p>
        </td>
    </tr>
    <tr>
        <td><img src="images/man.gif" align="absmiddle"
        width="160" height="78"></td>
        <td><p align="center"><a
        href="http://www.os2.iaccess.za/mme/"><font size="5"><b>MANHATTAN
        MINING EQUIPMENT</b></font></a> </p>
        <p align="left">Used mining, mineral processing and
        quarrying equipment. Searcheable database. </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/num2.gif" width="160" height="160"></td>
        <td><p align="center"><a
        href="http://www.anc.org.za/num/"><font size="5"><b>NATIONAL
        UNION OF MINEWORKERS</b></font></a> </p>
        <p align="left"><font size="3">The National Union of
        Mineworkers (NUM) was formed in 1982 and represents approximately
        357,000 members in the mining and electrical energy
        industries, the vast majority of the unionised workforce.
        Since its inception, the issues of wages, racial
        discrimination and health and safety have been the pivots
        of its campaigns for improved conditions for mine and
        energy workers. The NUM is the largest recognised
        collective bargaining agent representing workers in the
        mining industry and the electrical energy industry. </font></p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:miner@wn.apc.org"><font
        size="4">miner@wn.apc.org</font></a> </p>
        </td>
    </tr>
    <tr>
        <td><img src="images/Craneive.jpg" width="160"
        height="160"></td>
        <td><p align="center"><a href="http://truck.home.ml.org"><font
        size="5"><strong>WELTEVREDEN CAR AND TRUCK</strong></font></a> </p>
        <p align="left"><font size="3">A family owned Motor Truck
        Supply Company with over 100 years of trucking knowledge
        and experience under all conditions to cater for our
        clients needs. We supply all types of Light, Medium and
        Heavy Truck together with Bodies, Trailers and Ancillary
        Equipment. We also SPECIALIZE in mining markets.</font> </p>
        <p align="center"><font color="#FF0000"><strong>E-MAIL:<br>
        </strong></font><a href="mailto:pearsond@usa.net"><font
        size="4">pearsond@usa.net</font></a> </p>
        </td>
    </tr>
</table>
</center></div>

<p align="center"><br>
<a href="org1.htm"><img src="tb101.gif" alt="organisation"
border="0" width="101" height="17"></a> <a href="res1.htm"><img
src="tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="kruger.htm"><img src="tb104.gif"
alt="Krugerrand" border="0" width="101" height="17"></a> <a
href="new.htm"><img src="tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="info.htm"><img
src="tb106.gif" alt="Contacting us" border="0" width="101"
height="17"></a> <br>
</p>

<hr>

<address>
    <font color="#00FF00" size="2"> 1996, 1997 Chamber of Mines of
    South Africa<br>
    HTML Coding by Andrew Parsons :</font><font color="#FF0000"
    size="2"> </font><a href="mailto:aparsons@bullion.org.za"><font
    color="#FF0000" size="2">aparsons@bullion.org.za</font></a><font
    color="#FF0000" size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-457</DOCNO>
<DOCOLDNO>IA012-000121-B044-162</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/mining.htm 196.26.82.193 19970217005318 text/html 26842
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:56:35 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="World Mining and Minerals Directory"
content="Online Mining and Minerals Directory from the Chamber of Mines of South Africa">
<meta name="keywords"
content="gold, silver, coal, platinum, precious metals, mining, metals, stocks, publications, 
 investment, equipment, services">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>World Mining Directory: Chamber of Mines of South Africa</title>
<base href="http://www.bullion.org.za/">
</head>

<body background="http://www.bullion.org.za/images/BACKAV.gif"
bgcolor="#FFFFFF" text="#000080" vlink="#800080">

<table border="0" width="100%">
    <tr>
        <td align="center" valign="top" width="8%">&nbsp;</td>
        <td align="center" width="75%"><img
        src="http://www.bullion.org.za/images/wmd_banner.gif"
        alt="Chamber of Mines of South Africa World Mining Directory"
        width="500" height="50"></td>
    </tr>
    <tr>
        <td width="8%">&nbsp;</td>
        <td align="center" width="75%"><font color="#008000"><strong>Updated:
        5 February 1997<br>
        </strong></font></td>
    </tr>
    <tr>
        <td width="8%">&nbsp;</td>
        <td align="center" width="75%"><div align="center"><center><table
        border="0" cellpadding="0" width="100%"
        bordercolor="#000000" bordercolordark="#000080"
        bordercolorlight="#808080">
            <tr>
                <td align="center" width="50%" bgcolor="#FFFFFF"><font
                color="#FF0000" size="3"><strong>Welcome to the
                World's Largest<br clear="all">
                Repository of Mining and Minerals<br clear="all">
                Related Information on the 'Net<br>
                </strong></font></td>
                <td align="center" width="50%" bgcolor="#FFFFFF"><font
                color="#FF0000" size="3"><strong>Read what they're saying:<br>
                </strong></font><font color="#008040" size="3"><em><strong><img
                src="http://www.bullion.org.za/images/blue.gif"
                width="14" height="14"> </strong></em></font><a
                href="http://www.pcug.co.uk/~MJOURNAL/#MINSITES"><font
                color="#008040" size="3"><em><strong>Mining Journal</strong></em></font></a><font
                color="#008040" size="3"><strong> </strong><em><strong><img
                src="http://www.bullion.org.za/images/blue.gif"
                width="14" height="14"></strong></em></font><a
                href="http://www.pcug.co.uk/~MJOURNAL/#MINSITES"><font
                color="#008040" size="3"><strong><br>
                </strong></font></a><font color="#008040"
                size="3"><em><strong><img
                src="http://www.bullion.org.za/images/blue.gif"
                width="14" height="14"> </strong></em></font><a
                href="http://www.woza.co.za/minenet.htm"><font
                color="#008040" size="3"><em><strong>Woza Internet
                E-News</strong></em></font></a><font
                color="#008040" size="3"><em><strong> <img
                src="http://www.bullion.org.za/images/blue.gif"
                width="14" height="14"><br>
                </strong></em></font></td>
            </tr>
            <tr>
                <td align="center" bgcolor="#F6F6F6"><a
                href="/handling/resp2.htm"><font color="#800080"
                size="3"><b>CONTRIBUTE</b></font><font
                color="#800080" size="2"><b> </b></font><font
                color="#800080" size="3"><strong>YOUR<br>
                MINING RELATED URL</strong></font></a></td>
                <td align="center" bgcolor="#F6F6F6"><a
                href="samlnks.htm"><font color="#800080" size="3"><b>SOUTH
                AFRICAN MINING<br>
                AND MINERALS DIRECTORY</b></font></a></td>
            </tr>
        </table>
        </center></div></td>
    </tr>
</table>
<div align="center"><center>

<table border="0" cellpadding="2" width="100%">
    <tr>
        <td width="8%">&nbsp;</td>
        <td align="center" colspan="3"><font color="#008000"
        size="5"><strong>CATEGORIES</strong></font></td>
    </tr>
    <tr>
        <td width="8%">&nbsp;</td>
        <td colspan="3"><table border="0" cellpadding="4"
        cellspacing="3" width="100%" bgcolor="#F2F9FF">
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining5.htm#GENERAL"><font size="3"
                face="Arial"><em><strong>Launch Pads</strong></em></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>General mining and minerals
                resources on the 'net</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining3.htm#VARSITY" alt="Academic"><font
                size="3" face="Arial"><strong>Academic</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining related faculties and schools<br>
                </em></font><a href="/mining3.htm#A"><font
                color="#0000A0" size="3" face="Arial"><b>A</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#B"><font color="#0000A0"
                size="3" face="Arial"><b>B</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#C"><font color="#0000A0"
                size="3" face="Arial"><b>C</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#D"><font color="#0000A0"
                size="3" face="Arial"><b>D</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#E"><font color="#0000A0"
                size="3" face="Arial"><b>E</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#F"><font color="#0000A0"
                size="3" face="Arial"><b>F</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#G"><font color="#0000A0"
                size="3" face="Arial"><b>G</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#H"><font color="#0000A0"
                size="3" face="Arial"><b>H</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#I"><font color="#0000A0"
                size="3" face="Arial"><b>I</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#L"><font color="#0000A0"
                size="3" face="Arial"><b>L</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#M"><font color="#0000A0"
                size="3" face="Arial"><b>M</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#N"><font color="#0000A0"
                size="3" face="Arial"><b>N</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#P"><font color="#0000A0"
                size="3" face="Arial"><b>P</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#Q"><font color="#0000A0"
                size="3" face="Arial"><b>Q</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#S"><font color="#0000A0"
                size="3" face="Arial"><b>S</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#T"><font color="#0000A0"
                size="3" face="Arial"><b>T</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#U"><font color="#0000A0"
                size="3" face="Arial"><b>U</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining3.htm#W"><font color="#0000A0"
                size="3" face="Arial"><b>W</b></font></a></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining3.htm#BUSINESS"><font size="3"
                face="Arial"><strong>Business</strong></font></a></td>
                <td width="50%" bgcolor="#EAF4FF"><font
                color="#0000A0" size="4"><em>International business organisations</em></font></td>
            </tr>
            <tr>
                <td bgcolor="#FFE2D9"><a href="mining5.htm#JOBS"
                alt="Mining Careers"><font size="3" face="Arial"><strong>Careers</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining related careers and job
                opportunities</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining2.htm#COMPANIES"
                alt="Mining Companies"><font size="3"
                face="Arial"><strong>Companies</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining and exploration companies<br>
                </em></font><a href="/mining2.htm#A"><font
                color="#0000A0" size="3" face="Arial"><b>A</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#B"><font color="#0000A0"
                size="3" face="Arial"><b>B</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#C"><font color="#0000A0"
                size="3" face="Arial"><b>C</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#D"><font color="#0000A0"
                size="3" face="Arial"><b>D</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#E"><font color="#0000A0"
                size="3" face="Arial"><b>E</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#F"><font color="#0000A0"
                size="3" face="Arial"><b>F</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#G"><font color="#0000A0"
                size="3" face="Arial"><b>G</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#H"><font color="#0000A0"
                size="3" face="Arial"><b>H</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#I"><font color="#0000A0"
                size="3" face="Arial"><b>I</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#J"><font color="#0000A0"
                size="3" face="Arial"><b>J</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#K"><font color="#0000A0"
                size="3" face="Arial"><b>K</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#L"><font color="#0000A0"
                size="3" face="Arial"><b>L</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#M"><font color="#0000A0"
                size="3" face="Arial"><b>M</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#N"><font color="#0000A0"
                size="3" face="Arial"><b>N</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#O"><font color="#0000A0"
                size="3" face="Arial"><b>O</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#P"><font color="#0000A0"
                size="3" face="Arial"><b>P</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#Q"><font color="#0000A0"
                size="3" face="Arial"><b>Q</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#R"><font color="#0000A0"
                size="3" face="Arial"><b>R</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#S"><font color="#0000A0"
                size="3" face="Arial"><b>S</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#T"><font color="#0000A0"
                size="3" face="Arial"><b>T</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#U"><font color="#0000A0"
                size="3" face="Arial"><b>U</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#V"><font color="#0000A0"
                size="3" face="Arial"><b>V</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#W"><font color="#0000A0"
                size="3" face="Arial"><b>W</b></font></a><font
                color="#0000A0" size="3" face="Arial"><b> </b></font><a
                href="/mining2.htm#Y"><font color="#0000A0"
                size="3" face="Arial"><b>Y</b></font><font
                color="#0000A0" size="4"><b> </b></font></a></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining5.htm#courses"><font size="3"
                face="Arial"><strong>Education</strong></font></a></td>
                <td width="50%" bgcolor="#EAF4FF"><font
                color="#0000A0" size="4"><em>Further mining
                education programmes</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining5.htm#symp"><font size="3"
                face="Arial"><strong>Events</strong></font></a></td>
                <td width="50%" bgcolor="#EAF4FF"><font
                color="#0000A0" size="4"><em>Mining conferences,
                symposia, events, seminars</em></font></td>
            </tr>
            <tr>
                <td bgcolor="#FFE2D9"><p align="left"><a
                href="mining5.htm#GOVERNMENT" alt="Goverment"><font
                size="3" face="Arial"><strong>Government / Country</strong></font></a></p>
                </td>
                <td bgcolor="#EAF4FF"><a href="/mining5.htm#arg"><font
                color="#0000A0" size="4"><em>Argentina</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining5.htm#aus"><font
                color="#0000A0" size="4"><em>Australia</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining5.htm#bra"><font
                color="#0000A0" size="4"><em>Brazil</em></font></a><a
                href="/mining5.htm#uk"><font color="#0000A0"
                size="4"><em><br>
                Britain</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a
                href="/mining5.htm#can"><font color="#0000A0"
                size="4"><em><br>
                Canada</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a
                href="/mining5.htm#fin"><font color="#0000A0"
                size="4"><em><br>
                Finland</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a
                href="/mining5.htm#fra"><font color="#0000A0"
                size="4"><em><br>
                France</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a
                href="/mining5.htm#guy"><font color="#0000A0"
                size="4"><em><br>
                Guyana</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a
                href="/mining5.htm#hun"><font color="#0000A0"
                size="4"><em><br>
                Hungary</em></font></a><font color="#0000A0"
                size="4"><em> <br>
                </em></font><a href="/mining5.htm#ind"><font
                color="#0000A0" size="4"><em>Indonesia</em></font></a><font
                color="#0000A0" size="4"><em> </em></font><a
                href="/mining5.htm#jap"><font color="#0000A0"
                size="4"><em><br>
                Japan</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a href="#kor"><font
                color="#0000A0" size="4"><em><br>
                </em></font></a><a href="/mining5.htm#mon"><font
                color="#0000A0" size="4"><em>Mongolia</em></font></a><font
                color="#0000A0" size="4"><em> </em></font><a
                href="/mining5.htm#per"><font color="#0000A0"
                size="4"><em><br>
                Peru</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a
                href="/mining5.htm#saf"><font color="#0000A0"
                size="4"><em><br>
                South Africa</em></font></a><font color="#0000A0"
                size="4"><em> </em></font><a href="#us"><font
                color="#0000A0" size="4"><em><br>
                </em></font></a><a href="/mining5.htm#kor"><font
                color="#0000A0" size="4"><em>South Korea </em></font></a><a
                href="#mon"><font color="#0000A0" size="4"><em><br>
                </em></font></a><a href="/mining5.htm#us"><font
                color="#0000A0" size="4"><em>United States</em></font></a><font
                color="#0000A0" size="4"><em> <br>
                </em></font><a href="/mining5.htm#ven"><font
                color="#0000A0" size="4"><em>Venezuela</em></font></a><font
                color="#0000A0" size="4"><em> </em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining4.htm#invest"><font size="3"
                face="Arial"><strong>Investment</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining related commodities &amp;
                investment information</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining2.htm#RIGHTS" alt="Mineral Rights"><font
                size="3" face="Arial"><strong>Opportunities</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining properties and rights for
                sale</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining5.htm#SOCIETIES"
                alt="Mining Societies"><font size="3"
                face="Arial"><strong>Organisations</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining organisations &amp;
                professional associations</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining5.htm#PUBLICS"
                alt="Mining Publications"><font size="3"
                face="Arial"><strong>Publications</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining related publications and news</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="/mining5.htm#RECREATION"
                alt="Recreational Mining"><font size="3"
                face="Arial"><strong>Recreational</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Recreational mining reources</em></font></td>
            </tr>
            <tr>
                <td width="25%" bgcolor="#FFE2D9"><a
                href="mining2.htm#SERVICE" alt="Mining Service"><font
                size="3" face="Arial"><strong>Services</strong></font></a></td>
                <td bgcolor="#EAF4FF"><a href="/mining2.htm#con"><font
                color="#0000A0" size="4"><em>Consulting</em></font></a><font
                color="#0000A0" size="4"><em> <br>
                </em></font><a href="/mining2.htm#equip"><font
                color="#0000A0" size="4"><em>Equipment</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining2.htm#env"><font
                color="#0000A0" size="4"><em>Environmental</em></font></a><font
                color="#0000A0" size="4"><em> <br>
                </em></font><a href="/mining2.htm#geo"><font
                color="#0000A0" size="4"><em>Geological</em></font></a><font
                color="#0000A0" size="4"><em> <br>
                </em></font><a href="/mining2.htm#mark"><font
                color="#0000A0" size="4"><em>Metals and minerals
                marketing</em></font></a><font color="#0000A0"
                size="4"><em> <br>
                </em></font><a href="/mining2.htm#me"><font
                color="#0000A0" size="4"><em>Mineral Economics</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining2.htm#train"><font
                color="#0000A0" size="4"><em>Mining equipment
                training</em></font></a><font color="#0000A0"
                size="4"><em> <br>
                </em></font><a href="/mining2.htm#legal"><font
                color="#0000A0" size="4"><em>Mining law and legal
                Services<br>
                </em></font></a><a href="/mining2.htm#ref"><font
                color="#0000A0" size="4"><em>Refining and
                Metallurgical Services</em></font></a><font
                color="#0000A0" size="4"><em> <br>
                </em></font><a href="mining2.htm#Rescue"><font
                color="#0000A0" size="4"><em>Rescue Services</em></font></a><a
                href="/mining2.htm#res"><font color="#0000A0"
                size="4"><em><br>
                Resource information</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining2.htm#com"><font
                color="#0000A0" size="4"><em>Technology
                applications</em></font></a><font color="#0000A0"
                size="4"><em> <br clear="all">
                </em></font><a href="mining2.htm#Vehicle"><font
                color="#0000A0" size="4"><em>Vehicle Services</em></font></a></td>
            </tr>
            <tr>
                <td bgcolor="#FFE2D9"><a
                href="mining5.htm#UNIONS" alt="Mining Unions"><font
                size="3" face="Arial"><strong>Unions</strong></font></a></td>
                <td bgcolor="#EAF4FF"><font color="#0000A0"
                size="4"><em>Mining trade unions</em></font></td>
            </tr>
            <tr>
                <td bgcolor="#FFE2D9"><a href="mining4.htm#OTHER"
                alt="Other"><font size="3" face="Arial"><strong>Miscellaneous</strong></font></a></td>
                <td bgcolor="#EAF4FF"><a
                href="/mining4.htm#coalpages"><font
                color="#0000A0" size="4"><em>Coal</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining4.htm#enviro"><font
                color="#0000A0" size="4"><em>Environment</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining4.htm#goldpage"><font
                color="#0000A0" size="4"><em>Gold</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining4.htm#history"><font
                color="#0000A0" size="4"><em>Mining History</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining4.htm#numismatics"><font
                color="#0000A0" size="4"><em>Numismatics</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining4.htm#personal"><font
                color="#0000A0" size="4"><em>Personal pages</em></font></a><font
                color="#0000A0" size="4"><em><br>
                </em></font><a href="/mining4.htm#pot"><font
                color="#0000A0" size="4"><em>Pot luck</em></font></a></td>
            </tr>
        </table>
        </td>
    </tr>
</table>
</center></div>

<hr>

<blockquote>
    <blockquote>
        <blockquote>
            <p align="left"><font size="2"> 1995 - 1997 Chamber
            of Mines of South Africa<br>
            </font><font size="2" face="Times New Roman"><em><tt>HTML
            Coding by Andrew Parsons : </tt></em></font><a
            href="mailto:aparsons@bullion.org.za"><font size="2"
            face="Times New Roman"><em><tt>aparsons@bullion.org.za</tt></em></font></a></p>
        </blockquote>
    </blockquote>
</blockquote>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-458</DOCNO>
<DOCOLDNO>IA012-000121-B044-202</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/images.htm 196.26.82.193 19970217005357 text/html 4279
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:57:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>The Chamber of Mines Graphics Library</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<center><FONT SIZE=5 COLOR=0000A0><b>Chamber of Mines of South Africa</FONT></FONT><p>
<IMG SRC="/images/LOGO1.gif"><p>
<p><h2><CENTER><b><i>Image Library</i></b>
</h2>
<p><br>

<h4>Please Note</h4>
Copyright subsists in these images.  Any unauthorised reproduction, adaptation, distribution or commercial exploitation of the material is an act of copyright infringement.</b></center><br><br><p></center></center></center></center>
<FONT SIZE =4>
<A HREF="/images/cmine1.jpg"><IMG SRC="/images/thum1.jpg" ALIGN=MIDDLE> Surface dump reclamation (30k)</A><P>
<A HREF="/images/cmine2.jpg"><IMG SRC="/images/thum2.jpg" ALIGN=MIDDLE> Underground coal mining (50k)</A><P>
<A HREF="/images/cmine3.jpg"><IMG SRC="/images/thum3.jpg" ALIGN=MIDDLE> Johannesburg mine dump being reclaimed (33k)</A><P>
<A HREF="/images/cmine4.jpg"><IMG SRC="/images/thum4.jpg" ALIGN=MIDDLE> Opencast copper mining (45k)</A><P>
<A HREF="/images/cmine5.jpg"><IMG SRC="/images/thum5.jpg" ALIGN=MIDDLE> Chamber of Mines building, Hollard Street, Johannesburg (49k)</A><P>
<A HREF="/images/cmine6.jpg"><IMG SRC="/images/thum6.jpg" ALIGN=MIDDLE> Gold bars at Rand Refinery (45k)</A><P>
<A HREF="/images/cmine7.jpg"><IMG SRC="/images/thum7.jpg" ALIGN=MIDDLE> Board and pillar coal mining (39k)</A><P>
<A HREF="/images/cmine8.jpg"><IMG SRC="/images/thum8.jpg" ALIGN=MIDDLE> Rehabilitated area of working coal mine (33k)</A><P>
<A HREF="/images/cmine9.jpg"><IMG SRC="/images/thum9.jpg" ALIGN=MIDDLE> Longwall coal mining (43k)</A><P>
<A HREF="/images/mine10.jpg"><IMG SRC="/images/thum10.jpg" ALIGN=MIDDLE> Environmental rehabilitation (44k)</A><P>
<A HREF="/images/mine11.jpg"><IMG SRC="/images/thum11.jpg" ALIGN=MIDDLE> Gold pour (46k)</A><P>
<A HREF="/images/mine12.jpg"><IMG SRC="/images/thum12.jpg" ALIGN=MIDDLE> Opencast coal mining (33k)</A><P>
<A HREF="/images/bar.gif"><IMG SRC="/images/bar9.gif" ALIGN=MIDDLE> 400 oz 'London good delivery' gold bar (67k)</A><P>
<A HREF="/images/k-rand1.gif"><IMG SRC="/images/krand1_9.gif" ALIGN=MIDDLE> One ounce Krugerrand (20k)</A><P>
<A HREF="/images/k-rand3.gif"><IMG SRC="/images/krand3_9.gif" ALIGN=MIDDLE> Full set of Kruggerrands (138k)</A><P>
<A HREF="/images/miner.gif"><IMG SRC="/images/miner9.gif" ALIGN=MIDDLE> Underground gold mining operation (144k)</A><P>
<A HREF="/images/cross.jpg"><IMG SRC="/images/cross9.gif" ALIGN=MIDDLE> Cross-section of underground gold mine (1032k)</A><P>
<A HREF="/images/goldpor.jpg"><IMG SRC="/images/goldpor9.gif" ALIGN=MIDDLE> Gold pour (218k)</A><P>
<A HREF="/images/backfil.jpg"><IMG SRC="/images/backfil9.gif" ALIGN=MIDDLE> Backfill used underground (216k)</A><P>
<A HREF="/images/sa_flag2.gif"><IMG SRC="/images/flag9.gif" ALIGN=MIDDLE> SA Flag (22k)</A><P>
<A HREF="/images/madiba.jpg"><IMG SRC="/images/madiba9.gif" ALIGN=MIDDLE> President Nelson Mandela (84k)</A><P>
</FONT><br>
<center>

<a href=""> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<hr><br><br><br>

<IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>

<A HREF="org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  15 April 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>

</DOC>
<DOC>
<DOCNO>WT14-B39-459</DOCNO>
<DOCOLDNO>IA012-000121-B045-36</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/visit.htm 196.26.82.193 19970217005549 text/html 6562
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:59:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Mines of South Africa: Functions and Services</TITLE>
<CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<a name="top"></a>
<center><FONT SIZE=5 COLOR=0000A0><b>Chamber of Mines of South Africa</FONT></FONT><p>
<IMG SRC="LOGO1.gif"><p></center>
<p><h2><CENTER><b><i>Guided Visit to an Operational Gold Mine </i></b></h2>
<br><p>
<center>
<TABLE BORDER=1 cellpadding=4>
<TR><Th align=center valign=middle><a href="#basic"> Basic Information</a></Th>
<Th align=center valign=middle><a href="#min"> Minimum Requirements</a></Th>
<Th align=center valign=middle><a href="#note"> Important Notices</a></Th>
<Th align=center valign=middle><a href="#typical"> Typical Itinerary</a></Th>
</TR>
</table>
<TABLE BORDER=1 cellpadding=4>
<TR>
<Th align=center valign=middle><a href="#info"> Booking Information</a></Th>
</TR>
</table></CENTER>
<br><p><br><p>
<HR SIZE=4 WIDTH=80% ALIGN=center NOSHADE><p><P>
</center>
<A NAME="basic"></A>
<h3>Basic Information</h3>
Visits take place <U>only once a week</U> most often on Wednesdays, to a pre-booked mine, usually to the Carletonville area (situated a comfortable 45 minutes by road West of Johannesburg).  Visits to the other areas are considerably less frequent.  A minimum of two  weeks notice is required when making a booking, though late bookings can sometimes be considered.  <I><U>Book early to avoid disappointment</U></I>.<br><p>

<center><table border width=100%>
<tr> <th align=center>Area<th> Reporting Time<th> Departure Time<th> Return Time<th> Cost<th> Max. Visitors </tr>
<tr><th align=left> Carletonville <th> 06h30<th> 07h00<th> approx. 16h00<th> R200pp<th> 20
<tr><th align=left> Klerksdorp<th> 05h30<th> 06h00<th>  approx. 17h00<th> R200pp<th> 20
<tr><th align=left>Free State<th>04h30<th>  05h00<th>approx. 18h00<th> R200pp<th> 20
</center></table>

<b><FONT SIZE =2>Payment is required in CASH in South African currency (Rand).   Credit cards are <I><U>NOT </U></I>accepted.  <br>(Costs are subject to yearly increases)<br>
Departure times are <U>strictly adhered to</U> [to fit in with the mine's shift times]. Return times are approximate.<p></FONT></b></center>

<center><IMG SRC="line3.gif" ALIGN=MIDDLE></center><br><p>

<A NAME="min"></A>
<h3>Minimum Requirements</h3>
<UL>
<LI>Visitors must be aged between 16 and 60, and
<LI>In good health with, in particular, no blood pressure or heart disorders.  Claustrophobia sufferers proceed underground<U> at risk</U>. Pregnant visitors are <B><U>NOT</U> </B>allowed underground.
<LI>The underground visit is fairly strenuous and often leaves one sweaty and dirty.  It is therefore recommended that a fresh set of underwear be taken to change into after showering. <FONT SIZE=2> [<I>The mine provides soap/towels/deodorants/etc.</I>]</FONT>
<LI>Dress is <b>smart casual</b>.<br>
<b><FONT SIZE=2>[<I>Note : A complete change of clothing is provided at the mine for the underground visit.</I>]</FONT></b>
</UL>
<p>
<A NAME="note"></A>
<h3>Important Notices</h3>
<UL>
<LI>Report at the designated time to the Chamber representative in the foyer of the Chamber of Mines  building: 5 Hollard Street, MARSHALLTOWN, Johannesburg.  The Chamber occupies a full city block bounded by Sauer, Marshall, Hollard and Main streets.  Hollard Street is a pedestrian walkway.
<LI>There is <B><U>no parking</U></B> available in the Chamber of Mines building.  We suggest that the parking facilities at the Carlton Centre be used as it is open 24 hours. King's Parking in Sauer street (opposite the closed, rear entrance to the Chamber of Mines building) is open from 06h30.
<LI>Photographs may be taken while on surface, and underground on some mines, though many mines  prohibit photography underground due to the presence of methane gas. Check with the mine on arrival if cameras may be taken below surface.
</UL>
<p>

<A NAME="typical"></A>
<h3>A Typical Visit<FONT SIZE=2>  [Programme subject to change]</FONT> </h3>
<UL>
<LI>Depart in the early  morning by coach from the Chamber of Mines building.
<LI>Arrive at the mine.
<LI>Coffee/tea/snacks served to visitors on arrival.
<LI>A presentation on the mining operation and the local geology is given.
<LI>Change into underground gear.
<LI>Proceed deep underground (up to 2 Kms.+) for 1 - 2 1/2 hours.
<LI>Visit <I>actual </I>working areas.
<LI>Return to surface, shower and change into own clothing.
<LI>Witness a gold pour in the smelt house.
<LI>Visit a hostel and/or training centre. <FONT SIZE=2> [<I>Time permitting</I>.]</FONT> 
<LI>Pre-lunch drinks and lunch with senior Management.
<LI>Return in the late afternoon by coach to the Chamber of Mines building.
</UL>
<center><IMG SRC="line3.gif" ALIGN=MIDDLE></center><br><p>

<A NAME="info"></A>
<center><h3>For further information please contact <br>
Ms Betty Elliott or <A HREF="mailto:gbehrent@bullion.org.za">Mr Geoff Behrent:</a></h3></center>
<pre>
<IMG SRC="emm.gif" ALIGN=MIDDLE> <A HREF="mailto:gbehrent@bullion.org.za"><b> Geoff Behrent</b></A>
<IMG SRC="pobox.gif" ALIGN=MIDDLE> Postal Address: P O Box 809, Johannesburg, 2000, South Africa.
<IMG SRC="phone.gif" ALIGN=MIDDLE> Telephone +27 11 498 7204/7200/7100.
<IMG SRC="faxphone.gif" ALIGN=MIDDLE> Facsimile +27 11 838 4251.
</PRE><br><p>
<center>
<a href=""> <IMG SRC="nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br>
<IMG SRC="line3.gif" ALIGN=MIDDLE></center><br>
<a name="toolbar"></a>
<CENTER>
<A HREF="org1.htm"><IMG SRC="tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="res1.htm"><IMG SRC="tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="ess1.htm"><IMG SRC="tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="kruger.htm"><IMG SRC="tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="new.htm"><IMG SRC="tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="info.htm"><IMG SRC="tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  03 September 1996<BR>
&#169 1995 Chamber of Mines of South Africa<br>
This page is maintained by Geoff Behrent: <A HREF="mailto:gbehrent@bullion.org.za">gbehrent@bullion.org.za</a>
</FONT></Address>
</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT14-B39-460</DOCNO>
<DOCOLDNO>IA012-000121-B045-109</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/tmain.htm 196.26.82.193 19970217005649 text/html 4253
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 00:59:48 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>CHAMBER OF MINES OF SOUTH AFRICA</title>
</head>

<body background="images/Pat1.gif" bgcolor="#F2F2F2"
text="#0000A0" link="#0000FF" vlink="#800000">

<p align="center"><font size="6"><b>Chamber of Mines of South
Africa</b></font><br>
<font size="3"><i>Serving South Africa's Private Sector Mining
Industry Since 1889</i></font></p>
<div align="center"><center>

<table border="0" cellspacing="1">
    <tr>
        <td align="right" valign="top"><img
        src="images/hedger.jpg"
        alt="Welcome to our showcase on the South African mining industry"
        align="middle" width="158" height="232"><br>
        </td>
        <td align="center"><a href="/new.htm"><img
        src="images/spare2.gif" alt="What's New?" border="0"
        width="200" height="46"></a><br>
        <a href="org1.htm"><img src="images/spare3.gif"
        alt="Our Organisation" border="0" width="200" height="46"></a><br>
        <a href="res1.htm"><img src="images/spare4.gif"
        alt="Online Resources" border="0" width="200" height="46"></a><br>
        <a href="/kruger.htm"><img src="images/spare5.gif"
        alt="Krugerrand" border="0" width="200" height="46"></a><br>
        <a href="/info.htm"><img src="images/spare6.gif"
        alt="Contacting Us" border="0" width="200" height="46"></a> </td>
        <td valign="top"><img src="images/welc3.JPG"
        alt="The Chamber of Mines Online" align="middle"
        width="158" height="232"></td>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="0" cellpadding="4" width="71%" bgcolor="#FCDE32">
    <tr>
        <th><font color="#EC0000" size="2"><em> 1995, 1996
        Chamber of Mines of South Africa<br>
        </em></font><font color="#800040" size="2">Web Design and
        Management: </font><a href="mailto:twood@bullion.org.za"><font
        color="#800040" size="2">Timothy Wood</font></a></th>
    </tr>
</table>
</center></div>

<p align="center"><font color="#800080"><strong>This site is best
viewed with:<br>
</strong></font><a href="http://www.microsoft.com"><font
color="#008040" face="Arial Narrow"><strong><img
src="images/bestwith.gif" alt="MS Explorer" align="middle"
border="0" width="94" height="35"></strong></font></a><font
color="#008040" face="Arial Narrow"><strong> </strong></font><font
color="#0080FF" size="3" face="Arial"><em><strong>800x600x256</strong></em></font><a
href="http://www.netscape.com/comprod/mirror/client_download.html"><font
color="#0080FF" size="3" face="Arial"><em><strong><img
src="images/Netnow3.gif" alt="Netscape 3" align="middle"
border="0" width="95" height="35"></strong></em></font></a></p>
<div align="center"><center>

<table border="6" cellpadding="4" cellspacing="0"
bordercolor="#800000" bordercolorlight="#FF9D9D">
    <tr>
        <td align="center" bgcolor="#FF0000"><font
        color="#FFFFFF" size="4"><strong>DISCLAIMER</strong></font></td>
    </tr>
</table>
</center></div>

<p align="center"><font color="#000000" size="3">By entering any
of the resources on this site, you have accepted this disclaimer.
Whilst every effort has been made to ensure that information
contained herein is accurate, the Chamber of Mines of South
Africa disclaims all liability for any loss, damage, injury or
expense however caused, arising from the use of, or reliance
upon, in any manner, the information provided through this
service and does not warrant the truth, accuracy or completeness
of the content.</font></p>

<p align="center"><font color="#800080"><strong>Powered by The
Internet Solution<br>
</strong></font><a href="http://www.is.co.za"><font
color="#008040" face="Arial Narrow"><strong><img
src="images/islogo.gif" alt="Interne Solution" border="0"
width="82" height="37"></strong></font></a><font color="#008040"
face="Arial Narrow"><strong><br>
</strong></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-461</DOCNO>
<DOCOLDNO>IA012-000121-B046-108</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/mail.htm 196.26.82.193 19970217010036 text/html 14690
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:04:01 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>The Chamber of Mines Mail</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<h3 align="center"><b>Chamber of Mines of South Africa </b></h3>

<p align="center"><img src="LOGO1.gif" width="300" height="160"></p>

<h2 align="center"><b><i>E-Mail Addresses</i></b> </h2>

<p align="center"><br>
<img src="images/Mail2.gif" width="50" height="30"></p>

<p align="center"><font color="#FF0000" size="2" face="Arial"><b>PLEASE
NOTE</b></font><font size="2" face="Arial"><br>
Please ensure that you are using a valid e-mail address when
making an enquiry. We have received a number of enquiries that have outdated
or incorrect IP addresses and as a result have been unable to
respond.&nbsp;</font></p>
<div align="center"><center>

<table border="2" cellpadding="2">
    <caption align="top"><font color="#FF0000" size="3"><b>GENERAL
    ENQUIRIES</b></font></caption>
    <tr>
        <td bgcolor="#FFEEFF">Web Comments</td>
        <td bgcolor="#FFEEFF">Commercial Enquiries</td>
        <td bgcolor="#FFEEFF">Media Enquiries</td>
        <td align="center" valign="top" bgcolor="#FFEEFF">World
        Mining Directory</td>
    </tr>
    <tr>
        <td align="center"><a
        href="mailto:aparsons@bullion.org.za">Andrew Parsons</a></td>
        <td align="center"><a href="mailto:rboers@bullion.org.za">Reinoud
        Boers</a></td>
        <td align="center"><a href="mailto:lkriel@bullion.org.za">Llewellyn
        Kriel</a></td>
        <td align="center" valign="top"><a
        href="mailto:cjones@bullion.org.za">Cheryl Jones</a></td>
    </tr>
</table>
</center></div>

<p align="center">&nbsp;</p>
<div align="center"><center>

<table border="0" cellpadding="10">
    <tr>
        <td align="center" valign="top" bgcolor="#008080"><font
        color="#FFFFFF" size="4" face="Arial"><strong>E-MAIL</strong></font></td>
        <td align="center" valign="top" bgcolor="#008080"><font
        color="#FFFFFF" size="4" face="Arial"><strong>NAME</strong></font></td>
        <td align="center" valign="top" bgcolor="#008080"><font
        color="#FFFFFF" size="4" face="Arial"><strong>BUSINESS UNIT</strong></font></td>
        <td align="center" valign="top" bgcolor="#008080"><font
        color="#FFFFFF" size="4" face="Arial"><strong>TELEPHONE</strong></font></td>
    </tr>
    <tr>
        <td align="center" colspan="4"><a href="#A"><font
        color="#800040" size="4"><b>A </b></font></a><a href="#B"><font
        color="#800040" size="4"><b>B </b></font></a><a href="#D"><font
        color="#800040" size="4"><b>D </b></font></a><a href="#E"><font
        color="#800040" size="4"><b>E </b></font></a><a href="#F"><font
        color="#800040" size="4"><b>F </b></font></a><a href="#G"><font
        color="#800040" size="4"><b>G </b></font></a><a href="#H"><font
        color="#800040" size="4"><b>H </b></font></a><a href="#K"><font
        color="#800040" size="4"><b>K </b></font></a><a href="#L"><font
        color="#800040" size="4"><b>L </b></font></a><a href="#M"><font
        color="#800040" size="4"><b>M </b></font></a><a href="#O"><font
        color="#800040" size="4"><b>O </b></font></a><a href="#P"><font
        color="#800040" size="4"><b>P </b></font></a><a href="#R"><font
        color="#800040" size="4"><b>R </b></font></a><a href="#S"><font
        color="#800040" size="4"><b>S </b></font></a><a href="#V"><font
        color="#800040" size="4"><b>V </b></font></a><a href="#W"><font
        color="#800040" size="4"><b>W </b></font></a></td>
    </tr>
    <tr>
        <td><a name="A">avanacht@bullion.org.za</a></td>
        <td><a href="mailto:avanacht@bullion.org.za">Achterbergh, Anton
        van</a> </td>
        <td><a href="legal.htm">Legal</a></td>
        <td>498-7378</td>
    </tr>
    <tr>
        <td><a name="B">fbarker@bullion.org.za</a></td>
        <td><a href="mailto:fbarker@bullion.org.za">Barker, Dr
        Frans</a> </td>
        <td>Industrial Relations</td>
        <td>498-7290</td>
    </tr>
    <tr>
        <td>gbarlowj@bullion.org.za</td>
        <td><a href="mailto:gbarlowj@bullion.org.za">Barlow-Jones, Glenda</a> </td>
        <td>Managerial, Mining</td>
        <td>498-7330</td>
    </tr>
    <tr>
        <td>francois@bullion.co.za</td>
        <td><a href="mailto:francois@bullion.co.za">Basson,
        Franois</a> </td>
        <td><a href="/ppu1.htm">Public Policy Unit</a></td>
        <td>021-235-266</td>
    </tr>
    <tr>
        <td>rbaxter@bullion.org.za</td>
        <td><a href="mailto:rbaxter@bullion.org.za">Baxter, Roger</a> </td>
        <td><a href="econ.htm">Economics</a></td>
        <td>498-7663</td>
    </tr>
    <tr>
        <td>gbehrent@bullion.org.za</td>
        <td><a href="mailto:gbehrent@bullion.org.za">Behrent,
        Geoff</a> </td>
        <td><a href="comm.htm">Communications</a></td>
        <td>498-7200</td>
    </tr>
    <tr>
        <td>adnbel@pixie.co.za</td>
        <td><a href="mailto:adnbel@pixie.co.za">Beugger,
        Andre</a> </td>
        <td><a href="/associates/gauteng.htm">Centre for Human Development, Jhb</a></td>
        <td>834-1611</td>
    </tr>
    <tr>
        <td>rboers@bullion.org.za</td>
        <td><a href="mailto:rboers@bullion.org.za">Boers, Reinoud</a> </td>
        <td><a href="comm.htm">Communications</a></td>
        <td>498-7212</td>
    </tr>
    <tr>
        <td>jbotha@bullion.org.za</td>
        <td><a href="mailto:jbotha@bullion.org.za">Botha, Johann</a> </td>
        <td>Corporate and Industry Services</td>
        <td>498-7611</td>
    </tr>
    <tr>
        <td>pbunkell@bullion.org.za</td>
        <td><a href="mailto:pbunkell@bullion.org.za">Bunkell,
        Peter </a></td>
        <td><a href="/departments/comm.htm">Communications</a></td>
        <td>498-7205</td>
    </tr>
    <tr>
        <td><a name="D">adippena@bullion.org.za</a></td>
        <td><a href="mailto:adippena@bullion.org.za">Dippenaar,
        Dr Andr </a></td>
        <td><a href="/departments/edtr.htm">Education</a></td>
        <td>498-7278</td>
    </tr>
    <tr>
        <td><a name="E">vesselaa@bullion.org.za</a></td>
        <td><a href="mailto:vesselaa@bullion.org.za">Esselaar,
        Vic</a> </td>
        <td>Industrial Relations</td>
        <td>498-7555</td>
    </tr>
    <tr>
        <td><a name="F">afrederi@bullion.org.za</a></td>
        <td><a href="mailto:afrederi@bullion.org.za">Fredericks, Alvin</a> </td>
        <td>Technical Support</td>
        <td>498-7445</td>
    </tr>
    <tr>
        <td><a name="G">mgouws@bullion.org.za</a></td>
        <td><a href="mailto:mgouws@bullion.org.za">Gouws, Dr Mike</a> </td>
        <td>Safety</td>
        <td>498-7423</td>
    </tr>
    <tr>
        <td>rgrant@bullion.org.za</td>
        <td><a href="mailto:rgrant@bullion.org.za">Grant, Dr
        Richard</a> </td>
        <td><a href="econ.htm">Economics</a></td>
        <td>498-7457</td>
    </tr>
    <tr>
        <td><a name="H">shannig@bullion.org.za</a></td>
        <td><a href="mailto:shannig@bullion.org.za">Hannig, Sieg</a> </td>
        <td>Industrial Relations</td>
        <td>498-7462</td>
    </tr>
    <tr>
        <td>phenders@bullion.org.za</td>
        <td><a href="mailto:phenders@bullion.org.za">Henderson,
        Paul</a> </td>
        <td>Legal</td>
        <td>498-7370</td>
    </tr>
    <tr>
        <td>jhofsaje@bullion.org.za</td>
        <td><a href="mailto:jhofsaje@bullion.org.za">Hofsajer van Wyk,
        Jeanette</a> </td>
        <td>Information Services</td>
        <td>498-7214</td>
    </tr>
    <tr>
        <td>hhume@bullion.org.za</td>
        <td><a href="mailto:hhume@bullion.org.za">Hume, Dr Howard</a> </td>
        <td>Mining Technology</td>
        <td>498-7522</td>
    </tr>
    <tr>
        <td><a name="K">jkilani@bullion.org.za</a></td>
        <td><a href="mailto:jkilani@bullion.org.za">Kilani, Dr
        John</a> </td>
        <td>Environment</td>
        <td>498-7421</td>
    </tr>
    <tr>
        <td>lkriel@bullion.org.za</td>
        <td><a href="mailto:lkriel@bullion.org.za">Kriel,
        Llewellyn</a> </td>
        <td>Information Services</td>
        <td>498-7316</td>
    </tr>
    <tr>
        <td>dkruger@bullion.org.za</td>
        <td><a href="mailto:dkruger@bullion.org.za">Kruger, Dick</a> </td>
        <td>Technical Support</td>
        <td>498-7275</td>
    </tr>
    <tr>
        <td><a name="L">llagrang@bullion.org.za</a></td>
        <td><a href="mailto:llagrang@bullion.org.za">La Grange,
        Dr Lettie</a> </td>
        <td>Health Services</td>
        <td>498-7331</td>
    </tr>
    <tr>
        <td>sandra@bullion.co.za</td>
        <td><a href="mailto:sandra@bullion.co.za">Lopes, Sandra</a> </td>
        <td><a href="/ppu1.htm">Public Policy Unit</a></td>
        <td>021-235-266</td>
    </tr>
    <tr>
        <td>jlieb@is.co.za</td>
        <td><a href="mailto:jlieb@is.co.za">Liebenberg, Johann</a> </td>
        <td>Managerial, <a href="/ppu1.htm">Public Policy Unit</a></td>
        <td>021-235-266</td>
    </tr>
    <tr>
        <td><a name="M">tmain@bullion.org.za</a></td>
        <td><a href="mailto:tmain@bullion.org.za">Main, Tom</a> </td>
        <td>Managerial</td>
        <td>498-7300</td>
    </tr>
    <tr>
        <td>lminaar@bullion.org.za</td>
        <td><a href="mailto:lminaar@bullion.org.za">Minaar, Lolly</a> </td>
        <td>Industrial Relations</td>
        <td>498-7532</td>
    </tr>
    <tr>
        <td>gmoncur@bullion.org.za</td>
        <td><a href="mailto:gmoncur@bullion.org.za">Moncur,
        Gillian</a> </td>
        <td><a href="gold1.htm">Gold Marketing</a></td>
        <td>498-7560</td>
    </tr>
    <tr>
        <td>amorriso@bullion.org.za</td>
        <td><a href="mailto:amorriso@bullion.org.za">Morrison,
        Amber</a> </td>
        <td>Managerial</td>
        <td>498-7300</td>
    </tr>
    <tr>
        <td><a name="O">soberhol@bullion.org.za</a></td>
        <td><a href="mailto:soberhol@bullion.org.za">Oberholzer, Sandy</a> </td>
        <td>Legal</td>
        <td>498-7381</td>
    </tr>
    <tr>
        <td>tonderst@bullion.org.za</td>
        <td><a href="mailto:tonderst@bullion.org.za">Onderstal, Theresa</a> </td>
        <td><a href="legal.htm">Communications</a></td>
        <td>498-7217</td>
    </tr>
    <tr>
        <td>dowentho@bullion.org.za</td>
        <td><a href="mailto:dowentho@bullion.org.za">Owen-Thomas, Diann</a> </td>
        <td>Statistics</td>
        <td>498-7501</td>
    </tr>
    <tr>
        <td><a name="P">cpalos@bullion.org.za</td>
        <td><a href="mailto:cpalos@bullion.org.za">Palos,
        Christine </a></td>
        <td>Health Services</td>
        <td>498-7390</td>
    </tr>
    <tr>
        <td>aparsons@bullion.org.za</td>
        <td><a href="mailto:aparsons@bullion.org.za">Parsons, Dr Andrew </a></td>
        <td>Managerial</td>
        <td>498-7394</td>
    </tr>
    <tr>
        <td>dpollnow@bullion.org.za</td>
        <td><a href="mailto:dpollnow@bullion.org.za">Pollnow, Dr Daniel </a></td>
        <td><a href="gold1.htm">Managerial, Gold Marketing</a></td>
        <td>498-7332</td>
    </tr>
    <tr>
        <td><a name="R">vreddy@bullion.org.za</a></td>
        <td><a href="mailto:vreddy@bullion.org.za">Reddy, Vino</a> </td>
        <td>IR Bargaining Unit</td>
        <td>498-7367</td>
    </tr>
    <tr>
        <td><a name="S">alsmit@bullion.org.za</a></td>
        <td><a href="mailto:alsmit@bullion.org.za">Smit, Al</a> </td>
        <td><a href="comm.htm">Communications</a></td>
        <td>498-7272</td>
    </tr>
    <tr>
        <td>mspowart@bullion.org.za</td>
        <td><a href="mailto:mspowart@bullion.org.za">Spowart,
        Michael</a> </td>
        <td>Industrial Relations</td>
        <td>498-7413</td>
    </tr>
    <tr>
        <td>jstewart@bullion.org.za</td>
        <td><a href="mailto:jstewart@bullion.org.za">Stewart, Dr
        John</a> </td>
        <td>Managerial, Mining</td>
        <td>498-7312</td>
    </tr>
    <tr>
        <td><a name="V">mvythili@bullion.org.za</a></td>
        <td><a href="mailto:mvythili@bullion.org.za">Vythilingam, Madhu</a> </td>
        <td><a href="/statistics/statsd01.htm">Statistics</a></td>
        <td>498-7365</td>
    </tr>
    <tr>
        <td><a name="W">vwade@bullion.org.za</a></td>
        <td><a href="mailto:vwade@bullion.org.za">Wade, Vanessa</a> </td>
        <td>CoM Medical Aid Society</td>
        <td>498-7605</td>
    </tr>
    <tr>
        <td>rwilson@bullion.org.za</td>
        <td><a href="mailto:rwilson@bullion.org.za">Wilson,
        Robert </a></td>
        <td>CoM Pension Fund</td>
        <td>498-7624</td>
    </tr>
    <tr>
        <td>mwood@bullion.org.za</td>
        <td><a href="mailto:mwood@bullion.org.za">Wood, Maureen</a> </td>
        <td>CoM Services</td>
        <td>498-7611</td>
    </tr>
    <tr>
        <td>dwymer@bullion.org.za</td>
        <td><a href="mailto:dwymer@bullion.org.za">Wymer, Dr Dennis</a> </td>
        <td>Mining Technology</td>
        <td>498-7335</td>
    </tr>
</table>
</center></div>

<p align="center"><img src="/IMAGES/line3.gif" align="middle" width="590"
height="2"></p>

<p align="center"><a name="toolbar"></a> <a href="org1.htm"><img
src="tb101.gif" alt="organisation" border="0" width="101"
height="17"></a> <a href="res1.htm"><img src="tb102.gif"
alt="Resources" border="0" width="101" height="17"></a> <a
href="kruger.htm"><img src="tb104.gif" alt="Krugerrand"
border="0" width="101" height="17"></a> <a href="new.htm"><img
src="tb105.gif" alt="What's New?" border="0" width="101"
height="17"></a> <a href="info.htm"><img src="tb106.gif"
alt="Contacting us" border="0" width="101" height="17"></a> <br>
</p>

<hr>
<div align="left">

<address>
    <font size="2"> 1996, 1997 Chamber of Mines of South Africa<br>
    HTML Coding by Andrew Parsons : </font><a
    href="mailto:aparsons@bullion.org.za"><font size="2">aparsons@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</div>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-462</DOCNO>
<DOCOLDNO>IA012-000122-B001-208</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/speeches/trn2.htm 196.26.82.193 19970217010439 text/html 58127
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:07:02 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Speech by Mr TRN Main at the FT World Gold Conference 1996</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF">
<p align=center><img src="/images/save.gif" align=bottom> <a href="/speeches/venice.zip">Download</a> Address by Mr TRN Main <font size=2><tt>(MS WORD .DOC [zip.36k])</tt></font> <img src="/images/save.gif" align=bottom> <br>
</p>
<p align=center><img src="/images/wd1.gif" align=middle><br>
<font color="#800040"><font size=4><b>ADDRESS</b></font></font></p>
<p align=center><strong>by</strong><br>
<br>
<a href="/cvs/main.htm"><font size=3><strong>Mr TRN Main,</strong></font></a><font size=3><strong> Chief Executive of the Chamber of Mines of South Africa</strong></font><font size=2><strong>, <br>
</strong></font><br>
<font size=3>at the </font><font size=2><br>
</font><br>
<font color="#008000"><font size=4>Financial Times World Gold Conference, Venice.<br>
</font></font><font size=3><strong><i>Monday, 24 June 1995</i></strong></font></p>
<p align=center><br>
<img src="/images/linegr.gif" align=middle></p>
<p align=center><font color="#FF0000"><font size=5><strong>NEW INITIATIVES TO THE YEAR 2000<br>
IN SOUTH AFRICAN MINING</strong></font></font></p>
<p align=center><img src="/images/linegr.gif" align=middle><br>
</p>
<p align=center><font color="#800040"><font size=4><b>CONTENTS</b></font></font> </p>
<p><br>
<a href="#INTRODUCTION">1. <strong>INTRODUCTION</strong>	<br>
</a><a href="#TheRand">The Rand	<br>
</a><a href="#NewConstitution">New Constitution	<br>
</a><a href="#CabinetReshuffle">Cabinet Reshuffle	<br>
</a><a href="#GeneralEconomicComments">General Economic Comments	<br>
</a><br>
<a href="#FUTURE ">2. <strong>GOLD MINING IN SOUTH AFRICA: APPRAISING THE FUTURE</strong>	<br>
</a><br>
<a href="#2.1Introduction"><em>2.1 INTRODUCTION	</em><br>
</a><em><br>
</em><a href="#importance"><em>2.2 THE IMPORTANCE OF GOLD MINING TO SOUTH AFRICA	<br>
</em></a><a href="#ReservesProduction">Reserves and Production<br>
</a><a href="#ContributionGDPGGP">Contribution to GDP and GGP<br>
</a><a href="#exchangeearnings">Gold mining&#146;s contribution to foreign exchange earnings<br>
</a><a href="#employment">Gold mining&#146;s contribution to employment<br>
</a><a href="#miningfinancehouses">The role of the mining finance houses<br>
</a><br>
<a href="#FUNDAMENTALS"><em>2.3 FUNDAMENTALS OF GOLD MINING IN SOUTH AFRICA	<br>
</em></a><a href="#Geology">Geology<br>
</a><a href="#Grades">Grades<br>
</a><a href="#Depth">Depth<br>
</a><a href="#HumanCapital">Human Capital<br>
</a><a href="#RegulatoryEnvironment">Regulatory Environment	<br>
</a><a href="#RevenuesCosts">Revenues and costs	<br>
</a><a href="#Technology">Technology	<br>
</a><br>
<a href="#CONCLUSION"><strong>3. CONCLUSION	<br>
</strong></a><br>
</p>
<hr size=3 noshade>
<p>&#160;</p>
<p><br>
Mr Chairman, Ladies and Gentlemen<br>
<br>
It is a real challenge for a South African from the mining industry to tackle a subject like &quot;New Initiatives to the Year 2000 in 
South African Mining&quot; which I have been asked to speak on this morning. Not only is the gold mining industry itself in an 
incredibly challenging and fascinating period of change, but it is part of the dynamic change driving virtually every aspect of life 
in our country at present. It is therefore necessary for me at least to attempt to contextualise the gold mining industry within 
recent events in South Africa.<br>
<br>
<a name="INTRODUCTION"><strong>1.	INTRODUCTION<br>
</strong></a>Following our welcome political transition to democracy, it is now apparent that a new reality is upon South Africa. The 
so-called &#145;Mandela dividend&#146; has begun to wane as South Africa comes to grips with the demands of international integration. 
While the political process will remain a global icon for democracy and conflict resolution, the next phase of democratic 
consolidation requires addressing the imperatives of sustainable growth and development.<br>
<br>
This will be characterised by South Africa&#146;s full readmission to the international political economy and the country&#146;s efforts to 
deal with the pace, depth and breadth of change that is sweeping the globe. South Africa&#146;s future will, to a great extent, be 
determined by its success in aligning itself with the trends and forces shaping the global economy.<br>
<br>
Consequently, recent developments in South Africa require some elucidation. Primarily, there are three events that have 
caught the world&#146;s attention recently: the collapse of the Rand, the adoption of a new constitution and the withdrawal of the 
National Party from the Government of National Unity.<br>
<br>
<a name="TheRand"><strong>The Rand<br>
</strong></a>The Rand&#146;s recent depreciation cannot be ascribed to one factor. Its volatility was a consequence of increasing apprehension, 
whether valid or not, about the government&#146;s seeming inability to produce a coherent macroeconomic strategy. Beginning with 
the 1996/97 budget, the markets signalled that there was considerable disappointment in ex Minister Liebenberg&#146;s rather 
passive budget. There was some expectation of an announcement regarding exchange controls and improved revenue and 
expenditure trends.<br>
<br>
While a combination of factors was responsible, a central concern was a perception that the government has failed to address 
the exigencies of growth and development following the tabling of the South Africa Foundation and Labour Movement 
strategy documents. The RDP could not equate to a viable macroeconomic strategy and the country is in dire need of greater 
policy certainty - from a domestic and foreign investment point of view.<br>
<br>
The Rand slid further on rumours of Mr Liebenberg&#146;s resignation and the government&#146;s failure to act decisively must be seen 
as a primary cause of the instability. Mr Liebenberg&#146;s successor, Mr Trevor Manuel, did compound the problems by passing 
some comments about the markets which were open to misinterpretation. However, I do not believe that the depreciation was 
a negative response to Mr Manuel&#146;s appointment. South African business remains optimistic that Minister Manuel will bring 
the same drive to the finance portfolio which he applied to trade and industry. As with any change, be it in business or in 
government, there is a period of unfamiliarity - but we expect Minister Manuel to perform his task just as competently as his 
predecessors.<br>
<br>
<a name="NewConstitution"><strong>New Constitution<br>
</strong></a>The Constitutional Assembly, rather remarkably, managed to meet the deadline of 8 May 1996 and present the country with a 
new constitution. The constitution is by no means a perfect document but it is an incomparable improvement on what South 
Africa has endured previously. We are certainly looking forward to the positive impact that the constitution will have on the 
lives of all South Africa&#146;s citizens. It is, of course, still subject to analysis and codification by the Constitutional Court to ensure 
that it complies with the principles previously laid down.<br>
<br>
No doubt many of you will recall that the issue of the lockout clause to counter-balance the right to strike remains unresolved. 
The current formulation is prejudicial to employers and we believe that it is a dangerous signal given our dependence on 
international investment. Consequently, the clause will be subject to further debate in the Constitutional Court and we are 
hopeful of a more favourable formulation.<br>
<br>
<a name="CabinetReshuffle"><strong>Cabinet Reshuffle<br>
</strong></a>The withdrawal of the National Party from government and the subsequent cabinet reshuffle left many observers confused. I 
do not believe that the withdrawal was in any way remarkable or unexpected. There were indications for some time that there 
was considerable discomfort within the National Party about its role in government. Their participation in a coalition 
government necessarily diminished their capacity to act independently. <br>
<br>
I believe that the emergence of a more visible opposition, at least numerically, will contribute immeasurably to the democratic 
tradition that is evolving. Similarly, the ANC as the government of the day is now less constrained in its policy applications as 
well as more exposed to criticism thereof. The withdrawal should be viewed as another element in the transition process 
toward the next regular general election to be held in 1999.<br>
<br>
<a name="GeneralEconomicComments"><strong>General Economic Comments<br>
</strong></a>As I mentioned previously, the reality of international competition is beginning to tell in South Africa. Accordingly, it is 
heartening to see that the reality is reflected in much of the policy revision that is underway. The primary challenges are in the 
following areas:<br>
&#183; Growth and development strategy<br>
&#183; Liberalisation, deregulation, privatisation<br>
&#183; Foreign exchange controls<br>
&#183; Competition &amp; industrial policy<br>
&#183; Labour market policy<br>
&#183; Fiscal discipline<br>
&#183; Crime and violence<br>
<br>
&#183; Since coming to power, the government has yet to deliver a credible growth and development strategy. It is now imperative 
that a strategy be delivered that creates certainty for domestic and foreign investors alike, mapping out the government&#146;s 
economic programme in an unambiguous manner. Ideally, such a strategy should avoid attempting to develop an all-embracing 
policy in every conceivable area - prioritisation and firm action is required.<br>
&#183; Some of those priorities encompass clear policy on liberalisation, deregulation and privatisation. While we accept that there 
are no ideal models for South Africa to emulate in this regard, there is sufficient evidence from the lessons of the past to guide 
policy formulation in these critical areas.<br>
&#183; Similarly, competition and industrial policy are central concerns for the mining industry and greater certainty and clarity is 
required from the government to ensure that South Africa&#146;s international competitiveness is enhanced and that the industrial 
policy mistakes of the past are not repeated.<br>
&#183; Labour market policy is a central concern to the mining industry given the high proportion of labour costs. From a broader 
perspective, unemployment in South Africa is unacceptably high and an appropriate policy balance is required that prevents 
exploitation whilst creating the greatest number of job opportunities.<br>
&#183; The government&#146;s record on fiscal discipline is satisfactory although there is considerable room for improvement in terms of 
trimming the bureaucracy and weeding out petty corruption.<br>
&#183; Crime and violence has become endemic in every sphere and the drain on the economy is especially burdensome as 
measures are taken to prevent or insure losses.<br>
<br>
While we cannot profess to be entirely satisfied with developments in every area, we remain optimistic that the government 
will continue the trend toward international alignment and integration. We are encouraged by the market orientation of the 
government - after all, economic prosperity, unlike economic ruin, cannot be achieved through legislation and social progress, 
unlike social decline, cannot be created by regulation.<br>
<br>
<br>
<a name="FUTURE "><strong>2.	GOLD MINING IN SOUTH AFRICA: APPRAISING THE FUTURE <br>
</strong></a>I shall begin by explaining the centrality of gold mining to South Africa, including an overview of the role of the mining finance 
houses. I shall follow with an explanation of the fundamentals that govern gold mining in South Africa, introducing views on 
developments in the gold mining industry that point to its continued global dominance up to, and well beyond, the year 2000.<br>
<br>
<a name="2.1Introduction">2.1	<strong>Introduction</strong></a><br>
Recent press on the South African gold mining industry has painted a somewhat sombre and foreboding picture of its future. It 
certainly is true that the gold mining industry, undisputedly South Africa&#146;s economic foundation and mainstay, is facing 
significant challenges.<br>
<br>
Let me say immediately though, that the industry, despite the challenges of maturity, remains robust, energetic and more 
innovative than ever. It will, far into the twenty first century, remain a reliable economic generator and wealth creator for the 
Southern African region, not just South Africa. As such, we should expect South Africa to continue contributing the dominant 
share of world gold production for many years to come.<br>
<br>
Descriptions of a crisis in the industry are perhaps exaggerated. There are, indeed, serious concerns about the continuing 
decline in profitability in the face of high working costs and a relatively stagnant dollar gold price. However, the industry has 
responded to the challenges and we are seeing exciting progress where problems have been addressed creatively. It is 
apparent that this creativity is generating new production and revenue axioms, based principally on profit maximisation as 
opposed to the narrower focus on cost management.<br>
<br>
The industry is inherently resilient and adaptive, as demonstrated by 110 years of gold mining on the Witwatersrand. We 
should not underestimate some of the obstacles, but by the same token, we should not regard them as insurmountable and 
apocalyptic.<br>
<br>
<br>
<a name="importance"><strong>2.2	The importance of gold mining to South Africa<br>
</strong></a>Gold mining in South Africa, from its humble beginnings in the first recorded mine in Eesterling in the Northern Province in 
1871 to its pre-eminence as the largest gold mining industry in the world, has played a significant role in the economic 
development of the country over the past 120 years. Through gold mining, many towns and cities have come into being. 
Notable examples include Johannesburg, Welkom, Orkney, Springs, Benoni, Witbank and Klerksdorp. Much of the 
infrastructural development of roads, electricity generation, water reticulation, telecommunications, housing and the 
development of secondary industry, are products of the gold mining industry.<br>
<br>
<a name="ReservesProduction"><strong>Reserves and Production<br>
</strong></a>South Africa has about 40 per cent of known world gold reserves. The following graph shows South Africa&#146;s role in global 
mineral reserves and production:<br>
<br>
The South African mining industry has been the mainstay of the South African economy for over a century. Gold and 
diamonds are the two highly valued minerals which were largely instrumental in the development of the country's infrastructure 
and the establishment of secondary industry during the first half of the twentieth century.<br>
<br>
<a name="ContributionGDPGGP"><strong>Contribution to GDP and GGP<br>
</strong></a>Gold mining has played a pivotal role in the economic development of the domestic economy, contributing 4,8 per cent in 
broad macro-economic terms to GDP in 1995. This is substantially down from the 17 per cent direct contribution recorded in 
1980 when the gold price peaked. The following graph illustrates the contribution gold mining and other mining have made to 
GDP:<br>
<br>
Although the relative importance of gold mining has fluctuated over the last decade with the performance of the gold price, 
gold mining still contributes just under 5 per cent directly to GDP. Taking into consideration the indirect contribution to the 
economy and the multiplier effects, gold mining's total contribution to GDP is closer to 10 per cent. These multiplier effects 
include:<br>
&#183; Backward linkages, which arise from the purchase of goods and services by the gold mining industry which stimulate 
industrial production and the provision of services (e.g. gold mines consume 15 per cent of all electricity generated in South 
Africa).<br>
&#183; Forward linkages, arising from the use of mineral products in other domestic industries, such as jewellery fabrication and 
production of refined gold.<br>
&#183; Social multipliers which arise from the role of mining in the development of human resources and infrastructure such as 
schools, colleges, clinics, roads, and housing.<br>
&#183; The primary incomes multiplier which arises from household expenditures of primary incomes derived from mining.<br>
&#183; The employment multiplier, which arises from the employment created in other industries as a result of gold mining. This 
multiplier includes the benefits of the provision of employment for workers from deep rural communities and the transfer of 
funds back to these areas.<br>
&#183; The income terms-of-trade multiplier which arises from the positive impact that gold export earnings have on the balance of 
payments, foreign reserves, monetary policy and ultimately upon the general level of business activity in the country.<br>
&#183; The capital formation multiplier which arises from mining&#146;s influence in attracting foreign capital to the country (via the 
Johannesburg Stock Exchange or via direct investment), and in domestic capital formation.<br>
<br>
The gold mining industry also contributes substantially to the national fiscus, both directly and indirectly. For the fiscal year 
1994/95, the estimated total direct taxation paid by gold mining was R1,5 billion. Multiplier effects from gold mining in 
stimulating taxation paid by other companies which supply mining products or which use mining products, or by individuals 
who earn their primary incomes from gold mining, plus indirect taxes paid by the gold mining industry (such as tax on fuel) also 
need to be weighed in their contribution to the national fiscus.<br>
<br>
The contribution of gold mining to economic growth in certain provinces is significantly greater than the contribution it makes 
to the overall economy. As illustrated in Table 1 below, the mining sector was responsible for approximately 20 per cent of 
the Gross Geographic Product (GGP) of the Free State, 40,5 per cent of GGP of the North West Province, 24,6 per cent of 
the Northern Cape Province, 20,4 per cent of the Mpumulanga Province, and 20,1 per cent of the Northern Province. Gold 
mining played a significant role in the Free State, Gauteng, and the North West Province.<br>
</p>
<p>By the same token, the closure of some gold mines would have a significant impact on the economies and the socio-economic 
welfare of towns such as Welkom, Virginia, Carletonville and Stilfontein.<br>
<br>
In quantifying the overall contribution of the gold mining industry to the sub-economy of each region, consideration should be 
given to the multiplier effects generated by the industry. Multiplier effects are largely determined by the kind of industry which 
an activity supports, which in the case of mining tends to be more strongly connected to so called &quot;backward linkages&quot;, such 
as electricity, community services and manufacturing sectors. For example, in the Free State, the mining industry consumes 
some 76 per cent of electricity produced and 36 per cent of manufacturing output. Insofar as these purchases stimulate local 
industrial production, the eventual value added in the economy is larger than that raised in the gold mining sector alone. <br>
<br>
<a name="exchangeearnings"><strong>Gold mining&#146;s contribution to foreign exchange earnings<br>
</strong></a>The export of primary minerals from South Africa has accounted for the largest portion of total foreign exchange earnings for 
many years as illustrated in the following graph:<br>
<br>
Gold has been South Africa&#146;s largest export for a number of years and in 1995 earned about 20 per cent of South Africa&#146;s 
foreign exchange. Although declining from more than 50 per cent in 1983 to just more than 20 per cent in 1995, the 
importance of these earnings has been in the form of the &quot;incomes terms-of-trade multiplier&quot;. Gold mining, while being a very 
high net generator of foreign exchange, is also a very low net user of foreign exchange. Much of the materials used in gold 
mining are sourced from the domestic economy (which also shows that much of the mining technology has been developed 
locally). Manufacturing, on the other hand, is a very high net user of foreign exchange for the importation of machinery and 
equipment from overseas (and this implies the importation of technology). Due to the constraints of financial sanctions (and 
thus the requirement that South Africa maintain a current account surplus) much of the machinery imported by manufacturing 
was purchased via the foreign exchange earnings of gold mining. <br>
<br>
More recently, although South Africa has the capacity to run a current account deficit, this capacity has been constrained by 
the degree of capital inflows and access to international financing. In the past, monetary policy (high interest rates) was used to 
curtail the import propensity of domestic industry if the current account of the balance of payments was jeopardised. More 
recently, monetary policy has been used to maintain financial stability rather than to curb cyclical upswings in the domestic 
economy. However, if the deficit on the current account becomes too high the monetary authorities could be forced to curtail 
domestic business activity by way of higher interest rates. Importantly, the bulk of foreign exchange still needs to be derived 
from exports, and in this respect alone gold mining has a major role to play.<br>
<br>
The gold mining industry will therefore continue to play a substantial role in the export earnings of South Africa, thus impacting 
on the current account of the balance of payments, on monetary policy and on the general level of business activity in the 
country.<br>
<br>
<a name="employment"><strong>Gold mining&#146;s contribution to employment<br>
</strong></a>Gold mines employed some 340 000 workers in 1995, representing approximately 2,3 per cent of the total economically 
active population or 3,5 per cent of all those formally employed in the economy. Approximately R8 billion was paid to these 
mine workers as wages. Employment levels have been declining steadily since 1987 when approximately 520 000 people 
were employed in the gold mining sector. <br>
<br>
<a name="miningfinancehouses"><strong>The role of the mining finance houses<br>
</strong></a>The mining houses developed out of sheer necessity, primarily during the late 1880s and the early 1890s. They remain in many 
ways peculiar to South Africa, although similar transnational organisations have emerged and are emerging in other countries.<br>
<br>
The mining finance houses developed to bridge the immense problems associated with deep-level mining. Mines and 
companies formed partnerships to overcome poor communications and rudimentary physical infrastructure, consolidate 
financial resources and make the ventures attractive to cautious foreign investors.<br>
<br>
These early partnerships and companies were the precursors of the Group System or &#145;mining houses&#146; as they are known 
today. They continue to provide capital and expertise for the development of new mines and for the expansion, development 
and management of their member mines.<br>
<br>
The mining finance house flourished in South Africa largely because of the country&#146;s system of mineral rights. Unlike most 
other countries, South African mines operate within fixed mining lease areas and do not enjoy &#145;blue-sky&#146; potential. This means 
that each mine has finite reserves and usually cannot undertake new projects of its own accord. Thus, the mining houses play a 
crucial role in establishing new mining opportunities.<br>
<br>
The purpose and functions of a mining finance house might be summarised as follows:<br>
1. Absorbs the initial costs and risks associated with exploration and feasibility studies.<br>
2. Funds the initial development of the ore body in preparation to bring it to production. <br>
3. Equity finance is raised to bring the mine to production by way of shareholders&#146; capital or loans. This is usually 
accompanied by a subsequent rights issue to secure completion.<br>
4. Cash flow and development capital is maintained through progressive dilution of the mining house&#146;s equity stake over the 
mine&#146;s lifetime in addition to a management contract between the mining house and the mine.<br>
5. The management contract provides scarce managerial and technical skills, applying them to the complexities of deep level 
gold mining. Similarly, the management contract allows mines to benefit from the buying power and administrative overheads 
of the mining houses.<br>
<br>
The system has proved highly cost effective and efficient, as some other mining countries have found. Many more of our 
marginal mines would have closed down long ago - or much sooner than they did - had it not been for the backing and expert 
management of a mining house. The management contract system principally enables mining houses to buffer individual mines 
against unexpected external shocks which might otherwise destroy them.<br>
<br>
Much has been said and written lately on the issue of management contracts. I would not venture a position since the cases for 
and against each point of view have merit. However, I believe that it is essential for us to recognise that each South African 
gold mine is unique and consequently has unique financing, production, sales and administrative needs. These cannot be met 
by an inflexible system and as a result we have seen a number of management innovations to ensure that gold mines produce 
every ounce of gold that is economically viable. <br>
<br>
Consequently, management contracts can be expected to be renegotiated and most importantly, the groups will restructure 
according to their needs. These needs are increasingly being driven by internationalisation efforts and the challenge of strong 
competition in a global mineral resources market. Many have improved their commodity cycle exposure and are aggressively 
looking for new business opportunities. The mining houses will continue to exist and they will continue to be important players, 
albeit with modified means and ends.<br>
<br>
<br>
<a name="FUNDAMENTALS"><strong>2.3	FUNDAMENTALS OF GOLD MINING IN SOUTH AFRICA<br>
</strong></a>Gold mining in South Africa is best understood in terms of seven fundamental pillars that form an interactive system that makes 
mining our unique gold ore bodies possible:<br>
1. geology;<br>
2. grades;<br>
3. depth;<br>
4. human capital;<br>
5. regulatory environment;<br>
6. revenues and costs; and<br>
7. technology.<br>
<br>
<a name="Geology"><strong>Geology<br>
</strong></a>The gold-bearing reefs of the Witwatersrand Basin are placer deposits laid down over two million years ago in what was then 
an inland sea. The Wits Basin is unparalleled in its gold mineralisation although it does bear a geological resemblance to some 
shallow alluvial deposits elsewhere in the world.<br>
<br>
The gold-bearing reefs form a vast &#145;golden arc&#146; of approximately 250 kilometres, stretching from Welkom in the Free State to 
Evander in Mpumalanga. The reefs are characteristically a metre in thickness, dipping down at 20 degrees, and there is 
frequently more than one reef horizon. The hard quartzitic rock presents a number of complex rock engineering problems, 
exacerbated by frequent faults and dyke intrusions that make deep-level gold mining in South Africa geologically and 
seismically hazardous.<br>
<br>
<a name="Grades"><strong>Grades<br>
</strong></a>Grade recovery is the most fundamental issue in understanding the economics of mining. In South Africa, grade recovery is 
assessed in terms of the &#145;mill pay-limit&#146; concept. The pay-limit is the final arbiter in determining whether an ore body is 
payable or not.<br>
<br>
By definition, the mill pay limit of a gold mine is the minimum amount of gold which must be recovered from a ton of gold ore 
milled in order to break even at a certain level of working costs and gold price, excluding capital expenditure. The formula 
used to calculate the pay limit divides the average working cost per ton milled by the gold price per gram.<br>
<br>
As you can see in this slide, the recovered grade has declined significantly since 1970, falling from an average of 13 grams per 
ton to 4,5 grams per ton in 1995. The immediate explanation for this decline is simply that the reefs mined first had a richer 
gold mineralisation and they were relatively shallow which kept working costs down. <br>
<br>
Obviously, it is evident that the ore grades are declining and this is an irreversible trend that impacts on profitability enormously 
because it reduces a mine&#146;s flexibility to respond to strong price movements. We are now seeing creative strategies to ensure 
that the wasting assets are optimally mined and to prevent the temptation to poach higher-grades in a piece-meal fashion. <br>
<br>
The second noteworthy factor is that the sustained depreciation of the Rand against the Dollar made it viable for mines to 
extract lower-grade ores, contributing to a lower average grade for the industry as a whole.<br>
<br>
<a name="Depth"><strong>Depth<br>
</strong></a>As I explained previously, geology dictates that most gold mines must operate at substantial depths. Historically, the dipping 
reefs eventually rendered small mines unviable, leading to consolidation as the surface outcrops and shallow deposits were 
mined out. This was primarily because of the enormous costs and risks associated with increasing depths which small 
enterprises could not manage effectively.<br>
<br>
Ore bodies are now generally mined at depths between 2000 and 4000 metres, accessed through a system of shafts and sub 
vertical shafts. The cost of shaft construction dictates mine design to a great extent and we have seen the importance of 
economies of scale to achieve profitable extraction - hence the strength of the mining houses. This has encouraged the 
formation of super-mines and we expect to see further lease-area consolidation in the future. Similarly, we have seen 
co-operation between adjacent mines to mine previously economically inaccessible areas using each others&#146; infrastructure.<br>
<br>
Shafts and all the mine levels have to be equipped with the infrastructure necessary for mining such as compressed air, water, 
ventilation, roof supports, electricity and fixed track systems. Thousands of men, tons of timber and millions of litres of water 
have to be conveyed between the working areas and the surface each day. The temperature at these depths also demands 
vast ventilation and cooling systems that necessitate generating and transporting tons of crushed ice down to the working areas 
every day. There is also the risk of pressure bursts countered by innovative rock engineering techniques and seismic 
monitoring that are continually under development. <br>
<br>
All these aspects have a cost implication and as depths increase, costs tend to increase exponentially. Consequently, the 
viability of deep deposits is a central concern and one that receives constant attention. The basic mining method and hence the 
cost structure, in the absence of significant technological break-throughs, will remain much the same.<br>
<br>
<a name="HumanCapital"><strong>Human Capital<br>
</strong></a>It is evident that the unique gold mineralisation of the Witwatersrand Basin could not have been exploited anywhere else but in 
South Africa. A unique complex of factors combined to produce the cost structure that has enabled mining to continue for 
over 100 years. Labour has been a major element of that cost structure and the historical struggle to secure abundant labour 
at an economic rate remains central to South African gold mining. New human resource requirements will continue to stimulate 
developments in a number of areas.<br>
<br>
Estimates of an employment multiplier for the gold mining industry indicate that for every three people employed on a mine, 
another one person is employed by industries which serve the mining industry, both directly and indirectly. It is also estimated 
that every worker in the gold mining industry has between seven and ten dependants, thereby highlighting the social 
importance of the industry.<br>
<br>
Surrounding countries, such as Lesotho and Mozambique, between them supply some 40 per cent of the migrant labour 
employed in South African gold mines. Through the repatriation of part of the employee's earnings, these countries derive 
substantial benefits in the form of foreign exchange earnings, and the employment of their nationals.<br>
<br>
As can be expected in a mature industry such as South Africa&#146;s, employment has declined steadily since the late 1980s. As 
shown in the graph, 192 000 jobs, or 36,7 per cent of the labour in service since January 1987, have been lost. This can be 
ascribed to improved mining methods that reduce labour intensivity, diminishing ore bodies, declining profit margins and the 
increasing use of contractors.<br>
<br>
Because of the difficulties associated with deep-level gold mining, labour intensivity remains high by international standards in 
combination with high capital intensivity ratios. The bulk of the labour force is made up of semi-skilled employees drawn from 
South Africa and its neighbouring countries. While migrancy is not an ideal condition, we need to recognise the dual 
dependence that sustains many deep-rural communities that would otherwise be abandoned.<br>
<br>
Labour management issues have gained much press in recent years, partly as a result of the role organised labour played in the 
larger democratic process and because of changes within the industry. We do not expect the institutional relationship to 
become any easier. However, new participative management programmes are beginning to improve conditions in the 
workplace and disruptions and unrest are declining. Certainly, there is little prospect of gold mining employment re-attaining its 
1986 peak of over 600 000 jobs although employment is expected to stabilise at present levels for some time.<br>
<br>
The institutional aspects relate largely to the sweeping reforms that are underway in South Africa. Virtually no aspect of the 
legislative framework remains untouched and labour legislation has received special attention for obvious reasons.<br>
<br>
As part of a broader legislative revision process, a new Labour Relations Act, Employment Standards Act, Employment 
Equity Act and attempts to promote a tripartite &#145;Social Accord&#146; are all elements that will impact on the management-labour 
relationship but more especially on costs. The industry is responding to these developments positively through its collective 
bargaining structures and we expect to conclude a tough round of negotiations this year that will be a qualitative improvement 
over the evolving legislative framework.<br>
<br>
The industry has made significant progress in addressing the legacy of underdevelopment which impacts strongly on its 
employees. It should be noted that the industry addressed these issues over many years - they were not knee-jerk responses 
to external pressures or motivated by political correctness. Examples of this include the fight against race-based job 
reservation.<br>
<br>
In education, industry agreements have been negotiated on Adult Basic Education and Training (ABET), Paid Education and 
Training Leave (PETL) and competency-based training. At mine level, there is excellent progress with multi-skilling and 
up-skilling programmes. The industry is also intimately involved in health policy, and an AIDS agreement has been negotiated 
to ensure that employees are empowered to respond to the dangers of HIV and AIDS infection whilst protecting employees 
from possible discrimination if infected.<br>
<br>
Similarly, the annual review of wages and conditions of employment produces a variety of settlements covering issues such as 
industry restructuring, housing, contract labour, safety, affirmative action and union capacity building. Indeed, the industry&#146;s 
progressive interaction with its stakeholders has given it a significant advantage with regard to the ongoing national policy 
debates and any adjustments that are required will not be unexpected.<br>
<br>
A new Mine Health and Safety Act will be codified this year which we welcome. We remain vehemently opposed to the 
reversal of onus clause in the present Act which will shortly be further debated in the Constitutional Court to assess its 
constitutionality, but ultimately, the Act will contribute to a safer mining environment which is absolutely essential. The industry 
has been criticised repeatedly for its supposedly fatalistic attitude toward safety - that is not the case and safety criteria will 
remain at the heart of every mining enterprise. The industry has also invested extensively in social responsibility programmes 
with the objective of stimulating growth and development across a broader socio-economic plane.<br>
<br>
The net long-term result will be a better skilled workforce that is motivated and productive. In the interim though, we must 
recognise that there are immediate threats to the industry.<br>
<br>
In partial response to these threats and in order to improve the productivity of labour and capital, a number of strategies have 
been developed aimed at the restructuring of the industry towards productivity improvements&#146;. This includes full calendar year 
operations, (FULCO) two tier bargaining and investment in human capital as I have described. <br>
<br>
<a name="RegulatoryEnvironment"><strong>Regulatory Environment<br>
</strong></a>Government has played an important role in the development of gold mining in South Africa and it will continue to do so in 
terms of a common long-term interest. The mining industry&#146;s requirements in this regard are simple and, I believe, eminently 
reasonable: a sound, market-based economic system, a stable political environment, meaningful efforts to combat crime and 
lawlessness, a steady and predictable system of taxation which reflects the fact that we turn to account non-renewable assets, 
incentives to advance technology and a sufficient portion of distributable profits to be returned to shareholders.<br>
<br>
In addition there are a host of policy areas that require sound, co-operative governance to maximise the contributions of the 
industry. The South African mining industry, through the Chamber of Mines, is involved in policy formulation in a number of 
areas, including:<br>
&#183; Mining and minerals policy: a policy review process is currently underway involving government, business and labour. The 
intention is to develop a comprehensive policy that will enhance the mining industry&#146;s competitiveness and create opportunities 
for new mining and beneficiation investment.<br>
&#183; Energy: energy policy is being revised to manage the unique problems and opportunities in this sector. Electricity and liquid 
fuels are important cost elements for the industry and it is participating in the policy process to ensure optimal pricing and 
stable delivery. <br>
&#183; Water: water pricing and use has become a key policy area given that no new water sources will be available within South 
Africa after the completion of the Lesotho Highlands water scheme. The distribution of water to neglected communities, 
pollution and cost recovery pricing mechanisms are some of the issues under review which the industry is debating with other 
stakeholders as an important consumer.<br>
&#183; Science and technology: South Africa has a poor record in nurturing scientific and technology competencies which are critical 
for a developing economy such as ours. Accordingly, the mining industry is intimately involved in developing appropriate 
strategies and policies for its own needs as well as with regard to broader national requirements.<br>
&#183; Transport: the mining industry is reliant on cost effective and efficient transport across road, rail, air and sea. This sector has 
been dominated by state run institutions in the past and the challenge will be to secure internationally competitive services for 
domestic and international use.<br>
&#183; Taxation: South Africa&#146;s tax code is being systematically reviewed by the Katz Commission. The code is presently 
complicated and a deterrent to investment. The mining industry has been particularly troubled by the ring-fencing provision as 
well as additional levies and imposts. The industry is providing input on key aspects of the tax code revisions, particularly 
where the industry is treated unusually.<br>
&#183; Retirement benefits: the Smith Committee is currently investigating retirement benefits and the industry is closely involved in 
the deliberations to ensure that its interests, and especially those of its employees, are understood and catered for.<br>
&#183; Health: the mining industry maintains extensive health services up to tertiary level and is participating in policy debates about 
national health care provision and epidemiological problems in the industry such as HIV and tuberculosis.<br>
&#183; Workmen&#146;s compensation: occupational health and compensation policy is currently under review and the industry is an 
important stakeholder as the single largest private sector employer.<br>
&#183; Housing: a new national housing policy framework has been negotiated for South Africa, which the mining industry 
participated in through Business South Africa. The mining industry provides accommodation to its employees and remains 
closely involved in policy developments at national and provincial level.<br>
&#183; Privatisation: meaningful privatisation will have positive cost benefits for the mining industry, especially in terms of transport 
and telecommunications. <br>
&#183; Competition policy: the government has yet to deliver a comprehensive competition policy and this can be ascribed to 
interpretive confusion about company size and market capitalisation. The Chamber represents many of South Africa&#146;s largest 
corporations and it is therefore monitoring the policy process very keenly.<br>
&#183; Industrial policy: South Africa&#146;s previous industrial policy was oriented toward import substitution which left the economy 
structurally impaired. A new, outward oriented industrial policy is evolving and the mining industry has a clear stake in its 
development.<br>
&#183; Foreign exchange control: the mining industry has been advocating a relaxation of exchange controls for some time due to the 
negative impact of bottling-up domestic investment. Although no independent policy forums have been established to deal with 
foreign exchange policy, the industry liaises closely with the South African Reserve Bank and relevant government institutions 
to convey its views.<br>
&#183; Land: land reform is a central pillar of the democratic transition process and the mining industry has been actively involved in 
policy development as a land owner and in terms of the unique system of mineral rights in South Africa which separates them 
from surface rights.<br>
&#183; Environment: because of the environmental impact of mining, the industry has been participating in policy development 
through the Consultative National Environmental Process (CONNEP). It is essential that the industry secures an appropriate 
balance between conservation and mining activity to ensure that economic growth is maximised with minimal despoilation.<br>
&#183; Nuclear safety: since signing the Nuclear Non-Proliferation Treaty (NNPT) and the disbandment of the weapons 
programme, nuclear policy has been under review across all sectors. The industry produces uranium as a byproduct of certain 
of its operations and consequently has a keen interest in new policy formulation.<br>
&#183; Migrant labour: the mining industry is the single largest employer of domestic and foreign migrant workers and is therefore a 
key stakeholder in policy reforms regarding migrant labour. The industry was instrumental in enbaling foreign migrants to vote 
in the 1994 elections and has endorsed the right of long-service foreign employees to apply for South African citizenship.<br>
&#183; Education: education is one of the fundamental pillars of any growth strategy and the mining industry has been closely 
associated with policy development in a variety of fora dealing with academic, technical and vocational education.<br>
&#183; Provincial competencies: the industry&#146;s concern about the impact of costs on profitability motivates its interest in provincial 
developments, especially since the new constitution reflects a quasi-federalist state structure. The power of provinces to 
impose imposts, levies and taxes is of particular concern.<br>
&#183; Crime and violence: the cost of crime has become excessive and the mining industry is participating in policy formulation to 
combat crime and violence through Business Against Crime which assisted in drafting the National Crime Prevention Strategy.<br>
<br>
This list is certainly not exhaustive, but it is illustrative of the scope and complexity in which the Chamber of Mines is presently 
operating. The Chamber fulfils its advocacy interaction within a variety of international, national and industry fora and the 
following slides provide an indication of this:<br>
<br>
All these policy issues, and many new ones no doubt, will assume greater importance as the industry advances into late 
maturity. However, we are optimistic that there is sufficient recognition of gold&#146;s role in the economy to achieve resource 
optimisation. If it is to remain competitive, the industry must be provided with an operating and investment environment that 
does not disadvantage it vis-&agrave;-vis other mining countries, especially the emergent ones.<br>
<br>
<a name="RevenuesCosts"><strong>Revenues and costs<br>
</strong></a>The interaction between price and cost in the gold mining industry is a critical element. Key to understanding the price element, 
is a recognition that gold mines are price takers rather than price makers. Consequently, South Africa&#146;s gold mining industry 
has to focus on productivity and cost trends in order to maintain sufficient margins. This is made doubly difficult by the 
relatively stagnant dollar gold price although we do benefit temporarily from a depreciating Rand. <br>
<br>
Additional control measures are adopted in hedging strategies that will become increasingly important if new mines or new 
development is to take place in South African gold mining. While there is obviously a down- and an up-side risk, the capacity 
to lock in a price that will secure development over the long-lead times to production, is an attractive option that will no doubt 
gain more adherents in future, despite criticism of its price capping effect.<br>
<br>
Costs, incurred in mine development and maintenance as I described earlier, are compounded by the remains of an obsolete 
and restrictive legislative regime in terms of ring-fencing, the prohibition on Sunday work, and poor productivity. The major 
cost components are salaries, wages, power, water, stores and materials. The industry, is, to a very limited extent, able to 
control these components. <br>
<br>
However, the increasing tendency toward percentage levies on items such as electricity, liquid fuels, telecommunications and 
municipal services poses a real threat to cost containment. There is a danger that the indirect cost structure will become 
especially burdensome, resulting in accelerated declines in profitability and ultimately, closure. Indeed, we have seen South 
Africa move from being the cheapest gold producer to the most expensive.<br>
<br>
The success of cost containment measures begun in the early 1990s certainly rescued entire mines from demise. However, the 
efficacy of these measures is limited and new measures will have to be sought to ensure that costs are contained. The reality is 
that South African gold mines are in a sensitive price/cost squeeze that makes them overly vulnerable to downward price and 
upward cost movements. The handicap of deep ore bodies compared to open pit mines, friable ores and heap leaching 
techniques is a significant one.<br>
<br>
The challenge will therefore be to contain direct costs and to ensure that indirect costs such as levies and imposts are 
circumvented or rejected. As regards the price - well every South African is a gold bug!<br>
<br>
<a name="Technology"><strong>Technology<br>
</strong></a>Attempts to mechanise gold mining have not been as successful as those in the coal industry, largely because of the nature of 
the rock. However, one should not forget that technology developments are not isolated to mechanical mining - new gold 
recovery processes and computer aided mine design are examples of other areas where technology plays an important role in 
improving the prospects of the industry. Notably, cyanidation and the tube mill rescued the industry from a previous crisis late 
in the last century. An equivalent breakthrough in recent years was the development of the carbon-in-pulp process.<br>
<br>
Whilst we are not immediately expecting another technological break-through of equal magnitude, there are a number of new 
developments underway that promise to assist in surmounting the current problems.<br>
<br>
<em>The greatest development is taking place in improved mining systems:<br>
</em>&#183; Hydropower: hydropower technology is being applied to rock-drills, conveyor motors and impact ripper motors. This is an 
example of innovative re-use of existing resources, In this case the abundant water that has to be pumped out of the mines.<br>
&#183; Non-explosive mining methods: impact rippers utilise a hydraulically driven hammer which causes the already fractured rock 
to break away from the mined face. The system operates continuously, with associated productivity benefits<br>
&#183; Diamond wire saws: cut narrow slices of reef that reduce dilution. As a result, much smaller explosions are needed, 
improving safety, leaving smaller shaft pillars and reducing the time lost by stope evacuation for blasting.<br>
&#183; Penetrating cone fracture: use of a non-explosive propellant to break pre-stressed rock. It generates low velocity flyrock, 
with a controlled size distribution and minimal fines with very little damage to the surrounding rock.<br>
&#183; Ground penetrating radar: non-destructive means of mapping geological features up to 50 metres ahead of the face allowing 
miners to determine the state and structure of the rock.<br>
&#183; Remote-controlled mining / virtual reality: these systems remain experimental but we have seen considerable progress in the 
field with greater research being conducted on potential applications. Remote controlled mining will allow equipment to be 
operated from the surface, thus reducing the number of people who work underground, particularly at the face. Virtual reality 
applications will build on these systems by adding three dimensional environments that will improve mechanical dexterity.<br>
&#183; Winding ropes: new rope technologies are emerging that will allow far deeper shafts to be sunk which will impact positively 
on costs.<br>
<br>
<em>Safety systems are also under development:<br>
</em>&#183; Backfill: mine tailings, often combined with cement, are pumped underground to fill worked-out sections. Backfill reduces 
rockburst incidence and damage; allows complete or partial pillar removal; cuts ventilation costs; reduces timber usage which 
diminishes fire hazards and environmental impacts and it reduces the size of tailings dams.<br>
&#183; Rapid-yielding props: hydraulic props that can be moved close to the face in a fraction of the time. They allow the hanging 
and footwalls to converge rapidly under pressure but maintain sufficient support to save lives and limit damage to the working 
area.<br>
&#183; Seismic monitoring: monitors are placed across a wide network to detect seismic events at the mine. The data is used to 
monitor and pinpoint seismic activity, so as to enhance the design of stabilising pillars and identify faults and dykes. Monitoring 
also provides a three dimensional underground model that allows identification of especially seismically hazardous areas.<br>
&#183; Chilled water and ice: pumped underground and then ventilated to maintain a safe ambient temperature.<br>
&#183; Sequential grid mining: long pillars are left in a grid format which reduces rockburst incidence.<br>
&#183; Post-disaster surveillance probe: a portable remote controlled device used to access disaster areas. The probe provides 
video and audio feedback to rescuers about conditions in cut-off working areas.<br>
&#183; Self rescuers: workers in fiery mines are protected by belt-worn self rescuers that employ a chemical reaction to produce 
personal oxygen in the event of a fire or explosion underground that.<br>
<br>
<br>
<a name="CONCLUSION"><strong>3.	CONCLUSION<br>
</strong></a>In conclusion, the mining industry as a whole is vigorously addressing the most pressing issues facing it, some of which I have 
outlined for you today. The mining industry is able to achieve many of its objectives through the Chamber of Mines of South 
Africa, a voluntary employers&#146; organisation that provides services to its members but is not involved in prospecting, financing 
or managing mines. <br>
<br>
While the industry needs to act in concert on many issues, particularly areas of policy advocacy, the mines and mining finance 
houses remain free to develop their competencies and interests and it is this complementarity which sustains the industry 
through good and bad times.<br>
<br>
I can emphatically refute the view that the South African gold mining industry is close to death or collapse. We should not 
forget that gold has been mined commercially in South Africa for over 120 years. Throughout that period, the industry has 
faced numerous crises; from war to labour shortages. In each case, the industry co-operated to improve circumstances and 
the results have been evident to everyone since the great Witwatersrand gold mines caught the world&#146;s imagination. <br>
<br>
That process is being repeated as we approach the turn of the century - the industry has been, and will remain, the dominant 
world gold producer for many years to come. Much remains to be done, but there is sufficient evidence that the industry&#146;s 
dynamism will create the means to surmount any obstacles.<br>
<br>
Most importantly, South Africa has nearly 40 per cent of the world&#146;s known gold reserves. If cost and revenue constraints 
improve as they have done previously, there is every possibility that gold mining will enjoy a renaissance in South Africa.<br>
<br>
While this is a real prospect, the mining finance houses have not been lulled into complacency. Gold production within South 
Africa&#146;s borders may continue to decline, but the mining finance houses will essentially be producing &#145;South African&#146; gold 
throughout the world. Consequently, gold will remain central to South Africa&#146;s growth and development prospects although it 
may differ somewhat in form and substance.<br>
<br>
The mining industry as a whole has a substantial role to play in the socio-economic development and welfare of the country. In 
return, it requires an enabling operational environment characterised by stable political and economic fundamentals. If there is 
one abiding impression of South African gold mining, it is one of positive pragmatism - an unsentimental understanding of the 
threats tempered with in-depth knowledge of the current realities and a vision based on sound and meticulous strategic 
planning. Given this, the current initiatives will certainly prepare the South African gold mining industry for the year 2000 and 
many, many years beyond.<br>
<br>
Thank you.<br>
.</p>
<p align=center><a href="/org1.htm"><img src="/images/tb101.gif" alt="organisation" align=bottom border=0></a> <a href="/res1.htm"><img src="/images/tb102.gif" alt="Resources" align=bottom border=0></a> <a href="/ess1.htm"><img src="/images/tb103.gif" alt="Essentials" align=bottom border=0></a> <a href="/kruger.htm"><img src="/images/tb104.gif" alt="Krugerrand" align=bottom border=0></a> <a href="/new.htm"><img src="/images/tb105.gif" alt="What's New?" align=bottom border=0></a> <a href="/info.htm"><img src="/images/tb106.gif" alt="Contacting us" align=bottom border=0></a> <br>
</p>
<hr size=3>
<address><font size=2>&#169; 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </font><a href="mailto:twood@bullion.org.za"><font size=2>twood@bullion.org.za</font></a><font size=2> </font></address>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-463</DOCNO>
<DOCOLDNO>IA013-000132-B009-141</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/cvs/main.htm 196.26.82.193 19970217010535 text/html 2995
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:08:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Mines of South Africa: Staff</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<IMG ALIGN=RIGHT SRC="/persimages/main.gif" ALT="Photo of Tom Main">
<Center><FONT SIZE=5 COLOR=008080><B>Mr Tom Main</B></FONT><P></Center>

Tom Main is Chief Executive of the Chamber of Mines of South Africa, and his long history in the gold industry has included the international promotion of the Krugerrand as well as intimate involvement in the establishment of the World Gold Council.  Mr Main currently serves on the World Gold Council as a Director, member of the Executive Committee, and Chairman of the Councils Central Bank Advisory Board, bringing the experience of over 20 years of attendance at the annual meetings of the International Monetary Fund and the World Bank.  Mr Main first joined the Chamber of Mines in 1964.  In 1968 he moved to Barclays Bank, Limited in London where he served in a variety of positions, and resumed his career with the Chamber of Mines in 1971.  Since his return, his tenure has encompassed stints as Chief Economist, Assistant Manager, and Assistant General Manager to the Chamber.  He was elevated to his present position on January 1, 1989.  <p>

Founded in 1889, the Chamber counts among its members more than 100 mining concerns in South Africa, collectively responsible for much of the production of gold, diamonds, platinum, uranium, copper and coal.  Mr Mains mining industry involvement extends to his role as a Trustee of various South African mining industry pension funds.  he is also a member of a number of national advisory committees, and represents the Chamber of Mines on the South African Council of International Chamber of Commerce.  In addition, Mr Main serves as Chairman of the Nuclear Fuels Corporation of South Africa (Nufcor), and is a member of the Board of Rand Water which supplies water to Johannesburg and the Witwatersrand industrial complex.  Mr Main was the recipient of the COMEX Distinguished Leadership Award for 1993.  
<p>



<br>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  29 March 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>






























</DOC>
<DOC>
<DOCNO>WT14-B39-464</DOCNO>
<DOCOLDNO>IA013-000136-B026-123</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/Welcome.html 196.26.82.193 19970217044615 text/html 4536
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 04:49:57 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>CHAMBER OF MINES OF SOUTH AFRICA</title>
</head>

<body background="images/Pat1.gif" bgcolor="#F2F2F2"
text="#0000A0" link="#0000FF" vlink="#800000">

<p align="center"><font size="6"><b>Chamber of Mines of South
Africa</b></font><br>
<font size="3"><i>Serving South Africa's Private Sector Mining
Industry Since 1889</i></font></p>
<div align="center"><center>

<table border="0" cellspacing="1">
    <tr>
        <td align="right" valign="top"><img
        src="images/hedger.jpg"
        alt="Welcome to our showcase on the South African mining industry"
        align="middle" width="158" height="232"><br>
        </td>
        <td align="center"><a href="/new.htm"><img
        src="images/spare2.gif" alt="What's New?" border="0"
        width="200" height="46"></a><br>
        <a href="org1.htm"><img src="images/spare3.gif"
        alt="Our Organisation" border="0" width="200" height="46"></a><br>
        <a href="res1.htm"><img src="images/spare4.gif"
        alt="Online Resources" border="0" width="200" height="46"></a><br>
        <a href="/kruger.htm"><img src="images/spare5.gif"
        alt="Krugerrand" border="0" width="200" height="46"></a><br>
        <a href="/info.htm"><img src="images/spare6.gif"
        alt="Contacting Us" border="0" width="200" height="46"></a> </td>
        <td valign="top"><img src="images/welc3.JPG"
        alt="The Chamber of Mines Online" align="middle"
        width="158" height="232"></td>
    </tr>
</table>
</center></div><div align="center"><center>

<table border="0" cellpadding="4" width="71%" bgcolor="#FCDE32">
    <tr>
        <th><font color="#0000A0" size="2" face="Arial">LAST
        UPDATED: Friday 14 February 1997</font><font
        color="#0000A0" size="3" face="Arial"><br>
        </font><font color="#EC0000" size="2"><em> 1995, 1996,
        1997 Chamber of Mines of South Africa<br>
        </em></font><font color="#800040" size="2">Web Design </font><a
        href="mailto:ttim@tml.co.za"><font color="#800040"
        size="2">Timothy Wood</font></a><font color="#800040"
        size="2">&nbsp;&nbsp;Web Management </font><a
        href="mailto:aparsons@bullion.org.za"><font
        color="#800040" size="2">Andrew Parsons</font></a></th>
    </tr>
</table>
</center></div>

<p align="center"><font color="#800080"><strong>This site is best
viewed with:<br>
</strong></font><a href="http://www.microsoft.com"><font
color="#008040" face="Arial Narrow"><strong><img
src="images/bestwith.gif" alt="MS Explorer" align="middle"
border="0" width="94" height="35"></strong></font></a><font
color="#008040" face="Arial Narrow"><strong> </strong></font><font
color="#0080FF" size="3" face="Arial"><em><strong>800x600x256</strong></em></font><a
href="http://www.netscape.com/comprod/mirror/client_download.html"><font
color="#0080FF" size="3" face="Arial"><em><strong><img
src="images/Netnow3.gif" alt="Netscape 3" align="middle"
border="0" width="95" height="35"></strong></em></font></a></p>
<div align="center"><center>

<table border="6" cellpadding="4" cellspacing="0"
bordercolor="#800000" bordercolorlight="#FF9D9D">
    <tr>
        <td align="center" bgcolor="#FF0000"><font
        color="#FFFFFF" size="2"><strong>DISCLAIMER</strong></font></td>
    </tr>
</table>
</center></div>

<p align="center"><font color="#000000" size="1" face="Arial">By
entering any of the resources on this site, you have accepted
this disclaimer. Whilst every effort has been made to ensure that information
contained herein is accurate, the Chamber of Mines of South Africa disclaims
all liability for any loss, damage, injury or expense however
caused, arising from the use of, or reliance upon, in any manner,
the information provided through this service and does not warrant
the truth, accuracy or completeness of the content.</font></p>

<p align="center"><font color="#800080"><strong>Powered by The
Internet Solution<br>
</strong></font><a href="http://www.is.co.za"><font
color="#008040" face="Arial Narrow"><strong><img
src="images/islogo.gif" alt="Interne Solution" border="0"
width="82" height="37"></strong></font></a></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-465</DOCNO>
<DOCOLDNO>IA013-000136-B026-156</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/news/arch97.htm 196.26.82.193 19970217044632 text/html 3772
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 04:50:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Minesof South Africa: News Archive</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<center><b><h1><b>Chamber of Mines of South Africa </b></h1></b><p>
<IMG SRC="/LOGO1.gif"><p>
<h2><i><b>Mining News Archive</b></i></h2>
<IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p></center>
<br><P>

<Center>
<i><FONT SIZE=4 COLOR=008040><B>1997 News Archive</B></FONT></i><bR>
<table border=1 width=60% cellpadding=5>
<tr>
<th align=center><a href="#jan">January</a></th>
<th align=center><a href="">February</a></th>
<th align=center><A href="">March</A></th>
<th align=center><A href="">April</a></th>
<th align=center><A href="">May</a></th>
<th align=center><A href="">June</a></th>
</tr>
<tr><th align=center><A href="">July</a></th>
<th align=center><A href="">August</a></th>
<th align=center><A href="">September</a></th>
<th align=center><A href="">October</a></th>
<th align=center><A href="">November</a></th>
<th align=center><A href="">December</a></th>
</tr>
</table><P><P><br><hr><p>
</Center>

<FONT SIZE=4 COLOR=8000FF><a name="jan">JANUARY 1997</a></FONT><P>
   
<a href="1997/300197.htm">THURSDAY, 30 JANUARY 1997 </a><br>
<a href="1997/290197.htm">WEDNESDAY, 29 JANUARY 1997 </a><br>
<a href="1997/280197.htm">TUESDAY, 28 JANUARY 1997 </a><br>
<a href="1997/270197.htm">MONDAY, 27 JANUARY 1997 </a><br>
<a href="1997/240197.htm">FRIDAY, 24 JANUARY 1997 </a><br>
<a href="1997/230197.htm">THURSDAY, 23 JANUARY 1997 </a><br>
<a href="1997/220197.htm">WEDNESDAY, 22 JANUARY 1997 </a><br>
<a href="1997/210197.htm">TUESDAY, 21 JANUARY 1997 </a><br>
<a href="1997/200197.htm">MONDAY, 20 JANUARY 1997 </a><br>
<a href="1997/170197.htm">FRIDAY, 17 JANUARY 1997 </a><br>
<a href="1997/160197.htm">THURSDAY, 16 JANUARY 1997 </a><br>
    <a href="1997/150197.htm">WEDNESDAY, 15 JANUARY 1997 </a><br>
    <a href="1997/140197.htm">TUESDAY, 14 JANUARY 1997 </a><br>
    <a href="1997/130197.htm">MONDAY, 13 JANUARY 1997 </a><br>
    <a href="1997/100197.htm">FRIDAY, 10 JANUARY 1997 </a><br>
    <a href="1997/090197.htm">THURSDAY, 9 JANUARY 1997 </a><br>
    <a href="1997/080197.htm">WEDNESDAY, 8 JANUARY 1997 </a><br>
    <a href="1997/070197.htm">TUESDAY, 7 JANUARY 1997 </a><br>
    <a href="1997/060197.htm">MONDAY, 6 JANUARY 1997 </a><br>
    <a href="1997/030197.htm">FRIDAY, 3 JANUARY 1997 </a><br>
    <a href="1997/020197.htm">THURSDAY, 2 JANUARY 1997 </a><br>
    WEDNESDAY, 1 JANUARY 1997 - NEW YEAR'S DAY - HAPPY NEW YEAR<P><p><br>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>
 


<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT14-B39-466</DOCNO>
<DOCOLDNO>IA013-000136-B026-264</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/news/arch.htm 196.26.82.193 19970217044803 text/html 20157
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 04:51:23 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Minesof South Africa: News Archive</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<center><b><h1><b>Chamber of Mines of South Africa </b></h1></b><p>
<IMG SRC="/LOGO1.gif"><p>
<h2><i><b>Mining News Archive</b></i></h2>
<IMG SRC="/line3.gif" ALIGN=MIDDLE><br><p></center>
<br><P>

<Center>
<i><FONT SIZE=4 COLOR=008040><B>1996 News Archive</B></FONT></i><bR>
<table border=1 width=60% cellpadding=5>
<tr>
<th align=center>January</th>
<th align=center><a href="#feb">February</a></th>
<th align=center><A href="#mar">March</A></th>
<th align=center><A href="#apr">April</a></th>
<th align=center><A href="#may">May</a></th>
<th align=center><A href="#jun">June</a></th>
</tr>
<tr><th align=center><A href="#jul">July</a></th>
<th align=center><A href="#aug">August</a></th>
<th align=center><A href="#sep">September</a></th>
<th align=center><A href="#oct">October</a></th>
<th align=center><A href="#nov">November</a></th>
<th align=center><A href="#dec">December</a></th>
</tr>
</table><P><P><br><hr><p>
</Center>
<A NAME="feb"></A>
<FONT SIZE=4 COLOR=8000FF>FEBRUARY 1996</FONT><P>
<A HREF="290296.htm">THURSDAY, 29 FEBRUARY 1996</A><BR>
<A HREF="280296.htm">WEDNESDAY, 28 FEBRUARY 1996</A><BR>
<A HREF="270296.htm">TUESDAY, 27 FEBRUARY 1996</A><BR>
<A HREF="260296.htm">MONDAY, 26 FEBRUARY 1996</A><BR>
<A HREF="220296.htm">FRIDAY, 23 FEBRUARY 1996</A><BR>
<A HREF="220296.htm">THURSDAY, 22 FEBRUARY 1996</A><BR>
<A HREF="210296.htm">WEDNESDAY, 21 FEBRUARY 1996</A><BR>
<A HREF="200296.htm">TUESDAY, 20 FEBRUARY 1996</A><BR>
<A HREF="190296.htm">MONDAY, 19 FEBRUARY 1996</A><BR>
<A HREF="150296.htm">THURSDAY, 15 FEBRUARY 1996</A><BR>
<A HREF="140296.htm">WEDNESDAY, 14 FEBRUARY 1996</A><BR>
<br><P><P>
<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>
<A NAME="mar"></A>
<FONT SIZE=4 COLOR=8000FF>MARCH 1996</FONT><P>
<A HREF="290396.htm">FRIDAY, 29 MARCH 1996</A><BR>
<A HREF="280396.htm">THURSDAY, 28 MARCH 1996</A><BR>
<A HREF="270396.htm">WEDNESDAY, 27 MARCH 1996</A><BR>
<A HREF="260396.htm">TUESDAY, 26 MARCH 1996</A><BR>
<A HREF="250396.htm">MONDAY, 25 MARCH 1996</A><BR>
<A HREF="220396.htm">FRIDAY, 22 MARCH 1996</A><BR>
THURSDAY, 21 MARCH 1996: NO NEWS (Human Rights Day Public Holiday)<BR>
<A HREF="200396.htm">WEDNESDAY, 20 MARCH 1996</A><BR>
<A HREF="190396.htm">TUESDAY, 19 MARCH 1996</A><BR>
<A HREF="180396.htm">MONDAY, 18 MARCH 1996</A><BR>
<A HREF="150396.htm">FRIDAY, 15 MARCH 1996</A><BR>
<A HREF="140396.htm">THURSDAY, 14 MARCH 1996</A><BR>
<A HREF="130396.htm">WEDNESDAY, 13 MARCH 1996</A><BR>
<A HREF="120396.htm">TUESDAY, 12 MARCH 1996</A><BR>
<A HREF="110396.htm">MONDAY, 11 MARCH 1996</A><BR>
<A HREF="080396.htm">FRIDAY, 8 MARCH 1996</A><BR>
<A HREF="070396.htm">THURSDAY, 7 MARCH 1996</A><BR>
<A HREF="060396.htm">WEDNESDAY, 6 MARCH 1996</A><BR>
<A HREF="050396.htm">TUESDAY, 5 MARCH 1996</A><BR>
<A HREF="040396.htm">MONDAY, 4 MARCH 1996</A><BR>
<A HREF="010396.htm">FRIDAY, 1 MARCH 1996</A><BR>
<br><P><P>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>

<A NAME="apr"></A>
<FONT SIZE=4 COLOR=8000FF>APRIL 1996</FONT><P>

<A HREF="300496.htm">TUESDAY, 30 APRIL 1996</A><BR>
<A HREF="290496.htm">MONDAY, 29 APRIL 1996</A><BR>
<A HREF="260496.htm">FRIDAY, 26 APRIL 1996</A><BR>
<A HREF="250496.htm">THURSDAY, 25 APRIL 1996</A><BR>
<A HREF="240496.htm">WEDNESDAY, 24 APRIL 1996</A><BR>
<A HREF="230496.htm">TUESDAY, 23 APRIL 1996</A><BR>
<A HREF="220496.htm">MONDAY, 22 APRIL 1996</A><BR>
<A HREF="190496.htm">FRIDAY, 19 APRIL 1996</A><BR>
<A HREF="180496.htm">THURSDAY, 18 APRIL 1996</A><BR>
<A HREF="170496.htm">WEDNESDAY, 17 APRIL 1996</A><BR>
<A HREF="160496.htm">TUESDAY, 16 APRIL 1996</A><BR>
<A HREF="150496.htm">MONDAY, 15 APRIL 1996</A><BR>
<A HREF="120496.htm">FRIDAY, 12 APRIL 1996</A><BR>
<A HREF="110496.htm">THURSDAY, 11 APRIL 1996</A><BR>
<A HREF="100496.htm">WEDNESDAY, 10 APRIL 1996</A><BR>
<A HREF="090496.htm">TUESDAY, 9 APRIL 1996</A><BR>
FRIDAY 5 - MONDAY 8 APRIL 1996: NO NEWS (Easter Weekend)<BR>
<A HREF="040496.htm">THURSDAY, 4 APRIL 1996</A><BR>
<A HREF="030496.htm">WEDNESDAY, 3 APRIL 1996</A><BR>
<A HREF="020496.htm">TUESDAY, 2 APRIL 1996</A><BR>
<A HREF="010496.htm">MONDAY, 1 APRIL 1996</A>
<br><p><br>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>

<A NAME="may"></A>
<FONT SIZE=4 COLOR=8000FF>MAY 1996</FONT><P>
<A HREF="http://www.bullion.org.za/news/310596.htm">FRIDAY, 31 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/300596.htm">THURSDAY, 30 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/290596.htm">WEDNESDAY, 29 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/280596.htm">TUESDAY, 28 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/270596.htm">MONDAY, 27 MAY 1996</A><BR>
A computer crash on Friday deleted all our news documents - our apologies. [Editor]</A><BR>
<A HREF="http://www.bullion.org.za/news/230596.htm">THURSDAY, 23 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/220596.htm">WEDNESDAY, 22 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/210596.htm">TUESDAY, 21 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/200596.htm">MONDAY, 20 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/170596.htm">FRIDAY, 17 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/160596.htm">THURSDAY, 16 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/150596.htm">WEDNESDAY, 15 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/140596.htm">TUESDAY, 14 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/130596.htm">MONDAY, 13 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/100596.htm">FRIDAY, 10 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/090596.htm">THURSDAY, 9 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/080596.htm">WEDNESDAY, 8 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/070596.htm">TUESDAY, 7 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/060596.htm">MONDAY, 6 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/030596.htm">FRIDAY, 3 MAY 1996</A><BR>
<A HREF="http://www.bullion.org.za/news/020596.htm">THURSDAY, 2 MAY 1996</A><BR>
WEDNESDAY, 1 MAY 1996 - WORKERS' DAY <I>PUBLIC HOLIDAY</I> - Chamber site closed.<BR>

<br><p><br>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>

<A NAME="jun"></A>
<FONT SIZE=4 COLOR=8000FF>JUNE 1996</FONT><P>
<A HREF=http://www.bullion.org.za/news/280696.htm>FRIDAY, 28 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/270696.htm>THURSDAY, 27 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/260696.htm>WEDNESDAY, 26 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/250696.htm>TUESDAY, 25 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/240696.htm>MONDAY, 24 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/210696.htm>FRIDAY, 21 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/200696.htm>THURSDAY, 20 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/190696.htm>WEDNESDAY, 19 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/180696.htm>TUESDAY, 18 JUNE 1996</A><BR>
<B>MONDAY, 17 JUNE 1996 - Youth Day Public Holiday in SA - Site closed.</B><BR>
<A HREF=http://www.bullion.org.za/news/140696.htm>FRIDAY, 14 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/130696.htm>THURSDAY, 13 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/120696.htm>WEDNESDAY, 12 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/110696.htm>TUESDAY, 11 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/100696.htm>MONDAY, 10 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/070696.htm>FRIDAY, 7 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/060696.htm>THURSDAY, 6 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/050696.htm>WEDNESDAY, 5 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/040696.htm>TUESDAY, 4 JUNE 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/030696.htm>MONDAY, 3 JUNE 1996</A><BR>
<br><p><br>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>


<A NAME="jul"></A>
<FONT SIZE=4 COLOR=8000FF>JULY 1996</FONT><P>

<A HREF=http://www.bullion.org.za/news/310796.htm>WEDNESDAY, 31 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/300796.htm>TUESDAY, 30 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/290796.htm>MONDAY, 29 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/260796.htm>FRIDAY, 26 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/250796.htm>THURSDAY, 25 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/240796.htm>WEDNESDAY, 24 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/230796.htm>TUESDAY, 23 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/220796.htm>MONDAY, 22 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/190796.htm>FRIDAY, 19 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/180796.htm>THURSDAY, 18 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/170796.htm>WEDNESDAY, 17 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/160796.htm>TUESDAY, 16 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/150796.htm>MONDAY, 15 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/120796.htm>FRIDAY, 12 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/110796.htm>THURSDAY, 11 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/100796.htm>WEDNESDAY, 10 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/090796.htm>TUESDAY, 9 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/080796.htm>MONDAY, 8 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/050796.htm>FRIDAY, 5 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/040796.htm>THURSDAY, 4 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/030796.htm>WEDNESDAY, 3 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/020796.htm>TUESDAY, 2 JULY 1996</A><BR>
<A HREF=http://www.bullion.org.za/news/010796.htm>MONDAY, 1 JULY 1996</A><BR>


<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>



<A NAME="aug"></A>
<FONT SIZE=4 COLOR=8000FF>AUGUST 1996</FONT><P>
<A HREF="300896.HTM">FRIDAY, 30 AUGUST 1996 </A><BR>
<A HREF="290896.HTM">THURSDAY, 29 AUGUST 1996 </A><BR>
<FONT SIZE=3 COLOR=FF0080>16 - 28 AUGUST : SITE DOWN DUE TO TECHNICAL PROBLEMS.</FONT><BR>
<A HREF="150896.HTM">THURSDAY, 15 AUGUST 1996 </A><BR>
<A HREF="140896.HTM">WEDNESDAY, 14 AUGUST 1996 </A><BR>
<A HREF="130896.HTM">TUESDAY, 13 AUGUST 1996 </A><BR>
<A HREF="120896.HTM">MONDAY, 12 AUGUST 1996 </A><BR>
FRIDAY, 9 AUGUST 1996 - National Women's Day. Site closed.<BR>
<A HREF="080896.HTM">THURSDAY, 8 AUGUST 1996 </A><BR>
<A HREF="070896.HTM">WEDNESDAY, 7 AUGUST 1996 </A><BR>
<A HREF="060896.HTM">TUESDAY, 6 AUGUST 1996 </A><BR>
<A HREF="050896.HTM">MONDAY, 5 AUGUST 1996 </A><BR>
<A HREF="020896.HTM">FRIDAY, 2 AUGUST 1996 </A><BR>
<A HREF="010896.HTM">THURSDAY, 1 AUGUST 1996 </A><BR>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>

<A NAME="sep"></A>
<FONT SIZE=4 COLOR=8000FF>SEPTEMBER 1996</FONT><P>
<a href="300996.htm">MONDAY, 30 SEPTEMBER 1996</a><br>
<a href="270996.htm">FRIDAY, 27 SEPTEMBER 1996</a><br>
<a href="260996.htm">THURSDAY, 26 SEPTEMBER 1996</a><br>
<a href="250996.htm">WEDNESDAY, 25 SEPTEMBER 1996</a><br>
TUESDAY, 24 SEPTEMBER 1996 - Public Holiday - Heritage Day - in SA. Site closed.<BR>
<a href="230996.htm">MONDAY, 23 SEPTEMBER 1996</a><br>
<a href="200996.htm">FRIDAY, 20 SEPTEMBER 1996</a><br>
<a href="190996.htm">THURSDAY, 19 SEPTEMBER 1996</a><br>
<a href="180996.htm">WEDNESDAY, 18 SEPTEMBER 1996</a><br>
<a href="170996.htm">TUESDAY, 17 SEPTEMBER 1996</a><br>
<a href="160996.htm">MONDAY, 16 SEPTEMBER 1996</a><br>
<a href="130996.htm">FRIDAY, 13 SEPTEMBER 1996</a><br>
<a href="120996.htm">THURSDAY, 12 SEPTEMBER 1996</a><br>
<a href="110996.htm">WEDNESDAY, 11 SEPTEMBER 1996</a><br>
<a href="100996.htm">TUESDAY, 10 SEPTEMBER 1996</a><br>
<a href="090996.htm">MONDAY, 9 SEPTEMBER 1996</a><br>
<a href="060996.htm">FRIDAY, 6 SEPTEMBER 1996</a><br>
<a href="050996.htm">THURSDAY, 5 SEPTEMBER 1996</a><br>
<a href="040996.htm">WEDNESDAY, 4 SEPTEMBER 1996</a><br>
<a href="030996.htm">TUESDAY, 3 SEPTEMBER 1996</a><br>
<a href="020996.htm">MONDAY, 2 SEPTEMBER 1996</a><br>

<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>

<A NAME="oct"></A>
<FONT SIZE=4 COLOR=8000FF>OCTOBER 1996</FONT><P>
   <a href="311096.HTM">THURSDAY, 31 OCTOBER 1996 </a><br>
FRIDAY, 25/10/96 -- WEDNESDAY, 30/10/96 = SYSTEM DOWN. SITE CLOSED<BR>
    <a href="241096.HTM">THURSDAY, 24 OCTOBER 1996 </a><br>
    <a href="231096.HTM">WEDNESDAY, 23 OCTOBER 1996 </a><br>
    <a href="221096.HTM">TUESDAY, 22 OCTOBER 1996 </a><br>
    <a href="211096.HTM">MONDAY, 21 OCTOBER 1996 </a><br>
    <a href="181096.HTM">FRIDAY, 18 OCTOBER 1996 </a><br>
    <a href="171096.HTM">THURSDAY, 17 OCTOBER 1996 </a><br>
    <a href="161096.HTM">WEDNESDAY, 16 OCTOBER 1996 </a><br>
    <a href="151096.HTM">TUESDAY, 15 OCTOBER 1996 </a><br>
    <a href="141096.HTM">MONDAY, 14 OCTOBER 1996 </a><br>
    <a href="111096.HTM">FRIDAY, 11 OCTOBER 1996 </a><br>
    <a href="101096.HTM">THURSDAY, 10 OCTOBER 1996 </a><br>
    <a href="091096.HTM">WEDNESDAY, 9 OCTOBER 1996 </a><br>
    <a href="081096.HTM">TUESDAY, 8 OCTOBER 1996 </a><br>
    <a href="071096.HTM">MONDAY, 7 OCTOBER 1996 </a><br>
    <a href="041096.HTM">FRIDAY, 4 OCTOBER 1996 </a><br>
    <a href="031096.HTM">THURSDAY, 3 OCTOBER 1996 </a><br>
    <a href="021096.HTM">WEDNESDAY, 2 OCTOBER 1996 </a><br>
    <a href="011096.HTM">TUESDAY, 1 OCTOBER 1996 </a><br>


<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>

<A NAME="nov"></A>
<FONT SIZE=4 COLOR=8000FF>NOVEMBER 1996</FONT><P>
<a href="291196.htm">FRIDAY, 29 NOVEMBER 1996 </a><br>
<a href="281196.htm">THURSDAY, 28 NOVEMBER 1996 </a><br>
WEDNESDAY, 13 NOVEMBER TO WEDNESDAY 27 NOVEMBER 1996: SYSTEM DOWN - SITE CLOSED<BR>
<a href="121196.htm">TUESDAY, 12 NOVEMBER 1996 </a><br>
    <a href="111196.htm">MONDAY, 11 NOVEMBER 1996 </a><br>
    <a href="081196.htm">FRIDAY, 8 NOVEMBER 1996 </a><br>
    <a href="071196.htm">THURSDAY, 7 NOVEMBER 1996 </a><br>
    <a href="061196.htm">WEDNESDAY, 6 NOVEMBER 1996 </a><br>
    <a href="051196.htm">TUESDAY, 5 NOVEMBER 1996 </a><br>
    <a href="041196.htm">MONDAY, 4 NOVEMBER 1996 </a><br>
    <a href="011196.htm">FRIDAY, 1 NOVEMBER 1996 </a><br>


<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>


<A NAME="dec"></A>
<FONT SIZE=4 COLOR=8000FF>DECEMBER 1996</FONT><P>

 <a href="311296.htm">TUESDAY, 31 DECEMBER   1996 </a><br>
    <a href="301296.htm">MONDAY, 30 DECEMBER 1996 </a><br>
   FRIDAY, 27 DECEMBER 1996:  CHAMBER OF MINES CLOSED<br>
    THURSDAY, 26 DECEMBER 1996 - DAY OF GOODWILL - SITE CLOSED<br>
    WEDNESDAY, 25 DECEMBER 1996 - CHRISTMAS DAY - SITE CLOSED<br>
    <a href="241296.htm">TUESDAY, 24 DECEMBER 1996 </a><br>
    <a href="231296.htm">MONDAY, 23 DECEMBER 1996 </a><br>
    <a href="201296.htm">FRIDAY, 20 DECEMBER 1996 </a><br>
    <a href="191296.htm">THURSDAY, 19 DECEMBER 1996 </a><br>
    <a href="181296.htm">WEDNESDAY, 18 DECEMBER 1996 </a><br>
    <a href="171296.htm">TUESDAY, 17 DECEMBER 1996 </a><br>
    MONDAY, 16 DECEMBER 1996 - RECONCILIATION DAY  - SITE CLOSED<br>
    <a href="131296.htm">FRIDAY, 13 DECEMBER 1996 </a><br>
    <a href="121296.htm">THURSDAY, 12 DECEMBER 1996 </a><br>
    <a href="111296.htm">WEDNESDAY, 11 DECEMBER 1996 </a><br>
    <a href="101296.htm">TUESDAY, 10 DECEMBER 1996 </a><br>
    <a href="091296.htm">MONDAY, 9 DECEMBER 1996 </a><br>
    <a href="061296.htm">FRIDAY, 6 DECEMBER 1996 </a><br>
    <a href="051296.htm">THURSDAY, 5 DECEMBER 1996 </a><br>
    <a href="041296.htm">WEDNESDAY, 4 DECEMBER 1996 </a><br>
    <a href="031296.htm">TUESDAY, 3 DECEMBER 1996 </a><br>
    <a href="021296.htm">MONDAY, 2 DECEMBER 1996 </a><br>
   
<center>
<a href="/Welcome.html"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><br><br><p>
 


<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>






























</DOC>
<DOC>
<DOCNO>WT14-B39-467</DOCNO>
<DOCOLDNO>IA013-000132-B016-165</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/cvs/liebenb.htm 196.26.82.193 19970217013413 text/html 5082
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:37:33 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Mines of South Africa: Staff</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<IMG ALIGN=RIGHT SRC="/persimages/lieb.gif" ALT="Photo of Johann Liebenberg"></IMG>
<Center><FONT SIZE=5 COLOR=008080><B>Johann Liebenberg</B></FONT><P></Center>
Johann Liebenberg obtained a BA Pol Sc degree (Economics and Political Science majors) from the University of Pretoria in 1961 and joined the South African diplomatic service. After a short spell as a cadet diplomat in Pretoria he was transferred to the South African Embassy in Cologne, West Germany, where he served for four and a half years.<p>

After his transfer back to South Africa in 1968 he quit government service and was appointed Regional Secretary of the Industrial Council for the Motor Industry. He remained in this position until 1971 when he was promoted to the position of Executive Director, Motor Industry Centre for Financial Administration (MICFA), an organisation that administers medical aid schemes, pension and provident funds, accrued leave pay and holiday leave pay funds, etc for the South African motor industry.<p>

In his seven years in the industrial council and MICFA environment he acquired an intimate knowledge of labour relations in the South African context and in 1975 joined the Chamber of Mines as Assistant Industrial Relations Adviser. Eighteen months later he was promoted to the position of Industrial Relations Adviser- a position he held until the end of 1988.<p>

During his years at the head of the Chambers Industrial Relations Department (and for two years after that)  he was the Chambers Chief Negotiator in all collective bargaining between the Chamber and the then 11 trade unions and officials associations representing over 600 000 mine employees. He was appointed to the first National Manpower Commission when it was established in 1981 and remained a member of that Commission until a few months before the NMC became part of NEDLAC in February 1995.<p>

From 1975 until 1994 Johann represented the Chamber in the South African Employers Coordinating Committee on Labour Affairs (SACCOLA) and was chairperson of SACCOLA for three terms. When SACCOLA was absorbed into Business South Africa (BSA) at the beginning of 1994 he represented the Chamber on the Executive Committee of BSA and he was also one of two Chamber representatives on the Executive Council of NEDLAC.<p>

From 1976 he served on the Executive Committee of the International Organisation of Employers (IOE) in Geneva, Switzerland, until SACCOLAs membership was terminated in 1981 due to South Africas Apartheid policy.  He had the honour, however, of being the leader of the South African employer delegation which rejoined the IOE at that bodys Annual General Meeting in June 1994 and a few days later he also led the South African employers when South Africa was re-admitted to the ILO. For him personally to participate in South Africas readmission to the IOE and the ILO was doubly sweet as his father was the leader of the South African labour delegation compelled to withdraw from the ILO in 1963 because of South Africas policies. <p>

For a period of two and a half years in the late eighties,  Johann was a part time Professor of Industrial Relations at the Rand Afrikaans University.<p>

From the end of 1988 until  1993 he was one of four Senior General Managers reporting to the Chambers Chief Executive, each responsible for a number of Chamber departments. In 1993 he was appointed Public Policy Consultant and he is responsible for the following strategic business units in the Chamber:<br>
<ul>
<li><A HREF="/econ.htm">Economics Department</A>
<li><A HREF="/legal.htm">Legal Department</A>
<li><A HREF="/comm.htm">Communications Department</A>
<li><A HREF="/ppu1.htm">Public Policy Unit (Cape Town)</A>
</ul><p>
He currently concentrates mainly on the relationships between government and the mining industry. He and his family live in Cape Town and he frequently commutes to Johannesburg. He is a member of the Royal Cape Yacht Club and has a passion for sailing.<p><p>


<br>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  4 April 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>






























</DOC>
<DOC>
<DOCNO>WT14-B39-468</DOCNO>
<DOCOLDNO>IA013-000132-B016-216</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/cvs/pollnow.htm 196.26.82.193 19970217013446 text/html 4082
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:38:09 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa: Staff</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p><a name="top"></a></p>

<p align="center"><img src="../../images/persimages/poll.gif"
align="right" hspace="0" width="236" height="364"><font
color="#008080" size="5"><b>Dr Daniel Pollnow</b></font></p>

<p align="left">Daniel Pollnow was born and educated in France.
He is a science graduate from the University of Paris-Sud
(Orsay). In 1968 he received a doctorate in metallurgy and in 1972 a doctorate
of science in physics.</p>

<p>He began his working career in the steel industry where he was
involved in product and process development. In 1977 he joined
the International Gold Corporation (Intergold) the gold marketing
arm of the Chamber of Mines of South Africa. His first position
was editor of &quot;Gold Bulletin&quot;, a quarterly review of
research on gold and its applications in industry with a
circulation of 5 000 copies in over 50 countries. In 1980 he
established and managed the Industrial Division of Intergold
which promoted gold usage in dental, electronic and decorative applications,
and conducted a R &amp; D programme on a contract basis. In 1983
he became manager of the Johannesburg head office of Intergold.</p>

<p>In 1984 he was transferred to Rand Refinery where he became
general manager in 1985. At the time, the Refinery had an annual
production of close to 700 tons of fine gold, representing almost half
of South Africa' exports and one tenth of the country's GDP. The
main role of D Pollnow was to oversee the planning, design and
construction of a new refinery to serve the mining industry well into
the 21st century.</p>

<p>At the beginning of 1989, D Pollnow returned to the Chamber of
Mines as a senior general manager - one of a team of four reporting
directly to the Chief Executive. His responsibilities included
the business management of the Chamber's Health Care Services
(Medical Adviser, 640-bed referral hospital, and employee
assistance programme). In recent years, with the removal of
sanctions and renewed opportunities for active marketing of South
African gold, his portfolio has been progresssively re-directed
towards the Krugerrand and other value-added gold products, as
well as gold security matters. His current title is Gold
Marketing Consultant.</p>

<p>Dr Pollnow serves on the Board of Directors of <a
href="http://www.bullion.org.za/associates/rr.htm">Rand Refinery
Limited</a>, and on the executive committees of the Jewellery Council
of South Africa and of the South African Council of the <a
href="http://www.chamber-of-commerce.com/">International Chamber
of Commerce</a>. He is vice-chairman of the Conseillers du
Commerce Extrieur de la France in South Africa, and of the
French Benevolent Society in Johannesburg.</p>

<p align="center"><br>
<a name="toolbar"></a> <a href="/org1.htm"><img
src="../../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../../images/tb102.gif" alt="Resources" border="0"
width="101" height="17"></a> <a href="/kruger.htm"><img
src="../../images/tb104.gif" alt="Krugerrand" border="0"
width="101" height="17"></a> <a href="/new.htm"><img
src="../../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
</p>

<hr>

<address>
    <font size="2"> 1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-469</DOCNO>
<DOCOLDNO>IA012-000131-B024-91</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/organisation/cvs/stewart.htm 196.26.82.193 19970217013827 text/html 3557
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:41:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Mines of South Africa: Staff</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>

<IMG align=right SRC="/persimages/stew.gif" ALT="Photo of Dr Stewart">
<center><FONT SIZE=5 COLOR=008080><B>Dr John Stewart</B></FONT><P></center>

Dr John Michael Stewart was born in Boksburg in 1945.  He graduated from the University of the Witwatersrand, Johannesburg, with a BSc degree in Mechanical Engineering in 1967.  Since graduating, he has been involved in a wide range of mining-related research and development, mostly concerned with gold mining.  During the course of his research career he completed an MSc on the hydraulic transportation of solids, in 1973, and a PhD on human heat stress, in 1982.  He has also authored and co-authored in excess of 45 papers published in scientific journals or presented at local and international conferences.<p>

He joined the Chamber of Mines Research Organisation, COMRO, in 1973, where he progressed through the ranks to become head of COMRO in 1990.  Following the merging of COMRO into the CSIR in 1993, he was appointed Research Adviser in the Chamber of Mines.  He is still with the Chamber of Mines and presently holds the position of Mining Consultant.  In that position his responsibilities include mine safety, mining technology and research, the impact of mining on the environment, and technical mining matters in general.<p>
<B>Membership of Professional Bodies:</B><br>
<UL TYPE=square>
<LI>South African Institute of Mining and Metallurgy (fellow)
<li>Mine Ventilation Society of South Africa (fellow)
</UL>
<p>
<B>Representation on External Organisations:</B>
<UL TYPE=circle>
<LI>Board of Control - Schonland Nuclear Physics Research Centre, <A HREF="http://www.wits.ac.za">Wits University</A>
<li>Board of Control - Economic Geology Research Unit, <A HREF="http://www.wits.ac.za">Wits University</A>
<li>Engineering Research Review Panel, <A HREF="http://www.wits.ac.za">Wits University</A>
<li>International Committee for Coal Research
<li><A HREF="http://www.sacs.org.za/level2/science.htm">National Science and Technology Forum</A>
</UL>
<p>
<B>Supplementary</B>:	<br>
South African Employer representative at the following meetings of the International Labour Organisation:<br>
<UL TYPE=disk>
<LI>Technical Committee:  Safety and Health Convention, 1994 and 1995
<li>Coal Mines Committee meeting, 1995
<li>Member of the Technical Committee convened by the International Atomic Energy Agency to investigate the impact of radiation standards on the mining industry, 1991
</UL>
<p>

<br>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  4 April 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>






























</DOC>
<DOC>
<DOCNO>WT14-B39-470</DOCNO>
<DOCOLDNO>IA012-000131-B026-48</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/departments/infv.htm 196.26.82.193 19970217014233 text/html 2495
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:46:10 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Functions and Services</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font color="#0000A0"><font size=4><b>Chamber of Mines of South Africa </b></font></font></h1>
<p align=center><img src="../images/LOGO1.gif" align=bottom width=300 height=160></p>
<h2 align=center><b><i>Core Services and Functions</i></b></h2>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<h3 align=center>INFORMATION SERVICES</h3>
<p>The purpose of Information Services is to collect, process, store, retrieve and disseminate information relevant to the 
operation of the Chamber, by managing the functional flow of information within the Chamber and ensuring that the mining 
houses receive all relevant information timeously.</p>
<p>Information Services also provides a Library and Archiving Service, a duplicating faciliting and administers the Chamber's 
committee room system.</p>
<p><b><i>Main Units:</i></b></p>
<table width=100%>
<tr><td><table cellpadding=6 width=100%>
<tr><td width=50><i></i></td></tr>
<tr><td width=50><b><i>Title</i></b></td><td><b><i>Name</i></b></td></tr>
<tr><td width=50><i></i></td></tr>
<tr><td width=50><i>Manager</i></td><td><a href="mailto:jhofsaje@bullion.org.za"><i>Jeannette Hofsajer-Van Wyk</i></a></td></tr>
<tr><td width=50><i>Librarian</i></td><td><a href="mailto:mmoodley@bullion.org.za"><i>Manil Kanniappen</i></a></td></tr>
<tr><td width=50><i>Archivist</i></td><td><a href="mailto:lgovende@bullion.org.za"><i>Lully Govender</i></a></td></tr>
</table>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<p align=center><img src="../images/tb101.gif" align=bottom width=101 height=17><img src="../images/tb102.gif" align=bottom width=101 height=17><img src="../images/tb103.gif" align=bottom width=101 height=17><img src="../images/tb104.gif" align=bottom width=101 height=17><img src="../images/tb105.gif" align=bottom width=101 height=17><img src="../images/tb106.gif" align=bottom width=101 height=17></p>
<p><font size=2><i>Last Updated: 22 May 1996<br>
&#169; 1995 Chamber of Mines of South Africa<br>
</i></font></p>
</td></tr>
</table>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-471</DOCNO>
<DOCOLDNO>IA012-000131-B026-162</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/departments/edtr.htm 196.26.82.193 19970217014420 text/html 4336
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:47:56 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Functions and Services</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font color="#0000A0"><font size=4><b>Chamber of Mines of South Africa </b></font></font></h1>
<p align=center><img src="../images/LOGO1.gif" align=bottom width=300 height=160></p>
<h2 align=center><b><i>Core Services and Functions</i></b></h2>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<h3 align=center>EDUCATION AND TRAINING SERVICES</h3>
<div align=center><center>
<table border=1 cellpadding=4>
<tr><th><a href="#infoedu">Information</a></th><th><a href="#staff">Main Units and Staff</a></th><th><a href="#resedu">Resources</a></th></tr>
</table>
</center></div>
<p>The purpose of Education and Training Services is to enable Chamber of Mines members to develop competent employees 
who contribute optimally towards productivity, profitability and enhanced safety and health. To achieve this, the Unit 
influences national education and training legislation and policy and develops workable models of learning for Chamber 
members.</p>
<p><b><i>Main Units:</i></b></p>
<table width=100%>
<tr><td><table cellpadding=6>
<tr><td><i></i></td></tr>
<tr><td><b><i>Title</i></b></td><td><b><i>Name and Location</i></b></td></tr>
<tr><td><i></i></td></tr>
<tr><td><i>Adviser</i></td><td><a href="mailto:egous@bullion.org.za"><i>Dr Andre Dippenaar</i></a></td></tr>
<tr><td><i>Manager:<br>
Technical Training Services</i></td><td><i>Stella Carthy</i></td></tr>
<tr><td><i>Tertiary Education<br>
Financial Support</i></td><td><a href="mailto:btimp@bullion.org.za"><i>Brenda Timp</i></a></td></tr>
<tr><td><i>Bursaries</i></td><td><a href="mailto:mpretori@bullion.org.za"><i>Maryna Pretorius</i></a></td></tr>
<tr><td><i>Training of<br>
Winding Engine<br>
Drivers</i></td><td><a href="mailto:csargent@bullion.org.za"><i>Daan Verwey</i></a></td></tr>
<tr><td><a href="mailto:csargent@bullion.org.za"><i>Radiation Training</i></a></td><td><a href="mailto:csargent@bullion.org.za"><i>Craig Bridger</i></a></td></tr>
<tr><td><a href="mailto:csargent@bullion.org.za"><i>Environmental Control<br>
Training</i></a></td><td><a href="mailto:csargent@bullion.org.za"><i>Jan Swanepoel</i></a></td></tr>
<tr><td><a href="mailto:csargent@bullion.org.za"><i>Colliery Training<br>
College</i></a></td><td><a href="mailto:egous@bullion.org.za"><i>Mac van der Merwe</i></a></td></tr>
<tr><td><i>Rescue Drilling<br>
Unit</i></td><td><a href="mailto:egous@bullion.org.za"><i>Mac van der Merwe</i></a></td></tr>
<tr><td><i>Collieries Environmental<br>
Control Services</i></td><td><a href="mailto:egous@bullion.org.za"><i>Mac van der Merwe</i></a></td></tr>
<tr><td><i>Mining Industry<br>
Engineering Trades<br>
Training Board</i></td><td><i>Stella Carthy</i></td></tr>
</table>
<p><b><i>Departmental Resources</i></b></p>
<ul>
<li><a href="/agreements/mqa.htm">Mining Qualifications Forum Agreement</a> </li>
<li><a href="http://www.bullion.org.za/agreements/educat1.htm">Education Partnership Policy</a> </li>
<li><a href="/agreements/petl.htm">Paid Education and Training Leave (PETL) Agreement</a> </li>
<li><a href="/agreements/abet.htm">Adult Basic Education and Training (ABET) Agreement</a> <p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<p align=center><img src="../images/tb101.gif" align=bottom width=101 height=17><img src="../images/tb102.gif" align=bottom width=101 height=17><img src="../images/tb103.gif" align=bottom width=101 height=17><img src="../images/tb104.gif" align=bottom width=101 height=17><img src="../images/tb105.gif" align=bottom width=101 height=17><img src="../images/tb106.gif" align=bottom width=101 height=17></p>
<p><font size=2><i>&#169;</i><em>1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </em></font><a href="mailto:twood@bullion.org.za"><font size=2><em>twood@bullion.org.za</em></font></a><font size=2><em> </em></font></p>
</li>
</ul>
</td></tr>
</table>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-472</DOCNO>
<DOCOLDNO>IA012-000131-B029-71</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/departments/comm.htm 196.26.82.193 19970217015309 text/html 2908
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:56:28 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Functions and Services</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="../images/cmlogo2.jpg" bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font color="#0000A0"><font size=4><b>Chamber of Mines of South Africa </b></font></font></h1>
<p align=center><img src="../images/LOGO1.gif" align=bottom width=300 height=160></p>
<h2 align=center><b><i>Core Services and Functions</i></b></h2>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<h3 align=center>COMMUNICATION SERVICES</h3>
<h4>Communication Services fulfils an advisory function and is responsible for the Chamber's public relations 
services.</h4>
<h2><i>Main Units:</i></h2>
<table cellpadding=6>
<tr><td width=40%><font size=4><strong>Title</strong></font></td><td><font size=4><strong>Name and Location</strong></font></td></tr>
<tr><td width=40%><font size=4>Adviser</font></td><td><a href="mailto:pbunkell@bullion.org.za"><font size=4>Peter Bunkell</font></a></td></tr>
<tr><td width=40%><font size=4>Manager:<br>
Media Relations</font></td><td><a href="mailto:lkriel@bullion.org.za"><font size=4>Llewellyn Kriel</font></a></td></tr>
<tr><td width=40%><font size=4>Manager:<br>
International Liaison</font></td><td><a href="mailto:rboers@bullion.org.za"><font size=4>Reinoud Boers</font></a></td></tr>
<tr><td width=40%><font size=4>Managing Editor:<br>
Industry Publications</font></td><td><a href="mailto:cthom@bullion.org.za"><font size=4>Charl Thom</font></a></td></tr>
<tr><td width=40%><font size=4>Editor:<br>
General Publications</font></td><td><a href="mailto:asmit@bullion.org.za"><font size=4>Al Smit</font></a></td></tr>
<tr><td width=40%><font size=4>Language Services</font></td><td><a href="mailto:ecollen@bullion.org.za"><font size=4>Errol Collen</font></a></td></tr>
<tr><td width=40%><font size=4>Mine Visits</font></td><td><a href="mailto:gbehrent@bullion.org.za"><font size=4>Geoff Behrent</font></a></td></tr>
</table>
<p><font size=2><b><i></i></b></font>&nbsp;</p>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<p align=center><img src="../images/tb101.gif" align=bottom width=101 height=17><img src="../images/tb102.gif" align=bottom width=101 height=17><img src="../images/tb103.gif" align=bottom width=101 height=17><img src="../images/tb104.gif" align=bottom width=101 height=17><img src="../images/tb105.gif" align=bottom width=101 height=17><img src="../images/tb106.gif" align=bottom width=101 height=17></p>
<p><font size=2><i>Last Updated: 22 May 1995<br>
&#169; 1995 Chamber of Mines of South Africa</i></font></p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-473</DOCNO>
<DOCOLDNO>IA012-000131-B029-167</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/departments/econ.htm 196.26.82.193 19970217015412 text/html 2215
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:57:46 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Functions and Services</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font color="#0000A0"><font size=4><b>Chamber of Mines of South Africa </b></font></font></h1>
<p align=center><img src="../images/LOGO1.gif" align=bottom width=300 height=160></p>
<h2 align=center><b><i>Core Services and Functions</i></b></h2>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<h3 align=center>ECONOMIC SERVICES</h3>
<h2><a name="STA"><font size=4><b>Staff</b></font></a></h2>
<ul>
<li><a href="mailto:rgrant@bullion.org.za" name="STA">Dr Richard Grant, Chief Economist </a></li>
<li><a href="mailto:rbaxter@bullion.org.za" name="STA">Mr Roger Baxter, Senior Economist </a></li>
<li><a href="mailto:fadam@bullion.org.za" name="STA">Ms Firoza Adam, Trainee Economist </a></li>
<li><a name="STA">Ms Christelle Muthusamy, Secretary </a></li>
</ul>
<p><font size=4><b>Resources</b></font></p>
<p><font size=3><img src="/images/blue.gif" align=bottom width=14 height=14></font><a href="/publications/nbgold96.htm"><font size=3> The Importance of Gold Mining to South Africa</font></a><font size=2><br>
</font></p>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<p align=center><img src="../images/tb101.gif" align=bottom width=101 height=17><img src="../images/tb102.gif" align=bottom width=101 height=17><img src="../images/tb103.gif" align=bottom width=101 height=17><img src="../images/tb104.gif" align=bottom width=101 height=17><img src="../images/tb105.gif" align=bottom width=101 height=17><img src="../images/tb106.gif" align=bottom width=101 height=17></p>
<p><font size=2><i>&#169;</i><em>1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </em></font><a href="mailto:twood@bullion.org.za"><font size=2><em>twood@bullion.org.za</em></font></a><font size=2><em> </em></font></p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-474</DOCNO>
<DOCOLDNO>IA012-000131-B030-9</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/departments/legal.htm 196.26.82.193 19970217015523 text/html 2174
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:58:59 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Legal</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font color="#0000A0"><font size=4><b>Chamber of Mines of South Africa </b></font></font></h1>
<p align=center><img src="../images/LOGO1.gif" align=bottom width=300 height=160></p>
<h2 align=center><b><i>Core Services and Functions</i></b></h2>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<h3 align=center>LEGAL SERVICES</h3>
<h2><a name="STA"><b>Staff</b></a></h2>
<ul>
<li><a name="STA">Mr Peter Anscombe, Legal Adviser </a></li>
<li><a name="STA">Mr Anton van Achterbergh, Assistant Legal Adviser </a></li>
<li><a name="STA">Mr Paul Henderson, Assistant Legal Adviser </a></li>
<li><a name="STA">Ms Sandy Oberholzer, Assistant Legal Adviser </a></li>
<li><a name="STA">Mr Barry Shipman, Legal Counsellor </a></li>
<li><a name="STA">Ms Jean Hutton, Secretary </a></li>
<li><a name="STA">Ms Gloria Marr, Secretary </a></li>
<li><a name="STA">Ms Ruth Shube, Secretary </a></li>
<li><a name="STA">Ms Elaine Marr, Secretary </a></li>
<li><a name="STA">Ms Zanele Maseko, Secretary </a><p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<p align=center><img src="../images/tb101.gif" align=bottom width=101 height=17><img src="../images/tb102.gif" align=bottom width=101 height=17><img src="../images/tb103.gif" align=bottom width=101 height=17><img src="../images/tb104.gif" align=bottom width=101 height=17><img src="../images/tb105.gif" align=bottom width=101 height=17><img src="../images/tb106.gif" align=bottom width=101 height=17></p>
<p><font size=2><i>&#169;</i><em>1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </em></font><a href="mailto:twood@bullion.org.za"><font size=2><em>twood@bullion.org.za</em></font></a><font size=2><em> </em></font></p>
</li>
</ul>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-475</DOCNO>
<DOCOLDNO>IA012-000131-B030-88</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/departments/ppu1.htm 196.26.82.193 19970217015621 text/html 7044
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 01:59:55 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Functions and Services</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080">
<h1 align=center><font color="#0000A0"><font size=4><b>Chamber of Mines of South Africa </b></font></font></h1>
<p align=center><img src="../images/LOGO1.gif" align=bottom width=300 height=160></p>
<h2 align=center><b><i>Core Services and Functions</i></b></h2>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<h3 align=center>PUBLIC POLICY UNIT</h3>
<p align=center>&#160; </p>
<hr size=3 noshade width=500>
<div align=center><center>
<table width=450>
<tr><td align=center width=50%><img src="../images/sa_flag2.gif" align=bottom width=160 height=86></td><td align=center width=70%><blockquote>
<p align=left><br>
<a href="#ABOUT"><font size=4><b>About the PPU</b></font></a></p>
</blockquote>
<blockquote>
<p align=left><a href="#STA"><font size=4><b>Staff</b></font></a></p>
</blockquote>
</td></tr>
<tr><td align=center colspan=2 width=100%><br>
<a href="#In Session"><font size=4><b><tt>Read about our parliamentary review publication</tt></b></font></a><font size=4><tt> </tt></font></td></tr>
</table>
</center></div>
<hr size=3 noshade width=500>
<h2><a name="ABOUT"><b>About the Public Policy Unit</b></a></h2>
<p>This unit monitors legislative and public policy developments at National, Provincial and Local Government level. It provides 
information and advice to the principal committees of the Chamber and all other Chamber services on matters of public policy 
and coordinates the views of the mining industry to legislators and persons/organisations involved in the formulation of policy. 
The main purpose of this activity is to assist in creating the optimal political, economic and social environment in which the 
mining industry&#146;s full potential can be achieved.<br>
</p>
<p align=center>&nbsp;</p>
<h2 align=center><a name="STA">Staff</a></h2>
<p align=center><a name="STA"><b>Mr </b></a><a href="mailto:jliebenb@bullion.org.za"><b>Johann Liebenberg</b></a><b>, Public Policy Consultant </b></p>
<hr size=3 noshade width=580>
<p align=center><br>
<b>Managing the Cape Town Office</b>: <a href="mailto:fbasson@bullion.org.za">Mr Fran&ccedil;ois Basson</a>, Policy Analyst<br>
</p>
<blockquote>
<blockquote>
<ul>
<li>Ms Nina Allchurch, Editor </li>
<li>Mr Ricardo Hansby, Trainee Analyst </li>
<li>Ms Sandra Lopes, Secretary </li>
</ul>
</blockquote>
</blockquote>
<hr size=3 noshade width=580>
<p align=center><a name="In Session"><font color="#800080"><font size=6><strong><i>In Session</i></strong></font></font></a></p>
<table cellspacing=18 width=100%>
<tr><td valign=top><h2 align=left><font size=3><i>In Session</i> is a weekly summary of parliamentary activity produced while 
parliament is in session. It comprises 8 pages containing the following: </font></h2>
<ol>
<li>An editorial section summarising the main developments of the week being 
reviewed. </li>
<li>Summaries of all the parliamentary meetings (portfolio committees, select 
committees, National Assembly, Senate, Constitutional Assembly, Constitutional 
Committee and CA Theme Committee meetings physically monitored by the 
Public Policy Unit. </li>
<li>A brief sumary of all new legislation tabled during the week under review. </li>
<li>A complete list of all parliamentary meetings which took place during the week 
under review. </li>
</ol>
<p>Once a month a supplement listing all legislation tabled during the session is included, 
indicating how this legislation is progressing through the parliamentary system. </p>
<p><font size=3>Chamber staff do not monitor all parliamentary meetings, only those of particular interest 
to the mining industry. For an additional fee committees not already monitored can 
however be monitored on a regular basis for clients.</font> </p>
<p>The main strength of In Session is that it is not merely an abstraction of what appears in 
the media. The entire publication is based on what Public Policy Unit staff personally 
observe when physically attending parliamentary meetings. </p>
</td><td valign=top width=180><h3 align=left><font color="#008000"><font size=3>Download a sample 
edition of <i>In Session</i> 
You will need the Adobe 
Acrobat viewer to read 
<i>In Session</i> click </font></font><a href="http://www.adobe.com/Software/Acrobat/"><font color="#008000"><font size=3><b>here</b></font></font></a><font color="#008000"><font size=3> to 
download a copy from 
Adobe Software 
Corporation.<br>
</font></font></h3>
<p><a href="insess24.pdf"><b> </b><b><i>In Session</i></b></a><b> Vol. 1 No. 
24 September 4 - 8 
1995</b> (PDF 49k)<br>
</p>
<h3><font size=3>Subscribe! To find out 
more about <i>In Session</i> 
or to subscribe, please 
contact </font><a href="mailto:jliebenb@bullion.org.za"><font size=3>Johann 
Liebenberg</font></a><font size=3>. You can 
also </font><a href="info.htm#CT"><font size=3>telephone or fax</font></a><font size=3> 
your request to our 
Cape Town office.</font> </h3>
</td></tr>
<tr><td colspan=2><font color="#FF0000"><font size=4><strong>Cost</strong></font></font><br>
<font size=4><strong><tt>The cost of In Session is R3 000 per annum (for approximately 30 
editions) [Current Rand per US Dollar </tt></strong></font><a href="prices.htm#currency"><font size=4><strong><tt>exchange rate</tt></strong></font></a><font size=4><strong><tt>].</tt></strong></font></td></tr>
</table>
<p>Chamber staff do not monitor all parliamentary meetings, only those of particular interest to the mining industry. For an 
additional fee committees not already monitored can however be monitored on a regular basis for clients.<br>
</p>
<p>The main strength of In Session is that it is not merely an abstraction of what appears in the media. The entire publication is 
based on what Public Policy Unit staff personally observe when physically attending parliamentary meetings. </p>
<p align=center>&nbsp;</p>
<p align=center><img src="../images/line3.gif" align=bottom width=590 height=2></p>
<p align=center><img src="../images/tb101.gif" align=bottom width=101 height=17><img src="../images/tb102.gif" align=bottom width=101 height=17><img src="../images/tb103.gif" align=bottom width=101 height=17><img src="../images/tb104.gif" align=bottom width=101 height=17><img src="../images/tb105.gif" align=bottom width=101 height=17><img src="../images/tb106.gif" align=bottom width=101 height=17></p>
<p><font size=2><i>&#169;</i><em>1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </em></font><a href="mailto:twood@bullion.org.za"><font size=2><em>twood@bullion.org.za</em></font></a><font size=2><em> </em></font></p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-476</DOCNO>
<DOCOLDNO>IA012-000131-B030-159</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/gold1.htm 196.26.82.193 19970217015710 text/html 19177
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:00:31 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa: Gold Marketing</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<h1 align="center"><b>Chamber of Mines of South Africa </b></h1>

<p align="center"><img src="LOGO1.gif" width="300" height="160"></p>

<h2 align="center"><b><i>Core Services and Functions: Gold
Marketing</i></b></h2>
<div align="center"><center>

<table border="0" cellspacing="18" width="640">
    <tr>
        <td valign="top" width="350"><font size="4"><img
        src="purple.gif" width="14" height="14">&nbsp;</font><a
        href="#gmktng"><font size="4">Chamber Gold Marketing
        Function</font></a><p><font size="4"><img
        src="images/orange.gif" width="14" height="14">&nbsp;</font><a
        href="#NEXT"><font size="4">Marketing of South African
        Gold</font></a></p>
        <p><font size="4"><img src="images/green.gif" width="14"
        height="14">&nbsp;</font><a href="#faq"><font size="4">Gold
        FAQ</font></a></p>
        <p align="center"><font size="4"><img
        src="images/ANIMATED_GLOBE_WHITE_BACK.GIF"
        align="absmiddle" width="90" height="80"></font></p>
        <p align="center">&nbsp;</p>
        </td>
        <td align="center" valign="top" width="280"><font
        size="5"><b><i><img src="images/touchstones.jpg"
        align="absmiddle" border="3" width="307" height="218"></i></b><br>
        </font><font size="1" face="Arial">19<sup>th </sup>century
        needle set used to test<br>
        the </font><a href="#faq"><font size="1" face="Arial">finess</font></a><font
        size="1" face="Arial"> of gold articles with touchstones</font></td>
    </tr>
</table>
</center></div>

<p align="center"><a href="http://www.gold.org/"><img
src="images/Wgclogo.gif" alt="World Gold Council (WGC)"
border="0" width="395" height="40"></a></p>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<hr>

<p align="center">&nbsp;</p>

<p align="center"><a name="gmktng"></a><font size="5"> </font></p>

<h3 align="center"><font size="5">GOLD MARKETING</font></h3>

<p><font size="3">Gold producers are essentially price-takers. It
is critical for them to maximise demand for their product and to
influence all other factors which may have a positive impact on
the price of the gold which they produce.<br>
</font></p>

<p><font size="3">It is the purpose of the gold marketing
function of the Chamber to facilitate South African gold mining
industry policy-making on gold marketing and to monitor on behalf
of the industry the agencies which implement its policy. This
takes the form of active marketing of South African gold products,
increasingly with a value-added content. Insofar as such
marketing is best dealt with on an industry basis, it rests with </font><a
href="/associates/igc.htm"><font size="3">Intergold</font></a><font
size="3">, </font><a href="/associates/rr.htm"><font size="3">Rand
Refinery</font></a><font size="3"> and the Chamber.<br>
</font></p>

<p><font size="3">Intergold provides the industry with a flexible
structure to fund and conduct international marketing activities
of the </font><a href="kruger.htm"><font size="3">Krugerrand</font></a><font
size="3">, and distribute income from such activity. Since its
inception in 1967, more than 54,4 million Krugerrands of all four
denominations - one ounce, half ounce, quarter ounce and tenth
ounce - have been sold world-wide. The Krugerrand has achieved
international market leadership and world-wide tradability and is
the only South African world brand. In anticipation of favourable
de-regulatory and tax developments in several European countries
that have a traditional affinity for gold, current activities
concentrate on bringing the Krugerrand to these untried markets. For
instance, the Krugerrand is to be quoted on the gold market of
the Paris bourse in early 1996, which will be the first new
quotation of a gold coin since 1967. Another important area is
the development of new products suited to the developing markets which
now account for the bulk of physical gold offtake.<br>
</font></p>

<p><font size="3">Rand Refinery is the modern production tool of
the industry, through which value-added products are made to take advantage
of South African market opportunities. Rand Refinery is the
world&#146;s largest gold refinery, processing South Africa&#146;s
entire production of newly-mined gold. It has successfully
diversified its operations and expertise to meet the changing market
needs by producing value-added products such as investment bars,
granules, crystals, medallions, bullion coins and gold chemicals.<br>
</font></p>

<p><font size="3">The Chamber and its members also influence gold
usage through their support of </font><a
href="http://www.gold.org"><font size="3">World Gold Council</font></a><font
size="3">, the Geneva-based international organisation for the
promotion of gold.<br>
</font></p>

<p><font size="3">The Chamber gold marketing function intervenes
in domestic issues on behalf of member producers in such areas as
local beneficiation - giving support to local benefication
initiatives which meet business criteria - and liaison with the </font><a
href="http://www.resbank.co.za/"><font size="3">South African Reserve
Bank</font></a><font size="3"> which remains the compulsory channel
for the sale to the world markets of the bulk of the
country&#146;s newly-mined gold. </font></p>

<p align="center"><a href="/tmain.htm"><font size="5"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></font></a><font size="5"> </font><a
href="#top"><font size="5"><img src="../images/nb2.gif"
alt="Top of Page" align="middle" border="0" hspace="20"
width="60" height="17"></font></a><font size="5"> </font><a
href="#toolbar"><font size="5"><img src="../images/nb3.gif"
alt="Toolbar" align="middle" border="0" hspace="20" width="80"
height="17"></font></a><font size="5"> <br>
<br>
</font></p>

<hr size="4" noshade width="600">

<p><font size="5"><br>
</font></p>

<p><a name="NEXT"></a><font size="5"> </font></p>

<h3 align="center"><font size="5">MARKETING OF SOUTH AFRICAN GOLD</font></h3>

<p>Exchange control regulations in South Africa require that all
newly-mined gold be offered for sale to the Reserve Bank, which acts
as an agent for the Treasury, within 30 days of production. South African
gold producers therefore sell the bulk of their production to the
South African Reserve Bank. &nbsp;</p>

<p>The South African Reserve Bank disposes of the bullion, which
it has bought from the producers, on the international markets as
determined by a variety of macro-economic factors. The Bank has the choice
of selling gold, swapping it for dollars, or adding to
reserves.&nbsp;</p>

<p>The Chamber of Mines of South Africa has the right to market,
on behalf of the producers, gold in value-added or beneficiated
forms approved by the Minister of Finance, with an overall mass
per item of one kilogram or less. The understanding is that a
maximum of one third of the country's gold production will be
sold in this manner. The Krugerrand is marketed by the Chamber as
a part of this arrangment. Similarly, beneficiated gold in forms
other than the Krugerrand is sold internatioally by Rand Refinery
as part of this dispensation.&nbsp;</p>

<p>Small amounts of gold are also sold by Rand Refinery, on
behalf of the Reserve Bank, to industrial users and to the local jewellery
manufacturing industry.&nbsp;</p>

<p>The terms and conditions under which the Reserve Bank is
prepared to negotiate sales of gold bullion include the folowing:</p>

<ol>
    <li>Sales of gold bullion in the form of 12,5 kilogram
        &quot;good delivery&quot; bars of 9950+ fineness are directed
        to internationally accepted bullion dealers of the
        Reserve Bank's choice.</li>
</ol>

<ol type="1" start="2">
    <li>Transactions are done on a principal-to-principal basis
        and the Reserve Bank will not, under any circumstances,
        even consider effecting or negotiating any sale of gold
        bullion through the medium of third parties.</li>
</ol>

<ol>
    <li value="3">The Reserve Bank will not consider any form of
        discount whatsoever and sells gold only at market prices.</li>
</ol>

<ol type="1" start="4">
    <li>The Reserve Bank trades bullion in the wholesale markets. </li>
</ol>

<ol type="1" start="5">
    <li>The Reserve Bank will furthermore not consider selling
        gold on either a contract or consignment basis.</li>
</ol>

<ol type="1" start="6">
    <li>Should an institution wish to become a correspondent of
        the Reserve Bank it would have to be an acceptable participant
        in the various bullion markets and it would have to be in
        a position to quote two-way prices for all the various
        derivatives i.e. spot, forward, swaps, options, etc. </li>
</ol>

<p align="center"><font color="#FF0000" size="2" face="Arial"><strong>All
enquiries with respect to the sale of gold bullion should be
directed to:</strong></font></p>

<blockquote>
    <p align="center"><font size="3">The General Manager<br>
    International Banking Department<br>
    </font><a href="http://www.resbank.co.za/"><font size="3">South
    African Reserve Bank</font></a><font size="3"><br>
    P O Box 427<br>
    PRETORIA<br>
    0001<br>
    Phone: +27 12 313 - 3911<br>
    Fax: +27 12 313 - 3969<br>
    E-Mail: </font><a href="mailto:info@GWISE.resbank.co.za"><font
    size="3">info@GWISE.resbank.co.za</font></a><font size="3"><br>
    </font>&nbsp;</p>
</blockquote>

<p>The terms on which <a
href="http://www.bullion.org.za/kruger.htm">Krugerrands</a> are
sold by the Chamber of Mines are strictly applied. These terms
provide, inter alia, that: &nbsp;</p>

<blockquote>
    <ol>
        <li>The purchaser must be a bullion dealer or a
            registered bank actively engaged in trading gold on a
            daily basis.</li>
        <li>The ex-Rand Refinery vault price of the coins is
            based on the bullion market price, plus a premium of
            3 per cent on the 1 oz coin, 5 per cent on the 1/2 oz coin,
            7 per cent on the <font size="1">1</font>/<font
            size="1">4</font> oz coin and 9 per cent on the 1/10
            oz coin. Under no circumstances are discounts
            considered.</li>
    </ol>
</blockquote>

<p align="center"><font color="#FF0000" size="2" face="Arial"><strong>All
enquiries with respect to the sale of Krugerrands should be
directed to: </strong></font></p>

<blockquote>
    <blockquote>
        <blockquote>
            <p align="center">The Chief Executive<br>
            Chamber of Mines of South Africa<br>
            P O Box 61809<br>
            MARSHALLTOWN<br>
            2107&nbsp;</p>
            <p align="center">Phone: +27 11 498 - 7100<br>
            Fax: +27 11 838 - 4255</p>
            <p align="center">&nbsp;</p>
        </blockquote>
    </blockquote>
</blockquote>

<p>The terms on which beneficiated gold products other than the
Krugerrand are sold by <a
href="http://www.bullion.org.za/associates/rr.htm">Rand Refinery</a>
are essentially similar to those listed under points 2 to 6 above.</p>

<blockquote>
    <p>&nbsp;</p>
    <p align="center"><font color="#FF0000" size="2" face="Arial"><strong>All
    enquiries with respect to the sale of gold by Rand Refinery
    should be directed to:</strong></font>&nbsp;</p>
    <p align="center">The Managing Director<br>
    Rand Refinery Limited<br>
    P O Box 565<br>
    GERMISTON<br>
    1400</p>
    <p align="center">Tel: +27 11 873-2222<br>
    Fax: +27 11 825-1806</p>
</blockquote>

<p>&nbsp;</p>

<hr>

<h3 align="center"><font size="3">THE </font><a name="CHAMBER"><font
size="3">CHAMBER</font></a><font size="3"> OF MINES OF SOUTH
AFRICA</font></h3>

<p><font size="3">The Chamber of Mines of South Africa has the
right to market, on behalf of the producers, gold in value-added
or beneficiated forms approved by the Minister of Finance, with
an overall mass per item of one kilogram or less. The understanding
is that a maximum of one third of the country's gold production
will be sold in this manner. The </font><a href="kruger.htm"><font
size="3">Krugerrand</font></a><font size="3"> is marketed by the
Chamber as a part of this arrangement.</font></p>

<p><font size="3">The prime objective of the Krugerrand
distribution arrangements is to allow the consumer ready access
to the coin. Another objective is to ensure that the Krugerrand
is an integral part of the international gold trading and always
has a two-way market, which is essential to the confidence of prospective
purchasers.</font></p>

<p><a href="http://www.bullion.org.za/kruger.htm#DEALERS"><font
size="3">Primary Krugerrand distributors</font></a><font size="3">
have been appointed, which have the exclusive access to coins directly
from the Chamber. These distributors share the following
characteristics: </font></p>

<ol>
    <li><font size="3">Substantial experience and regular trade
        in gold bullion and coins. </font></li>
    <li><font size="3">Provision of, or access to, an effective
        distribution network. </font></li>
    <li><font size="3">Substantial financial standing. </font></li>
    <li><font size="3">Willingness to participate in two-way
        trading. </font></li>
    <li><font size="3">Ability to purchase substantial volumes at
        all times. </font></li>
</ol>

<p align="center"><font size="3">All enquiries with respect to
the sale of Krugerrands should be directed to:<br>
<br>
</font><a
href="mailto:dpollnow@bullion.org.za%3e%20Dr%20Daniel%20Pollnow%3c/a%3e,%20Gold%20Marketing%20Consultant%3cbr%3e%20or%20%3cbr%3e%3cA%20HREF="
mailto:gmoncur@bullion.org.za><font size="3">Ms Gillian Moncur</font></a><font
size="3">, Gold Marketing Assistant</font><font size="5"><br>
</font></p>

<p align="center"><a href="/tmain.htm"><font size="5"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></font></a><font size="5"> </font><a
href="#top"><font size="5"><img src="../images/nb2.gif"
alt="Top of Page" align="middle" border="0" hspace="20"
width="60" height="17"></font></a><font size="5"> </font><a
href="#toolbar"><font size="5"><img src="../images/nb3.gif"
alt="Toolbar" align="middle" border="0" hspace="20" width="80"
height="17"></font></a><font size="5"> <br>
<br>
</font></p>

<hr size="4" noshade width="600">

<p align="center">&nbsp;</p>

<p align="center"><a name="faq"></a><font size="5"> </font></p>

<h2 align="center"><font size="5">GOLD FAQ</font></h2>

<h3 align="center"><font color="#008000" size="5">Gold Weights</font></h3>
<div align="center"><center>

<table border="1" width="50%">
    <tr>
        <th align="left" bgcolor="#EAEA00"><font size="2"
        face="Arial">1 Kilogram</font></th>
        <th><font size="2" face="Arial">=</font></th>
        <th align="right"><font size="2" face="Arial">32,1507
        ounces</font></th>
    </tr>
    <tr>
        <th align="left" bgcolor="#EAEA00"><font size="2"
        face="Arial">1 Ton</font></th>
        <th><font size="2" face="Arial">=</font></th>
        <th align="right"><font size="2" face="Arial">32 150,7
        ounces</font></th>
    </tr>
    <tr>
        <th align="left" bgcolor="#EAEA00"><font size="2"
        face="Arial">1 Ounce</font></th>
        <th><font size="2" face="Arial">=</font></th>
        <th align="right"><font size="2" face="Arial">31,1035
        &nbsp;&nbsp;grams</font></th>
    </tr>
</table>
</center></div>

<p align="center"><font size="5"><br>
</font></p>

<h3 align="center"><font color="#008000" size="5">Caratage</font></h3>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <th><font size="3" face="Arial">Caratage is the weight
        fraction of gold in a gold alloy, expressed in 24ths. For example,
        24 carat gold is pure gold, and 18 carat gold alloy
        contains 18/24ths or 75% by weight of gold.</font></th>
    </tr>
</table>
</center></div>

<p align="center"><font size="5"><br>
</font></p>

<h3 align="center"><font color="#008000" size="5">Fineness</font></h3>
<div align="center"><center>

<table border="1" width="80%">
    <tr>
        <th><font size="3" face="Arial">Fineness is the weight
        fraction of gold in a gold alloy, expressed in <br>
        1 000ths or 10 000ths. For example, 9999 gold contains 9
        999 parts<br>
        per 10 000 fine gold by weight.</font></th>
    </tr>
</table>
</center></div>

<p align="center"><font size="5"><br>
</font></p>

<p align="center">&nbsp;</p>

<p align="center"><a href="/tmain.htm"><font size="5"><img
src="../images/nb1.gif" alt="Main Menu" align="middle" border="0"
hspace="20" width="60" height="17"></font></a><font size="5"> </font><a
href="#top"><font size="5"><img src="../images/nb2.gif"
alt="Top of Page" align="middle" border="0" hspace="20"
width="60" height="17"></font></a><font size="5"> </font><a
href="#toolbar"><font size="5"><img src="../images/nb3.gif"
alt="Toolbar" align="middle" border="0" hspace="20" width="80"
height="17"></font></a><font size="5"> <br>
<br>
</font></p>

<p align="center"><a name="toolbar"></a><font size="5"> </font><a
href="org1.htm"><font size="5"><img src="tb101.gif"
alt="organisation" border="0" width="101" height="17"></font></a><font
size="5"> </font><a href="res1.htm"><font size="5"><img
src="tb102.gif" alt="Resources" border="0" width="101"
height="17"></font></a><font size="5"> </font><a
href="kruger.htm"><font size="5"><img src="tb104.gif"
alt="Krugerrand" border="0" width="101" height="17"></font></a><font
size="5"> </font><a href="new.htm"><font size="5"><img
src="tb105.gif" alt="What's New?" border="0" width="101"
height="17"></font></a><font size="5"> </font><a href="info.htm"><font
size="5"><img src="tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></font></a><font size="5"> <br>
</font></p>

<hr>
<div align="center"><center>

<address>
    <font size="5"><br>
    </font><font size="2"> 1996 Chamber of Mines of South
    Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</center></div>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-477</DOCNO>
<DOCOLDNO>IA012-000131-B030-199</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/gauteng.htm 196.26.82.193 19970217015756 text/html 3919
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:01:26 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Gauteng Centre for Human Development</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#E0DDB6" text="#800040">
<p align=center><font color="#400080"><font size=5><strong>GAUTENG CENTRE FOR HUMAN DEVELOPMENT</strong></font></font></p>
<div align=center><center>
<table width=50%>
<tr><td width=50%><font color="#0080FF">12th Floor</font></td><td align=right width=50%><font color="#0080FF">P O Box 809</font></td></tr>
<tr><td width=50%><font color="#0080FF">MacLaren Street	</font></td><td align=right width=50%><font color="#0080FF">Johannesburg</font></td></tr>
<tr><td><font color="#0080FF">Marshalltown</font></td><td align=right><font color="#0080FF">2000</font></td></tr>
<tr><td><font color="#0080FF">2001</font></td><td align=right></td></tr>
<tr><td><font color="#0080FF">Tel.: (011) 834-1611</font></td><td align=right><font color="#0080FF">Fax: (011)834-1614</font></td></tr>
</table>
</center></div>
<p align=center><font color="#0080FF">E-Mail:</font> <a href="mailto:adnbel@pixie.co.za">Andr&eacute; Beugger</a></p>
<p><br>
<font size=4>The Gauteng Centre for Human Development (GCHD) is a Johannesburg based psycho-social 
service organization specializing in the development and operation of Employee Assistance 
Programmes (EAP). An EAP is a management system for coping with hard-to-reach and troubled 
employees and, where arranged, their immediate dependants in the most cost effective way. A 
&#145;troubled&#146; employee would be anyone facing a personal or work-related difficulty such as 
interpersonal conflict, stress, substance abuse and the like.<br>
</font><br>
<font size=4>GHCD began operating in 1987 as an Employee Assistance Programme provider to the sector of the 
mining industry based in Johannesburg and environs. Subsequently its operations have expanded and 
now include other large non-mining industry employers.<br>
<br>
GCHD is actively engaged in providing employee assistance programme services to in excess of 
65000 employees and offers psycho-social training and development as part of the preventative focus 
of such programmes.<br>
<br>
GCHD is professionally staffed with a multi-disciplinary and multi-cultural metal health team 
comprising registered social workers, psychologists and psychiatrist. All are seasoned practitioners 
with expertise in mental health, substance abuse, employee assistance services, training and 
development. the NAM (network alliance) allows access to a large array of associated services and 
products, such as assessment of senior staff for appointments and promotion, and auditing of EA 
Programmes.<br>
<br>
At present, the collective service of the core staff is in excess of 50 years. Senior staff have extensive 
public speaking experience and have presented papers<br>
<br>
<em><strong>The components of the GCHD service which lend added value are :</strong></em></font></p>
<ul>
<li><font size=4>Up to date professional and ethical principles and practices which are tested and scrutinised by 
its user base,</font></li>
<li><font size=4>International linkages which contribute to the value of service delivery, eg. new technologies and 
professional networking,</font></li>
<li><font size=4>Multi-disciplinary teamwork,</font></li>
<li><font size=4>Accessibility, on-site/off-site service delivery,</font></li>
<li><font size=4>Proactive management strategies,</font></li>
<li><font size=4>Proven expertise in EAP services since 1987,</font></li>
<li><font size=4>A confidential customer needs orientation, coupled with audit skills and</font></li>
<li><font size=4>A quality and service-driven focus.</font></li>
</ul>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-478</DOCNO>
<DOCOLDNO>IA012-000131-B030-235</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/teba.htm 196.26.82.193 19970217015818 text/html 2091
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:01:56 GMT
Content-type: text/html
</DOCHDR>
<html>
<head>
<BODY background="back3.gif" Bgcolor="#ffffff" text="#000080" link="#0000ff" vlink="#800000">
<a name="top"></a>
<title>THE EMPLOYMENT BUREAU OF AFRICA</title></head>
<center>
<IMG SRC="teba.jpg" ALIGN=MIDDLE border=0 alt="TEBA><br>
<font size=7><i><b>The Employment Bureau of Africa</b></i></font><br>
<p>
<IMG SRC="/line3.gif"></CENTER>
<br><p>
<center><b><h3>Contacting Us</h3></b></center>
<pre><b>
<IMG SRC="/build.gif" ALIGN=MIDDLE> Physical Address: 121 Eloff Street Extension, Johannesburg
<IMG SRC="/phone.gif" ALIGN=MIDDLE> Telephone +27 11 493-3158/9 
<IMG SRC="/faxphone.gif" ALIGN=MIDDLE> Facsimile +27 11 493-0559
<IMG SRC="/pobox.gif" ALIGN=MIDDLE> Postal Address: PO Box 62251, MARSHALLTOWN, 2107, SOUTH AFRICA
<IMG SRC="/emm.gif" ALIGN=MIDDLE> Internet E-Mail <A HREF="mailto:cwesting@bullion.org.za"> info@bullion.org.za</A>
</b></pre>
<br><center>
<a href=/main.htm> <IMG SRC="/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br>
<IMG SRC="/line3.gif" ALIGN=MIDDLE>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  5 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>



</DOC>
<DOC>
<DOCNO>WT14-B39-479</DOCNO>
<DOCOLDNO>IA012-000131-B031-40</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/tcash.htm 196.26.82.193 19970217015852 text/html 2052
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:02:12 GMT
Content-type: text/html
</DOCHDR>
<html>
<head>
<BODY background="back3.gif" Bgcolor="#ffffff" text="#000080" link="#0000ff" vlink="#800000">
<a name="top"></a>
<title>TEBA SAVINGS FUND</title></head>
<center>
<IMG SRC="/associates/tecsh.jpg" ALIGN=MIDDLE border=0 alt="TEBA><br>
<font size=7><i><b>Teba Cash</b></i></font><br>
<p>
<IMG SRC="/line3.gif"></CENTER>
<br><p>
<center><b><h3>Contacting Us</h3></b></center>
<pre><b>
<IMG SRC="/build.gif" ALIGN=MIDDLE> Physical Address: 270 Princess Park Drive, Pretoria
<IMG SRC="/phone.gif" ALIGN=MIDDLE> Telephone +27 12 21-6883 
<IMG SRC="/faxphone.gif" ALIGN=MIDDLE> Facsimile +27 12 325-6609
<IMG SRC="/pobox.gif" ALIGN=MIDDLE> Postal Address: PO Box 214, PRETORIA, 0002, SOUTH AFRICA
<IMG SRC="/emm.gif" ALIGN=MIDDLE> Internet E-Mail <A HREF="mailto:cwesting@bullion.org.za"> info@bullion.org.za</A>
</b></pre>
<br><center>
<a href=/main.htm> <IMG SRC="/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br>
<IMG SRC="/line3.gif" ALIGN=MIDDLE>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  5 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>



</DOC>
<DOC>
<DOCNO>WT14-B39-480</DOCNO>
<DOCOLDNO>IA012-000131-B031-75</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/rma.htm 196.26.82.193 19970217015912 text/html 2146
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:02:46 GMT
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>Loading Images! Please be patient!</title>
<BODY background="back3.gif" Bgcolor="#ffffff" text="#000080" link="#0000ff" vlink="#800000">
<a name="top"></a>
<title>RAND MUTUAL ASSURANCE COMPANY</title></head>
<center>
<IMG SRC="rma.jpg" ALIGN=MIDDLE border=0 alt="RMA><br>
<font size=7><i><b>Rand Mutual Assurance Company</b></i></font><br>
<p>
<IMG SRC="/line3.gif"></CENTER>
<br><p>
<center><b><h3>Contacting Us</h3></b></center>
<pre><b>
<IMG SRC="/build.gif" ALIGN=MIDDLE> Physical Address: 16th Floor, Edura House, 41 Fox Street, Johannesburg
<IMG SRC="/phone.gif" ALIGN=MIDDLE> Telephone +27 11 836-2530/8 
<IMG SRC="/faxphone.gif" ALIGN=MIDDLE> Facsimile +27 11 492-1253
<IMG SRC="/pobox.gif" ALIGN=MIDDLE> Postal Address: PO Box 61413, MARSHALLTOWN, 2107, SOUTH AFRICA
<IMG SRC="/emm.gif" ALIGN=MIDDLE> Internet E-Mail <A HREF="mailto:cwesting@bullion.org.za"> info@bullion.org.za</A>
</b></pre>
<br><center>
<a href=/main.htm> <IMG SRC="/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br>
<IMG SRC="/line3.gif" ALIGN=MIDDLE>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A></CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  5 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>



</DOC>
<DOC>
<DOCNO>WT14-B39-481</DOCNO>
<DOCOLDNO>IA012-000131-B031-131</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/rr.htm 196.26.82.193 19970217020006 text/html 17220
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:03:37 GMT
Content-type: text/html
</DOCHDR>
<html>
<head>
<CENTER>
<BODY BGCOLOR=#FEFCDA BACKGROUND="/images/goldbck3.gif" TEXT=#0000A0 VLINK=#008080 ALINK=#008080>
<a name="top"></a>
<title>RAND REFINERY</title></head>

<IMG SRC="/images/rdrf2.gif" ALIGN=MIDDLE border=0 alt="RR"><p>
<i><font size=7><b>Rand Refinery Limited</b></font></i><p>
<IMG SRC="/images/line3.gif" ALIGN=MIDDLE><p>
</CENTER>
<p>

<Center><TABLE BORDER=3 cellpadding=5 cellspacing=5 width=80%>
<TR><Td align=center valign=middle><a href="#miss"><B><I><FONT SIZE=4 COLOR=0000A0>Mission Statement and Company Philosophy</FONT></I></B></a></Td>
</TR>
</table>

<TABLE BORDER=3 cellpadding=5 cellspacing=5 width=80%>
<b>
<Td align=center valign=middle><a href="#goldrr">Gold</a></Td>
<Td align=center valign=middle><a href="#rr1">Rand Refinery</a></Td>
<Td align=center valign=middle><a href="#process">Processes</a></Td>
<Td align=center valign=middle><a href="#electrolytic">Electrolytic Gold</a></Td>
</TR>
<Td align=center valign=middle><a href="#kruger">Krugerrand</a></Td>
<Td align=center valign=middle><a href="#smelting">Smelting</a></Td>
<Td align=center valign=middle><a href="#goldprice">Gold Price</a></Td>
<Td align=center valign=middle><a href="#goldbar">Gold Bars</a></Td>
</tr>
<Td align=center valign=middle><a href="#weights">Gold Weights</a></Td>
<Td align=center valign=middle><a href="#caratage">Caratage</a></Td>
<Td align=center valign=middle><a href="#fineness">Fineness</a></Td>
<Td align=center valign=middle><a href="#info">Contacting Us</a></Td>
</tr>
</table></Center>
<p><br><p><br><p>
</b>
<blockquote>

<A NAME="miss"></A>
<FONT SIZE=4><B>Mission Statement and Company Philosophy</b></FONT><br>

The companys mission is to provide a cost-effective, quality service to its customers with the object of contributing to the prosperity of its members.<br>

As a responsive and innovative service organisation, Rand Refinery believes in and actively supports: <br>

<ul>
<li> Reform that will bring all South Africans closer together - politically, socially and economically.
<li> The removal of all discrimination based on colour, sex or creed.
<li> Respect for the dignity and self-esteem of the individual.
<li> Freedom of movement and association.
<li> Free enterprise.
</ul>

<A NAME="goldrr"></A>
<FONT SIZE=4><b>GOLD</b></FONT><br>

Gold, for many thousands of years a prized metal throughout the world, has fascinated man who has bestowed great value on it because of its beauty, its purity and its scarcity.  South Africa burst on the international scene over 100 years ago with the discovery of the largest and most productive gold fields.  Today, these gold fields employ over 750 000 people, contributing to the well-being of southern Africa and providing gold for the markets of the world.<p>

Demand for gold has grown and changed somewhat from that of 100 years ago.  The advances of technology have generated many new applications for gold in communications, electronics, dentistry and space technology.  Jewellers are experimenting with new alloys and producing artifacts of purity and durability previously unknown. <p>

Investors are also demanding gold which is highly refined and bearing a mark they can trust. <p>

Thus efficient refining and the availability of pure gold are more important than even before. <p>

Rand Refinery, situated on the outskirts of Johannesburg, grew with the increasing and changing demand for refined gold, and is now the worlds largest refinery, processing South Africas entire production of newly-minted gold.<p>

This production (some 620 tons in 1988) constitutes about 40 per cent  of the free worlds annual gold output. <p>

The gold processed at Rand Refinery represents over 38,4 per cent of the value of South Africas exports and is the end product of an industry that in 1988 accounted for 7,5 per cent of the countrys gross domestic product.<p>

<A NAME="rr1"></A>
<FONT SIZE=4><b>RAND REFINERY</b></FONT><br>

When gold was first discovered on the Witwatersrand in 1886, it was sent to London for refining; only in 1920 was Rand Refinery established to cater for the needs of the local mines. In 1923, the first full year of refining, nine million ounces (285 tons) of find gold were produced.  By 1959 output had reached 20 million ounces (624 tons) and by 1970, a peak year in South African gold production, 32 million ounces (1 000 tons).<p>

A private enterprise service organisation, Rand Refinery is an associated company of the Chamber of Mines of South Africa and refines gold and silver on a co-operative basis for mines which are members of the Chamber. Co-operation ensures the efficiencies and economies associated with a large-scale enterprise, a consistent assay mark and the security essential for such a valuable end product.<p>

The refining section upgrades impure gold bullion from South Africas gold mines into gold and silver of commercial purity; the smelter section treats by-product materials to recover gold and silver; the bullion office liaises with the South African Reserve Bank and administers sales of precious metals and the distribution of proceeds back to the mines.  Other important functions are performed by laboratories which assess incoming and outgoing materials, the engineering department which deals with the maintenance of the plant and the transport of bullion, and by the vital security force. The more conventional departments include administration, accounts, data processing and personnel.  The company employs 360 people, many of them housed on the Rand Refinery grounds.<p>

Rand Refinery has continued to grow with the changing needs of the industry.  Thus the refinery was completely modernised in 1966, the smelter plant was rebuilt in 1986 to incorporate the latest and most appropriate technolgy, and finally, in 1989 a totally new refinery has been completed which incorporates the ultimate in security measures and process mechanisation.<p>

<A NAME="process"></A>
<FONT SIZE=4><b>THE PROCESS</b></FONT><br>

Each year Rand Refinery processes on average 800 tons of bullion received from the mines.  This bullion contains approximately 84 per cent gold, 10 per cent silver and 6 per cent base metals.

<FONT SIZE=2>
<dl>
<dt>a)  Evaluation
<dd> On arrival at the refinery, the bullion bars are first dried and weighed and the results are verified (by computer) against those of the mines.<p>

<dd> If the weights agree, the bars are loaded in lots of up to 350 Kilograms into an induction furnace where they are melted and samples are taken for analysis of the precious metal contents.<p>

<dd> This analysis is done by X-ray fluorescence spectrometry and takes only 10-15 minutes to complete.  The results are immediately compared (by computer) with those of the mines.<p>

<dt> b) Refining
<dd> If the analyses agree, the molten metal is transferred to a refining (induction) furnace in quantities of up to 750 kilograms.<br>
<center>
<IMG SRC="/images/gref1.gif" alt="schematic of the refining process"></IMG>
</center>
<dd> Chlorine gas is blown into the melt, coverting base metals and silver to their chlorides which either rise to the surface and are poured off or, being volitile, are removed with the off-gas. It takes 60 to 90 minutes depending on impurity content, before the remaining gold reaches the required minimum of 99,5 per cent.<p>

<dd> The refined gold is transferred in ladles to a one-ton capacity holding/casting furnace.<p>


<dt> c) Casting
<dd> The gold is sampled and mechanically cast into 400 oz (12,5kg) good delivery bars, which are subsequently quenched, dried, stamped, weighed and packed - all on a mechanised coveyor assembly.<p>

<dd> The analyses of these refined gold samples is done by the X-ray fluoresence spectrometers.<p>

<dt>Sales

<dd>All newly-mined gold must be offered to the South African Reserve Bank within 30 days of production.The sale is made by Rand Refinery on behalf of the producers and the agreed prices is the average of the last two available London gold fixings.  In practice the time lapse between the delivery of an impure mine bar to Rand Refinery and correspondding payment by the Reserve Bank is normally two to five working days.  The Reserve Bank may either add the purchased gold to the countrys official gold reserves or sell it on the international markets.<p>

<dd>Rand Refinery does not purchase gold from the mines, but refines it on behalf of depositers who pay refining charges.</FONT></dl><p>

<A NAME="electrolytic"></A>
<FONT SIZE=4><b>ELECTROLYTIC GOLD</b></FONT><br>

Gold refined to a purity of 99,5 per cent is not always pure enough for certain industrial and technical applications or for the production of small investment bars.  To attain a purity of 99,9 per cent, gold is further refined electrolytically.
<center>
<IMG SRC="/images/gref2.gif" alt="schematic of electrolytic process"></IMG>
</center>
<FONT SIZE=2>
<dl>
<dt> The 99,5 per cent gold is cast into rectangular slabs (anodes).<p>
<dt> These gold anods are then immersed in a hydrochloric acid/gold chloride solution and slowly dissolved by the passage of an electric current (electrolysis).  Pure gold deposits in a crystalline sponge form on titanium (cathode) plates.  This process removes most of the silver and trance impurityies, especialy platinum group metals, not removed by chlorination.<p>

<dt> The cathode deposits are then melted and cast into billets from which the Refinerys final products, such as one kilogram bars, are subsequently made.<br></FONT></dl><p>

<A NAME="silver"></A>
<FONT SIZE=4><b>SILVER</b></FONT><br>

The chlorides produces in the gold refining process contain approximately 50 per cent silver and are treated to recover this:<br>

<FONT SIZE=2>
<dl>
<dt> The molten chlorides previously poured off the refining furnaces are de-golded in separate furnaces to speed up the recycling of traces of gold dispersed n the,.  They are then quenched in water and pumped to reaction tanks<p>

<dt> In the reaction tanks, base metals are removed by washing and then metallic silver is precipitated by the addition of zinc dust.<p>

<dt>This silver (99 per cent pure) is dried in a centrifuge, then melted in a resistance furnace, from which silver anodes are cast.<p>

<dt>These anodes are refined  electrolytically to produce silver crystals at least 99,9 per cent pure, which are either vacuum dried and sold, or cast into 1 000 oz (31kg) bars for sale.<br></FONT></dl><p>

<A NAME="kruger"></A>
<FONT SIZE=4><b><A HREF="/kruger.htm">THE KRUGERRAND</A></b></FONT><br>

Rand Refinery makes blanks for the minting of the Krugerrand family of 1 ounce, 1/2 ounce, 1/4 ounce and 1/10 ounce coins, the most successful gold bullion coins ever produced.<br>

<FONT SIZE=2>
<dl>
<dt>Refined gold and copper are melted together to produce the 22-carat coinage alloy which is cast into strip on a continuous casting machine.<p>
This produces in parallel two coils of up to 600 kilograms each.<p>

<dt>The strip is rolled to the exact thickness required, and coin blanks are punched out.<p>

<dt>The blanks are individualy inspected and weighted to ensure that each contains not less than the amount of gold indicated by the face value of the coin.<p>

<dt>The blanks are sent to the South African Mint in Pretoria for striking into coins, and returned to Rand Refinery for storage and sale to selected distributors.<br></FONT></dl><p>

<A NAME="smelting"></A>
<FONT SIZE=4><b>SMELTING</b></FONT><br>

Smelting is Rand Refinerys other major function and this operation accounts for one per cent of gold throughput.  Every year some 3 800 tons of by-products from mining operations and other precious metal processing plants are treated to produce over six tons of gold and 15 tons of silver.<br>
<center>

</center>

Destined for this process are all the materials arising from bullion smelting on the mines and containing small amounts of gold, such as slag, flue dust, furnace linings and crucibles.  Other materials include activated carbon, sweeps, ashes, concentrates and computer scrap.  Receipts at Rand Refinery contain on average 1,8 kilograms of gold and 4,0 kilograms of silver per ton.<p>

The end product of the smelting process is dor bullion, a mixture of approximately 30 per cent gold and 70 per cent silver, which is sent to the refining section.  By-products of the smelting process are leady copper matte and flue dust which are sold overseas, and barren residue slag which is sold for use in shot-blasting and glass colouring.<p>

<FONT SIZE=2>
<dl>
<dt>When products from the mine are delivered to the smelter at Rand Refinery, they are first sampled and analysed.<p>

<dt>They are then mixed thoroughly with fluxes such as limestone and iron mill-scale to prepare a feed of consistent composition for smelting in a s,2 MVA electric arc furnace.<p>

<dt>Included in the feed is lead which acts as a collector for gold and silver during smelting.<p>

<dt>This lead is tapped out of the arc furnace into a ladle and transferred molten into a top-blown rotary converter in which the lead is oxidised to slag, leaving dor bullion which is poured into bars and sent to the refinery.<br></FONT></dl><p>

<A NAME="goldprice"></A>
<FONT SIZE=4><b>GOLD PRICE AND SOUTH AFRICAN GOLD MINE PRODUCTION</b></FONT><br>

South African gold mines are prevented from exploiting ore reserves for short-term profit.  Each mine is requried to mine at the lowest average grade possible which still yields a profit: this is called its pay limit.  Pay limits are dependent on the rand gold price and working costs.  As the rand gold price increases, lower grade ores become profitable to exploit, pay limits fall and gold production may decline.  Conversely, when the rand gold price decreases gold production may rise.<p>

<A NAME="goldbar"></A>
<FONT SIZE=4><b>GOLD BARS</b></FONT><br>

The refined gold bars produces by Rand Refinery have a standard shape which facilitates their handling. Each bar weighs between 400 and 410 oz and is stamped with :<p>
<ul>
<li><i>RAND REFINERY LIMITED</i>
<li>The recognised assay stamp or chop of Rand Refinery (a springbok head encircled by the words : RAND REFINERY LTD: SOUTH AFRICA);
<li>The actual fineness of the bar, for example : FINENESS 9968;
<li>A serial number.</ul>

Trading is on the basis of actual fine gold content i.e. the weight of each bar multiplied by its fineness.<P>

<a name="weights"></a>
<FONT SIZE=4><b>GOLD WEIGHTS</b></font>
<table border width=50%>
<tr><th align=left> 1 Kilogram<th> =<th align=right> 32,1507 ounces</tr>
<tr><th align=left> 1 Ton<th> =<th align=right> 32 150,7 ounces</tr>
<tr><th align=left> 1 Ounce<th> =<th align=right> 31,1035 grams</tr>
</table>
<P>
<A NAME="caratage"></A>
<FONT SIZE=4><b>CARATAGE</b></font>
 Caratage is the weight fraction of gold in a gold alloy, expressed in 24ths.  For example, 24 carat gold is pure gold, and 18 carat gold alloy contains 18/24ths or 75% by weight of gold.<P>

<A NAME="fineness"></A>
<FONT SIZE=4><b>FINENESS</b></font>
Fineness is the weight fraction of gold in a gold alloy, expressed in 1 000ths or 10 000ths.  For example, 9999 gold contains 9 999 parts per 10 000 fine gold by weight.<p>


<Center><IMG SRC="/linegr.gif" ALIGN=MIDDLE><p></Center><br><p>

<CENTER><font size=5><a href="/gold1.htm#gmktng"><b>Read about the marketing of South African Gold</b></a><br><p><p></CENTER></font>

</blockquote>

<A NAME="info"></A>
<center><b><h3>Contacting Us</h3></b></center></font>
<pre><b>
<IMG SRC="/images/build.gif" ALIGN=MIDDLE> Physical Address: Refinery Road, Industries West, Germiston
<IMG SRC="/images/phone.gif" ALIGN=MIDDLE> Telephone +27 11 873-2222 
<IMG SRC="/images/faxphone.gif" ALIGN=MIDDLE> Facsimile +27 11 825-1806
<IMG SRC="/images/pobox.gif" ALIGN=MIDDLE> Postal Address: PO Box 565, GERMISTON, 1400, SOUTH AFRICA
<IMG SRC="/images/emm.gif" ALIGN=MIDDLE> Internet E-Mail <A HREF="mailto:twood@bullion.org.za"> info@bullion.org.za</A>
</b></pre>
<br>
<br>
<CENTER></font>
<IMG SRC="/images/line3.gif" ALIGN=MIDDLE><p>
<a name="toolbar"></a>

<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="Organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/contact/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  18 April 1996<BR>
&#169 1996 Chamber of Mines of South Africa / Rand Refinery Limited<br>
HTML Coding by Cheryl Jones : <A HREF="mailto:cjones@bullion.org.za">cjones@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>



</DOC>
<DOC>
<DOCNO>WT14-B39-482</DOCNO>
<DOCOLDNO>IA012-000131-B031-177</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/nufcor.htm 196.26.82.193 19970217020033 text/html 2159
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:04:02 GMT
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>Loading Images! Please be patient!</title>
<BODY background="back3.gif" Bgcolor="#ffffff" text="#000080" link="#0000ff" vlink="#800000">
<a name="top"></a>
<title>NUCLEAR FUELS CORPORATION</title></head>
<center>
<IMG SRC="/associates/nufcr.jpg" ALIGN=MIDDLE border=0 alt="Nufcor><br>
<font size=6><i><b>Nuclear Fuels Corporation of South Africa</b></i></font><br><p>

<IMG SRC="/line3.gif"></CENTER>
<br><p>
<center><b><h3>Contacting Us</h3></b></center>
<pre><b>
<IMG SRC="/build.gif" ALIGN=MIDDLE> Physical Address: 41 Wessels Street, Rivonia, Sandton
<IMG SRC="/phone.gif" ALIGN=MIDDLE> Telephone +27 11 838-6210
<IMG SRC="/faxphone.gif" ALIGN=MIDDLE> Facsimile +27 11 838-2776
<IMG SRC="/pobox.gif" ALIGN=MIDDLE> Postal Address: PO Box 2655, RIVONIA, 2128, SOUTH AFRICA
<IMG SRC="/emm.gif" ALIGN=MIDDLE> Internet E-Mail <A HREF="mailto:cwesting@bullion.org.za"> info@bullion.org.za</A>
</b></pre>
<br><center>
<a href=/main.htm> <IMG SRC="/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br>
<IMG SRC="/line3.gif" ALIGN=MIDDLE>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  5 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>









</DOC>
<DOC>
<DOCNO>WT14-B39-483</DOCNO>
<DOCOLDNO>IA012-000131-B031-206</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/associates/igc.htm 196.26.82.193 19970217020047 text/html 2053
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:04:28 GMT
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>Loading Images! Please be patient!</title>
<BODY background="back3.gif" Bgcolor="#ffffff" text="#000080" link="#0000ff" vlink="#800000">
<a name="top"></a>
<title>INTERNATIONAL GOLD CORPORATION</title></head>
<center>
<IMG SRC="/associates/igc.jpg" ALIGN=MIDDLE border=0 alt="IGC><br>
<font size=7><i><b>International Gold Corporation</b></i></font><br>
<p>
<IMG SRC="/line3.gif"></CENTER>
<br><p>
<center><b><h3>Contacting Us</h3></b></center>
<pre><b>
<IMG SRC="/phone.gif" ALIGN=MIDDLE> Telephone +27 11 498-7100
<IMG SRC="/faxphone.gif" ALIGN=MIDDLE> Facsimile +27 11 838-4255
<IMG SRC="/pobox.gif" ALIGN=MIDDLE> Postal Address: PO Box 61809, MARSHALLTOWN, 2107, SOUTH AFRICA
<IMG SRC="/emm.gif" ALIGN=MIDDLE> Internet E-Mail <A HREF="mailto:cwesting@bullion.org.za"> info@bullion.org.za</A>
</b></pre>
<br><center>
<a href=/main.htm> <IMG SRC="/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<br>
<IMG SRC="/line3.gif" ALIGN=MIDDLE>
<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
Last Updated:  5 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>




</DOC>
<DOC>
<DOCNO>WT14-B39-484</DOCNO>
<DOCOLDNO>IA012-000131-B032-120</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/agreements/educat1.htm 196.26.82.193 19970217020356 text/html 3526
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:07:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Minesof South Africa: Education Partnership Policy</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<a name="top"></a>
<center>
<IMG SRC="/images/logo2.gif"><p>



<FONT SIZE=5 COLOR=008040><B>EDUCATION PARTNERSHIP POLICY</B></FONT><p>

<IMG SRC="/images/linegr.gif" ALIGN=MIDDLE><p>
<IMG SRC="/images/wd1.gif" ALIGN=MIDDLE><br>
</CENTER>

<B>DEFINITION</B><br>
The Education partnership policy of the Chamber of Mines of South Africa may be defined as the process of developing competent manpower through a quality partnership between industry and further and higher education institutions capable of assisting with the development of future mining industry employees.<p>

<B>VISION</B><br>
The COMSA and its education partners will co-operate to ensure a consistent supply of competent manpower to the mining industry.<p>

To this end we will have:
<UL>
<LI>a common understanding of industrys skills and knowledge requirements i.e. competency profile;
<li>a forecast of manpower requirements;
<li>career options for potential students;
<li>an education and training system that is aligned with the National Qualifications Framework;
<li>respect for the value of teaching and research;
<li>relevant academic, practical and experiential education and training;
<li>regular contact with partners;
<li>pooling of resources where appropriate;
<li>restructured learning experiences in the industry;
<li>centres of excellence which are internationally competitive;
<li>articulation between supported institutions.
</UL>
<p>

<B>PRINCIPLES</B><br>

The COMSA and its co-operative education partners will ensure that:
<UL>
<li>education and training are responsive to the needs of industry;
<LI>the education and training system allows for the integration of academic, practical and experiential learning;
<LI>the co-operative education system is aligned in all respects with the Mining Industry Qualifications Framework;
<LI>commitment to excellence pervades the system;
<LI>the approach to all mining industry-related education and training is standards-based;
<LI>the system allows for flexibility in the meeting of partners needs;
<LI>funding support should be focused, and influential.
</UL>

<B>OVERALL STRATEGY</B><br>

The overall strategy to achieve the envisaged co-operative education system will require:<br>
<UL>
<LI>definition and review of the mining industrys manpower needs (quality and quantity);
<LI>ensuring that the providers align their outputs with industry needs;
<LI>re-design of education partnerships
</UL>
<p><P>
<Center><IMG SRC="/images/linegr.gif" ALIGN=MIDDLE><p></Center><br><p>

<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/tb101.gif" BORDER=0 ALT="Organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/kruger.htm"><IMG SRC="/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>






























</DOC>
<DOC>
<DOCNO>WT14-B39-485</DOCNO>
<DOCOLDNO>IA012-000130-B038-173</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/policy/saf/saf.htm 196.26.82.193 19970217021459 text/html 43541
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:18:00 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Growth For All: An Economic Strategy for South Africa. Prepared by the South Africa Foundation, Johannesburg, February 1996</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><font color="#800040" size="6">GROWTH FOR ALL</font><br>
<font color="#008040" size="5"><b>An Economic Strategy for South
Africa</b></font></p>

<p align="center"><img src="saf.gif" align="middle" width="532"
height="321"></p>

<p align="center"><font color="#0000A0" size="4"><b><i>Prepared
by the South Africa Foundation</i></b></font><br>
<font color="#0000A0" size="3"><i>Johannesburg, February 1996</i></font></p>

<p align="center"><b>Hosted on this site by </b><a
href="http://www.bullion.org.za/"><b>The Chamber of Mines of
South Africa</b></a><br>
<applet code="TickerTape"
codebase="http://www.netobjective.com/java/classes"
align="baseline" width="400" height="26"><param name="TEXT"
value="Growth%20for%20All.%20%20An%20economic%20strategy%20for%20South%20Africa.%20%20Prepared%20by%20the%20South%20Africa%20Foundation.%20%20If%20you%20experience%20problems%20please%20mail%20a%20notice%20to%20Timothy%20Wood%20by%20clicking%20on%20this%20text..."><param
name="FONT" value="Courier"><param name="FONTSIZE" value="13"><param
name="STYLE" value="BOLD"><param name="FGCOLOR" value="RED"><param
name="BGCOLOR" value="WHITE"><param name="DELAY" value="100"><param
name="CLICKURL" value="mailto:twood@bullion.org.za"><param
name="DEBUG"></applet> </p>

<hr size="3" noshade width="80%">

<p align="center"><a href="#down"><font color="#FF0000" size="4"><em><b><tt>Go
to the Executive Summary of Growth For All</tt></b></em></font></a></p>

<p align="center"><font color="#FF0000" size="3"><b>RELATED
DOCUMENTS:</b></font></p>

<blockquote>
    <ul>
        <li><p align="left"><a
            href="http://www.anc.org.za/cosatu/docs/discuss.html"><font
            size="3"><b>A Draft Programme for the Alliance</b></font></a><font
            size="3"><b> - COSATU Discussion Document, 22
            November 1996</b></font></p>
        </li>
        <li><p align="left"><a
            href="http://www.anc.org.za/ancdocs/policy/s&amp;st.html"><font
            size="3"><b>The State and Social Transformation</b></font></a><font
            size="3"><b> - ANC Discussion Document, November 1996</b></font></p>
        </li>
        <li><p align="left"><a
            href="http://www.polity.org.za/govdocs/policy/growth.html"><font
            size="3"><b>Growth, Employment and Redistribution: A
            Macroeconomic Strategy</b></font></a><font size="3"><b>
            - </b>Government Policy Document, 14 June 1996.</font></p>
        </li>
        <li><p align="left"><a
            href="http://www.polity.org.za/govdocs/commissions/fintoc.html"><font
            size="3"><strong>Restructuring the South African
            Labour Market</strong></font></a><font size="3"> -
            Report of the Presidential Commission to Investigate
            Labour Market Policy, 19 June 1996.</font></p>
        </li>
        <li><p align="left"><a
            href="http://www.anc.org.za/cosatu/docs/jobs.html"><font
            size="3"><strong>Social Equity and Job Creation: The
            Key to a Stable Future</strong></font></a><font
            size="3"> - Proposals by the South African Labour
            Movement on Macroeconomic Strategy, 4 April 1996.</font></p>
        </li>
        <li><p align="left"><a
            href="http://www.nedlac.org.za/doc1.html"><font
            size="3"><strong>Framework for Social Partnership and
            Agreement-Making in Nedlac</strong></font></a><font
            size="3"> - Discussion Document prepared by Nedlac,
            November 1995.</font></p>
        </li>
    </ul>
</blockquote>

<hr size="3" noshade width="80%">

<p align="center"><font size="3"><b>All documents are in MS Word
6.0+ format.</b></font></p>

<p align="center"><a href="exec.zip" name="down"><img
src="/images/save.gif" border="0" width="16" height="16">Download
the Executive Summary<img src="/images/save.gif" border="0"
width="16" height="16"><font size="2"> </font><br>
</a><font size="2"><tt>(.ZIP 26KB)</tt></font><tt><br>
</tt></p>

<p align="center"><font color="#008040" size="5">EXECUTIVE
SUMMARY</font></p>

<ul>
    <li><a href="#INTRO">Introduction</a> </li>
    <li><a href="#need">The need for a reform programme</a> </li>
    <li><a href="#record">South Africa's long-term economic and
        social record</a> </li>
    <li><a href="#challenge">The growth challenge</a> </li>
    <li><a href="#pillars">Pillars of market-friendly growth in
        South Africa</a> </li>
    <li><a href="#already">Reforms already underway</a> </li>
    <li><a href="#ref1">Reforms required (1)</a>: Dealing with
        crime and violence </li>
    <li><a href="#ref2">Reforms required (2)</a>: Streamlining
        government spending and revenues </li>
    <li><a href="#ref3">Reforms required (3)</a>: A brisk
        privatisation programme </li>
    <li><a href="#ref4">Reforms required (4)</a>: A flexible
        labour market </li>
    <li><a href="#ref5">Reforms required (5)</a>: A vigorous
        export drive </li>
    <li><a href="#concl" name="conc">Conclusion</a> </li>
    <li><a href="#how">How should government implement a reform
        programme?</a> </li>
</ul>

<p><a name="INTRO"><b>Introduction</b></a><br>
In the past two years the &#145;South African miracle&#146;
slogan has swept into use worldwide. This euphoric slogan is both
true and beguiling. It is true because the transfer of political
power was unexpectedly smooth, and the use of this power since
has been eminently responsible. But it is also beguiling, because
it draws attention away from the country&#146;s immense economic chal-lenges. If these
economic challenges are not met, and economic policy is not
trans-formed, then the world will forget about the political
miracle before long, because its economy will have failed.</p>

<p>Put slightly differently, when observers analyse the long-term
performance of the South African economy in 40 years time, they
will use one crucial yardstick: the growth of real output per person. If
it does not surge upwards, then South Africans will be little
bet-ter off in the year 2035 than they are now, and poverty will
still hold millions of people in an iron grip. By contrast, rapid growth
and job-creation are alleviating poverty rapidly in many other
developing countries.</p>

<p>Some foreign observers are already nervous about South
Africa&#146;s eco-nomic prob-lems. They also note an apparent
inability to adopt the kind of aggressive and flexible growth
strategy that could raise the economy&#146;s growth performance
towards its potential. That level is somewhere above 5% p.a. -
way above the economy&#146;s current trend growth of some 3% p.a.
And even this trend may not last, unless an effective new growth
strat-egy is adopted.</p>

<p>It is thus worrying that government actions and plans
regarding eco-nomic policy exhibit no sense of urgency. Gradual approaches
to restructuring seem to be preferred vir-tually everywhere, ranging from
civil service reform to the abolition of ex-change controls.
Moreover, some new shackles and rigidities - likely to constrain
growth further - are being imposed on the economy. Most
importantly, features of labour market legislation look
ill-suited to a middle-income country with high unemployment and
little capacity to create jobs. Indeed, unemployment is South
Africa&#146;s biggest economic challenge.</p>

<p><a name="need"><b>The need for a reform programme</b><br>
</a>South Africa&#146;s economic problems have many dimensions.
They can only be solved by a compre-hensive reform &#145;programme&#146;
- a growth strategy based on a series of pil-lars which must fit together
neatly, otherwise the edifice will not stand. This document
pro-poses such a comprehensive strategy - one which can only
succeed if all its ele-ments are accepted, and if it is carried
forward as a partnership between all the parties involved. It
needs to be implemented with great vigour, and marketed
aggressively at home and abroad, if the economy&#146;s
performance is to rise towards its underlying potential.</p>

<p>Business cannot operate in a vacuum, nor can investment and
job creation feed on political miracles forever. Local and foreign
investors expect from government a policy framework and operating environment
that is conducive to growth, favours investment, and is
imaginative about job creation. A credible growth strategy is
urgently needed that will entice new investment and make South
Africa internationally competitive. Only then will job growth be
sustainable and the benefits flowing to the majority of the
population real.</p>

<p>The economic strategy proposed targets growth and job
creation, while safety nets and focused programmes for the
poorest members of society are part of the kind of dynamic, but
stable, economic environment which is needed. Indeed, the
strategy aims at &#145;Growth for All&#146;, leaving no groups
untouched by the benefits of growth. The pub-lic should be
clearly informed about the short-term costs and ulti-mate
benefits of the strat-egy, since only then will it be politically
credible.</p>

<p><a name="record"><b>South Africa&#146;s long-term economic and
social record</b><br>
</a>The South African economy has performed badly for a long
time, with growth slow, exports weak and unemployment rising steadily.
Despite a strong upturn in 1995-96, and some commendable policy
moves undertaken in recent years, many of the factors causing
this poor per-formance are still at work. Unless firm policy
action is taken, under rela-tively optimistic assumptions the economy
will grow roughly as fol-lows over the next decade:</p>

<pre>
	Change in real GDP				:    trend growth of 3% p.a.
	open unemployment rate				:    leap from 32,7% in 1994 to 40,4% in 2004
	Real government spending per person		:    rise at less than 1% p.a.
</pre>

<p>This is a recipe for economic stagnation, with higher
unemployment and poorer social conditions for much of the
population. That, in turn, may eventually precipitate financial
crisis, through fiscal pressures and/or the flight of foreign
capital. In short,</p>

<p>South Africa needs a development strategy 1996-2015 which can
deliver:</p>

<ul>
    <li>rapid and sustained growth (5 - 6% p.a.);<br>
        </li>
    <li>job growth rapid enough (3,5 - 4% p.a.) to cut
        unemployment markedly. </li>
</ul>

<p>Such an outcome would more than double per capita incomes,
easing the country&#146;s burden of poverty and providing hope
for future generations. </p>

<p><a name="challenge"><b>The growth challenge</b><br>
</a>For South Africa, the long-term growth challenge is to shift
the economy from being sub-stantially reliant on natural
resources, to being far stronger in production based on human
resources - i.e. skilled workers, and more sophisticated
technology, found in industry and services. This requires investment
rates far higher than at present. The 1994-96 forecast for all
developing countries is that fixed investment will average about
30% of GDP to sup-port 6% p.a. output growth; in South Africa
this ratio is under 20%. </p>

<p>The main role of government in facilitating this growth should
be to create a suita-bly enabling market-friendly environment, and
allow markets to respond appropriately. By contrast, some statements
which have emerged from the Government of National Unity have
given the impression of an approach involving coercion instead of
enticement. Gov-ernment should seek to work with business, not
against it.</p>

<p>In practice, govern-ment should implement the following sets
of measures:</p>

<ul>
    <li>Sound macroeconomic policy - control over monetary
        expansion, achieving low inflation, and with low fiscal
        deficits. </li>
    <li>Limited government spending - lower but more efficient
        government spending and taxes, focusing on encouraging growth
        and alleviating poverty. </li>
    <li>Market freedoms - less negative state interference in the
        economy, and more scope for markets to allocate resources (deregulation,
        privatisation). </li>
    <li>An outwardly-oriented economy - a competitive currency,
        low trade barriers, freer capital movement and a stress
        on export markets (particularly non-mining exports). </li>
</ul>

<p>Together, these elements should yield much faster growth and
thus enable govern-ment to meet its stated goals of providing far
better prospects for poor people. In fact, the approach proposed
will provide the only sustainable means of reducing poverty over
the long term. Most mainstream economists world-wide would agree
with these elements. Many countries have implemented reform programmes
along these lines, often with consid-erable success (see the
Background Paper, &#145;Market-oriented reform programmes do
work&#146;). The shocking statistics on current trends summarised
above illustrate how urgently such a programme is needed in South
Africa.</p>

<p><a name="pillars"><b>Pillars of market-friendly growth in
South Africa</b> <br>
</a>Five pillars of market-friendly growth in South Africa are
depicted below, and listed at the bottom of the diagram. Some of their
components are already being implemented by gov-ernment, and are shown
in shaded blocks. Others have been promised but have not yet
materialised (e.g. the stream-lining of public spending), or have
not yet been considered seriously (e.g. a vigorous export drive). </p>

<p align="center"><img src="saf2.gif" align="middle" width="305"
height="237"></p>

<p>Only through implementing a full-scale reform programme,
incorporating all these components, will government be able to stimulate
growth in a sustainable fash-ion. Ulti-mately, such a programme should
aim to give private firms the right long-term signals - making
them want to invest, expand their output, and employ more
workers. </p>

<p>The new government has already made some very creditable
policy changes along these lines. But other critical elements are either
missing, being implemented hesitantly, or being rejected for seemingly
ideological reasons. Above all, no credible and comprehen-sive
policy framework exists - only a broad conglomeration of plans
and objectives.</p>

<p>Most developing countries are implementing reform programmes
of this kind already. Unless South Africa joins the reform bandwagon
quickly, and acts decisively, foreign interest and investment may move
to more exciting places, like China, Chile or Colombia. Indeed,
several international studies already suggest that South Africa
is not a promising site for foreign investment, due to its underdeveloped
human resource base, high unem-ployment and social instability,
high wages relative to competitors, and the implemen-tation of
some govern-ment policies which do not encourage growth and job
creation.</p>

<p><a name="reforms"><b>Reforms already underway</b> <br>
</a>Important economic reforms already underway (or achieved) in
South Africa include:</p>

<p>The <b>legal system</b> in South Africa is largely sound, with
property rights fairly clear and legal and accounting standards
high. <br>
<tab INDENT="5" align="left">But the curse of crime and violence is undermining the rules
govern-ing eco-nomic behaviour, and the social fabric of the country
(see below).</p>

<p>The macroeconomic stability record has been fairly solid, for
a long time, under difficult circumstances. This was strengthened by
the South African Reserve Bank&#146;s increased free-dom since
the late 1980s to implement anti-infla-tionary monetary policy via
interest rates and other means.</p>

<p><b>Financial liberalisation</b> - the financial sector has
been deregulated considerably since the late 1970s, and is far
stronger than in most developing countries. <br>
<tab INDENT="5" align="left">The big area where South Africa is lagging concerns exchange
controls. Some have been eased recently, but the overall control
framework remains tight, imped-ing growth and the efficient allocation
of resources.</p>

<p>The economy has been considerably deregulated since the 1970s:
the informal sector has been substantially freed, direct controls
over imports have been almost eliminated, price controls are gone,
draconian controls over agricultural markets have fallen away,
and so on. But further reform is needed in some areas, e.g.
telecommunications. Government also needs to act to raise the competitive
temperature of the economy, most importantly via low-ering trade
barriers and preventing firms from abusing market power.</p>

<p>Foreign investment has been freely permitted for decades and
foreigners are not discimi-nated against, apart from a few small impediments.
If anything, though, foreign direct investment should be encouraged
more than at present.</p>

<p>Trade liberalisation has proceeded steadily since the
mid-1980s, and some results are impressive (e.g. import licenses
are largely gone, tariffs have been cut and simplified). This
process will continue, in line with South Africa&#146;s
international commitments.</p>

<p><a name="crime"><b>REFORMS REQUIRED (1): Dealing with crime
and violence</b></a></p>

<p>The risk of falling victim to a crime has soared over the last
few years: the incidence of car theft and burglary has doubled since
1988, and violent crimes like rape, murder and child abuse have risen dramatically.
South Africa also scores high in international crime
com-parisons. Continued political violence in KwaZulu-Natal,
reports of large-scale com-mercial crime and widespread rent and service
boycotts in townships have contributed to the perva-sive belief
that the authority of the state is fraying. </p>

<p>Crime imposes direct financial, physical and emotional costs
on society, visible in high insurance premiums and very high expenditure
on protection services. The indirect costs, though, are far greater.
Crime harms the economy by reducing tourism revenues and
investment, by persuading many talented and highly-skilled
individuals to emigrate, by raising the costs of making and enforcing contracts,
and in many other ways. The poor suf-fer disproportionately from
crime, in terms of financial loss as well as pain and suffering. </p>

<p>The causes of crime are many. The lack of legitimate
government in the past, and retaliation through a strategy of ungovernability,
engendered widespread lawlessness. Social and eco-nomic factors
are also important; with unemployment high, for example, many
young peo-ple have given up looking for jobs in the formal sector
of the economy. </p>

<p>In addition, law enforcement is inadequate, with policing
hampered by low salaries, poor morale, deficient management practices,
poor procedures, virtually non-existent information systems and staff
shortages. The justice and prisons systems are constrained by
inadequate resources, poor procedures and confusion about the
interpretation of laws. Damage was also inflicted by the lack of political
will to be tough on crime in the initial period of the new
government.</p>

<p>There are no simple solutions to crime, and a comprehensive
effort needs to be made in this area, by government in partnership
with various communities, including business:</p>

<ul>
    <li>The now legitimate state needs to exercise firm authority
        against crime; </li>
    <li>Rent and services boycotts must be dealt with firmly and
        decisively; </li>
    <li>Economic reform and growth are urgently needed, to
        provide jobs for unemployed people; </li>
    <li>A better staffed, managed, trained and equipped police
        force is required, backed up by a streamlined justice
        system, and the political will to create a sound balance
        between crime and punishment through an effective penal
        system; </li>
    <li>The new police force needs to be supported by
        communities, and its presence should be highly visible to
        them. </li>
</ul>

<p><a name="stream"><b>REFORMS REQUIRED (2): Streamlining
government spending and revenues</b></a></p>

<p>Government management of taxes, spending and the budget
deficit is important to growth since it affects every aspect of
how the economy functions. The fiscal situation has deterio-rated
severely in the past decade, and urgently needs drastic reform:</p>

<ol>
    <li>The budget deficit is dangerously high by historical and
        international standards. Government is taking up a large
        share of net private sector savings, and under-mining
        private investment. Moreover, the deficit threatens to
        balloon in the next (and inevi-table) economic downturn. It needs
        to be cut sharply, towards 0 - 2% of GDP, in line with
        recent international norms. The deficit reduction target
        should be at least 1,5% of GDP per year, for as long as
        the economic upturn lasts (the target is currently about
        0,5% per year). </li>
    <li>Government taxes have soared in the last 20 years. Not
        only is there little scope to raise them further (apart
        from VAT), but many - led by company tax - are harsh by
        world standards, and should be pared. In addition, the
        tax system should be sim-plified and the efficiency of tax
        collection drastically upgraded. Tax incentives for
        investment should be seriously considered, but more
        research on the issue is required. </li>
    <li>Government spending is also high and has been rising as a
        share of GDP for decades. It should be cut by about 2% of GDP
        per year for at least two years, in large part by targeting
        it towards facilitating economic growth and benefiting
        the poor. In par-ticular: <ul>
            <li>the civil service should be rationalised, with
                market-related salaries paid, but per-haps 150
                000 jobs cut over five years; </li>
            <li>many government subsidies (e.g. export and
                regional subsidies, child benefit allow-ances)
                should be cut or eliminated; </li>
            <li>spending on education, health and housing should
                not be raised, but kept constant in real terms; </li>
            <li>total welfare spending should be pared,
                particularly where it is not directed towards very
                poor people; </li>
            <li>many government services should aim to recover
                costs; </li>
            <li>rapid privatisation (see below) would help ease
                fiscal pressures; </li>
            <li>since government capital spending does not
                necessarily boost growth, projects pro-posed
                should be evaluated on strict economic grounds.</li>
        </ul>
        <p>Through implementing such measures firmly, the
        long-term capacity of government to develop the economy
        and deliver goods and services to the population -
        particularly the poorest people - would be enhanced. </p>
    </li>
    <li>Government should introduce an effective low-cost social
        safety net designed to sustain poor and destitute people
        - partly by targeting existing programmes more precisely
        at the poor, partly through new initiatives. This is
        particularly necessary in the transition period before
        the growth strategy begins providing jobs and incomes on
        the nec-essary scale. </li>
</ol>

<p><a name="brisk"><b>REFORMS REQUIRED (3): A brisk privatisation
programme</b></a></p>

<p>International studies agree that privatisation - the private
ownership and/or management of economic activities, rather than
by government - is highly desirable. Locally, it would have
several worthwhile effects:</p>

<ul>
    <li>The economy would benefit from increased efficiency after
        privatisation. </li>
    <li>Privatisation would assist important state enterprises to
        deliver critical services by allowing them to upgrade
        their technologies, management and international
        mar-kets. </li>
    <li>It would enable gov-ernment to retire debt and
        significantly reduce its interest pay-ments, making
        finance available for social needs. </li>
    <li>It would send a strong, positive signal to local and
        foreign investors, demonstrating that government is
        committed to implement-ing market-friendly policies. </li>
</ul>

<p>To avoid the possibility of abuse by private monopolies,
government ought to pri-vatise into competitive markets, or
ensure that adequate regulatory regimes are in place. In some
cases, government should provide for the delivery of services to
the poor by linking privatisation to incentives to provide such
services. But the ability of new owners to restructure the
companies they have acquired must not be impeded.</p>

<p>A three-phase privatisation programme is proposed, which would
need to be thor-oughly marketed to all domestic and potential
foreign constituents. During the first phase, which can start immediately, all
non-controversial government holdings in commercial enterprises
should be sold off, particularly the large IDC holdings in Iscor,
Sasol and Alusaf. This phase could generate about R20 billion in income
for the state. </p>

<p>During the second phase, which might also yield about R20
billion, the more com-plex enterprises such as Transnet and Telkom
could be sold off, either as a whole or in part. Some enterprises may have
to be given time to sort out their pension fund liabilities and
allow them to reorganise. Finally, the privatisation of Eskom
needs to be considered, because of its high value and attractiveness
to potential investors. In total, these privati-sa-tion receipts
could top R60 billion. </p>

<p>In addition, government pension funds should be fully
privatised, with a shift towards mandatory defined-contribution
schemes for civil servants. This would entail ini-tial costs for
government, but the long-term benefits would be considerable.</p>

<p><a name="flexible"><b>REFORMS REQUIRED (4): A flexible labour
market</b></a></p>

<p>The South African labour market is one of the most rigid in
the world. Unemploy-ment is exceptionally high, unionised workers
earn far more than their non-union counter-parts, and the formal-informal
gap seems to be the highest anywhere. Combined with wages which
are high in relation to productivity, by world standards, this
inefficiency and inflexibility has impeded growth (particularly
via undermining industrial exports) and led to the economy having
virtually no capacity to cre-ate jobs.</p>

<p>Prospects for the next few years look bleak. Even if the
government&#146;s current macro-economic and spending policies
fall into place, unemployment is likely to rise for the
fore-seeable future. Many explanations have been advanced for
South Africa&#146;s high unemployment, but most are unconvincing and
should also apply in many other developing coun-tries with low unemploy-ment. The inescapable
conclusion is that the labour market func-tions exceptionally
badly, especially at the low-skills end.</p>

<p>This has devastating consequences for poor people. Due to the
lack of low-wage jobs, most receive no wage income at all, which
substantially worsens inequality in society as a whole. Only the creation
of large numbers of relatively low-wage jobs can solve the
poverty problem; alternative strategies like land reform,
developing the informal sector or large government social programmes can
at best be sup-portive measures. </p>

<p>What aspects of the labour market prevent low wage formal jobs
from being created? It is clear that the Continental-type industrial
relations system established in South Africa is poor at job-creation, and
hampers firms from adjusting to competitive pressures.</p>

<p>Reforms are needed to allow a free entry flexible wage sector
of the formal labour market to emerge next to the existing high-wage
capital-intensive sector. Such a two-tier labour market would
require: </p>

<ul>
    <li>the elimination of extensions of industrial council
        agreements to non-parties; </li>
    <li>maintaining only those minimum labour standards (e.g.
        health and safety regula-tions) that do not hurt the poor
        and the unem-ployed; </li>
    <li>avoiding implementing minimum wage regulations which
        threaten jobs; and </li>
    <li>making the second (or free entry) tier more flexible
        through legislative changes aimed at encour-aging new
        jobs, new investment, and the employment of youths.</li>
</ul>

<p>The rights and privileges of existing workers would not be
affected much, while this strategy would empower the unemployed and
new workers, by giving them the ability - which they lack at present
- to compete for jobs. In the medium term this strat-egy should
deliver large numbers of jobs, while as labour markets tighten,
wages should rise too. Together, these would help to eliminate
the poverty in which so many South Afri-cans are engulfed.</p>

<p><a name="export"><b>REFORMS REQUIRED (5): A vigorous export
drive</b></a></p>

<p>Healthy industrial exports contribute heavily to growth in the
long term, but South Africa&#146;s record in this respect is
poor. It is essential that a strategy be developed to promote
more rapid growth in exports of manufactured goods. Some of the
key elements of such a strat-egy have already been dealt with: </p>

<ul>
    <li>lower tariffs, to make domestic industry more competitive
        and provide it with inputs at world prices; </li>
    <li>privatisation, to attract new technology and open up new
        markets abroad; </li>
    <li>taxes at internationally competitive levels; </li>
    <li>more flexible labour markets to encourage the creation of
        export-oriented labour-intensive business. </li>
</ul>

<p>Many other measures to facilitate exports might also deserve
consideration. Even the most appropriately designed policies to encourage
exports will only partly succeed, however, if they are introduced
against the background of an inappropriately strong exchange
rate. An appropriately aligned exchange rate is a major factor
behind export growth. Finding mechanisms to allow the rand to
reach a market-determined level that ensures international
competitiveness will be a difficult challenge. </p>

<p>Indicators suggesting that the rand may be too strong for the
long-term health of the economy include weak export growth, large
export subsidies, huge Reserve Bank for-ward losses, evidence that
services firms are more profitable than goods-producing firms,
and the swelling current account deficit, despite the economy
growing only slowly.</p>

<p>At the very least, the export competitiveness gained from
better access to markets since the 1994 election should be maintained.
It might further be argued that a more appro-priately valued exchange rate,
maintained over time, would help to build up the country&#146;s
non-mining exports base.</p>

<p>One danger, of course, is that a downward adjustment in the
rand might lead to wage pressure and inflation. Prices would rise,
but an inflationary spiral could be avoided through keeping
fiscal and monetary policies strict, making deals with unions and
cutting tariffs at the same time.</p>

<p>The obvious way of improving the international competitiveness
of non-mining exports would be to eliminate a range of controls
over markets which serve to keep the rand strong. Exchange controls and
export subsidies should go, Reserve Bank interven-tions in the
forward market should be terminated, and so on. </p>

<p>But such a market-oriented strategy for the rand should be
com-ple-mented by:</p>

<ul>
    <li>tight fiscal and monetary policies, to contain inflation; </li>
    <li>policies to render the labour market more flexible, with
        wages able to move towards market-clearing levels; and </li>
    <li>efforts to limit upward pressures on the currency when
        capital inflows are positive, e.g. taxing short-term
        inflows.</li>
</ul>

<p><a name="Conclusion"><b>Conclusion</b></a></p>

<p>Even though the Government of National Unity has adopted many
positive policies, and has implemented some courageous measures,
the current approach to economic management will not deliver the
rapid growth and job-creation South Africa needs. Instead, a
vigorous and com-prehensive growth strategy along the lines
described above is required - termed &#145;Growth for All&#146;.
The country has no alternative: world experience points in this
direction, and powerful international forces are pushing the
economy that way. </p>

<p>The underlying economic reality is so harsh that drastic
measures are required soon. A half-hearted approach to economic reform
- doing what is easy, and avoiding harsh decisions - will provide
only modest benefits, if any. In particular, if the need to
render the labour market less rigid is not tackled firmly, then
the reform pro-gramme proposed would not boost the economy&#146;s labour-absorption capacity
- and very poor people would not benefit. The RDP, for example,
can only succeed if large numbers of jobs are cre-ated soon - and
this is most unlikely to happen with current economic policies.</p>

<p>Reform programmes can be painful, particularly in the first
couple of years. But while the costs of reform can be
considerable, the alternatives to it in the long term (sluggish
growth, unemployment, poverty, crime) are far worse. Government
needs to be decisive and firm about reform, overriding opposition
from those who will lose out from it, while providing a
&#145;social safety net&#146; to ease the transitional costs to
society.</p>

<p>It is critical that a strategy like that outlined in this
document is mar-keted to all stakeholders - domestic and
international - as a national vision. Policymakers need to
create, cultivate and eventually perpetuate the belief amongst
all parties that South Africa has not only undergone a smooth and
successful political transition, but will also
&#145;deliver&#146; economically. The political miracle must be
complemented by an eco-nomic miracle.</p>

<p><a name="how"><b>How should government implement a reform
programme?</b></a></p>

<p>Decisive and immediate action by government is needed, to
demonstrate its commitment to its policies and build up its credibility
quickly. The envisaged reform programme would require:</p>

<ul>
    <li>A public announcement of its major components, which
        would reinforce exist-ing market-ori-ented policies and introduce
        various new ones; </li>
    <li>Tough action targets (or ranges) announced by government
        regarding the vari-ous fields of policy, both short-term (what
        it will do in the next year to 18 months) and medium-term (where
        it plans to end up in three to ten years&#146; time). </li>
    <li>Some decisive actions immediately, to show that
        government is committed to its programme and begin
        changing the way major economic actors behave.</li>
</ul>

<p>Where are unequivocal government commitments needed? One major
short-term gov-ernment pledge regarding each of the five areas
stressed in this document would help, along the following lines: </p>

<ol>
    <li>An unequivocal commitment by government to be tough on
        crime and firm on punishment. </li>
    <li>A plan to cut the headline budget deficit by 1,5% of GDP
        in each of the next two years. This should be
        complemented by: <ol>
            <li>a firm government commitment to public sector
                wage restraint, and to rendering such wages more market-determined; </li>
            <li>an overhauling of the Inland Revenue and Customs
                depart-ments; </li>
            <li>an overhauling of the Department of Education to
                render it more effi-cient, with private education
                being encouraged; and </li>
            <li>the introduction of an effective national social
                safety net, targeted at very poor people - e.g.
                via low-wage public works, school feeding
                schemes.</li>
        </ol>
    </li>
    <li>An early commitment to privatisation, via a plan to sell
        most or all Industrial Development Corporation hold-ings
        within eighteen months. </li>
    <li>A strategy to eliminate or drastically ease non-essential
        minimum labour stan-dards that inhibit job creation
        (though keep essential ones, like health and safety). </li>
    <li>Announcing that certain percentages of financial sector
        assets would be permit-ted to move abroad within six and twelve
        months.</li>
</ol>

<p>In addition, the policy programme should include as many as
possible of the follow-ing medium-term commitments:</p>

<ol>
    <li>Crime and violence <ul>
            <li>A real increase in the police budget, with
                improvements looming in salaries and training,
                backed up by streamlined and effective justice
                and prison systems. </li>
            <li>A strategic plan for the police force, updating
                its administrative structures and procedures, as
                well as its technology and computers. </li>
            <li>The creation of a comprehensive national
                crime-monitoring and crime statistics sys-tem. </li>
            <li>Strong moves to monitor and punish white-collar
                crime. </li>
            <li>Ruthless action to be taken against possessors of
                illegal weapons. </li>
            <li>Tough action on township residents not paying
                rent or for services. </li>
        </ul>
    </li>
    <li>Government revenues and spending  A guarantee that
        public spending will be steered down progressively as a
        share of GDP, with the deficit to be reduced to average
        no more than 2% of GDP over the business cycle.
        Accompanying this must be a clear timetable of how these targets
        are to be reached.<ul>
            <li>A commitment to not raising income tax rates
                except in certain specific cir-cumstances, to
                steering company and individual tax rates down
                over three to five years, and a drastic
                simplification in the tax system (fewer brackets, less
                allow-ances etc). </li>
            <li>A plan to cut net government employment by
                perhaps 100 000 over three years, and by 150 000
                over five years.</li>
        </ul>
    </li>
    <li>Privatisation<ul>
            <li>A plan to sell all small state firms in
                non-problem industries within two years (e.g. Aventura). </li>
            <li>Clear strategies and timing announced regarding
                government policy towards large state firms in
                industries which present modest regulatory
                problems (e.g. Telkom). </li>
            <li>A plan for government to step back from certain
                areas of the economy and to concentrate on
                providing only basic services. More official
                functions (like the Gov-ernment Printer?) could
                be subcontracted out, while the government&#146;s involvement
                in areas like non-basic health services could be
                reduced. </li>
            <li>A strategy to manage civil service pension funds
                privately, and to move towards pension prefunding
                via a mandatory defined contribution system.</li>
        </ul>
    </li>
    <li>The labour market<ul>
            <li>A plan to coordinate the reform programme with
                organised labour. </li>
            <li>Immediate moves to allow youth and regional
                differentiation in all wage con-tracts. </li>
            <li>Subsidised entry by young workers into very
                low-cost jobs, but in an environ-ment where they
                will receive training and acquire experience
                (i.e. a revamped apprenticeship scheme). </li>
            <li>The elimination of extensions of Industrial
                Council agreements to non-parties. </li>
            <li>Extensive amendments to legislation to create a
                free entry labour-absorbing tier in the for-mal
                sector.</li>
        </ul>
    </li>
    <li>Vigorous export drive<ul>
            <li>A plan to eliminate outright all export subsidies
                within two years, and to replace them, where
                appropriate, with effective supply-side measures
                designed to boost productivity (e.g. training). </li>
            <li>Eliminate the bulk of exchange controls on
                residents within one to two years. (Possible exceptions
                might include &#145;blocked rands&#146;, to be
                phased out over a longer period.) </li>
            <li>Terminating the SA Reserve Bank&#146;s forward
                foreign exchange market com-mitments, while
                promising less intervention in the future. </li>
            <li>A commitment to keeping the real exchange rate of
                the rand competitive for local non-mining
                exporters, with the Reserve Bank calculating a
                range of measures of the &#145;real&#146; rand.</li>
        </ul>
    </li>
</ol>

<p>This list may look daunting, and it is. But given South
Africa&#146;s circumstances the gov-ernment does not have the
time to implement reforms gradually. The issues at stake are
discussed at some length in Chapters 8-9 below. It is recommended
that readers examine these chapters in detail.</p>

<hr size="3" noshade width="80%">

<address>
    <font size="2">Last Updated: 26 June 1996<br>
     1996 Chamber of Mines of South Africa / South Africa
    Foundation<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-486</DOCNO>
<DOCOLDNO>IA012-000130-B038-219</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/policy/MINPOLICY/compol3.htm 196.26.82.193 19970217021600 text/html 6330
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:19:10 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa Mining and Minerals Policy</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><img src="../../images/LOGO1.gif" width="300"
height="160"><br>
</p>

<h2 align="center"><font size="3">Mining and Minerals Policy in
the New South Africa</font></h2>

<h3 align="center"><font color="#800040" size="5"><i>CHAMBER OF
MINES VISION STATEMENT</i></font></h3>

<h5 align="center"><font color="#008040">January 1996</font></h5>

<h4 align="center">Related Information</h4>
<div align="center"><center>

<table border="1" cellpadding="7" cellspacing="1" width="550">
    <tr>
        <td align="center" valign="top" width="250"><img
        src="../../images/save.gif" width="16" height="16"> <a
        href="polvis.pdf"><b>DOWNLOAD</b></a><img
        src="../../images/save.gif" width="16" height="16"> <br>
        <i>Policy Vision Statement</i> <font color="#FF0000"
        size="1" face="Arial">(PDF 10k) </font></td>
        <td align="center" valign="top" width="250"><img
        src="../../images/blue.gif" width="14" height="14"><a
        href="#VISION"><b>FULL TEXT</b></a><img
        src="../../images/blue.gif" width="14" height="14"><br>
        <i>Policy Vision Statement</i></td>
    </tr>
</table>
</center></div>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<h2 align="center"><a name="VISION">VISION</a> STATEMENT</h2>

<p align="center"><i>The following is submitted in response to
the invitation in the </i><a href="/policy/discuss.htm#policy2"><i>Discussion
Document on a Minerals and Mining Policy for South Africa</i></a><i>
to prepare a statement of a vision of a minerals and mining
policy.</i><br>
</p>

<h3 align="center">POLICY TO SECURE THE FUTURE OF THE<br>
SOUTH AFRICAN MINING AND MINERALS INDUSTRY</h3>

<p>For over a century the mining and minerals industry has
constituted the core of the international trading sector in the
South African economy. Today it still accounts directly and
indirectly for some 60% of export earnings and is one of the most important
sectors in terms of GNP, employment and other indicators. Given
the enormous extent of the country&#146;s remaining reserves - in
gold, platinum, chrome, manganese, vanadium, coal and many other
minerals - the potential exists for the industry to remain a key
component of the economy for many decades to come.</p>

<p>If this potential is to be realised, in what is an
increasingly international business, South Africa must be able to
compete against other developed and developing countries to
attract both foreign and domestic investment - the fiscal,
legislative and operating environments must therefore be internationally
competitive. The level and structure of domestic costs are of
special importance: if working costs at any mine exceed the
revenue generated by the ore extracted, it will no longer be worth operating
the mine concerned, and what could otherwise have been turned to
profitable account - creating wealth and employment - will be
wasted.</p>

<p>It follows from the above that pressure on working costs
adversely affects a mine&#146;s current profitability and also
its longevity. This has critical implications for public policies
towards taxation, as well as workplace, environmental and other
standards. Public policy in this area must be cautious and
pragmatic and must nurture mining operations rather than provoke
their premature closure.</p>

<p>Against this general background, the owners believe that the
primary thrust of public policy must be on ensuring an
&quot;enabling&quot; environment, i.e. a macroeconomic as well as
legislative and regulatory environment in which mining and
associated mining activities can be profitably undertaken by the private
sector in a manner which will benefit all the stakeholders.</p>

<p>The owners recognise that South Africa&#146;s political
history and current circumstances impose pressures on government
to help those who were previously discriminated against and/or
who need special assistance to participate effectively in mining
within the formal economy. There is scope within the framework of
existing law and policy for the government to do so by using its own resources
and improving its administrative capacity. Further, where
economically feasible and appropriate the owners will themselves
seek to respond directly to these needs through such measures as
provision of adult basic education and training, encouragement of
small-scale mining and help to retrenched employees.</p>

<p align="center">&nbsp;</p>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p align="center"><a href="/org1.htm"><img
src="../../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../../images/tb102.gif" alt="Resources" border="0"
width="101" height="17"></a><a href="/kruger.htm"><img
src="../../images/tb104.gif" alt="Krugerrand" border="0"
width="101" height="17"></a> <a href="/new.htm"><img
src="../../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
</p>

<hr>

<address>
    <font size="2">Last Updated: 13 February 1996<br>
     1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood: </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-487</DOCNO>
<DOCOLDNO>IA012-000130-B039-12</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/policy/MINPOLICY/compol1.htm 196.26.82.193 19970217021634 text/html 27786
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:20:05 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of South Africa Mining and Minerals Policy</title>
</head>

<body bgcolor="#FFFFFF" text="#000080">

<p align="center"><img src="../../images/LOGO1.gif" width="300"
height="160"><br>
</p>

<h2 align="center">Mining and Minerals Policy in the New South
Africa</h2>
<div align="center"><center>

<table border="1" cellpadding="5" cellspacing="1" width="550">
    <tr>
        <td align="center" valign="top" width="250"><img
        src="../../images/save.gif" width="16" height="16"> <a
        href="minpol.pdf"><b>DOWNLOAD</b></a><img
        src="../../images/save.gif" width="16" height="16"> <br>
        <i>Mining and Minerals Policy<br>
        in the New South Africa</i><br>
        <font color="#FF0000" size="1" face="Arial">(PDF 132k)</font> </td>
        <td align="center" valign="top" width="250"><img
        src="../../images/blue.gif" width="14" height="14"><a
        href="#SUMMARY"> <b>SUMMARY</b></a><img
        src="../../images/blue.gif" width="14" height="14"><br>
        <i>Mining and Minerals Policy<br>
        in the New South Africa</i></td>
    </tr>
</table>
</center></div>

<h4 align="center"><font color="#008000">Related Documents</font></h4>

<ul>
    <li>Tripartite Discussion Document<a
        href="/policy/discuss.htm#policy2"><i> A Minerals and
        Mining Policy for South Africa </i></a>(November 1995) </li>
    <li>National Union of Mineworkers, <a
        href="http://www.anc.org.za/num/mining.html"><i>Mining
        and Minerals Policy for a Non-discriminatory, Efficient
        and Prosperous Mining Industry in South Africa</i></a>
        (August 1995). </li>
    <li>African National Congress, <a
        href="gopher://gopher.anc.org.za:70/00/anc/policy/minen.anc"><i>Draft
        ANC Minerals and Energy Discussion Document</i></a> (November
        1994) </li>
</ul>

<p><br>
</p>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
<br>
</p>

<hr size="6" noshade width="600">

<p align="center"><a name="SUMMARY"></a> </p>

<h4 align="center">SUMMARY<br>
<img src="../../images/wd1.gif" align="middle" width="32"
height="31"><br>
<font size="4" face="Arial">Mining and Minerals Policy in the New
South Africa</font></h4>

<h5 align="center"><i>June 1995</i></h5>

<ul>
    <li><a href="#REP"><b>Representivity of views</b></a> </li>
    <li><a href="#PRIN"><b>Fundamental Premises</b></a> </li>
    <li><a href="#KEYPOINTS"><b>Key Points</b></a> <ul>
            <li><a href="#KEYPOINTS">The Role of Government</a> <ul>
                    <li><a href="#REGENV"><i>Regulatory
                        Environment</i></a> </li>
                    <li><a href="#REGAGENT"><i>Regulatory Agency</i></a> </li>
                    <li><a href="#TAX"><i>Taxation</i></a> </li>
                    <li><a href="#INVEST"><i>Investment</i></a> </li>
                    <li><a href="#ENVIRON"><i>The Environment</i></a> </li>
                    <li><a href="#SADC"><i>Southern African
                        Regional Co-operation</i></a> </li>
                    <li><a href="#PROVAUTH"><i>Provincial and
                        Local Authorities</i></a> </li>
                    <li><a href="#ENERGY"><i>Energy Policy</i></a> </li>
                    <li><a href="#STATUTE"><i>Minerals Advisory
                        Council</i></a> </li>
                </ul>
            </li>
            <li><a href="#MINING">Mining</a> <ul>
                    <li><a href="#RIGHTS"><i>Mineral Rights</i></a> </li>
                    <li><a href="#PROSDATA"><i>Prospecting Data</i></a> </li>
                    <li><a href="#HEALTH"><i>Health and Safety</i></a> </li>
                    <li><a href="#RESEARCH"><i>Research and
                        Development</i></a> </li>
                    <li><a href="#SMALL"><i>Small-Scale Mining</i></a> </li>
                    <li><a href="#DOWN"><i>Downscaling</i></a> </li>
                    <li><a href="#BENEFIC"><i>Beneficiation</i></a> </li>
                    <li><a href="#MARKET"><i>Promotion and
                        Marketing</i></a> </li>
                </ul>
            </li>
            <li><a href="#HUMAN">Human Resource Development</a> <ul>
                    <li><a href="#ABET"><i>Education and Training</i></a> </li>
                    <li><a href="#IR"><i>Industrial Relations</i></a> </li>
                    <li><a href="#HOUSING"><i>Accommodation</i></a> </li>
                    <li><a href="#MIGRANT"><i>Migrant Labour</i></a> </li>
                    <li><a href="#AA"><i>Affrimative Action /
                        Employment Equity</i></a> </li>
                </ul>
            </li>
        </ul>
    </li>
</ul>

<p><br>
</p>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
<br>
<a name="REP"></a> </p>

<h4 align="center">REPRESENTIVITY OF VIEWS</h4>

<p align="center"><img src="../../images/linegr.gif"
align="middle" width="402" height="5"><br>
</p>

<p align="center">The comments presented in this document have
been collated by the Chamber of Mines of South Africa, not only
on behalf of its members, but also on behalf of a number of
non-member mining organisations.<br>
</p>

<p>Together, these organisations either employ, or represent
mining companies which employ, close to 90 per cent of all
persons working in the South African mining industry. The views
expressed in this document are thus substantially representative
of the South African mining industry, in respect of the interests
of employers and mine owners.<br>
</p>

<p>In particular, this document represents the majority views of
the mining companies associated with the following organisations:<br>
</p>

<blockquote>
    <p>AGGREGATE &amp; SAND PRODUCERS ASSOCIATION OF SA (ASPASA)<br>
    ANGLO AMERICAN CORPORATION OF SOUTH AFRICA LIMITED<br>
    ANGLO AMERICAN PLATINUM CORPORATION LIMITED<br>
    ANGLOVAAL LTD<br>
    ASSOCIATION OF INDUSTRIAL METALS, MINERALS &amp; MINING (AIM3)<br>
    DE BEERS CONSOLIDATED MINES LIMITED<br>
    GENCOR LIMITED<br>
    GOLD FIELDS OF SOUTH AFRICA LIMITED<br>
    ISCOR MINING DIVISION<br>
    JCI LIMITED<br>
    LONRHO SOUTH AFRICA LIMITED<br>
    RANDGOLD LIMITED<br>
    RICHARDS BAY MINERALS<br>
    SA CEMENT PRODUCERS ASSOCIATION (SACPA)<br>
    SASOL MINING DIVISION<br>
    SOUTHERN AFRICAN GRANITE ASSOCIATION (SAGA)<br>
    </p>
</blockquote>

<p><br>
</p>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p><a name="PRIN"></a> </p>

<h4>FUNDAMENTAL PREMISES</h4>

<p><b>First</b>, metals and minerals in the ground do not
constitute wealth. Wealth is created only when the capital
invested in the process of converting minerals in the ground into
saleable products is returned in real terms with a profit.
Production of a product at a loss, or at a profit insufficient to provide
a real, market-related return on investment, does not add wealth
to the country and should not be supported by the state.<br>
</p>

<p><b>Second</b>, more than most business activities mining is a
risky undertaking. It is inherently more risky in contemporary
South African conditions particularly where many gold, and to a
lesser extent platinum, operations take place at depths unknown elsewhere.
In the South African context risk is compounded because of:<br>
</p>

<ul>
    <li>the inevitably imperfect geological assessment of ore
        reserves at depth </li>
    <li>natural hazards such as flooding and seismicity </li>
    <li>the huge amounts of capital and long lead times involved
        in exploration and in bringing many new mines into
        production. </li>
</ul>

<p>During the extended periods of development and the long
operational lives of such mines, many factors can change in commodity
markets, technology and in the external and internal environment, which
could render the venture unprofitable.<br>
</p>

<p><b>Third</b>, mining is an international business and South
Africa has to compete against other developed and developing
countries to attract both foreign and domestic investment. The
fiscal, legislative and operating environments must therefore -
while recognising the nature of South African deposits - be internationally
competitive.<br>
</p>

<p><b>Fourth</b>, the nature and the extent of risk are such that
mining can effectively be undertaken only by the private sector.
In no mining country of significance has the state successfully
been able to play this role. Further, the state should not risk
public funds in mining ventures. The role of the government (amplified
in the next section) is to create a policy and regulatory framework,
as well as a general macroeconomic environment, conducive to the
private sector's willingness to take the necessary risks and to
bring to bear the requisite capital, technology, human and other
resources.<br>
</p>

<p><b>Fifth</b>, given the high risks inherent in exploration and
in the establishment of mines, companies willing to make the
investment must be satisfied that they will have absolute
security of tenure of a mineral deposit.<br>
</p>

<p><b>Sixth</b>, mines have finite lives. They are also
place-bound: labour, services and infrastructure must be brought
to the mine, and not vice versa. Further, mining necessarily
impacts on the physical environment. The combination of these
characteristics makes mining an unusual form of business; subject
to cost considerations which cannot be passed on to the customer
because of the international nature of operations, it places
obligations on all concerned to manage the resources involved in
such a way as to ensure that the long-term returns to the economy
as a whole are positive.<br>
</p>

<p><b>Seventh</b>, minerals left in the ground do not in any way
contribute to the economy. The concept of the &#145;pay
limit&#146; is therefore crucial to understanding the economics
of any particular mine, as well as to influencing its life
expectancy. The pay limit in any mine is the grade of ore at
which unit working costs equal the revenue generated by
incurrence of those costs. Working cost increases not matched, as
is often the case, by price increases raise the pay limit and
progressively preclude the mining of those parts of the orebody
whose grade is below the pay limit. What could otherwise have been
turned to profitable account - creating wealth and generating
employment - is left fallow underground.<br>
</p>

<p><b>Eighth</b>, it follows from the previous point that
anything that puts pressure on working costs adversely affects
not only the mine's current profitability but also its longevity.
This has important implications for policies towards taxation as
well as workplace and environmental standards and other factors.<br>
</p>

<p><b>Ninth</b>, a shift is under way in the locality of the
South African industry's main competitors. Whereas they were
previously situated in high-income countries, they are now
increasingly found in less developed nations where a combination
of geological conditions, transport costs, wage structures and
regulations governing safety and environmental protection give
them a competitive advantage over South Africa. This advantage
applies not only to internationally traded commodities but also
to a country's ability to attract international investment.
Without deprecating a widely shared commitment to improving
standards, the principal stakeholders in the South African mining
industry will have urgently to evolve mutually acceptable and competitive operational
systems and workplace standards to ensure the industry's enduring
success in the international marketplace.<br>
</p>

<p><b>Tenth</b>, South Africa has an exceptional minerals
endowment. Not only does it possess a very wide variety of
minerals, but in several of them - including strategically
important metals such as platinum, vanadium, manganese and chrome
- it has by far the lion's share of the world's known economic reserves.
In each of these not only is the country already the world's
largest producer, but it also has the potential to produce far
more than world markets can absorb. In these circumstances,
provided there is effective competition in both producer and
end-use markets, expansion of the country's supply capacity must
be approached with circumspection because of the likely damage to
price and hence to the ability of existing South African producers
to create wealth for the country.<br>
</p>

<p><b>Eleventh</b> and last, while there are variations across
different commodities and regions, in general terms minerals
development in South Africa is in a mature phase in that new
discoveries are not compensating for depletion of reserves. In
order to ensure their survival as world-class businesses, and
taking advantage of the removal of international sanctions, the
country's larger mining companies are accelerating their efforts
to look abroad for business development opportunities. This does
not gainsay that there are vast areas of South Africa where
potentially mineral-bearing deposits are covered by barren rocks;
exploration of this potential, already begun, will however become increasingly
expensive.<br>
</p>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p align="center"><a name="KEYPOINTS"></a> </p>

<h4 align="center">KEY POINTS</h4>

<h4 align="center"><u>The Role of Government</u><a name="REGENV"></a></h4>

<p><b>Regulatory Environment</b><br>
</p>

<ul>
    <li>Creation by government of a macro and regulatory
        environment conducive to economic growth and in which the
        mining industry can make effective use of its human and
        capital resources. </li>
</ul>

<p><br>
</p>

<p><a name="REGAGENT"></a> <b>Regulatory Agency</b><br>
</p>

<ul>
    <li>Single regulatory agency at national level for mining,
        viz. Department of Mineral and Energy Affairs (DMEA). </li>
    <li>DMEA also to promote industry's interests in relation to
        other departments and agencies of the government. </li>
    <li>Subject to environmental and other relevant factors,
        mining to continue to take precedence in use of land. </li>
</ul>

<p><br>
</p>

<p><a name="TAX"></a> <b>Taxation</b><br>
</p>

<ul>
    <li>Stable system of taxation. </li>
    <li>Taxation on profits, not via levies or imposts that
        increase costs. </li>
    <li>Retain system of accelerated depreciation and capital
        allowances. </li>
    <li>Abolition of ring-fencing. </li>
</ul>

<p><br>
</p>

<p><a name="INVEST"></a> <b>Investment</b><br>
</p>

<ul>
    <li>Security and continuity of tenure must be assured. </li>
    <li>Need for internationally competitive taxation, labour
        market conditions and regulatory framework. </li>
</ul>

<p><br>
</p>

<p><a name="ENVIRON"></a> <b>The Environment</b><br>
</p>

<ul>
    <li>Balance between environmental concerns and economic
        development. </li>
    <li>Support for &#145;polluter pays&#146; principle. </li>
    <li>Special mechanisms needed to ensure effective
        environmental management by artisanal operators. </li>
</ul>

<p><br>
</p>

<p><a name="SADC"></a> <b>Southern African Regional Co-operation</b><br>
</p>

<ul>
    <li>Promotion of regional co-operation - in which removal of
        barriers to flows of capital, labour, goods and services,
        is the long-term aim. </li>
    <li>Regional (continental) co-operation should provide
        extensive business opportunities for South African mining
        and related companies. </li>
</ul>

<p><br>
</p>

<p><a name="PROVAUTH"></a> <b>Provincial and Local Authorities</b><br>
</p>

<ul>
    <li>Services provided to a mine by provincial or local
        authorities should be charged on an efficient and
        equitable basis. </li>
    <li>If no services are provided, no rates should be charged. </li>
    <li>Provincial and local governments&#146; taxes, levies and
        surcharges should accord with the principle that mining
        be taxed on profits. </li>
    <li>The Minister of Finance, together with the Financial and
        Fiscal Commission, should assess the level of taxes in
        their entirety after canvassing the views of the owners
        and other interested parties prior to finalising
        recommendations. </li>
</ul>

<p><br>
</p>

<p><a name="ENERGY"></a> <b>Energy Policy</b><br>
</p>

<ul>
    <li>Mining and minerals processing are substantial consumers
        of electricity and their competitiveness is in part
        dependent on the cost of electricity. </li>
    <li>Safety and operational considerations require reliable
        and stable electricity supply. </li>
    <li>Direct bulk supply of electricity by the power generator
        (Eskom) is favoured by the industry over that by local authorities. </li>
    <li>The mining industry supports deregulation of the liquid
        fuels industry. </li>
</ul>

<p><br>
</p>

<p><a name="STATUTE"></a> <b>Minerals Advisory Council</b><br>
</p>

<ul>
    <li>A tripartite statutory mineral advisory council should be
        created as a matter of urgency. </li>
</ul>

<p><br>
</p>

<hr>

<p><a name="MINING"></a></p>

<h4>KEY POINTS</h4>

<h4><u>Mining</u><a name="RIGHTS"></a></h4>

<p><b>Mineral Rights</b> </p>

<ul>
    <li>Retention of the existing system of public and private
        ownership of mineral rights. </li>
    <li>Enhanced accessibility to state-held mineral rights,
        especially, but not necessarily, for small-scale
        ventures. </li>
</ul>

<p><br>
</p>

<p><a name="PROSDATA"></a> <b>Prospecting Data</b> </p>

<ul>
    <li>Prospecting data are valuable intellectual property
        obtained at risk and expense. </li>
    <li>Changes to the existing arrangements should recognise
        free market principles in the publication and trading of
        such data. </li>
    <li>Prospecting data in respect of state-owned mineral rights
        should be available to potential investors. </li>
</ul>

<p><br>
</p>

<p><a name="HEALTH"></a> <b>Health and Safety</b> </p>

<ul>
    <li>Safety of employees is a key concern, and employee
        consultation and participation in safety planning are
        essential. </li>
    <li>Regulations must be realistic, affordable and practically
        enforceable. </li>
    <li>Owners recognise the need to promote the good health of
        its employees. </li>
    <li>Key objective is an affordable, equitable and sustainable
        health-care system for employees. </li>
    <li>Leon Report generally endorsed by owners, with particular
        support for creation of tripartite body to formulate the
        new act and its companion regulations. </li>
</ul>

<p><br>
</p>

<p><a name="RESEARCH"></a> <b>Research and Development</b> </p>

<ul>
    <li>Owners remain committed to R&amp;D serving their own
        interests funded by themselves, and recognise the
        potential contribution of user-driven public sector
        research for common interests. </li>
    <li>Safeguards needed to ensure SIMRAC funding system is not
        &#145;abused&#146;. </li>
</ul>

<p><br>
</p>

<p><a name="SMALL"></a> <b>Small-Scale Mining</b> </p>

<ul>
    <li>Large-scale industry supportive of government promotion
        of small-scale mining. </li>
    <li>Small operators to have access to state-owned mineral
        rights. </li>
    <li>SBDC, or similar funding conditional on enterprises being
        run on sound business principles. </li>
    <li>No lowering of safety and health and environmental
        standards for new entrants to small-scale mining sector. </li>
</ul>

<p><br>
</p>

<p><a name="DOWN"></a> <b>Downscaling</b> </p>

<ul>
    <li>Finite nature of mineral resources makes mine closures
        inevitable </li>
    <li>Government has a socio-economic obligation to assist in
        alleviating the consequences of downscaling and closure. </li>
    <li>Community involvement is essential. </li>
</ul>

<p><br>
</p>

<p><a name="OWNER"></a> <b>Industry Ownership</b> </p>

<ul>
    <li>A wider spread in the ownership of assets, through
        natural business processes is supported by the existing
        owners. </li>
    <li>Government intervention is neither appropriate nor
        necessary. </li>
</ul>

<p><br>
</p>

<p><a name="BENEFIC"></a> <b>Beneficiation</b> </p>

<ul>
    <li>The mining industry has long undertaken beneficiation
        projects, on the basis of commercial viability. </li>
    <li>Recent projects continue this trend. </li>
    <li>Beneficiation projects should come about through market
        forces and not government intervention. </li>
</ul>

<p><br>
</p>

<p><a name="MARKET"></a> <b>Promotion and Marketing</b> </p>

<ul>
    <li>The industry energetically promotes, markets and sells
        its products domestically and internationally. </li>
    <li>Owners are emphatically opposed to government
        intervention in minerals marketing. </li>
</ul>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p><a name="HUMAN"></a> </p>

<h4>KEY POINTS</h4>

<h4><u>Human Resource Development</u></h4>

<p><br>
</p>

<p><a name="ABET"></a> <b>Adult Basic Education and Training</b> </p>

<ul>
    <li>Government has primary role at all levels of education. </li>
    <li>Mining industry invests large sums in training and
        education for its own as well as for wider needs. </li>
    <li>Education system must produce high quality people, with
        flexible skills and attitudes. </li>
</ul>

<p><br>
</p>

<p><a name="IR"></a> <b>Industrial Relations</b> </p>

<ul>
    <li>Industrial relations matters are best left to employers
        and employees. </li>
    <li>Government responsible for regulatory environment which
        gives opportunity for workplace parties to settle their
        own affairs. </li>
    <li>The draft Labour Relations Act has much to commend it.
        The framework potentially now exists for introduction of
        a balanced and performance-based system of industrial
        relations that will underpin workplace efficiency and
        national economic growth. </li>
</ul>

<p><br>
</p>

<p><a name="HOUSING"></a> <b>Accommodation</b> </p>

<ul>
    <li>Mining industry is a major provider of accommodation. </li>
    <li>Accommodation should be affordable and sustainable. </li>
    <li>Culture of payment should be encouraged. </li>
    <li>Policy development should take place in consultation with
        stakeholders. </li>
</ul>

<p><br>
</p>

<p><a name="MIGRANT"></a> <b>Migrant Labour</b> </p>

<ul>
    <li>Notwithstanding the negative consequences, organised
        recruitment from rural areas has brought many benefits to
        the industry, the employees and the rural communities. </li>
    <li>Employers and employees should have the right to agree
        the conditions of employment suited to their mutual
        needs. </li>
    <li>South Africa's neighbours are heavily dependent on
        migrant workers' remittances. </li>
    <li>There should be no constraint on the employment of labour
        by the mining industry either from within or beyond the country&#146;s
        borders. </li>
</ul>

<p><br>
</p>

<p><a name="AA"></a> <b>Affirmative Action / Employment Equity</b> </p>

<ul>
    <li>Owners are committed to ensuring that all employees can
        compete equally on the basis of merit. </li>
    <li>There is a commitment to the removal of any
        discrimination that remains. </li>
    <li>Owners favour voluntarism and are opposed to government
        intervention. </li>
</ul>

<p><br>
</p>

<p align="center"><a href="/main.htm"><img
src="../../images/nb1.gif" alt="Main Menu" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a href="#top"><img
src="../../images/nb2.gif" alt="Top of Page" align="middle"
border="0" hspace="20" width="60" height="17"></a> <a
href="#toolbar"><img src="../../images/nb3.gif" alt="Toolbar"
align="middle" border="0" hspace="20" width="80" height="17"></a> <br>
</p>

<p align="center"><br>
<br>
<a name="toolbar"></a> <a href="org1.htm"><img
src="../../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="res1.htm"><img
src="../../images/tb102.gif" alt="Resources" border="0"
width="101" height="17"></a> <a href="kruger.htm"><img
src="../../images/tb104.gif" alt="Krugerrand" border="0"
width="101" height="17"></a> <a href="new.htm"><img
src="../../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="info.htm"><img
src="../../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> <br>
</p>

<hr>

<address>
    <font size="2">Last Updated: 5 February 1996<br>
     1996 Chamber of Mines of South Africa<br>
    HTML Coding by Timothy Wood : </font><a
    href="mailto:twood@bullion.org.za"><font size="2">twood@bullion.org.za</font></a><font
    size="2"> </font>
</address>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-488</DOCNO>
<DOCOLDNO>IA012-000130-B039-72</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/policy/MINPOLICY/compol2.htm 196.26.82.193 19970217021724 text/html 23481
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:20:47 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Mines of South Africa Mining and Minerals Policy</TITLE>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<center>
<IMG SRC="/images/LOGO1.gif"><br><p>
<h2>Mining and Minerals Policy in the New South Africa</h2>

<h4>Related Information</a></h4>
<TABLE BORDER=1 cellpadding=4>
<TR><Th align=center valign=middle><a href="compol1.htm">Chamber Policy Document</a></th>
<Th align=center valign=middle><a href="compol3.htm">Chamber Vision Statement</a></th>
<Th align=center valign=middle><a href="mpolwshp.htm"><Blink>Policy Workshops</Blink></a></th>
</TR>
<tr><Th align=center valign=middle><a href="/policy/discuss.htm#policyprocess">Tripartite Policy Process</a></th>
<Th align=center valign=middle><a href="/policy/discuss.htm#policy2">Tripartite Discussion Document</a></th>
<Th align=center valign=middle><a href="/policy/discuss.htm#link">Other Documents</a></th></tr>
</TABLE>

<table border=0 width=550 cellspacing=18>

<td align=center valign=top width=250>
<hr width=250 noshade size=2>
<IMG SRC="/images/save.gif"><A HREF="minpol6.zip"> <b>DOWNLOAD</b></a><IMG SRC="/images/save.gif"> <br>
<i><b> Chamber of Mines Submission<br> on Mining and Minerals Policy</b></i><br>
<FONT SIZE=2> (ZIP 29.7k)</FONT>
<br></FONT>
<hr width=250 noshade size=2><br><p>
</pre></font size>
</td>

<td align=center valign=top width=250>
<hr width=250 noshade size=2>
<IMG SRC="/images/blue.gif"><A HREF=#TEXT> <b>FULL TEXT INDEX</b></a><IMG SRC="/images/blue.gif"><br>
<i><b>Chamber of Mines Submission<br> on Mining and Minerals Policy</b></i><br><p>
<hr width=250 noshade size=2>
</td></table></CENTER>


<a name="TEXT"></a>
<CENTER>FULL TEXT<br>
<IMG SRC="/images/wd1.gif" ALIGN=MIDDLE><br><h2>
Mining and Minerals Policy in the New South Africa</h2>
<FONT SIZE=3 COLOR=800080>Submission Prepared by the Chamber of Mines of South Africa<br>
on behalf of its <A HREF="members.htm">members</A> and <A HREF="#REP">certain other mining organisations</A><br>
in response to the November 1995 <a href="/policy/discuss.htm#policy2">Tripartite Discussion Document</a></FONT>

<h5><i>February 1996</i></h5></CENTER>
<Center>
<A NAME="top"></A>
<FONT SIZE=4 COLOR=008000><B>INDEX</B></FONT></Center>
<ul>
<li><A HREF=#REP> <b>Representivity of Views</b></a>
<li><A HREF=#preamble> <b>Preamble</b></a>
<li><A HREF=#comment> <b>General Comment</b></a>
<li><A HREF=#tax> <b>Taxation</b></a>
<li><A HREF=#transport> <b>Transport</b></a>
<li><A HREF=#comp> <b>Competition</b></a>
<li><A HREF=#access> <b>Access & Ownership</b></a>
<li><A HREF="compol21#resource"> <b>Resource Management</b></a>
<li><A HREF="compol21.htm#exploration"> <b>Exploration</b></a>
<li><A HREF="compol21.htm#environment"> <b>Environmental Management</b></a>
<li><A HREF="compol21.htm#small scale"> <b>Small-Scale Mining and Mineral Development</b></a>
<li><A HREF="compol21.htm#exploit"> <b>Exploitation</b></a>
<li><A HREF="compol21.htm#downscale"> <b>Downscaling</b></a>
<li><A HREF="compol22.htm#mining safety"> <b>Mining Safety and Health</b></a>
<li><A HREF="compol22.htm#human"> <b>Human Resources</b></a>
<li><A HREF="compol22.htm#mineral"> <b>Mineral Beneficiation</b></a>
<li><A HREF="compol22.htm#Mineral mark"> <b>Mineral Marketing</b></a>
<li><A HREF="compol22.htm#research"><b>Research and Development</b></a>
<li><A HREF="compol22.htm#regional"> <b>Regionalisation and Internationalisation</b></a>
<li><A HREF="compol22.htm#govern"> <b>Governance</b></a>
</ul>

<A NAME="REP"></A>
<B>REPRESENTIVITY OF VIEWS</B><BR>
The submissions in this document have been prepared by the Chamber of Mines of South Africa on behalf of and with the participation of its members and a number of organizations that are not members of the Chamber.<p>

Together, these organizations either employ, or represent mining companies which employ, close to 90 per cent of all persons working in the South African mining industry.  The views expressed in this document are thus substantially representative of the South African mining industry, in respect of the interests of employers and mine owners.<p>

In particular, this document has been endorsed by the following organizations:<p>

	<UL>
<LI>AGGREGATE & SAND PRODUCERS ASSOCIATION OF SA (ASPASA)
<LI>	ANGLO AMERICAN CORPORATION OF SOUTH AFRICA LIMITED
<LI>	ANGLO AMERICAN PLATINUM CORPORATION LIMITED
<LI>	ANGLOVAAL LIMITED
<LI>	DE BEERS CONSOLIDATED MINES LIMITED
<LI>	GENCOR LIMITED
<LI>	GOLD FIELDS OF SOUTH AFRICA LIMITED
<LI>	ISCOR LIMITED, MINING DIVISION
<LI>	JCI LIMITED
<LI>	LONRHO SOUTH AFRICA LIMITED
<LI>	RANDGOLD AND EXPLORATION COMPANY LIMITED
<LI>	RICHARDS BAY MINERALS
<LI>	SA CEMENT PRODUCERS ASSOCIATION (SACPA)
<LI>	SASOL LIMITED
<LI>	TRANS HEX GROUP LIMITED</UL><p>

In addition, the Association of Industrial Minerals, Metals and Mining (AIM3), Falconbridge Limited and Shell South Africa (Pty) Limited have endorsed this document subject to certain exceptions and/or additions which are dealt with in separate submissions by them.<p>

The South African Granite Association (SAGA) has endorsed the document in principle.<p>


<A NAME="preamble"></A>
<B>PREAMBLE</B><BR>

The comments set forth below on the discussion document on a mining and minerals policy for South Africa must be read subject to the following qualifications:<P>

<ol>
<dt><B><li></B>We obviously support and therefore do not comment on those parts of the discussion document that reflect views advanced in the base document submitted by employers and referred to on page 10 of the discussion document.</DT>


<dt><B><li>.</B>	<DT>We have not commented on those statements in the discussion document whose ambiguity makes it impossible for us to comment meaningfully on how they relate to or may be expressed in mining and minerals policy.</DT><P>


<dt><B><li></B>	<DT>In general we have sought to avoid raising narrow points of interpretation in order to limit the length of our comment.</DT><P>


<dt><B><li></B>	<DT>We have sought to confine our comments as far as possible to those proposals which in our view would work against the interests of mining.</DT><P>


<dt><B><li></B>	<DT>The discussion document contains a number of statements which are factually inaccurate.  We have not commented on them in any detail, save to draw attention to the inaccuracy in certain cases.</DT><P>


<dt><B><li></B>	<DT>We have not commented in any detail on those statements in the discussion document that are irrelevant to minerals policy or in respect of which the current process of mining and minerals policy formulation does not provide an appropriate forum or range of participants for the development of policy.</DT></DL><P>

<center>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><p><p>

<A NAME="comment"></A>
<B>GENERAL COMMENT</B><BR>

Policy should be aimed at securing a market-based economic system in which government has a dual role.  First, it should create a stable market environment conducive to economic growth in which businesses can operate profitably, be internationally competitive and satisfy their shareholders and employees expectations.  Second, government should facilitate access to resources for those who were previously discriminated against and/or who need special assistance to participate effectively in the formal economy.  Against this background we broadly agree with the points of departure, but believe that a number of statements are ambiguous and require clarification before one can comment meaningfully on them (for example the use of the word "intervention" in paragraph 1.1 i) and the word "promote" in paragraphs 1.1 iv) and v) which could be taken to imply a greater role for government than we believe would be desirable).<P>


<DL>
<dt><B>1.2.2	vi)</B><br>
<dd>the listings requirements of The Johannesburg Stock Exchange 	seek to facilitate the listing of securities of exploration companies 	whether on the main board, the development capital market or the 	venture capital market.  To the extent that these requirements 	inhibit the mobilisation of funds for small mining ventures, they do 	so to no greater degree than the requirements applicable to other 	sectors.<P>



<dt><B>1.2.3	ii)</B><br>
<dd>While we agree with the first sentence, the subsequent assertions 	are so sweeping as to imply that there is nothing in the current 	system that has made and continues to make South Africa 	attractive to investors which is palpably untrue.  There are factors 	which inhibit investment, for example exchange controls and, 	specifically in relation to the mining industry, statutory restrictions 	on working on Sundays.<P>


<dt><B>1.2.3	iv)</B><br>
<dd>The dissemination of information referred to in this statement must 	be qualified so as to exclude the general dissemination of trade 	secrets, or financial, commercial, scientific or technical information 	supplied in confidence to the State and treated consistently as 	confidential by the supplier of the information, the disclosure of 	which could cause harm to the commercial or financial interest of 	that party.<P>


<dt><B>1.2.3	v) & vi)</B><br>	
<dd>The institutional framework for regulating and promoting the mineral sector is currently fragmented and needs to be revised.  Realistic objectives should be formulated within the constraints of available skills and resources.<P>


<dt><B>1.2.3	x)</B><br>
<DD>We disagree that the State should itself play a direct role.  Mining 	is subject to 	risks which are best borne by the private sector. The 	State may be able to play a role in providing financial assistance 	provided it does so through agencies such as the IDC which adopt 	long term economic viability as the criterion for their support.  	Economic viability is the key.  South Africa is reintegrating into a 	competitive global market. Economically unsustainable projects will 	drain our resources at the expense of lost opportunities.  Let us not 	repeat or suffer variations on the theme of Mossgas.<P>


<dt><B>1.2.3	xii)</B><br>	
<dd>There should be no statutory restriction on the performance of work 	on Sundays.
</DL>

<center>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><p><p>

<A NAME="tax"></A>
<DL>
<dt><B>1.3 	TAXATION</B><BR>

<dt><B>1.3.2	vi</B><BR>	<dd>The first sentence of this paragraph appears to suggest that a 	resource rent or severance tax be imposed.  We are fundamentally 	opposed to a resource tax.  The Margo Commission was opposed to 	such a tax, regarding it as a discriminatory surcharge on income 	tax. If imposed on revenue or on physical production, severance 	taxes raise costs at the margin and render unpayable bodies of ore 	that, but for the tax, would be payable.   The Commission also 	pointed to the practical difficulties in designing severance taxes for 	each of various minerals being mined.  Not all could stand the same 	rate of tax nor could all grades of the same ore stand the same rate.  	The Marais Technical Committee on Mining Taxation took the view 	that where the State owns mineral rights it should endeavour to 	turn them to account in a manner which produces an optimal 	return.  In such cases it is appropriate that it should charge the 	miner a lease payment or sell the mineral rights outright for a lump 	sum.<P>

<dt><B>1.3.2	vii)</B><BR>
	<dd>The issue is not one of raising more tax for government 	programmes, but rather providing an environment that is conducive 	to the development of business enterprises. This is the only way of 	increasing economic growth and employment on a sustainable 	basis, thus broadening the tax base which then can lead to a 	reduction of the already high tax burden on all South Africans. The 	government has committed itself to ensuring that the level of 	taxation does not rise in real terms (as a percentage of GDP). This 	rules out raising the general level of taxation. The imposition of ad 	hoc taxes and levies leads to uncertainty, raises costs of business, 	discourages new investment and removes the discipline imposed by 	a national budget process.<P>

	The premise that the return of mineral rights to the State will result in increased rentals to the State is fundamentally flawed. Any form of royalty, or tax on input costs of any mining project, or potential mining project, will raise the investment hurdle rate, thus  jeopardising investment.  This will be to the detriment of wealth and employment creation. Again it must be said that any impost, levy or tax (including a mineral rights tax) on input costs reduces the large potential of the mining industry to create wealth.  The governments primary focus should not be on raising tax revenue, but should rather be on allowing wealth to be created in the economy by the private sector to the benefit of all South Africans.<P>

<dt><B>1.3.3	iv)</B><br>	<dd>We are strongly opposed to a mineral rights tax.<P>

<dt><B>1.3.3	v)</B><br>
	<dd>We disagree - mines should be taxed only on profits and not in a 	way that increases their costs. It is not so much one small levy that 	impacts on the input costs of mining, but rather the aggregate of 	the multitude of proposed levies that raises input costs, raises the 	investment hurdle rate and sterilises mineral resources in the 	ground.  We repeat our position that the State should only tax 	profits, and that there should be no form of tax, impost or levy on 	input costs. Taxes on input costs reduce the large potential wealth 	creating ability of the mining industry.  A levy would be hostile to 	investment in mining and to the viability of a mine.  It would not be 	constrained by the discipline imposed within a national budget. We 	oppose the levy in principle.<P>

<dt><B>1.3.3	vi)</B><br>	<dd>We oppose in principle the imposition of such a levy.  The 	proposition implies that all raw material could be profitably 	beneficiated to the maximum extent in South Africa which is 	absolute nonsense  To penalise producers because their markets are 	such that their profitability requires the export of unbeneficiated 	products or to penalise them because they are unable to beneficiate 	economically cannot be in their interests or those of the country.  	The proposition implies that South Africa beneficiates very little, 	which again is incorrect when one has regard, for example, to the 	enormous beneficiation of ore involved in the production of gold.  	Reality is infinitely more complex than one might infer from the 	proposition.<P>

	In the case of gold jewellery for example, South Africa has no special advantage, and hence little investment has been made in gold jewellery fabrication. In the case of iron ore and its beneficiation, South Africa does have ample supplies of low cost, good quality iron ore and chrome deposits, a low electricity price, and the technological know how for the production of steel. Massive investment has thus been made into this sector.<P>

	Therefore government should not try and impose levies to induce outcomes, but rather provide an enabling business and investment environment which allows decisions on investment and business by the private sector to be taken in a free market environment.<P>

<dt><B>1.3.3	ix)</B><br>	<dd>The most significantly adverse form of ring-fencing is that created 	under section 36(7F) of the Income Tax Act, 1962 which restricts 	the deduction of capital expenditure on a particular mine to the 	income generated by that mine only.  This ring-fence should be 	abolished, not reassessed:-<P>

<ul>
<li> 	it is contrary to the basic principle of taxation that the taxpayer is the company and not its individual mining or other ventures;<P>

<li>	the risk in new mining ventures is very high and it is natural that investors should seek to use existing operations as a basis to expand and thereby spread the risk;

<li>	in pursuing the companys aim of achieving the best return on capital that it can the company may need to devote the revenue from one mine to the development of another;

<li>	it is a disincentive to future investment in mining.
</ul><P>
<dt><B>1.3.3	xvi)</B><br>	<dd>We disagree.  The proposal is fundamentally flawed.  It ignores the 	fact and merit of competitive private enterprise and the existence of 	separate companies. The income earning, employing and tax paying 	entity is the company which exists in law and fact as an entity 	capable of pursuing particular commercial objectives and regulating 	conditions of employment with its employees.  This proposal is 	another of several such proposals in the discussion document that 	have no place in a document about mining and minerals policy.<P>

<center>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><p><p>

<A NAME="transport"></A>
<dt><B>1.5 	TRANSPORT</B><P>

<dt><B>1.5.2	i)</B><br>	<DD>Transport costs are so crucial an element in the competitiveness of 	South African producers that prices must reflect the true cost of 	transport.<P>

<dt><B>1.5.2	iv) & v)</B><br>		<dd>This is not relevant to government policy on mining and minerals.  	Several smaller producers as well as traders arrange to export 	tonnage by acquiring throughput capacity at the Richards Bay Coal 	Terminal from current shareholders by means of private 	commercial arrangements.<P>

<dt><B>1.5.3	iv)</B><br>	<dd>These are not matters for government policy on mining and 	minerals.<P>

	It needs to be stressed that RBCT was and continues to be developed using private capital, hence is a private facility, and that potential exporters who are not investors are not automatically excluded. Potential exporters, desirous of using the RBCT, have made commercial arrangements to buy in:  e.g. Sasols purchase of shares from Shell.  Detractors of RBCT who suggest it is a closed shop are quick to ignore the substantial investment already sunk into the facility.<P>

<center>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><p><p>

<A NAME="comp"></A>
<dt><B>1.6 	COMPETITION</B><P>

	<dt><B>General Comment</B><BR>

	We make the following general comment on this section.  It is not for minerals/mining policy to determine competition policy in South Africa.  Policy should be expressed in the new Competition Act currently being drafted and in legislation relating to companies and associations which will be applicable to mining/minerals in the same way as any other industry.<P>

	The issues, arguments and policy proposals raised in the discussion document are deeply flawed and are based on a profound misunderstanding of the nature of competition in the international minerals industry and wrong assertions about oligopolies and on a simplistic view of the structure of South African mining houses as well as of large conglomerates in east Asia.<P>

	The material in section 1.6 is ill informed and does not provide a sensible basis for discussion on a subject which, in any event, cannot be adequately dealt with in a process focused on the development of mining and minerals policy.<P>

<center>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><p><p>

<A NAME="access"></A>
<dt><B>2. ACCESS AND OWNERSHIP</B><P>

<b>General Comment</b><P>

It is plain that past racially discriminatory legislation inhibited black ownership of assets.  We take the view that with the removal of  improper forms of discrimination a better spread of ownership will develop and be sustained through natural business activities but not through government intervention.<P>

It is acknowledged that, at senior management level in particular, the industry has not yet succeeded in developing talent from the majority of South Africas population;  this is a situation that has evolved largely as a result of past legislation.  Looking forward and given the countrys demography, competitiveness and long-term success will depend fundamentally on the development of all available human resources.  Throughout the industry, therefore, there are a variety of training, development and career advancement programmes designed to enhance the contributions made by all employees and hence their progress to higher occupational levels, and in these ways to contribute to the industrys continuing viability in the long term.<P>

Owners are committed to creating conditions in which employees of all races can compete equally on the basis of merit.  To this end, companies have committed themselves to the removal of any discrimination which still exists and to facilitating the development of disadvantaged persons.  These endeavours seek to ensure that all employees with potential will have an equal opportunity to gain the requisite competencies and be promoted into skilled, supervisory and managerial ranks as such positions become available.<P>

The challenge facing the industry is not only to recruit more black people but to ensure that such recruits occupy positions of real power and discharge their responsibilities with competence.  This should be achieved through voluntarism and emphatically not through government intervention, particularly if the latter were to involve compulsory quotas.<P>

Racial discrimination in the workplace is wrong.  Legislation aimed at its removal would not be confined to the mining industry.  It would be of general application and is not a subject that should be dealt with in formulating policy on mining and minerals.<P>


<center>
<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
</center><hr><br><br><br>

<a name="toolbar"></a>
<CENTER>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr>
<address>
<FONT SIZE =2>
28 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Cheryl Jones : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>




















</DOC>
<DOC>
<DOCNO>WT14-B39-489</DOCNO>
<DOCOLDNO>IA012-000130-B039-109</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/policy/MINPOLICY/mpolwshp.htm 196.26.82.193 19970217021744 text/html 5974
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:21:21 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Chamber of Mines of South Africa Hosting: South African Mining and Minerals Policy</TITLE>
<BODY BGCOLOR="#ffffff" TEXT="#000080">
<center>
<h1>MINING AND MINERALS POLICY<BR> STEERING COMMITTEE</h1>
<h2><I>POLICY WORKSHOPS</I></ah2>

<table border=0 width=550 cellspacing=18>
<td align=center valign=top width=250>
<hr width=250 noshade size=2>
<IMG SRC="/images/red.gif"> <L1><A HREF="#12MARCH"> <b>1 & 2 MARCH</b></a><IMG SRC="/images/red.gif"> <br>
<i><b> Policy Workshop 1</b></i><br>
<hr width=250 noshade size=2><br>
</pre>
</td>

<td align=center valign=top width=250>
<hr width=250 noshade size=2>
<IMG SRC="/images/blue.gif"><A HREF="#1920MARCH"> <b>19 & 20 MARCH</b></a><IMG SRC="/images/blue.gif"><br>
<i><b>Policy Workshop 2</b></i><br>
<hr width=250 noshade size=2>
</td></table>

<table border=0 width=600 cellspacing=18>
<td align=center valign=top width=600>
<hr width=550 noshade size=2>
<IMG SRC="/images/yellow.gif"> <L1><b>INFORMATION</b><IMG SRC="/images/yellow.gif"> <br>
The Secretariat<br>
Minerals and Mining Policy Workshops<br>
PO Box 395<br>
WITS<br>
2050<br>
Tel: (011) 403-8013 (Mr R Goode), Fax: (011) 403-8023/4<br>
<B>NOTE</B><br>Bookings are made on a first come, first served basis.  Payments must accompany registration applications.  Please make all cheques out to the Minerals and Mining Policy Workshop.<br>
For cancellations later than 22 February 1996 for Workshop 1 and 11 March 1996 for Workshop 2, respectively, there will be no refund.
<hr width=600 noshade size=2><br><br>
</td></table>

<br><p>

<A NAME="12MARCH"></A>
<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=center valign=middle><B><H2>WORKSHOP ONE</H2></B>
<I><H3>Friday 1 March and Saturday 2 March 1996</H3></I>
Auditorium, Council for Geoscience
<br>280 Pretoria Street, Silverton, Pretoria<BR>
</Th>
</TR>
</table>

<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=center valign=middle><B>Day One</B>: 08h00 to 17h30</Th>
<Th><B>Day Two</B>: 08h00 to 17h00</TH>
</TR>
</table>
</b>

<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=left valign=middle>
<ol>
<li>	Registration
<lI>	Background Briefing
	<ul>
		<li> Investment Climate
		<li> Taxation
		<li> Training and Education
		<li> Industrial Relations and Employment
		<li> Safety and Health
		<li> Competition and Ownership
	</ul>
	<br>		
<Center><B><I>TOPICS FOR DISCUSSION</I></B></Center>

<li>	Proposals of a Common Vision

<li>	Business Environment
	<ul>
		<li> National and Provincial Powers
		<li> Administration and Regulation
		<li> Mineral Marketing
		<li> Beneficiation
		<li> Research and Development
		<li> Environmental Issues
		<li> Mining Impact on Surface Usage
		<li> Southern African Regional Issues
	</ul>

<li>	Human Resources	
	<ul>
		<li> Eliminating Residual Racism
		<li> Housing
		<li> Downscaling
		<li> Migrant Labour
	</ul>

<li>	Closing Statement
</ol>
<I><Center><B>A light lunch and refreshments will be available on both days</B></Center></I>
</TH>
</TR>
</table>


<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=center valign=middle><B>COSTS</B><br>
The cost of attending the workshops is R100.00 (incl VAT) per person.  The fee will cover the provision of refreshments and a finger lunch.</TH>
</TR>
</table>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<hr><br><br><br>

<A NAME="1920MARCH"></A>
<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=center valign=middle><B><H2>WORKSHOP TWO</H2></B>
<I><H3>Tuesday 19 March and Wednesday 20 March 1996</H3></I>
Auditorium, Council for Geoscience
<br>280 Pretoria Street, Silverton, Pretoria<BR>
</Th>
</TR>
</table>

<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=center valign=middle><B>Day One</B>: 08h00 to 17h30</Th>
<Th><B>Day Two</B>: 08h00 to 17h00</TH>
</TR>
</table>


<TABLE BORDER=1 cellpadding=4 width=80%>
<TR><Th align=left valign=middle>
<ol>
<li>	Registration
<li>	Opening Statement
<li>	Mineral Tenure
	<ul>
		<li> Mineral Rights
		<li> System of Access to Mineral Rights
		<li> Access to Exploration Information
		<li> Optimal Exploration
		<li> Trust Lands
	</ul>

<li>	Small Scale Mining
	<ul>
		<li> Development of Small Scale Mining
		<li> Artisanal Mining
		<li> Access to Exploration Information
	</ul>
<li>	Reformulation of a Common Vision
</ol>
<I><Center><B>A light lunch and refreshments will be available on both days</B></Center></I>
</TH>
</TR>
</table>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>
<hr><br><br><br>

<a name="toolbar"></a>

<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
</CENTER>
<BR>
<hr></b>
<address>
<FONT SIZE =2>
13 February 1996<BR>
&#169 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : <A HREF="mailto:twood@bullion.org.za">twood@bullion.org.za</a>
</FONT></address>
</BODY>
</HTML>




















</DOC>
<DOC>
<DOCNO>WT14-B39-490</DOCNO>
<DOCOLDNO>IA012-000130-B039-130</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/deplabor.htm 196.26.82.193 19970217021825 text/html 4162
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:21:56 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Press Release</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font size="5"><strong><img
src="../images/logo2.gif" width="102" height="64"></strong></font></p>

<p align="center"><font color="#008000" size="5"><em><strong>Press
Release</strong></em></font></p>

<p align="center"><font color="#FF0000" size="3"
face="Courier New"><b><u>EMBARGO:NONE</u></b></font></p>

<p align="center"><font face="Arial"><b><u>CHAMBER OF MINES SAYS
&quot;DEPARTMENT OF LABOUR'S REPORT IS NEGATIVE AND
MISLEADING&quot;</u></b></font></p>

<p align="center"><font color="#800040" size="2"><strong>DATE: 19
December 1996</strong></font>&nbsp;</p>

<p><font size="2"><b>The President of the Chamber of Mines, Nick
Segal, comments - in a press release issued to SAPA on 19
December 1996 - on the report titled: GOLD MINING&#146;S LABOUR
MARKETS, LEGACIES OF THE PAST, CHALLENGES OF THE PRESENT which
was issued by the Department of Labour on 17 December 1996</b></font><b>.</b></p>

<hr>

<p>The report summarises some past research into the mining
industry, and presents a critical, provocative and in numerous
instances, unwarranted view of the industry.<br>
</p>

<p>It is unfortunate that the dominant thrust of the report is
focused on the past with consequently minimal acknowledgement of
the many recent positive developments that now characterise the mining
industry. There is an insinuation that the mining industry
remains committed to practices prevalent in the apartheid era.
This is simply not true.<br>
</p>

<p>While the report does give some recognition to contemporary
industry initiatives, its tone and content are essentially
negative. The statistical data presented are, in many cases,
hopelessly out of date and it is clear that the authors have not
sought to understand the significant progress that has been made
in important areas of their findings, for example, workplace restructuring and
training and education. Their statements about wages are grossly
misleading.<br>
</p>

<p>Most surprising is the report&#146;s failure to acknowledge
recent major advances in the creation of systems to improve
health and safety in the industry. It gives no attention to the
new proposed Mine Health and Safety Act, a legislative framework
constructed by labour, government and employers over a period of
several years.<br>
&nbsp;</p>

<p align="center"><font color="#008000" size="2">&nbsp;</font><font
color="#008000" size="5"><b>ends ...</b></font></p>

<p align="center"><font size="1" face="Arial"><b>Where not
attributed to Chamber or other executives, please feel free to
quote the above. <br>
The term &quot;spokesman&quot; or &quot;spokesperson&quot; is
acceptable instead of the title.</b></font></p>

<p align="center">&nbsp;</p>

<p align="center"><font color="#E30000"><strong>Please direct
enquiries to Llewellyn Kriel, <br>
Communication Manager: Media, Chamber of Mines of SA </strong></font><a
href="mailto:lkriel@bullion.org.za"><font color="#E30000"><strong>lkriel@bullion.org.za</strong></font></a></p>

<p align="center"><a href="/org1.htm"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../images/tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> </p>

<p align="left"><font size="2"><em> 1996, Chamber of Mines of
South Africa</em></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-491</DOCNO>
<DOCOLDNO>IA012-000130-B039-164</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/1996address_3.htm 196.26.82.193 19970217021852 text/html 5464
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:22:27 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Press Release</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font size="5"><strong><img
src="file:///F:/images/logo2.gif" width="102" height="64"></strong></font></p>

<p align="center"><font color="#008000" size="5"><em><strong>Press
Release</strong></em></font></p>

<p align="center"><font color="#FF0000" size="2"
face="Courier New"><b><u>EMBARGO:10h00, 5 November 1996</u></b></font></p>

<p align="center"><font size="4" face="Arial"><b>CHAMBER
RESTRUCTURED<br>
TO MEET MINING'S ADVOCACY NEEDS</b></font></p>

<p align="center"><font color="#800040" size="2"><strong> 5
NOVEMBER 1996</strong></font></p>

<p>THE CHAMBER OF MINES of SA has completed a restructuring
exercise begun some time ago to shift its fundamental focus to
the activity of lobbying with government, labour and &quot;other
significant protagonists in the national public policy
arena&quot;, the Chamber&#146;s outgoing president At du Plessis
told its <a
href="http://www.bullion.org.za/speeches/1996/PresidentialAddress_1996.htm">annual
general meeting</a> in Johannesburg today.&nbsp;</p>

<p>He said the creation of an institution with
&quot;advocacy&quot; as its primary operational function would
see &quot;a modernised entity competently positioned to represent
the interests of its members ... which are inseparably related to
the extensive process of legislative and regulatory review that
continues to preoccupy central government (and) ensure that the
mining industry&#146;s voice does not go unheard&quot;.&nbsp;</p>

<p>Against this backdrop, he said, the Chamber had embarked on a
vigorous drive to attract more members to enable it to be fully
representative of the entire SA mining industry. The
Chamber&#146;s constitution had been amended to eliminate
barriers to entry and make membership of the Chamber &quot;an
attractive and beneficial option&quot; to those companies still
outside its membership ranks.&nbsp;</p>

<p>&quot;Several major mining companies which have previously not
been full members of the Chamber have joined its ranks and indications
are that others will follow in due course,&quot; Du Plessis told
the meeting.&nbsp;</p>

<p>Among its advocacy roles in the past year, Du Plessis said the
Chamber had &quot;made constructive contributions to the Consultative
National Environmental Policy Process (CONEPP), and had succeeded
in limiting the impact on the mining industry of potentially
damaging provisions contained in the Development Facilitation
Act&quot;.&nbsp;</p>

<p>Other arenas of legislative review in which the Chamber had
been or was being active on behalf of its members were in the formulation
of the Labour Relations Act, the Mine Health and Safety Act, the
Employment Standards Act and the Manpower Training Act.&nbsp;</p>

<p>Discussions were continuing on the creation of a social plan
and around employment equity, he said. The Chamber, which is 106
years old this year, had also played a significant role in the
formulation of the Green Paper on minerals policy recently submitted
to the Minister of Minerals and Energy Penuell Maduna. &nbsp;</p>

<p>He added that the reversal of onus clauses - sections 86(2)
and (3) of the Mine Health and Safety Act which effectively makes
mine owners and managers guilty until proven innocent in the
event of a mine accident - remained problematic for the industry
and it &quot;refuses to endorse&quot; these sections. However,
the Chamber was in bilateral debate on these with the National Union
of Mineworkers and &quot;there is reason to believe that an
acceptable solution will be found&quot;.&nbsp;</p>

<p align="center"><font color="#008000" size="2">&nbsp;</font><font
color="#008000" size="5"><b>ends ...</b></font></p>

<p align="center"><font size="1" face="Arial"><b>Where not
attributed to Chamber or other executives, please feel free to
quote the above. <br>
The term &quot;spokesman&quot; or &quot;spokesperson&quot; is
acceptable instead of the title.</b></font></p>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<p align="center"><font color="#E30000"><strong>Please direct
enquiries to Llewellyn Kriel, <br>
Communication Manager: Media, Chamber of Mines of SA </strong></font><a
href="mailto:lkriel@bullion.org.za"><font color="#E30000"><strong>lkriel@bullion.org.za</strong></font></a></p>

<p align="center"><a href="/org1.htm"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../images/tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> </p>

<p align="left"><font size="2"><em> 1996, Chamber of Mines of
South Africa</em></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-492</DOCNO>
<DOCOLDNO>IA012-000130-B039-200</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/1996address_2.htm 196.26.82.193 19970217021915 text/html 8520
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:22:51 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Press Release b</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font size="5"><strong><img
src="file:///F:/images/logo2.gif" width="102" height="64"></strong></font></p>

<p align="center"><font color="#008000" size="5"><em><strong>Press
Release</strong></em></font></p>

<p align="center"><font color="#FF0000" size="2"
face="Courier New"><b><u>EMBARGO:10h00, 5 November 1996</u></b></font></p>

<p align="center"><font size="4" face="Arial"><b>CHAMBER
PRESIDENT CONFIDENT<br>
DESPITE SOME MINING SECTOR WOES</b></font></p>

<p align="center"><font color="#800040" size="2"><strong>5
NOVEMBER 1996</strong></font></p>

<p>DESPITE SOME disappointing production figures and the
prevailing negative sentiments towards, especially gold mining,
the outgoing President of the Chamber of Mines voiced generally
bullish sentiments at the organisation&#146;s 106<sup>th</sup>
annual general meeting in Johannesburg today.&nbsp;</p>

<p>Given the correct domestic climate in labour relations and an
enabling legislative environment from government&#146;s side, At
du Plessis said South African mining would remain buoyant and a
major contributor to the nation&#146;s wealth. He also pointed
that, despite unfavourable conditions in the gold mining
industry, several mega-projects were not only indicative of the
faith the industry had in its own future, but would contribute
considerably to offsetting such negative factors as the gold
price and the high cost-to-profit ratio.&nbsp;</p>

<p>&quot;With an estimated capital investment value approaching
R20-billion, the gold mining sector is considering the
development of several mega-ventures that will yield substantial
tonnages of gold and provide thousands of jobs well into the 21st
century,&quot; Du Plessis told the meeting.&nbsp;</p>

<p>&quot;One of these projects is aimed at exploiting a gold
reserve in excess of 60-million ounces. This is reliably believed
to be the biggest payable reserve anywhere in the world and, when
the mine comes fully on stream just after the turn of the
century, it will have a life of at least 60 years.&nbsp;</p>

<p>&quot;In the same area south west of Johannesburg, the
development of two major shaft systems is being considered.
Should this project proceed it will entail the sinking of two
mega-shafts costing in the region of R5-billion each. Mining
depths would be between 3 400 and 5 000 metres and estimated reserves
are in excess of 50-million ounces at an <i>in situ</i> grade of
12 grams per ton. The life of this project would be some 25
years,&quot; he said .&nbsp;</p>

<p>Additional development projects in northern Free State held an
estimated gold resource of 40-million ounces and a decision is imminent
on whether to proceed with a R3-billion capital investment for shaft
sinking and ancillary infrastructure, Du Plessis added.&nbsp;</p>

<p>&quot;These developments, linked to various other projects
within existing mines, uphold my view that South Africa&#146;s
gold production is likely to stabilise at an annual level of some
500 tons and that SA will remain the world&#146;s principal
producer of gold for many years to come.&quot;<font size="5">&nbsp;</font></p>

<p>Turning to coal and platinum, Du Plessis said coal sales
amounted to R13-billion last year and platinum group metals (PGM) sales
amounted to some R6,6-billion in 1995.&nbsp;</p>

<p>Regarding labour, Du Plessis said the current ongoing
re-organisation of work - including multi-tasking, multi-skilling
and a flattening of managerial and supervisory hierarchies -
should continue as they &quot;have significant potential to
reduce working costs and deliver productivity improvements in
both capital and labour&quot;.&nbsp;</p>

<p>However, he warned that Section Nine of the Mines and Works
Act - &quot;an antiquated provision which continues to prohibit most
mines from working on Sundays - endures as a grave impediment to
enhanced productivity. Combined with an excessive number of
public holidays - a total of 12 - and an 11-shift fortnight, some
90 days or 25 per cent of the working year are lost to the
industry not to mention the inevitable downtime in closing and
starting up a mine.&nbsp;</p>

<p>&quot;Clearly, if mining is to be allowed to make its best
possible contribution to reconstruction and development in South
Africa, the Chamber will need to persuade Government to adopt a
more flexible approach and to place the determination of operational
schedules in the negotiating arena shared by management and
organised labour.&quot; &nbsp;</p>

<p>Du Plessis emphasised that &quot;Cosatu seriously will have to
reconsider the stance it has adopted in Nedlac relating to Sunday work,
public holidays and hours of work. A revision of attitude is essential to
demonstrate Cosatu&#146;s sincerity in assisting the country to
grow economically.&quot;&nbsp;</p>

<p>He said flexible remuneration packages linked to productivity
achievements were already established paradigms in the mining industry,
and would become progressively prevalent as the integrated needs of
reducing working costs and improving productivity increasingly
govern operational imperatives. Associated with the many training
programmes currently in place and designed to promote personal development,
flexible remuneration packages will provide employees with the
opportunity to substantially determine their personal levels of
income, he added.&nbsp;</p>

<p>However, he warned management that the requirement to adapt to
new conditions and practices is by no means the exclusive responsibility
of employees. Management also had an obligation to review and,
where necessary, change its practices and views. Employee
participation in work-related issues was now essential and
management must be encouraged to do all that is possible to
create trust between themselves and employees.&nbsp;</p>

<p>&quot;Commitment to the personal growth of employees will need
to coincide with the creation of opportunities for promotion so that
positions of seniority more equitably correspond with South Africa&#146;s
population profile. This is by no means a project to be pursued
without impeccable attention being devoted to competence. The
frequently hazardous nature of mining operations demands that only
suitably qualified individuals occupy particularly those
positions of seniority which incorporate responsibility for the
lives of colleagues,&quot; Du Plessis said.&nbsp;</p>

<p>&quot;The positive consequence of an unequivocal commitment to
human development is a high level of trust between management and
employees.&quot; </p>

<p align="center"><font color="#008000" size="2">&nbsp;</font><font
color="#008000" size="5"><b>ends ...</b></font></p>

<p align="center"><font size="1" face="Arial"><b>Where not
attributed to Chamber or other executives, please feel free to
quote the above. <br>
The term &quot;spokesman&quot; or &quot;spokesperson&quot; is
acceptable instead of the title.</b></font></p>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<p align="center"><font color="#E30000"><strong>Please direct
enquiries to Llewellyn Kriel, <br>
Communication Manager: Media, Chamber of Mines of SA </strong></font><a
href="mailto:lkriel@bullion.org.za"><font color="#E30000"><strong>lkriel@bullion.org.za</strong></font></a></p>

<p align="center"><a href="/org1.htm"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../images/tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> </p>

<p align="left"><font size="2"><em> 1996, Chamber of Mines of
South Africa</em></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-493</DOCNO>
<DOCOLDNO>IA012-000130-B039-228</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/1996address.htm 196.26.82.193 19970217021934 text/html 4998
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:23:11 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Press Release a</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font size="5"><strong><img
src="file:///F:/images/logo2.gif" width="102" height="64"></strong></font></p>

<p align="center"><font color="#008000" size="5"><em><strong>Press
Release</strong></em></font></p>

<p align="center"><font color="#FF0000" size="2"
face="Courier New"><b><u>EMBARGO:10h00, 5 November 1996</u></b></font></p>

<p align="center"><font size="4" face="Arial"><b>CHAMBER AIMS TO
FACE CHALLENGES<br>
&quot;TRANSPARENTLY AND PRODUCTIVELY&quot;</b></font></p>

<p align="center"><font color="#800040" size="2"><strong>5
NOVEMBER 1996</strong></font></p>

<p>THE CHAMBER OF MINES recognised the need to confront &quot;all
reasonable challenges&quot; engendered by South Africa&#146;s transformation
transparently and productively, the outgoing president of the
organisation, At du Plessis, told its <a
href="http://www.bullion.org.za/speeches/1996/PresidentialAddress_1996.htm">annual
general meeting</a> in Johannesburg today.&nbsp;</p>

<p>He said the mining industry was &quot;still too frequently
accused of being wedded to the inequitable standards of the
previous era. It is an unwarranted accusation and one that
demands consistent repudiation, particularly in dealing with
members of Government.&quot;&nbsp;</p>

<p>In this context Du Plessis singled out &quot;the intolerable
eruptions of violence&quot; which were the subject of a recent
commission of enquiry. He added that the Chamber had already
publicly supported the recommendations from the chairman of that commission
that his terms of reference be extended to enable a thorough
probe into all mine violence.&nbsp;</p>

<p>&quot;It is now incumbent on all interested parties -
management and organised labour in particular - to create a
climate in which lethal assault is universally censured as a
mechanism for the resolution of grievance,&quot; Du Plessis said.
&nbsp;</p>

<p>&quot;Tribal affiliations, ethnic allegiances or any other
conflict-creating practices cannot be permitted to endure as a
rationale for murderous onslaught. Such activity has never been
condoned by the mining industry,&quot; he said. </p>

<p>The Chamber&#146;s support for an expanded investigation was
&quot;an unequivocal expression of its determination to identify
practical measures aimed at eradicating violence on mines,&quot;
Du Plessis told the meeting.&nbsp;</p>

<p>In the spirit of transparency Du Plessis said during the past
year the new Minister and Deputy Minister responsible for mining and
energy had visited the industry and committed themselves to the promotion
and protection of its interests and to improving its image.
&nbsp;</p>

<p>&quot;They are aware of the vital role mining has played and
must continue to play in the development of South Africa and its people.
The industry&#146;s obligation to them is to demonstrate that it
truly is bound to the democratic principles of the new South Africa.&nbsp;</p>

<p>&quot;With that accomplished the mining industry will
increasingly be left to conduct its business with minimum
Government intervention.&quot; he added.</p>

<p align="center"><font color="#008000" size="2">&nbsp;</font><font
color="#008000" size="5"><b>ends ...</b></font></p>

<p align="center"><font size="1" face="Arial"><b>Where not
attributed to Chamber or other executives, please feel free to
quote the above. <br>
The term &quot;spokesman&quot; or &quot;spokesperson&quot; is
acceptable instead of the title.</b></font></p>

<p align="center">&nbsp;</p>

<p align="center">&nbsp;</p>

<p align="center"><font color="#E30000"><strong>Please direct
enquiries to Llewellyn Kriel, <br>
Communication Manager: Media, Chamber of Mines of SA </strong></font><a
href="mailto:lkriel@bullion.org.za"><font color="#E30000"><strong>lkriel@bullion.org.za</strong></font></a></p>

<p align="center"><a href="/org1.htm"><img
src="../images/tb101.gif" alt="organisation" border="0"
width="101" height="17"></a> <a href="/res1.htm"><img
src="../images/tb102.gif" alt="Resources" border="0" width="101"
height="17"></a> <a href="/kruger.htm"><img
src="../images/tb104.gif" alt="Krugerrand" border="0" width="101"
height="17"></a> <a href="/new.htm"><img
src="../images/tb105.gif" alt="What's New?" border="0"
width="101" height="17"></a> <a href="/info.htm"><img
src="../images/tb106.gif" alt="Contacting us" border="0"
width="101" height="17"></a> </p>

<p align="left"><font size="2"><em> 1996, Chamber of Mines of
South Africa</em></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-494</DOCNO>
<DOCOLDNO>IA012-000130-B040-42</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/myburgh2.htm 196.26.82.193 19970217021958 text/html 6524
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:23:29 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>CHAMBER OF MINES SUPPORTS WIDER PROBE INTO MINE VIOLENCE
<BR> (Monday, 14 October 1996)</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>







In a letter to President Nelson Mandela, the Chamber of Mines has given its unreserved support for the extension of the terms of reference of the Myburgh Commission of Inquiry into mine violence, and has offered full co-operation in such a probe.<BR><P>
In his report to President Mandela after probing recent incidents of violence on three mines within the Gold Fields group, Judge John Myburgh requested that his terms of reference be extended for six months to discuss with the Chamber of Mines, the National Union of Mineworkers and other interested parties "what steps, if any, must be taken to address issues such as migrant labour, the hostel system on SA mines and inter-group violence on mines".<BR><P>
In his letter to President Mandela, the President of the Chamber of Mines, At du Plessis, said:  "I wish to advise you that all the members of the Chamber support, without reservation, the recommendations ... regarding the extension of the terms of reference of the Myburgh Commission. The members of the Chamber will co-operate fully with this Commission in an endeavour to arrive at sound conclusions on the steps that might be taken, if any, to address issues such as migrant labour,  the hostel system and inter-group violence."<BR><P> 
Du Plessis also pointed out that Judge Myburgh had put his recommendation to 
the parties involved in the recent inquiry and that, following an adjournment for
legal representatives to take instructions, he was informed that all parties 
supported the recommendation.<BR><P>
Copies of the Chambers letter were also sent to Minister of Labour Tito Mboweni, Minister of Mineral and Energy Affairs Penuell Maduna, and James Motlatsi, President of the National Union of Mineworkers.<BR><P>
<I>Full text of letter follows:</I><BR><P> 

<FONT SIZE=3 COLOR=800080>
14 October 1996<BR><P>


President N R Mandela<BR>
Private Bag X1000<BR>
CAPE TOWN<BR>
8000<BR><P>


Dear Mr Mandela<BR><P>

<B>REPORT OF MYBURGH COMMISSION OF INQUIRY INTO RECENT VIOLENCE AND OCCURRENCES ON CERTAIN MINES.</B><BR><P>

The Chamber of Mines has just had sight of the report of the Commission of Inquiry appointed to investigate the recent violence and occurrences at three mines that are members of the Chamber. The recommendations made by the Myburgh Commission can be classified into two distinct categories, namely:<BR><P>

1.	a series of recommendations on action to be taken in the short and medium term by the three mines concerned as well as the other stakeholders directly or indirectly involved in the recent violence and other occurrences; and<BR><P>

2.	a recommendation that you extend the terms of reference of the Myburgh Commission for a period of six months, and that during this period "the chairman of the Commission must preside at meetings, called by him, of senior representatives of the Chamber of Mines, NUM, and other interested parties. At the meetings the parties must discuss, and try to reach agreement on, what steps, if any, must be taken to address issues such as migrant labour, the hostel system on South African mines, and inter-group violence on mines" (Clauses 10.1 and 10.2 of the Commissions report).  In clause 30.12, Judge Myburgh states that he put this recommendation to the parties during argument.  When the Commission reconvened following an adjournment to allow legal representatives to take instructions, he was informed that all parties supported the recommendation.<BR><P>

The recommendations referred to in 1 above deal with action to be taken by specified mines and other involved stakeholders whereas the recommendations referred to in 2 above would, if accepted, directly affect others in the mining industry.<BR><P>

I have been informed by the managements of East Driefontein, Leeudoorn and Northam that they endorse the Commissions recommendations regarding the short and medium term action to be taken to normalise the situation on these three mines.<BR><P>

I also wish to advise you that all the members of the Chamber support, without reservation, the recommendations quoted in 2 above regarding the extension of the terms of reference of the Myburgh Commission. The members of the Chamber will co-operate fully with this Commission in an endeavour to arrive at sound conclusions on the steps that might be taken, if any, to address issues such as migrant labour,  the hostel system and inter-group violence. <BR><P>

I am taking the liberty of sending copies of this letter to Mr Tito Mboweni, Minister of Labour, Mr Penuell Maduna, Minister of Minerals and Energy, and Mr James Motlatsi, President of the National Union of Mineworkers.<BR><P>

Yours sincerely<BR>
A J du Plessis<BR>
PRESIDENT<BR><P></FONT>




<p>Enquiries to LLEWELLYN KRIEL, Communication Manager: Media <a href="mailto:lkriel@bullion.org.za">lkriel@bullion.org.za</a><br>
</p>
<p><a href="/main.htm"><img src="/images/nb1.gif" alt="Main Menu" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
</p>
<p><br>
<img src="/images/line3.gif" align=middle width=590 height=2><br>
</p>
<p><a href="/org1.htm"><img src="/images/tb101.gif" alt="organisation" align=bottom border=0 width=101 height=17></a> <a href="/res1.htm"><img src="/images/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></a> <a href="/ess1.htm"><img src="/images/tb103.gif" alt="Essentials" align=bottom border=0 width=101 height=17></a> <a href="/kruger.htm"><img src="/images/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></a> <a href="/new.htm"><img src="/images/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></a> <a href="/info.htm"><img src="/images/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></a> <br>
</p>
</body>

</html>



</DOC>
<DOC>
<DOCNO>WT14-B39-495</DOCNO>
<DOCOLDNO>IA012-000130-B040-67</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/krugrnew.htm 196.26.82.193 19970217022026 text/html 3431
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:23:53 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>KRUGERRAND READIES FOR EVENTUAL END TO EXCHANGE CONTROL<BR> (Friday, 11 October 1996)</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>



In a move aimed at preparing South African sales of Krugerrand coins to follow the same system as sales on world markets, the Chamber of Mines, which markets Krugerrands, has changed the tendering system for SA banks with effect from 11 October 1996.<BR><P>
The new system, whereby local banks tender for the number of Krugerrands and in  the various denominations they require weekly, is based upon two future (and thus unknown) gold fixings rather than on two historical fixings as in the past. This is the same system used on the rest of the worlds gold coin markets.<BR><P>
The Chambers gold marketing consultant, Dan Pollnow, explains: "Once exchange controls fall away, there will be no reason to remain outside of the world system."<BR><P>
The Chamber of Mines makes at least 6 000 ounces of Krugerrands in the four denominations - one ounce, half-ounce, quarter-ounce and one-tenth ounce - weekly. Tenders close on a Friday morning, and coins are sold to the highest tenderers on the following Monday afternoon.<BR><P>
"In the past, South African banks would place their tenders with the Chamber each Friday morning, based on the gold price as at two fixings during the immediately preceding Thursday.<BR><P>
"In future, and in line with international practice, they will place their tenders based on a view they might take of the gold fixings on that Friday afternoon and the following Monday morning," says Pollnow.<BR><P>
He adds the change should not have any significant effect on local banks, except insofar as they will be required to operate in the same way as bullion dealers buying Krugerrands for the international market.<BR><P>


<p>Enquiries to LLEWELLYN KRIEL, Communication Manager: Media <a href="mailto:lkriel@bullion.org.za">lkriel@bullion.org.za</a><br>
</p>
<p><a href="/main.htm"><img src="/images/nb1.gif" alt="Main Menu" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
</p>
<p><br>
<img src="/images/line3.gif" align=middle width=590 height=2><br>
</p>
<p><a href="/org1.htm"><img src="/images/tb101.gif" alt="organisation" align=bottom border=0 width=101 height=17></a> <a href="/res1.htm"><img src="/images/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></a> <a href="/ess1.htm"><img src="/images/tb103.gif" alt="Essentials" align=bottom border=0 width=101 height=17></a> <a href="/kruger.htm"><img src="/images/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></a> <a href="/new.htm"><img src="/images/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></a> <a href="/info.htm"><img src="/images/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></a> <br>
</p>
</body>

</html>





</DOC>
<DOC>
<DOCNO>WT14-B39-496</DOCNO>
<DOCOLDNO>IA012-000130-B040-109</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/wages96.htm 196.26.82.193 19970217022051 text/html 4957
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:24:25 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title></title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#000080" vlink="#001F76">
<h3 align=center><b>CHAMBER &amp; NUM SIGN CRUCIAL WAGE AGREEMENT- </b></h3>
<h3 align=center><b>(13h30, Wednesday, 11 Sept. 1996)</b><br>
</h3>
<p>Agreement has been reached between the Chamber of Mines of South Africa and the National Union of Mineworkers 
(NUM) on the <a href="/agreements/wage96.htm">1996 review of wages and other conditions of employment</a>. The review covers conditions applicable to the 
194 000-odd NUM members employed in the category 1 to 8 bargaining unit on gold and coal mines which are members of 
the Chamber.<br>
</p>
<p>The minimum wage rates that apply to mines associated with the different mining houses have been adjusted across the various 
surface and underground employment grades in the following ranges:<br>
</p>
<p><b>Gold Mines</b><br>
Anglo American Corp (Gold &amp; Uranium Division) - 9,5% to 10%<br>
Avmin - 8,5% to 10%<br>
Gengold - 8,5% to 10%<br>
Gold Fields (Gold) - 8,5% to 9,5%<br>
JCI (Gold Division) - 8,01% to 9,51%<br>
The increases agreed upon for mines associated with Randgold vary from mine to mine and are in the range of 5% to 10,4%<br>
</p>
<p><b>Collieries</b><br>
Amcoal - 9,25% to 10,75%<br>
Ingwe - 9,25% to 10,75% <br>
Duiker - 8,9% to 13% (these increases encompass an alignment of certain rates)<br>
Gold Fields (Coal) - 9,5% to 9,75%<br>
JCI (Coal Division) - 8,38% to 10%<br>
Kangra - 9,25% to 10%<br>
</p>
<p>Among other matters, the agreement between the Chamber and NUM also deals with:<br>
</p>
<p>&#183; The restructuring of the Mineworkers&#146; Provident Fund and the Mineworkers&#146; Assurance and Benefits Scheme in 
accordance with certain principles as agreed. The restructuring process will be undertaken by a joint working party. 
Agreement has also been reached on the contribution rates for 1996/97 and 1997/98. <br>
</p>
<p>&#183; A framework agreement on industrial-relations related education and training. In terms of this framework there will be joint 
development at Group or mine level of training modules, with employers financing the development and presentation of the 
training. <br>
</p>
<p>&#183; The granting of paid leave to representatives on specified tripartite bodies for the purpose of attending meetings of such 
bodies. These bodies pertain in particular to the interests of the mining industry - including those established in terms of the 
new Mine Health and Safety Act and the Mining Qualifications Authority among others.<br>
</p>
<p>&#183; Seven days unpaid paternity leave per annum.<br>
</p>
<p>&#183; The position of employees whose services are terminated due to statutory occupational diseases and injuries sustained on 
duty.<br>
</p>
<p>&#183; The establishment of a working party to consider the possibility of a two-year wage review cycle.<br>
</p>
<p>&#183; In principle agreement that it is desirable for a statutory bargaining forum to be instituted by the Chamber and its collective 
bargaining partners, and the establishment of a working party to make recommendations on the manner in which this should be 
given effect.<br>
</p>
<p>&#183; Agreement that the activities of the job grading committee (which was agreed to in 1995) will be continued, and that the 
issue of broadbanding will be addressed by the committee.<br>
</p>
<p>Enquiries to LLEWELLYN KRIEL, Communication Manager: Media <a href="mailto:lkriel@bullion.org.za">lkriel@bullion.org.za</a><br>
</p>
<p><a href="/main.htm"><img src="/images/nb1.gif" alt="Main Menu" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#top"><img src="/images/nb2.gif" alt="Top of Page" align=middle border=0 hspace=20 width=60 height=17></a> <a href="#toolbar"><img src="/images/nb3.gif" alt="Toolbar" align=middle border=0 hspace=20 width=80 height=17></a> <br>
<br>
</p>
<p><br>
<img src="/images/line3.gif" align=middle width=590 height=2><br>
</p>
<p><a href="/org1.htm"><img src="/images/tb101.gif" alt="organisation" align=bottom border=0 width=101 height=17></a> <a href="/res1.htm"><img src="/images/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></a> <a href="/ess1.htm"><img src="/images/tb103.gif" alt="Essentials" align=bottom border=0 width=101 height=17></a> <a href="/kruger.htm"><img src="/images/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></a> <a href="/new.htm"><img src="/images/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></a> <a href="/info.htm"><img src="/images/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></a> <br>
</p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-497</DOCNO>
<DOCOLDNO>IA012-000130-B040-136</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/dsput96.htm 196.26.82.193 19970217022106 text/html 4037
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:24:45 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Chamber of Mines of SA: Press Release</title>
</head>

<body bgcolor="#FFFFFF" text="#0000A0">

<p align="center"><font size="5"><strong><img
src="file:///F:/images/logo2.gif" width="102" height="64"></strong></font></p>

<p align="center"><font color="#008000" size="5"><em><strong>Press
Release</strong></em></font></p>

<p align="center"><font size="4" face="Arial"><strong><u>NUM
DECLARES DISPUTE WITH CHAMBER ON WAGE TALKS </u></strong></font></p>

<p align="center"><font color="#0080FF" size="3"><strong><i>The
Chamber of Mines' chief negotiator, Dr Frans Barker, issued the
following statement on 1 August 1996.</i></strong></font><font
color="#0080FF"><strong><br>
</strong></font></p>

<p>&quot;On 31 July and 1 August 1996 the Chamber of Mines and
the National Union of Mineworkers (NUM) held further meetings in
their 1996 round of wage negotiations. The negotiations cover the
wages and other conditions of employment for NUM members employed
on gold and coal mines, members of the Chamber.</p>

<p>&quot;The parties have not at this stage been able to reach
agreement on increases to minimum wage rates. The Chamber has tabled
differential wage increase offers for the mines of the different
mining Houses. The offers vary in the case of coal mines in a
range of up to 9 10%. The wage offers for gold mines are in a
range of up to 7,5%. The NUM&#146;s wage demand is for a 13%
increase in all cases.</p>

<p>&quot;The NUM has indicated that it intends at this time to
apply to the Department of Labour for the establishment of a conciliation
board. That board will likely be charged with attempting to reach
agreement between the parties.</p>

<p>&quot;Apart from minimum wage increases, the following items
have also not as yet been resolved:<br>
 The financing of industrial relations education and training.<br>
 Additional payment for maternity leave.<br>
 Additional compensation for employees whose services have been
terminated on medical grounds.<br>
 Broadbanding in respect of Gold Fields&#146; mines.<br>
 Implementation date.</p>

<p>&quot;Apart from the above items, there are a number of mining
House and mine-specific issues which are also outstanding.</p>

<p>&quot;The parties both expressed the hope that the process
could be taken forward in the constructive and positive fashion
that has characterised the negotiations thus far.&quot;</p>

<p align="center"><strong>Please direct enquiries to Llewellyn
Kriel, <br>
Communication Manager: Media, Chamber of Mines of SA </strong><a
href="mailto:lkriel@bullion.org.za"><strong>lkriel@bullion.org.za</strong></a></p>

<p align="center"><a href="/main.htm"><img src="/images/nb1.gif"
alt="Main Menu" align="middle" border="0" hspace="20" width="60"
height="17"></a> <a href="#toolbar"><img src="/images/nb3.gif"
alt="Toolbar" align="middle" border="0" hspace="20" width="80"
height="17"></a> <br>
<br>
<img src="/images/line3.gif" align="middle" width="590"
height="2"><br>
</p>

<p align="center"><a href="/org1.htm"><img
src="/images/tb101.gif" alt="organisation" border="0" width="101"
height="17"></a> <a href="/res1.htm"><img src="/images/tb102.gif"
alt="Resources" border="0" width="101" height="17"></a> <a
href="/kruger.htm"><img src="/images/tb104.gif" alt="Krugerrand"
border="0" width="101" height="17"></a> <a href="/new.htm"><img
src="/images/tb105.gif" alt="What's New?" border="0" width="101"
height="17"></a> <a href="/info.htm"><img src="/images/tb106.gif"
alt="Contacting us" border="0" width="101" height="17"></a> </p>

<p align="left"><font size="2"><em> 1996, Chamber of Mines of
South Africa</em></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT14-B39-498</DOCNO>
<DOCOLDNO>IA012-000130-B040-158</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/constit1.htm 196.26.82.193 19970217022120 text/html 2635
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:25:02 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>THE PRESIDENT OF THE CHAMBER OF MINES OF S.A. COMMENTS ON THE OMISSION FROM THE NEW CONSTITUTION OF THE REPUBLIC OF SOUTH AFRICA OF A CLAUSE SECURING EMPLOYERS' RIGHT TO LOCKOUT STRIKERS AS A BALANCE TO WORKERS' RIGHT TO STRIKE, WHICH <U>IS </U>ENTRENCHED IN THE CONSTITUTION
- Wednesday, 8 May 1996</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>




"The Chamber of Mines and its members are disturbed that the right to lock-out has been omitted as an equitable balance to the right to strike in South Africas new Constitution, and are deeply concerned that revisions to wording regarding the Labour Relations Act (LRA) fail to safeguard employers against the might of labour.<BR><P>
"Section 241.2 merely provides for 'consultation' regarding amendments to the LRA, and makes no provision for negotiation. This is very worrying against the backdrop of Cosatus (the Congress of South African Trade Unions) recent bully-boy tactics which underline the federations<A HREF="http://www.bullion.org.za/releases/nostrike.htm"> preference for threats</A> and confrontation over negotiation.<BR><P>
We are also acutely aware of the difficulties faced by those who oppose the might of Cosatu and the ANC, no matter how reasonable and justifiable their positions may be."<BR><P>

<I>Issued in the name of the President of the Chamber of Mines,<B> Mr At du Plessis</I></B><BR><P>


<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>




</DOC>
<DOC>
<DOCNO>WT14-B39-499</DOCNO>
<DOCOLDNO>IA012-000130-B040-187</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/unctad.htm 196.26.82.193 19970217022139 text/html 3786
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:25:14 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>MARGIN FOR ERROR IN POLICY MAKING GREATLY REDUCED, CHAMBER CEO (Thursday, 2 May 1996)</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>



IT IS CRITICAL that correct decisions are taken to ensure reconstruction and development is meaningful and sustainable since the margin for error in policy making had been reduced dramatically in the last two decades, Chamber of Mines CEO Tom Main said today.<BR><P>
In his capacity as chairman of the International Chamber of Commerce - South Africa (ICC-SA), <A HREF="/speeches/Africa_Connect.htm">Main was opening the United Nations Conference on Trade and Development (UNCTAD)/Africa Connect conference</A>, and warned that the world we have re-entered has reduced national policy options amid greater demands for international compliance, especially in terms of the global trade regime.<BR><P>
"Consequently, SA will have to manage its reconstruction and development in a context of diminished national sovereignty," Main said.<BR><P>
"South Africas future will, to a great extent, be determined by its success in re-integrating with the global economy, he said. However, we need to recognise that SA forms part of a community and, as such, requires the assistance of a wide range of global partners, including international organisations and national governments."<BR><P>
He said it was ICC-SAs firm conviction that an equitable and sensible world trade regime would "contribute immeasurably to alleviating global poverty and dissolving the artificial and harmful North-South polarisation".<BR><P>
He said he was "cautiously optimistic" that government was pursuing enlightened policy reforms that would help develop SA into a truly world-class player.<BR><P>
Although SAs relationships with the rest of Africa had developed spectacularly, Main warned that the direction of flows had been somewhat singular. Noting this was a function of the market rather than SA hegemony, he said the country should be acutely aware of the need to develop strong reciprocal trade flows through the continent.<BR><P>
"It is imperative that African countries integrate themselves more effectively into the global economy by pursuing policies that are aligned with international trends. Similarly, Africa needs access to new markets and improved access to existing ones.<BR><P>
"The increasing use of informal protectionist trade measures must be strongly condemned because of the multiple impacts on developing countries" Main told the conference in Midrand.<BR><P>



<center>

<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT14-B39-500</DOCNO>
<DOCOLDNO>IA012-000130-B040-209</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/krparis.htm 196.26.82.193 19970217022152 text/html 3233
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:25:32 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>KRUGERRAND LAUNCHES ON PARIS BOURSE TODAY - (Friday, 26 April 1996)</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>




SOUTH AFRICAs best known internationally branded product, the Krugerrand, will be launched on the gold market of the Paris Bourse at 12 noon today.<BR><P>
The chairman of the SA Chamber of Mines Gold Producers Committee, Kelvin Williams, announced the debut of the one ounce denomination of the worlds foremost gold coin on the French exchange at a function in Paris last night. VIP guests included new SA Finance Minister Trevor Manuel and SAs ambassador to France, Barbara Masekela.<BR><P>
Williams explained that, to enable gold coins to be traded free of VAT in France, they had to be listed on the Paris Bourses gold market.  He said gold coins, and the Krugerrand in particular, gave the man-in-the-street convenient access to gold, and the French people had a renowned fondness for the metal, both for its value and its beauty.  The Krugerrand had become accepted as a financial instrument and would now occupy such a role on the Paris Bourse, Williams said.<BR><P>
Since its introduction in 1967, the Krugerrand had reached global pre-eminence, and there were now twice as many Krugerrands in circulation as all other gold bullion coins combined. Williams said the Krugerrand had single-handedly created a new sector of demand for gold, and had already consumed some 1 500 tons of gold - three times SAs current annual production.<BR><P>
Despite the VAT concessions in France, resale of gold in that country was subject to a 8% tax rate. Williams said he hoped this would be relaxed or eliminated in the near future.<BR><P>
Frances biggest operator in the gold coin market, CPR-Or, has been appointed a Krugerrand distributor, Williams said, adding that research had also confirmed solid consumer interest in gold coins.<BR><P>

<A HREF="http://www.bullion.org.za/speeches/bourse.htm">Full text of speech by Kelvin Williams</A>
<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>



</DOC>
<DOC>
<DOCNO>WT14-B39-501</DOCNO>
<DOCOLDNO>IA012-000130-B041-12</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/nostrike.htm 196.26.82.193 19970217022218 text/html 2783
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:25:59 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>STRIKE CALL CONFIRMS COSATU'S PREFERENCE FOR THREATS OVER NEGOTIATION (Thursday, 25 April 1996)</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>


"THE HARD LINE attitude adopted by the Congress of South African Trade Unions on the constitutional lockout clause confirms the perception that Cosatu prefers threats and consequent damage to the national economy rather than exhausting the negotiation process," the President of the Chamber of Mines, At du Plessis, said today.<BR><P>
"Meaningful interaction aimed at exploring all possible routes to mutually acceptable solutions to areas of dispute, must supersede decisions to resort to damaging and confrontational industrial action - particularly stayaways and strikes.<BR><P>
"After many years of selective political deprivation, South Africa now has a democracy, and all parties should be attempting more assiduously than ever to embrace appropriate democratic principles to resolve differences. Threats of stayaways and strikes such as planned by Cosatu for Tuesday are far removed from the spirit of democratic goodwill that should and can prevail in SA.<BR><P>
"We are all aware that stayaways and strikes, no matter how short-lived, seriously damage our economy and undermine critical investor confidence - both domestic and foreign.   South Africa is in need of high economic growth rates, and actions by all parties involved should be aimed at obtaining exactly that - and not pursuing activities that will result in the opposite."<BR><P>

<center>

<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>







</DOC>
<DOC>
<DOCNO>WT14-B39-502</DOCNO>
<DOCOLDNO>IA012-000130-B041-38</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/fincttee.htm 196.26.82.193 19970217022259 text/html 5672
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:26:35 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>CHAMBER OF MINES TELLS PARLIAMENTARY FINANCE COMMITTEE: BUDGET DOES NOT HELP JOBS, GROWTH
</b></TITLE><br>                  
                  
<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>

EMBARGO : 16H00, WED. 20 MAR. 1996<BR><P>


Addressing the Parliamentary Joint Standing Committee on Finance today, Chamber of Mines chief executive Tom Main said the 1996/97 Budget had failed actively to address job creation, growth and development, was politically timid with no clear priorities and merely postponed the day of serious government expenditure control and drastic reduction of the budget deficit.<BR><P>
He related the Budget to Deputy President Thabo Mbekis "A Framework for Growth and Development" presented in February, and said the Chamber supported the broad goals and macro-economic policy directions signalled in the last three annual budgets. He concluded, however,  that the budget presented last week had failed to translate these broad policy objectives into practical and concrete measures which would create the necessary environment for sustained growth, job creation and development.<BR><P>
Main said it could be argued legitimately that "every policy should now be tested against the question: Will it support or reduce job creation and job preservation?".<BR><P>
He pointed out that governments role in the economy was to set basic rules and influence growth and development, but that it had to guard against taxes impeding economic activity, especially through discouraging investment, permitting runaway government spending and facilitating budget deficit growth.<BR><P>
Main said Finance Minister Chris Liebenbergs Budget lacked a vision on how to effect sustainable job creation by failing to allow free enterprise to flourish. He said it was the belief of the Chamber, representing the bulk of SAs mining industry, that government must help create favourable conditions for private sector growth.<BR><P>
Identifying five primary areas of focus - government spending, Budget deficit, fiscal control, growth and savings and investment - Main gave a detailed analysis of the Budgets failure to meet its objectives.<BR><P>
"High government spending is threatening to choke the private sector through high taxes," Main told the committee. "International comparisons indicate SA is increasingly diverging from world trends."<BR><P>
Since SA competes globally for capital, export markets and resources, it was imperative that local government macro-economic management be brought in line with the rest of the world. This was not happening rapidly enough.<BR><P>
Main also warned that governments tendency increasingly to finance current spending from loans and the growing burden of servicing such debt could see SA fall into the same destructive spiral that afflicted many Latin American countries, and had caused even higher levels of unemployment in those countries.<BR><P>
In averting fiscal crisis,  government needed to gradually ease tax rates towards internationally acceptable levels, streamline its spending to focus on economic growth and the very poor, and aggressively pursue the privatisation of parastatals to ease its own fiscal burden.<BR><P>
Prerequisites for growth were efficiency, competitiveness, private ownership, the rule of law and macro-economic stability. Government was urged to deregulate to a greater extent, eliminate services which could be better provided by private suppliers and step up moves towards contracting out.<BR><P>
On savings and investments, Main said gross domestic savings had fallen to 16,5% of GDP, well below the level necessary to sustain investment and growth, while gross domestic fixed investment at 16,8% of GDP was far below the 30% in most rapidly growing countries.<BR><P>
Main said the Chamber understood the reasons for not increasing the VAT rate this year, but, nevertheless, had to draw attention to the fact that this decision encouraged consumption and discouraged savings. <BR><P>
"It is essential the fiscal system more rapidly moves toward taxing consumption rather than income," Main said.<BR><P>

For details of the 1996/97 SA Budget :<BR> 
<A HREF="http://www.saica.co.za">http://www.saica.co.za</A> or 
<A HREF="http://www.iafrica.com">http://www.iafrica.com </A> or
<A HREF="http://www.atd.co.za/fm">http://www.atd.co.za/fm </A><BR><P>
See also:<A HREF="http://www.bullion.org.za/96budcom.htm"> http://www.bullion.org.za/96budcom.htm</A>


<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT14-B39-503</DOCNO>
<DOCOLDNO>IA012-000130-B041-67</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/96budcom.htm 196.26.82.193 19970217022315 text/html 4625
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:26:55 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>CHAMBER OF MINES SAYS BUDGET IS "POLITICALLY TIMID"</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>

<B>The  President of the Chamber of Mines,  At du Plessis, comments on the 1996/97 SA Budget: 13 March 1996<BR><P></B>
THE CHAMBER OF MINES views todays Budget as politically timid, postponing the day of serious deficit and expenditure reduction.<BR><P>
We certainly welcome the reductions in the secondary tax on companies (STC) and, most importantly, the small reduction in the formula tax rate for gold mines. <BR><P>
However, we share the doubts expressed by others that so small an increase in the police budget will contribute meaningfully towards the implementation of effective provincial and central government initiatives to fight crime. The high crime rate in SA is still one of the most serious deterrents to investment.<BR><P>
Furthermore, without significant relief from tax costs, we are less able to achieve the levels of growth and job creation we all agree are needed. The benefits of tax cost reduction are important, even if we ignore the existence of international competition.<BR><P>
The Budget does not reduce meaningfully the disparities in the business and investment environments between South Africa and its major competitors. <BR><P>
This means capital flows into the country will continue to be speculative and not made into any productive capacity with concurrent employment benefits. What is required is a macro-economic and fiscal environment that does not disadvantage the SA business and investment communities compared with other countries.<BR><P>
While governments commitment to job creation is laudable and to be welcomed, the absence of any concrete provisions to give substance to the sentiments voiced was conspicuous.<BR><P>
Job creation cannot be achieved riding purely on the back of social upliftment - important though the latter is. The only way to create sustainable employment opportunities would be through massive growth in the private sector.<BR><P>
 The Chamber sees governments intention to implement a 17% tax on gross interest income and net rental income of retirement funds as premature in the light of the recommendation of the Smith Committee that government should develop an overall policy on retirement provision as a matter of priority. <BR><P>
Nevertheless, despite the pressure on Minister Liebenberg to secure substantial additional tax revenue from the retirement industry, the 17% rate is preferable to the 30% recommended by the Katz Commission.<BR><P>
The Chamber would have preferred the budget to have followed the international norm of moving from direct to indirect taxation. VAT exemptions on basic foodstuffs already provide relief to low-income households, and a 1% increase in the VAT rate would have little impact on inflation. This would have provided more room for the abolition of STC and more meaningful reduction in the deficit.<BR><P>
We welcome the setting up of the Expenditure Analysis Unit and the State Debt Management Authority, which will go a long way towards more effective and efficient government expenditure.<BR><P>
For details of the 1996/97 SA Budget : 
<A HREF="http://www.saica.co.za">http://www.saica.co.za</A> or 
<A HREF="http://www.iafrica.com">http://www.iafrica.com </A> or
<A HREF="http://www.atd.co.za/fm">http://www.atd.co.za/fm </A>



<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT14-B39-504</DOCNO>
<DOCOLDNO>IA012-000130-B041-94</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/safebill.htm 196.26.82.193 19970217022342 text/html 3414
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:27:13 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>
<center><b><h3>DRAFT MINE HEALTH AND SAFETY BILL - KEY ROLE FOR  PARLIAMENTARY PORTFOLIO COMMITTEE (Sunday, 10 March 1996)</b></TITLE><br>                  
                  

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>

Mining employers are optimistic that the new draft Mine Health and Safety Bill due to be considered by the Parliamentary Portfolio Committee on Mineral and Energy Affairs this week has potential to bring about improvements in mine safety and health, provided certain points of difference are wisely resolved.<BR><P>
In a submission to the committee on Friday, employers warned that the collective effect of certain provisions - and the absence of others - could render important aspects of the Bill impractical, and that these mitigated against the achievement of improvements in mine health and safety which the proposed new legislation seeks to effect.<BR><P>
The employers, who include members of the Chamber of Mines and other mining companies collectively employing about 95% of the 595 000 workers on SA mines, had accepted right at the outset of the process that it would be appropriate for the parliamentary portfolio committee to resolve any outstanding issues between negotiating partners, and will present their views to the committee this week.<BR><P>
Employers stressed that the draft Bill was the product of intensive tripartite negotiations and that, while the bulk of its provisions reflected areas of agreement between employers, labour and the government mining engineers department, certain important aspects remained unresolved.<BR><P>
These included, among others, deprivation of access to the Supreme Court; the inability of courts to suspend an inspectors order on an urgent appeal prior to a full court hearing, even when justified; and inconsistent application of requirements that mine managers take reasonably practicable safety measures.<BR><P>
Employers also strongly believe that, in relation to the responsibilities of mine owners and managers, the inclusion in the Bill of a provision based on the concept of being guilty until proven innocent is unconstitutional, contrary to a fundamental principle of democratic society and was unacceptable. <BR><P>

<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>




</DOC>
<DOC>
<DOCNO>WT14-B39-505</DOCNO>
<DOCOLDNO>IA012-000130-B041-120</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/mdbaparl.htm 196.26.82.193 19970217022400 text/html 3259
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:27:42 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>

<center><b><h3>CHAMBER OF MINES WELCOMES MANDELA'S CALL FOR INDUSTRY RESTRUCTURING</b></TITLE><br>                  

                  



<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>





WHILE WELCOMING President Nelson Mandelas call during his opening of parliament on Friday to restructure the mining industry, the Chamber of Mines has warned that such a process cannot succeed without the full commitment and co-operation of government.<BR><P>

"The SA mining industry is fully supportive of President Mandelas positive speech and his calls for a 'new patriotism' and renewed efforts to build prosperity for all," said Chamber president At du Plessis.<BR><P>

"The mining industry is already well-advanced in extensive restructuring efforts, and President Mandelas calls in this regard are therefore welcomed. However, government has a pivotal role to play in assisting and enabling us to propel the process toward effective conclusion," he said.<BR><P>

"Mining sadly remains heavily encumbered by the debilitating burden of archaic and prejudicial laws such as those prohibiting Sunday blasting.  Such laws have no place in the kind of future the President envisages, and severely hamstring our efforts to restructure and save and even create jobs."<BR><P>

Commenting on statements made by Mandela during a television interview last night, Du Plessis said the mining industry fully recognised its responsibility in terms of international competition and did not look to government for protection. "However, our best efforts in the international arena will come to naught unless we are free to compete on an equal footing. It is governments responsibility to assist in this by creating the kind of enabling environment the industry and indeed the country needs," he said.<BR><P>

A meaningful and durable process of restructuring mining in SA could only succeed with the complete commitment and active support of all three parties involved - government, labour and management, Du Plessis said.<BR><P>



<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>








</BODY>

</HTML>
</DOC>
<DOC>
<DOCNO>WT14-B39-506</DOCNO>
<DOCOLDNO>IA012-000130-B041-165</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/petlsign.htm 196.26.82.193 19970217022429 text/html 3550
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:28:02 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>



<center><b><h3>CHAMBER OF MINES & NUM SIGN LONG-AWAITED P.E.T.L. AGREEMENT

      </b></TITLE><br>                  

                  



<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>



THE CHAMBER OF MINES OF S.A. and the National Union of Mineworkers today signed an agreement outlining the principles of Paid Education and Training Leave (PETL) in the mining industry.<BR><P>

Some 12 months in the making, the PETL agreement follows on last years signing of the Adult Basic Education and Training (ABET) agreement between the Chamber and NUM, and signifies another important step in developing the skills and competencies of SAs hundreds of thousands of mineworkers.<BR><P>

Chamber President At du Plessis said the agreement and the mine-level procedures under its auspices could now be co-ordinated into the system to be developed by the Mining Qualifications Authority (MQA) expected to be established under the new Mine Health and Safety Act due later this  year.<BR><P>

"The focus of the MQA will be on competency orientation" he said, which meant skills acquired by miners, although originally intended to meet the needs of the mine providing such training, would be portable to other industries.  This would have a positive impact in the event of retrenchment of workers.<BR><P>

Du Plessis went on to say the agreement should not be seen in isolation since it was part of a "process of integrated human resource development acknowledging the primacy of education and training".<BR><P>

Acting NUM president, Gwede Mantashe, said the agreement would enable employers and unions to exert pressure on government now to ratify the International Labour Organisations Convention 140 on standards for paid education and training leave.<BR><P>

Du Plessis said the agreement signed today recognised that education and training should be based on the operational requirements and constraints of mines, and the needs of the employee.<BR><P>

The agreement recognised that "there is a need to identify jointly education and training programmes and courses that qualify to be conducted during working hours on basic pay, or outside working hours on a voluntary basis", he said.<BR><P> 

It also ensured disclosure of information relevant to discussions between parties involved, and regular joint reviews of programmes.<BR><P>
<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>
</DOC>
<DOC>
<DOCNO>WT14-B39-507</DOCNO>
<DOCOLDNO>IA012-000130-B041-190</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/releases/nrsgrad1.htm 196.26.82.193 19970217022456 text/html 4300
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:28:22 GMT
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE></TITLE><CENTER><BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></CENTER>

<center><b><h3>South Africa's first Nurse Clinicians graduate with 29

                      distinctions</b></TITLE><br>

                     

                      

<BODY BGCOLOR="#ffffff" TEXT="#000080" VLINK=naut.gif></h3></center>



                             

SOUTH Africa's first 50 Primary Health Care (PHC) Nurse

Clinicians, specially trained for primary health work at

clinics throughout the country, were awarded their

certificates by Minister of Health Dr Nkosazana Zuma at a

graduation ceremony arranged by the Chamber of Mines on

12 Dec. 1995.<br><p>



With 29 distinctions among them, the nurses represent the

cream of  South African PHC delivery and will now form

the vanguard of a new national drive to hugely upgrade

primary health services throughout the country, but

especially in remote and often impoverished areas.<br><p>



Minister Zuma praised the nurses saying that much of the

country's health needs rested on the shoulders of PHC

workers. The graduates, representing all nine provinces,

comprised the first intake in a joint Chamber of

Mines/Department of Health initiative to empower nurses

to maintain fully fledged clinical services, complemented

by new diagnostic,  epidemiological, managerial and

training and communications skills.<br><p>



Dr Zuma said having a healthy nation depended on many

things, not only health care workers, and called on

communities to support the efforts of PHC Nurse

Clinicians.<br><p>



She urged the graduates to ensure they left no stone

unturned in spreading their knowledge and expertise among

the people of their home communities. "It is part of

primary health care, not only to look after the ill, but

to impart knowledge and skills to your entire community

to prevent unnecessary illness or injury," she said.<br><p>



Dr Zuma said the initial training course had already

sparked immense interest nationwide, with several other

major sponsors entering negotiations with government to

assist in providing similar programmes to the mining

industry's initiatives.<br><p>



There were three distinctions among the seven graduates

from Northern Province, two among the four graduates from

North West, four among the seven from Free State, one

among Gauteng's three representatives, one among the

Northern Cape's four, five among the Western Cape's five

graduates, one among the Eastern Cape's six, five among

KwaZulu/Natal's six and seven among  Mpumalanga's eight

graduates.<br><p>



Thethe Gina from Nongoma in KwaZulu/Natal won the Chamber

of Mines Award for Best Overall Student with 90% average

in both theory and clinical studies, and Yvonne Jansen-

van Rensburg from the Free State won the Promex Floating

Trophy for Best Clinical Student.<br><p>



The multi-million rand training programme is entirely

funded and provided by the members of  the Chamber of

Mines, is registered with the SA Nursing Council and is

underwritten by the University of Potchefstroom.<br><p>


<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>

<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>

<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

</center><br><br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><br><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>

</HTML>




</DOC>
<DOC>
<DOCNO>WT14-B39-508</DOCNO>
<DOCOLDNO>IA012-000130-B042-4</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/speeches/stateof.htm 196.26.82.193 19970217022538 text/html 13158
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 02:29:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>The Chamber of Mines Speeches: State of the South African Mining Industry, October 1995</TITLE>
<BODY BGCOLOR="#ffffff" TEXT="#000080">

<center>
<IMG SRC="/images/LOGO1.gif" ALIGN=MIDDLE><P>
<FONT SIZE=5 COLOR=800040><B>THE STATE OF THE SOUTH AFRICAN MINING INDUSTRY</B></FONT><br>
<FONT SIZE=4 COLOR=000080>OCTOBER 1995</FONT><p>

<FONT SIZE=3 COLOR=008000><B><A HREF="/cvs/main.htm">Mr TRN Main</A>,  Chief Executive Officer of The Chamber of Mines of South Africa</B></FONT><P><P>

</center>


THE SOUTH  African mining industry, in all its diversity, is currently at a momentous crossroads in its history.
But it has been at such fateful junctions before; and it will doubtless be at similar ones again in the future.<p>

However, neither of these facts, important though they be, can detract from the magnitude nor significance of
the situation in which the industry finds itself today. The gold mining industry, the financial bastion of
Southern African economic development for more than 100
years, currently finds itself at one of the most critical
stages in its illustrious history. Spiralling production
costs, declining ore grades, the need to dig ever deeper,
robust international competition and a gold price that
remains doggedly below $400/oz. contribute to the
formation of an unholy alliance as far as gold is
concerned.<p>

Fortunately, counterbalancing the situation for gold,
South African coal has begun to show encouraging signs in
terms of its international competitiveness, and the
country remains blessed with an estimated 55-billion
tonnes of generally high grade  economically recoverable
coal ore. Approximately 96% of the country's coal is
bituminous, and has a sulphur content lower than that of
most other major producers (although it does have a
slightly higher ash content).<p>


The country remains the world's largest producer of gem-
quality diamonds and a significant producer of industrial
diamonds. Fourthly, the region also has large reserves of
other strategic minerals placing it among the foremost
producers in the world. In fact, the only strategic
mineral that does not occur in large quantities in SA is
crude oil.<p>

However, gold remains the country's mineral mainstay -
and consequently this industry's current woes tend to
occupy centre stage in any discussion on mining in South
Africa at the moment.<p>

Before discussing the present position of mining in SA
and the outlook for the future, it is important to point
out that, while cognisant of the seriousness of the
current position, the South African gold mining industry
remains optimistic.<p>



<b>CURRENT REALITIES</b><br>
The bulk of gold deposits in SA occur in geological
formations which require very large mining operations. No
other country mines at the depths applicable in SA, and
ultra-deep level mining - up to 4 000m underground -
places huge demands on technology. Such mines are
characterised by hard quartzite rock and narrow seams,
necessitating  higher treatment costs and reducing
options in terms of mechanisation. In addition to the
working environment in South African gold mines being
geologically and seismically hazardous, safety factors
are even made even more problematic by the fact that, for
the foreseeable future, SA gold mines will remain highly
labour intensive.<p>

All these factors force up production costs. Compounding
this are the remains of an obsolete and restrictive
legislative regime (e.g. ring fencing which prohibits off-
setting expenditure on one mine against  that of another
and negatively impacts on taxation,  and a continued
prohibition on Sunday blasting), and an insufficiently
productive workforce.<p>



Massive cost containment measures begun several years ago
have resulted in enormous savings and, in many instances,
rescued entire mines from certain demise. However, there
is a limit to the extent to which even these measures can
sustain their efficacy, and the industry is now having to
investigate new and untried programmes. While this
process is underway, it is logical to assume that
uncertainties will persist.<p>

Following recent watershed wages and conditions of
employment agreements being signed between the industry
and labour, new measures now being developed include
greater involvement of labour in management operations
(especially in health and safety issues), a formalised
two-tier bargaining structure to enable mine-specific
issues to be negotiated at the appropriate levels while
retaining the established centralised bargaining forums,
and joint efforts to scrap archaic and counter-productive
legislative restrictions.<p>



However, other macro-economic issues also bear down upon
the gold mining industry in SA. These include continued
high inflation, exchange controls which bottle up
liquidity, a past industrial policy directed towards self-
sufficiency through fostering import substitution and the
high domestic cost of capital.<p>

Furthermore, despite South Africa's stunningly peaceful
transition to democracy, a number of outdated ideologies
- such as excessive state interference - still find
favour in certain political quarters and raise their
heads with disquieting regularity. Other factors such as
the high crime rate, continued labour militancy, high
illiteracy levels, poverty and its social consequences
such as squatting, scepticism about long-term regional
stability within the sub-continent and perceptions
regarding a poor work ethic in South Africa, continue to
confound efforts to attract substantial and crucial
foreign investment<p>



<b>VISIONS OF THE FUTURE.</b><br>

Having spelt out the substantial current difficulties
facing mining in SA, it is probably more indicative of
the underlying mood of the industry to focus attention on
the future.<p>

One of the surest indicators of long-term confidence is
the number of prospective new mines waiting in the wings
for the opportunity to launch into development.  In this
case estimates of up to 15 new mines in excess of 4 000
metres deep and with estimated 30-year life spans, have
already been identified for development once
circumstances become advantageous.<p>

Backing up this optimism are the country's reserves of
the necessary technological and engineering expertise,
much of it having been developed locally perforce because
of the unique mining conditions under which we operate.
In fact, in the field of ultra-deep level mining, South
Africa leads the rest of the world in knowledge and
ability.<p>

Arising from an established and proven tradition of
financing the economically daunting development of large
capital-intensive mining operations, SA has the necessary
financial infrastructure through the mining houses, such
as Anglo American Corporation, Anglovaal, De Beers,
Gencor and Gold Fields of SA. Other conglomerates are
currently undergoing rigorous restructuring programmes to
better gear themselves for the challenges of the 21st
century.<p>


Unlike most of its northern neighbours and many of the
emerging mining nations, South Africa boasts an
established and sophisticated transport, harbour and
communications infrastructure. In addition the country's
stature as a reliable supplier of minerals to domestic
and foreign markets, even through the sanctions era, has
ensured it an enviable reputation as trustworthy and
credible - an invaluable asset when other younger
competitors are clamouring for such favoured status.<p>

In the face of the on-going domestic debate on mining and
mineral rights in SA (a debate which has rightfully
worried many potential investors) it is vital to
understand the fundamental truth that unexploited mineral
resources locked within the earth do not represent
wealth. They only do so once they can be mined profitably
and on a sustainable basis - a role custom-designed for
SA mining.<p>


However, to be the kind of world class performer it is
capable of, South Africa requires operational and
economic environments that are, at the very least,
comparative with or better than those within which its
competitors operate.<p>

The operational environment should include the necessary
and proven flexibility of  modern working arrangements,
the right to work on a continuous basis and a literate,
capable and motivated workforce. The industry is actively
pursuing the expeditious achievement of this kind of
operational environment.<p>



Concomitantly, the optimal economic environment should
include a post-transitional government committed to the
development and perpetuation of a market-based economic
system where the production of goods and services is
directed by free market forces.<p>

Also necessary are national policies which, through
appropriate, equitable and affordable social programmes
in areas such as education, housing and health care,
enhance labour productivity and  lead to the ultimate
realisation of the legitimate aspirations of its citizens
- without penalising precisely those sectors which propel
the economic well-being of the nation.<p>

The country's economy requires a predictable, equitable
and internationally competitive taxation system, the
containment of government expenditure appropriate to its
domestic needs and international competitiveness, the
encouragement of private savings, the control of
inflation and the abolition of exchange controls.<p>


For the mining industry to contribute to the process of
nation building, it specifically requires a stable
taxation system free from frequent or ad hoc changes,
confined to the taxation of profits and one in which
indirect taxation or imposts, such as regional levies and
import surcharges, are avoided  - a fundamental concept
accepted by the World Bank.<p>

Provision should also be created for accelerated or
enhanced depreciation commensurate with the capital and
time risk inherent in mining and which encourage the
advancement of technology.  Provision for the renewal of
mining resources by encouraging further investment
(through abolishing ring fencing, for example) and
allowing for a sufficient portion of distributable
profits to be returned to shareholders.<p>



As regards the social environment, the mining industry is
anxious that South Africa's disparate society should live
and exist in harmony in a social and political
environment with equal opportunity and fair play for all.<p>

As regards labour relations, the role of government
should be limited to creating enabling legislation and to
being a neutral facilitator. The rules for these
relations are most effectively written by the parties
directly involved.<p>

Besides the efforts of individual mining houses and
mines, the industry is vigorously addressing pertinent
issues through the Chamber of Mines of South Africa, a
voluntary employers' organisation which provides services
to its members and the industry, but is not involved in
prospecting, financing or managing mines.  It is a
valuable and convenient vehicle for its members to act in
concert  where this is appropriate.<p>

The Chamber and its members are actively pursuing with
government and other bodies, initiatives to eliminate
political and criminal violence, and progress towards the
establishment of an acceptable dispensation for all South
Africans.<p>

South Africa's mining industry has as substantial a role
to play in the economic development and welfare of the
country from this point on as it has played to date.
What it requires is the correct enabling operational and
economic environments to allow the industry to flourish.<p>

If one salient characteristic can be identified in the
current scenario, it would be one of overriding positive
pragmatism -  a realistic understanding of the threats,
tempered with in-depth knowledge of the current realities
and a vision of the future based on sound research and
meticulous planning.<p>


<center>

<a href="/main.htm"> <IMG SRC="/images/nb1.gif" ALIGN=MIDDLE border=0 alt="Main Menu" hspace=20></a>
<a href="#top"> <IMG SRC="/images/nb2.gif" ALIGN=MIDDLE border=0 alt="Top of Page" hspace=20></a>
<a href="#toolbar"> <IMG SRC="/images/nb3.gif" ALIGN=MIDDLE border=0 alt="Toolbar" hspace=20></a>

<br><p>

<br><IMG SRC="/images/line3.gif" ALIGN=MIDDLE><p>

<a name="toolbar"></a>
<A HREF="/org1.htm"><IMG SRC="/images/tb101.gif" BORDER=0 ALT="organisation"></A>
<A HREF="/res1.htm"><IMG SRC="/images/tb102.gif" BORDER=0 ALT="Resources"></A>
<A HREF="/ess1.htm"><IMG SRC="/images/tb103.gif" BORDER=0 ALT="Essentials"></A>
<A HREF="/kruger.htm"><IMG SRC="/images/tb104.gif" BORDER=0 ALT="Krugerrand"></A>
<A HREF="/new.htm"><IMG SRC="/images/tb105.gif" BORDER=0 ALT="What's New?"></A>
<A HREF="/info.htm"><IMG SRC="/images/tb106.gif" BORDER=0 ALT="Contacting us"></A>
<BR>

</BODY>
</HTML>


</DOC>
<DOC>
<DOCNO>WT14-B39-509</DOCNO>
<DOCOLDNO>IA013-000133-B046-201</DOCOLDNO>
<DOCHDR>
http://w3.bullion.org.za:80/publications/basemetals.htm 196.26.82.193 19970217031332 text/html 39183
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.12
Date: Monday, 17-Feb-97 03:16:51 GMT
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Chamber of Mines of South Africa: Base Metals and Minerals Mined</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#FFFFFF" text="#0000A0">
<p align=center><font color="#800040"><font size=2>CHAMBER OF MINES OF SOUTH AFRICA</font></font></p>
<p align=center><font color="#0080FF"><font size=4><b>BASE METALS AND MINERALS MINING IN SOUTH AFRICA</b> </font></font></p>
<div align=center><center>
<table width=400>
<tr><td width=50%><menu>
<li><a href="#Andalusite">Andalusite</a></li>
<li><a href="#Antimony">Antimony</a></li>
<li><a href="#Asbestos">Asbestos</a></li>
<li><a href="#Chromium">Chromium</a></li>
<li><a href="#Cobalt">Cobalt</a></li>
<li><a href="#Copper">Copper</a></li>
<li><a href="#Fluorspar">Fluorspar</a></li>
<li><a href="#Granite">Granite</a></li>
<li><a href="#Iron">Iron</a></li>
<li><a href="#Lead">Lead</a></li>
</menu>
</td><td width=50%><menu>
<li><a href="#Manganese">Managanese</a></li>
<li><a href="#Nickel">Nickel</a></li>
<li><a href="#Silver">Silver</a></li>
<li><a href="#Tin">Tin</a></li>
<li><a href="#Titanium">Titanium</a></li>
<li><a href="#Uranium">Uranium</a></li>
<li><a href="#Vanadium">Vanadium</a></li>
<li><a href="#Vermiculite">Vermiculite</a></li>
<li><a href="#Zinc">Zinc</a></li>
<li><a href="#Zirconium">Zirconium</a></li>
</menu>
</td></tr>
</table>
</center></div>
<p><a name="Andalusite"><b>Andalusite</b></a></p>
<p>South Africa, with more than 50 million tons of alumino-silicates, contains around 40 per cent of the world's known reserves of 
these minerals and accounts for nearly half of Western world production A natural silicate of aluminium andalusite is the 
material used in refractory bricks which line blast furnaces. In South Africa andalusite is mined in the eastern Transvaal near 
Lydenburg and in Namaqualand south of the Orange River. The Republic's production-in 1989 was some 284 000 tons. 
Apart from a tiny deposit in France, South Africa possesses the only andalusite reserves in the world, with the Cullinan group 
dominating the world market for the mineral. </p>
<p>Like platinum, manganese, chrome. vanadium and cobalt, among others, andalusite is regarded by the United States as a 
'strategic' mineral. Furthermore, as French andalusite has a different particle size, there is no material available which can be 
substituted for South African (coarse grade) andalusite; as a result, the US is reliant on the Republic for its entire imports of 
andalusite. </p>
<p><a name="Antimony"><b>Antimony</b></a> </p>
<p>South Africa's known antimony ore reserves total some 260 000 tons, representing 5,5 per cent of global reserves. Antimony 
plays a small but significant role in South Africa's base-metals output. The country's sole supplier is JCI and 
Anglovaal-controlled Consolidated Murchison, an underground mining operation, which produced 8 800 tons of antimony 
concentrate in 1989, Consolidated Murchison, the world's most reliable supplier of quality antimony sulphide concentrates, 
beneficiates most of the concentrate into antimony trioxide, a vital ingredient in flame-retardant industrial products while the 
main (though declining) use of antimony metal is in the storage-battery industry. Antimony is also essential in producing solder, 
bearings, space-probe components. lubricants, vulcanising agents, medical preparations and tracer bullets. Although South 
Africa accounts for only 12 per cent of global output, it is the world's no 3 producer and is believed to be the main source of 
antimony oxide imports into the United States. </p>
<p>Consolidated Murchison faces a considerable scaling-down of operations owing to a weak antimony market. The market is 
likely to remain that way until a domestically-troubled China, which accounts for about one third of world production, is able 
to reinstate a centralised marketing system. </p>
<p><a name="Asbestos"><b>Asbestos</b></a> </p>
<p>Although South Africa possesses only about 10 per cent of the West's asbestos fibre reserves and produces around nine per 
cent of its output, it has the third largest reserves of chrysotile asbestos in the world and remains an important supplier on an 
international scale for this and other types of asbestos fibre. In 1989 the Republic's asbestos production was 155 000 tons, 
while 165 00O tons were exported. </p>
<p>The country's production is dominated by Hanova Mining's two producers: The Griqualand Exploration and Finance Company 
(Gefco) with a mine at Kuruman in the northern Cape and one at Penge in the eastern Transvaal, and Msauli Asbes which has 
a mine in the eastern Transvaal near the Swaziland border; smaller mines exist in the Pietersburg area. Gefco, which supplies 
high-tensile-strength blue crocidolite asbestos (used in the manufacture of large diameter concrete pipes) and amosite fibre, is 
expanding production at both of its mines in response to strengthening world demand and advancing dollar prices. Msauli 
markets chrysotile asbestos a product that has not suffered as badly as Gefco's from the stringent measures introduced in 
numerous countries to limit the use of asbestos because of health hazards. The company is still experiencing strong international 
demand for its short fibre chrysotile product, especially from the Far East where the building industry continues to boost 
demand. </p>
<p>The use of asbestos is now mainly restricted to the 'safe' core businesses of building materials and piping in water-reticulation 
systems. In spite of its restricted use, which was compounded by the news in mid 1989 that the US government was to phase 
in a ban on almost all uses of asbestos, the international market remains healthy. </p>
<p><a name="Chromium"><b>Chromium</b></a> </p>
<p>About 58 per cent of the West's chromium ores and a staggering 77 per cent of the world's known reserves of chromite, the 
principal chromium mineral of economic importance, are located in South Africa's Bushveld igneous Complex. In 1989 the 
Republic produced about 35 per cent of world chrome ore output and chromite production reached 4.3 million tons, in 
addition, the country supplied more than </p>
<p>I million tons of chrome alloys such as charge chrome and high-carbon ferro-chrome - some 40 per cent of Western 
production. The United States imports some three quarters of its chromium and 60 per cent of its ferrochrome from South 
Africa. </p>
<p>More than 60 per cent of all chromium produces is destined for the production of stainless steels and the closely-related 
heat-resistant steels. Chromium, together with other metals such as copper, nickel, titanium and vanadium, is added to iron to 
produce steels with greatly increased strength and rust- and corrosion-resistance. Ferrochrome is an essential ingredient of 
stainless steel. </p>
<p>Notwithstanding a consolidation period in 1990, world stainless steel demand is set to advance again at three to four per cent 
annually, and local ferrochrome producers such as Samancor (the West's main supplier of chrome ore and the world's largest 
ferrochrome producer), Consolidated Metallurgical Industries and Middelburg Steel and Alloys (MSA), are substantially 
increasing their production capacity with new, more efficient plants. These traditional producers are being joined by 
newcomers like Chrome Corp Technology and Southern Witwatersrand Exploration, while Barplats plans to produce chrome 
concentrate and Anglovaal has bought the Lavino chrome mine in the eastern Transvaal. Meanwhile, MSA - the only South 
African producer to date to have extended beneficiation into stainless steel - will probably have to face competition in this area 
from Samancor and Highveld Steel, which are likely to establish a 270 000 tons a year hot-rolled plant in South Africa to 
produce stainless steel billets for downstream processing in Taiwan. </p>
<p>The chemical industry absorbs some 25 per cent of chromium production, Chromium chemicals have a great variety of uses. 
Widely used as pigments, they also feature as tanning salts, oxidising agents and catalysts. Other applications include the 
chromium plating of metal surfaces, photography and pyrotechnics. </p>
<p>The third main use for chromium and its compounds is in refractories, which account for some 14 per cent of production. 
Because of their high melting point, stability and chemical neutrality, chromite sands and refractory bricks containing chromite 
are used for casting moulds and furnace linings. </p>
<p>By 1990 South African ferrochrome producers should provide 1,5 million tons of ferrochrome, more than half of world 
demand. Yet South Africa, while refining about 65 per cent of its chromite ore prior to export and exporting about 90 per cent 
of its ferrochrome output, produces only about 100 000 tons or one per cent of the world's annual stainless steel output 
(though this will increase if over three per cent if the Highveld/Samancor stainless steel project goes ahead and MSA competes 
the uprating of its capacity to 170 000 tons) -and sells more than 50 per cent of this in the domestic market alone. Finally, no 
chromium metal and only a very small amount of chromium chemicals are produced locally. Because the beneficiated product 
at even its lowest stage of refinement is worth many more times than that of the raw material there is great scope for increased 
earnings from the establishment of chromium-chemical and additional stainless steel industries, especially if significant inroads 
are made into the potentially huge markets for stainless steel products such as exhaust pipes and rods in reinforced concrete. </p>
<p><a name="Cobalt"><b>Cobalt</b></a> </p>
<p>In South Africa, cobalt is found as a minor element in the base-metal sulphides of the Merensky reef of the Bushveld Igneous 
Complex (BIC) from which platinum group metals are extracted; it is also found in a number of chromite layers of the BIC. 
The Republic's cobalt reserves, which remain classified data, have been estimated to a depth of 600 metres in the Merensky 
Reef, although mining is taking place below this level. </p>
<p>Significant South African production of the metal started a decade ago when Rustenburg Platinum Mines added a cobalt unit 
to its copper nickel refinery in the western Transvaal. Today, Western Platinum produces nickel cobalt sulphate from 
concentrates previously sent overseas for treatment, while Impala Platinum produces cobalt powder. </p>
<p>Cobalt is a vital industrial metal which forms part of the US National Defense stockpile Alloyed with other metals, cobalt 
imparts exceptional strength and corrosion-resistance at high temperatures. In the manufacture of jet engines, as well as in 
certain aerospace and armaments applications, cobalt has no substitute. Other applications for the metal include its use in the 
chemicals industry, as a bonding agent between steel wires and rubber in tyres, in high-resolution magnetic tape coatings, the 
production of tungsten-carbide drills and cutting tools, as well as in paints, cattle feed, the fabrication of prosthetic devices, and 
as a catalyst in hydrocarbon refining. </p>
<p><a name="Copper"><b>Copper</b></a> </p>
<p>South Africa's copper occurrences stretch from Phalaborwa and Messina in the north-eastern and northern Transvaal, through 
the Bushveld Igneous Complex (BIC) and the northern and north-western Cape to Namaqualand. Six of the occurrences 
support major mining operations, copper in the BIC are being recovered as a by-product of the platinum industry. Several 
companies operate underground copper mines, although Palabora Mining Company has the only open pit operation - which is 
the second largest in the world. Palabora, whose major share-holders are RTZ of the UK and AAC, is a highly efficient low 
grade producer which in 1989 produced 126 000 tons of copper out of a total South African output of nearly 197 000 tons 
-ranking the country about 11th in world output. </p>
<p>In line with a likely rise in Western mine production of copper, South African producers are increasing output. Palabora has 
installed an in pit crushing system and a new smelter to increase production of copper cathode and copper concentrates, as 
well as a variety of other minerals such as magnetite and vermiculite. Meanwhile, GFSA controlled O'Kiep, which produces 
nearly 40 000 tons of blister copper annually. is expanding its operations. </p>
<p>Although slowly being superseded by fibre optics in its main application - the generation and transmission of electricity and 
information -copper still has widespread use in the manufacture of electrical wire and cable, in the automotive and construction 
industries, as well as in alloys and tubing for a host of applications. </p>
<p>By the end of the '80s, significant tonnages of copper metal output came on stream, and the market was close to being in 
balance. For the next few years. however, it is likely that there will be a sizeable surplus of copper, which renewed disruption 
would only trim, and no return to deficit is foreseen. </p>
<p><a name="Fluorspar"><b>Fluorspar</b></a> </p>
<p>South Africa's fluorspar (natural calcium fluoride) reserves exceed 30 million tons. The Republic has the third largest reserves 
in the world and accounts for around 30 per cent of the Western worlds and some 10 per cent of all known reserves. In 1989, 
the Republic's production exceeded 368 000 tons. Although export sales increased by some 10 000 tons to 323 400 tons, the 
export market remains weak with little prospect of a significant improvement in the fluorspar market generally and a number of 
mines remain on a care and-maintenance basis. </p>
<p>Fluorspar is used mainly in the aluminium, steel and chemicals industries. In 1989, fluorspar demand world-wide increased 
slightly and, currently, acid-grade fluorspar (acidspar) demand is hardening. Although no immediate significant impact is 
anticipated regarding demand for acidspar, the decision by Western leaders to tighten the requirements of the 1987 Montreal 
protocol on chlorofluoro-carbon emissions, with the aim of eliminating such emissions entirely by the year 2000, is bound to 
have a substantial effect eventually an the acidspar market. </p>
<p><a name="Granite"><b>Granite</b></a> </p>
<p>Republic's two main deposits of gabbronorite, an extremely hardy, add-resistant stone which is the source of black granite are 
in the Belfast and Rustenburg areas of the Transvaal. In addition to these deposits, which represent hundreds of years' supply 
at current production levels, substantial reserves of black granite have been discovered recently in Transkei and near the Cape 
west coast. </p>
<p>Over half of South Africa's production is grey granite; however, it is the black granite market which has seen spectacular 
growth as European demand has turned away from marble to building materials resistant to acid rain and air pollution. South 
Africa's granite exports, (comprising mainly black granite) in 1989 were 790 000 tons - worth some R283 million. Black 
granite exports from the country's five major producers are expected to increase further in 1990 and the country's international 
market share is expected to rise sharply in the 90's. Furthermore, current world demand for the highest-grade, absolute black 
granite is estimated at around 350 000 tons a year with South African producers, who are adding value by cutting granite tiles, 
accounting for around 200 000 tons. </p>
<p><a name="Iron"><b>Iron</b></a><b> ore</b> </p>
<p>South Africa is well endowed with iron ore and has hearty 6 billion tons, or 10 per cent, of the West's estimated iron ore 
reserves. The country produced almost 30 million tons of iron ore in 1989, representing about five per cent of the iron ore 
requirements of the free market economies, and exported nearly 15 million tons. </p>
<p>The Republic's principal deposits are located in the northern Cape at Sishen, from where export ore is transported via a 
purpose built rail link to Saldanha Bay on the Atlantic Ocean some 800 kilometres away. Other high grade haematite deposits 
occur near Sishen at Thabazimbi on the northern rim of the Bushveld igneous Complex (BIC) and elsewhere on the BIC 
Finally in the northern Transvaal, lies the unexploited Rhenosterkoppie deposit which contains large reserves of low grade iron 
ore. Iron is largely used in the form of alloys with other metals in the production of a variety of steels from cast iron to stainless 
steels. Added value in the context of iron arises from a higher production of ferro-alloys and speciality steels, made by the 
alloying of iron with other metals found in abundance locally. As well as exporting mined ore, Iscor is making steel to compete 
on world markets. Highveld Steel makes vanadium steel and, in a joint project with Samancor, is likely to start producing 
stainless steel by mid 1993. Middelburg Steel and Alloys produces stainless steel and the corrosion-resistant steel 3CR12, 
which has made a significant impact on local and world markets. </p>
<p><a name="Lead"><b>Lead</b></a> </p>
<p>South Africa possesses around 5 million tons of lead deposits, representing some four per cent of global reserves and has the 
fifth largest reserves world-wide. In 1989 the country produced more than 78 000 tons of lead in concentrates and was the 
world's third biggest exporter, with exports of nearly 83 000 tons. </p>
<p>In South Africa, the most important deposit is GFSA's Black Mountain lead/zinc/copper/silver mine at Aggeneys, south of the 
Namibian border, </p>
<p>in the west of the country, which started operations in 1980 and led to South Africa's becoming a net exporter of lead for the 
first time. Also in the Aggeneys area. two other notable base-mineral deposits in which lead occurs in significant amounts are 
situated at Gemsberg and O'Okiep, both of which are also controlled by GFSA. Lead is found, too, at Prieska in the northern 
Cape, where Anglovaal operates an ageing base-metals mine. </p>
<p>Lead is one of the most widely used metals in the industrial world. By far the biggest use for lead is in car batteries, which 
consume at least half of the world's annual production. The continuing expansion of the motor industry with the consequent 
demand for replacement batteries has underpinned the steady growth in demand for lead, though its use in fuel additives is 
declining as consumption of 'unleaded' petrol continues to increase in the United States and the European Community. Supply 
of the metal was forecast to overtake demand during 1989 and to be headed towards greater surplus in 1990. </p>
<p><a name="Manganese"><b>Manganese</b></a> </p>
<p>With reserves totalling in excess of 12,5 billion tons, some 90 per cent of the West's (and 82 per cent of the world's) known 
manganese ore deposits are located in the northern Cape and the western Transvaal. South Africa is the Western world's 
leading producer of manganese ores. The country's annual output in 1989 was 3,6 million tons out of total Western production 
of around 12,5 million tons and it is the world's primary exporter. </p>
<p>High grade metallurgical manganese ore is generally smelted and refined to produce ferromanganese, an alloy which has long 
been used in the processing of steel. With an annual production of 650 000 tons of manganese alloys. South Africa accounts 
for nearly 20 per cent of the West's combined output of ferromanganese and ferrosilicomanganese and 16,5 per cent of world 
production, with much of the manganese alloy production in other countries originating from South African ore. Manganese is 
classified as a 'strategic' metal by the United States: that country relies on the Republic for around 30 per cent of its total 
manganese content in all forms. including some 25 per cent of its ferromanganese intake. </p>
<p>Just as the main downstream use of ferrochrome is stainless steel. ferromanganese .s beneficiated as carbon steel. As an 
alloying agent, ferromanganese is invaluable in imparting strength, toughness and abrasion-resistance to steel, with the world 
crude steel market consuming more than 90 per cent of manganese output. The metal is also used as an alloying agent to 
strengthen aluminium and is added to copper to form a wide range of manganese bronzes. </p>
<p>Manganese dioxide is a powerful oxidising agent with a variety of chemical applications, including use in dry cell batteries and 
in acid leaching to recover uranium and zinc from their ores. </p>
<p>Considerable value added potential exists in the production of manganese chemicals. These are used principally in making 
fungicides for agricultural use - a sector hardly touched on by South Africa, which supplies only some three per cent of the 
world's manganese chemicals requirements. </p>
<p>Samancor, (the world's primary producer of manganese ores), Highveld Steel and Associated Manganese are the Republic's 
main producers of ferro manganese, with Samancor's accounting for almost two thirds of South Africa's ferromanganese 
exports. Against a background of rationalised manganese production world-wide, a shortage of high grade manganese ore in 
international markets and still high demand for carbon steels which has seen impressive price gains for both manganese ores 
and alloys, these local producers are benefiting from a tight market and are set to increase output by around 20 per cent over 
the next two years. </p>
<p><a name="Nickel"><b>Nickel</b></a> </p>
<p>More than 10.5 million tons of nickel, representing almost 20 per cent of the West's nickel reserves, are located in South 
Africa's Bushveld Igneous Complex where the nickel bearing horizons occur over a total length of some 250 kilometres. </p>
<p>In 1989 the Republic produced an estimated 40 000 tons of nickel out of total Western output of around 600 000 tons, and 
exported approximately 60 per cent of production. South Africa's nickel is derived mainly as a by product from the mining 
operations of the three major platinum producers Rustenburg Platinum Impala Platinum and Western Platinum: other significant 
producers are Palabora Mining and Lebowa Platinum Mines' Atok Section. </p>
<p>Nickel is vital to the steel industry and especially the stainless steel industry, which is the metal's biggest market. It has played a 
key role, too, in the development of the chemical, aerospace and armaments industries. The metal's greatest value lies in the 
alloys it can form with other elements, where it adds strength and corrosion resistance over a wide range of temperatures. </p>
<p>Nickel production in the West is likely to have reached 587 000 tons in 1989 and. in spite of a forecast surplus for 1990, it is 
likely that more nickel mines may come on stream in South Africa in the near future, especially if the Samancor-Highveld Steel 
stainless steel joint venture is given the go-ahead. Potgietersrus Platinum may soon start to mine the Platreef with its good 
grades of 0,35 per cent nickel and 0,15 per cent copper in addition to its platinum and palladium. Southern Witwatersrand 
Exploration, too, has a project on the Platreef. In the eastern Transvaal. AAC's proposed Uitkomst nickel/platinum/copper 
mine plans to produce some 17 000 tons of nickel a year, boosting South Africa's output of the metal by nearly 50 per cent. </p>
<p><a name="Silver"><b>Silver</b></a> </p>
<p>In South Africa, silver is an important constituent of gold and platinum ores and occurs too in the ores of the base metals (zinc, 
lead, and copper) mined at Black Mountain. O'Okiep, Prieska and Palabora. In 1989, the Republic's production amounted to 
some 200 tons and was valued at about R80 million. </p>
<p>Silver is used for coinage, photographic materials, brazing materials, and as a catalyst. Pure silver, like gold, can be rolled into 
foil, drawn into fine wire, and beaten to leaf. However, as silver is too soft in its refined state to stand up under constant wear, 
it is usually alloyed with copper before it is made into any consumable such as coins, jewellery and tableware. </p>
<p>Silver compounds are used to coat films and in silver plating. The metal's high electrical and thermal conductivity and superior 
oxidation resistance have led to its widespread use in electrical and electronic applications. Other applications of the metal 
include the manufacture of silver paints, while silver batteries find special uses in aircraft and various types of military 
equipment. </p>
<p>As the '90s opened, the silver surplus was on the increase again, while the price of the metal remained at a critical low point. 
The strength of the dollar, the lack of speculative buying by investors, destocking by fabricators and, most importantly, the 
striking increase in silver output in the last three years, have greatly increased supply. However, rising industrial usage, in 
particular, could bolster support levels for the metal. Total fabrication demand was expected to reach 15 795 tons in 1989 
compared with 14 808 tons in 1988. </p>
<p><a name="Tin"><b>Tin</b></a> </p>
<p>South Africa produces about 1,3 million tons of tin in-concentrate per annum, while exports in 1989 reached 345 000 tons. 
Currently, there are three tin mines operating in the Republic -Rooiberg Tin, Zaaiplaats and Union Tin, all of which are located 
in the Bushveld Igneous Complex. </p>
<p>Tin is soft, pliable, easily adaptable to cold working, and it forms alloys readily with other metals, imparting hardness and 
strength. It is corrosion resistant, solderable and non toxic, and finds its major application in the making of tin plate to prevent 
the steel in cans from rusting. The second most important use of the metal is in tin-lead solders and coatings in micro-circuitry 
for telecommunications and electronic equipment. Other important uses include tin-foil, while tin compounds are used as 
stabilisers in the manufacture of PVC. </p>
<p>The tin price, which plummeted after the collapse of a price-fixing cartel in 1985. has regained ground. In 1988 consumption 
of 89 000 tons exceeded supply of 176 00O tons by 7,4 per cent. </p>
<p><a name="Titanium"><b>Titanium</b></a> </p>
<p>South Africa's reserves of titanium contained in ilmenite, as well as rutile and leucoxene, are concentrated mainly in extensive 
titanium-bearing deposits in black sands in the Richard's Bay and St Lucia areas of northern Natal. The Richard's Bay titanium 
reserves, which total more than 30 million tons, are the fourth largest in the world. </p>
<p>The Republic's sole producer of titanium ore to date is Richard's Bay Minerals (RBM) - in which RTZ has a controlling 
interest and Gencor a significant stake although AAC is investigating the possibility of recovering heavy minerals from deposits 
of sea sand on the Namaqualand coast. RBM suction-dredges sands from artificial ponds and treats titanium ore to make a 
concentrate which is then separated into its various heavy mineral components - zircon, rutile, ilmenite, monazite and magnetite. 
The ilmenite, which is commercially the most important, is upgraded and smelted to produce a titanium slag with a titanium 
dioxide content of 85 per cent; most of the rutile output, estimated to amount to some 60 000 tons a year at present, is 
exported. </p>
<p>During the last two decades or so the importance of titanlure - one of the toughest, lightest and most corrosion resistant 
materials known to man - has steadily increased throughout the world. Titanlure has become one of the most highly rated of all 
metals. Titanlure alloys are used in the manufacture of aerospace components, guided missiles, military hardware, camera 
bodies, tube condensers and turbine blades with increased usage in the nuclear industry, chemical plants medicine and marine 
parts. </p>
<p>Ilmenite and rutile are rich in titanium dioxide, which is most commonly used to add opacity to paints, paper, plastics, fibres, 
floor coverings and enamels - to name but a few - while the pigment industry is the world's largest user of titanlure dioxide. </p>
<p><a name="Uranium"><b>Uranium</b></a> </p>
<p>South Africa's uranium resources, which exceed 500 000 tons, are the second-largest in the West. In 1989 the country 
produced some 3 460 tons of uranium oxide (U308 - 'yellowcake'), accounting for around 10 per cent of Western output and 
eight per cent of world production. </p>
<p>All uranium oxide in South Africa is produced as a by-product from mining operations. At the uranium-calcining works of the 
Nuclear Fuels Corporation (Nufcor), ammonium diuranate slurries are blended into a mixture of consistent quality and then 
calcinated into granular exportable concentrates containing about 95 per cent 0308. Nufcor processes and markets, both 
internationally and locally. South Africa's entire uranium oxide output, which is used in the manufacture of fuel for nuclear 
power stations. </p>
<p>In recent times, holders of uranium inventories have released this material on the spot market, which has kept the market under 
pressure, and has led to softening prices As a result of this price weakness, during 1988 West Driefontein, Randfontein and 
Harmony an stopped producing uranium. </p>
<p>Notwithstanding this softening in prices (which was evident for most of the '80s), still relatively high stockpiles, production 
suspensions and shutdowns, and cancellations of new nuclear power installations world-wide resulting from environmentalist 
lobbying, to which the 1986 Chernobyl disaster gave renewed impetus, consumption has been outpacing output since 1986. 
Many experts believe that in the future nations will have little alternative but to use more nuclear power - in part owing to the 
need to reduce the usage of fossil fuels in order to curb the 'greenhouse' effect. By the mid `90s it is forecast that there will be 
a squeeze in the uranium market. Around the turn of the century inventories of uranium oxide are expected to have declined 
from the present level of 204 000 tons to 68 000 tons by, which time nuclear generating capacity may have expanded by one 
third from 1988's 261 000 megawatts to 347 000 megawatts. </p>
<p><a name="Vanadium"><b>Vanadium</b></a> </p>
<p>South Africa's Bushveld Igneous Complex contains more than 5 million tons of vanadium ore reserves, which represents about 
half of Western world reserves and one-third of the global total. </p>
<p>In 1989. South Africa produced more than 30 000 tons of vanadium pentoxide (V205) -equivalent to around 70 per cent of 
world production, excluding the Soviet Union and China - along with small amounts of ferrovanadium and other proprietary 
vanadium alloys. Of this total, AAC's Highveld Steel accounted for an estimated 23 000 tons of vanadium pentoxide, about 6 
000 tons being exported to European markets in the form of 98-99 per cent-pure fused flake and the balance as raw 
vanadium-bearing slag sent to European converters for refining into pentoxide or ferrovanadium alloy used by steel mills. Apart 
from Highveld, which has its own vanadium-and titanium rich magnetite ore mine, other South African producers of pentoxide 
are coming on stream Rand Mines has a 42 per cent interest in the Vansa mine which started Production in mid 1988 and is 
beneficiating to the pentoxide stage for export, while a joint venture between Union Steel Corporation and Rhombus 
Exploration plans to begin production of pentoxide flake at a rate of 9 000 tons a year. </p>
<p>The steel industry world-wide consumes about 85 per cent of vanadium. where it is used extensively as an alloying agent 
because of its abrasion-resisting and hardening qualities The main uses of the metal are in structural steels especially pipelines, 
and in tool steels Vanadium is also used in the manufacture of high strength, low alloy steels, intruding specialised alloys for the 
aerospace industry. Other applications for vanadium are in heavy duty rails and high-strength, cold formed steels for the 
automotive industry, it is also used in the pentoxide form as a catalyst for industrial chemical processes. </p>
<p>South Africa is the major player in the vanadium market and, because of the accessibility of high-grade vanadium-bearing 
deposits and the expansion of capacity, it is likely to remain so. By the early '80s, expansion by the Republic's vanadium 
producers may see production increase by about one-third or </p>
<p>13 800 tons, a figure equivalent to 34 per cent of 1988's total global demand. </p>
<p>Finally, although the country refines small quantities of ferrovanadium (the next stage in the `industrial pipeline' after pentoxide) 
for the domestic steel industry there are strong reasons for not beneficiating the product locally for the export market. These 
include import tariffs on pentoxide (a step along the industrial pipeline or value added chain from unrefined slag) by European 
countries, the United States and Japan; while ferrovanadium the end product of converters, is subject to levies so severe that 
exports of this product are not feasible. </p>
<p><a name="Vermiculite"><b>Vermiculite</b></a> </p>
<p>With vermiculite ore reserves at nearly 80 million tons, South Africa has the West's second largest reserves of the metal: 
representing about 40 per cent of the world total, excluding the centrally-planned economies. The Republic also produces 
nearly 40 per cent of Western output of vermiculite concentrate. </p>
<p>Palabora Mining produces most of South Affica's vermiculite. In 1989 the company produced nearly 196 000 tons of 
vermiculite concentrate out of total South African output of around 228 000 tons. Palabora continues to be the world's largest 
contributor to international trade in the metal and its vermiculite also has the largest volume yield. </p>
<p>Vermiculite, a partially decomposed mica with the unique characteristic of expanding some 30 times in volume when heated. is 
widely used in fire proofing and acoustical plasters, for heat insulation, as a growing medium in horticulture. agriculture and 
hydrophonics and in other applications where its light weight and other industrial properties can be utilised. </p>
<p><a name="Zinc"><b>Zinc</b></a> </p>
<p>South Africa, with around 15 million tons of zinc reserves, contains some five per cent of global deposits of the metal. Large, 
economically viable deposits of mixed sulphides are found in three areas of the Cape in the Black Mountain/Gamsberg area, 
around Prieska, and near Pering in the north of the province. Black Mountain/Gamsberg is the biggest and highest grade zinc 
deposit in southern Africa. </p>
<p>Black Mountain mine is the largest South African supplier of zinc concentrate. with most of the remainder coming from Shell's 
Pering mine. Zinc Corporation (Zincor), the sole South African refiner of zinc concentrate, produces in the region of 77 000 
tons of metal a year. The Republic's zinc-metal exports currently exceed 15 000 tons a year and export prospects remain 
good, with zinc consumption in 1989 reaching an estimated air time high at 5.5 million tons. </p>
<p>Zinc's main application is in the protection of iron and other metals from corrosion, it is also used in three main semi fabricating 
areas: galvanising, the manufacture of zinc based casting alloys and in brass. Current high zinc prices are partly the result of a 
consumer switch towards quality - for instance, the increased use in car bodies of galvanised steel which has greater resistance 
to rust than ordinary mild steel. In South Africa. there is growing demand for galvanised steel from the mining industry - over 
the next few years about 60 000 tons of galvanised steel are expected to be used in mine shafts alone. </p>
<p>Finally, zinc chromate is used extensively as an undercoating; while zinc oxide is utilised in rubber production, paints, ceramics, 
floor coverings and pharmaceuticals. </p>
<p><a name="Zirconium"><b>Zirconium</b></a> </p>
<p>Zirconium is spread widely through the earth's crust, being present in several mineral forms, although only two are of current 
commercial significance: namely, zircon sand containing zirconium as the silicate, and baddeleyite as a form of zirconium oxide. </p>
<p>South Africa contains almost 7 million tons of about 20 per cent of the West's zirconium minerals and accounts for around 25 
per cent of Western output. </p>
<p>In South Africa, the only significant producer of zircon sand (zirconium silicate) is Richard's Bay Minerals (RAM) with a 
production capacity of 150 000 tons per year. </p>
<p>The only commercial source of baddeleyite is at Phalaborwa. Palabora Mining recovers the mineral as a by-product of its 
opencast copper operations. In 1989 the company produced some 16 700 tons of zircorlia products, including more than 13 
00g tons of baddeleyite concentrates. The State owned Phosphate Development Corporation (Foskor) recovers baddeleyite 
from phosphate processing. </p>
<p>Both zircon and baddeleyite are utilised in the form of sand or micronised powders, the major applications being in foundries 
and refractories. Other uses include abrasives, ceramics, alloys, chemicals and leather tanning. Zirconium metal is renowned 
for its excellent corrosion resistance and is employed as a component for alloys in chemical processing plants and in aerospace 
engineering. It is also used for fuel cladding in nuclear reactors. Finally, high technology zirconium ceramics are being tested for 
hot section service in the future generation of uncooled internal-combustion engines. </p>
<p align=center><a href="new.htm"><font size=3><img src="/images/tb105.gif" alt="What's New?" align=bottom border=0 width=101 height=17></font></a><a href="org1.htm"><font size=3><img src="/images/tb101.gif" alt="organisation" align=bottom border=0 width=101 height=17></font></a><a href="res1.htm"><font size=3><img src="/images/tb102.gif" alt="Resources" align=bottom border=0 width=101 height=17></font></a><a href="kruger.htm"><font size=3><img src="/images/tb104.gif" alt="Krugerrand" align=bottom border=0 width=101 height=17></font></a><a href="info.htm"><font size=3><img src="/images/tb106.gif" alt="Contacting us" align=bottom border=0 width=101 height=17></font></a><font size=3> </font></p>
<hr size=3>
<address><font size=2>&#169; 1996 Chamber of Mines of South Africa<br>
HTML Coding by Timothy Wood : </font><a href="mailto:twood@bullion.org.za"><font size=2>twood@bullion.org.za</font></a><font size=2> </font></address>
</body>

</html>
</DOC>
